Scientific Programme

Saturday, 29 August 2020

General
12:30 - 13:15
Auditorium 1

GS1, Opening Ceremony

Welcome and introduction
Nicolaus Kröger (Germany) 12:30 - 12:35

Welcome and introduction to the conference
Rafael Duarte (Spain) 12:35 - 12:40

Welcome from the Nurses Group
John Murray (United Kingdom) 12:40 - 12:44

EBMT Patient Advocacy Committee: Welcome note
Bregje Verhoeven (Netherlands) 12:44 - 12:48

Introduction of the Keynote speaker
Rafael Duarte (Spain) 12:48 - 12:50

Keynote Lecture: How the treatment is evolving in transplant-eligible newly diagnosed Multiple Myeloma?
María-Victoria Mateos (Spain) 12:50 - 13:15

Industrial Theatre
12:30 - 18:30
Industry Theatre

IT1, TLS in the context of new treatments in hematology - Sanofi Genzyme Industry Theatre Session

IT3, Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite Industry Theatre Session

IT4, KYMRIAH in the Real World - Novartis Industry Theatre Session
Scientific Programme

Industrial Theatre
12:30 - 18:30

IT5, How I manage CMV in HSCT patients - MSD Industry Theatre Session

IT6, Gene therapy: From clinical trials to clinical practice - Bluebirdbio Industry Theatre Session

Chairs:
Franco Locatelli (Italy)

IT2, Clinical Data on Treosulfan-based Conditioning Treatment (Trecondi®) in Paediatric Patients - Medac Industry Theatre Session

e-Posters
12:30 - 18:30
ePoster Area

Lymphoma

LONG TERM SURVIVAL AFTER 2 YEARS EVENT FREE SURVIVAL IN RELAPSED DLBCL AFTER AUTOLOGOUS TRANSPLANTATION IN THE TWO RANDOMIZED TRIALS LY.12 AND CORAL

EXPLORATORY ANALYSIS OF BRENTUXIMAB VEDOTIN PLUS CHP (A+CHP) AS FRONTLINE TREATMENT FOR PATIENTS WITH CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMAS (ECHELON-2): IMPACT OF CONSOLIDATIVE STEM CELL TRANSPLANTATION

BRENTUXIMAB VEDOTIN FOR RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN LYMPHOMA: A STUDY OF THE LWP-EBMT

ALLOGENEIC STEM CELL TRANSPLANTATION AS A CURATIVE OPTION IN RELAPSE/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GETH/GELTAMO STUDY

ADAM17 INHIBITOR INCB7839 WITH RITUXIMAB AS CONSOLIDATION AFTER AUTOLOGOUS HCT FOR DIFFUSE LARGE B CELL LYMPHOMA: A NOVEL RELAPSE PREVENTION STRATEGY

COMPARISON OF REDUCED-INTENSITY CONDITIONING (RIC) REGIMENS FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT) FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A CIBMTR ANALYSIS

HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH NON-HODGKIN LYMPHOMA: THE SPANISH EXPERIENCE

EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSIONS FOR PATIENTS AFFECTED BY ADVANCED LYMPHOID MALIGNANCIES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY
Scientific Programme

BRENTUXIMAB-VEDOTIN IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY PRIOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HODGKIN LYMPHOMA: REAL-WORLD DATA FROM A TWO CENTERS STUDY

NON-MYELOABLATIVE CONDITIONING REGIMEN BEFORE T-CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ADVANCED LYMPHOMA

IMPACT OF KIR LIGAND MISMATCH AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY IN 383 PATIENTS FROM THE SFGM-TC

THE IMPACT AND CHALLENGES OF PERFORMING BEAM CONDITIONED AUTOLOGOUS TRANSPLANTS IN 'OLDER' PATIENTS WITH LYMPHOMA

ACCESSIBILITY AND IMPACT ON LONG-TERM OVERALL SURVIVAL OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS: A SINGLE INSTITUTION INTENTION-TO-TREAT ANALYSIS

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TRANSFORMED FOLLICULAR LYMPHOMA (FL): RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY FROM GELTH/GELTAMO GROUP

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANTATION

SIGNIFICANT ROLE OF UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA

HIGH DOSE CHEMOTHERAPY TEAM FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN LYMPHOMA: RESULTS OF A PROSPECTIVE STUDY

AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIV+ AND HIV- LYMPHOMA PATIENTS: A PROPENSITY SCORE MATCHED ANALYSIS

AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR DOUBLE HIT LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

ALLOGENEIC STEM CELL TRANSPLANTATION CAN BE SUCCESSFULLY DELIVERED FOLLOWING BTKI THERAPY FAILURE FOLLOWING R-BAC RE-INDUCTION CHEMOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA

CLINICAL OUTCOMES OF EBV+ PTLD PATIENTS FOLLOWING HCT WHO FAIL RITUXIMAB: A RETROSPECTIVE CHART REVIEW STUDY FROM FRANCE

THE IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) ON THE OUTCOME OF POOR-RISK NON-HODGKIN LYMPHOMA (NHL): UPDATE OF A RETROSPECTIVE INTENT-TO-TRANSPLANT (ITT) ANALYSIS

REDUCING THE COST OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMAS AT LIMITED-RESOURCE CENTERS IN DEVELOPING COUNTRIES

COMPARISON OF MITOXANTRONE - MELPHALAN AND BEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS

NIVOLUMAB RE-CHALLENGE IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: WHERE IS THE PLACE FOR ALLOHSCT?

OUTCOME OF TRANSPLANT ELIGIBLE MANTLE CELL LYMPHOMA PATIENTS WITH FIRST-LINE REGIMENS IN A REAL-WORLD SETTING: A PORTUGUESE MULTICENTER RETROSPECTIVE ANALYSIS
EVALUATION OF FRACTIONATED ICE AS AN ALTERNATIVE OUTPATIENT OPTION FOR RELAPSED/REFRACTORY LYMPHOMAS

EFFICACY OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

RISK FACTORS FOR INTENSIVE CARE UNIT ADMISSION IN PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B-CELL LYMPHOMA

DIFFERENT OUTCOMES WITH DIFFERENT DONORS IN ALLOGENEIC STEM CELL TRANSPLANTATIONS IN MALIGNANT LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE

THE IRISH EXPERIENCE OF THIOTEPA, CARMUSTINE AND ETOPOSIDE CONDITIONING PRIOR TO ASCT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS

TARGETED AND IMMUNOCHEMOTHERAPY IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AS TREATMENT OPTION FOR RARE TRANSDIFFERENTIATION OF LYMPHOID NEOPLASMS INTO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS TO ACHIEVE LONG-TERM SURVIVAL

OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH PERIPHERAL T CELL LYMPHOMAS: A RETROSPECTIVE ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG)

TREATMENT OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA AFTER HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. A STUDY OF THE POLISH LYMPHOMA RESEARCH GROUP

PLACE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH T-CELL LYMPHOMAS: PAVLOV UNIVERSITY EXPERIENCE

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA: TOXICITY AND SURVIVAL STUDY

AUTOIMMUNE COMPLICATIONS IN CHILDREN WITH HODGKIN DISEASE (HD) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT)

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIV-RELATED LYMPHOMA

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS OF 23 PATIENTS

NIVOLUMAB BASED RESPONSE ADAPTED TREATMENT IN PRIMARY REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS

AUTOLOGOUS STEM CELL TRANSPLANT IN A SERONEGATIVE A PATIENT WITH PLASMABLASTIC LYMPHOMA (PBL)

COMPAIRING THE EFFICACY AND TOXICITY BETWEEN TWO CONDITIONING REGIMEN IN LYMPHOMA PATIENTS IN WEST OF IRAN (BENDAMUSTIN) OR (CCNU) WITH (ETOPOSIDE, CITARABINE, MELPHALANE)
Acute leukaemia

- Acute leukaemia
  - Allogeneic transplantation in patients with HIV-infection: an updated pair-matched cohort study by the European Society for Blood and Marrow Transplantation
  - Comparable outcomes of AML patients receiving haplo-HCT with thiotepa/busulfan/fludarabine conditioning and post-transplant cyclophosphamide versus a matched unrelated donor with fludarabine/busulfan conditioning, regardless of disease status
  - Trends and predictive factors for outcome of relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplant: improved survival for young patients in recent years
  - Anti-CD3/CD33 bispecific antibodies efficiently redirect donor T cells against HLA loss leukemia relapses
  - Polycomb repressive complex 2 (PRC2) emerges as a key driver of HLA class II negative post-transplantation relapse
  - Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring <i>IKZF1</i> gene mutations: a study by the acute leukemia working party of the EBMT
  - Allogeneic hematopoietic stem cells transplant in children and adults with relapsed/refractory B-ALL: focus on anti-CD19, anti-CD22 monoclonal antibodies
  - The value of allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia with and without <i>ASXL1</i>, <i>RUNX1</i>, and <i>TP53</i> mutations
  - Allogeneic stem cell transplantation in patients with acute myeloid leukemia and Karnovsky performance status score equal or lower than 80%. A study from the ALWP-EBMT
  - RIC combined with anti-thymocyte globulin and post-transplant cyclophosphamide provides higher GVHD-free/relapse free survival in fit young adults with acute myeloid leukemia
  - Low-dose memory donor lymphocyte infusion after αβ T cell-depleted HSCT among children with high-risk leukemia: results of a prospective randomized single-center trial
  - Development of a cord blood stem cell-derived dendritic cell vaccine to prevent relapse after cord blood transplantation in AML
  - The Brazilian experience with haploidentical hematopoietic cell transplants (haplo-HCT) with post-transplant cyclophosphamide (PTCY) in pediatric patients with hematological malignancies
  - Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT
  - Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the ALWP of the EBMT
  - Graft failure after unmanipulated haplo-HSCT with PT-CY in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT
IMPLICATIONS OF NOVEL RISKS SCORES (AML-DRG AND AML-HCT-CR) IN ALLOGENEIC CD34+
SELECTED GRAFT TRANSPLANT OUTCOMES
Rosalia Alonso Trillo, Marta Garcia Recio, Martina Pennisi, Christina Cho, Sean M. Devlin, Josel D. Ruiz,
Molly A. Maloy, Ana Alarcon Tomas, Nerea Castillo, Richard J. Lin, Ioannis Politikos, Miriam Sanchez
Escamilla, Michael Scordo, Gunjan L. Shah, Juliet N. Barker, Hugo Castro-Malaspina, Boglarka
Gyurkocza, Parastoo B. Dahi, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Craig S.
Sauter, Brian C. Shaffer, Roni Shouval, Roni Tamari, Marcel R. M. van den Brink, James W. Young, Sergio
A. Giralt, Miguel Perales (Spain)

DOWNREGULATION OF HLA-DR IN BLASTS OF PATIENTS WITH ACUTE LEUKAEMIA RELAPSING
AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION

DIFFERENTIAL IMPACT OF NPM1 MUTATION ON THE POST-TRANSPLANT OUTCOME OF ADULT
FLT3ITD MUTATED AML RECEIVING ALLOGENEIC TRANSPLANT IN CR1 AND AFTER CR1

A REGION-WIDE RETROSPECTIVE ANALYSIS OF OUTCOME FOR PATIENTS WITH NEWLY
DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA

PRE-HARVEST HIGHER DONOR FOXP3 MRNA AND LOWER CD4+ T CELL CONCENTRATION
PREDICT INCREASED RISK OF ALL RELAPSE AFTER MYELOABLATIVE HCT WITH T-REPLETE
BONE MARROW GRAFTS

EPIDEMIOLOGY, MANAGEMENT AND ECONOMIC IMPACT OF ACUTE MYELOID LEUKAEMIA AND
MYELODYSPLASTIC SYNDROME IN SPAIN: A CLAIMS DATABASE ANALYSIS

PRE-TRANSPLANT BONE MARROW CELLULARITY AND BLOOD COUNT RECOVERY ARE NOT
ASSOCIATED WITH RELAPSE OR SURVIVAL RISK FOLLOWING ALLOGENEIC STEM CELL
TRANSPLANT FOR AML IN CR1

IMMUNOTHERAPY SALVAGE FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS
BY THE ALWP OF THE EBMT

COMPARISON OF PRE-TRANSPLANT COMORBIDITY INDICES IN ACUTE LEUKEMIA PATIENTS
UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

SALVAGE USE OF VENETOCLAX-BASED THERAPY FOR RELAPSED AML POST ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANT

FACTORS PREDICTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PH-
NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA

ROLE OF CHIMERISM AND FLOW-CYTOMETRIC MONITORING OF MEASURABLE RESIDUAL
DISEASE (MRD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-
HSCT) IN PREDICTING RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)

SORAFENIB PROLONGED MAINTENANCE IN FLT3-MUTATED AML POST TRANSPLANTATION

PULMONARY COMPLICATIONS (PC) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (ALLO-HSCT) IN CHILDREN WITH HIGH-RISK ACUTE LEUKEMIA (AL)

MORE THAN TWO CYCLES OF CONSOLIDATION THERAPY PRE-TRANSPLANTATION BENEFITS
AML PATIENTS IN CR1 WHO UNDERWENT HLA-MATCHED SIBLING ALLOGRAFTS: A
MULTICENTER STUDY

WHAT CAN CNV ANALYSIS ADD TO THE ROUTINE GENETIC DESCRIPTION OF AML CASES?

COMPARISON OF THE PROGNOSTIC ABILITY OF THE HCT-CI THE MODIFIED EBMT AND THE
EBMT-ADT PRE-TRANSPLANT RISK SCORES FOR ACUTE LEUKEMIA
GO-FLAG REGIMEN AS A BRIDGE THERAPY TO ALLOGENEIC STEM CELL TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS

THE IMPACT OF ALLOGENEIC TRANSPLANTATION IN AML AND MDS WITH CHROMOSOME 3 ABNORMALITIES

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS CHEMOTHERAPY-ALONE IN THE TREATMENT OF PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS WITH MIXED LINEAGE LEUKEMIA (MLL) REARRANGEMENTS: SINGLE CENTER EXPERIENCE

POSTTRANSPLANTATION BENDAMUSTINE FOR GVHD PROPHYLAXIS IN REFRACTORY ACUTE LEUKEMIA PATIENTS

IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE

FLAT REGIMEN AS MYELOABLATIVE CONDITIONING WITH LIMITED TOXICITIES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS IN 30 PATIENTS

TYROSINE KINASE INHIBITOR TREATMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR CYTOGENETIC INTERMEDIATE-RISK AML ACCORDING TO THE MOLECULAR RISK BASED ON ELN 2017 RISK STRATIFICATION SYSTEM; SINGLE CENTER EXPERIENCE IN KOREA

THE PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY WT1 GENE EXPRESSION IN PERIPHERAL BLOOD BEFORE AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN AML PATIENTS

IMPACT OF POSTTRANSPLANT TYROSINE KINASE INHIBITORS ADMINISTRATION ON LONG TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

THE INFLUENCE OF ANTI-THYMOCYTE GLOBULIN (ATG) ON THE OUTCOMES OF PATIENTS WITH AML W/WO MEASURABLE RESIDUAL DISEASE (MRD) AT THE TIME OF UNRELATED DONOR TRANSPLANTATION

MLL-AF6 FUSION GENE POSITIVE AML TREATED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION HAS EXCELLENT OVERALL SURVIVAL

BENEFICIAL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

INDUCTION OF SYNERGISTIC APOPTOSIS AND OVERCOMING OF DRUG RESISTANCE BY COTARGETING OF BCL-2 AND NA/H EXCHANGER 1 PATHWAY IN ACUTE MYELOID LEUKEMIA CELLS

GEMTUZUMAB-OZOGAMICIN FOR BRIDGING TO TRANSPLANT IN REFRACTORY/RELAPSED CD33 POSITIVE ACUTE LEUKEMIA - IS IT WORTHWHILE?

THE EFFECTS OF CYTOMEGALOVIRUS INFECTION ON TRANSPLANT OUTCOMES IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

AZACYTIDINE AND DONOR LYMPHOCYTES INFUSIONS IN RELAPSED AML AFTER ALLOGENEIC HSCT: RESULTS IN 40 PATIENTS

THE RESULTS OF AML RELAPSE AFTER ALLOGENEIC TRANSPLANTATION TREATMENT, SINGLE CENTRE APPROACH EVALUATION
Scientific Programme

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A SINGLE CENTER ANALYSIS

THE OPTIMAL TIME FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

IMPACT OF ABO MISMATCH ALLOGENEIC TRANSPLANT IN ACUTE MYELOID LEUKEMIA: A SINGLE CENTRE EXPERIENCE

DONOR SOURCE IMPACTS ON LONG TERM SURVIVAL FOLLOWING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN AML PATIENTS AGED 60 AND ABOVE

EXTRA-MEDULLARY RECURRENCE OF ACUTE MYELOID LEUKEMIA AS MYELOID SARCOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE SERIES

SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA: SINGLE CENTER EXPERIENCE

ALLOGENEIC STEM CELL TRANSPLANTS IN ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE EXPERIENCE

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA NOT RESPONDING TO FIRST INDUCTION THERAPY

Aplastic anaemia

LNP023 - A NEW ORAL COMPLEMENT FACTOR-B INHIBITOR NORMALIZES HEMOGLOBIN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH POOR RESPONSE TO ECULIZUMAB, BOTH AS ADD-ON AND MONOTHERAPY

EPIGENETIC AGING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH POOR SURVIVAL IN PATIENTS WITH SEVERE APLASTIC ANEMIA: RESULTS FROM DNA-METHYLATION GRIMAGE

GVHD AND RELAPSE FREE SURVIVAL (GRFS) AFTER ALLOGENEIC TRANSPLANTATION FOR IDIOPATHIC SEVERE APLASTIC ANEMIA: AN ANALYSIS FROM THE SAAWP DATA QUALITY INITIATIVE PROGRAM OF EBMT

OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANAEMIA: A STUDY ON BEHALF OF THE EBMT SAAWP AND PDWP

REDUCED INTENSITY CONDITIONING IS EFFECTIVE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND-BLACKFAN ANEMIA

PROSPECTIVE STUDY OF ECULIZUMAB BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMOLYTIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA / APLASTIC ANEMIA

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT FOR FANCONI ANEMIA IN INDIA

ALTERNATE DONOR HSCT FOR 109 CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA: A SINGLE CENTER RETROSPECTIVE ANALYSIS

SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS WITH REFRACTORY ACTIVE INFECTION: A PROSPECTIVE MULTICENTER CLINICAL STUDY IN CHINA
INCIDENCE AND MANAGEMENT OF APLASTIC ANEMIA IN SPAIN (IMAS). AN AMBISPECTIVE STUDY OF BIODONOSTIA / PETHHEMA

ALLOGENEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS FOR CHILDREN WITH APLASTIC ANEMIA

OUTCOME OF PEDIATRIC ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE

OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT FOR SEVERE APLASTIC ANEMIA IN PAKISTAN: DATA FROM A DEVELOPING COUNTRY

IMPACT OF CD34+-STEM CELL BOOST ON OUTCOME AND HEMATOLOGICAL RECONSTITUTION IN PATIENTS WITH SEVERE APLASTIC ANEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY

HEMATOPOIETIC STEM CELL TRANSPLANT IN ADULTS WITH ACQUIRED SEVERE APLASTIC ANEMIA

HEMATOPOIETIC STEM CELL TRANSPLANT IN FANCONI ANEMIA USING MATCHED RELATED AND HAPLOIDENTICAL DONORS- A SINGLE CENTRE EXPERIENCE

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC SEVERE APLASTIC ANEMIA: RESULTS OF A SINGLE CENTER

EFFECT OF SINGLE UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION ON APLASTIC ANEMIA IN CHILDREN

IMMUNOSUPPRESSIVE THERAPY IN PEDIATRIC APLASTIC ANEMIA, SINGLE CENTRE EXPERIENCE

CYCLOSPORINE, DANAZOL AND ROMIPLOSTIM IN SEVERE APLASTIC ANEMIA IN PRETRANSPLANT PERIOD: RETROSPECTIVE ANALYSIS OF FIVE CASES

Autoimmune diseases

AUTOLOGOUS NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR STIFF PERSON SYNDROME

BEAM VS CYCLOPHOSPHAMIDE-BASED CONDITIONING REGIMEN IN AGGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE ANALYSIS OF EUROPEAN BLOOD AND MARROW TRANSPLANTATION SOCIETY

A NOVEL TARGETED APPROACH TO ACHIEVE IMMUNE SYSTEM RESET: CD45-TARGETED ANTIBODY DRUG CONJUGATES AMELIORATE DISEASE IN PRECLINICAL AUTOIMMUNE DISEASE MODELS AND ENABLE AUTOHSCT

LONG TERM FOLLOW UP OF SYSTEMIC SCLEROSIS FRENCH PATIENTS INCLUDED IN THE ASTIS TRIAL USING SCOT TRIAL GLOBAL RANK COMPOSITE SCORE (GRCS)

ADVANCES IN MULTIPLE SCLEROSIS (MS) TREATMENT: CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION
Scientific Programme

POST TRANSPLANTATION CYCLOPHOSPHAMIDE IMPROVES OUTCOME AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ANIMAL MODEL OF MULTIPLE SCLEROSIS

THE LONG-TERM SAFETY AND EFFICACY OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS INDIRECTLY COMPARED TO ALEMTUZUMAB: A SYSTEMATIC REVIEW

RECONSTITUTION OF NATURAL OR VACCINATION-DRIVEN IMMUNITY AFTER AHSCT IN MULTIPLE SCLEROSIS

HIGH-DOSE IMMUNODEPLETION WITH AUTOLOGOUS STEM CELL RESCUE FOR TREATMENT OF AGGRESSIVE MULTIPLE SCLEROSIS

HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT CHANGE THE EXPRESSION OF ENDOTHELIAL MARKERS IN SKIN BIOPSIES OF SYSTEMIC SCLEROSIS PATIENTS

AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NON HEMATOLOGICAL DISEASES. THE DUTCH EXPERIENCE OF MS PATIENTS GOING ABROAD

ANALYSIS OF COST AND CHARGES FOR NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES

AUTOLOGOUS STEM CELL TRANSPLANTATION IN BEHÇET’S DISEASE: A RETROSPECTIVE STUDY

SAFETY AND TOLERABILITY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE SCLEROSIS: A SINGLE CENTER EXPERIENCE

OUTCOME OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY TAKAYASU ARTERITIS, A RETROSPECTIVE SURVEY FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EBMT

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS IN NORWAY

THE USE OF AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS AFTER ALEMTUZUMAB TREATMENT FAILURE: A CASE SERIES

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF SYSTEMIC SCLEROSIS, AN OPTION FORREFRACTORY PATIENTS

A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE

e-Posters
12:30 - 18:30

CAR-based Cellular Therapy – clinical

KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): RESULTS FROM PHASE 2 OF ZUMA-2

SAFETY AND EFFICACY RESULTS FROM TRANSCEND NHL 001, A MULTICENTER PHASE 1 STUDY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

CD19/CD22 DUAL TARGETED (CHIMERIC ANTIGEN RECEPTOR) CAR-T THERAPY FOR RELAPSED OR REFR ACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
AN UPDATE OF THE EBMT SURVEY ON CAR T-CELL ACTIVITY IN EUROPE. ON BEHALF OF THE CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY (CTIWP)

THIRD-GENERATION CAR T CELLS WITHIN THE HEIDELBERG CAR TRIAL 1 (HD-CAR-1) DISPLAY AN EXCELLENT SAFETY PROFILE AND MIGHT IMPROVE PERSISTENCE OF CAR T CELLS

OUTPATIENT TREATMENT WITH LISOCABTAGENE MARALEUCEL IN 3 CLINICAL STUDIES OF RELAPSED/REFRACTORY LARGE B-CELL NHL, INCLUDING SECOND-LINE TRANSPLANT NONELIGIBLE PATIENTS: TRANSCEND NHL 001, OUTREACH, AND PILOT

CORRELATIVE ANALYSES OF PATIENT AND CLINICAL CHARACTERISTICS ASSOCIATED WITH EFFICACY IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE JULIET TRIAL

CAR T CELLS (CART) OR ALLOGENEIC TRANSPLANTATION (ALLOHCT) FOR MULTIPLY RELAPSED DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)? A RETROSPECTIVE INTENT-TO-TREAT (ITT) COMPARISON

HIGH ACTIVATION OF BCMA CAR-T CELLS CONTRIBUTES TO INCREASED RESPONSE RATE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

A COMPARISON OF 2-YEAR OUTCOMES IN ZUMA-1 (AXICABTAGENE CILOLEUCEL; AXI-CEL) AND SCHOLAR-1 IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL)

CD19-TARGETED CAR-T CELL THERAPY FOR 32 B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS WHO RELAPSED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)

INTERNATIONAL PROGNOSTIC INDEX PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED AND REFRACTORY LARGE DIFFUSE B CELL LYMPHOMA TREATED WITH COMMERCIAL CAR T CELLS

THE PHASE 1B PORTIA STUDY: SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

REAL-WORLD EVIDENCE OF THE USE OF TISAGENLECLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS. THE SPANISH EXPERIENCE

NATIONAL IMPLEMENTATION OF THE USE OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN NATIONAL HEALTH SERVICE ENGLAND (NHSE)

REAL-WORLD CLINICAL FEATURES OF NEUROTOXICITY COMPLICATING CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR HIGH GRADE LYMPHOMA AND MANAGEMENT INCLUDING THE OFF-LABEL USE OF ANAKINRA

ASSOCIATION OF AXI-CEL CAR-T CELL CONCENTRATION WITH TREATMENT RESPONSE AND SIDE EFFECTS AND IMPACT OF DEXAMETHASONE TREATMENT ON KINETICS

SIMPLIFIED-EASIX (SEASIX) IS AN EARLY PREDICTOR OF SEVERE CYTOKINE RELEASE SYNDROME AND IMMUNE-EFFECTOR-CELLS-ASSOCIATED NEUROTOXICITY SYNDROME IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T CELLS

NIVOLUMAB AS SALVAGE THERAPY IN PATIENTS WHO FAILED TO ACHIEVE COMPLETE REMISSION AFTER ANTI-CD19 CAR T-CELL THERAPY FOR DLBCL
SURVEILLANCE OF MINIMAL RESIDUAL DISEASE (MRD) IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) BY CIRCULATING TUMOR DNA (CTDNA) PROFILING AFTER CHIMERIC ANTIGEN RECEPTOR T (CAR-T)

A DIGITAL-PCR ASSAY FOR PRECISE IN-VIVO QUANTIFICATION OF ADOPTIVELY TRANSFERRED CD19-CAR T CELLS AFTER TREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)

FEASIBILITY OF MANUFACTURING TISAGENLECLEUCEL IN PATIENTS LESS THAN 3 YEARS OF AGE WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

AXICABTAGENE CILOLEUCEL CD19 CAR T-CELLS FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: REAL-WORLD OUTCOMES, TOXICITY AND PREDICTORS OF RESPONSE FROM A PROSPECTIVE UK COHORT

MARKERS OF INITIAL AND LONG-TERM RESPONSES TO IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) IN THE CRB-401 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

SINUSOIDAL OBSTRUCTION SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) TREATED WITH ARI-0001 CELLS

HUMORAL IMMUNE RESPONSE IN PATIENTS WITH CD19-POSITIVE RELAPSED/REFRACTORY B-CELL MALIGNANCIES RECRUITED INTO THE CART19-BE-01 CLINICAL TRIAL, AN ACADEMIC CAR19

REAL-WORLD DATA FROM KINGS COLLEGE HOSPITAL: INFECTION COMPLICATIONS POST CAR-T TREATMENT IN HIGH-GRADE B CELL NON-HODGKIN LYMPHOMA

SENESCENT/EXHAUSTED PHENOTYPE OF CD19-TARGETED CAR-T CELLS AND IMMUNOREGULATORY ENVIRONMENT CORRELATE WITH REDUCED RESPONSE TO CAR-T CELL THERAPY IN RELAPSED/REFRACTORY B CELL MALIGNANCIES

CHARACTERISATION OF EARLY AND LATE CYTOPENIAS IN LYMPHOMA PATIENTS FOLLOWING TREATMENT WITH ANTI-CD19 CAR-T THERAPY

CD4+ CAR-T CELLS MAINTAIN MEMORY PHENOTYPES AND MEDIATE LONGER-TERM ANTITUMOR ACTIVITY IN VIVO

IMPACT OF ETHNICITY IN R/R DLBCL AND B-CELL ALL PATIENTS TREATED WITH TISAGENLECLEUCEL

IMPACT OF DIFFERENT CHEMOTHERAPY REGIMENS AND DURATION OF DLBCL ON LYMPHOPHERESIS AND CAR-T CELL IMMUNOPHENOTYPING

CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY IMPROVE PROGRESSION FREE SURVIVAL IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

CHALLENGES IN PROVIDING GOOD LEUKAPHERESIS PRODUCTS FOR THE PRODUCTION OF CAR T CELLS FOR PATIENTS WITH RELAPSED/REFRACTORY NHL OR ALL

NKG2D CAR T CELLS ARE NOT AFFECTED BY SOLUBLE NKG2D LIGANDS

EMERGING CYTOKINE RELEASE SYNDROME IS ASSOCIATED WITH REDUCTION OF CD4+CD25HIGH127DIM T REGULATORY CELLS IN PATIENTS AFTER CAR T CELL THERAPY

EXCELLENT PROLIFERATION AND PERSISTENCE OF ALLOGENEIC CAR-T CELLS DESPITE IMMUNOSUPPRESSION WITH CYCLOSPORINE A

A FRENCH BIOBANKING NETWORK TO CREATE A UNIQUE COLLECTION OF SAMPLES OF PATIENTS TREATED WITH CAR-T CELLS
Scientific Programme

CAR T CELL THERAPY DIRECTED AGAINST CD19 IN PATIENTS WITH B-CELL LYMPHOMA AFTER AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IS FEASIBLE AND SAFE

LYMPHOCYTE COLLECTION FOR GENERATION OF CAR T-CELLS IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE

BASELINE HYPOALBUMINEMIA DOES NOT APPEAR TO BE AN ADVERSE PROGNOSTIC FACTOR IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMAS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)

FACTORS PREDICTING CD3+ COLLECTION FOR THE PRODUCTION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS

CYTOPENIAS AFTER TISAGENLECLEUCEL IN PAEDIATRIC/YOUNG ADULT PATIENTS WITH REFRACTORY/RELAPSE B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL): A REAL-LIFE SINGLE-CENTRE EXPERIENCE

THE RISK OF HEPATITIS B REACTIVATION IS CONTROLLABLE IN B-CELL MALIGNANCIES PATIENTS WITH CONCOMITANT HEPATITIS B VIRUS INFECTION AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY

CUMULATIVE RITUXIMAB EXPOSURE PRIOR TO AXICABTAGENE CILOLEUCEL IS NOT ASSOCIATED WITH PERSISTENT LEUKOPENIA AND THROMBOCYTOPENIA AT DAY +90 POST INFUSION

COMPREHENSIVE IMMUNE CELL MONITORING REVEALS AN ALTERED LYMPHOCYTE SUBSET PHENOTYPE IN PATIENTS NOT RESPONDING TO TISAGENLECLEUCEL ONE MONTH POST INFUSION

NEUROTOXICITY ASSOCIATED WITH CAR T CELL THERAPY: NEUROLOGICAL MANAGEMENT AND WORK-UP OF 11 ADULT PATIENTS

NUTRITIONAL ASSESSMENT OF PATIENTS UNDERGOING CD19-TARGETED CAR-T THERAPY FOR NON-HODGKIN’S LYMPHOMA AND THE SHORT TERM EFFECT OF TREATMENT ON NUTRITIONAL STATUS

EFFECTIVENESS OF AUTOLOGOUS LEUKAPHERESIS COLLECTIONS FOR CAR T-CELL MANUFACTURING IN PATIENTS WITH B-CELL MALIGNANCIES

DEFINITION AND IMPLEMENTATION OF CLINICAL AND QUALITY ENDPOINTS IN CENTERS ADMINISTERING A COMMERCIAL CAR-T PRODUCT

CAR-T IN BREAST AND OTHER EXTRA-MEDULLARY RELAPSED/REFRACTORY ALL

PREDICTING CAR T-CELL INFUSION AFTER SUCCESSFUL MANUFACTURING: REAL-WORLD DATA

EVALUATION OF THE INTEREST OF A DRUG RECONCILIATION ACTIVITY IN PATIENTS TREATED WITH CAR T-CELLS: A DESCRIPTIVE STUDY

e-Posters
12:30 - 18:30
ePoster Area

CAR-based Cellular Therapy – preclinical

MODULATION OF CYTOSOLIC CA\(^{2+}\) REGULATES CAR-T CELL DIFFERENTIATION AND THERAPEUTIC POTENCY
**Scientific Programme**

**BREAKING PD-L1-MEDIATED RESISTANCE IN ANTI-CD19 AND ANTI-CD22 CAR T CELLS WITH PD-1/CD28 FUSION RECEPTORS**

**ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR-INVARIANT NATURAL KILLER T CELLS EXERT BOTH DIRECT AND INDIRECT ANTITUMOR EFFECTS THROUGH HOST CD8 T CELL CROSS-PRIMING**

**DUVELISIB GENERATES CAR T CELLS WITH ENHANCED MITOCHONDRIAL BIOGENESIS AND REDUCED EXPRESSION OF PD-1, TIM-3, AND LAG-3, ENABLING GREATER ANTI-LEUKEMIA CYTOTOXICITY AGAINST CLL**

**NKG2D CHIMERIC ANTIGEN RECEPTOR-EXPRESSING LYMPHOCYTES TARGET ACUTE MYELOID LEUKEMIA CELLS**

**CLINICAL-GRADE MANUFACTURING OF ROR1 CAR T-CELLS USING A NOVEL VIRUS-FREE PROTOCOL**

**LENTIVIRALLY AND ALPHARETROVIRALLY ENGINEERED CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS ARE HIGHLY CYTOTOXIC AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA**

**NOVEL STRATEGIES TO ENHANCE THE SAFETY OF CAR T-CELL IMMUNOTHERAPY: THE IMSAVAR PROJECT**

**ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD NK CELLS ARE GOOD SOURCES FOR EFFECTIVE CAR THERAPY AGAINST CD19 POSITIVE LEUKEMIA**

**ENHANCEMENT OF CYTOTOXICITY, EXPANSION AND PERSISTENCE OF CD19 CAR-T CELLS VIA PRE-SENSITIZATION OF B CELL MALIGNANCIES BY BCL-2 SELECTIVE INHIBITORS**

**TYROSINE KINASE INHIBITOR FOLLOWED BY CART THERAPY FOR THE TREATMENT OF RELAPSED PHILADELPHIA CHROMOSOME-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**e-Posters**

**12:30 - 18:30**

**ePoster Area**

**Cellular Therapies other than CARs**

**CTLA4IG PRIMED SEQUENTIAL DLI IMPROVES GVHD AND RELAPSE-FREE SURVIVAL COMPARED TO UNPRIMED DLI IN PATIENTS UNDERGOING PTCY-BASED HAPLOIDENTICAL HCT FOR ADVANCED HEMATOLOGICAL MALIGNancies**

**HLA-MISMATCHED MOBILIZED CELLULAR THERAPY (MICROTANSPLANT, MST) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES**

**DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH PTCY: A STUDY ON BEHALF OF THE CTIW OF THE EBMT**

**SAFETY, EFFECTIVENESS AND PERSISTENCE OF LOW-DOSE DONOR MEMORY T CELL INFUSIONS AFTER AB T CELL-DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PROPHYLACTIC DONOR LYMPHOCYTE INFUSION AFTER T-CELL-REPLETE HAPLOIDENICAL HSCT PREVENTS DISEASE RELAPSE AND PROLONGS SURVIVAL IN PATIENTS WITH HIGH-RISK ACUTE LEUKEMIA**

**BASELINE IMMUNE STATUS PREDICTS RESPONSE TO ADOPTIVE THERAPY WITH CMV CTLS FOR REFRACTORY CMV**
Scientific Programme

Efficacy and Safety of Donor Lymphocyte Infusion After Haploidentical Stem Cell Transplantation: A Retrospective Multicenter Study on Behalf of GETH (Grupo Español Trasplante Hematopoético)

Phase I Study of Adoptive Transfer of Haploidentical Expanded NK Cells

Off-Target HLA Cross-Reactivity by (Third Party) Virus-Specific T Cells Is Surprisingly Affected by HLA Restriction and HLA Background But Not by Virus Specificity

Adoptive Immunotherapy of Refractory Viral Infections After Allogeneic HSCT: An Academic Network Framing the Use of an ATMP Under Hospital Exemption

How to Benefit from Exhaustion: Patient-Derived Inhibited T Cells as a Novel Source of Tumor- Reactive T Cell Clones

Efficient CRISPR/Cas9-Mediated Inactivation of the Glucocorticoid Receptor for Antigen-Specific T-Cell Immunotherapy

Comparison of Outcome Post-Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients

Automated Application for Depletion of TCRab+, CD19+ and CD45RA+ Cells from Apheresis Products Using the Clinimacs Prodigy (R)

The First Functional HLA-A*01:01-Restricted EBV-LMP2-Specific T-Cell Receptors for TCR Gene Therapy of Patients with EBV-Associated Type II/III Malignancies

Good Response Rates of WJ-MSC, Comparable to BM-MSC, in the Treatment of Refractory GVHD

An 'All in One' T-Cell Product from Non-Transplantable Cord Blood Units for Virus- and Leukemia-Specific T-Cell Immunotherapy

Clinical Success of Granulocyte Transfusions in Adult Neutropenic Patients After Chemotherapy and/or Allogeneic Transplantation - Time Matters!

Impact of Long-Term Cryopreservation of Autologous Hematopoietic Stem Cells Products

Optimizing Lentiviral Vector Transduction to Gene Modify Cord Blood CD8+ T Cells for Off-The-Shelf Adoptive Cell Therapy to Treat Cancer

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Stem Cell Transplantation. Single Centre Experience

Case Report: Chronic Active Epstein-Barr Virus Infection (CAEBV) Controlled by Allogeneic Hematopoietic Stem Cell Transplantation (ALLOHSCT) and Transfusion of EBV-Specific T-Cells

Chronic leukaemia and other myeloproliferative disorders

Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and EBMT
RELAPSE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IN THE PATHWAY INHIBITOR (PI) ERA: NO LONGER A DEAD-END STREET

THE 10-YEARS <u>E</u>BMT <u>L</u>ANDSCAPE OF <u>A</u>LLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) FOR <u>C</u>HRONIC LYMPHOCYTIC LEUKEMIA

DETERMINANTS OF SURVIVAL IN MYELOFIBROSIS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY BY THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT

Splenectomy doesn’t preclude subsequent allogeneic hematopoietic cell transplantation in myelofibrosis patients: A French nationwide study using a multistate model

INCIDENCE OF LATE RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: THE EXPERIENCE OF THREE UNIVERSITY TRANSPLANT CENTRES IN ROME

AUSTRALASIAN TRENDS IN ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS IN MOLECULAR ERA

CML RELAPSE AFTER ALLOGENEIC HSCT: SURVIVAL, TREATMENT EFFICACY AND PROGNOSTIC FACTORS FOR OUTCOME

CHRONIC MYELOID LEUKEMIA: ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN THE ERA OF TYROSINE KINASE INHIBITORS

REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT WITH CAMPATH T-CELL DEPLETION FOR MYELOFIBROSIS IN THE ERA OF JAK INHIBITORS - A SINGLE CENTRE EXPERIENCE

ALLOGENEIC STEM CELL TRANSPLANTATION IN ADVANCED SYSTEMIC MASTOCYTOSIS AFTER CYTOREDUCTIVE TREATMENT WITH CLADRIBINE - A SINGLE CENTER EXPERIENCE ON TWO PATIENTS

ALLOGENEIC STEM CELL TRANSPLANTATION FOR IDIOPATIC MYELOFIBROSIS: A SINGLE CENTRE EXPERIENCE

A CASE OF SUCCESSFUL SECOND HAPLOIDENTICAL BONE MARROW TRANSPLANTATION AFTER SECONDARY GRAFT FAILURE IN A PATIENT WITH REFRACtORY CHRONIC MYELOID LEUKEMIA

e-Posters
12:30 - 18:30
ePoster Area

Conditioning regimens


POPULATION PHARMACOKINETIC ESTIMATION OF ATG EXPOSURE PREDICTS IMMUNE RECONSTITUTION AND SURVIVAL IN ADULTS UNDERGOING EX VIVO CD34-SELECTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
FLAMSA-BASED REDUCED INTENSITY CONDITIONING VERSUS MYELOABLATIVE CONDITIONING IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH ACTIVE DISEASE AT THE TIME OF TRANSPLANTATION: AN ALWP/EBMT ANALYSIS

TOTAL BODY IRRADIATION/FLUDARABINE VERSUS THIOTEPA/BUSULFAN/FLUDARABINE FOR ADULTS WITH ACUTE LYMPHOBlastic LEUKEMIA TREATED WITH HAPLOIDENTICAL HCT. A STUDY BY ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

BUSULFAN-CYCLOPHOSPHAMIDE VERSUS CYCLOPHOSPHAMIDE-BUSULFAN AS CONDITIONING REGIMEN BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A PROSPECTIVE RANDOMIZED TRIAL

RABBIT ANTI-THYMOCYTE GLOBULIN (ATG) EXPOSURE AFTER EX VIVO T-CELL-DEPLETED HEMATOPOIETIC CELL TRANSPLANTATION IS VARIABLE AND IMPACTS IMMUNE RECONSTITUTION AND SURVIVAL IN CHILDREN AND YOUNG ADULTS

A RETROSPECTIVE COMPARATIVE STUDY OF BEAM VS FEAM VS TEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT

REDUCED INTENSITY VERSUS MYELOABLATIVE CONDITIONING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS < 60 WITH ACUTE LYMPHOBlastic LEUKEMIA: A MULTI-CENTER CANADIAN EXPERIENCE

COMBINING CLOFARABINE AND FLUDARABINE WITH EXPOSURE TARGETED BUSULFAN FOR PEDIATRIC LEUKEMIA: AN EFFECTIVE, LOW TOXIC, TBI-FREE CONDITIONING REGIMEN

BENDA-BEAM HIGH-DOSE THERAPY PRIOR TO AUTO-SCT IS EFFECTIVE IN RESISTANT/RELAPSED DLBCL: A PHASE II STUDY

REDUCED-TOXICITY CONDITIONING WITH FLUDARABINE, THIOTEPA AND MELPHALAN IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH IMPAIRED LUNG FUNCTION

ALLOGENEIC STEM CELL TRANSPLANT WITH MINIMAL-INTENSITY CONDITIONING IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA: A SINGLE CENTRE RETROSPECTIVE REVIEW

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBlastic LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT

A PROSPECTIVE COHORT STUDY COMPARING LONG-TERM OUTCOMES WITH AND WITHOUT PALIFERMIN IN PATIENTS RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES

PHARMACOKINETICS OF MELPHALAN IN LYMPHOMA PATIENTS UNDERGOING BEAM AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT

MELPHALAN IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION: DOES ONE SIZE FIT ALL?

COMPARISON OF TOTAL BODY IRRADIATION- VS CHEMOTHERAPY-BASED CONDITIONINGS FOR EARLY COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ALL

DIFFERENTIAL ALEMtUZUMAB DOSAGES IN T-CELL DEPLETE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTS FOR MYELOID MALIGNANCIES

THE INFLUENCE OF TDM ON ACHIEVING BUSULFAN TARGET EXPOSURE AND RELATED DETERMINANTS, IN BOTH CHILDREN AND ADULTS WHO UNDERWENT AN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
NOVEL REDUCED INTENSITY CONDITIONING (RIC) APPROACH TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH BENIGN AND MALIGNANT DISORDERS OF T CELL PROLIFERATION OR DYSREGULATION

PROFOUND LYMPHOPENIA AT THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION IS NOT PREDICTIVE OF SURVIVALS AFTER ALLO-TRANSPLANTATION

LIPID CORE NANOPARTICLES AS VEHICLE FOR ETOPOSIDE IN THE CONDITIONING REGIMEN OF MARROW TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA NOT RESPONDING TO INDUCTION THERAPY: A PILOT STUDY

A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF SHORT-TERM EVEROLIMUS IN ADDITION TO POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-EVER)

ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS ≥ 65 YEARS WITH HEMATOLOGICAL MALIGNANCIES AFTER MYELOABLATIVE TREOSULFAN-BASED CONDITIONING: RESULTS IN 118 PATIENTS

BUTYRYLCHOLINESTERASE ACTIVITY AFTER CYCLOPHOSPHAMIDE CONDITIONING AS A PREDICTIVE MARKER OF LIVER TRANSPLANT-RELATED COMPLICATIONS AND ITS CORRELATION WITH TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS

FLUDARABINE-MELPHALAN CONDITIONING RESULTS IN FAVORABLE LEUKEMIA-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH ACTIVE OR MEASURABLE RESIDUAL AML

SEQUENTIAL CONDITIONING: FLAMSA-TBI VERSUS FLAMSA-TREO IN HIGH RISK ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS)

INCREASED NON-RELAPSE MORTALITY AND POOR OVERALL SURVIVAL IN ELDERLY PATIENTS TREATED WITH FLUDARABINE AND MYELOABLATIVE DOSE OF BUSULFAN: TRANSPLANT COMPLICATIONS WORKING GROUP OF THE JSHTC

TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE IMPROVES THE OUTCOME OF PATIENTS WITH POOR-RISK ACUTE LEUKEMIA

A CD45-TARGETED ANTIBODY DRUG CONJUGATE ENABLES ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS A SINGLE AGENT IN MICE

INFLUENCE OF THE CELL SOURCE TYPE AND CONDITIONING TYPE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME

PRECONDITIONING INTENSITY IMPACTS ON IMMUNE RECONSTITUTION AND OUTCOMES FOLLOWING CORD BLOOD TRANSPLANTATION

FINAL RESULTS OF A PROSPECTIVE, MULTICENTER, NON-INTERVENTIONAL STUDY ON THIOTHEPA-BASED AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (ASCT) FOR CNS OR NON-CNS LYMPHOMA

POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY), CYCLOSPORIN (CSA) AND MYCOPHENOLATE (MMF) FOR PATIENTS GRAFTED FROM HLA IDENTICAL SIBLINGS OR MATCHED UNRELATED DONORS

COMPARISON OF FLUDARABINE + BUSULFAN AND FLUDARABINE+BUSUFAN+ LOW-DOSE ATG CONDITIONING REGIMENS IN PATIENTS WITH MYELOID MALIGNANCIES WHO HAD ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPAMIDE
CONDITIONING REGIMEN COMPARISON FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-HODGKIN LYMPHOMA

PK-GUIDED BUSULFAN CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) WITH PTCY AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES

A THIOTEPA BASED INTENSIFIED REDUCED INTENSITY CONDITIONING REGIME IN ADULT CORD BLOOD TRANSPLANT IS A PROMISING ALTERNATIVE IN PATIENTS UNABLE TO RECEIVE MYELOABLATIVE CONDITIONING

HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE USING AS CONDITIONING FLUDARABINE MELPHALAN PLUS LOW DOES OF TOTAL BODY IRRADIATION. LONG TERM FOLLOW-UP OF 60 PATIENTS

TREOSSULFAN-BASED CONDITIONING IN PAEDIATRIC T-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE

COMPARISON OF BEAM AND TEAM AS CONDITIONING REGIMEN FOR LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

ASSESSMENT OF THE SAFETY AND EFFICACY OF THE CONDITIONING REGIMEN BEEAC BEFORE AUTO-HSCT FOR THE TREATMENT OF PRIMARY-REFRACTORY AND RELAPSED FORMS OF MALIGNANT LYMPHOMAS

ALLOGENEIC STEM CELL TRANSPLANTATION AFTER TOTAL-BODY IRRADIATION USING HELICAL TOMOTHERAPY: A SINGLE CENTER EXPERIENCE

FEASIBILITY OF CLAMSA-RIC AS AN ALTERNATIVE CONDITIONING REGIMEN COMPARED TO FLAMSA-RIC IN HEAVILY PRETREATED REFRACTORY AML PATIENTS - A RETROSPECTIVE SINGLE CENTER ANALYSIS

THIOTEPA, BUSULPHAN AND FLUDARABINE CONDITIONING IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA

FLAMSA-BASED HIGH-DOSE SEQUENTIAL CONDITIONING REGIMEN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): IS IT EFFECTIVE IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED ACUTE LEUKEMIA?

INCREASING IN SERUM TOTAL AMYLASE LEVELS AFTER TOTAL BODY IRRADIATION CONDITIONING REGIMEN AS A PREDICTIVE MARKER OF TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS

EVOLUTION OF DONOR CHIMERISM AFTER HAPLOIDENTICAL STEM CELL TRANSPLANT - CLINICAL CORRELATIONS

THIOTEPA-BUSULFAN-FLUDARBINE AS CONDITIONING REGIMEN FOR PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

THE RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA-HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE REGIMEN IN CHILDREN

ANALYSIS OF DIFFERENCES IN PREVENTIVE MEASURES AFTER HIGH-DOSE CYCLOPHOSPHAMIDE AMONG BELGIAN STEM CELL TRANSPLANT CENTRES

IRRADIATION-FREE RE-CONDITIONING FOR T-CELL DEPLETED HAPLO-IDENTICAL STEM CELL TRANSPLANTATION

LOW GRAFT CD4 CELL DOSE PREDICTS RELAPSE IN THE ATG-BASED MYELOABLATIVE CONDITIONING REGIMEN
CLINICAL EFFICACY OF HAPLOID TRANSPLANTATION WITH BU/CY/MEL PRETREATMENT SCHEME TO IMPROVE 68 CASES OF UNICENTRIC REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA

REDUCING INTENSITY CONDITIONING (RIC) PROTOCOL HARMONISATION IN THE UK

HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN HIGH-RISK HEMATOLOGICAL MALIGNANCIES, ALGERIAN EXPERIENCE

INTERUPTION OF CONDITIONING FOR ALLO-HCT DOES NOT AFFECT CLINICAL OUTCOMES OTHER THAN CHRONIC GVHD

THERAPEUTIC DRUG MONITORING OF BUSULFAN IN PEDIATRIC POPULATION

REDUCED INTENSITY CONDITIONING FOLLOWED BY HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION (RIC-HAPLOHCT) AND POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS, FOR HEMATOLOGICAL DISORDERS: SINGLE CENTRE EXPERIENCE

HIGH DOSE TREATMENT WITH LEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION DURING THE SHORTAGE OF MOSTLY USED AGENTS IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA

REDUCED DOSE ALEMTUZUMAB IN REDUCED INTENSITY CONDITIONING VOLUNTEER DONOR UNRELATED TRANSPLANT FOR MYELOID MALIGNANCIES IS SAFE AND EFFICACIOUS. A SINGLE CENTRE EXPERIENCE

DESCRIBE AND EXPLORE A PATIENTS’ OUTLOOK ON DENTAL CARE IN THE CONTEXT OF THEIR MEDICAL DIAGNOSIS AND TREATMENT PRIOR TO AND FOLLOWING ALLOGENEIC HSCT

SAFETY AND EFFICACY OF LOW-DOSE BENDA-EAM AS COMPARED TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION OF REFRACTORY/RELAPSED LYMPHOMA PATIENTS

CONDITIONING REGIMEN WITH FLUDARABIN/TREOSULFAN COMPARED TO BUSULFAN/CYCLOPHOSPHAMID PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN YOUNGER PATIENTS WITH AML AND MDS: A SINGLE CENTER RETROSPECTIVE ANALYSIS

OUTCOMES OF UNRELATED DONOR STEM CELL TRASPLANTATION WITH OR WITHOUT ANTI-THYMOCYTE GLOBULIN USED AS GRAFT-VERSUS HOST DISEASE (GVHD) PROPHYLAXIS: A SINGLE CENTER EXPERIENCE

BUSULFAN-FLUDARABINE CONDITIONING REGIMEN FOR CORD BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE TWO-CENTER STUDY

ATG IN CONDITIONING FOR SIBLING ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE

e-Posters
12:30 - 18:30
ePoster Area

Data Management

SUPPORTING TOOLS FOR ACCURATE DATA COLLECTION - DO WE GET THE BENEFIT?

ARE TRANSPLANTS TRULY AVAILABLE TO ALL, REGARDLESS OF GEOGRAPHY, SOCIOECONOMIC STATUS AND ETHNIC GROUP? A BSBMTCT REPORT

MISMATCHED DONOR AND GRADE 2 TO 4 ACUTE GVHD AS TWO-RISK MODEL FOR CYTOMEGALOVIRUS VIREMIA AND DISEASE AFTER ALLOGENEIC TRANSPLANTATION - SINGLE INSTITUTE ANALYSIS OF 1180 PATIENTS
Experimental stem cell transplantation

LOW-DOSE DECITABINE IMPROVES REFRACTORY PROLONGED ISOLATED THROMBOCYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A RANDOMIZED MULTICENTER CLINICAL TRIAL

AUTOPHAGY IN ENDOTHELIAL CELLS REGULATES THEIR HAEMATOPOIESIS-SUPPORTING ABILITY

2ND ALLO-HSCT FOR PATIENTS WHO DIAGNOSED RECURRENT ALL AFTER THE 1ST ALLO-HSCT

ESTABLISHING A TRANSPLANT SHARING PROGRAM

Experimental transplantation

SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECO SYSTEM MICROBIOTA BIO THERAPEUTICS

IMPACT OF GUT FUNGAL COMPOSITION ON OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

MONITORING HEMATOPOIETIC CELL MICROPARTICLES IN ALLOGRAFTS AND TRANSPLANT RECIPIENTS

EARLY HEPATIC COMPLICATIONS DURING THE FIRST YEAR AFTER BONE MARROW TRANSPLANTATION IN PATIENTS WITH LEUKEMIA

PERFORMANCE OF BONE MARROW TRANSPLANTATION CENTER IN IMAM REZA HOSPITAL, KERMANSHAH, IRAN

Gene Therapy

CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT β-THALASSEMIA

LENTIVIRAL HEMATOPOIETIC STEM AND PROGENITOR CELL GENE THERAPY (HSPC-GT) FOR METACHROMATIC LEUKODYSTROPHY (MLD): CLINICAL OUTCOMES FROM 33 PATIENTS

A SINGLE DOSE OF SHORT HALF-LIFE CD117 ANTIBODY DRUG CONJUGATE ENABLES HEMATOPOIETIC STEM CELL BASED GENE THERAPY IN NONHUMAN PRIMATES

LENTI-D HEMATOPOIETIC STEM CELL GENE THERAPY STABILIZES NEUROLOGIC FUNCTION IN BOYS WITH CEREBRAL ADRENOLEUKODYSTROPHY

SAFETY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH GENE ADDITION THERAPY FOR TRANSFUSION-DEPENDENT β-THALASSEMIA, SICKLE CELL DISEASE, AND CEREBRAL ADRENOLEUKODYSTROPHY
EX-VIVO AUTOLOGOUS HAEMATOPOIETIC STEM CELL GENE THERAPY IN MUCOPOLYSACCHARIDOSIS TYPE IIIA

Graft-versus-host disease - clinical

KD025 FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) - LONG-TERM FOLLOW-UP OF A PHASE 2A STUDY (KD025-208)

A PHASE 2 STUDY OF F-652, A NOVEL TISSUE-TARGETED RECOMBINANT HUMAN INTERLEUKIN-22 (IL-22) DIMER, FOR TREATMENT OF NEWLY DIAGNOSED ACUTE LOWER GI GVHD

THE MAGIC BIOMARKER ALGORITHM PREDICTS OUTCOMES FOR CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE

A NOVEL TREATMENT IN CHRONIC OCULAR GRAFT-VS-HOST DISEASE (OGVHD): A PHASE II CLINIC TRIAL WITH TRANSDERMAL PROGESTERONE

EARLY CD4+ T-CELL RECONSTITUTION IS AN EXCELLENT PREDICTOR OF OUTCOMES IN PEDIATRIC PATIENTS WHO DEVELOP MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST-DISEASE: A DUAL CENTER VALIDATION

EFFECT OF SINGLE OR DOUBLE MISMATCHES AT EACH HLA LOCUS ON THE OUTCOMES AFTER SINGLE CORD BLOOD TRANSPANTATION: THE JSHCT HLA WG STUDY

INTERIM ANALYSIS OF KD025-213: A PHASE 2, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KD025 IN SUBJECTS WITH CGVHD (THE ROCKSTAR STUDY)

ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) AND RITUXIMAB FOR IMMUNOMODULATION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT FAILURE IN PATIENTS WITH NON-MALIGNANT DISORDERS: RESULTS OF A MULTICENTRE, RANDOMIZED, OPEN-LABEL STUDY

EXPERIENCE USING DUAL T-CELL DEPLETION WITH ATG AND PTCY FOR GVHD PROPHYLAXIS IN RIC ALLOHCT USING IN 10/10 MATCHED RELATED AND UNRELATED DONORS

MACHINE LEARNING APPLIED TO THE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE IMPROVES SURVIVAL ESTIMATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

SINGLE-CELL MOLECULAR ANALYSIS DEFINES CHARACTERIZATION OF SPECIFIC T CELL SUBSETS CORRELATE WITH HUMAN CHRONIC GVHD AND BRONCHIOLITIS OBLITERANS

A PHASE II TRIAL EVALUATING THE USE OF THE HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PREVENTION

REDUCED CALCIUM SIGNALING IS ASSOCIATED WITH GVHD: RESULTS FROM PRECLINICAL ALLOSCT MODELS AND FROM A PROSPECTIVE MULTICENTER STUDY

IDENTIFICATION OF PREDICTIVE MODELS INCLUDING POLYMORPHISMS IN CYTOKINES GENES ASSOCIATED WITH ACUTE GRAFT VERSUS HOST DISEASE AND OVERALL SURVIVAL AFTER IDENTICAL HLA-ALLOGENEIC STEM-CELL TRANSPLANTATION

SEARCH FOR CIRCULATING ENDOTHELIAL CELLS OF DONOR ORIGIN AFTER ALLO-HSCT: POTENTIAL CLINICALLY RELEVANT IMPLICATIONS IN THE CONTEXT OF GRAFT-VERSUS-HOST DISEASE
DOUBLE LUNG TRANSPLANTATION IN ADULTS FOR CHRONIC PULMONARY GRAFT VERSUS HOST DISEASE AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

REDUCED INFLAMMATORY TISSUE INFILTRATION DURING INTESTINAL STEROID-REFRACTORY GVHD

IMPACT OF ANTITHYMOCYTE GLOBULIN DOSE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN STEM CELL TRANSPLANTATION FROM UNRELATED DONORS

DECREASED SOLUBLE HLA-E LEVELS IN PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION ARE ASSOCIATED WITH SEVERE ACUTE AND EXTENDED CHRONIC GRAFT-VERSUS-HOST DISEASE AND INFERIOR OVERALL SURVIVAL

EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON PRODUCTION OF SERUM SOLUBLE CD163: RELATIONSHIP TO IMMUNOSUPPRESSION AND DISEASE ACTIVITY IN CHRONIC GRAFT VERSUS HOST DISEASE

POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE OVERCOMES THE DETRIMENTAL EFFECT OF A SINGLE-LOCUS HLA MISMATCHED IN UNRELATED DONOR ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

ALLOGENIC PERIPHERAL BLOOD TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS FROM HAPLOIDENTICAL AND MATCHED DONORS: ‘SIR-PTCY’ RESULTS IN 249 PATIENTS

A NEW HOPE IN THE TREATMENT OF STEROID-REFRACTORY GRAFT VERSUS HOST DISEASE (SR-GVHD) AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AH SCT): RUXOLITINIB

AZACITIDINE IS SAFE AND ACTIVE IN THE TREATMENT OF STEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST-DISEASE - INTERIM RESULTS OF THE PHASE II AZTEC TRIAL

BASILIXIMAB AS TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

EFFICACY AND TOLERANCE OF NILOTINIB IN PATIENTS WITH REFRACTORY CHRONIC GVHD WHO ARE REFRACTORY/INTOLERANT TO IMATINIB: A PROSPECTIVE MULTICENTER PHASE II STUDY OF THE SF GM-TC

EVALUATION OF THE PROGNOSTIC VALUE OF HISTOLOGIC ASSESSMENT OF ACUTE GRAFT-VERSUS-HOST-DISEASE OF THE UPPER GASTROINTESTINAL TRACT ACCORDING TO LERNER EARLY AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION

CYCLOSPORINE A ALONE VERSUS MYCOPHENOLATE MOFETIL PLUS CYCLOSPORINE A BASED GVHD PROPHYLAXIS FOR PATIENTS WITH AML UNDERGOING MUD TRANSPLANTATION. A STUDY FROM THE ALWP

TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS INDEPENDENTLY ASSOCIATED WITH RUXOLITINIB ADMINISTRATION IN PATIENTS WITH GRAFT-VERSUS-HOST-DISEASE

DIAGNOSTIC SIGNIFICANCE OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD)

LONG TERM OUTCOMES OF RUXOLITINIB THERAPY IN STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN AND ADULTS

INVESTIGATING ANTIBIOTIC EXPOSURE AND RISK OF SEVERE ACUTE GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EFFICACY AND TOXICITY OF RUXOLITINIB IN PATIENTS WITH STEROID-RESISTANT ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION

PATIENT CHARACTERIZATION AND SURVIVAL OUTCOMES IN PAEDIATRIC CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS: A POPULATION-BASED STUDY IN SWEDEN

CYTOKINE LEVELS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION: A MATCH-PAIR ANALYSIS OF HOME CARE VERSUS HOSPITAL CARE

FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH STEROID-RESISTANT GRAFT VERSUS HOST DISEASE COLONIZED BY ANTIBIOTIC-RESISTANT BACTERIA - SINGLE-CENTER ANALYSIS OF 15 PROCEDURES

INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE: RESULTS FROM A PROSPECTIVE MULTICENTRE ANALYSIS OF 2 COHORTS

THE CXCL9 POLYMORPHISM RS884304 COUNTERACTS CALCINEURIN-INHIBITOR REPRESSION OF EARLY CXCL9 RECONSTITUTION AND ASSOCIATES WITH SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE

EARLY INTRODUCTION OF RUXOLINITIB FOR CHILDREN WITH GRAFT VERSUS HOST DISEASE - A STITCH IN TIME SAVES NINE

POST-TRANSPLANT CYCLOPHOSPHAMIDE AS AN EFFECTIVE STRATEGY FOR GVHD PREVENTION IN BOTH HLA-MATCHED AND MISMATCHED ALLOGENEIC TRANSPLANTS

SERUM AUTOANTIBODIES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY

OPTIMIZED STARTING DOSE OF CYCLOSPORINE REDUCES RISK OF ACUTE GVHD AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

SUCCESS OF IMMUNOSUPPRESSION IN PATIENTS WITH CHRONIC GVHD: ANALYSIS ON 108 ADULT LONG-TERM SURVIVORS AFTER MATCHED AND HAPLO HSCT

INCIDENCE AND OUTCOME OF LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE DURING TAPERING OR AFTER STOPPING CALCINEURIN INHIBITORS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING AND MATCHED UNRELATED COMPARED TO HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, A STUDY ON BEHALF OF GETH

MESENCHYMAL STROMAL CELLS (MSC) FOR STEROID-REFRACTORY ACUTE GVHD, A SINGLE CENTER PHASE I/II TRIAL

T-LYMPHOCYTE TRANSCRIPTIONAL SIGNATURE IN ECP-TREATED PAEDIATRIC PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE

EFFICACY OF LOW-DOSE RUXOLITINIB AS SAVAGE THERAPY IN HEAVILY PRETREATED PATIENTS WITH MODERATE/SEVERE STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE

RESTRICTIVE USE OF INTRAVENOUS ANTIBIOTICS IN ALLOGENEIC SCT PTS WITH FEVER DUE TO CYTOKINE RELEASE SYNDROME ALLOWS MICROBIOTA PROTECTION WITHOUT INCREASE OF INFECTIONS AND TRM

EXTRACORPOREAL PHOTOPHERESIS (ECP) AS FIRST-LINE TREATMENT FOR ACUTE GVHD (AGVHD) IN PEDIATRIC PATIENTS WHO UNDERWENT T-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION (APLO-HSCT)
EFFICACY OF METHOXSALEN STERILE SOLUTION IN CONJUNCTION WITH THE THERAKOS (R) CELLEX (R) PHOTOPHERESIS SYSTEM IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD: INTERIM ANALYSIS

MICRO RNA PROFILING OF ACOUSTICALLY-ISOLATED EXTRACELLULAR VESICLES IDENTIFIES POTENTIAL BIOMARKERS FOR POST-ALLO-HSCT COMPLICATIONS

COLONIZATION PLAYS AN IMPORTANT ROLE IN THE OUTCOME OF ALLOGENEIC TRANSPLANTATION

ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) SCORE AT THE ONSET OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PREDICTING OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION-A RETROSPECTIVE ANALYSIS

CARFILZOMIB IN ADDITION TO STANDARD CYCLOSPORINE/ METHOTREXATE COMBINATION EFFECTIVELY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS

COMPARISON OF EXCLUSIVE POSTTRANSPLANT CYCLOPHOSPHAMIDE VERSUS A CALCINEURIN INHIBITOR BASED REGIMEN AS GVHD PROPHYLAXIS IN ALLOGENEIC BONE MARROW TRANSPLANTATION FROM HLA IDENTICAL SIBLING

SIROLIMUS VERSUS CYCLOSPORINE WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND MYCOPHENOLATE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN HAPLOIDENTICAL TRANSPLANTS: A RETROSPECTIVE ANALYSIS OF ONE SINGLE INSTITUTION

TARGETED SEQUENCE CAPTURE METAGENOMICS (VIROCAP) TO DETECT VIRUS IN STOOL SAMPLES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS

EXTRACORPOREAL PHOTOPHERESIS AND PRODUCTION OF SERUM IL-34 AND ELAFIN IN CHRONIC GRAFT VERSUS HOST DISEASE

IMPACT OF UPPER AND LOWER ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE ON GRADING AND OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS IN 122 CONSECUTIVE PATIENTS

PRELIMINARY EXPERIENCE WITH THE USE OF RUXOLITINIB, IBRUTINIB OR IMATINIB FOR THE TREATMENT OF ACUTE OR CHRONIC GVHD

RUXOLITINIB WITH OR WITHOUT IBRUTINIB AS AN ALTERNATIVE FIRST LINE THERAPY FREE OF CORTICOSTEROIDS OR CALCINEURIN INHIBITORS IN TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE

CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS

IMPACT OF KIR/HLA INCOMPATIBILITIES AFTER POSTTRANSPLANT CYCLOPHOSPHAMIDE BASED T CELL-REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

ELEVATED PTH LEVELS AMONG CHRONIC GRAFT-VERSUS-HOST DISEASE PATIENTS AND OTHER LONG TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

CONCURRENCE OF GVHD AND NON-INFECTIOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION
ACUTE GVHD INCIDENCE IN MISMATCHED UNRELATED DONOR HSCT IN PAEDIATRIC ADULT PATIENTS: A STUDY FROM THE TURIN METROPOLITAN TRANSPLANT CENTER

PRACTICAL IMPLEMENTATION OF THE NIH DIAGNOSTIC CRITERIA FOR ORAL CHRONIC GVHD IN A MULTIDISCIPLINARY TEAM IN THE LATE FOLLOW UP OF ALLOGENIC HSCT PATIENTS

THE IMPACT OF ANTIBIOTIC-MEDIATED MODIFICATION OF THE INTESTINAL MICROBIOME ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: SYSTEMATIC REVIEW AND META-ANALYSIS

CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS FROM WHARTON’S JELLY IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE

PREDICTIVE ROLE OF ENDOSCOPIC/HISTOLOGICAL EXAMINATIONS FOR GASTRO-INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM CELLS TRANSPLANT: ‘A POSTERIORI’ ANALYSIS IN A SINGLE CENTER

THE INCIDENCE, RISK FACTORS, AND OUTCOMES OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

PROGNOSTIC CT FINDINGS AROUND THE ONSET OF ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE

THYMoglobulin and grafalon effect on allogeneic stem cell transplant - pooled data from wroclaw medical university, Poland and university medical center ljubljana, Slovenia

THE ROLE OF LOW-DOSE ANTI-THYMOCYTE GLOBULIN IN MATCHED SIBLING DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES

NEPHROTIC SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AS A FORM OF CHRONIC GRAFT versus HOST DISEASE: SINGLE CENTER EXPERIENCE

CORRELATION AMONG TOTAL NUCLEATED CELLS (TNC), CD34+, CD3+ CELL CONTENT IN G-CSF-PRIMED BONE MARROW COLLECTIONS AND THEIR RELATIVE INFLUENCE ON DEVELOPMENT OF ACUTE GVHD

PREDICTION FOR LETHAL ACUTE GRAFT VERSUS HOST DISEASE AND NON-RELAPSE MORTALITY BY EARLY PLASMA BIOMARKERS: A SINGLE CENTER RETROSPECTIVE STUDY IN JAPAN

RUXOLITINIB IN THE TREATMENT OF CORTICOSTEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD): ONE SINGLE CENTER EXPERIENCE

OUTCOME OF PATIENTS ALIVE AT 1-YEAR POST ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM A SINGLE INSTITUTION

RUXOLITINIB IN STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: EXPERIENCE IN OUR CENTRE

LOW-DOSE OF RUXOLITINIB: AN EFFECTIVE THERAPY FOR REFRACTORY BOS PATIENTS

SIROLIMUS BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PAEDIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT FOR BENIGN DISEASE

DETECTION OF BIOMARKERS PREDICTIVE OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY

OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) AFTER PD-1 BLOCKADE IN RELAPSED/REFRACTORY (R/R) LYMPHOMAS: A SINGLE CENTER EXPERIENCE
CD3+ DOSE IN PERIPHERAL BLOOD PROGENITOR CELLS PRODUCTS FOR ALLOTRANSPLANT FROM MATCHED UNRELATED DONORS FOR AML: IMPACT ON CHRONIC GRAFT VERSUS HOST DISEASE AND SURVIVAL

CYCLOPHOSPHAMIDE FOR SALVAGE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE ANALYSIS

A ROLE OF METHOTREXATE IN THE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE - A MULTICENTER OBSERVATIONAL STUDY ON BEHALF OF POLISH ADULT LEUKEMIA GROUP (PALG)

EVALUATION OF EXTRACORPOREAL PHOTOPHERESIS USED AS SECOND-LINE TREATMENT FOR GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HSCT IN A BRAZILIAN CENTER

THE OPTIMAL GVHD PROPHYLAXIS IN UNRELATED TRANSPLANTATIONS OF NON-MANIPULATED HEMATOPOIETIC STEM CELLS IN CHILDREN

ANALYSIS OF HISTOLOGY'S IMPACT IN PATIENTS WITH ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE

IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT). UNICENTRIC EXPERIENCE

FECAL MICROBIOTA TRANSPLANTATION FOR Treating STERoid-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE OF THE GUT: A PILOT STUDY

EARLY RECOVERY OF LYMPHOCYTES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS RISK FACTOR OF CGVHD

FAVORABLE OUTCOME USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN HAPLOIDENTICAL (HAPLO-SCT) AND MATCHED RELATED DONORS (MRD): SINGLE CENTER EXPERIENCE IN CHILE

COMBINED THERAPY WITH MSC INFUSIONS TO OVERCOME STERoid-DEPENDENCY IN A CASE OF SEVERE PULMONARY CGVHD

MULTIPLE STRICTURES OF THE SMALL INTESTINE DEMANDING SURGICAL INTERVENTION AS A COMPLICATION OF GRAFT VERSUS HOST DISEASE: A CASE REPORT

A REMARKABLY LONG REMISSION ACHIEVED WITH IBRUTINIB MONOTHERAPY IN A PATIENT WHO WAS DIAGNOSED WITH STEROID REFRACTORY SCLEROSING CHRONIC GVHD

INCREASED RISK OF ACUTE GVHD IN PATIENTS WITH MYELOFIBROSIS AFTER ALLO TRANSPLANT IN THE ABSENCE OF JAK-STAT INHIBITION

AUTOIMMUNE MYOSITIS AS PARANEOPLASTIC COMPLICATION OF A SQUAMOUS CELL CARCINOMA OF THE TONGUE AFTER SEVERE CHRONIC GRAFT VERSUS HOST DISEASE

UNUSUAL CAUSE OF DYSPNEA IN POST-TRANSPLANT PATIENT

e-Posters
12:30 - 18:30

Graft-versus-host disease - preclinical and animal models

DIETARY STEARIC ACID LEADS TO A SEVERE AGVHD BY MODULATING THE GUT MICROBIOTA AND GLUCOSE METABOLISM
Scientific Programme

GRANULOCYTE COLONY-STIMULATING FACTOR-PRIMED DONOR T CELLS ATTENUATE MURINE ACUTE GVHD THROUGH REGULATING T CELL DIFFERENTIATION IN TARGET ORGANS

MTOR REGULATE GENERATION AND FUNCTION OF PMN-MDSCS AND PLAY PROTECTION ROLE IN ACUTE GRAFT-VERSUS-HOST DISEASE

FULL REGULATORY T CELL RECONSTITUTION BEFORE T CELL TRANSFER PREVENTS GRAFT-VERSUS-HOST DISEASE BY SUPPRESSING COSTIMULATION AND T CELL ACTIVATION IN A HAPLOIDENTICAL MODEL

TARGETING OF CHEMOKINE RECEPTOR 7 PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE

ENHANCING REGULATORY T CELL FUNCTION AND HOMING TO THE GUT TO IMPROVE GRAFT-VERSUS-HOST DISEASE PREVENTION AFTER ADOPTIVE TRANSFER IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION

LYG1-DEFICIENT DONOR SPLENOCYTES ATTENUATED THE SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE VIA SKewing CD4+ T CELL POLARIZATION TOWARDS TREG CELLS

ATTENUATION OF MURINE CHRONIC GRAFT VERSUS HOST DISEASE BY THE NRF2 ACTIVATOR MANGIFERIN

CHEMOTHERAPY AND INFLAMMATION INDUCED DAMAGE OF INTESTINAL EPITHELIUM IS ASSOCIATED WITH INCREASED T CELL CHEMOTAXIS

INKT CELLS PROMOTE IMMUNE TOLERANCE BY SELECTIVE DENDRITIC CELL APOPTOSIS

ACTIVE PARTICIPATION OF CXCR4+ T LYMPHOCYTES IN ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC TRANSPLANTATION

A MURINE MODEL REVEALS A CRITICAL ROLE FOR REACTIVE OXYGEN SPECIES IN HYPERACUTE GRAFT-VERSUS-HOST DISEASE

MAPPING THE ROAD OF GVHD AND GVT. A LONGITUDINAL STUDY OF IMMUNE-TRANSCRIPTOME SIGNATURES AS NOVEL APPROACH TO SOLVE POST-ALLOGENEIC TRANSPLANTATION DILEMMAS

CELL-FREE DNA LEVELS ARE INCREASED IN ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS AND MICE

DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION

ENDOTHELIAL MICROPARTICLES DELIVERING LNCRNA NEAT1 ARE INVOLVED IN THE PATHOPHYSIOLOGY OF AGVHD FOLLOWING ALLO-HSCT

B-T CELL INTERACTIONS IN GRAFT-VERSUS-HOST DISEASE

IDENTIFICATION OF POTENTIAL MICROBIOME MARKERS FOR AGVHD EARLY DIAGNOSIS

e-Posters
12:30 - 18:30

Granulocyte and osteoclast disorders

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR OSTEOPETROSIS
Haematopoietic stem cells

HAPLOIDENTICAL DONOR BEATS MATCHED SIBLING DONOR FOR PRE-TRANSPLANTATION MRD POSITIVE ALL: A PHASE 3 BIOLOGICALLY RANDOMIZED STUDY

RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED RELATED DONOR WITH TCRαβ+/CD19+-DEPLETION AND A FIXED DOSE MEMORY T CELL (CD45RA-DEPLETED) ADD-BACK

CLONAL DYNAMICS AND GENOMIC INTEGRITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN HUMAN ALLOGENIC TRANSPLANTATION RECIPIENTS

ALLOGENIC TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELL GRAFTS RESULTS IN A MASSIVE DECREASE OF PRIMITIVE HEMATOPOIETIC PROGENITOR FREQUENCIES IN RECONSTITUTED BONE MARROWS

TREATMENT OF PURE RED CELL APLASIA AFTER MAJOR ABO INCOMPATIBLE ALLOGENIC STEM CELL TRANSPLANTATION: A FRENCH RETROSPECTIVE STUDY

FEASIBILITY AND OUTCOMES OF A THIRD ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM THE ALWP OF EBMT

CHANGES IN VIABILITY MARKERS OF HAEMATOPOIETIC STEM CELLS FOLLOWING LONG-TERM CRYOPRESERVATION

HIGH PRE-TRANSPLANT INTERLEUKIN-18 IS ASSOCIATED WITH POOR HEMATOPOIETIC RECOVERY AFTER ALLOGENIC STEM CELL TRANSPLANTATION AND PREDICTS INCREASED NON-RELAPSE MORTALITY

MICROBIAL DIVERSITY, SURVIVAL, AND ACUTE GVHD IN ADULT RECIPIENTS OF ALLO-HSCT AFTER MYELOABLATIVE CONDITIONING: RESULTS OF A NUTRITIONAL INTERVENTION TRIAL

UK EXPERIENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACTivating PI3K MUTATIONS

RECONSTRUCTION OF THE DONOR-RECIPIENT HAEMATOPOIETIC CELL PHYLOGENY USING SOMATIC MUTATIONS TO ESTABLISH NUMBERS OF ENGRAFTING LONG-TERM HSCS IN REAL-WORLD TRANSPLANTATION

SUCCESSFUL CLEARANCE OF DONOR SPECIFIC ANTI-HLA ANTIBODIES AFTER DESSENSITIZATION WITH RITUXIMAB, VELCADE AND PLASMA-EXCHANGE FOLLOWED BY A HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

IMPACT OF PRE-TRANSPLANTATION MINIMAL RESIDUAL DISEASE DETERMINED BY FLOW CYTOMETRY ON OUTCOME OF ACUTE LEUKEMIA PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

ECONOMIC BURDEN OF CYTOMEGALOVIRUS INFECTION IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SPANISH MULTICENTER, RETROSPECTIVE STUDY

INCIDENCE AND OUTCOME OF CLONAL AND MALIGNANT TRANSFORMATION (CMT) AMONG PEDIATRIC PATIENTS WITH INHERITED BONE MARROW FAILURE SYNDROMES (IBMFSS)

IMPACT OF POST-TRANSPLANT IMMUNOSUPPRESSION WEA VS. BOOST IN EARLY MIXED CHIMERISM FOLLOWING G-CSF-PRIMED MARROW TRANSPLANT IN THALASSEMIC PATIENTS

COMPARISON OF THE CONDITIONING REGIMENS WITH TMLI, NON-RADIATION AND TBI FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
VALIDATION OF DISEASE RISK COMORBIDITY INDEX (DRCI) FOR OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) WITH PARTIALLY T-CELL DEPLETED GRAFT

ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS PRETREATED WITH JAK1/JAK2 INHIBITORS

THE DETERMINATIVE ROLE OF PATIENT-CONTROLLED-ANALGESIA (PCA) IN THE EARLY COURSE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

HIGH SURVIVAL RATE AND LOW INCIDENCE OF AGVHD AFTER CD34+ STEM CELLS SELECTION AND CD3+ T CELLS ADDBACK IN PEDIATRIC MUD HSCT

IMPACT OF ABO INCOMPATIBILITY ON OUTCOMES AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA

COMPARISON OF OUTCOMES AFTER HAPLOIDENTICAL VERSUS UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER REVIEW

EFFECT OF DIFFERENT TIMINGS OF UMBILICAL CORD CLAMPING ON THE LEVEL OF CD34+ CELLS IN FULL-TERM NEONATES

SEQUENTIAL CONDITIONING REGIMEN (FLAMSA-BU-MEL) IN HLA-MATCHED OR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN REFRACTORY MYELOID DISEASE

SEQUENCE CYTOREDUCTIVE CHEMOTHERAPY FOLLOWED BY MA CONDITIONING REGIMEN HSCT WITH INTERMEDIATE - OR ADVERSE RISK AML IN CR: A SINGLE CENTER STUDY

INVESTIGATION OF VIROLOGICAL FEATURES AND CLINICAL OUTCOMES ASSOCIATED WITH PRE-ENGRAFTMENT CYTOMEGALOVIRUS DNAEMIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS

CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE AS A PREDICTOR OF ENGRAFTMENT AND SURVIVAL IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

USE OF PLERIXAFOR IN POOR MOBILIZER PATIENTS WITH MYELOMA AND LYMPHOMA: CLONOGENIC CAPACITY AND ENGRAFTMENT DATA

OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRICS: A SINGLE CENTER EXPERIENCE FROM INDIA

RELAPSE/REFRACTORY FOLLICULAR LYMPHOMA: LONG TERM OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA

PRE-EMPTIVE USE OF SORAFENIB COMBINED WITH DLI POST HSCT IN AML FLT3+: A SINGLE CENTER EXPERIENCE

USE OF ELTROMBOPAG FOR THE MANAGEMENT OF POOR GRAFT FUNCTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN

TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH ELTROMBOPAG

EFFICACY OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED TO CHEMOTHERAPY AS POST-REMISSION TREATMENT FOR CHILDREN WITH INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION

THE TREATMENT OF BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA IRREVERSIBLY DEPLETES NAIVE T LYMPHOCYTES

DESENSITIZATION PROTOCOL IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH ANTI-HLA DONOR-SPECIFIC ANTIBODIES (DSA): A SINGLE-CENTER EXPERIENCE

ASSOCIATION BETWEEN METABOLIC ALTERATION WITH TYPE AND INDICATION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION

RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES FOR PATIENTS RECEIVING UMBILICAL CORD BLOOD TRANSPLANTS AT THE ROYAL MARSDEN HOSPITAL BETWEEN 2007 AND 2017

HIGHER COST AND NO SURVIVAL BENEFIT WITH ADDITION OF RITUXIMAB TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL

ASSOCIATION BETWEEN METABOLIC ALTERATIONS WITH AGE AND GENDER OF PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION

HAPLOIDENTICAL HSCT IN CHILDREN WITH VERY HIGH-RISK HAEMATOLOGIC MALIGNANCIES: A SINGLE-CENTRE EXPERIENCE

COMPARATIVE STUDY OF THE HEMATOPOIETIC RECONSTITUTION INFUSED TOTAL NUCLEATED CELL DOSE IS NOT ASSOCIATED WITH ENGRAFTMENT IN AUTOLOGOUS STEM CELL TRANSPLANTATION

A COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND BFM 95 CHEMOTHERAPY PROTOCOL IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

THE IMPACT OF CD34+ CELL AND IMMUNEFECTOR CELL DOSE ON TRANSPLANT OUTCOMES

TREOSULFAN COMBINED WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANTATION OF MYELOID DISEASES, ALLOWS HIGH OVERALL SURVIVAL WITH LOW RELATED TOXICITY

OUTCOME OF RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

MOTIVATION FOR ANTIFUNGAL USE IN PEDIATRIC HSCT PATIENTS IN AN INSTITUTION IN SOUTHERN BRAZIL

IMPACT OF THE USE OF GRANULOCYTIC COLONY-STIMULATING FACTOR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN RARE FORMS OF PRIMARY IMMUNODEFICIENCIES (PIDS) IN ARGENTINA

PHASE II STUDY OF PLERIXAFLOR AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL, PET POSITIVE AFTER TWO R-DHAP

THE EFFECT OF CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE ON THE HEMATOPOIETIC RECOVERY AND SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION

THE EVENTUAL ROLE OF DONOR AND RECIPIENT VITAMIN D LEVELS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT SETTING

AVERAGE LENGTH OF HOSPITAL STAY FOR PEDIATRIC BLOOD AND MARROW TRANSPLANTS IN THE BACKDROP OF CELL SOURCE, TRANSPLANT TYPE AND OUTCOME
ONE CENTER EXPERIENCE IN OFFLINE TECHNIQUE VALIDATION WITH BIOLOGICAL QUALITY TESTS

A MONOCENTRIC CLINICAL OBSERVATION OF ALLOGENEIC TRANSPLANTATION IN 22 PATIENTS WITH ACUTE MEGAKARYOCYTIC LEUKEMIA

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN IN SCIENTIFIC CENTRE OF PEDIATRICS AND CHILD SURGERY

THE OUTCOME OF ALLOTRANSPLANT USING TBF CONDITIONING FROM MATCHED SIBLING RELATED DONORS IN HIGH RISK MYELODYSPLASIA AND ACUTE MYELID LEUKEMIA: A RETROSPECTIVE SINGLE CENTER EXPERIENCE

EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA: RETROSPECTIVE ANALYSIS IN OUR CENTER

CARDIOVASCULAR RISK IN PATIENTS BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

INFECTIONS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PEDIATRIC RECIPIENTS IN PERU: EXPERIENCE OF A REFERRAL CENTER

HAEMATOPOIETIC STEM CELL PRODUCT VIABILITY: A COMPARATIVE STUDY BETWEEN BAGS AND VIALES

TRANSFUSION SUPPORT IN THE FIRST 30 AND 100 DAYS AFTER HAPLOIDENTICAL VERSUS HLA-MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MACS IN A PERUVIAN HEALTH CHILDRENS INSTITUTE: THREE-YEAR EXPERIENCE

COLLECTION, CRYOPRESERVATION AND AUTOLOGOUS TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELLS IN KAUNAS, LITHUANIA 2015-2019

EVALUATION OF OVERALL SURVIVAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT): UNICENTRIC EXPERIENCE

MONITORING OF THE EXPRESSION OF THE VEGF-A GENE (VASCULAR ENDOTHELIAL GROWTH FACTOR) DURING THE EVOLUTION OF PEDIATRIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION. A PILOT STUDY

REFRACTORY T-CELL CUTANEOUS LYMPHOMA TREATED WITH ALLOGENEIC HAPLOIDENTIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT

VITAMIN D DEFICIENCY AND OUTCOMES IN ADULT ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE OVER LAST YEARS

CAUSES OF COMPLICATIONS IN ADULTS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

e-Posters

12:30 - 18:30

ePoster Area

Haemoglobinopathy and inborn errors
SUCCESSFUL HLA-MISMATCHED HSCT IN PAEDIATRIC PATIENTS WITH HEMOGLOBINOPATHIES USING ATG SEROTHERAPY AND POSTTRANSPLANT CYCLOPHOSPHAMIDE

OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH CEREBRAL ADRENOLEUKODYSTROPHY VARY BY DONOR CELL SOURCE, CONDITIONING REGIMEN, AND STAGE OF CEREBRAL DISEASE STATUS

OUTCOME OF NON MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE SICKLE CELL DISEASE: A 100 PATIENT EXPERIENCE FROM SAUDI ARABIA

HIGH DOSE STEM CELL THERAPIES, LIKE MGTA-456, ENABLE COMPLETE NEURAL AND PERIPHERAL DISEASE CROSS-CORRECTION THROUGH RAPID AND ROBUST HEMATOPOIETIC ENGRAFTMENT

HLA SET-UP IS A MAJOR PREDICTOR OF ENGRAFTMENT IN HAPLO-IDENTICAL TRANSPLANT FOR SEVERE THALASSEMA (ST) USING POST-CYCLOPHOSPHAMIDE (PTCY)

CTLA4IG-BASED T CELL COSTIMULATION BLOCKADE IN PTCY BASED HAPLOIDENTICAL HCT FOR THALASSEMA MAJOR [TM] AND SICKLE CELL DISEASE [SCD] RESULTS IN IMPROVED DISEASE-FREE SURVIVAL WITHOUT GVHD

LENTIGLOBIN GENE THERAPY TREATMENT OF TWO PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA

BONE MARROW TRANSPLANT IN PATIENTS WITH SICKLE CELL ANAEMIA. EXPERIENCE IN ONE CENTRE

Marina García Morín, Laura Escobar Fernández, Eduardo Bardón Cancho, Cristina Beléndez Bieler, Jorge Huerta Aragonés, Carmen Garrido Colino, Cristina Mata Fernández, Elena Cela de Julián (Spain)

OUTCOMES IN CEREBRAL ADRENOLEUKODYSTROPHY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE

NEURODEVELOPMENTAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MUCOPOLYSACCHARIDOSIS TYPE II: A PROSPECTIVE, LONGITUDINAL STUDY

HEMATOPOIETIC RECOVERY AND TRANSFUSION NEED AFTER HAPLOIDENTICAL TRANSPLANTATION IN BETA THALASSEMA PATIENTS

PRE- AND POST-TRANSPLANT RITUXIMAB REDUCES THE HIGH INCIDENCE OF PRIMARY GRAFT FAILURE AND IMMUNE-MEDIATED CYTOPENIA FOLLOWING CORD BLOOD TRANSPLANT FOR LYSOSOMAL STORAGE DISEASE IN CHILDREN

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE: THE SPANISH EXPERIENCE

LONG-TERM QUALITY OF LIFE IN PATIENTS WITH THALASSEMA MAJOR FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD

HIGH INCIDENCE OF AUTOIMMUNE CYTOPENIAS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH THALASSEMA AND SICKLE CELL DISEASE: THE IMPACT OF MATCHED UNRELATED DONOR

ADDING AZATHIOPRINE/HYDROXYUREA PRECONDITIONING TO ALEMTUZUMAB/TBI MAY REDUCE RISK OF GRAFT FAILURE IN MATCHED SIBLING DONOR ALLOGENEIC HSCT IN ADULT SICKLE CELL PATIENTS

A PHASE II STRATIFIED TRIAL TO ASSESS HAPLOIDENTICAL T-DEPLETED STEM CELL TRANSPLANTATION IN PATIENTS WITH SICKLE CELL DISEASE WITH NO AVAILABLE SIBLING DONOR
Scientific Programme

COMBINED UMBILICAL CORD BLOOD AND BONE MARROW FROM HLA-IDENTICAL SIBLING DONORS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMIA MAJOR

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF METABOLISM USING ALTERNATE DONORS: A PROSPECTIVE SINGLE STUDY

UMBILICAL CORD BLOOD TRANSPLANTATION IN CHILDREN WITH LEUKODYSTROPHIES: SINGLE CENTER EXPERIENCE IN CHINA

PEARSON SYNDROME IN A PATIENT TRANSPANTED FOR DIAMOND-BLACKFAN ANEMIA

CHALLENGES AND SUCCESSES WITH PRE-TRANSPLANT IMMUNE SUPPRESSION IN ALTERNATIVE DONOR TRANSPLANTS

HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CLASS 3 THALASSEMIA MAJOR USING POST-TRANSPLANT CYCLOPHOSPHAMIDE

Immunodeficiency diseases and macrophages

IMPACT OF DIFFERENT \textit{ex vivo} T-CELL DEPLETION STRATEGIES ON OUTCOMES FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY

OUTCOMES AND IMMUNE RECONSTITUTION AFTER T-CELL REPLETE HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FOR PEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCIES

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY IN JAPAN: OVERVIEW OF A NATIONWIDE RETROSPECTIVE ANALYSIS

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY IN JAPAN: A NATIONWIDE RETROSPECTIVE ANALYSIS

UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY: SINGLE-INSTITUTION EXPERIENCE IN CHINA

IMMUNODEFICIENCY - CENTROMERIC INSTABILITY - FACIAL DYSMORPHISM (ICF) SYNDROME: EVALUATION OF CHARACTERISTICS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

THIOTEPA VERSUS MELPHALAN CONTAINING CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATIONS WITH TCR\textsubscript{a}\textsubscript{b}/CD19 GRAFT DEPLETION FOR PRIMARY IMMUNODEFICIENCIES

IMPROVED TRANSPLANT SURVIVAL AND LONG-TERM DISEASE OUTCOME FOR CHILDREN WITH CD40 LIGAND DEFICIENCY

HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES INCLUDING IMMUNE RECONSTITUTION IN PRIMARY IMMUNODEFICIENCIES: 5 YEARS OF SINGLE CENTRE EXPERIENCE

OUTCOMES OF STEM CELL TRANSPLANT FOR RIPK1 DEFICIENCY: A SINGLE CENTRE EXPERIENCE
Scientific Programme

IMPROVING THE RESULT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY WITH SERIOUS INFECTION IN DEVELOPING COUNTRIES USING RIC REGIMENT

SINGLE-CENTER EXPERIENCE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCR αβ DEPLETION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCY SYNDROMES

HAPLO-IDENTICAL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY - A TERTIARY CARE CENTRE EXPERIENCE FROM SOUTH INDIA

NECROTIZING ENTEROCOLITIS IN A TWO-MONTH-OLD SCID PATIENT AFTER BONE MARROW TRANSFUSION - SURGICAL INTERVENTION AT DAY +1: YES OR NO?

UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH TWO DIFFERENT CONDITIONING REGIMEN FOR CHRONIC GRANULOMATOUS DISEASE: SINGLE-INSTITUTION EXPERIENCE IN CHINA

THE OUTCOMES OF UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE IN CHILDREN WITH RAG GENE MUTATION

LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) IN ADA-SCID PATIENTS: THE SHADOW OF MALIGNANCIES

HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR X-LINKED AGAMMAGLOBULINAEMIA COMPLICATED BY CHRONIC NOROVIRUS ENTEROPATHY

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CD40 LIGAND DEFICIENCY

DIAGNOSTIC MARKERS FOR AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR CHRONIC GRANULOMATOUS DISEASE (CGD) IN CHILDHOOD

e-Posters
12:30 - 18:30

Infectious complications

PNEUMOCYSTIS PNEUMONIA AFTER ALLOGENEIC HCT: A CASE-CONTROL STUDY ON RISK FACTORS, TIMING, AND PCR USE, FROM THE IDWP OF EBMT

UPPER AND/OR LOWER RESPIRATORY TRACT INFECTION CAUSED BY HUMAN CORONAVIRUS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

SUCCESSFUL TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WITH JCV-TARGETED T-CELL THERAPY

EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY

TUBERCULOSIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT

FAECAL MICROBIOTA TRANSPLANT (FMT) CAN REDUCE THE HIGH NRM ASSOCIATED WITH MULTI-DRUG RESISTANT ORGANISM (MDRO) COLONISATION PRIOR TO ALLOGENEIC HCT
EPIDEMIOLOGY, RISK FACTORS AND OUTCOMES OF CMV INFECTION IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT): A SINGLE INSTITUTIONAL COHORT STUDY

USE OF LETERMOVIR IN OFF-LABEL INDICATIONS: INFECTIOUS DISEASES WORKING PARTY EBMT RETROSPECTIVE STUDY

RISK OF INFECTIOUS Complications IN ADULT PATIENTS AFTER ALLOGENEIC HSCT DEPENDING ON THE SITE OF CENTRAL VENOUS CATHETER INSERTION - MULTICENTRE PROSPECTIVE STUDY

INFECTION PREVENTION PRACTICES AMONG EBMT HEMATOPOIETIC CELL TRANSPLANT CENTERS: A SURVEY OF THE INFECTIOUS DISEASES WORKING PARTY OF THE EBMT

PRIMARY LETERMOVIR PROPHYLAXIS IN CMV SEROPosITIVE PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL LIFE EXPERIENCE

HEV INFECTION IN HCT RECIPIENTS - RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY (IDWP) OF EBMT

THE ROLE OF COMBINATION PROPHYLAXIS IN PREVENTING CYTOMEGALOVIRUS (CMV) INFECTION AFTER EX VIVO AB T-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANT (HHCT) IN CHILDREN

IMPACT OF CMV SEROSTATUS AND CMV REACTIVATION AFTER HAPLOIDENTICAL-SCT WITH PT-CY

COMPARISON OF IMMUNE CELL RESPONSE TO CYTOMEGALOVIRUS PROTEINS VERSUS PEPTIDES USING AN IFN-γ ELISPOT ASSAY TO MONITOR CYTOMEGALOVIRUS-SPECIFIC IMMUNITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

HUMAN HERPESVIRUS TYPE 6 REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION: RISK FACTORS AND CLINICAL IMPACT

INCREMENTAL INPATIENT HEALTHCARE RESOURCE USE AND COSTS AMONG CMV SEROPOSITIVE ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS MANAGED THROUGH PREEMPTIVE APPROACH

POOR RECOVERY AND IMPAIRED FUNCTION OF V61+ T CELLS IN REFRACTORY/RECURRENT CMV REACTIVATION AFTER HEMATOPOIETIC TRANSPLANTATION

SAFETY AND EFFICACY OF BRINCIDOFOVIR FOR REFRACTORY ADENOVIRUS INFECTION IN CHILDREN RECEIVING ALLOGENEIC SCT: A RETROSPECTIVE ANALYSES FROM THE ITALIAN PEDIATRIC HEMATOLOGY ONCOLOGY ASSOCIATION (AIEOP)

ALLOPLUS: RESULTS OF THE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS -POSITIF PATIENTS, A RETROSPECTIVE STUDY OF THE SFGM-TC

SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN PATIENTS WHO UNDERWENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A PROSPECTIVE STUDY TO MEASURE FEASIBILITY, SAFETY AND HEALTH CARE RESOURCE USE

FREQUENCY, RISK FACTORS AND OUTCOME OF ACTIVE TUBERCULOSIS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

INFECTIOUS COMPLICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA AFTER NEW AGENTS' THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION

SURVEILLANCE FOR REACTIVATION OF TOXOPLASMA GONDII USING POLYMERASE CHAIN REACTION ASSAY AND PRE-EMPTIVE THERAPY AVOIDS UNIVERSAL PROPHYLAXIS AND PREVENTS SYMPTOMATIC INFECTION
Scientific Programme

CYTOMEGALOVIRUS (CMV) IMPACT ON CLINICAL OUTCOMES AND RESOURCE USE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE INFLUENCE OF RECURRENT EPISODES OF CMV INFECTION

FECAL MICROBIOTA TRANSPLANTATION IN CHILDREN TO TREAT ACUTE GVHD OR MULTI-DRUG RESISTANT BACTERIA COLONIZATION

VACCINATION AGAINST TICK-BORNE ENCEPHALITIS (TBE) AFTER AUTOLOGOUS AND ALLOGENEIC BONE MARROW TRANSPLANTATION

RIFAXIMIN USE FAVOURED MICAFUNGIN RESISTANT CANDIDA SPP INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

BASELINE CHARACTERISTICS AND EARLY POLY-FUNCTIONAL ASSESSMENT OF T CELLS TO IDENTIFY PATIENTS AT HIGHER RISK TO DEVELOP SEVERE HCMV REACTIVATION AFTER ALLOGENEIC HSCT

IMPACT OF HHV-6 REACTIVATION AFTER T-REG/T-CON IMMUNOTHERAPY IN ALLOGENEIC TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE STUDY

ADENOVIRUS INFECTIONS AFTER HCT: INFECTIOUS DISEASES WORKING PARTY RETROSPECTIVE EBMT REGISTRY STUDY

CLINICAL IMPACT OF COLONIZATION BY MULTIDRUG-RESISTANT ENTEROBACTERIACEAE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

POST-ALLOGENEIC TRANSPLANTATION PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, CLINICAL AND BIOLOGICAL FEATURES, TREATMENT AND OUTCOMES: A RETROSPECTIVE STUDY FROM THE SFGM-TC

RESPIRATORY VIRAL INFECTIONS IN ADULT PATIENTS UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION FROM UNRELATED DONORS AFTER MYELOABLATIVE CONDITIONING REGIMEN

EFFICACY OF LETERMOVIR FOR PROPHYLAXIS OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTI CENTER RETROSPECTIVE ANALYSIS AMONG JAPANESE PATIENTS

RISK FACTORS AND CLINICAL OUTCOMES OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL AND MATCHED-SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

STANDARDIZED MONITORING OF CYTOMEGALOVIRUS-SPECIFIC CELLULAR IMMUNITY CAN IMPROVE RISK STRATIFICATION OF RECURRENT CYTOMEGALOVIRUS REACTIVATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

IMPACT OF LEVOFLOXACIN FOR PROPHYLAXIS OF PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS AFTER ALLOGENEIC HSCT: A SINGLE-CENTER MATCHED ANALYSIS IN AN ENDEMIC COUNTRY FOR CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) AFTER HCT - A RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT

ORAL RIBAVIRIN IS A HIGHLY EFFICACIOUS TREATMENT FOR LOWER RESPIRATORY TRACT INFECTION DUE TO RESPIRATORY SYNCYTIAL OR PARAINFLUENZA VIRUS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS

TIMING OF INDUCTION TREATMENT FOR REACTIVATION OF CYTOMEGALOVIRUS IMPACTS OVERALL SURVIVAL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT

PREDICTION OF BLOODSTREAM INFECTION RISK USING CITRULLINE AS BIOMARKER OF INTESTINAL MUCOSITIS IN HEMATO-ONCOLOGY PATIENTS
**Scientific Programme**

**PREDICTION OF CMV REACTIVATION BY THE RECIPIENT IGG TITER BEFORE ALLO-HCT**

**COMPARISON OF INFECTIOUS COMPLICATIONS AMONG PATIENTS RECEIVING UNMANIPULATED HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETED HAPLOIDENTICAL TRANSPLANT**

**THE CUMULATIVE INCIDENCE OF MULTIPLE DNA VIRUS REACTIVATION IS NOT DIFFERENT IN NON-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION AND UNRELATED ALLOGENIC STEM CELL TRANSPLANTATION**

**NEUTROPHILS RESPONSE TO HUMAN CMV REACTIVATION IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS**

**CLINICAL EFFICACY OF LETERMOVIR PROPHYLAXIS FOR CMV INFECTION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**AT-HOME FOSCARNET ADMINISTRATION IN ALLOGENIC HEMATOPOIETIC TRANSPLANTANTATION PATIENTS WITH CYTOMEGALOVIRUS INFECTION: A SAFETY FEASIBLE MODEL**

**EFFECTS OF THE ANTIBIOTICS CHANGE OR THE ADDITION OF ANTI-MRSA DRUGS FOR PERSISTENT FEBRILE NEUTROOPENIA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION**

**THERAPEUTIC DRUG MONITORING OF POSACONAZOLE AND SUBSEQUENT DOSING IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

**IS PREEMPTIVE STRATEGY ENOUGH? RELATIONSHIP BETWEEN CMV REACTIVATION AND STEROID THERAPY FOR GHVD IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: 97 PATIENTS FROM TURKEY**

**PROPHYLAXIS WITH AZITHROMYCIN IN ALLOGENIC CORD BLOOD TRANSPLANT AND ASSOCIATION WITH RELAPSE RATE AND TRANSPLANT OUTCOMES**

**REACTIVATED VARICELLA ZOSTER (VZV) INFECTION (SHINGLES), AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HCT) FOR HAEMATOLOGICAL DISEASE IN CHILDREN: A SIGNIFICANT PROBLEM AND PROPOSAL FOR FUTURE MANAGEMENT**

**LETTERMOVIR PROPHYLAXIS REDUCES INPATIENT RESOURCE CONSUMPTION BY BEING EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REAL-WORLD EXPERIENCE**

**ANALYSIS OF CMV REACTIVATION RISK AFTER T CELL REPLETE HAPLOIDENTICAL AND MATCHED DONOR ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION**

**INCIDENCE AND IMPACT OF EPSTEIN-BARR VIRUS EVENTS IN THE EARLY PHASE AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ASPERGILLUS NON-FUMIGATUS INVASIVE ASPERGILLOSES IN CHILDREN AND ADULTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) & CHEMOTHERAPY**

**INTRAVENOUS PENTAMIDINE FOR PNEUMOCYSTIS JIROVECII PROPHYLAXIS IN HEMATOLOGICAL PATIENTS TREATED WITH CHEMOTHERAPY, HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) AND CAR-T CELL THERAPY**

**INTENSIFICATION OF CMV PROPHYLAXIS WITH THE USE OF GANCICLOVIR DURING THE CONDITIONING IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. COMPARISON WITH A STANDARD STRATEGY. 113 PATIENTS**

**LOW RELAPSE RISK FOR REDUCED INTENSITY CONDITIONED ALEMTUZUMAB-BASED ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMAS IS OFFSET BY CYTOMEGALOVIRUS RISK: DATA FROM SINGLE CENTRE STUDY**
PROPHYLACTIC DOSE TRIMETHOPRIM/SULFAMETHOXAZOLE DOES NOT LEAD TO DELAYED NEUTROPHIL AND PLATELET ENGRAFTMENT IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

HIGH DOSE VALACICLOVIR AS CMV PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION

EPIDEMIOLOGICAL SCREENING FOR BACTERIAL RESISTANCE BY DIFFERENT TECHNIQUES IN ALLO-HSCT PATIENTS

INVASIVE MOLD DISEASE IN A REAL-WORLD HEMATO-ONCOLOGY SETTING: VALUE OF A DIAGNOSTIC-DRIVEN CARE PATHWAY

SINGLE CENTER ANALYSIS ON THE MANAGEMENT OF ACRYLIC RESISTANT HERPES SIMPLEX VIRUS STOMATITIS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

EARLY BACTEREMIA FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION WITHOUT THE USE OF PROPHYLACTIC ANTIBIOTIC: CHANGING EPIDEMIOLOGY AND ANTIMICROBIAL RESISTANCE (2016-2018)

DIAGNOSTIC YIELD OF BRONCHOALVEOLAR LAVAGE (BAL) IN HAEMATOLOGICAL PATIENTS AFTER ALLOGENEIC/AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) - COMPARISON WITH BAL PERFORMANCE IN NON-TRANSPLANTED PATIENTS

A NOVEL EFFICIENCY STRATEGY TO PREVENT HBV-RELATED HEPATITIS AFTER ALLOGENEIC HSCT FROM HBsAG-POSITIVE DONORS TO RECIPIENTS

BK Virus Effect on Developing Late Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients: Single Center Experience

VERSATILE EFFECTS OF LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-INSTITUTION ANALYSIS

IMPACT OF A CHANGE IN ANTIBACTERIAL PROPHYLAXIS IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION IN ONE SINGLE CENTER

INTRAVESICAL INSTILLATION OF CIDOVOFIR IS EFFICIENT FOR THE TREATMENT OF BK VIRUS HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC TRANSPLANTATION

MANAGEMENT OF BK POLYOMA VIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE

RISK FACTORS AND OUTCOME OF EARLY CLOSTRIDIUM DIFFICILE INFECTION IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

RISK FACTORS FOR CYTOMEGALOVIRUS INFECTION IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

IMPACT OF HYPOGAMMAGLOBULINEMIA ON OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

THE USE OF RIFAXIMINE IN ANTI-BACTERIAL PROPHYLAXIS IN PATIENT UNDERGOING HSCT

BKV VIRUS - HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: INCIDENCE, SEVERITY AND RISK FACTORS

RUXOLITINIB FOR STEROID-REFRACTORY GVHD ABOLISHES ANTIVIRAL IMMUNE RESPONSE FOLLOWING T-CELL TRANSFER FOR REFRACTORY ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Scientific Programme

RISK FACTORS FOR CMV REACTIVATION AND DISEASE AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - DEFINING THE TARGET POPULATION FOR LETERMOVIR PROPHYLAXIS

ISAVUCONAZOLE (ISA) USE IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) RECIPIENTS: A SINGLE-CENTER EXPERIENCE

TIME- AND THERAPY-DEPENDENT BACTERIURIA IN CHILDREN AND YOUNG ADULTS FOLLOWING ALLOGENEIC HSCT

PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF MARIBAVIR COMPARED WITH VALGANCICLOVIR FOR TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) RECIPIENTS (STUDY DESIGN)

INCIDENCE AND RISK FACTORS OF VIRAL COMPLICATIONS IN ADULT PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM HUNGARY

CONTRIBUTING FACTORS TO PRE ENGRAFTMENT BACTEREMIA AND PNEUMONIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A LEBANESE SINGLE CENTER EXPERIENCE

UNICENTRIC STUDY: PROPHYLAXIS STRATEGY AGAINST GVHD WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (CPYT) AND ITS RELATIONSHIP WITH CYTOMEGALOVIRUS

EPIDEMIOLOGY AND CLINICAL FEATURES OF FEBRILE NEUTROPENIC EPISODES: THREE YEARS EXPERIENCE AT HEMATOLOGY WARDS

USE OF CMV-HYPERIMMUNE GLOBULINS (CMV-HYG) AS PRE-EMPTIVE THERAPY OR TREATMENT OF CMV INFECTION IN HSCT RECIPIENTS

TOXOPLASMOsis DISEASE AFTER ALLO-HSCT. WHAT HAVE WE LEARNT?

TUBERCULOSIS IN PATIENTS WHO RECEIVE AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT. TWO CASE REPORT

POLYOMAVIRUS BK INFECTION IN BONE MARROW TRANSPLANTATION RECIPIENTS. A COMPARATIVE ANALYSIS ON CHILDREN AND ADULTS

LEFLUNOMIDE, SUCCESSFUL PRE-EMPTIVE THERAPY IN RESISTANT CYTOMEGALOVIRUS REACTIVATION IN A HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT

LETEmOVIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

INFECTIOUS COMPLICATIONS IN HEMATOLOGIC PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION

EARLY MORTALITY IN PATIENTS WITH MULTIPLE MYELOMA - A SINGLE CENTER EXPERIANCE

CMV RETINITIS IN A STEM CELL TRANSPLANT RECIPIENT TREATED WITH FOSCARNET INTRAVITREAL INJECTION AND CMV SPECIFIC IMMUNOGLOBULIN

e-Posters
12:30 - 18:30
ePoster Area

Minimal residual disease, tolerance, chimerism and immune reconstitution

T CELL CHIMERISM AFTER HCT DOES NOT PREDICT FOR GRAFT LOSS IN NON-MALIGNANT DISEASES, AND IS A FAILURE OF MYELOSUPPRESSION RATHER GRAFT REJECTION
FASTER ENGRAFTMENT AND RECONSTITUTION OF INNATE-IMMUNITY AFTER ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) THAN POST-TRANSPLANT-CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS AFTER MYELOABLATIVE CONDITIONING (MAC) PERIPHERAL-BLOOD-STEM-CELL (PBSC) ALLOGENIC TRANSPLANTATION (ALLO-SCT)

CMV SEROPOSITIVITY DRIVES T CELL RECONSTITUTION AFTER CD34-SELECTED ALLOGENIC HCT DESPITE REDUCTION OF VIREMIA WITH LETERMOVIR

COMPARING OUTCOMES OF PATIENTS HAVING MIXED T CHIMERISM AND UNRELATED DONOR ALLOGRAFTS FOR ACUTE LEUKAEMIA/MDS TO PATIENTS WITH COMPLETE CHIMERISM - SINGLE CENTRE RETROSPECTIVE STUDY

CMV INFECTION IS ASSOCIATED WITH REDUCED THYMIC FUNCTION AND LESS REGULATORY T CELLS AFTER PEDIATRIC ALLOGENIC HSCT

IMPACT OF PRE-TRANSPLANT MRD BURDEN MEASURED BY MULTICOLOR FLOW CYTOMETRY ON RELAPSE AND SURVIVAL IN AML PATIENTS UNDERGOING ALLO-SCT IN CR

FLOW-BASED PRE-TRANSPLANT MRD DETECTION STRONGLY IMPACTS ON THE OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION WITH AB T CELL DEPLETION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

CMV-SPECIFIC T CELL COUNTS EARLY AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION STRATIFY THE RISK OF SUBSEQUENT CMV REACTIVATIONS: RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY

IMPROVED RELAPSE-FREE-SURVIVAL IN PATIENTS WITH HIGH NATURAL KILLER CELL DOSES IN GRAFTS AND DURING EARLY IMMUNE RECONSTITUTION AFTER ALLOGENIC TRANSPLANTATION WITH PERIPHERAL BLOOD STEM CELLS

POTENTIAL INFLUENCE OF IMMUNODEFICIENCY-RELATED HEREDITARY PREDISPOSITION GENE VARIANTS ON RELAPSE AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

COMPARABLE RESULTS OF PREEMPTIVE RECOMBINANT IL-2 AND DONOR LYMPHOCYTE INFUSION IN HEMATOLOGICAL MALIGNANCY PATIENTS WITH LATE-ONSET MINIMAL RESIDUAL DISEASE AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

SURVIVAL ANALYSIS ACCORDING TO MINIMAL RESIDUAL DISEASE BY FLOW CYTOMETRY BEFORE ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA

IMPACT OF RESIDUAL CIRCULATING TUMOR DNA STATUS POST ALLOGENEIC SCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: INTERIM RESULTS OF A PROSPECTIVE STUDY

EARLY CD4+ T CELL RECONSTRUCTION AS PREDICTOR FOR OUTCOMES AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULT PATIENTS: A VALIDATION COHORT ANALYSIS

PATTERN OF RECONSTITUTION OF RECENT THYMIC EMIGRANTS AFTER REDUCED INTENSITY CONDITIONING BASED ON TARGETED BUSULFAN IN PAEDIATRIC RECIPIENTS OF ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

A RISK SCORE SYSTEM BASED ON POST-TRANSPLANTATION MINIMAL RESIDUAL DISEASE FOR STRATIFICATION OF RELAPSE IN B-ALL PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION

OUTCOME OF CHILDREN WITH HEMATOLOGICAL MALIGNANCIES WHO DEVELOP MIXED DONOR CHIMERISM AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

PROPHYLACTIC HIGH-DOSE DONOR CD45RO+ MEMORY T-CELLS INFUSION AFTER ALLOGENIC TRANSPLANTATION: SAFETY AND OUTCOME
MULTICOLOR FLOW CYTOMETRY PANEL WITH CCD79A GATING TO DETECT MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA POST ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT

NON-INVASIVE MONITORING OF MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE BY CIRCULATING CELL-FREE NUCLEIC ACIDS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

TORQUE TENO VIRUS AS BIOMARKER TO PREDICT COMPLICATIONS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

PREEMPTIVE INTERFERON-α TREATMENT COULD PROTECT AGAINST RELAPSE AND IMPROVE SURVIVAL OF ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

THE ADDITION OF BUSULFAN REDUCES THE INCIDENCE OF MIXED CHIMERISM FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APADEMIA

A NEW MULTIVARIATE MODEL TO DESCRIBE IMPACT OF IMMUNE RECONSTITUTION ON THE DEVELOPMENT OF RELAPSE IN CHILDREN UNDERGOING ALLO-HSCT FOR HEMATOLOGIC MALIGNANCIES AT DAY +100

ACQUISITION OF COMPLETE CHIMERISM IN BONE MARROW, PERIPHERAL BLOOD AND LEUKOCYTE SUBSETS DEPENDS ON THE TRANSPLANT SETTING AND CORRELATES WITH THE CLINICAL OUTCOME

EARLY LYMPHOID SUBSETS RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AS PREDICTOR OF RELAPSE AND SURVIVAL IN ACUTE LEUKEMIAS

COMPARISON OF IMMUNE RECONSTITUTION BETWEEN 30MG/KG AND 60MG/KG ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC MYELOABLATIVE PERIPHERAL BLOOD STEM CELL TRANSPLANTATION

FUNCTIONAL IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COMPARISON OF PRE- AND POST-TRANSPLANTATION CYTOKINE RESPONSES IN STIMULATED WHOLE-BLOOD

MEASURABLE RESIDUAL DISEASE (MRD) TESTING FOR ACUTE LEUKEMIA IN EBMT TRANSPLANT CENTERS: A SURVEY ON BEHALF OF THE ALWP OF THE EBMT

TBF REGIMEN INDUCES FULL DONOR CHIMERISM AFTER ALLOGRAFTS IN MYELOFIBROSIS

REAL WORLD UTILITY OF TREATING MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA

COMPARISON OF IMMUNE RECOVERY IN CORD BLOOD AND T AND B DEPLETED HAPLOIDENTICAL GRAFTS RECIPIENTS

THE BCR-ABL P210 CHIMERIC TRANSCRIPT IN VITRO TRANSFER INTO BONE MARROW MESENCHYMAL STROMAL CELLS VIA EXOSOMES

PROGNOSTIC SIGNIFICANCE OF DONOR-SPECIFIC ISOAGGLUTININ RE-APPEARANCE IN ABO-MISMATCHED STEM CELL TRANSPLANT RECIPIENTS

Maryam Pourabdollah, Christine Cserti, Dennis Dong Hwan Kim, Eshetu Atenafu, Ivan Pasic, Zeyad Al-Shalbani, Aijun Law, Wilson Lam, Armin Gerbitz, Jeffery Lipton, Auro Viswabandya, Rajat Kumar, Jonas Mattson, Fotios Michelis, Nayana Sondi, Jacob Pendergrast (Canada)

IMMUNE-RECONSTITUTION OF LYMPHOCYTE SUBPOPULATIONS WITH RESPECT TO MSC-TREATMENT FOR STEROID REFRACTORY GVHD FOLLOWING HSCT
DAY+100 FULL DONOR CHIMERISM IN THE BONE MARROW CONFERS BETTER OVERALL SURVIVAL IN REDUCED INTENSITY CONDITIONED WITH ALEMTUZUMAB ALLOGENEIC STEM CELL TRANSPLANTATION FOR LYMPHOMAS

DONOR FACTORS INFLUENCE OUTCOMES OF PATIENTS RECEIVING DONOR LYMPHOCYTE INFUSION FOR MIXED CHIMERISM AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION

DETERMINE PATIENTS AT RISK OF RELAPSE AND DEATH IN ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME USING CHIMERISM ON BONE MARROW SAMPLES AT DAY 28 AFTER HSCT

CONCURRENT- SYNERGISTIC ASSESSMENT OF TWO TECHNIQUES IN MONITORING MINIMAL RESIDUAL DISEASE FOR PH(-) ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANTATION LEADS TO FAVORABLE CLINICAL OUTCOMES

DONOR CHIMERISM EVALUATION OF MRD-SUSPECTED CELLS ISOLATED BY FLOW CELL SORTING IS AN ACCESSIBLE TOOL FOR MRD VERIFICATION IN PATIENTS AFTER ALLOGENEIC HSCT

ONE-STEP CHECK PURITY OF CD3+ SORTED CELLS ALONG MONITORING HEMATOPOIETIC CHIMAERISM AFTER HSCT

DONOR LYMPHOCYTE INFUSIONS AUGMENT GRAFT VERSUS MALIGNANCY EFFECT FOLLOWING ALEMTUZUMAB-BASED REDUCED INTENSITY ALLOGRAFTS: REFLECTIONS ON A SINGLE CENTRE STUDY

MYELOID-DERIVED SUPPRESSOR CELLS RECOVER QUICKLY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS

PERSISTENT MIXED CHIMERISM WITHOUT RELAPSE IN CHILDREN AFTER HSCT FOR HEMATOLOGIC MALIGNANCY

Multiple myeloma

DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF HIGH-RISK PATIENTS IN CASSIOPEIA

EVALUATION OF PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (PET/CT) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PHASE 3 CASSIOPEIA STUDY PATIENTS: CASSIOPET STUDY RESULTS

CONCORDANCE OF POSTCONSOLIDATION MINIMAL RESIDUAL DISEASE RATES BY MULTIPARAMETRIC FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING IN CASSIOPEIA

LONG-TERM FOLLOW-UP OF THE RANDOMIZED PHASE 3 PETHERA/GEM 2005MENOS65 STUDY SUPPORTS THE USE OF VTD (BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE) AS PRETRANSPLANT INDUCTION REGIMEN FOR MULTIPLE MYELOMA (MM)

DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE

HOW TO ASSESS RISK OF PROGRESSION IN MULTIPLE MYELOMA PATIENTS ACHIEVING COMPLETE REMISSION AFTER AUTOLOGOUS TRANSPLANT: SUB ANALYSIS FROM THE GEM2012MENOS65 PHASE III CLINICAL TRIAL
OUTCOMES OF ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS

25 YEARS OF AUTOLOGOUS TRANSPLANTATION FOR MYELOMA IN EBMT CENTRES - CHANGING PRACTICE PATTERNS

PROGNOSIS IN DIFFERENT RISK-GROUPS OF MULTIPLE MYELOMA WITH MINIMAL RESIDUAL DISEASE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BORTEZOMIB-INTEGRATED CONDITIONING: A SINGLE-CENTER EXPERIENCE

UNINTERRUPTED MOBILIZATION AND TRANSPLANTATION PROCEDURE WITH NON-CRYOPRESERVED YIELD IS FEASIBLE WITHOUT INCREASEMENT OF COMPLICATION RISK IN MULTIPLE MYELOMA PATIENTS

CONDITIONING WITH BORTEZOMIB-MEL200 IN COMPARISON TO MEL200 IMPROVES SURVIVAL AMONG MYELOMA PATIENTS IN≤PR PRIOR TO AUTO-HCT: A STUDY FROM THE CMWP OF THE EBMT

RESULTS OF DEFERRED AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED STAGES OF SYSTEMIC AL AMYLOIDOSIS

IN VITRO STIMULATION WITH CD40L/IL-21 CAN RETRIEVE B-CELL DYSFUNCTION IN MULTIPLE MYELOMA PATIENTS SUFFERING FROM SECONDARY IMMUNODEFICIENCY

ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA; EXCELLENT OUTCOMES FOR EARLY TRANSPLANTATION

SEQUENTIAL HEART TRANSPLANTATION FOLLOWED BY HIGH DOSE CHEMOTHERAPY PLUS AUTOLOGOUS STEM CELL REINFUSION IN CARDIAC AL AMYLOIDOSIS

AUTOGRAFT CELLULAR COMPOSITION AND OUTCOME IN MYELOMA PATIENTS: RESULTS OF THE PROSPECTIVE MULTICENTER GOA STUDY

RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE

PHASE 3, OPEN-LABEL, NONINFERIORITY STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): BODY WEIGHT SUBGROUP ANALYSIS OF COLUMBA

ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) IS A RELIABLE PREDICTOR FOR OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION

ABERRANT PHENOTYPE PLASMA CELL MULTIPARAMETRIC FLOW CYTOMETRY (MFC) DETECTION IN AUTOGRAFT PRODUCTS OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

RETROSPECTIVE MULTI-CENTER STUDY OF ADOLESCENT AND YOUNG ADULT (AYA) MULTIPLE MYELOMA IN KANSAI MYELOMA FORUM REGISTRY

MAINTENANCE THERAPY WITH ELOTUZUMAB AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

AUTOLOGOUS STEM CELL TRANSPLANTATION CANDIDACY IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS

NOVEL PROTOCOL FOR AUTOLOGOUS HSCT IN MULTIPLE MYELOMA ACHIEVES ‘ZERO’ CENTRAL LINE ASSOCIATED BLOOD STREAM INFECTIONS (CLABSI)

OUTCOMES OF NON-CRYOPRESERVED VERSUS CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
**Scientific Programme**

DOWN REGULATION OF AUTOPHAGY ENHANCES BORTEZOMIB-INDUCED APOPTOSIS OF MYELOMA CELL BY UP REGULATION OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES

RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE

FAVORABLE LONG-TERM OUTCOMES WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HIGH RISK PATIENTS WITH MULTIPLE MYELOMA WHO ARE POSITIVE AT FDG-PET/CT

LONG TERM SURVIVAL OF MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELATION TO AVAILABILITY OF NOVEL DRUGS

MULTIPLE MYELOMA (MM) IN FIRST RELAPSE PATIENTS. ROLE OF THE SECOND AUTOLOGOUS STEM-CELL TRASPLANT (ASCT) IN REAL LIFE: EXPERIENCE OF TWO SPANISH CENTERS

ROLE OF ANALYSIS OF CHIMERISM IN MULTIPLE MYELOMA PATIENTS UNDERWENT AUTOGENIC STEM CELL TRANSPLANTATION

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE

USE OF NETUPITRANT/PALONOSETRON IN MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE

THE EFFECT OF UCP-2 AND NR3C1 GENES ON TREATMENT EFFICACY AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA

SAFETY AND EFFECTIVENESS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA IN FIRST LINE

PLASMAPHERESIS ASSISTED THE TREATMENT OF 1 CASE OF HYPERGLOBULINEMIA AFTER CART THERAPY

**e-Posters**

12:30 - 18:30 ePoster Area

**Myelodysplastic syndromes**

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OF ADULT PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA: A NORDIC RETROSPECTIVE STUDY

DECITABINE MONOTHERAPY BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION RESULTED IN SUPERIOR SURVIVAL FOR MYELODYSPLASTIC SYNDROME PATIENTS WITH EXCESS BLASTS

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM: A STUDY FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT

IMPACT OF MUTATION PROFILE IN CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

NEW INSIGHTS OF MYELODYSPLASTIC SYNDROME (MDS) WITH ERYTHROID PREDOMINANCE BASED ON THE NEXT-GENERATION SEQUENCING AND SINGLE-CELL RNA SEQUENCING

IMPACT OF TREATMENT PRIOR TO ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: RESULTS OF THE LATIN AMERICAN BONE MARROW TRANSPLANT REGISTRY
RESULTS OF LATIN AMERICAN RECORD OF BONE MARROW TRANSPLANTATION IN MYELODYSTROPHIC SYNDROME

OUTCOME AND MUTATIONAL PROFILE IN MDS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

e-Posters
12:30 - 18:30

New drug- and cell-based immune therapies

NIVOLUMAB INCREASES ANTIGEN SPECIFIC IMMUNE RESPONSES AGAINST LEUKEMIC PROGENITOR AND STEM CELLS (LSC/LPC)

PROPHYLACTIC OR PREEMPTIVE LOW-DOSE AZACITIDINE AND DONOR LYMPHOCYTE INFUSION TO PREVENT DISEASE RELAPSE FOLLOWING ALLOGENEIC TRANSPLANTATION IN 60 PATIENTS WITH HIGH RISK AML OR MDS

ELTROMBOPAG FOR THE TREATMENT OF POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTS: A MULTICENTER SURVEY UPDATE

DONOR NK CELLS INFUSION AS A STRATEGY OF IMMUNOTHERAPY TO PREVENT HHV6 REACTIVATION IN PEDIATRIC PATIENTS AFTER CD45RA-DEPLETED TRANSPLANTATION

DEVELOPMENT OF CELL VACCINE BASED ON AUTOLOGOUS DENDRITIC CELLS LOADED WITH LIPID NANOPARTICLES CONTAINING CMV PP65 MESSENGER RNA

SMAC MIMETICS (SM) AND NATURAL KILLER (NK) CELLS - A PROMISING COMBINATION TO OVERCOME CELL DEATH RESISTANCE OF RHABDOMYOSARCOMA (RMS) CELLS

‘KIT’-MEDIATED BLASTMODULATION TO LEUKEMIA-DERIVED DC SIGNIFICANTLY IMPROVES ANTILEUKEMIC ACTIVITIES IN WHOLE BLOOD INDEPENDENT OF AML-PATIENTS’ SUBTYPES

ROLE OF EXOSOMES AS PROMOTORS OR BIOMARKERS TO STUDY ACTIVATION OF LEUKEMIA-DERIVED DENDRITIC CELLS (DCLEU)-MEDIATED ANTILEUKEMIC ACTIVATION OF ADAPTIVE AND INNATE IMMUNE-REACTIVE CELLS AGAINST AML-BLASTS

BLINATUMOMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA: REPORT FROM A SINGLE CENTER

IMMUNOMODULATION OF BLASTS WITH CLINICALLY APPROVED RESPONSE MODIFIERS TO IMPROVE ANTILEUKEMIC T-CELL REACTIVITY IN AML: AN EX VIVO SIMULATION OF THE CLINICAL SITUATION

IFNY SECRETION OF ADAPTIVE AND INNATE IMMUNE CELLS AS A PARAMETER TO DISPLAY LEUKAEMIA DERIVED DENDRITIC CELL (DC<sub>LEU</sub>) MEDIATED IMMUNE RESPONSES IN AML

TREATMENT OF SEVERE HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA) WITH THE MASP-2 INHIBITOR NARSOPLIMAB (OMS721)
Non-haematopoietic stem cells

THE POTENTIAL ROLES OF MUCOSA-ASSOCIATED INVARIANT T CELLS IN THE PATHOGENESIS OF GUT GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

FACTORS INFLUENCING THE PRESENCE OF BONE MARROW MESENCHYMAL STEM CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

ANALYSIS OF THE GENETIC STABILITY OF DONORS’ BONE MARROW STROMA MESENCHYMAL CELLS DURING CULTIVATION

EFFECT OF MATERNAL AND NEONATAL FACTORS ON THE YIELD OF WHARTON’S JELLY MESENCHYMAL STEM CELLS

THE POLISH EXPERIENCE OF WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF PAEDIATRIC PATIENTS

THE POLISH EXPERIENCE OF WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF ADULT PATIENTS

A RETROSPECTIVE ANALYSIS OF BONE MARROW EXAMINATION RESULTS FROM A SINGLE CENTER INSTITUTION: CAN WE REDUCE THE OCCURRENCE OF UNNECESSARY BONE MARROW EXAMINATIONS?

Non-infectious early complications

IMPACT OF DONOR-DIRECTED HLA ALLO-ANTIBODIES ON PRIMARY GRAFT FAILURE AFTER UNRELATED DONOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION

ELTROMOPAG TREATMENT AIDED IN PLATELET RECOVERY AND REDUCED PLATELET INFUSION FOR PATIENTS WITH POST-TRANSPLANTATION THROMBOCYTOPENIA

IMPACT OF FLUID OVERLOAD (FO) IN POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL DISEASES

INCIDENCE, RISK FACTORS, AND OUTCOMES OF PATIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER STEM CELL TRANSPLANT: A MULTI-INSTITUTIONAL ANALYSIS

USE OF ECULIZUMAB IN CHILDREN WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY - A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF IEWP AND PDWP EBMT

REDUCED POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSES IN T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES

ABO ISOAGGLUTININ LEVELS IN GUIDED MANAGEMENT OF ABO INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

METHYLPPREDNISOLONE STRATIFIED INTERVENTION BASED ON RISK CLASSIFICATION IN THE TREATMENT OF PRE-ENGRAFTMENT SYNDROME AFTER UNRELATED CORD BLOOD TRANSPLANTATION: A PROSPECTIVE, NON-RANDOMIZED, AND OPEN-LABEL STUDY
PRETRANSPLANT NUTRITION MEASURES AND SYSTEMIC INFLAMMATORY RESPONSE PREDICT OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

A MULTI-CENTRE, MULTI-NATIONAL, PROSPECTIVE OBSERVATIONAL REGISTRY STUDY OF DEFIBROTIDE IN PATIENTS DIAGNOSED WITH SEVERE VENO-OCLUSION DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)

DEFIBROTIDE TREATMENT FOR VENO-OCLUSION DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES BY SEVERITY AND MULTI-ORGAN FAILURE STATUS IN AN OBSERVATIONAL REGISTRY STUDY

INTRODUCTION OF NEW PEDIATRIC EBMT CRITERIA FOR VOD Diagnosis: IS IT LIFE-SAVING OR MONEY-WASTING?

PROSPECTIVE PILOT STUDY ON FRAILTY AND FUNCTION ASSESSMENT DURING CLINICS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

HISTOLOGIC FEATURES OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY WITH AND WITHOUT CONCOMITANT ACUTE GRAFT-VERSUS-HOST DISEASE

HIGH SURVIVAL RATE OF PEDIATRIC PATIENTS WITH PRIMARY GRAFT FAILURE WHO UNDERGO A SECOND PROCEDURE. THE EXPERIENCE OF 3 SPANISH PEDIATRIC TRANSPLANT UNITS

CHEMOTHERAPY-INDUCED GUT MUCOSAL INJURY INITIATES MICROBIAL DISRUPTION IN STEM CELL TRANSPLANT RECIPIENTS

BACTERIAL AND METABOLIC PROFILING OF THE SALIVA IDENTIFIES UNIQUE PATTERNS OF MICROBIOTA INJURY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT WITH SEVERE ORAL MUCOSITIS

DIAGNOSIS AND MANAGEMENT OF SECONDARY HLH/MAS FOLLOWING HSCT AND CAR-T CELL THERAPY IN ADULTS: AN EBMT-WIDE SURVEY ON BEHALF OF THE ADWP AND TCWP

IMPACT OF ABO INCOMPATIBILITY ON COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION- RETROSPECTIVE, INTERNATIONAL, MULTICENTER ANALYSIS BY THE TRANSPLANT COMPLICATIONS WORKING PARTY EBMT

HYPOALBUMINEMIA PRIOR ALLOHCT IS A RELEVANT NEGATIVE PREDICTOR FOR SURVIVAL

INCIDENCE AND CLINICAL IMPACT OF ATRIAL FIBRILLATION DIAGNOSED DURING HOSPITAL STAY FOR ALLOGENEIC STEM CELL TRANSPLANTATION

TRANSPLANTATION-ASSOCIATED MICROANGIOPATHY (TAM) IN RECIPIENTS OF UNMANIPULATED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTS USING PTCY FOR GVHD PROPHYLAXIS: INCIDENCE AND OUTCOME

IGF-1 AND IGFBP-3 GENE POLYMORPHISMS PREDICT CIRCULATING IGF LEVELS AND SYSTEMIC INFLAMMATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

LOW RISK OF EARLY TOXICITY AND UNPLANNED 100-DAY READMISSIONS AFTER MATCHED AND MISMATCHED RELATED AND UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

KERATINOCYTE GROWTH FACTOR DECREASES HOSPITAL READMISSION AND REGIMEN-RELATED TOXICITIES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA

ELTROMBOPAG FOR TREATING THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE
SYSTEMIC CORTICOSTEROID THERAPY IS UNLIKELY TO BE THE PRIMARY CAUSE OF HYPERGLYCEMIA FOLLOWING TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE

COST-EFFECTIVENESS ANALYSIS OF DEFIBROTIDE FOR THE TREATMENT OF SEVERE VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME IN SPAIN

NEUROLOGIC COMPLICATIONS IN 169 CONSECUTIVE ALLOGENEIC STEM CELL TRANSPLANTS: ETIOLOGY, CLINICAL SYNDROMES AND OUTCOME

VENETOCLAX, HYPOMETHYLATING AGENTS AND DLI FOR SALVAGE TREATMENT OF MYELOID MALIGNANCIES RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EVALUATION OF TGF-BETA LEVEL AFTER SUPPLEMENTATION WITH WHEY PROTEIN CONCENTRATE FOR ORAL MUCOSITIS PROPHYLAXIS

TREOSULFAN-INDUCED MYALGIA IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

VALIDATION OF EARLY INCREASE OF SC5B-9 AS A PREDICTIVE MARKER FOR LATER TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY

DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF HEPATIC VENO-OCCCLUSIVE DISEASE AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

EARLY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION IMPROVES OUTCOME OF VERY SEVERE HEPATIC VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER UNMANIPULATED HAPLOIDENTICAL HSCT WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

DOES THE TYPE OF NUTRITIONAL SUPPORT AFFECT THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION? A PEDIATRIC CENTER EXPERIENCE

NEUROLOGICAL COMPLICATIONS IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY

ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS ADMITTED TO THE INTENSIVE CARE UNIT - REAPPRAISAL OF PROGNOSIS AND PROGNOSTIC FACTORS: A SINGLE CENTER STUDY

ENTERAL VERSUS PARENTERAL NUTRITION IN ADULT HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS SUFFERING FROM GASTROINTESTINAL MUCOSITIS

DELAYED ENGRAFTMENT AND PROLONGED HOSPITAL STAY FOLLOWING OMISSION OF FOLINIC ACID AFTER METHOTREXATE FOR GVHD PROPHYLAXIS IN ALLOGENEIC TRANSPLANT RECIPIENTS

THE USEFULNESS OF LIVER STIFFNESS MEASUREMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT SINUSOIDAL OBSTRUCTION SYNDROME

ENDOTHELIAL CELL COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION, A SINGLE CENTRE ANALYSIS ON 99 CONSECUTIVE PATIENTS UNDERGOING ALLO-SCT

Giorgia Mancini, Matteo Candelora, Giuseppina Urbano, Francesco Saraceni, Monica Poiani, Marianna Mariani, Irene Federici, Giuseppe Tarantino, Ilaria Scortechini, Attilio Olivieri (Italy)

INFLUENCE OF ABO-INCOMPATIBILITY ON THE OUTCOME OF STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY ON CHILDREN AND YOUNG ADULTS

EASIX IS USEFUL FOR PREDICTING THE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS
SECOND TRANSPLANTATION USING A NOVEL CONDITIONING REGIMEN WITH DIFFERERNT DONOR FOR GRAFT FAILURE AFTER FIRST HAPLOIDENTICAL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

A SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME

VENO-OCCCLUSIVE DISEASE: ONLINE, INTERPROFESSIONAL, CASE-BASED EDUCATION SIGNIFICANTLY IMPROVES KNOWLEDGE AND SKILLS OF THE ENTIRE CARE TEAM

HYPERHEMOLYSIS SYNDROME IS A NOVEL CAUSE OF SEVERE HEMOLYTIC ANEMIA AFTER ALLOGENEIC TRANSPLANTATION WITH VERY POOR RESPONSE TO TREATMENT AND OUTCOME

EASIX AS A PREDICTIVE BIOMARKER OF COMPLICATIONS AND OUTCOME IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

SURVIVAL WITH NORMAL PULMONARY FUNCTION IS POSSIBLE DESPITE SIGNIFICANT AND PROLONGED RESPIRATORY SUPPORT, INCLUDING PROLONGED HIGH FREQUENCY OSCILLATORY VENTILATION (HFOV) IN CHILDREN

USE OF INTRAVESICAL HYALURONIC ACID TO TREAT HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION

CURRENT PRACTICE IN NUTRITION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AUSTRIA, GERMANY AND SWITZERLAND

INCIDENCE AND SEVERITY OF CYTOKINE RELEASE SYNDROME FOLLOWING HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL INFUSION

ENGRAFTMENT SYNDROME FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY FROM A SINGLE CENTER

WERNICKE’S ENCEPHALOPATHY IN A CHILD WITH B LYMPHOBlastic LYMPHOMA AFTER HAPLO-HSCT

ECULIZUMAB FOR THE TREATMENT OF SEVERE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: MULTICENTER EXPERIENCE

IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) AS GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN TERMS OF SINUSOIDAL OBSTRUCTION SYNDROME (SOS)

ISCHEMIC STROKE IN CHILDREN AND YOUNG ADULTS WITH MALIGNANT HEMATOLOGICAL AND ONCOLOGICAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

MELPHALAN DOSE ADJUSTMENT AND CRYOTHERAPY REDUCE ORAL MUCOSITIS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

CLINICAL FEATURES AND RISK FACTORS OF ENGRAFTMENT SYNDROME IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

REAL-LIFE EXPERIENCE OF TWO ITALIAN HEMATOLOGY CENTRES ON EFFICACY AND SAFETY OF ORAL NEPA (NETUPITANT/PALONOSETRON) IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

EARLY TREATMENT WITH DARATUMUMAB FOR REFRACTORY POST-ALLOGENEIC STEM CELL TRANSPLANT PURE RED CELL APLASIA

PROGNOSTIC FACTORS FOR EARLY MORTALITY OF HEMATOLOGICAL PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT: PRELIMINARY RESULTS OF A PROSPECTIVE MULTICENTER STUDY
Scientific Programme

ACUTE KIDNEY INJURY DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS: INCIDENCE AND RISK FACTORS

T-PA/UKRONASE IN COMBINATION WITH TPE AS A SUBSTITUTIONAL THERAPY FOR TREATMENT OF TA-TMA

HEMOPHAGOCYTIC SYNDROME AFTER EX-VIVO LYMPHODEPLETED HEMATOPOIETIC TRANSPLANTATION

IMMUNOADSORPTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MAJOR ABO INCOMPATIBILITY

IMMUNE-MEDIATED FEVER AFTER T-CELL REPLETE HAPLOIDENTICAL HSCT USING PERIPHERAL BLOOD STEM CELL GRAFTS AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

Non-infectious late effects, quality of life and fertility

EASIX-1YEAR- THE FIRST BIOMARKER PREDICTING LATE MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

AN UPDATED REPORT ON SECONDARY SOLID CANCER FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THALASSEMIA MAJOR

ALLOGENEIC STEM-CELL TRANSPLANTATION IN AML AND MDS USING CONDITIONING REGIMENS WITH DIFFERENT DOSE-INTENSITIES; 15 YEARS LATER

EMPLOYMENT STATUS AND RETURN TO WORK AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: RESULTS FROM A NATIONWIDE SURVEY

FUNCTIONAL OUTCOME MEASURES IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): FOCUS ON THE 2-MINUTE WALK TEST

FERTILITY IN ADULT FEMALE ALLOGENEIC STEM CELL RECIPIENTS

A RISK SCORE MODEL (HAD-TCG) TO EVALUATE THE RISK OF STROKE IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

BRONCHIOLITIS OBLITERANS SYNDROME IN THE CHANGING LANDSCAPE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

CURRENT STATUS AND NEEDS OF LONG-TERM FOLLOW-UP CLINICS FOR HEMATOPOIETIC CELL TRANSPLANT SURVIVORS: RESULTS OF A NATIONWIDE SURVEY IN JAPAN

SURVIVORSHIP CARE FOR ALLOGENEIC TRANSPLANT PATIENTS IN THE UK: CURRENT SERVICE PROVISION AND BARRIERS TO IMPLEMENTATION

CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN EPSTEIN-BARR VIRUS RELATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (EBV-PTLD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)

INCIDENCE, RISK FACTORS AND OUTCOMES OF DIFFUSE ALVEOLAR HEMORRHAGE AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION

WHOLE BODY VIBRATION TRAINING DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION - THE EFFECTS ON PATIENTS' PHYSICAL CAPACITY, FATIGUE, BODY COMPOSITION AND QUALITY OF LIFE

MULTI-MORBIDITY IN ADULT SURVIVORS OF STEM CELL TRANSPLANTATION (SCT)
Scientific Programme

GONADOTOXICITY AFTER TREOSULFAN-BASED MYELOABLATIVE CONDITIONING REGIMEN FOR ALLOGENEIC HSCT IN GIRLS WITH LEUKEMIA

REDUCED-INTENSITY TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH HIGH-RISK OR ADVANCED HEMATOLOGICAL MALIGNANCIES IN LAST 10 YEARS - SINGLE CENTRE EXPERIENCE

FATHERHOOD AFTER A MYELOABLATIVE TREOSULFAN BASED ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS ON 453 PATIENTS

COMPARISON OF CENTRAL NERVOUS SYSTEM RELAPSE OUTCOMES FOLLOWING HAPLOIDENTICAL VS IDENTICAL-SIBLING TRANSPLANT FOR ACUTE LYMPHOBLASTIC LEUKEMIA

OLDER AGE AND PERIPHERAL BLOOD AS A STEM CELL SOURCE ARE THE MAJOR NEGATIVE PREDICTORS OF SURVIVAL LONG TERM

PREVALENCE OF BRONCHIOLITIS OBLITERANS SYNDROME (BOS) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLOHSCT) IN THE US, EUROPE AND JAPAN

NETUPITANT-PALONOSETRON (NEPA) TO PREVENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MULTIPLE MIELOMA (MM) PATIENTS RECEIVING HIGH-DOSE (HD) MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)

MOST FREQUENT LATE EFFECTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA DOES NOT SEEM TO WORSEN PERFORMANCE STATUS

IN VolVING STEM CELL TRANSPLANT PATIENTS AND THEIR FAMILIES TO IMPROVE THE ANTHONY NOLAN MY TRANSPLANT TRACKER APP

EARLY MENOPAUSE AND RISK FACTORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PREMENOPAUSAL ADULT WOMEN

MUSCULOSKELETAL COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS

CLINICAL CHARACTERISTICS AND MANAGEMENT OF LATE RELAPSE OF ACUTE MYELOID LEUKAEMIA MORE THAN FIVE YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

FOLLOWING UP WITH ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING 5+ YEARS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

LOW BACK PAIN AND LASER ACUPUNCTURE IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELLS TRANSPLANTATION

EFFECTS OF CONTROLLED EXERCISE ON PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

LONG-TERM OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANT IN AN ASIAN POPULATION: A SINGLE-CENTER EXPERIENCE

DEVELOPMENT OF GUILLAIN-BARRE-LIKE SYNDROME IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELLS TRANSPLANTATION
Nurses Posters - Adult

ROLE OF QUICKSOFA IN PREDICTING SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL PATIENTS

<i>BOLUS:</i> TARGETED SPECIALIST HAEMATOLOGY/BMT PODCASTS: AN EFFECTIVE METHOD OF EDUCATION

A PATHWAY FOR RECOVERY: D+100 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT) FOLLOW UP PILOT FOR LYMPHOMA

REDUCING ACCIDENTAL FALLS CAUSED BY ORTHOSTATIC HYPOTENSION IN BONE MARROW TRANSPLANT RECIPIENTS

THE EFFECT OF MOTIVATIONAL INTERVIEW PERFORMED AFTER STEM CELL TRANSPLANTATION ON SEXUAL EXPERIENCE, SEXUAL SELF-AWARENESS AND SEXUAL SELF-EFFICACY

STUDY ON COGNITIVE FUNCTION AND RELATED FACTORS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

THE EFFECT OF RELAXING BREATHING EXERCISES ON PAIN, FATIGUE AND LEUKOCYTE COUNT IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

UNDERSTANDING OF PROGNOSIS, QUALITY OF LIFE AND PSYCHIATRIC STATUS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY OF 348 PATIENTS

AN OUTPATIENT MODEL OF CARE TO SAFELY DELIVER AUTOLOGOUS STEM CELL TRANSPLANTATION

EFFECTS OF TREATMENTS FOR HAEMATOLOGICAL MALIGNANCIES ON SEXUALITY AND FERTILITY: WHEN DO PATIENTS NEED IT AND WHOM REALLY WANTS TO KNOW?

EFFICACY OF THERAPEUTIC EDUCATION TO REDUCE RISKS AND COMPLICATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OBSERVATIONAL PROSPECTIVE COHORT STUDY

SELF-EFFICACY AND SELF-CARE PRACTICES OF PATIENTS WHO HAVE BEEN TRANSPLANTED WITH ALLOGENEIC HEMATOPOIETIC STEM CELLS ACCORDING TO THE DEVELOPMENT OF AN INDIVIDUAL EDUCATION PROGRAM

DETERMINING THE SYMPTOMS AND COPING METHODS OF PATIENTS AT HOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

THE EFFECT OF ORAL CARE PROTOCOL ON ORAL MUCOSITIS IN PATIENTS HEMATOPOIETIC STEM CELL TRANSPLANTATION

PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) WITHIN AN AMBULATORY CARE SETTING; A PATIENTS’ PERSPECTIVE

REDUCING ANTITHYMCOCYTE GLOBULIN (ATG) INFUSION RELATED REACTION BY INCREASING THE INFUSION DURATION IN ADULT SCT PATIENTS; A SINGLE INSTITUTION EXPERIENCE FROM SAUDI ARABIA

NURSE LED TELEPHONE FOLLOW UP FOR LATE EFFECTS SERVICE

NURSING CARE OF 15 PATIENTS WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CHIMERIC ANTIGEN RECEPTOR T CELLS
NURSING CARE OF A PATIENT WITH HEREDITARY DIFFUSE LEUKOENCEPHALOPATHY COMPLICATED WITH AXONAL DEGENERATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

EFFECT OF NURSES EDUCATION PROGRAM ON CATHETER RELATED BLOOD STREAM INFECTIONS

THE CURRENT SITUATION AND INFLUENCING FACTORS OF MANAGEMENT OF CENTER VENOUS ACCESS DEVICE-ASSOCIATED SKIN IMPAIRMENT DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION

EXERCISE SUPPORT FOR PEOPLE POST TREATMENT AS PART OF THEIR RETURN TO WORK JOURNEY: A CASE STUDY EXEMPLAR

ONCOSAFETY: A NEW TOOL FOR HEMATOLOGY NURSES TO AVOID CHEMOTHERAPY ERRORS

PATIENT INFORMATION SHEET FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION: THE IMPACT OF THE DISEASE AND TREATMENT ON SEXUAL FUNCTION AND SEXUALITY

CHANGING PRACTICE BY USING CYCLOPRIME 1.5G/M2 PRIMING REGIME UP FRONT FOR LYMPHOMA PATIENTS TO ENSURE GOOD MOBILISATION OF STEM CELLS

THE CHALLENGES OF LOOKING AFTER AN INCREASING NUMBER OF SURVIVORS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION

VENO-OCCULSIVE DISEASE (VOD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANT NURSING CONSIDERATIONS AND MANAGEMENT: A CASE STUDY

RECOGNIZING LOW HEALTH SKILLS AND LOW LITERACY DURING CONSULTATION

PRE-HABILITATION PRIOR TO STEM CELL TRANSPLANT - ONE CENTRES EXPERIENCE

THE IMPORTANCE OF NURSES TRAINING IN NEW THERAPY USING THE EXAMPLE OF CAR-T CELL THERAPY

PLASMAPHERESIS: TAKING THE EDGE OFF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTIBODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION

INCIDENCE & CHARACTERISTICS OF VARICELLA ZOSTER VIRUS INFECTION POST HEMATOPOIETIC STEM CELL TRANSPLANTATION; EXPERIENCE OF A SINGLE CENTER IN SAUDI ARABIA

SEMI-STRUCTURED INTERVIEW ASSESSMENT OF THE CLINICAL NURSE EDUCATOR ROLE IN SUPPORTING NEWLY QUALIFIED NURSES DURING TRANSITION TO POST-REGISTRATION PRACTICE INSIDE THE BONE MARROW TRANSPLANT SETTING

TRAINING NURSING PROGRAMME IN NEW THERAPIES: CAR T CELLS

NURSES' ROLE IN IMPROVING PATIENTS' FOOD INTAKE IN THE ACUTE HSCT PHASE

USE THE AVAILABLE KNOWLEDGE - ENSURE THAT THE PATIENT RECEIVES THE BEST CARE IN STEM CELL TRANSPLANTATION

THE PSYCHO EMOTIONAL DISAGUE IN ADULT PATIENTS SUBJECT TO MIDOLLO TRANSPLANT: INITIAL STUDY OF A SINGLE CENTER

NURSING CARE OF 15 PATIENTS WITH HEMATOLOGICAL MALIGNANT TUMOR COMPLICATED WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CAR-T CELLS

RETROSPECTIVE OBSERVATIONAL STUDY ON THE TRANSMISSION OF HEALTHCARE ASSOCIATED INFECTIONS AMONG NEUTROPENIC PATIENTS WITHIN THE HEMATOLOGY UNIT OF PIACENZA HOSPITAL
GUIDE FOR PATIENTS AND DONORS BEFORE A PERIPHERAL BLOOD STEM CELL COLLECTION
Natalia Lorente del Río, Cristina Alberquilla Ramos, Salvador Aleza Esteras, Isabel María Fernández Morales, María Del Carmen Freire Mourón, Ana García Carulla, Carmen Granado Rodilla, Mercedes Jiménez Meoro, Rosario López López, Marta Vela Garicano, Jesús Zalvide Torrente, Laura Bibiloni Martínez (Spain)

IMPACT OF AN IMPROVEMENT PLAN ON THE REDUCTION OF BACTERIEMIA BY CENTRAL CATHETER IN A PATIENT RECIPIENT OF A CELLULAR THERAPY

ARE TYMPANIC THERMOMETERS RELIABLE IN HEMATOPOIETIC STEM CELL RECIPIENTS?

RELATIONSHIPS BETWEEN THE HEALTHCARE NEEDS AND QUALITY OF LIFE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS

PAIN ASSESSMENT DURING BONE MARROW BIOPSY PROCEDURE AND BONE MARROW ASPIRATE PROCEDURE: A SPECIFIC NURSING ASSESSMENT

AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION IN SYSTEMIC SCLEROSIS: CASE STUDY

LEADERSHIP - LEADING THE TEAM

PAIN ASSESSMENT IN ONCO_HEMATOLOGICAL PATIENT SUBJECTED TO CENTRAL VENOUS CATHETER POSITIONING (CVC) OR PERIPHERALLY INSERTED CENTRAL CATHETER POSITIONING (PICC)

TOCILIZUMAB MANAGEMENT IN THE CYTOKINE RELEASE SYNDROME

COMPLICATIONS ASSOCIATED WITH THE COLLECTION OF PERIPHERAL BLOOD PROGENITOR CELLS

IS IT WORTH FIGHTING TOGETHER FOR AN INDIVIDUAL ACCESS TO A MEDICINE WITH A NON REIMBURSEMENT DECISION? YES IT IS!

INCIDENCE OF ACUTE GUT GVHD IN PATIENTS WHO HAVE UNDERGONE ALLOGENIC STEM CELL TRANSPLANT: CASE STUDY

COMPLETION TIME TO HLA TYPING

GYNECOLOGICAL TREATMENT EXPERIENCE OF MENOPAUSAL SYNDROME AND SEXUAL DISORDERS IN FEMALE PATIENTS WHO UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION

Nurses Posters - Paediatric

TRANSITION STRATEGY: FROM PEDIATRIC TO ADULT HEALTH CARE AND LONG TERM FOLLOW-UP

CAREGIVER EDUCATION AND TRAINING FOR SELF ADMINISTRATION OF ORAL DRUGS IN A PAEDIATRIC CENTER

EXERCISE THERAPY ON CANCER-RELATED FATIGUE AND QUALITY OF LIFE IN CHILDREN UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION

SEXUAL HEALTH FOR YOUNG PEOPLE UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION
EVALUATION OF A PREVENTIVE SKIN CARE PROTOCOL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS RECEIVING THIOTEPA

CAR-T: THE DUTCH PEDIATRIC NURSING EXPERIENCE

SUBSTITUTIVE THERAPY WITH S.C. IMMUNOGLOBULINS IN PEDIATRIC HSCT RECEPIENTS: A SINGLE CENTER EXPERIENCE

PEDIATRIC PHOTOAPHAERESIS: THE DILEMMA OF VASCULAR ACCESSES

TOTALLY IMPLANTABLE VASCULAR ACCESS DEVICES RUPTURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: PROPHYLAXIS AND TREATMENT

USE OF VOLUMETRIC PUMPS FOR THE INFUSION OF HEMATOPOIETIC STEM CELLS AS A STANDARD METHOD IN PEDIATRIC PATIENTS

PEDIATRIC PATIENT TRANSFER FROM A TPH WARD TO ICU: HOW CAN WE IMPROVE OUR COMMUNICATION?

CARING FOR MINOR SIBLING DONORS

EFFECTIVE MOBILISATION WITH PLERIXAFOR FOLLOWING CRANIA-SACRAL RADIOTHERAPY AND HIGH-DOSE CHEMOTHERAPY: A CASE REPORT OF AN ELEVEN-YEAR OLD BOY WITH GLOIABLASTOMA MULTIFORME

EARLY RECOGNITION OF PEDIATRIC GVHD: EDUCATION AND AWARENESS AMONGST NURSES

RISK ASSESSING PAEDIATRIC PATIENTS' NUTRITIONAL NEEDS PRIOR TO BONE MARROW TRANSPLANT

---

Nurses Posters - Research

FAMILY CAREGIVERS SUPPORT NEEDS DURING ALLO-HSCT - A LONGITUDINAL STUDY (PRELIMINARY RESULTS)

PAIN AND ANXIETY MANAGEMENT DURING BONE MARROW ASPIRATES IN ITALIAN TRANSPLANT PROGRAMS. A NATIONWIDE SURVEY ON BEHALF OF GITMO NG

PREVALENCE, PREDICTORS AND OUTCOMES OF CLABSİ AMONG HSCT PATIENTS

CREATION OF THE LABMT NURSES GROUP

SYMPTOMS AND QUALITY OF LIFE OF CHILDREN AND ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY

SOCIAL SUPPORT MODERATES THE EFFECTS OF HEALTH STRESSORS ON HEALTH CARE ADHERENCE AND PSYCHOLOGICAL DISTRESS IN LONG-TERM HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS

SYMPTOM DISTRESS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A PROSPECTIVE STUDY

NURSE INVOLVEMENT AND IMPACT OF JACIE ACCREDITATION ON NURSE PRACTICE

CONSTRUCTION OF QUALITY INDICATORS SYSTEM OF NUTRITION CARE FOR ADULT PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION THROUGH AN EVIDENCE-BASED APPROACH
**Scientific Programme**

- ARE CAREGIVERS RECEIVING ENOUGH INFORMATION TO CARE? A PILOT STUDY ON A HAEMATOLOGICAL TRANSPLANT UNIT
- MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A THREE YEARS FOLLOWING UP
- VENOUS ACCESS IN AUTOLOGOUS VERSUS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT DONORS: A RETROSPECTIVE STUDY OF AN APHERESIS UNIT
- A STUDY TO ASSESS THE LEVEL OF BURNOUT AMONG NURSES WORKING IN BONE MARROW TRANSPLANT (BMT) UNIT OF A TERTIARY CARE CANCER HOSPITAL
- DO WE KNOW ENOUGH ABOUT THE BONE MARROW DONATION?
- ASSOCIATION OF AIR BORN PARTICLE SIZE AND PARTICLE COUNT WITH INCIDENCE OF INFECTIONS IN HEPA FILTERED ROOMS-A SINGLE CENTRE EXPERIENCE
- SYSTEMATIC REVIEW OF SIGNS AND SYMPTOMS OF THE HUMAN HERPES VIRUS 6 AND THEIR ASSESSMENT TOOLS
- A STUDY TO ASSESS PERCEIVED STRESSORS AND COPING STRATEGIES ADOPTED BY PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL INFUSION IN SELECTED CANCER HOSPITAL, INDIA
- ROLE OF THERAPEUTIC APHERESIS IN ALLOGENEIC TRANSPLANTATION: A CASE REPORT
- SYMPTOMS OF ELDERLY PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER INDUCTION CHEMOTHERAPY

**Paediatric issues**

- PROSPECTIVE OPEN-LABEL PHASE II TRIAL OF INDIVIDUALIZED ANTI-THYMOCYTE GLOBULIN SHOWS IMPROVED EARLY CD4+ T-CELL RECONSTITUTION AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE PARACHUTE-TRIAL
- EBMTC LESSONS FROM 40 YEARS OF HIGH DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN NEUROBLASTOMA: A REPORT FROM THE PAEDIATRIC WORKING PARTY
- INCIDENCE OF SECONDARY MALIGNANCIES AFTER TBI/VP16 CONDITIONING FOR CHILDHOOD ALL: RESULTS OF THE PROSPECTIVE ALL-SCT-BFM-2003 TRIAL
- OUTCOME AND RISK FACTORS OF AUTOIMMUNE CYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY
- EBMTC SURVEY ON 40 YEARS OF HIGH-DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN EWING TUMOURS (ET). A REPORT FROM THE PAEDIATRIC WORKING PARTY
Scientific Programme

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS IN CHILDREN - RETROSPECTIVE REPORT ON BEHALF OF I-BFM SCT COMMITTEE AND EBMT PEDIATRIC DISEASES WP

IS THE EBMT RISK SCORE PREDICTIVE OF OUTCOMES IN PAEDIATRIC ACUTE LEUKEMIA?

TCRαβ+/CD19+-DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION

THE GREAT ORMOND STREET (GOS) PAEDIATRIC CO-MORBIDITY SCORE FOR OUTCOME POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION

HIGH PREVALENCE OF CAROTID PLAQUES IN YOUNG ADULTS AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD

HAPLOIDENTICAL DONOR OR UNRELATED DONOR FOR INFANTS WITH SEVERE COMBINED IMMUNODEFICIENCY?

A ‘RISK-ADJUSTED’ CYTOREDUCTION WITHOUT RADIATION FOR PATIENTS WITH FANCONI ANEMIA UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION (HCT)

USE OF RUXOLITINIB IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD)

HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN REFRACTORY CYTOPENIA OF CHILDHOOD (RCC): IMPROVED ENGRAFTMENT FOLLOWING A TREOSULFAN BASED CONDITIONING REGIMEN

PHARMACOKINETICS OF ACTIVE ATG IMPACTS T-CELL RECOVERY AFTER TCRαβ/CD19-DEPLETED HSCT IN PAEDIATRIC PATIENTS

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A MULTICENTRE STUDY FROM INDIA

IMMUNE RECOVERY AND LONG-TERM SURVIVAL FOLLOWING HAPLOIDENTICAL T AND B CELL DEPLETED STEM CELL TRANSPLANTATION - INFLUENCE OF VARIOUS ATG DOSES

OUTCOMES OF HAPLOIDENTICAL VS MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC HIGH-RISK ALL AND AML IN 1ST AND 2ND CR

COMBINED TCR ALPHA BETA AND CD45RA DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BENIGN HAEMATOLOGICAL CONDITIONS, SINGLE CENTRE EXPERIENCE

GENETIC SUSCEPTIBILITY TO HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME IN PEDIATRIC PATIENTS UNDERGOING HSCT

HAPLO HSCT WITH IN VIVO T-CELL DEPLETION AFTER REDUCED INTENSITY CONDITIONING REGIMEN AND MYELOABLATIVE MUD AND MMUD DONOR HSCT IN PEDIATRIC PATIENTS AFFECTED BY MALIGNANCIES

THINKING BEYOND HLH: CLINICAL FEATURES OF PATIENTS WITH CONCURRENT PRESENTATION OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND THROMBOTIC MICROANGIOPATHY

LANDMARK ANALYSIS IN HIGH RISK CHILDHOOD ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE STUDY

DEFIBROTIDE IN HEMATOPOIETIC STEM CELL TRANSPLANT: AN STUDY OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYETICO (GETH) AND GRUPO ESPAÑOL DE TRASPLANTE DE MEDULA EN NIÑOS (GETMON)
NIVOLUMAB-BASED THERAPY PRIOR TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC HODGKIN'S LYMPHOMA

HUMAN LEUKOCYTE ANTIGEN DISPARITIES REDUCE RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH JUVENILE MYELOMONOCYTIC LEUKEMIA

SCHOOL DURING AND AFTER ALLOGENEIC HSCT: A SURVEY OF PRACTICES IN THREE EUROPEAN COUNTRIES

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HURLER SYNDROME: SINGLE CENTER EXPERIENCE

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH FANCONI ANAEMIA: EXPERIENCE OF THE SPANISH WORKING GROUP FOR BONE MARROW TRANSPLANTATION IN CHILDREN (GETMON)

IMPACT OF MEMORY T-CELL DOSES INFUSED WITH T-CELL DEPLETED HAPLOIDENTICAL STEM CELL GRAFTS ON TRANSPLANT OUTCOMES

THE ROLE OF DONOR KIR GENOTYPING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISORDERS

SINGLE-CENTER EXPERIENCE OF TCRαβ/CD19 DEPLETED STEM CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANEMIA

DETECTION OF RECIPIENT-SPECIFIC α/β-T-CELLS DURING THE PRE-ENGRAFTMENT PHASE DOES NOT PREDICT GRAFT REJECTION IN PATIENTS AFTER HAPLOSCRT: PRELIMINARY RESULTS OF SINGLE CENTRE PROSPECTIVE TRIAL

IMPROVED SURVIVAL AFTER MIBG THERAPY IN COMBINATION WITH MEGACHEMOTHERAPY THAN AFTER STAND-ALONE THERAPY IN CHILDREN WITH NEUROBLASTOMA - POLISH NATION-WIDE RETROSPECTIVE STUDY

THE IMPACT OF HOUSEHOLD INCOME ON ACUTE HOSPITALIZATION DAYS IN PEDIATRIC ALLOGENEIC TRANSPLANT RECIPIENTS

USE OF RIC REGIMENS COMBINED WITH TCRAB DEPLETION AND POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC MISMATCHED SCT

THE ROLE OF HLA-DP MATCHING IN DONOR SELECTION FOR MUD-HSCT IN CHILDREN WITH HEMATOLOGIC MALIGNANT DISEASES

CLINICAL IMPLICATION ON RECOVERY OF γδ T CELLS AFTER TCRαβ-DEPLETED HAPLOIDENTICAL HSCT IN PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE

EARLY INITIATION OF CYCLOSPORINE-MYCOPHENOLATE PLUS ANTITHYMOCYTE GLOBULIN IN HAPLO TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN: LOW INCIDENCE OF SEVERE ACUTE GVHD WITH ENCOURAGING SURVIVAL

FEASIBILITY AND SAFETY OF SURGICAL FERTILITY PRESERVATION TECHNIQUES PROXIMAL TO INITIATION OF CONDITIONING THERAPY IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT

VENO-OCLUSION DISEASE WITH EMPHASIS ON RENAL MANIFESTATIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS: A SINGLE CENTER EXPERIENCE

OUTCOME AFTER HSCT IN CHILDREN WITH JMML FROM A HISTORICAL POINT OF VIEW

THE IMPACT RECOVERY ABSOLUTE LYMPHOCYTE COUNT AT DAYS +21 ON OUTCOME ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC ALL

T-CELL-RICH HAPLOIDENTICAL STEM CELL TRANSPLANTATION IMPROVES SURVIVAL IN CHILDREN WITH ACUTE LEUKEMIA RELAPSED AFTER ALLOGENEIC TRANSPLANTATION
HIGH PREVALENCE OF VITAMIN C DEFICIENCY IN A LARGE PAEDIATRIC COHORT UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE FROM 2003-2019

EX VIVO T CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE

LONG-TERM ERYTHROPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: HOST DETERMINES RESULT

BOOST WITH CD34+ CELLS FOR POOR GRAFT FUNCTION TREATMENT AFTER HSCT IN PAEDIATRIC PATIENTS. A MULTICENTER STUDY

NO DIFFERENCE IN SURVIVAL AFTER HLA MISMATCHED VERSUS HLA MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION

ALLOGENIC STEM CELL TRANSPLANTATION FOR FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE

STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-ANAPLASTIC PERIPHERAL T-CELL LYMPHOMA ON BEHALF OF THE EBMT-PEDIATRIC DISEASES WORKING PARTY

FIRST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RASGRP1 DEFICIENCY

SUCCESSFUL HSCT IN IMMUNE DISREGULATORY DISEASES

LEVOFLOXACIN BASED PROPHYLAXIS IN CHILDREN RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT AFFECT THE INCIDENCE OF ACUTE GVHD AND BLOODSTREAM INFECTIONS

RITUXIMAB-INDUCED SECONDARY HYPOGAMMAGLOBULINEMIA: MEMORIAL SLOAN KETTERING'S 10-YEAR EXPERIENCE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS

‘INCURABLE’ PAEDIATRIC MYELOID LEUKAEMIA TREATED WITH NOVEL CELL-BASED THERAPEUTICS

EFFECT OF SERUM PANEL REACTIVE ANTIBODIES ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE

SINGLE CENTRE EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR INHERITED BONE MARROW FAILURE SYNDROMES

IS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION A GOOD INDICATION FOR PATIENTS WITH SIFD SYNDROME?

TIME COURSE AND IMPACT OF BODY WEIGHT CHANGE EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HIGH RISK EWING SARCOMA, A SINGLE CENTER EXPERIENCE

CONDITIONING FOR RETRANSPLANTATION FROM THE SAME DONOR AFTER PARTIAL AUTOLOGOUS RECONSTITUTION IN PATIENTS WITH PID: IMMUNOSUPPRESSION IS NOT REQUIRED

TOCILIZUMAB TREATMENT FOR CRS IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Scientific Programme

IDIOPATHIC PNEUMONIA SYNDROME (IPS) AFTER PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FROM UNRELATED DONOR FOR HURLER SYNDROME (MUCOPOLYSACCHARIDOSIS TYPE 1) SUCCESSFULLY TREATED WITH ETANERCEPT AND STEROIDS

EFFECT OF DESSENSITIZATION PROTOCOL ON TRANSPLANTATION SUCCESS IN CHILDREN WITH ANTI-HLA ANTIBODIES

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOHSCT) WITH DIFFERENT INTENSITY CONDITIONING REGIMENS IN INFANT AML

VENETOCLAX/DECITABINE FOR PEDIATRIC MDR-AML RELAPSED AFTER TWO ALLO HSCTS

HIGHER INCIDENCE OF CMV AND BKV REACTIVATION IN HAPLOIDENTICAL TRANSPLANTS COMPARATIVE TO MUD OR MSD TRANSPLANTS - SINGLE CENTRE RETROSPECTIVE ANALYSIS

USE OF POLyclONAL IGM-ENRICHED IMMUNOGLOBULINS FOR THE TREATMENT OF SEPTIC EPISODES IN CHILDREN WITH ONCOHEMATOLOGICAL DISEASES

PAEDIATRIC BONE MARROW TRANSPLANT CARE ON BMT VERSUS NON-BMT PAEDIATRIC WARDS

CHRONIC HEALTH PROBLEMS IN CHILDREN AFTER ALLOGENEIC HSCT: THE TOP OF THE ICEBERG?

HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: SINGLE-CENTER SERIES OF 14 CASES

NON-WHITE HISPANIC ETHNICITY AS A RISK FACTOR FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC TRANSPLANT

PNEUMATOSIS INTESTINALIS AS A RARE POST-TRANSPLANT COMPLICATION IN PEDIATRIC PATIENTS

THE CHALLENGES AND OUTCOMES SURROUNDING INTRAVESICULAR CIDOFOVIR ADMINISTRATION: A PAEDIATRIC PHARMACY PERSPECTIVE

THE EXPERIENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RARE HEMATOLOGIC DISEASE

SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH DNA LIGASE IV DEFICIENCY WITH NONMYELOABLATIVE CONDITIONING REGIMEN

HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT-HD-CYCLOPHOSPHAMIDE FOR RELAPSED B-LYMPHOBLASTIC LYMPHOMA (B-LBL) WITH MLL-REARRANGEMENT IN 1 Y.O. CHILD: A CLINICAL CASE

Pharmacology

ELTROMBOPAG THERAPY IN STEM CELL TRANSPLANT RECIPIENTS SHOWS EFFECTIVE IRON MOBILISATION

CLINICAL IMPACT OF MODEL PK GUIDED-CYCLOSPORINE DOSE INDIVIDUALIZATION IN CHILDREN UNDERGOING HSCT

INFLUENCE OF CYP2D6 METABOLIZER STATUS ON THE CONTROL OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING BY ONDANSETRON ON PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Scientific Programme

ESTIMATION OF GLOMERULAR FILTRATION RATE IN ADULTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: CYSTATIN C VERSUS CREATININE

USE OF SUBLINGUAL TACROLIMUS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH HISTORY OF ANAPHYLAXIS TO INTRAVENOUS CYCLOSPORINE

ORAL CLONAZEPAM FOR SEIZURE PROPHYLAXIS IN ADULT PATIENTS TREATED WITH HIGH DOSE BUSULFAN

DISSOLUTION TIME FOR CONVENTIONAL AND LYOPHILIZED CYCLOPHOSPHAMIDE: A SINGLE CENTER STUDY

OUTCOMES OF EBV VIREMIA AND PTLD AFTER RITUXIMAB: A PHARMACOCOST ANALYSIS

PHARMACOLOGICAL INTERACTIONS IN THE POST-TRANSPLANT PHASE OF HEMATOPOYETIC PROGENITORS TRANSPLANTATION

EVALUATION OF SIDE EFFECTS AND EFFICACY OF LOMUSTINE (CCNU) AND BANDAMUSTINE IN PATIENTS WITH LYMPHOMA

Psychological issues

INVESTIGATING THE LONG-TERM OUTCOMES OF ADULT PATIENTS WHO UNDERWENT HAEMATOPOIETIC STEM CELL TRANSPLANT FOR PRIMARY IMMUNODEFICIENCY DURING CHILDHOOD

THE IMPACT OF MEDICAL AND SOCIAL REHABILITATION ON THE QUALITY OF LIFE IN CHILDREN WITH ONCOLOGIC AND HEMATOLOGIC DISEASES

THE IMPACT OF PRE-TRANSPLANT DEPRESSION AND ANXIETY ON THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION, A STUDY OF THE TCWP OF THE EBMT

ASSOCIATIONS BETWEEN FAMILY FUNCTION DOMAINS AND COPING STRATEGIES OF ADOLESCENTS UNDERGOING HSCT

HOW PATIENTS' VIEWS ARE HELPING SHAPE PLANS FOR A NEW TRANSPLANT PSYCHOLOGY SERVICE

CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: TWO DIFFERENT ANALYTICAL APPROACHES

ARC CLINIC: APPLYING PSYCHOLOGICAL INSIGHTS TO PROMOTE EARLY REHABILITATION IN MYELOMA POST-TRANSPLANT

FROM HOSPITALIZATION TO RETURN HOME: A TRANSITIONAL ACTION RESEARCH IN THE HEMATOLOGY SECTOR

1000 IN 10 . 10 YEARS OF CLINICAL PSYCHOLOGY PRACTICE WITH 1000 PATIENTS IN THE SAME BMT UNIT IN MARSEILLE, FRANCE

IMPLEMENTATION OF PSYCHOLOGICAL SUPPORT AND DEVELOPMENT OF EDUCATIONAL PROGRAM FOR CHILDREN AND ADOLESCENTS UNDERGOING HSCT AND THEIR PARENTS IN RUSSIA
Quality Management

- Comparing Compliance for Collection Facility JACIE Standards 6.1 and 7th Editions
- Integration of Theory and Practice: Scenario-Based Skill Training in Administering CAR-T Cells
- “TPFMEA”, An International Model for Assessing Risks in a Stem Cell Transplant Program
- Defining Patient-Important Outcomes After Pediatric Hematopoietic Stem Cell Transplant
- Implementation of JACIE Accreditation at a Novel Transplant Program: The Impact on the Clinical Practice
- How One Processing Centre Prepared for its First JACIE Inspection?
- Tips for Generating Successful ‘Teamworking’ in Our Healthcare Facilities: The Experience of a Hospital Unit in a French Cancer Center
- Implementation of a Quality System for Running a Cell and Gene Therapy Clinical Trial Within a JACIE-Accredited Transplant Program
- New Online Platforms in Quality Management: Coordination and Multidisciplinary Care
- Risk Management Assessment in Implementing CAR-T Cell Therapy in a Clinical Unit
- Febrile Reaction After HSC Infusion Is More Frequent If No Steroid Premedication Is Given Which Results in More Frequent Use of Antibiotics Early Post-Transplant
- Searching for Other Topics of Qualification Plans in the Transplant Program Clinical Part - The One Center Experience
- Practice Patterns in Chronic GVHD Patient Management and Patient Reported Outcome Measures Across the EBMT Allogeneic Transplantation Network
- Maintaining Donor Safety and Welfare Throughout Cellular Therapy Product Donation
- Digital JACIE at The Christie
- Integration of Cellular Therapy in the JACIE (Joint Accreditation Committe ISCT-EBMT) Quality Management Plan. Single Center Experience
- Audit - A Method to Evaluate Interventions - Experiences From an Attempt to Improve Nutritional Status in Patients Treated with Autologous Hematopoietic Stem Cell Transplantation
- Quality of Life Assessment After Pediatric Hematopoietic Stem Cell Transplantation
- Retrospective Analysis of Time to Alternative Donor Identification and Hematopoietic Stem Cells Procurement in the Absence of Matched-Sibling Donors in a Single Center in Spain
GOVERNANCE, RISKS AND REGULATORY ASPECTS OF UNLICENSED LENTIVIRAL VECTOR-MODIFIED AUTOLOGOUS STEM CELL TREATMENT

UNIQUE SUPPORTIVE CARE ALGORITHMS FOR CHILDREN UNDERGOING HAPLOIDENTICAL HSCT FOR BENIGN HAEMATOLOGICAL DISORDERS

QUALITY OF LIFE IN PARENTS OF TURKISH AND SYRIAN PEDIATRIC BONE MARROW TRANSPLANT AND ONCOLOGY PATIENTS

COLLECTION OF AUTOLOGOUS MONONUCLEAR CELLS IN NON-CYTOKINE STIMULATED DONORS: COMPARING TWO APHERESIS METHODS

EFFECTIVE CAR-T CELL DELIVERY: A MULTIDISCIPLINARY APPROACH AT MFT

HAEMOPOIETIC PROGENITOR CELL PROFICIENCY TESTING

VALIDATION AND COMPARISON OF AEROBIC AND ANAEROBIC BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ALERT (R) 3D (TM) AND VIRTUO (TM) MICROBIAL BIObURDEN SYSTEMS FOR HAEMATopoIETIC PROGENITOR CELLS (HPC)

START-UP OF AN ADHERENCE RECEPTION FOR ALLOGENIC STEM CELL TRANSPLANTED PATIENTS AT THE HEMATOLOGICAL DEPARTMENT LINKÖPING, SWEDEN

ENUMERATION OF RESIDUAL RED BLOOD CELLS IN MIS-MATCHED ALLOGENIC PBSC COLLECTIONS - TRADITIONAL HAEMATOLOGY ANALYSER VS FLOW CYTOMETRY

INVESTIGATION AND ANALYSIS OF FACTORS AFFECTING GASTROINTESTINAL NUTRITION RECOVERY AFTER MULTIPLE MYELOMA AUTOLOGOUS STEM CELL TRANSPLANTATION AND EFFECTS OF NUTRITIONAL INTERVENTION

CHARACTERISTICS OF IRON DEFICIENCY ANEMIA IN PRE-MENOPAUSAL WOMEN IN KOREA

LEUKEMIA AND ITS TYPES

Regenerative medicine

WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL THERAPY IMPROVES THE QUALITY OF LIFE AND SELF-SUFFICIENCY OF CHILDREN WITH AUTISM SPECTRUM DISORDER

MARROW DERIVED CELLS BRING A LONG LASTING RELIEF WHEN INJECTED INTRAARTICULARLY TO THE JOINTS WITH DEGENERATIVE ARTHRITIS

OSTEOGENIC DIFFERENTIATION CAPACITY OF ADIPOSE-DERIVED STEM CELLS AFFECTED WITH COLD STORAGE

Solid tumours

SUCCESSFUL KIR ALLOREACTIVE HSCT IN A CHILD WITH RESISTANT EWING SARCOMA

TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS
Scientific Programme

**VOC PATTERN RECOGNITION OF LUNG CANCER: A COMPARATIVE EVALUATION OF DIFFERENT DOG- AND ENOSE-BASED STRATEGIES USING DIFFERENT SAMPLING MATERIALS**

**Statistics**

**USE OF VARIABLE SELECTION METHODS TO IDENTIFY CLINICAL AND IMMUNOLOGICAL FACTORS ASSOCIATED WITH THE CLINICAL OUTCOME OF PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THE IMPACT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION ON WORK AND PRODUCTIVITY LOSS IN PATIENTS WITH ACUTE LEUKAEMIA: RESULTS FROM A RAPID REVIEW**

**GEOGRAPHIC AND SOCIOECONOMIC IMPACTS ON SURVIVAL AMONG ALLOGENEIC TRANSPLANT RECIPIENTS**

**Stem cell donor**

**DONOR-RECIPIENT HLA MATCHING FOR UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION: Outcomes: A STUDY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY (CTIWP) OF THE EBMT**

**PRESENCE OF AGE-RELATED CLONAL HEMATOPOIESIS (ARCH) IN DONOR DOES NOT INCREASE THE RISK OF LATE SECONDARY MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Kyoung Ha Kim, Tae Hyung Kim, Jae-Sook Ahn, Ivan Pasic, Zeyad Al-Shaibani, Arjun Law, Wilson Lam, Fotios Michilis, Armin Gerbitz, Auro Viswambanda, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Zhaolei Zhang, Tamir Biezuner, Liran Shlush, Dennis Dong Hwan Kim (Canada)

**SERIOUS EVENTS AND ADVERSE REACTIONS IN RELATION TO BLOOD STEM CELL DONATION REPORTED TO WMDA IN 2018**

**THE IMPROVEMENT IN OVERALL SURVIVAL FROM UNRELATED DONOR TRANSPLANT IN AUSTRALIA AND NEW ZEALAND IS DRIVEN BY A REDUCTION IN TRANSPLANT RELATED MORTALITY**

**POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING, UNRELATED AND HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA, A COMPARATIVE STUDY OF THE ALWP EBMT**

**ALLOREACTIVITY AGAINST HLA-DPB1 IN HOST-VERSUS-GRAFT DIRECTION IS ASSOCIATED WITH INCREASED RISK OF GRAFT FAILURE AFTER MATCHED UNRELATED DONOR TRANSPLANTATION FOR NONMALIGNANT DISEASES**

**IMPACT OF KIR ON PATIENTS WITH LYMPHOID DISEASES AFTER T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**INDICATIONS AND SAFETY OF MULTIPLE BONE MARROW HARVESTS IN PEDIATRIC DONORS FOR MATCHED SIBLING RECIPIENT TRANSPLANTATION**

**HEALTHY VOLUNTARY STEM CELL DONORS: FOLLOW UP AFTER HPC APHERESIS DONATION: THE EXPERIENCE OF ITALIAN BONE MARROW DONOR REGISTRY**
ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH INHERITED DISORDERS

HAPLOIDENTICAL REDUCED-INTENSITY HEMATOPOIETIC CELL TRANSPLANTATION USING BUSULFAN, FLUDARABINE, AND ANTITHYMOCYTE GLOBULIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

THE RESULTS OF A TELECONFERENCE ABOUT THE EXPERIENCES AND EXPECTATIONS OF RELATED HEMATOPOIETIC STEM CELL DONORS AFTER DONATION

IMPACT OF THE ESTABLISHMENT OF THE TURKISH NATIONAL DONOR REGISTRY (TURKOK) ON A SINGLE CENTER'S TRANSPLANT OUTCOME: INTERNATIONAL STEM CELL DONORS VERSUS NATIONAL

YOUNG MALE DONORS MAY RESULT IN BETTER OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA WITH PT-CY

DONORS OF PERIPHERAL HEMATOPOIETIC STEM CELLS, OUR EXPERIENCE FOR LAST 10 YEARS

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS OVER 70 YEARS: A MONOCENTRIC EXPERIENCE OF 48 PATIENTS

COMPARISON OF TRANSPLANT OUTCOMES AND ECONOMIC COSTS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML AND MDS BETWEEN THE DIFFERENT TYPE OF DONORS

HIGH DISEASE-FREE SURVIVAL OF THE SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH DONOR CHANGE AND MAINLY REDUCED-INTENSITY CONDITIONING IN RELAPSED HEMATOLOGICAL MALIGNANCES

EPIDEMIOLOGICAL STUDY OF RARE ANTIGENS OF THE MAIN HISTOCOMPATIBILITY COMPLEX AMONG HEMATOPOIETIC STEM CELL DONORS IN BELARUS

IMPACT OF DONOR-RECIPIENT SEX MISMATCH IN PATIENTS RECEIVING PARTIAL T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE MONOCENTRIC STUDY

HAPLOIDENTICAL DONOR SELECTION AND ITS IMPLICATIONS IN TRANSPLANTATION OUTCOME. OUR EXPERIENCE AT HUDGC DR. NEGRIN

OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ACCORDING TO DONOR AVAILABILITY, DURATION FROM DIAGNOSIS TO TRANSPLANT AND DONOR-SPECIFIC PARAMETERS - A SINGLE CENTER ANALYSIS

THE BENEFITS OF HLA-MATCHED RELATED DONORS FOR PATIENTS LACKING HLA-IDENTICAL SIBLING IN THE ABSENCE OF POWERFUL LOCAL UNRELATED REGISTRY IN COUNTRIES WITH PREVALENT COUSIN MARRIAGES

DONOR AGE INFLUENCES THE GRAFT-VERSUS-HOST-DISEASE-FREE AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANT IN ELDERLY PATIENTS IN LATIN AMERICA

A STUDY OF THE UNCERTAINTY, UNCERTAINTY APPRAISAL AND GROWTH AND THE AFFECTED FACTORS ON HEMATOPOIETIC STEM CELL DONORS

WITHDRAWL OF VOLUNTEER DONORS FROM THE INTERNATIONAL REGISTRIES: A SINGLE CENTRE EXPERIENCE

OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION FOR AML AND MYELODYSPLASTIC SYNDROME IN ELDERLY WITH REDUCED-INTENSITY CONDITIONING

HAPLOIDENTICAL VS UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS WITH HEMATOLOGIC MALIGANACIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
HEPATITIS E VIRUS (HEV) CONTAMINATED HEMATOPOIETIC STEM CELL GRAFT IN A MATCHED UNRELATED DONOR TRANSPLANTATION

HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MATCH RELATED DONORS IN CHILDHOOD: SINGLE CENTER EXPERIENCE

FIRST EXPERIENCE WITH UNRELATED STEM CELL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN A TRANSPLANT CENTER FROM NORTH MACEDONIA

e-Posters
12:30 - 18:30

Stem cell mobilization, collection and engineering

TWO YEAR ANALYSIS OF A PROSPECTIVE PHASE I/II CLINICAL TRIAL IN ADULTS USING TCR ALPHA/BETA DEPLETED STEM CELL TRANSPLANTATION FROM MATCHED RELATED AND UNRELATED DONORS

A NEW BSA-BASED THRESHOLD PREDICTS OPTIMAL PBSC COLLECTION IN T-CELL DEPLETED HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION

PHASE 1 CLINICAL STUDY OF MGTA-145 IN COMBINATION WITH PLERIXAFOR SHOWS RAPID SINGLE-DAY MOBILIZATION AND COLLECTION OF CD34+ HSCS WITHOUT G-CSF

DEPLETION OF αβ T-CELLS AND B-CELLS BEFORE HLA-HAPLOIDENTICAL HSCT IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISORDERS: A REPORT OF 473 PROCEDURES

ACOUSTOPHORESIS ENABLES THE LABEL-FREE SEPARATION OF DISTINCT SUBSETS FROM CULTURED BONE MARROW STROMAL CELLS

FEASIBILITY OF MODIFIED CD45RA NEGATIVE DONOR LYMPHOCYTES INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

BEYOND STEM CELLS - DOES IT MATTER WHAT'S IN THE BAG IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA AND LYMPHOMA?

EXPRESSIONS OF CO-INHIBITORY MARKERS INCREASE EFFECTOR MEMORY T CELLS IN G-CSF MOBILIZED PERIPHERAL STEM CELLS

LIPEGFILGRASTIM COMBINED WITH CHEMOTHERAPY WAS MORE COST-EFFECTIVE THAN PEGFILGRASTIM IN THE MOBILIZATION OF CD34+ CELLS IN NHL PATIENTS

MOBILIZATION AND HARVEST OF PERIPHERAL BLOOD STEM CELLS (PBSC) FOR ALLOGENEIC STEM CELL TRANSPLANTATION FROM 335 PEDIATRIC SIBLING HEALTHY DONORS

A COMPARISON OF CHEMO-FREE STRATEGY WITH G-CSF PLUS PLERIXAFOR ON DEMAND VERSUS ID-CYCLOPHOSPHAMIDE AND G-CSF AS PBSC MOBILIZATION IN MULTIPLE MYELOMA: AN EXPLORATIVE COST ANALYSIS

EVALUATION OF VIA FREEZETM QUAD FOR LIQUID NITROGEN-FREE CGMP-COMPATIBLE CONTROLLED-RATE FREEZING OF HEMATOPOIETIC PROGENITOR CELL GRAFTS

CD34+ CELL SUBSETS IN STEM CELL PRODUCTS AND THEIR RELATIONSHIP WITH ENGRAFTMENT KINETICS
Scientific Programme

PLERIXAFOR ON DEMAND IN COMBINATION WITH LOW-DOSE CYCLOPHOSPHAMIDE AND G-CSF FOR THE MOBILIZATION OF HSC IN MULTIPLE MYELOMA PATIENTS: HIGH EFFICACY AND LOW TOXICITY

PERFORMANCE QUALIFICATION OF LOVOTM MEDICAL DEVICE FOR WASHING AND CONCENTRATING 3 AND MORE HEMATOPOIETIC PROGENITOR CELL CRYOPRESERVED BAGS FROM WORK-UP REQUEST TO DONATION IN THREE WEEKS: A DEDICATED REGISTRY INTEGRATED UNRELATED DONOR STEM CELL COLLECTION CENTER IS SAFE, EFFICIENT AND CONVENIENT FOR DONORS

LOW-DOSE CYCLOPHOSPHAMIDE + G-CSF IS NO MORE EFFECTIVE THAN G-CSF ALONE WHEN MOBILIZING AND COLLECTING STEM CELLS FOR AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA PATIENTS

FIRST INTERIM RESULTS OF NIS OPTIMOB - NATIONWIDE TRIAL OF MOBILIZATION AND COLLECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS

THE IMPACT OF PLERIXAFOR 'ON DEMAND' ON THE HEMATOPOIETIC STEM CELL (HSC) COLLECTION, PRODUCT'S QUALITY AND ENGRAFTMENT

ELEVATED SERUM LACTATE DEHYDROGENASE AFTER STEM CELL MOBILISATION PREDICTS SUCCESSFUL STEM CELL COLLECTION IN CHILDREN

INFLUENCE OF THE DMSO WASH STRATEGY ON ADVERSE REACTIONS DURING INFUSION OF HEMATOPOIETIC PROGENITORS

BONE MARROW DONOR CHARACTERISTICS: INFLUENCE ON HARVEST YIELD AND DONOR RECOVERY

PLERIXAFOR SALVAGES AUTOLOGOUS STEM CELL MOBILISATION PROCEDURES IN MYELOMA PATIENTS PREVIOUSLY TREATED WITH LENALIDOMIDE OR AUTOLOGOUS HSCT: COST-EFFECTIVENESS OF UPFRONT USE SHOULD BE EXPLORED

EFFECT OF SHIPPING TIME AND TRANSPORT CONDITIONS ON THE VIABILITY OF CORD BLOOD LEUKOCYTES

OPTIMIZATION OF A STEM CELL MOBILIZATION STRATEGY FOR PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA

AUTOLOGOUS LYMPHAPHERESIS FOR THE PRODUCTION OF CAR-T CELLS

RED BLOOD CELL DEPLETION AND/OR VOLUME REDUCTION IN BONE MARROW PROCESSING: A COMPARISON OF TWO METHODS

CORRELATION OF INTRA-OPERATIVE TOTAL NUCLEATED COUNT AND DONOR CHARACTERISTICS WITH FINAL ALLOGENEIC BONE MARROW GRAFT CHARACTERISTICS AND RECIPIENT CLINICAL OUTCOMES

MULTICENTRE EVALUATION OF THE HPC MODUS (XN-20) FOR TIMING THE HARVEST OF STEM CELLS FROM PERIPHERAL BLOOD

IMPACT OF CHANGE OF MOBILISATION METHOD ON ADEQUACY OF STEM CELL COLLECTION IN MULTIPLE MYELOMA PATIENTS: SINGLE CENTRE EXPERIENCE

TWO DIFFERENT PLERIXAFOR STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE

AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS (PBSCS) MOBILIZATION AND COLLECTION-PRINCESS NOORAH ONCOLOGY CENTER EXPERIENCE, KAMC - JEDDAH - SAUDI ARABIA

REVIEW OF PLERIXAFOR USE IN A TERTIARY PAEDIATRIC ONCOLOGY CENTRE
Scientific Programme

UNUSUAL HIGH COUNT OF CD34+ AFTER CHEMO MOBILIZATION WITH MATRIX IN PATIENT WITH PRIMARY CNS LYMPHOMA IS ASSOCIATED WITH PROMPT AND ROBUST ENGRAFTMENT

LEUKOCYTAPHERESIS - ONE TECHNIQUE, DIVERSE OPPORTUNITIES IN THE THERAPY OF PATIENTS

COMPARISON OF CONTINUOUS MONONUCLEAR CELL COLLECTION (CMNC) AND MONONUCLEAR CELL CELL (MNC) METHODS FOR CELL PROLIFERATION (APERESIS) IN PATIENTS WITH BONE MARROW TRANSPLANTATION

e-Posters
12:30 - 18:30

Stem cell source

OPTIMIZING OUTCOMES OF ACUTE LEUKEMIA AFTER TRANSPLANTS WITH SINGLE UNRELATED CORD BLOOD UNITS SELECTED ACCORDING TO CURRENT INTERNATIONAL RECOMMENDATIONS FOR CELL DOSE AND HLA MATCH

IMPACT OF HLA-MISMATCH ON OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE ANALYSIS BY THE JSHCT HLA WORKING GROUP

CLINICAL IMPACT OF DONOR EPITOPE-SPECIFIC HLA ANTIBODIES AND THIRD-PARTY HLA ANTIBODIES IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION

ADDITION OF TOCILIZUMAB TO CYCLOSPORINE-A AND MYCOPHENOLATE MOFETIL FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS SIGNIFICANTLY ABROGATES SEVERE ACUTE GVHD AFTER DOUBLE-UNIT CORD BLOOD TRANSPLANTATION IN ADULTS

THE USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) IN UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION

COMPARATIVE STUDY OF HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETION VS UNRELATED CORD BLOOD TRANSPLANT FOR ADULTS WITH HAEMATOLOGICAL MALIGNANCIES

USE OF G-CSF MOBILIZED BONE MARROW GRAFTS IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION (BMT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) DECREASES RISK OF SEVERE ACUTE GVHD

CMV-SPECIFIC FUNCTIONAL IMMUNE RECONSTITUTION IS SLOWER AFTER UMBILICAL CORD BLOOD COMPARED WITH MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION

REDUCED INTENSITY (RIC) VS MYELOABLATIVE CONDITIONING (MAC) IN CORD BLOOD TRANSPLANTATION FOR AML (40-60 YEARS) ACROSS MISMATCHED HLA BARRIERS - ANALYSIS BY CTIWP/EUROCORD OF EBMT

COST OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REAL WORLD: AN ANALYSIS USING THE JAPANESE NATIONAL DATABASE

ASSOCIATION BETWEEN THE DOSE OF CD3+ AND CD34+ CELLS IN THE GRAFT AND POST-TRANSPLANT OUTCOMES

HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A RELATED DONOR WITH HLA-1 ANTIGEN MISMATCH IN THE GRAFT-VERSUS-HOST DIRECTION USING LOW-DOSE ANTITHYMOCYTE GLOBULIN: MULTICENTER PHASE II TRIAL
INTRA-BONE CORD-BLOOD TRANSPLANT OF UNWASHED UNITS WITH ATG-FREE AND SIROLIMUS-BASED GVHD PROPHYLAXIS: FAST IMMUNE-RECONSTITUTION AND LONG-TERM DISEASE CONTROL IN 22 PATIENTS WITH HIGH-RISK DISEASES

ANTI-HLA DONOR SPECIFIC ANTIBODIES (DSA) DOES NOT AFFECT GRAFT AND SURVIVAL IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) WITH ORIGINAL POST-TRANSPLANT CYCLOFOSFAMIDE (PT-CY) SCHEDULE

MESENCHYMAL STEM/STROMAL CELL PRODUCTION COMPLIANT WITH GOOD MANUFACTURING PRACTICE: COMPARISON BETWEEN BONE MARROW AND WHARTON’S JELLY

EFFICIENT DMSO REMOVAL AND HIGH CELL RECOVERY WITH LOVO CELL PROCESSING SYSTEM IN HPC-A CONCENTRATES: A SINGLE CENTRE EXPERIENCE

Special Session
13:30 - 14:30  Auditorium 1

SS1, Impact of COVID-19 in Hematology, Transplantation and Cellular Therapy

Chairs:
Rafael Duarte (Spain)
Nicolaus Kröger (Germany)

The challenge of COVID-19 for HSCT: EBMT recommendations and prospective registry study 13:30 - 13:42
Per Ljungman (Sweden)

The challenge of COVID-19 for HSCT in Italy 13:42 - 13:54
Fabio Ciceri (Italy)

The challenge of COVID-19 for HSCT in Spain 13:54 - 14:06
Anna Sureda (Spain)

The challenge of COVID-19 for HSCT in the UK 14:06 - 14:18
Kim Orchard (United Kingdom)

Q&A 14:18 - 14:30

Nurses Group
13:30 - 14:30  Auditorium 2

NG01, Nurses Education Day: Steroids - The haematology bad boys. Love them, loathe them, can’t live without them

Chairs:
Julia Ruiz Pato (Spain)

Welcome and introduction 13:30 - 13:35
John Murray (United Kingdom)

Jörg Halter (Switzerland)

How does it work? Mechanism of action 13:55 - 14:15
Agnès Bonnin (France)
Scientific Programme

Q&A

Educational
13:30 - 14:30
Auditorium 3

E1, Autoimmune diseases

Chairs:
Tobias Alexander (Germany)
Raffaella Greco (Italy)

Current indications and scientific correlations of HSCT in autoimmune diseases
Maria Carolina Oliveira Rodrigues (Brazil)

HSCT in Multiple Sclerosis: State of the art and future questions
Giovanni Mancardi (Italy)

HSCT in Systemic Sclerosis: State of the art and future questions
Jacob M. van Laar (Netherlands)

Q&A

Psy Day
13:30 - 14:30
Auditorium 4

Psy1, Workshop I: Survivorship programme

Chairs:
Frank Schulz-Kindermann (Germany)

Introduction
Anna Barata (United States)

Survivorship
Karen Syrjala (United States)

Working therapeutically with despair: Supporting patients with prolonged hospital admissions post-BMT
Surabhi Chaturvedi (United Kingdom)

Text chat Q&A

Pharmacists Day
13:30 - 14:30
Auditorium 5

Pharm1, Pharmacotherapy in HSCT

Chairs:
Rick Admiraal (Netherlands)
GFR estimation in HSCT patients: Is creatinine enough?  
Claudia Langebrake (Germany)  
13:30 - 13:45

ATG vs. post-cyclophosphamide  
Eolia Brissot (France)  
13:45 - 14:00

EVALUATION OF THE ROBUSTNESS OF THERAPEUTIC DRUG MONITORING COUPLED WITH BAYESIAN FORECASTING OF BUSULFAN WITH REGARD TO INACCURATE DOCUMENTATION  
Adrin Dadkhah, Dzenefa Alihodzic, Astrid Broeker, Nicolaus Kroeger, Claudia Langebrake, Sebastian Wicha (Germany)  
14:00 - 14:15

Text chat Q&A  
14:15 - 14:30

Educational  
15:00 - 16:00  
Auditorium 1

E2, Educational forum on microbiota and allogeneic HSCT  
Chairs:  
Ernst Holler (Germany)  
Grzegorz Basak (Poland)

Current understanding of the impact of microbiome on HSCT alloreactive phenomena and outcome  
Daniela Weber (Germany)  
15:00 - 15:15

Gut microbiota and GVHD in children  
Riccardo Masetti (Italy)  
15:15 - 15:30

Preventive and therapeutic interventions in the microbiota  
Florent Malard (France)  
15:30 - 15:45

Q&A  
15:45 - 16:00

Nurses Group  
15:00 - 16:00  
Auditorium 2

NG02, Nurses Education Day: Steroids - The haematology bad boys. Love them, loathe them, can’t live without them  
Chairs:  
Isabel Salcedo (Spain)

Osteonecrosis  
Nicola Chesman (United Kingdom)  
15:00 - 15:25

Effects on immune system: Infections  
Lucrecia Yáñez San Segundo (Spain)  
15:25 - 15:50

Q&A  
15:50 - 16:00
Educational  
15:00 - 16:00  
**Auditorium 3**

**E3, Infectious complications: New therapies and prevention**

**Chairs:**  
Jan Styczynski (Poland)  
Rafael de la Cámara (Spain)

- **Multiresistant bacteria in children and adults: Insight on new antibiotics**  
  15:00 - 15:15  
  Dina Averbuch (Israel)

- **Management strategies in the new adenovirus landscape**  
  15:15 - 15:30  
  Per Ljungman (Sweden)

- **How to structure an effective HSCT vaccine programme**  
  15:30 - 15:45  
  Catherine Cordonnier (France)

- **Q&A**  
  15:45 - 16:00

**Psy Day**

15:00 - 16:00  
**Auditorium 4**

**Psy2, Workshop II: Donors, caregivers and the transplant team**

**Chairs:**  
Surabhi Chaturvedi (United Kingdom)

- **The dynamics of donor commitment**  
  15:00 - 15:15  
  Suzanna M. van Walraven (Netherlands)

- **Supporting transplant caregivers**  
  15:15 - 15:30  
  Maria Die Trill (Spain)

- **Supporting the transplant team**  
  15:30 - 15:45  
  Alice Polomeni (France)

- **Text chat Q&A**  
  15:45 - 16:00

**Pharmacists Day**

15:00 - 16:00  
**Auditorium 5**

**Pharm2, Management of adverse events**

**Chairs:**  
Vera Pires (Portugal)

- **Management of adverse events of CAR T (tisagenlecleucel) in paediatrics**  
  15:00 - 15:15  
  Barbara de Moerloose (Belgium)

- **CAR T and the clinical pharmacist - Standardisation of toxicity management across the UK**  
  15:15 - 15:30  
  Jackie Chappell (United Kingdom)  
  Sumantha Gabriel (United Kingdom)
Scientific Programme

Management of mucositis in HSCT
Filipa Cosme Silva (Portugal)
15:30 - 15:45

Text chat Q&A
15:45 - 16:00

Educational
16:30 - 17:30
Auditorium 1

E4, Therapies to bring resistant acute leukaemia into HSCT
Chairs:
Mohamad Mohty (France)

Novel targeted therapy before HSCT for AML/MDS
Guillermo García-Manero (United States)
16:30 - 16:45

New conditioning regimen for relapsed acute leukaemia
Ali Bazarbachi (Lebanon)
16:45 - 17:00

Sequential therapy for AML
Rémy Duléry (France)
17:00 - 17:15

Q&A
17:15 - 17:30

Nurses Group
16:30 - 17:30
Auditorium 2

NG03, GVHD
Chairs:
John Murray (United Kingdom)
Klára Kabatova Maxova (Czech Republic)

GVHD practical tips
Eye
Sandra Schoenfeld (Switzerland)
16:30 - 16:42

Oral
Nathaniel Simon Triester (United States)
16:42 - 16:54

Genital
Angela Leather (United Kingdom)
16:54 - 17:06

Scoring system
John Murray (United Kingdom)
17:06 - 17:18

Q&A
17:18 - 17:30
Joint Session
16:30 - 17:30 Auditorium 3

**JS1, Joint session LABMT: Towards an EBMT-LABMT confluence - Benefits of a mixed chimera**

**Chairs:**
Rafael Duarte (Spain)
Gregorio Jaimovich (Argentina)

- **Development opportunities from an EBMT perspective**
  16:30 - 16:40
  Alejandro Madrigal (United Kingdom)

- **Development opportunities from an LABMT perspective**
  16:40 - 16:50
  Amado Karduss (Colombia)

- **Conditioning regimens: Is less better?**
  16:50 - 17:00
  Manuel Abecasis (Portugal)

- **Accreditation: Experience on implementing the “FACT-JACIE International Stepwise Accreditation Programme” in Latin America**
  17:00 - 17:20
  Patricia Abichain (Argentina)
  Raquel Espada (Spain)

- **Q&A**
  17:20 - 17:30

**Psy Day**
16:30 - 17:30 Auditorium 4

**Psy3, How do I...?**

**Chairs:**
Anna Barata (United States)

- **How do I... Evaluate psychosocial factors and complexities that may influence the HSCT process and outcomes?**
  16:30 - 16:45
  Alex King (United Kingdom)

- **How do I... Address the psycho-oncologists well-being?**
  16:45 - 17:00
  Frank Schulz-Kindermann (Germany)

- **How do I... Identify unmet needs and plan research?**
  17:00 - 17:15
  Corinna Bergelt (Germany)

- **Text chat Q&A**
  17:15 - 17:30

**Pharmacists Day**
16:30 - 17:30 Auditorium 5

**Pharm3, Update infectious diseases in HSCT**

**Chairs:**
Agnès Bonnin (France)
Scientific Programme

What's new in antivirals?  
Per Ljungman (Sweden)  
16:30 - 16:45

What's new in vaccines? The Dutch guidelines for HSCT patients  
Marjolein Hensgens (Netherlands)  
16:45 - 17:00

The effect of antibiotics on the microbiome in HSCT patients: Is it relevant?  
Florent Malard (France)  
17:00 - 17:15

Text chat Q&A  
17:15 - 17:30

Meet the Expert  
17:30 - 18:30

MTE1, Meet the Expert session 1 - Room MTE1

Viral infections in HSCT recipients: The challenges in 2020  
Francisco Marty (United States)  
17:30 - 18:30

Meet the Expert  
17:30 - 18:30

MTE2, Meet the Expert session 2 - Room MTE2

Extracorporeal photopheresis in the management of acute and chronic GVHD  
Daniel Couriel (United States)  
17:30 - 18:30

Meet the Expert  
17:30 - 18:30

MTE3, Meet the Expert session 3 - Room MTE3

The role of donor registries in the changing landscape of allogeneic HSCT in 2020  
Juliana Villa (Spain)  
17:30 - 18:30

Meet the Expert  
17:30 - 18:30

MTE4, Meet the Expert session 4 - Room MTE4

How to manage chronic GVHD in 2020 and beyond  
Steven Pavletic (United States)  
17:30 - 18:30
Meet the Expert
17:30 - 18:30
Meet the Expert Rooms

**MTE5, Meet the Expert session 5 - Room MTE5**

**The role of cord blood banks in the changing landscape of allogeneic HSCT in 2020**
Sergio Querol Giner (Spain)

Meet the Expert
17:30 - 18:30
Meet the Expert Rooms

**MTE6, Meet the Expert session 6 - Room MTE6**

**How to establish a CAR T-cell Delivery Centre**
Claire Roddie (United Kingdom)

Meet the Expert
17:30 - 18:30
Meet the Expert Rooms

**MTE7, Meet the Expert session 7 - Room MTE7**

**How to manage acute promyelocytic leukaemia in 2020. Current role of haematopoietic cell transplantation**
Miguel Ángel Sanz Alonso (Spain)

Social Events
17:40 - 18:00
Auditorium 1

**Yoga session**
Sunday, 30 August 2020

Non-Profit Symposium
08:30 - 10:00
Auditorium 1

IS2, How does MRD impact outcome of stem cell transplantation in AML, now and in the future? - AML Hub non-profit symposium

Chairs:
Gert Ossenkoppele (Netherlands)

Welcome and introduction
08:30 - 08:35
Gert Ossenkoppele (Netherlands)

Challenges in MRD measurement by Multiparameter Flow Cytometry (MFC) in AML
08:35 - 08:50
Jacqueline Cloos (Netherlands)

New developments in molecular MRD assessment in AML
08:50 - 09:05
Christian Thiede (Germany)

Does current evidence support the use of MRD guided treatment before transplant in patients with AML?
09:05 - 09:20
Adriano Venditti (Italy)

Why should we use MRD assessment post hematopoietic stem cell transplantation?
09:20 - 09:35
Charles Craddock (United Kingdom)

Round table discussion: Use of MRD guided treatment decisions before and after transplantation
09:35 - 09:50

Summary and conclusions: Establishing MRD as surrogate endpoint in AML, and what does the future hold
09:50 - 10:00
Gert Ossenkoppele (Netherlands)

Special Session
08:30 - 10:00
Auditorium 5

SS2, Global Committee Session - The impact of infections on HSCT performance worldwide

Chairs:
Norbert-Claude Gorin (France)
Nicolaus Kröger (Germany)

Introduction
08:30 - 08:33
Norbert-Claude Gorin (France)

Impact (known or potential) of community respiratory virus infections on the outcome of recipients of an allogeneic HSCT or CAR T-cell therapy
08:33 - 08:48
Rodrigo Martino (Spain)
Scientific Programme

**Tropical diseases and HSCT**
Francesca Norman (Spain) 08:48 - 09:03

**Parasitic infections in HSCT**
Gregorio Jaimovich (Argentina) 09:03 - 09:18

**Impact of infections in Asia**
Alok Srivastava (India) 09:18 - 09:33

**Particularities of infections in limited-resource countries**
Asma Quessar (Morocco) 09:33 - 09:48

**Conclusions and Q&A**
Nicolaus Kröger (Germany) 09:48 - 09:50

---

**Industrial Theatre**

**IT1, TLS in the context of new treatments in hematology - Sanofi Genzyme Industry Theatre Session**

**IT3, Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite Industry Theatre Session**

**IT4, KYMRIAH in the Real World - Novartis Industry Theatre Session**

**IT2, Clinical Data on Treosulfan-based Conditioning Treatment (Trecondi®) in Paediatric Patients - Medac Industry Theatre Session**

**IT5, How I manage CMV in HSCT patients - MSD Industry Theatre Session**
IT6, Gene therapy: From clinical trials to clinical practice - Bluebirdbio Industry Theatre Session

Chairs:
Franco Locatelli (Italy)

Acute Leukaemia

ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH HIV-INFECTION: AN UPDATED PAIR-MATCHED COHORT STUDY BY THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION

COMPARABLE OUTCOMES OF AML PATIENTS RECEIVING HAPLO-HCT WITH THIOTEPA/BUSULFAN/FLUDARABINE CONDITIONING AND POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS A MATCHED UNRELATED DONOR WITH FLUDARABINE/BUSULFAN CONDITIONING, REGARDLESS OF DISEASE STATUS

TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT: IMPROVED SURVIVAL FOR YOUNG PATIENTS IN RECENT YEARS

ANTI-CD3/CD33 BISPECIFIC ANTIBODIES EFFICIENTLY REDIRECT DONOR T CELLS AGAINST HLA LOSS LEUKEMIA RELAPSES

POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) EMERGES AS A KEY DRIVER OF HLA CLASS II NEGATIVE POST-TRANSPLANTATION RELAPSE

ALLOGENEIC HCT FOR ADULTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA HARBORING <i>IKZF1</i> GENE MUTATIONS: A STUDY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT IN CHILDREN AND ADULTS WITH RELAPSED/REFRACTORY B-ALL: FOCUS ON ANTI-CD19, ANTI-CD22 MONOCLONAL ANTIBODIES

THE VALUE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH AND WITHOUT <i>ASXL1</i>, <i>RUNX1</i> AND <i>TP53</i> MUTATIONS

ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT

RIC COMBINED WITH ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE PROVIDES HIGHER GVHD-FREE/RELAPSE FREE SURVIVAL IN FIT YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA

LOW-DOSE MEMORY DONOR LYMPHOCYTE INFUSION AFTER αβ T CELL-DEPLETED HSCT AMONG CHILDREN WITH HIGH-RISK LEUKEMIA: RESULTS OF A PROSPECTIVE RANDOMIZED SINGLE-CENTER TRIAL

DEVELOPMENT OF A CORD BLOOD STEM CELL-DERIVED DENDRITIC CELL VACCINE TO PREVENT RELAPSE AFTER CORD BLOOD TRANSPLANTATION IN AML
Scientific Programme

THE BRAZILIAN EXPERIENCE WITH HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTS (HAPLO-HCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

BETTER LEUKEMIA-FREE SURVIVAL WITH ALLOGENIC THAN WITH AUTOLOGOUS HCT IN AML PATIENTS WITH ISOLATED TRISOMY 8: A STUDY FROM THE ALWP OF THE EBMT

ALLOGENIC STEM CELL TRANSPLANTATION FOR AML PATIENTS WITH RUNX1 MUTATION IN FIRST COMPLETE REMISSION: A STUDY ON BEHALF OF THE ALWP OF THE EBMT

GRAFT FAILURE AFTER UNMANIPULATED HAPLO-HSCT WITH PT-CY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION, ON BEHALF OF THE ALWP-EBMT

IMPLICATIONS OF NOVEL RISKS SCORES (AML-DRG AND AML-HCT-CR) IN ALLOGENIC CD34+ SELECTED GRAFT TRANSPLANT OUTCOMES

DOWNREGULATION OF HLA-DR IN BLASTS OF PATIENTS WITH ACUTE LEUKAEMIA RELAPSING AFTR ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPANTATION

ESTABLISHMENT OF A NATIONAL STEM CELL TRANSPLANT CLINICAL TRIALS NETWORK: THE UK IMPACT PARTNERSHIP FOR ACCELERATED CELLULAR THERAPIES

DIFFERENTIAL IMPACT OF NPM1 MUTATION ON THE POST-TRANSPLANT OUTCOME OF ADULT FLT3ITD MUTATED AML RECEIVING ALLOGENIC TRANSPLANT IN CR1 AND AFTER CR1

A REGION-WIDE RETROSPECTIVE ANALYSIS OF OUTCOME FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA

PRE-HARVEST HIGHER DONOR FOXP3 MRNA AND LOWER CD4+ T CELL CONCENTRATION PREDICT INCREASED RISK OF ALL RELAPSE AFTER MYELOABLATIVE HCT WITH T-REPLETE BONE MARROW GRAFTS

EPIDEMIOLOGY, MANAGEMENT AND ECONOMIC IMPACT OF ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME IN SPAIN: A CLAIMS DATABASE ANALYSIS

PRE-TRANSPLANT BONE MARROW CELLULARITY AND BLOOD COUNT RECOVERY ARE NOT ASSOCIATED WITH RELAPSE OR SURVIVAL RISK FOLLOWING ALLOGENIC STEM CELL TRANSPLANT FOR AML IN CR1

IMMUNOTHERAPY SALVAGE FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS BY THE ALWP OF THE EBMT

COMPARISON OF PRE-TRANSPLANT COMORBIDITY INDICES IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

SALVAGE USE OF VENETOCLAX-BASED THERAPY FOR RELAPSED AML POST ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT

FACTORS PREDICTING THE OUTCOME OF ALLOGENIC STEM CELL TRANSPLANTATION IN PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA

ROLE OF CHIMERISM AND FLOW-CYTOMETRIC MONITORING OF MEASURABLE RESIDUAL DISEASE (MRD) AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN PREDICTING RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)

SORAFENIB PROLONGED MAINTENANCE IN FLT3-MUTATED AML POST TRANSPLANTATION

Page 81 / 353
PULMONARY COMPLICATIONS (PC) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN CHILDREN WITH HIGH-RISK ACUTE LEUKEMIA (AL)

MORE THAN TWO CYCLES OF CONSOLIDATION THERAPY PRE-TRANSPLANTATION BENEFITS AML PATIENTS IN CR1 WHO UNDERWENT HLA-MATCHED SIBLING ALLOGRAFTS: A MULTICENTER STUDY

WHAT CAN CNV ANALYSIS ADD TO THE ROUTINE GENETIC DESCRIPTION OF AML CASES?

COMPARISON OF THE PROGNOSTIC ABILITY OF THE HCT-CI THE MODIFIED EBMT AND THE EBMT-ADT PRE-TRANSPLANT RISK SCORES FOR ACUTE LEUKEMIA

GO-FLAG REGIMEN AS A BRIDGE THERAPY TO ALLOGENEIC STEM CELL TRANSPLANTATION IN REFRactory/RELapsed AML PATients

THE IMPACT OF ALLOGENEIC TRANSPLANTATION IN AML AND MDS WITH CHROMOSOME 3 ABNORMALITIES

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS CHEMOTHERAPY-ALONE IN THE TREATMENT OF PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS WITH MIXED LINEAGE LEUKEMIA (MLL) REARRANGEMENTS: SINGLE CENTER EXPERIENCE

POSTTRANSPLANTATION BENZAMUSTINE FOR GVHD PROPHYLAXIS IN REFRactory ACUTE LEUKEMIA PATients

IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE

FLAT REGIMEN AS MYELOABLATIVE CONDITIONING WITH LIMITED TOXICITIES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS IN 30 PATIENTS

TYROSINE KINASE INHIBITOR TREATMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR CYTOGENETIC INTERMEDIATE-RISK AML ACCORDING TO THE MOLECULAR RISK BASED ON ELN 2017 RISK STRATIFICATION SYSTEM; SINGLE CENTER EXPERIENCE IN KOREA

THE PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY WT1 GENE EXPRESSION IN PERIPHERAL BLOOD BEFORE AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN AML PATIENTS

IMPACT OF POSTTRANSPLANT TYROSINE KINASE INHIBITORS ADMINISTRATION ON LONG TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

THE INFLUENCE OF ANTI-THYMCYTO GLOBULIN (ATG) ON THE OUTCOMES OF PATIENTS WITH AML W/WO MEASURABLE RESIDUAL DISEASE (MRD) AT THE TIME OF UNRELATED DONOR TRANSPLANTATION

MLL-AF6 FUSION GENE POSITIVE AML TREATED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION HAS EXCELLENT OVERALL SURVIVAL

BENEFICIAL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

INDUCTION OF SYNERGISTIC APOPTOSIS AND OVERCOMING OF DRUG RESISTANCE BY COTARGETING OF BCL-2 AND NA/H EXCHANGER 1 PATHWAY IN ACUTE MYELOID LEUKEMIA CELLS
Scientific Programme

GEMTUZUMAB-OZOGAMICIN FOR BRIDGING TO TRANSPLANT IN REFRACTORY/RELAPSED CD33 POSITIVE ACUTE LEUKEMIA - IS IT WORTHWHILE?

THE EFFECTS OF CYTOMEGALOVIRUS INFECTION ON TRANSPLANT OUTCOMES IN ACUTE LYMPHOCYTIC LEUKEMIA PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

AZACYTIDINE AND DONOR LYMPHOCTYES INFUSIONS IN RELAPSED AML AFTER ALLOGENEIC HSCT: RESULTS IN 40 PATIENTS

THE RESULTS OF AML RELAPSE AFTER ALLOGENEIC TRANSPLANTATION TREATMENT, SINGLE CENTRE APPROACH EVALUATION

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A SINGLE CENTER ANALYSIS

THE OPTIMAL TIME FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

IMPACT OF ABO MISMATCH ALLOGENEIC TRANSPLANT IN ACUTE MYELOID LEUKEMIA: A SINGLE CENTRE EXPERIENCE

DONOR SOURCE IMPACTS ON LONG TERM SURVIVAL FOLLOWING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN AML PATIENTS AGED 60 AND ABOVE

EXTRA-MEDULLARY RECURRENCE OF ACUTE MYELOID LEUKEMIA AS MYELOID SARCOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE SERIES

SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA: SINGLE CENTER EXPERIENCE

ALLOGENEIC STEM CELL TRANSPLANTS IN ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE EXPERIENCE

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA NOT RESPONDING TO FIRST INDUCTION THERAPY

Aplastic anaemia

LNP023 - A NEW ORAL COMPLEMENT FACTOR-B INHIBITOR NORMALIZES HEMOGLOBIN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH POOR RESPONSE TO ECULIZUMAB, BOTH AS ADD-ON AND MONOTHERAPY

EPIGENETIC AGING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH POOR SURVIVAL IN PATIENTS WITH SEVERE APLASTIC ANEMIA: RESULTS FROM DNA-METHYLATION GRIMAGE

GVHD AND RELAPSE FREE SURVIVAL (GRFS) AFTER ALLOGENEIC TRANSPLANTATION FOR IDIOPATHIC SEVERE APLASTIC ANEMIA: AN ANALYSIS FROM THE SAAWP DATA QUALITY INITIATIVE PROGRAM OF EBMT

OUTCOME OF HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANAEMIA: A STUDY ON BEHALF OF THE EBMT SAAWP AND PDWP

REDUCED INTENSITY CONDITIONING IS EFFECTIVE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND-BLACKFAN ANEMIA
Scientific Programme

PROSPECTIVE STUDY OF ECLIZUMAB BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMOLYTIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA / APLASTIC ANEMIA

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT FOR FANCONI ANEMIA IN INDIA

ALTERNATE DONOR HSCT FOR 109 CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA: A SINGLE CENTER RETROSPECTIVE ANALYSIS

SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS WITH REFRACTORY ACTIVE INFECTION: A PROSPECTIVE MULTICENTER CLINICAL STUDY IN CHINA

INCIDENCE AND MANAGEMENT OF APLASTIC ANEMIA IN SPAIN (IMAS). AN AMBISPECTIVE STUDY OF BIODONOSTIA / PETHEMA

ALLOGENEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS FOR CHILDREN WITH APLASTIC ANEMIA

OUTCOME OF PEDIATRIC ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE

OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT FOR SEVERE APLASTIC ANEMIA IN PAKISTAN: DATA FROM A DEVELOPING COUNTRY

IMPACT OF CD34+-STEM CELL BOOST ON OUTCOME AND HEMATOLOGICAL RECONSTITUTION IN PATIENTS WITH SEVERE APLASTIC ANEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY

HEMATOPOIETIC STEM CELL TRANSPLANT IN ADULTS WITH ACQUIRED SEVERE APLASTIC ANEMIA

HEMATOPOIETIC STEM CELL TRANSPLANT IN FANCONI ANEMIA USING MATCHED RELATED AND HAPLOIDENTICAL DONORS- A SINGLE CENTRE EXPERIENCE

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC SEVERE APLASTIC ANEMIA: RESULTS OF A SINGLE CENTER

EFFECT OF SINGLE UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION ON APLASTIC ANEMIA IN CHILDREN

IMMUNOSUPPRESSIVE THERAPY IN PEADIATRIC APLASTIC ANEMIA, SINGLE CENTRE EXPERIENCE

CYCLOSPORINE, DANAZOL AND ROMIPLOSTIM IN SEVERE APLASTIC ANEMIA IN PRETRANSPLANT PERIOD: RETROSPECTIVE ANALYSIS OF FIVE CASES

Autoimmune diseases

AUTOLOGOUS NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR STIFF PERSON SYNDROME

BEAM VS CYCLOPHOSPHAMIDE-BASED CONDITIONING REGIMEN IN AGGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE ANALYSIS OF EUROPEAN BLOOD AND MARROW TRANSPLANTATION SOCIETY
A NOVEL TARGETED APPROACH TO ACHIEVE IMMUNE SYSTEM RESET: CD45-TARGETED ANTIBODY DRUG CONJUGATES AMELIORATE DISEASE IN PRECLINICAL AUTOIMMUNE DISEASE MODELS AND ENABLE AUTOHSCT

LONG TERM FOLLOW UP OF SYSTEMIC SCLEROSIS FRENCH PATIENTS INCLUDED IN THE ASTIS TRIAL USING SCOT TRIAL GLOBAL RANK COMPOSITE SCORE (GRCS)

ADVANCES IN MULTIPLE SCLEROSIS (MS) TREATMENT: CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION

POST TRANSPLANTATION CYCLOPHOSPHAMIDE IMPROVES OUTCOME AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ANIMAL MODEL OF MULTIPLE SCLEROSIS

THE LONG-TERM SAFETY AND EFFICACY OF AUTOLOGOUS HEMATopoietic STEM CELL TRANSPLANTATION FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS INDIRECTLY COMPARED TO ALEMTUZUMAB: A SYSTEMATIC REVIEW

RECONSTITUTION OF NATURAL OR VACCINATION-DRIVEN IMMUNITY AFTER AHSCT IN MULTIPLE SCLEROSIS

HIGH-DOSE IMMUNODEPLETION WITH AUTOLOGOUS STEM CELL RESCUE FOR TREATMENT OF AGGRESSIVE MULTIPLE SCLEROSIS

HEMATopoietic STEM CELL TRANSPLANTATION DOES NOT CHANGE THE EXPRESSION OF ENDOTHELIAL MARKERS IN SKIN BIOPSIES OF SYSTEMIC SCLEROSIS PATIENTS

AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NON HEMATOLOGICAL DISEASES. THE DUTCH EXPERIENCE OF MS PATIENTS GOING ABROAD

ANALYSIS OF COST AND CHARGES FOR NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES

AUTOLOGOUS STEM CELL TRANSPLANTATION IN BEHÇET’S DISEASE: A RETROSPECTIVE STUDY

SAFETY AND TOLERABILITY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE SCLEROSIS: A SINGLE CENTER EXPERIENCE

OUTCOME OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY TAKAYASU ARTERITIS, A RETROSPECTIVE SURVEY FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EBMT

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS IN NORWAY

THE USE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS AFTER ALEMTUZUMAB TREATMENT FAILURE: A CASE SERIES

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF SYSTEMIC SCLEROSIS, AN OPTION FOR REFRACTORY PATIENTS

A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE
CAR-based Cellular Therapy - clinical

**KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): RESULTS FROM PHASE 2 OF ZUMA-2**

**SAFETY AND EFFICACY RESULTS FROM TRANSCEND NHL 001, A MULTICENTER PHASE 1 STUDY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA**

**CD19/CD22 DUAL TARGETED (CHIMERIC ANTIGEN RECEPTOR) CAR-T THERAPY FOR RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)**

**AN UPDATE OF THE EBMT SURVEY ON CAR T-CELL ACTIVITY IN EUROPE. ON BEHALF OF THE CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY (CTIWP)**

**THIRD-GENERATION CAR T CELLS WITHIN THE HEIDELBERG CAR TRIAL 1 (HD-CAR-1) DISPLAY AN EXCELLENT SAFETY PROFILE AND MIGHT IMPROVE PERSISTENCE OF CAR T CELLS**

**OUTPATIENT TREATMENT WITH LISOCABTAGENE MARALEUCEL IN 3 CLINICAL STUDIES OF RELAPSED/REFRACTORY LARGE B-CELL NHL, INCLUDING SECOND-LINE TRANSPLANT NONELIGIBLE PATIENTS: TRANSCEND NHL 001, OUTREACH, AND PILOT**

**CORRELATIVE ANALYSES OF PATIENT AND CLINICAL CHARACTERISTICS ASSOCIATED WITH EFFICACY IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE JULIET TRIAL**

**CAR T CELLS (CART) OR ALLOGENEIC TRANSPLANTATION (ALLOHCT) FOR MULTIPLY RELAPSED DIFFUSE LARGE B CELL LYMPOMA (DLBCL)? A RETROSPECTIVE INTENT-TO-TREAT (ITT) COMPARISON**

**HIGH ACTIVATION OF BCMA CAR-T CELLS CONTRIBUTES TO INCREASED RESPONSE RATE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**

**A COMPARISON OF 2-YEAR OUTCOMES IN ZUMA-1 (AXICABTAGENE CILOLEUCEL; AXI-CEL) AND SCHOLAR-1 IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL)**

**CD19-TARGETED CAR-T CELL THERAPY FOR 32 B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS WHO RELAPSED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)**

**INTERNATIONAL PROGNOSTIC INDEX PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED AND REFRACTORY LARGE DIFFUSE B CELL LYMPHOMA TREATED WITH COMMERCIAL CAR T CELLS**

**THE PHASE 1B PORTIA STUDY: SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA**

**REAL-WORLD EVIDENCE OF THE USE OF TISAGENLECLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS. THE SPANISH EXPERIENCE**

**NATIONAL IMPLEMENTATION OF THE USE OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN NATIONAL HEALTH SERVICE ENGLAND (NHSE)**

**REAL-WORLD CLINICAL FEATURES OF NEUROTOXICITY COMPLICATING CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR HIGH GRADE LYMPHOMA AND MANAGEMENT INCLUDING THE OFF-LABEL USE OF ANAKINRA**
CORRELATIVE MARKERS OF TOXICITY IN PATIENTS WITH DLBCL TREATED WITH CD19 CAR T CELL THERAPY

EARLIER STEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)

ASSOCIATION OF AXI-CEL CAR-T CELL CONCENTRATION WITH TREATMENT RESPONSE AND SIDE EFFECTS AND IMPACT OF DEXAMETHASONE TREATMENT ON KINETICS

SIMPLIFIED-EASIX (SEASIX) IS AN EARLY PREDICTOR OF SEVERE CYTOKINE RELEASE SYNDROME AND IMMUNE-EFFECTOR-CELLS-ASSOCIATED NEUROTOXICITY SYNDROME IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T CELLS

NIVOLUMAB AS SALVAGE THERAPY IN PATIENTS WHO FAILED TO ACHIEVE COMPLETE REMISSION AFTER ANTI-CD19 CAR T-CELL THERAPY FOR DLBCL

SURVEILLANCE OF MINIMAL RESIDUAL DISEASE (MRD) IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) BY CIRCULATING TUMOR DNA (CTDNA) PROFILING AFTER CHIMERIC ANTIGEN RECEPTOR T (CAR-T)

A DIGITAL-PCR ASSAY FOR PRECISE IN-VIVO QUANTIFICATION OF ADOPTIVELY TRANSFERRED CD19-CAR T CELLS AFTER TREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)

FEASIBILITY OF MANUFACTURING TISAGENLECLEUCEL IN PATIENTS LESS THAN 3 YEARS OF AGE WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

AXICABTAGENE CILOLEUCEL CD19 CAR T-CELLS FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: REAL-WORLD OUTCOMES, TOXICITY AND PREDICTORS OF RESPONSE FROM A PROSPECTIVE UK COHORT

MARKERS OF INITIAL AND LONG-TERM RESPONSES TO IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) IN THE CRB-401 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

SINUSOIDAL OBSTRUCTION SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) TREATED WITH ARI-0001 CELLS

HUMORAL IMMUNE RESPONSE IN PATIENTS WITH CD19-POSITIVE RELAPSED/REFRACTORY B-CELL MALIGNANCIES RECRUITED INTO THE CART19-BE-01 CLINICAL TRIAL, AN ACADEMIC CAR19

REAL-WORLD DATA FROM KINGS COLLEGE HOSPITAL: INFECTION COMPLICATIONS POST CAR-T TREATMENT IN HIGH-GRADE B CELL NON-HODGKIN LYMPHOMA

SENESCENT/EXHAUSTED PHENOTYPE OF CD19-TARGETED CAR-T CELLS AND IMMUNOREGULATORY ENVIRONMENT CORRELATE WITH REDUCED RESPONSE TO CAR-T CELL THERAPY IN RELAPSED/REFRACTORY B CELL MALIGNANCIES

CHARACTERISATION OF EARLY AND LATE CYTOPENIAS IN LYMPHOMA PATIENTS FOLLOWING TREATMENT WITH ANTI-CD19 CAR-T THERAPY

CD4+ CAR-T CELLS MAINTAIN MEMORY PHENOTYPES AND MEDIATE LONGER-TERM ANTITUMOR ACTIVITY IN VIVO

IMPACT OF ETHNICITY IN R/R DLBCL AND B-CELL ALL PATIENTS TREATED WITH TISAGENLECLEUCEL

IMPACT OF DIFFERENT CHEMOTHERAPY REGIMENS AND DURATION OF DLBCL ON LYMPHOPHERESIS AND CAR-T T-CELL IMMUNOPHENOTYPING

CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY IMPROVE PROGRESSION FREE SURVIVAL IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Scientific Programme

CHALLENGES IN PROVIDING GOOD LEUKAPHERESIS PRODUCTS FOR THE PRODUCTION OF CAR T CELLS FOR PATIENTS WITH RELAPSED/REFRACTORY NHL OR ALL

NKG2D CAR T CELLS ARE NOT AFFECTED BY SOLUBLE NKG2D LIGANDS

EMERGING CYTOKINE RELEASE SYNDROME IS ASSOCIATED WITH REDUCTION OF CD4+CD25HIGH127DIM T REGULATORY CELLS IN PATIENTS AFTER CAR T CELL THERAPY

EXCELLENT PROLIFERATION AND PERSISTENCE OF ALLOGENEIC CAR-T CELLS DESPITE IMMUNOSUPPRESSION WITH CYCLOSPORINE A

A FRENCH BIOBANKING NETWORK TO CREATE A UNIQUE COLLECTION OF SAMPLES OF PATIENTS TREATED WITH CAR-T CELLS

CAR T CELL THERAPY DIRECTED AGAINST CD19 IN PATIENTS WITH B-CELL LYMPHOMA AFTER AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IS FEASIBLE AND SAFE

LYMPHOCYTE COLLECTION FOR GENERATION OF CAR T-CELLS IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE

BASELINE HYPOALBUMINEMIA DOES NOT APPEAR TO BE AN ADVERSE PROGNOSTIC FACTOR IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMAS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)

FACTORS PREDICTING CD3+ COLLECTION FOR THE PRODUCTION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS

CYTOPENIAS AFTER TISAGENLECLEUCEL IN PAEDIATRIC/YOUNG ADULT PATIENTS WITH REFRACTORY/RELAPSE B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL): A REAL-LIFE SINGLE-CENTRE EXPERIENCE

THE RISK OF HEPATITIS B REACTIVATION IS CONTROLLABLE IN B-CELL MALIGNANCIES PATIENTS WITH CONCOMITANT HEPATITIS B VIRUS INFECTION AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY

CUMULATIVE RITUXIMAB EXPOSURE PRIOR TO AXICABTAGENE CILOLEUCEL IS NOT ASSOCIATED WITH PERSISTENT LEUKOPENIA AND THROMBOCYTOPENIA AT DAY +90 POST INFUSION

COMPREHENSIVE IMMUNE CELL MONITORING REVEALS AN ALTERED LYMPHOCYTE SUBSET PHENOTYPE IN PATIENTS NOT RESPONDING TO TISAGENLECLEUCEL ONE MONTH POST INFUSION

NEUROTOXICITY ASSOCIATED WITH CAR T CELL THERAPY: NEUROLOGICAL MANAGEMENT AND WORK-UP OF 11 ADULT PATIENTS

NUTRITIONAL ASSESSMENT OF PATIENTS UNDERGOING CD19-TARGETED CAR-T THERAPY FOR NON-HODGKIN’S LYMPHOMA AND THE SHORT TERM EFFECT OF TREATMENT ON NUTRITIONAL STATUS

EFFECTIVENESS OF AUTOLOGOUS LEUKAPHERESIS COLLECTIONS FOR CAR T-CELL MANUFACTURING IN PATIENTS WITH B-CELL MALIGNANCES

DEFINITION AND IMPLEMENTATION OF CLINICAL AND QUALITY ENDPOINTS IN CENTERS ADMINISTERING A COMMERCIAL CAR-T PRODUCT

CAR-T IN BREAST AND OTHER EXTRA-MEDULLARY RELAPSED/REFRACTORY ALL

PREDICTING CAR T-CELL INFUSION AFTER SUCCESSFUL MANUFACTURING: REAL-WORLD DATA
**Scientific Programme**

**EVALUATION OF THE INTEREST OF A DRUG RECONCILIATION ACTIVITY IN PATIENTS TREATED WITH CAR T-CELLS: A DESCRIPTIVE STUDY**

**e-Posters**

**08:30 - 19:00**

**ePoster Area**

**CAR-based Cellular Therapy - preclinical**

**MODULATION OF CYTOSOLIC CA\(^{2+}\) REGULATES CAR-T CELL DIFFERENTIATION AND THERAPEUTIC POTENCY**

**BREAKING PD-L1-MEDIATED RESISTANCE IN ANTI-CD19 AND ANTI-CD22 CAR T CELLS WITH PD-1/CD28 FUSION RECEPTORS**

**ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR-INVARIANT NATURAL KILLER T CELLS EXERT BOTH DIRECT AND INDIRECT ANTITUMOR EFFECTS THROUGH HOST CD8 T CELL CROSS-PRIMING**

**DUVELISIB GENERATES CAR T CELLS WITH ENHANCED MITOCHONDRIAL BIOGENESIS AND REDUCED EXPRESSION OF PD-1, TIM-3, AND LAG-3, ENABLING GREATER ANTI-LEUKEMIA CYTOTOXICITY AGAINST CLL**

**NKG2D CHIMERIC ANTIGEN RECEPTOR-EXPRESSING LYMPHOCYTES TARGET ACUTE MYELOID LEUKEMIA CELLS**

**CLINICAL-GRADE MANUFACTURING OF ROR1 CAR T-CELLS USING A NOVEL VIRUS-FREE PROTOCOL**

**LENTIVIRALLY AND ALPHARETROVIRALLY ENGINEERED CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS ARE HIGHLY CYTOTOXIC AGAINST ACUTE LYMPHOBlastic LEUKEMIA**

**NOVEL STRATEGIES TO ENHANCE THE SAFETY OF CAR T-CELL IMMUNOTHERAPY: THE IMSAVAR PROJECT**

**ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD NK CELLS ARE GOOD SOURCES FOR EFFECTIVE CAR THERAPY AGAINST CD19 POSITIVE LEUKEMIC CELLS**

**ENHANCEMENT OF CYTOTOXICITY, EXPANSION AND PERSISTENCE OF CD19 CAR-T CELLS VIA PRE-SENSITIZATION OF B CELL MALIGNANCIES BY BCL-2 SELECTIVE INHIBITORS**

**TYROSINE KINASE INHIBITOR FOLLOWED BY CART THERAPY FOR THE TREATMENT OF RELAPSED PHILADELPHIA CHROMOSOME-POSITIVE B-CELL ACUTE LYMPHOBlastic LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**Cellular Therapies other than CARs**

**CTLA4IG PRIMED SEQUENTIAL DLI IMPROVES GVHD AND RELAPSE-FREE SURVIVAL COMPARED TO UNPRIMED DLI IN PATIENTS UNDERGOING PTCY-BASED HAPLOIDENTICAL HCT FOR ADVANCED HEMATOLOGICAL MALIGNANCIES**

**HLA-MISMATCHED MOBILIZED CELLULAR THERAPY (MICROTTRANSPLANT, MST) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES**

Page 89 / 353
DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH PTCY: A STUDY ON BEHALF OF THE CTIWP OF THE EBMT

SAFETY, EFFECTIVENESS AND PERSISTENCE OF LOW-DOSE DONOR MEMORY T CELL INFUSIONS AFTER AB T CELL-DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION

PROPHYLACTIC DONOR LYMPHOCYTE INFUSION AFTER T-CELL-REPLETE ALLOGENEIC HSCT PREVENTS DISEASE RELAPSE AND PROLONGS SURVIVAL IN PATIENTS WITH HIGH-RISK ACUTE LEUKEMIA

BASELINE IMMUNE STATUS PREDICTS RESPONSE TO ADOPTIVE THERAPY WITH CMV CTLS FOR REFRACTORY CMV

EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY ON BEHALF OF GETH (GRUPO ESPANOL TRASPLANTE HEMATOPOYETICO)

PHASE I STUDY OF ADOPTIVE TRANSFER OF HAPLOIDENTICAL EXPANDED NK CELLS

OFF-TARGET HLA CROSS-REACTIVITY BY (THIRD PARTY) VIRUS-SPECIFIC T CELLS IS SURPRISINGLY Affected BY HLA RESTRICTION AND HLA BACKGROUND BUT NOT BY VIRUS SPECIFICITY

ADOPTIVE IMMUNOTHERAPY OF REFRACTORY VIRAL INFECTIONS AFTER ALLOGENEIC HSCT: AN ACADEMIC NETWORK FRAMING THE USE OF AN ATMP UNDER HOSPITAL EXEMPTION

HOW TO BENEFIT FROM EXHAUSTION: PATIENT-DERIVED INHIBITED T CELLS AS A NOVEL SOURCE OF TUMOR-REACTIVE T CELL CLONES

EFFICIENT CRISPR/CAS9-MEDIATED INACTIVATION OF THE GLUCOCORTICOID RECEPTOR FOR ANTIGEN-SPECIFIC T-CELL IMMUNOTHERAPY

COMPARISON OF OUTCOME POST-SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION VERSUS DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS

AUTOMATED APPLICATION FOR DEPLETION OF TCRAB+, CD19+ AND CD45RA+ CELLS FROM APHERESIS PRODUCTS USING THE CLINIMACS PRODIGY (R)

THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES

GOOD RESPONSE RATES OF WJ-MSC, COMPARABLE TO BM-MSC, IN THE TREATMENT OF REFRACTORY GVHD

AN ‘ALL IN ONE’ T-CELL PRODUCT FROM NON-TRANSPLANTABLE CORD BLOOD UNITS FOR VIRUS- AND LEUKEMIA-SPECIFIC T-CELL IMMUNOTHERAPY

CLINICAL SUCCESS OF GRANULOCYTE TRANSFUSIONS IN ADULT NEUTROPENIC PATIENTS AFTER CHEMOTHERAPY AND/OR ALLOGENEIC TRANSPLANTATION - TIME MATTERS!

IMPACT OF LONG-TERM CRYOPRESERVATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS PRODUCTS

OPTIMIZING LENTIVIRAL VECTOR TRANSDUCTION TO GENE MODIFY CORD BLOOD CD8+ T CELLS FOR OFF-THE-SHELF ADOPTIVE CELL THERAPY TO TREAT CANCER

DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTRE EXPERIENCE

CASE REPORT: CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION (CAEBV) CONTROLLED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) AND TRANSFUSION OF EBV-SPECIFIC T-CELLS
Scientific Programme

e-Posters
08:30 - 19:00
ePoster Area

Chronic leukaemia and other myeloproliferative disorders

- TIMING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A JOINT STUDY FROM THE INTERNATIONAL MDS/MPN WORKING GROUP AND EBMT
- RELAPSE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IN THE PATHWAY INHIBITOR (PI) ERA: NO LONGER A DEAD-END STREET
- THE 10-YEARS <u>E</u>BMT <u>L</u>ANDSCAPE OF <u>A</u>LGGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) FOR <u>C</u>HRONIC LYMPHOCYTIC LEUKEMIA
- DETERMINANTS OF SURVIVAL IN MYELOFIBROSIS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY BY THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT
- SPLENECTOMY DOESN'T PRECLUDE SUBSEQUENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MYELOFIBROSIS PATIENTS: A FRENCH NATIONWIDE STUDY USING A MULTISTATE MODEL
- INCIDENCE OF LATE RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS
- HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: THE EXPERIENCE OF THREE UNIVERSITY TRANSPLANT CENTRES IN ROME
- AUSTRALASIAN TRENDS IN ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS IN MOLECULAR ERA
- CML RELAPSE AFTER ALLOGENEIC HSCT: SURVIVAL, TREATMENT EFFICACY AND PROGNOSTIC FACTORS FOR OUTCOME
- CHRONIC MYELOID LEUKEMIA: ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN THE ERA OF TYROSINE KINASE INHIBITORS
- REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT WITH CAMPATH T-CELL DEPLETION FOR MYELOFIBROSIS IN THE ERA OF JAK INHIBITORS- A SINGLE CENTRE EXPERIENCE
- ALLOGENIC STEM CELL TRANSPLANTATION IN ADVANCED SYSTEMIC MASTOCYTOSIS AFTER CYTOREDUCTIVE TREATMENT WITH CLADRIBEINE - A SINGLE CENTER EXPERIENCE ON TWO PATIENTS
- ALLOGENEIC STEM CELL TRANSPLANTATION FOR IDIOPATIC MYELOFIBROSIS: A SINGLE CENTRE EXPERIENCE
- A CASE OF SUCCESSFUL SECOND HAPLOIDENTICAL BONE MARROW TRANSPLANTATION AFTER SECONDARY GRAFT FAILURE IN A PATIENT WITH REFRACTORY CHRONIC MYELOID LEUKEMIA

Conditioning regimens

Page 91 / 353
Scientific Programme


POPULATION PHARMACOKINETIC ESTIMATION OF ATG EXPOSURE PREDICTS IMMUNE RECONSTITUTION AND SURVIVAL IN ADULTS UNDERGOING EX Vivo CD34-SELECTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

FLAMSA-BASED REDUCED INTENSITY CONDITIONING VERSUS MYELOABLATIVE CONDITIONING IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH ACTIVE DISEASE AT THE TIME OF TRANSPLANTATION: AN ALWP/EBMT ANALYSIS

TOTAL BODY IRRADIATION/FLUDARABINE VERSUS THIOTEPA/BUSULFAN/FLUDARABINE FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH HAPLOIDENTICAL HCT. A STUDY BY ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

BUSULFAN-CYCLOPHOSPHAMIDE VERSUS CYCLOPHOSPHAMIDE-BUSULFAN AS CONDITIONING REGIMEN BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A PROSPECTIVE RANDOMIZED TRIAL

RABBIT ANTI-THYMOCYTE GLOBULIN (ATG) EXPOSURE AFTER EX Vivo T-CELL-DEPLETED HEMATOPOIETIC CELL TRANSPLANTATION IS VARIABLE AND IMPACTS IMMUNE RECONSTITUTION AND SURVIVAL IN CHILDREN AND YOUNG ADULTS

A RETROSPECTIVE COMPARATIVE STUDY OF BEAM VS FEAM VS TEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT

REDUCED INTENSITY VERSUS MYELOABLATIVE CONDITIONING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS < 60 WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTI-CENTER CANADIAN EXPERIENCE

COMBINING CLOFARABINE AND FLUDARABINE WITH EXPOSURE TARGETED BUSULFAN FOR PEDIATRIC LEUKEMIA: AN EFFECTIVE, LOW TOXIC, TBI-FREE CONDITIONING REGIMEN

BENDA-BEAM HIGH-DOSE THERAPY PRIOR TO AUTO-SCT IS EFFECTIVE IN RESISTANT/RELAPSED DLBCL: A PHASE II STUDY

REDUCED-TOXICITY CONDITIONING WITH FLUDARABINE, THIOTEPA AND MELPHALAN IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH IMPAIRED LUNG FUNCTION

ALLOGENEIC STEM CELL TRANSPLANT WITH MINIMAL-INTENSITY CONDITIONING IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA: A SINGLE CENTRE RETROSPECTIVE REVIEW

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT

A PROSPECTIVE COHORT STUDY COMPARING LONG-TERM OUTCOMES WITH AND WITHOUT PALIFERMIN IN PATIENTS RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES

PHARMACOKINETICS OF MELPHALAN IN LYMPHOMA PATIENTS UNDERGOING BEAM AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT

MELPHALAN IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION: DOES ONE SIZE FIT ALL?

COMPARISON OF TOTAL BODY IRRADIATION- VS CHEMOTHERAPY-BASED CONDITIONINGS FOR EARLY COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ALL
DIFFERENTIAL ALEMTUZUMAB DOSAGES IN T-CELL DEPLETE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTS FOR MYELOID MALIGNANCIES

THE INFLUENCE OF TDM ON ACHIEVING BUSULFAN TARGET EXPOSURE AND RELATED DETERMINANTS, IN BOTH CHILDREN AND ADULTS WHO UNDERWENT AN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

NOVEL REDUCED INTENSITY CONDITIONING (RIC) APPROACH TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH BENIGN AND MALIGNANT DISORDERS OF T CELL PROLIFERATION OR DYSREGULATION

PROFOUND LYMPHOPENIA AT THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION IS NOT PREDICTIVE OF SURVIVALS AFTER ALLO-TRANSPLANTATION

LIPID CORE NANOPARTICLES AS VEHICLE FOR ETOPOSIDE IN THE CONDITIONING REGIMEN OF MARROW TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA NOT RESPONDING TO INDUCTION THERAPY: A PILOT STUDY

A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF SHORT-TERM EVEROLIMUS IN ADDITION TO POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-EVER)

ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS ≥ 65 YEARS WITH HEMATOLOGICAL MALIGNANCES AFTER MYELOABLATIVE TREOSULFAN-BASED CONDITIONING: RESULTS IN 118 PATIENTS

BUTYRYLCHOLINESTERASE ACTIVITY AFTER CYCLOPHOSPHAMIDE CONDITIONING AS A PREDICTIVE MARKER OF LIVER TRANSPLANT-RELATED COMPLICATIONS AND ITS CORRELATION WITH TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS

FLUDARABINE-MELPHALAN CONDITIONING RESULTS IN FAVORABLE LEUKEMIA-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH ACTIVE OR MEASURABLE RESIDUAL AML

SEQUENTIAL CONDITIONING: FLAMSA-TBI VERSUS FLAMSA-TREO IN HIGH RISK ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS)

INCREASED NON-RELAPSE MORTALITY AND POOR OVERALL SURVIVAL IN ELDERLY PATIENTS TREATED WITH FLUDARABINE AND MYELOABLATIVE DOSE OF BUSULFAN: TRANSPLANT COMPLICATIONS WORKING GROUP OF THE JSHCT

TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE IMPROVES THE OUTCOME OF PATIENTS WITH POOR-RISK ACUTE LEUKEMIA

A CD45-TARGETED ANTIBODY DRUG CONJUGATE ENABLES ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS A SINGLE AGENT IN MICE

INFLUENCE OF THE CELL SOURCE TYPE AND CONDITIONING TYPE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME

PRECONDITIONING INTENSITY IMPACTS ON IMMUNE RECONSTITUTION AND OUTCOMES FOLLOWING CORD BLOOD TRANSPLANTATION

FINAL RESULTS OF A PROSPECTIVE, MULTICENTER, NON-INTERVENTIONAL STUDY ON THIOTEPA-BASED AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (ASCT) FOR CNS OR NON-CNS LYMPHOMA

POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY), CYCLOSPORIN (CSA) AND MYCOPHENOLATE (MMF) FOR PATIENTS GRAFTED FROM HLA IDENTICAL SIBLINGS OR MATCHED UNRELATED DONORS
COMPARISON OF FLUDARABINE + BUSULFAN AND FLUDARABINE+BUSUFAN+ LOW-DOSE ATG CONDITIONING REGIMENS IN PATIENTS WITH MYELOID MALIGNANCIES WHO HAD ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

CONDITIONING REGIMEN COMPARISON FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-HODGKIN LYMPHOMA

PK-GUIDED BUSULFAN CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) WITH PTCY AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES

A THIOTEPA BASED INTENSIFIED REDUCED INTENSITY CONDITIONING REGIME IN ADULT CORD BLOOD TRANSPLANT IS A PROMISING ALTERNATIVE IN PATIENTS UNABLE TO RECEIVE MYELOABLATIVE CONDITIONING

HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE USING AS CONDITIONING FLUDARABINE MELPHALAN PLUS LOW DOSES OF TOTAL BODY IRRADIATION. LONG TERM FOLLOW-UP OF 60 PATIENTS

TREOSULFAN-BASED CONDITIONING IN PAEDIATRIC T-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE

COMPARISON OF BEAM AND TEAM AS CONDITIONING REGIMEN FOR LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

ASSESSMENT OF THE SAFETY AND EFFICACY OF THE CONDITIONING REGIMEN BEEAC BEFORE AUTO-HSCT FOR THE TREATMENT OF PRIMARY-REFRACTORY AND RELapsed FORMS OF MALIGNANT LYMPHOMAS

ALLOGENEIC STEM CELL TRANSPLANTATION AFTER TOTAL-BODY IRRADIATION USING HELICAL TOMOTHERAPY: A SINGLE CENTER EXPERIENCE

FEASIBILITY OF CLAMSA-RIC AS AN ALTERNATIVE CONDITIONING REGIMEN COMPARED TO FLAMSA-RIC IN HEAVILY PRETREATED REFRACtORY AML PATIENTS - A RETROSPECTIVE SINGLE CENTER ANALYSIS

THIOTEPA, BUSULPHAN AND FLUDARABINE CONDITIONING IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA

FLAMSA-BASED HIGH-DOSE SEQUENTIAL CONDITIONING REGIMEN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): IS IT EFFECTIVE IN PATIENTS WITH PRIMARY REFRACtORY OR RELapsed ACUTE LEUKEMIA?

INCREASING IN SERUM TOTAL AMYLASE LEVELS AFTER TOTAL BODY IRRADIATION CONDITIONING REGIMEN AS A PREDICTIVE MARKER OF TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS

EVOLUTION OF DONOR CHIMERISM AFTER HAPLOIDENTICAL STEM CELL TRANSPLANT - CLINICAL CORRELATIONS

THIOTEPA-BUSULFAN-FLURABINE AS CONDITIONING REGIMEN FOR PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

THE RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA-HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE REGIMEN IN CHILDREN

ANALYSIS OF DIFFERENCES IN PREVENTIVE MEASURES AFTER HIGH-DOSE CYCLOPHOSPHAMIDE AMONG BELGIAN STEM CELL TRANSPLANT CENTRES
IRRADIATION-FREE RE-CONDITIONING FOR T-CELL DEPLETED HAPLO-IDENTICAL STEM CELL TRANSPLANTATION

LOW GRAFT CD4 CELL DOSE PREDICTS RELAPSE IN THE ATG-BASED MYELOABLATIVE CONDITIONING REGIMEN

CLINICAL EFFICACY OF HAPLOID TRANSPLANTATION WITH BU/CY/MEL PRETREATMENT SCHEME TO IMPROVE 68 CASES OF UNICENTRIC REFRACTORY OR RELAPSED ACUTE MYELOID LEUKAEMIA

REDUCING INTENSITY CONDITIONING (RIC) PROTOCOL HARMONISATION IN THE UK

HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN HIGH-RISK HEMATOLOGICAL MALIGNANCIES, ALGERIAN EXPERIENCE

INTERRUPTION OF CONDITIONING FOR ALLO-HCT DOES NOT AFFECT CLINICAL OUTCOMES OTHER THAN CHRONIC GVHD

THERAPEUTIC DRUG MONITORING OF BUSULFAN IN PEDIATRIC POPULATION

REDUCED INTENSITY CONDITIONING FOLLOWED BY HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION (RIC-HAPLOHCT) AND POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS, FOR HEMATOLOGICAL DISORDERS: SINGLE CENTRE EXPERIENCE

HIGH DOSE TREATMENT WITH LEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION DURING THE SHORTAGE OF MOSTLY USED AGENTS IN PATIENTS WITH RELAPSED OR REFRACtORY LYMPHOMA

REDUCED DOSE ALEMTUZUMAB IN REDUCED INTENSITY CONDITIONING VOLUNTEER DONOR UNRELATED TRANSPLANT FOR MYELOID MALIGNANCIES IS SAFE AND EFFICACIOUS. A SINGLE CENTRE EXPERIENCE

DESCRIBE AND EXPLORE A PATIENTS’ OUTLOOK ON DENTAL CARE IN THE CONTEXT OF THEIR MEDICAL DIAGNOSIS AND TREATMENT PRIOR TO AND FOLLOWING ALLOGENEIC HSCT

SAFETY AND EFFICACY OF LOW-DOSE BENDA-EAM AS COMPARED TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION OF REFRACtORY/RELAPSED LYMPHOMA PATIENTS

CONDITIONING REGIMEN WITH FLUDARABIN/TREOSULFAN COMPARED TO BUSULFAN/CYCLOPHOSPHAMID PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN YOUNGER PATIENTS WITH AML AND MDS: A SINGLE CENTER RETROSPECTIVE ANALYSIS

OUTCOMES OF UNRELATED DONOR STEM CELL TRANSPLANTATION WITH OR WITHOUT ANTI-THYMOCYTE GLOBULIN USED AS GRAFT-VERSUS HOST DISEASE (GVHD) PROPHYLAXIS: A SINGLE CENTER EXPERIENCE

BUSULFAN-FLUDARABINE CONDITIONING REGIMEN FOR CORD BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE TWO-CENTER STUDY

ATG IN CONDITIONING FOR SIBLING ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE

e-Posters
08:30 - 19:00

ePoster Area

Data Management

SUPPORTING TOOLS FOR ACCURATE DATA COLLECTION - DO WE GET THE BENEFIT?
ARE TRANSPLANTS TRULY AVAILABLE TO ALL, REGARDLESS OF GEOGRAPHY, SOCIOECONOMIC STATUS AND ETHNIC GROUP? A BSBMTCT REPORT

MISMATCHED DONOR AND GRADE 2 TO 4 ACUTE GVHD AS TWO-RISK MODEL FOR CYTOMEGALOVIRUS VIREMIA AND DISEASE AFTER ALLOGENEIC TRANSPLANTATION - SINGLE INSTITUTE ANALYSIS OF 1180 PATIENTS

Experimental stem cell transplantation

LOW-DOSE DECITABINE IMPROVES REFRACTORY PROLONGED ISOLATED THROMBOCYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A RANDOMIZED MULTICENTER CLINICAL TRIAL

AUTOPHAGY IN ENDOTHELIAL CELLS REGULATES THEIR HAEMATOPOIESIS-SUPPORTING ABILITY

2ND ALLO-HSCT FOR PATIENTS WHO DIAGNOSED RECURRENCE ALL AFTER THE 1ST ALLO-HSCT

ESTABLISHING A TRANSPLANT SHARING PROGRAM

Experimental transplantation

SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTICS

IMPACT OF GUT FUNGAL COMPOSITION ON OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

MONITORING HEMATOPOIETIC CELL MICROPARTICLES IN ALLOGRAFTS AND TRANSPLANT RECIPIENTS

EARLY HEPATIC COMPLICATIONS DURING THE FIRST YEAR AFTER BONE MARROW TRANSPLANTATION IN PATIENTS WITH LEUKEMIA

PERFORMANCE OF BONE MARROW TRANSPLANTATION CENTER IN IMAM REZA HOSPITAL, KERMANSHAH, IRAN

Gene Therapy

CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT β-THALASSEMIA

LENTIVIRAL HEMATOPOIETIC STEM AND PROGENITOR CELL GENE THERAPY (HSPC-GT) FOR METACHROMATIC LEUKODYSTROPHY (MLD): CLINICAL OUTCOMES FROM 33 PATIENTS
Scientific Programme

A SINGLE DOSE OF SHORT HALF-LIFE CD117 ANTIBODY DRUG CONJUGATE ENABLES HEMATOPOIETIC STEM CELL BASED GENE THERAPY IN NONHUMAN PRIMATES

LENTI-D HEMATOPOIETIC STEM CELL GENE THERAPY STABILIZES NEUROLOGIC FUNCTION IN BOYS WITH CEREBRAL ADRENOLEUKODYSTROPHY

SAFETY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH GENE ADDITION THERAPY FOR TRANSFUSION-DEPENDENT β-THALASSEMIA, SICKLE CELL DISEASE, AND CEREBRAL ADRENOLEUKODYSTROPHY

EX-VIVO AUTOLOGOUS HAEMATOPOIETIC STEM CELL GENE THERAPY IN MUCOPOLYSACCHARIDOSIS TYPE IIIA

g-Posters
08:30 - 19:00
ePoster Area

Graft-versus-host disease - clinical

KD025 FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) - LONG-TERM FOLLOW-UP OF A PHASE 2A STUDY (KD025-208)

A PHASE 2 STUDY OF F-652, A NOVEL TISSUE-TARGETED RECOMBINANT HUMAN INTERLEUKIN-22 (IL-22) DIMER, FOR TREATMENT OF NEWLY DIAGNOSED ACUTE LOWER GI GVHD

THE MAGIC BIOMARKER ALGORITHM PREDICTS OUTCOMES FOR CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE

A NOVEL TREATMENT IN CHRONIC OCULAR GRAFT-VS-HOST DISEASE (OGVHD): A PHASE II CLINIC TRIAL WITH TRANSDERMAL PROGESTERONE

EARLY CD4+ T-CELL RECONSTITUTION IS AN EXCELLENT PREDICTOR OF OUTCOMES IN PEDIATRIC PATIENTS WHO DEVELOP MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST-DISEASE: A DUAL CENTER VALIDATION

EFFECT OF SINGLE OR DOUBLE MISMATCHES AT EACH HLA LOCUS ON THE OUTCOMES AFTER SINGLE CORD BLOOD TRANSPLANTATION: THE JSHCT HLA WG STUDY

INTERIM ANALYSIS OF KD025-213: A PHASE 2, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KD025 IN SUBJECTS WITH CGVHD (THE ROCKSTAR STUDY)

ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) AND RITUXIMAB FOR IMMUNOMODULATION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT FAILURE IN PATIENTS WITH NON-MALIGNANT DISORDERS: RESULTS OF A MULTICENTRE, RANDOMIZED, OPEN-LABEL STUDY

EXPERIENCE USING DUAL T-CELL DEPLETION WITH ATG AND PTCY FOR GVHD PROPHYLAXIS IN RIC ALLOHCT USING IN 10/10 MATCHED RELATED AND UNRELATED DONORS

MACHINE LEARNING APPLIED TO THE GRADING OF ACUTE GRAFT VERSUS HOST DISEASE IMPROVES SURVIVAL ESTIMATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

SINGLE-CELL MOLECULAR ANALYSIS DEFINES CHARACTERIZATION OF SPECIFIC T CELL SUBSETS CORRELATE WITH HUMAN CHRONIC GVHD AND BRONCHIOLITIS OBLITERANS

A PHASE II TRIAL EVALUATING THE USE OF THE HISTONE DEACYLASE INHIBITOR PANOBINOSTAT FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PREVENTION
REDUCED CALCIUM SIGNALING IS ASSOCIATED WITH GVHD: RESULTS FROM PRECLINICAL ALLOSCT MODELS AND FROM A PROSPECTIVE MULTICENTER STUDY

IDENTIFICATION OF PREDICTIVE MODELS INCLUDING POLYMORPHISMS IN CYTOKINES GENES ASSOCIATED WITH ACUTE GRAFT VERSUS HOST DISEASE AND OVERALL SURVIVAL AFTER IDENTICAL HLA-ALLOGENEIC STEM-CELL TRANSPLANTATION

SEARCH FOR CIRCULATING ENDOTHELIAL CELLS OF DONOR ORIGIN AFTER ALLO-HSCT: POTENTIAL CLINICALLY RELEVANT IMPLICATIONS IN THE CONTEXT OF GRAFT-VERSUS-HOST DISEASE

DOUBLE LUNG TRANSPLANTATION IN ADULTS FOR CHRONIC PULMONARY GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

REDUCED INFLAMMATORY TISSUE INFILTRATION DURING INTESTINAL STEROID-REFRACTORY GVHD

IMPACT OF ANTITHYMOCYTE GLOBULIN DOSE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN STEM CELL TANSPLANTATION FROM UNRELATED DONORS

DECREASED SOLUBLE HLA-E LEVELS IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ARE ASSOCIATED WITH SEVERE ACUTE AND EXTENDED CHRONIC GRAFT-VERSUS-HOST DISEASE AND INFERIOR OVERALL SURVIVAL

EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON PRODUCTION OF SERUM SOLUBLE CD163: RELATIONSHIP TO IMMUNOSUPPRESSION AND DISEASE ACTIVITY IN CHRONIC GRAFT VERSUS HOST DISEASE

POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE OVERC OMES THE DETRIMENTAL EFFECT OF A SINGLE-LOCUS HLA MISMatchED IN UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

ALLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS FROM HAPLOIDENTICAL AND MATCHED DONORS: 'SIR-PTCY' RESULTS IN 249 PATIENTS

A NEW HOPE IN THE TREATMENT OF STERIOD-REFRACTORY GRAFT VERSUS HOST DISEASE (SR-GVHD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT): RUXOLITINIB

AZACITIDINE IS SAFE AND ACTIVE IN THE TREATMENT OF STEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST-DISEASE - INTERIM RESULTS OF THE PHASE II AZTEC TRIAL

BASILIXIMAB AS TREATMENT OF STERIOD-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

EFFICACY AND TOLERANCE OF NILOTINIB IN PATIENTS WITH REFRACTORY CHRONIC GVHD WHO ARE REFRACTORY/INTOLERANT TO IMATINIB: A PROSPECTIVE MULTICENTER PHASE II STUDY OF THE SFGM-TC

EVALUATION OF THE PROGNOSTIC VALUE OF HISTOLOGIC ASSESSMENT OF ACUTE GRAFT-VERSUS-HOST-DISEASE OF THE UPPER GASTROINTESTINAL TRACT ACCORDING TO LERNER EARLY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

CYCLOSPORINE A ALONE VERSUS MYCOPHENOLATE MOFETIL PLUS CYCLOSPORINE A BASED GVHD PROPHYLAXIS FOR PATIENTS WITH AML UNDERGOING MUD TRANSPLANTATION. A STUDY FROM THE ALWP

TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS INDEPENDENTLY ASSOCIATED WITH RUXOLITINIB ADMINISTRATION IN PATIENTS WITH GRAFT-VERSUS-HOST-DISEASE
Scientific Programme

DIAGNOSTIC SIGNIFICANCE OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD)

LONG TERM OUTCOMES OF RUXOLITINIB THERAPY IN STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN AND ADULTS

INVESTIGATING ANTIBIOTIC EXPOSURE AND RISK OF SEVERE ACUTE GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EFFICACY AND TOXICITY OF RUXOLITINIB IN PATIENTS WITH STEROID-RESISTANT ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION

PATIENT CHARACTERIZATION AND SURVIVAL OUTCOMES IN PAEDIATRIC CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS: A POPULATION-BASED STUDY IN SWEDEN

CYTOKINE LEVELS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION: A MATCH-PAIR ANALYSIS OF HOME CARE VERSUS HOSPITAL CARE

FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH STEROID-RESISTANT GRAFT VERSUS HOST DISEASE COLONIZED BY ANTIBIOTIC-RESISTANT BACTERIA - SINGLE-CENTER ANALYSIS OF 15 PROCEDURES

INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE: RESULTS FROM A PROSPECTIVE MULTICENTRE ANALYSIS OF 2 COHORTS

THE CXCL9 POLYMORPHISM RS884304 COUNTERACTS CALCINEURIN-INHIBITOR REPRESSION OF EARLY CXCL9 RECONSTITUTION AND ASSOCIATES WITH SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE

EARLY INTRODUCTION OF RUXOLINITIB FOR CHILDREN WITH GRAFT VERSUS HOST DISEASE - A STITCH IN TIME SAVES NINE

POST-TRANSPLANT CYCLOPHOSPHAMIDE AS AN EFFECTIVE STRATEGY FOR GVHD PREVENTION IN BOTH HLA-MATCHED AND MISMATCHED ALLOGENEIC TRANSPLANTS

SERUM AUTOANTIBODIES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY

OPTIMIZED STARTING DOSE OF CYCLOSPORINE REDUCES RISK OF ACUTE GVHD AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

SUCCESS OF IMMUNOSUPPRESSION IN PATIENTS WITH CHRONIC GVHD: ANALYSIS ON 108 ADULT LONG-TERM SURVIVORS AFTER MATCHED AND HAPLOHSCT

INCIDENCE AND OUTCOME OF LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE DURING TAPERING OR AFTER STOPPING CALCINEURIN INHIBITORS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING AND MATCHED UNRELATED COMPARED TO HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, A STUDY ON BEHALF OF GETH

MESENCHYMAL STROMAL CELLS (MSC) FOR STEROID-REFRACTORY ACUTE GVHD, A SINGLE CENTER PHASE I/II TRIAL

T-LYMPHOCYTE TRANSCRIPTIONAL SIGNATURE IN ECP-TREATED PAEDIATRIC PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE

EFFICACY OF LOW-DOSE RUXOLITINIB AS SAVAGE THERAPY IN HEAVILY PRETREATED PATIENTS WITH MODERATE/SEVERE STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
RESTRICTIVE USE OF INTRAVENOUS ANTIBIOTICS IN ALLOGENEIC SCT PTS WITH FEVER DUE TO CYTOKINE RELEASE SYNDROME ALLOWS MICROBIOTA PROTECTION WITHOUT INCREASE OF INFECTIONS AND TRM

EXTRACORPOREAL PHOTOPHERESIS (ECP) AS FIRST-LINE TREATMENT FOR ACUTE GVHD (AGVHD) IN PEDIATRIC PATIENTS WHO UNDERWENT T-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION (APLO-HSCT)

EFFICACY OF METHOXSALEN STERILE SOLUTION IN CONJUNCTION WITH THE THERAKOS (R) CELLEX (R) PHOTOPHERESIS SYSTEM IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD: INTERIM ANALYSIS

MICRO RNA PROFILING OF ACOUSTICALLY-ISOLATED EXTRACELLULAR VESICLES IDENTIFIES POTENTIAL BIOMARKERS FOR POST-ALLO-HSCT COMPLICATIONS

COLONIZATION PLAYS AN IMPORTANT ROLE IN THE OUTCOME OF ALLOGENEIC TRANSPLANTATION

ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) SCORE AT THE ONSET OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PREDICTING OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION-A RETROSPECTIVE ANALYSIS

CARFILZOMIB IN ADDITION TO STANDARD CYCLOSPORINE/ METHOTREXATE COMBINATION EFFECTIVELY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS

COMPARISON OF EXCLUSIVE POSTTRANSPLANT CYCLOPHOSPHAMIDE VERSUS A CALCINEURIN INHIBITOR BASED REGIMEN AS GVHD PROPHYLAXIS IN ALLOGENEIC BONE MARROW TRANSPLANTATION FROM HLA IDENTICAL SIBLING

SIROLIMUS VERSUS CYCLOSPORINE WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND MYCOPHENOLATE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN HAPLOIDENTICAL TRANSPLANTS: A RETROSPECTIVE ANALYSIS OF ONE SINGLE INSTITUTION

Mario Andres Sanchez Salinas, Rafael Hernani Morales, Ana Benzaquen Vallejos, Juan Carlos Hernandez Boluda, Ariadna Perez Martinez, Paula Amat Martinez, Montserrat Gomez Calafat, Rosa Goterris Viciedo, Carlos Solano Vercet (Spain)

TARGETED SEQUENCE CAPTURE METAGENOMICS (VIROCAP) TO DETECT VIRUS IN STOOL SAMPLES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS

EXTRACORPOREAL PHOTOPHERESIS AND PRODUCTION OF SERUM IL-34 AND ELAFIN IN CHRONIC GRAFT VERSUS HOST DISEASE

IMPACT OF UPPER AND LOWER ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE ON GRADING AND OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS IN 122 CONSECUTIVE PATIENTS

Monica Poiani, Francesco Saraceni, Ilaria Scortechini, Giorgia Mancini, Marianna Mariani, Giorgia Micucci, Chiara Montagna, Giuseppina Urbano, Federica Monaco, Giuseppe Tarantino, Irene Federici, Attilio Olivieri (Italy)

PRELIMINARY EXPERIENCE WITH THE USE OF RUXOLITINIB, IBRUTINIB OR IMATINIB FOR THE TREATMENT OF ACUTE OR CHRONIC GVHD

RUXOLITINIB WITH OR WITHOUT IBRUTINIB AS AN ALTERNATIVE FIRST LINE THERAPY FREE OF CORTICOSTEROIDS OR CALCINEURIN INHIBITORS IN TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE

CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS

IMPACT OF KIR/HLA INCOMPATIBILITIES AFTER POSTTRANSPLANT CYCLOPHOSPHAMIDE BASED T CELL-REPLETATE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
ELEVATED PTH LEVELS AMONG CHRONIC GRAFT-VERSUS-HOST DISEASE PATIENTS AND OTHER LONG TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

CONCURRENCE OF GVHD AND NON-INFECTIONOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION

ACUTE GVHD INCIDENCE IN MISMATCHED UNRELATED DONOR HSCT IN PAEDIATRIC ADULT PATIENTS: A STUDY FROM THE TURIN METROPOLITAN TRANSPLANT CENTER

PRACTICAL IMPLEMENTATION OF THE NIH DIAGNOSTIC CRITERIA FOR ORAL CHRONIC GVHD IN A MULTIDISCIPLINARY TEAM IN THE LATE FOLLOW UP OF ALLOGENIC HSCT PATIENTS

THE IMPACT OF ANTIBIOTIC-MEDIATED MODIFICATION OF THE INTESTINAL MICROBIOME ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: SYSTEMATIC REVIEW AND META-ANALYSIS

CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS FROM WHARTON’S JELLY IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE

PREDICTIVE ROLE OF ENDOSCOPIC/HISTOLOGICAL EXAMINATIONS FOR GASTRO-INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM CELLS TRANSPLANT: ‘A POSTERIORI’ ANALYSIS IN A SINGLE CENTER

THE INCIDENCE, RISK FACTORS, AND OUTCOMES OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

PROGNOSTIC CT FINDINGS AROUND THE ONSET OF ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE

THYMoglobulin and Grafalon effect on allogeneic stem cell transplant - pooled data from Wroclaw Medical University, Poland and University Medical Center ljubljana, Slovenia

THE ROLE OF LOW-DOSE ANTI-THYMOCYTE GLOBULIN IN MATCHED SIBLING DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES

NEPHROTIC SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AS A FORM OF CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE

CORRELATION AMONG TOTAL NUCLEATED CELLS (TNC), CD34+, CD3+ CELL CONTENT IN G-CSF-PRIMED BONE MARROW COLLECTIONS AND THEIR RELATIVE INFLUENCE ON DEVELOPMENT OF ACUTE GVHD

PREDICTION FOR LETHAL ACUTE GRAFT VERSUS HOST DISEASE AND NON-RELAPSE MORTALITY BY EARLY PLASMA BIOMARKERS: A SINGLE CENTER RETROSPECTIVE STUDY IN JAPAN

RUXOLITINIB IN THE TREATMENT OF CORTICOSTEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD): ONE SINGLE CENTER EXPERIENCE

OUTCOME OF PATIENTS ALIVE AT 1-YEAR POST ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM A SINGLE INSTITUTION

RUXOLITINIB IN STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: EXPERIENCE IN OUR CENTRE

LOW-DOSE OF RUXOLITINIB: AN EFFECTIVE THERAPY FOR REFRACTORY BOS PATIENTS

SIROLIMUS BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PAEDIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT FOR BENIGN DISEASE
DETECTION OF BIOMARKERS PREDICTIVE OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY

OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) AFTER PD-1 BLOCKADE IN RELAPSED/REFRACTORY (R/R) LYMPHOMAS: A SINGLE CENTER EXPERIENCE

CD3+ DOSE IN PERIPHERAL BLOOD PROGENITOR CELLS PRODUCTS FOR ALLOTRANSPLANT FROM MATCHED UNRELATED DONORS FOR AML: IMPACT ON CHRONIC GRAFT VERSUS HOST DISEASE AND SURVIVAL

CYCLOPHOSPHAMIDE FOR SALVAGE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE ANALYSIS

A ROLE OF METHOTREXATE IN THE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE - A MULTICENTER OBSERVATIONAL STUDY ON BEHALF OF POLISH ADULT LEUKEMIA GROUP (PALG)

EVALUATION OF EXTRACORPOREAL PHOTOPHERESIS USED AS SECOND-LINE TREATMENT FOR GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HSCT IN A BRAZILIAN CENTER

THE OPTIMAL GVHD PROPHYLAXIS IN UNRELATED TRANSPLANTATIONS OF NON-MANIPULATED HEMATOPOIETIC STEM CELLS IN CHILDREN

ANALYSIS OF HISTOLOGY’S IMPACT IN PATIENTS WITH ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

RUXOLITINIB IN CHRONIC GRAFT VersUS HOST DISEASE: SINGLE CENTER EXPERIENCE

IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT). UNICENTRIC EXPERIENCE

FECAL MICROBIOTA TRANSPLANTATION FOR TREATING STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE OF THE GUT: A PILOT STUDY

EARLY RECOVERY OF LYMPHOCYTES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS RISK FACTOR OF CGVHD

FAVORABLE OUTCOME USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN HAPLOIDENTICAL (HAPLO-SCT) AND MATCHED RELATED DONORS (MRD): SINGLE CENTER EXPERIENCE IN CHILE

COMBINED THERAPY WITH MSC INFUSIONS TO OVERCOME STEROID-DEPENDENCY IN A CASE OF SEVERE PULMONARY CGVHD

MULTIPLE STRICTURES OF THE SMALL INTESTINE DEMANDING SURGICAL INTERVENTION AS A COMPLICATION OF GRAFT VERSUS HOST DISEASE: A CASE REPORT

A REMARKABLY LONG REMISSION ACHIEVED WITH IBRUTINIB MONOTHERAPY IN A PATIENT WHO WAS DIAGNOSED WITH STEROID REFRACTORY SCLEROSING CHRONIC GVHD

INCREASED RISK OF ACUTE GVHD IN PATIENTS WITH MYELOFIBROSIS AFTER ALLO TRANSPLANT IN THE ABSENCE OF JAK-STAT INHIBITION

AUTOIMMUNE MYOSITIS AS PARANEOPLASTIC COMPLICATION OF A SQUAMOUS CELL CARCINOMA OF THE TONGUE AFTER SEVERE CHRONIC GRAFT VERSUS HOST DISEASE

UNUSUAL CAUSE OF DYSPNEA IN POST-TRANSPLANT PATIENT
Graft-versus-host disease - preclinical and animal models

DIETARY STEARIC ACID LEADS TO A SEVERE AGVHD BY MODULATING THE GUT MICROBIOTA AND GLUCOSE METABOLISM

GRANULOCYTE COLONY-STIMULATING FACTOR-PRIMED DONOR T CELLS ATTENUATE MURINE ACUTE GVHD THROUGH REGULATING T CELL DIFFERENTIATION IN TARGET ORGANS

MTOR REGULATE GENERATION AND FUNCTION OF PMN-MDSCS AND PLAY PROTECTION ROLE IN ACUTE GRAFT-VERSUS-HOST DISEASE

FULL REGULATORY T CELL RECONSTITUTION BEFORE T CELL TRANSFER PREVENTS GRAFT-VERSUS-HOST DISEASE BY SUPPRESSING COSTIMULATION AND T CELL ACTIVATION IN A HAPLOIDENTICAL MODEL

TARGETING OF CHEMOKINE RECEPTOR 7 PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE

ENHANCING REGULATORY T CELL FUNCTION AND HOMING TO THE GUT TO IMPROVE GRAFT-VERSUS-HOST DISEASE PREVENTION AFTER ADOPTIVE TRANSFER IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION

LYG1-DEFICIENT DONOR SPLENOCYTES ATTENUATED THE SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE VIA SKEWING CD4+ T CELL POLARIZATION TOWARDS TREG CELLS

ATTENUATION OF MURINE CHRONIC GRAFT VERSUS HOST DISEASE BY THE NRF2 ACTIVATOR MANGIFERIN

CHEMOTHERAPY AND INFLAMMATION INDUCED DAMAGE OF INTESTINAL EPITHELIUM IS ASSOCIATED WITH INCREASED T CELL CHEMOTAXIS

INKT CELLS PROMOTE IMMUNE TOLERANCE BY SELECTIVE DENDRITIC CELL APOPTOSIS

ACTIVE PARTICIPATION OF CXCR4+ T LYMPHOCYTES IN ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC TRANSPLANTATION

A MURINE MODEL REVEALS A CRITICAL ROLE FOR REACTIVE OXYGEN SPECIES IN HYPERACUTE GRAFT-VERSUS-HOST DISEASE

MAPPING THE ROAD OF GVHD AND GVT. A LONGITUDINAL STUDY OF IMMUNE-TRANSCRIPTOME SIGNATURES AS NOVEL APPROACH TO SOLVE POST-ALLOGENEIC TRANSPLANTATION DILEMMA

CELL-FREE DNA LEVELS ARE INCREASED IN ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS AND MICE

DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION

ENDOTHELIAL MICROPARTICLES DELIVERING LINCRNA NEAT1 ARE INVOLVED IN THE PATHOPHYSIOLOGY OF AGVHD FOLLOWING ALLO-HSCT

B-T CELL INTERACTIONS IN GRAFT-VERSUS-HOST DISEASE

IDENTIFICATION OF POTENTIAL MICROBIOME MARKERS FOR AGVHD EARLY DIAGNOSIS
Granulocyte and osteoclast disorders

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR OSTEOPETROSIS

Haematopoietic stem cells

HAPLOIDENTICAL DONOR BEATS MATCHED SIBLING DONOR FOR PRE-TRANSPLANTATION MRD POSITIVE ALL: A PHASE 3 BIOLOGICALLY RANDOMIZED STUDY

RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED RELATED DONOR WITH TCRβ+/CD19+-DEPLETION AND A FIXED DOSE MEMORY T CELL (CD45RA-DEPLETED) ADD-BACK

CLONAL DYNAMICS AND GENOMIC INTEGRITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN HUMAN ALLOGENEIC TRANSPLANTATION RECIPIENTS

ALLOGENEIC TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELL GRAFTS RESULTS IN A MASSIVE DECREASE OF PRIMITIVE HEMATOPOIETIC PROGENITOR FREQUENCIES IN RECONSTITUTED BONE MARROWS

TREATMENT OF PURE RED CELL APLASIA AFTER MAJOR ABO INCOMPATIBLE ALLOGENIC STEM CELL TRANSPLANTATION: A FRENCH RETROSPECTIVE STUDY

FEASIBILITY AND OUTCOMES OF A THIRD ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM THE ALWP OF EBMT

CHANGES IN VIABILITY MARKERS OF HAEMATOPOIETIC STEM CELLS FOLLOWING LONG-TERM CRYOPRESERVATION

HIGH PRE-TRANSPLANT INTERLEUKIN-18 IS ASSOCIATED WITH POOR HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND PREDICTS INCREASED NON-RELAPSE MORTALITY

MICROBIAL DIVERSITY, SURVIVAL, AND ACUTE GVHD IN ADULT RECEPIENTS OF ALLO-HSCT AFTER MYELOABLATIVE CONDITIONING: RESULTS OF A NUTRITIONAL INTERVENTION TRIAL

UK EXPERIENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACTIVATING PI3K MUTATIONS

RECONSTRUCTION OF THE DONOR-RECIPIENT HAEMATOPOIETIC CELL PHYLOGENY USING SOMATIC MUTATIONS TO ESTABLISH NUMBERS OF ENGRAFTING LONG-TERM HSCS IN REAL-WORLD TRANSPLANTATION

SUCCESSFUL CLEARANCE OF DONOR SPECIFIC ANTI-HLA ANTIBODIES AFTER DESENSITIZATION WITH RITUXIMAB, VELCADE AND PLASMA-EXCHANGE FOLLOWED BY A HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

IMPACT OF PRE-TRANSPLANTATION MINIMAL RESIDUAL DISEASE DETERMINED BY FLOW CYTOMETRY ON OUTCOME OF ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

ECONOMIC BURDEN OF CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SPANISH MULTICENTER, RETROSPECTIVE STUDY
INCIDENCE AND OUTCOME OF CLONAL AND MALIGNANT TRANSFORMATION (CMT) AMONG PEDIATRIC PATIENTS WITH INHERITED BONE MARROW FAILURE SYNDROMES (IBMFSS)

IMPACT OF POST-TRANSPLANT IMMUNOSUPPRESSION WEAN VS. BOOST IN EARLY MIXED CHIMERISM FOLLOWING G-CSF-PRIMED MARROW TRANSPLANT IN THALASSEMIC PATIENTS

COMPARISON OF THE CONDITIONING REGIMENS WITH TMLI, NON-RADIATION AND TBI FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

VALIDATION OF DISEASE RISK COMORBIDITY INDEX (DRCI) FOR OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) WITH PARTIALLY T-CELL DEPLETED GRAFT

ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS PRETREATED WITH JAK1/JAK2 INHIBITORS

THE DETERMINATIVE ROLE OF PATIENT-CONTROLLED-ANALGESIA (PCA) IN THE EARLY COURSE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

HIGH SURVIVAL RATE AND LOW INCIDENCE OF AGVHD AFTER CD34+ STEM CELLS SELECTION AND CD3+ T CELLS ADDBACK IN PEDIATRIC MUD HSCT

IMPACT OF ABO INCOMPATIBILITY ON OUTCOMES AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA

COMPARISON OF OUTCOMES AFTER HAPLOIDENTICAL VERSUS UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER REVIEW

EFFECT OF DIFFERENT TIMINGS OF UMBILICAL CORD CLAMPING ON THE LEVEL OF CD34+ CELLS IN FULL-TERM NEONATES

SEQUENTIAL CONDITIONING REGIMEN (FLAMSA-BU-MEL) IN HLA-MATCHED OR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN REFRACTORY MYELOID DISEASE

SEQUENCE CYTOREDUCTIVE CHEMOTHERAPY FOLLOWED BY MA CONDITIONING REGIMEN HSCT WITH INTERMEDIATE - OR ADVERSE RISK AML IN CR: A SINGLE CENTER STUDY

INVESTIGATION OF VIROLOGICAL FEATURES AND CLINICAL OUTCOMES ASSOCIATED WITH PRE-ENGRAFTMENT CYTOMEGALOVIRUS DNAEMIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS

CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE AS A PREDICTOR OF ENGRAFTMENT AND SURVIVAL IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

USE OF PLEXIRIXAFOR IN POOR MOBILIZER PATIENTS WITH MYELOMA AND LYMPHOMA: CLONOGENIC CAPACITY AND ENGRAFTMENT DATA

OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRICS: A SINGLE CENTER EXPERIENCE FROM INDIA

RELAPSE/REFRACTORY FOLLICULAR LYMPHOMA: LONG TERM OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA

PRE-EMPTIVE USE OF SORAFENIB COMBINED WITH DLI POST HSCT IN AML FLT3+: A SINGLE CENTER EXPERIENCE

USE OF ELTROMBOPAG FOR THE MANAGEMENT OF POOR GRAFT FUNCTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN
TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH ELTROMBOPAG

EFFICACY OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED TO CHEMOTHERAPY AS POST-REMISSION TREATMENT FOR CHILDREN WITH INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION

THE TREATMENT OF BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA IRREVERSIBLY DEPLETES NAIVE T LYMPHOCYTES

DESENSITIZATION PROTOCOL IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH ANTI-HLA DONOR-SPECIFIC ANTIBODIES (DSA): A SINGLE-CENTER EXPERIENCE

ASSOCIATION BETWEEN METABOLIC ALTERATION WITH TYPE AND INDICATION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION

RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES FOR PATIENTS RECEIVING UMBILICAL CORD BLOOD TRANSPLANTS AT THE ROYAL MARSDEN HOSPITAL BETWEEN 2007 AND 2017

HIGHER COST AND NO SURVIVAL BENEFIT WITH ADDITION OF RITUXIMAB TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL

ASSOCIATION BETWEEN METABOLIC ALTERATIONS WITH AGE AND GENDER OF PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION

HAPLOIDENTICAL HSCT IN CHILDREN WITH VERY HIGH-RISK HAEMATOLOGIC MALIGNANCIES: A SINGLE-CENTRE EXPERIENCE

COMPARATIVE STUDY OF THE HEMATOPOIETIC RECONSTITUTION

INFUSED TOTAL NUCLEATED CELL DOSE IS NOT ASSOCIATED WITH ENGRAFTMENT IN AUTOLOGOUS STEM CELL TRANSPLANTATION

A COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND BFM 95 CHEMOTHERAPY PROTOCOL IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

THE IMPACT OF CD34+ CELL AND IMMUNEFECTOR CELL DOSE ON TRANSPLANT OUTCOMES

TREOSULFAN COMBINED WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANTATION OF MYELOID DISEASES, ALLOWS HIGH OVERALL SURVIVAL WITH LOW RELATED TOXICITY

OUTCOME OF RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

MOTIVATION FOR ANTIFUNGAL USE IN PEDIATRIC HSCT PATIENTS IN AN INSTITUTION IN SOUTHERN BRAZIL

IMPACT OF THE USE OF GRANULOCYTIC COLONY-STIMULATING FACTOR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN RARE FORMS OF PRIMARY IMMUNODEFICIENCIES (PIDS) IN ARGENTINA

PHASE II STUDY OF PLERIXAFLOR AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL, PET POSITIVE AFTER TWO R-DHAP
THE EFFECT OF CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE ON THE HEMATOPOIETIC RECOVERY AND SURVIVAL IN ACUTE LYMPHOBlastic LEUKEMIA (ALL) PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION

THE EVENTUAL ROLE OF DONOR AND RECIPIENT VITAMIN D LEVELS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT SETTING

AVERAGE LENGTH OF HOSPITAL STAY FOR PEDIATRIC BLOOD AND MARROW TRANSPLANTS IN THE BACKDROP OF CELL SOURCE, TRANSPLANT TYPE AND OUTCOME

ONE CENTER EXPERIENCE IN OFFLINE TECHNIQUE VALIDATION WITH BIOLOGICAL QUALITY TESTS

A MONOCENTRIC CLINICAL OBSERVATION OF ALLOGENEIC TRANSPANTATION IN 22 PATIENTS WITH ACUTE MEGAKARYOCYTIC LEUKEMIA

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN IN SCIENTIFIC CENTRE OF PEDIATRICS AND CHILD SURGERY

THE OUTCOME OF ALLOTRANSPLANT USING TBF CONDITIONING FROM MATCHED SIBLING RELATED DONORS IN HIGH RISK MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE SINGLE CENTER EXPERIENCE

EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHO CYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA: RETROSPECTIVE ANALYSIS IN OUR CENTER

CARDIOVASCULAR RISK IN PATIENTS BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

INFECTIONS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PEDIATRIC RECIPIENTS IN PERU: EXPERIENCE OF A REFERRAL CENTER

HAEMATOPOIETIC STEM CELL PRODUCT VIABILITY: A COMPARATIVE STUDY BETWEEN BAGS AND VIALS

TRANSFUSION SUPPORT IN THE FIRST 30 AND 100 DAYS AFTER HAPLOIDENTICAL VERSUS HLA-MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MACS IN A PERUVIAN HEALTH CHILDREN'S INSTITUTE: THREE-YEAR EXPERIENCE

COLLECTION, CRYOPRESERVATION AND AUTOLOGOUS TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELLS IN KAUNAS, LITHUANIA 2015-2019

EVALUATION OF OVERALL SURVIVAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT): UNICENTRIC EXPERIENCE

MONITORING OF THE EXPRESSION OF THE VEGF-A GENE (VASCULAR ENDOTHELIAL GROWTH FACTOR) DURING THE EVOLUTION OF PEDIATRIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION. A PILOT STUDY

REFRACTORY T-CELL CUTANEOUS LYMPHOMA TREATED WITH ALLOGENEIC HAPLOIDENTIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT

VITAMIN D DEFICIENCY AND OUTCOMES IN ADULT ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE OVER LAST YEARS
CAUSES OF COMPLICATIONS IN ADULTS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Haemoglobinopathy and inborn errors

SUCCESSFUL HLA-MISMATCHED HSCT IN PAEDIATRIC PATIENTS WITH HEMOGLOBINOPATHIES USING ATG SEROTHERAPY AND POSTTRANSPLANT CYCLOPHOSPHAMIDE

OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH CEREBRAL ADRENOLEUKODYSTROPHY VARY BY DONOR CELL SOURCE, CONDITIONING REGIMEN, AND STAGE OF CEREBRAL DISEASE STATUS

OUTCOME OF NON MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE SICKLE CELL DISEASE: A 100 PATIENT EXPERIENCE FROM SAUDI ARABIA

HIGH DOSE STEM CELL THERAPIES, LIKE MGTA-456, ENABLE COMPLETE NEURAL AND PERIPHERAL DISEASE CROSS-CORRECTION THROUGH RAPID AND ROBUST HEMATOPOIETIC ENGRAFTMENT

HLA SET-UP IS A MAJOR PREDICTOR OF ENGRAFTMENT IN HAPLO-IDENTICAL TRANSPLANT FOR SEVERE THALASSEMIA (ST) USING POST-CYCLOPHOSPHAMIDE (PTCY)

CTLA4IG-BASED T CELL COSTIMULATION BLOCKADE IN PTCY BASED HAPLOIDENTICAL HCT FOR THALASSEMIA MAJOR (TM) AND SICKLE CELL DISEASE (SCD) RESULTS IN IMPROVED DISEASE-FREE SURVIVAL WITHOUT GVHD

LENTIGLOBIN GENE THERAPY TREATMENT OF TWO PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA

BONE MARROW TRANSPLANT IN PATIENTS WITH SICKLE CELL ANAEMIA. EXPERIENCE IN ONE CENTRE
Marina García Morín, Laura Escobar Fernández, Eduardo Bardón Cancho, Cristina Beléndez Bieler, Jorge Huerta Aragonés, Carmen Garrido Colino, Cristina Mata Fernández, Elena Cela de Julián (Spain)

OUTCOMES IN CEREBRAL ADRENOLEUKODYSTROPHY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE

NEURODEVELOPMENTAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MUCOPOLYSACCHARIDOSIS TYPE II: A PROSPECTIVE, LONGITUDINAL STUDY

HEMATOPOIETIC RECOVERY AND TRANSFUSION NEED AFTER HAPLOIDENTICAL TRANSPLANTATION IN BETA THALASSEMIA PATIENTS

PRE- AND POST-TRANSPLANT RITUXIMAB REDUCES THE HIGH INCIDENCE OF PRIMARY GRAFT FAILURE AND IMMUNE-MEDIATED CYTOPENIA FOLLOWING CORD BLOOD TRANSPLANT FOR LYSOSOMAL STORAGE DISEASE IN CHILDREN

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE: THE SPANISH EXPERIENCE

LONG-TERM QUALITY OF LIFE IN PATIENTS WITH THALASSEMIA MAJOR FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD

HIGH INCIDENCE OF AUTOIMMUNE CYTOPENIAS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE: THE IMPACT OF MATCHED UNRELATED DONOR
Scientific Programme

ADDING AZATHIOPRINE/HYDROXYUREA PRECONDITIONING TO ALEMTUZUMAB/TBI MAY REDUCE RISK OF GRAFT FAILURE IN MATCHED SIBLING DONOR ALLOGENEIC HSCT IN ADULT SICKLE CELL PATIENTS

A PHASE II STRATIFIED TRIAL TO ASSESS HAPLOIDENTICAL T-DEPLETED STEM CELL TRANSPLANTATION IN PATIENTS WITH SICKLE CELL DISEASE WITH NO AVAILABLE SIBLING DONOR

COMBINED UMBILICAL CORD BLOOD AND BONE MARROW FROM HLA-IDENTICAL SIBLING DONORS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMA MAJOR

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF METABOLISM USING ALTERNATE DONORS: A PROSPECTIVE SINGLE STUDY

UMBILICAL CORD BLOOD TRANSPLANTATION IN CHILDREN WITH LEUKODYSTROPHIES: SINGLE CENTER EXPERIENCE IN CHINA

PEARSON SYNDROME IN A PATIENT TRANSPLANTED FOR DIAMOND-BLACKFAN ANEMIA

CHALLENGES AND SUCCESSES WITH PRE-TRANSPLANT IMMUNE SUPPRESSION IN ALTERNATIVE DONOR TRANSPLANTS

HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CLASS 3 THALASSEMA MAJOR USING POST-TRANSPLANT CYCLOPHOSPHAMIDE

Immunodeficiency diseases and macrophages

IMPACT OF DIFFERENT <i>EX VIVO</i> T-CELL DEPLETION STRATEGIES ON OUTCOMES FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFIENCY

OUTCOMES AND IMMUNE RECONSTITUTION AFTER T-CELL REPLETE HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FOR PEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFIENCIES

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY IN JAPAN: OVERVIEW OF A NATIONWIDE RETROSPECTIVE ANALYSIS

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFIENCY IN JAPAN: A NATIONWIDE RETROSPECTIVE ANALYSIS

UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR PRIMARY IMMUNODEFIENCY: SINGLE-INSTITUTION EXPERIENCE IN CHINA

IMMUNODEFIENCY - CENTROMERIC INSTABILITY - FACIAL DYSMORPHISM (ICF) SYNDROME: EVALUATION OF CHARACTERISTICS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

THIOTEPA VERSUS MELPHALAN CONTAINING CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATIONS WITH TCRαβ/CD19 GRAFT DEPLETION FOR PRIMARY IMMUNODEFIENCIES

IMPROVED TRANSPLANT SURVIVAL AND LONG-TERM DISEASE OUTCOME FOR CHILDREN WITH CD40 LIGAND DEFICIENCY
HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES INCLUDING IMMUNE RECONSTITUTION IN PRIMARY IMMUNODEFICIENCIES: 5 YEARS OF SINGLE CENTRE EXPERIENCE

OUTCOMES OF STEM CELL TRANSPLANT FOR RIPK1 DEFICIENCY: A SINGLE CENTRE EXPERIENCE

IMPROVING THE RESULT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY WITH SERIOUS INFECTION IN DEVELOPING COUNTRIES USING RIC REGIMENT

SINGLE-CENTER EXPERIENCE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCR αβ DEPLETION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCY SYNDROMES

HAPLO-IDENTICAL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY - A TERTIARY CARE CENTRE EXPERIENCE FROM SOUTH INDIA

NECROTIZING ENTEROCOLITIS IN A TWO-MONTH-OLD SCID PATIENT AFTER BONE MARROW TRANSFUSION - SURGICAL INTERVENTION AT DAY +1: YES OR NO?

UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH TWO DIFFERENT CONDITIONING REGIMEN FOR CHRONIC GRANULOMATOUS DISEASE: SINGLE-INSTITUTION EXPERIENCE IN CHINA

THE OUTCOMES OF UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE IN CHILDREN WITH RAG GENE MUTATION

LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) IN ADA-SCID PATIENTS: THE SHADOW OF MALIGNANCIES

HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR X-LINKED AGAMMAGLOBULINAEMIA COMPlicated BY CHRONIC NOROVIRUS ENTEROPATHY

HEMATOPOETIC STEM CELL TRANSPLANTATION IN CD40 LIGAND DEFICIENCY

DIAGNOSTIC MARKERS FOR AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR CHRONIC GRANULOMATOUS DISEASE (CGD) IN CHILDHOOD

Infectious complications

PNEUMOCYSTIS PNEUMONIA AFTER ALLOGENEIC HCT: A CASE-CONTROL STUDY ON RISK FACTORS, TIMING, AND PCR USE, FROM THE IDWP OF EBMT

UPPER AND/OR LOWER RESPIRATORY TRACT INFECTION CAUSED BY HUMAN CORONAVIRUS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

SUCCESSFUL TREATMENT OF PROGRESSIVE MULTIFOCALE LEUKOENCEPHALOPATHY WITH JCV-TARGETED T-CELL THERAPY

EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIONOUS DISEASES WORKING PARTY STUDY
Scientific Programme

TUBERCULOSIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT

FAECAL MICROBIOTA TRANSPLANT (FMT) CAN REDUCE THE HIGH NRM ASSOCIATED WITH MULTI-DRUG RESISTANT ORGANISM (MDRO) COLONISATION PRIOR TO ALLOGENEIC HCT

EPIDEMIOLOGY, RISK FACTORS AND OUTCOMES OF CMV INFECTION IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT): A SINGLE INSTITUTIONAL COHORT STUDY

USE OF LETERMOVIR IN OFF-LABEL INDICATIONS: INFECTIOUS DISEASES WORKING PARTY EBMT RETROSPECTIVE STUDY

RISK OF INFECTIOUS COMPLICATIONS IN ADULT PATIENTS AFTER ALLOGENEIC HSCT DEPENDING ON THE SITE OF CENTRAL VENOUS CATHETER INSERTION - MULTICENTRE PROSPECTIVE STUDY

INFECTION PREVENTION PRACTICES AMONG EBMT HEMATOPOIETIC CELL TRANSPLANT CENTERS: A SURVEY OF THE INFECTIOUS DISEASES WORKING PARTY OF THE EBMT

PRIMARY LETERMOVIR PROPHYLAXIS IN CMV SEROPosITIVE PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL LIFE EXPERIENCE

HEV INFECTION IN HCT RECIPIENTS - RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY (IDWP) OF EBMT

THE ROLE OF COMBINATION PROPHYLAXIS IN PREVENTING CYTOMEGALOVIRUS (CMV) INFECTION AFTER EX VIVO AB T-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANT (HHCT) IN CHILDREN

IMPACT OF CMV SEROSTATUS AND CMV REACTIVATION AFTER HAPLOIDENTICAL-SCT WITH PT-CY

COMPARISON OF IMMUNE CELL RESPONSE TO CYTOMEGALOVIRUS PROTEINS VERSUS PEPTIDES USING AN IFN-γ ELISPOT ASSAY TO MONITOR CYTOMEGALOVIRUS-SPECIFIC IMMUNITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

HUMAN HERPESVIRUS TYPE 6 REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: RISK FACTORS AND CLINICAL IMPACT

INCREMENTAL INPATIENT HEALTHCARE RESOURCE USE AND COSTS AMONG CMV SEROPosITIVE ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS MANAGED THROUGH PREEMPTIVE APPROACH

POOR RECOVERY AND IMPAIRED FUNCTION OF V61+ T CELLS IN REFRACTORY/RECURRENT CMV REACTIVATION AFTER HEMATOPOIETIC TRANSPLANTATION

SAFETY AND EFFICACY OF BRINCIDOFOVIR FOR REFRACTORY ADENOVIRUS INFECTION IN CHILDREN RECEIVING ALLOGENEIC SCT: A RETROSPECTIVE ANALYSES FROM THE ITALIAN PEDIATRIC HEMATOLOGY ONCOLOGY ASSOCIATION (AIEOP)

ALLOPLUS: RESULTS OF THE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS -POSITIF PATIENTS, A RETROSPECTIVE STUDY OF THE SFGM-TC

SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN PATIENTS WHO UNDERWENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A PROSPECTIVE STUDY TO MEASURE FEASIBILITY, SAFETY AND HEALTH CARE RESOURCE USE

FREQUENCY, RISK FACTORS AND OUTCOME OF ACTIVE TUBERCULOSIS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
INFECTIOUS COMPLICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA AFTER NEW AGENTS' THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION

SURVEILLANCE FOR REACTIVATION OF TOXOPLASMA GONDII USING POLYMERASE CHAIN REACTION ASSAY AND PRE-EMPTIVE THERAPY AVOIDS UNIVERSAL PROPHYLAXIS AND PREVENTS SYMPTOMATIC INFECTION

CYTOMEGALOVIRUS (CMV) IMPACT ON CLINICAL OUTCOMES AND RESOURCE USE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE INFLUENCE OF RECURRENT EPISODES OF CMV INFECTION

FECAL MICROBIOTA TRANSPLANTATION IN CHILDREN TO TREAT ACUTE GVHD OR MULTI-DRUG RESISTANT BACTERIA COLONIZATION

VACCINATION AGAINST TICK-BORNE ENCEPHALITIS (TBE) AFTER AUTOLOGOUS AND ALLOGENEIC BONE MARROW TRANSPLANTATION

RIFAXIMIN USE FAVOURED MICAFUNGIN RESISTANT CANDIDA SPP INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

BASELINE CHARACTERISTICS AND EARLY POLY-FUNCTIONAL ASSESSMENT OF T CELLS TO IDENTIFY PATIENTS AT HIGHER RISK TO DEVELOP SEVERE HCMV REACTIVATION AFTER ALLOGENEIC HSCT

IMPACT OF HHV-6 REACTIVATION AFTER T-REG/T-CON IMMUNOTHERAPY IN ALLOGENEIC TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE STUDY

ADENOVIRUS INFECTIONS AFTER HCT: INFECTIOUS DISEASES WORKING PARTY RETROSPECTIVE EBMT REGISTRY STUDY

CLINICAL IMPACT OF COLONIZATION BY MULTIDRUG-RESISTANT ENTEROBACTERIACEAE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

POST-ALLOGENEIC TRANSPLANTATION PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, CLINICAL AND BIOLOGICAL FEATURES, TREATMENT AND OUTCOMES: A RETROSPECTIVE STUDY FROM THE SFGM-TC

RESPIRATORY VIRAL INFECTIONS IN ADULT PATIENTS UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION FROM UNRELATED DONORS AFTER MYELOABLATIVE CONDITIONING REGIMEN

EFFICACY OF LETERMOVIR FOR PROPHYLAXIS OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTI CENTER RETROSPECTIVE ANALYSIS AMONG JAPANESE PATIENTS

RISK FACTORS AND CLINICAL OUTCOMES OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL AND MATCHED-SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

STANDARDIZED MONITORING OF CYTOMEGALOVIRUS-SPECIFIC CELLULAR IMMUNITY CAN IMPROVE RISK STRATIFICATION OF RECURRENT CYTOMEGALOVIRUS REACTIVATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

IMPACT OF LEVOFLOXACIN FOR PROPHYLAXIS OF PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS AFTER ALLOGENEIC HSCT: A SINGLE-CENTER MATCHED ANALYSIS IN AN ENDEMIC COUNTRY FOR CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) AFTER HCT - A RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT

ORAL RIBAVIRIN IS A HIGHLY EFFICACIOUS TREATMENT FOR LOWER RESPIRATORY TRACT INFECTION DUE TO RESPIRATORY SYNCYTIAL OR PARAINFLUENZA VIRUS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS
Scientific Programme

TIMING OF INDUCTION TREATMENT FOR REACTIVATION OF CYTOMEGALOVIRUS IMPACTS OVERALL SURVIVAL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT

PREDICTION OF BLOODSTREAM INFECTION RISK USING CITRULLINE AS BIOMARKER OF INTESTINAL MUCOSITIS IN HEMATO-ONCOLOGY PATIENTS

PREDICTION OF CMV REACTIVATION BY THE RECIPIENT IGG TITER BEFORE ALLO-HCT

COMPARISON OF INFECTIOUS COMPLICATIONS AMONG PATIENTS RECEIVING UNMANIPULATED HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETED HAPLOIDENTICAL TRANSPLANT

THE CUMULATIVE INCIDENCE OF MULTIPLE DNA VIRUS REACTIVATION IS NOT DIFFERENT IN NON-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION AND UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION

NEUTROPHILS RESPONSE TO HUMAN CMV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

CLINICAL EFFICACY OF LETERMOVIR PROPHYLAXIS FOR CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

AT-HOME FOSCARNET ADMINISTRATION IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION PATIENTS WITH CYTOMEGALOVIRUS INFECTION: A SAFETY FEASIBLE MODEL

EFFECTS OF THE ANTIBIOTICS CHANGE OR THE ADDITION OF ANTI-MRSA DRUGS FOR PERSISTENT FEBRILE NEUTROPENIA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION

THERAPEUTIC DRUG MONITORING OF POSACONAZOLE AND SUBSEQUENT DOSING IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS

IS PREEMPTIVE STRATEGY ENOUGH? RELATIONSHIP BETWEEN CMV REACTIVATION AND STEROID THERAPY FOR GHVD IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: 97 PATIENTS FROM TURKEY

PROPHYLAXIS WITH AZITHROMYCIN IN ALLOGENEIC CORD BLOOD TRANSPLANT AND ASSOCIATION WITH RELAPSE RATE AND TRANSPLANT OUTCOMES

REACTIVATED VARICELLA ZOSTER (VZV) INFECTION (SHINGLES), AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HCT) FOR HAEMATOLOGICAL DISEASE IN CHILDREN: A SIGNIFICANT PROBLEM AND PROPOSAL FOR FUTURE MANAGEMENT

LETTERMOVIR PROPHYLAXIS REDUCES INPATIENT RESOURCE CONSUMPTION BY BEING EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REAL-WORLD EXPERIENCE

ANALYSIS OF CMV REACTIVATION RISK AFTER T CELL REPLETE HAPLOIDENTICAL AND MATCHED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

INCIDENCE AND IMPACT OF EPSTEIN-BARR VIRUS EVENTS IN THE EARLY PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

ASPERGILLUS NON-FUMIGATUS INVASIVE ASPERGILLOSIS IN CHILDREN AND ADULTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) & CHEMOTHERAPY

INTRAVENOUS PENTAMIDINE FOR PNEUMOCYSTIS JIROVECII PROPHYLAXIS IN HEMATOLOGICAL PATIENTS TREATED WITH CHEMOTHERAPY, HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) AND CAR-T CELL THERAPY

Page 113 / 353
INTENSIFICATION OF CMV PROPHYLAXIS WITH THE USE OF GANCICLOVRIR DURING THE CONDITIONING IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. COMPARISON WITH A STANDARD STRATEGY. 113 PATIENTS

LOW RELAPSE RISK FOR REDUCED INTENSITY CONDITIONED ALEMTUZUMAB-BASED ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMAS IS OFFSET BY CYTOMEGALOVIRUS RISK: DATA FROM SINGLE CENTRE STUDY

PROPHYLACTIC DOSE TRIMETHOPRIM/SULFAMETHOXAZOLE DOES NOT LEAD TO DELAYED NEUTROPHIL AND PLATELET ENGRAFTMENT IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

HIGH DOSE VALACICLOVRIR AS CMV PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION

EPIDEMIOLOGICAL SCREENING FOR BACTERIAL RESISTANCE BY DIFFERENT TECHNIQUES IN ALLO-HSCT PATIENTS

INVASIVE MOLD DISEASE IN A REAL-WORLD HEMATO-ONCOLOGY SETTING: VALUE OF A DIAGNOSTIC-DRIVEN CARE PATHWAY

SINGLE CENTER ANALYSIS ON THE MANAGEMENT OF ACYCLOVRIR RESISTANT HERPES SIMPLEX VIRUS STOMATITIS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

EARLY BACTEREMIA FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION WITHOUT THE USE OF PROPHYLACTIC ANTIBIOTIC: CHANGING EPIDEMIOLOGY AND ANTIMICROBIAL RESISTANCE (2016-2018)

DIAGNOSTIC YIELD OF BRONCHOALVEOLAR LAVAGE (BAL) IN HAEMATOLOGICAL PATIENTS AFTER ALLOGENEIC/AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) - COMPARISON WITH BAL PERFORMANCE IN NON-TRANSPLANTED PATIENTS

A NOVEL EFFICIENCY STRATEGY TO PREVENT HBV-RELATED HEPATITIS AFTER ALLOGENEIC HSCT FROM HB5AG- POSITIVE DONORS TO RECIPIENTS

BK VIRUS EFFECT ON DEVELOPING LATE HEMORRHAGIC CYSTITIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS: SINGLE CENTER EXPERIENCE

VERSATILE EFFECTS OF LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-INSTITUTION ANALYSIS

IMPACT OF A CHANGE IN ANTIBACTERIAL PROPHYLAXIS IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION IN ONE SINGLE CENTER

INTRAVESICAL INSTILLATION OF CIDOVOFIR IS EFFICIENT FOR THE TREATMENT OF BK VIRUS HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC TRANSPLANTATION

MANAGEMENT OF BK POLYOMA VIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE

RISK FACTORS AND OUTCOME OF EARLY CLOSTRIDIUM DIFFICILE INFECTION IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

RISK FACTORS FOR CYTOMEGALOVIRUS INFECTION IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

IMPACT OF HYPOGAMMAGLOBULINEMIA ON OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

THE USE OF RIFAXIMINE IN ANTI-BACTERIAL PROPHYLAXIS IN PATIENT UNDERGOING HSCT
BKV VIRUS - HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: INCIDENCE, SEVERITY AND RISK FACTORS

RUXOLITINIB FOR STEROID-REFRACTORY GVHD ABOLISHES ANTIVIRAL IMMUNE RESPONSE FOLLOWING T-CELL TRANSFER FOR REFRACTORY ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION

RISK FACTORS FOR CMV REACTIVATION AND DISEASE AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - DEFINING THE TARGET POPULATION FOR LETERMOVIR PROPHYLAXIS

ISAVUCONAZOLE (ISA) USE IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) RECIPIENTS: A SINGLE-CENTER EXPERIENCE

TIME- AND THERAPY-DEPENDENT BACTERIURIJA IN CHILDREN AND YOUNG ADULTS FOLLOWING ALLOGENEIC HSCT

PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF MARIBAVIR COMPARED WITH VALGANCICLOVIR FOR TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) RECIPIENTS (STUDY DESIGN)

INCIDENCE AND RISK FACTORS OF VIRAL COMPLICATIONS IN ADULT PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM HUNGARY

CONTRIBUTING FACTORS TO PRE ENGRAFTMENT BACTERIEMIA AND PNEUMONIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A LEBANESE SINGLE CENTER EXPERIENCE

UNICENTRIC STUDY: PROPHYLAXIS STRATEGY AGAINST GVHD WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (CPYT) AND ITS RELATIONSHIP WITH CYTOMEGALOVIRUS

EPIDEMIOLOGY AND CLINICAL FEATURES OF FEBRILE NEUTROPENIC EPISODES: THREE YEARS EXPERIENCE AT HEMATOLOGY WARDS

USE OF CMV-HYPERIMMUNE GLOBULINS (CMV-HYG) AS PRE-EMPTIVE THERAPY OR TREATMENT OF CMV INFECTION IN HSCT RECIPIENTS

TOXOPLASMOSIS DISEASE AFTER ALLO-HSCT. WHAT HAVE WE LEARNT?

TUBERCULOSIS IN PATIENTS WHO RECEIVE AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT. TWO CASE REPORT

POLYOMAVIRUS BK INFECTION IN BONE MARROW TRANSPLANTATION RECIPIENTS. A COMPARATIVE ANALYSIS ON CHILDREN AND ADULTS

LEFLUNOMIDE, SUCCESSFUL PRE-EMPTIVE THERAPY IN RESISTANT CYTOMEGALOVIRUS REACTIVATION IN A HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT

LETTERMOVIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

INFECTIOUS COMPLICATIONS IN HEMATOLOGIC PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION

EARLY MORTALITY IN PATIENTS WITH MULTIPLE MYELOMA - A SINGLE CENTER EXPERIANCE

CMV RETINITIS IN A STEM CELL TRANSPLANT RECIPIENT TREATED WITH FOSCARNET INTRAVITREAL INJECTION AND CMV SPECIFIC IMMUNOGLOBULIN
Lymphoma

LONG TERM SURVIVAL AFTER 2 YEARS EVENT FREE SURVIVAL IN RELAPSED DLBCL AFTER AUTOLOGOUS TRANSPLANTATION IN THE TWO RANDOMIZED TRIALS LY.12 AND CORAL

EXPLORATORY ANALYSIS OF BRENTUXIMAB VEDOTIN PLUS CHP (A+CHP) AS FRONTLINE TREATMENT FOR PATIENTS WITH CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMAS (ECHELON-2): IMPACT OF CONSOLIDATIVE STEM CELL TRANSPLANT

BRENTUXIMAB VEDOTIN FOR RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH Hodgkin LYMPHOMA: A STUDY OF THE LWP-EBMT

ALLOGENIC STEM CELL TRANSPLANTATION AS A CURATIVE OPTION IN RELAPSE/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GETH/GETLAMO STUDY

ADAM17 INHIBITOR INCB7839 WITH RITUXIMAB AS CONSOLIDATION AFTER AUTOLOGOUS HCT FOR DIFFUSE LARGE B CELL LYMPHOMA: A NOVEL RELAPSE PREVENTION STRATEGY

COMPARISON OF REDUCED-INTENSITY CONDITIONING (RIC) REGIMENS FOR ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT) FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A CIBMTR ANALYSIS

HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH NON-HODGKIN LYMPHOMA: THE SPANISH EXPERIENCE

EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSIONS FOR PATIENTS AFFECTED BY ADVANCED LYMPHOID MALIGNANCIES AFTER ALLOGENIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY

BRENTUXIMAB-VEDOTIN IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY PRIOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH Hodgkin LYMPHOMA: REAL-WORLD DATA FROM A TWO CENTERS STUDY

NON-MYELOABLATIVE CONDITIONING REGIMEN BEFORE T-CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ADVANCED LYMPHOMA

IMPACT OF KIR LIGAND MISMATCH AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR Hodgkin LYMPHOMA: A RETROSPECTIVE STUDY IN 383 PATIENTS FROM THE SFGM-TC

THE IMPACT AND CHALLENGES OF PERFORMING BEAM CONDITIONED AUTOLOGOUS TRANSPLANTS IN ‘OLDER’ PATIENTS WITH LYMPHOMA

ACCESSIBILITY AND IMPACT ON LONG-TERM OVERALL SURVIVAL OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS: A SINGE INSTITUTION INTENTION-TO-TREAT ANALYSIS

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TRANSFORMED FOLLICULAR LYMPHOMA (FL): RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY FROM GELTH/GETLAMO GROUP

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANTATION

SIGNIFICANT ROLE OF UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA
HIGH DOSE CHEMOTHERAPY TEAM FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN LYMPHOMA: RESULTS OF A PROSPECTIVE STUDY

AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIV+ AND HIV- LYMPHOMA PATIENTS: A PROPENSITY SCORE MATCHED ANALYSIS

AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR DOUBLE HIT LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

ALLOGENEIC STEM CELL TRANSPLANTATION CAN BE SUCCESSFULLY DELIVERED FOLLOWING BTKI THERAPY FAILURE FOLLOWING R-BAC RE-INDUCTION CHEMOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA

CLINICAL OUTCOMES OF EBV+ PTLD PATIENTS FOLLOWING HCT WHO FAIL RITUXIMAB: A RETROSPECTIVE CHART REVIEW STUDY FROM FRANCE

THE IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) ON THE OUTCOME OF POOR-RISK NON-HODGKIN LYMPHOMA (NHL): UPDATE OF A RETROSPECTIVE INTENT-TO-TRANSPLANT (ITT) ANALYSIS

REDUCING THE COST OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMAS AT LIMITED-RESOURCE CENTERS IN DEVELOPING COUNTRIES

COMPARISON OF MITOXANTRONE - MELPHALAN AND BEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS

NIVOLUMAB RE-CHALLENGE IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: WHERE IS THE PLACE FOR ALLOHSCT?

OUTCOME OF TRANSPLANT ELIGIBLE MANTLE CELL LYMPHOMA PATIENTS WITH FIRST-LINE REGIMENS IN A REAL-WORLD SETTING: A PORTUGUESE MULTICENTER RETROSPECTIVE ANALYSIS

EFFECT OF FRACTIONATED ICE AS AN ALTERNATIVE OUTPATIENT OPTION FOR RELAPSED/REFRACTORY LYMPHOMAS

EFFECTIVENESS OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

RISK FACTORS FOR INTENSIVE CARE UNIT ADMISSION IN PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B-CELL LYMPHOMA

DIFFERENT OUTCOMES WITH DIFFERENT DONORS IN ALLOGENEIC STEM CELL TRANSPLANTATIONS IN MALIGNANT LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE

THE IRISH EXPERIENCE OF THIOTEPA, Carmustine And Etoposide Conditioning Prior To ASCT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS

TARGETED AND IMMUNOCHEMOTHERAPY IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AS TREATMENT OPTION FOR RARE TRANSDIFFERENTIATION OF LYMPHOID NEOPLASMS INTO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS TO ACHIEVE LONG-TERM SURVIVAL

OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH PERIPHERAL T CELL LYMPHOMAS: A RETROSPECTIVE ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG)
TREATMENT OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA AFTER HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. A STUDY OF THE POLISH LYMPHOMA RESEARCH GROUP

PLACE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH T-CELL LYMPHOMAS: PAVLOV UNIVERSITY EXPERIENCE

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA: TOXICITY AND SURVIVAL STUDY

AUTOIMMUNE COMPLICATIONS IN CHILDREN WITH HODGKIN DISEASE (HD) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT)

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIV-RELATED LYMPHOMA

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS OF 23 PATIENTS

NIVOLUMAB BASED RESPONSE ADAPTED TREATMENT IN PRIMARY REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS

AUTOLOGOUS STEM CELL TRANSPLANT IN A SEROPOSITIVE A PATIENT WITH PLASMABLASTIC LYMPHOMA (PBL)

COMPAIRING THE EFFICACY AND TOXICITY BETWEEN TWO CONDITIONING REGIMEN IN LYMPHOMA PATIENTS IN WEST OF IRAN (BENDAMUSTIN) OR (CCNU) WITH (ETOPOSIDE, CITARABINE, MELPHALANE)

e-Posters
08:30 - 19:00
ePoster Area

Minimal residual disease, tolerance, chimerism and immune reconstitution

T CELL CHIMERISM AFTER HCT DOES NOT PREDICT FOR GRAFT LOSS IN NON-MALIGNANT DISEASES, AND IS A FAILURE OF MYELOSUPPRESSION RATHER GRAFT REJECTION

FASTER ENGRAFTMENT AND RECONSTITUTION OF INNATE-IMMUNITY AFTER ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) THAN POST-TRANSPLANT-CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS AFTER MYELOABLATIVE CONDITIONING (MAC) PERIPHERAL-BLOOD-STEM-CELL (PBSC) ALLOGENEIC-TRANSPLANTATION (ALLO-SCT)

CMV SEROPOSITIVITY DRIVES T CELL RECONSTITUTION AFTER CD34-SELECTED ALLOGENEIC HCT DESPITE REDUCTION OF VIREMIA WITH LETERMOVIR

COMPAIRING OUTCOMES OF PATIENTS HAVING MIXED T CHIMERISM AND UNRELATED DONOR ALLOGRAFTS FOR ACUTE LEUKAEMIA/MDS TO PATIENTS WITH COMPLETE CHIMERISM - SINGLE CENTRE RETROSPECTIVE STUDY

CMV INFECTION IS ASSOCIATED WITH REDUCED THYMIC FUNCTION AND LESS REGULATORY T CELLS AFTER PEDIATRIC ALLOGENEIC HSCT

IMPACT OF PRE-TRANSPLANT MRD BURDEN MEASURED BY MULTICOLOR FLOW CYTOMETRY ON RELAPSE AND SURVIVAL IN AML PATIENTS UNDERGOING ALLO-SCT IN CR

FLOW-BASED PRE-TRANSPLANT MRD DETECTION STRONGLY IMPACTS ON THE OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION WITH AB T CELL DEPLETION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
CMV-SPECIFIC T CELL COUNTS EARLY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION STRATIFY THE RISK OF SUBSEQUENT CMV REACTIVATIONS: RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY

IMPROVED RELAPSE-FREE-SURVIVAL IN PATIENTS WITH HIGH NATURAL KILLER CELL DOSES IN GRAFTS AND DURING EARLY IMMUNE RECONSTITUTION AFTER ALLOGENEIC TRANSPLANTATION WITH PERIPHERAL BLOOD STEM CELLS

POTENTIAL INFLUENCE OF IMMUNODEFICIENCY-RELATED HEREDITARY PREDISPOSITION GENE VARIANTS ON RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNancies

COMPARABLE RESULTS OF PREEMPTIVE RECOMBINANT IL-2 AND DONOR LYMPHOCYTE INFUSION IN HEMATOLOGICAL MALIGNANCY PATIENTS WITH LATE-ONSET MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

SURVIVAL ANALYSIS ACCORDING TO MINIMAL RESIDUAL DISEASE BY FLOW CYTOMETRY BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA

IMPACT OF RESIDUAL CIRCULATING TUMOR DNA STATUS POST ALLOGENEIC SCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: INTERIM RESULTS OF A PROSPECTIVE STUDY

EARLY CD4+ T CELL RECONSTRUCTION AS PREDICTOR FOR OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULT PATIENTS: A VALIDATION COHORT ANALYSIS

PATTERN OF RECONSTITUTION OF RECENT THYMIC EMIGRANTS AFTER REDUCED INTENSITY CONDITIONING BASED ON TARGETED BUSULFAN IN PAEDIATRIC RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

A RISK SCORE SYSTEM BASED ON POST-TRANSPLANTATION MINIMAL RESIDUAL DISEASE FOR STRATIFICATION OF RELAPSE IN B-ALL PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION

OUTCOME OF CHILDREN WITH HEMATOLOGICAL MALIGNancies WHO DEVELOP MIXED CHIMERSIM AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

PROPHYLACTIC HIGH-DOSE DONOR CD45RO+ MEMORY T-CELLS INFUSION AFTER ALLOGENEIC TRANSPLANTATION: SAFETY AND OUTCOME

MULTICOLOR FLOW CYTOMETRY PANEL WITH CCD79A GATING TO DETECT MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA POST ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT

NON-INVASIVE MONITORING OF MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE BY CIRCULATING CELL-FREE NUCLEIC ACIDS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

TORQUE TENO VIRUS AS BIOMARKER TO PREDICT COMPLICATIONS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

PREEMPTIVE INTERFERON-α TREATMENT COULD PROTECT AGAINST RELAPSE AND IMPROVE SURVIVAL OF ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

THE ADDITION OF BUSULFAN REDUCES THE INCIDENCE OF MIXED CHIMERISM FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA

A NEW MULTIVARIATE MODEL TO DESCRIBE IMPACT OF IMMUNE RECONSTITUTION ON THE DEVELOPMENT OF RELAPSE IN CHILDREN UNDERGOING ALLO-HSCT FOR HEMATOLOGIC MALIGNancies AT DAY +100
ACQUISITION OF COMPLETE CHIMERISM IN BONE MARROW, PERIPHERAL BLOOD AND LEUKOCYTE SUBSETS DEPENDS ON THE TRANSPLANT SETTING AND CORRELATES WITH THE CLINICAL OUTCOME

EARLY LYMPHOID SUBSETS RECONSTITUTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AS PREDICTOR OF RELAPSE AND SURVIVAL IN ACUTE LEUKEMIAS

COMPARISON OF IMMUNE RECONSTITUTION BETWEEN 30MG/KG AND 60MG/KG ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC MYELOABLATIVE PERIPHERAL BLOOD STEM CELL TRANSPLANTATION

FUNCTIONAL IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COMPARISON OF PRE- AND POST-TRANSPLANTATION CYTOKINE RESPONSES IN STIMULATED WHOLE-BLOOD

MEASURABLE RESIDUAL DISEASE (MRD) TESTING FOR ACUTE LEUKEMIA IN EBMT TRANSPLANT CENTERS: A SURVEY ON BEHALF OF THE ALWP OF THE EBMT

TBF REGIMEN INDUCES FULL DONOR CHIMERISM AFTER ALLOGRAFTS IN MYELOFIBROSIS

REAL WORLD UTILITY OF TREATING MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA

COMPARISON OF IMMUNE RECOVERY IN CORD BLOOD AND T AND B DEPLETED HAPLOIDENTICAL GRAFTS RECIPIENTS

THE BCR-ABL P210 CHIMERIC TRANSCRIPT IN VITRO TRANSFER INTO BONE MARROW MESENCHYMAL STROMAL CELLS VIA EXOSOMES

PROGNOSTIC SIGNIFICANCE OF DONOR-SPECIFIC ISOGGUTININ RE-APPEARANCE IN ABO-MISMATCHED STEM CELL TRANSPLANT RECIPIENTS

Maryam Pourabdollah, Christine Cserti, Dennis Dong Hwan Kim, Eshetu Atenafu, Ivan Pasic, Zeyad Al-Shalbani, Aljun Law, Wilson Lam, Armin Gerbitz, Jeffery Lipton, Auro Viswambadya, Rajat Kumar, Jonas Mattson, Fotios Michelis, Nayana Sondi, Jacob Pendergrast (Canada)

IMMUNE-RECONSTITUTION OF LYMPHOCYTE SUBPOPULATIONS WITH RESPECT TO MSC-TREATMENT FOR STEROID REFRACTORY GVHD FOLLOWING HSCT

DAY+100 FULL DONOR CHIMERISM IN THE BONE MARROW CONFERS BETTER OVERALL SURVIVAL IN REDUCED INTENSITY CONDITIONED WITH ALEMTUZUMAB ALLOGENEIC STEM CELL TRANSPLANTATION FOR LYMPHOMAS

DONOR FACTORS INFLUENCE OUTCOMES OF PATIENTS RECEIVING DONOR LYMPHOCYTE INFUSION FOR MIXED CHIMERISM AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION

DETERMINE PATIENTS AT RISK OF RELAPSE AND DEATH IN ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME USING CHIMERISM ON BONE MARROW SAMPLES AT DAY 28 AFTER HSCT

CONCURRENT- SYNERGISTIC ASSESSMENT OF TWO TECHNIQUES IN MONITORING MINIMAL RESIDUAL DISEASE FOR PH(-) ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANTATION LEADS TO FAVORABLE CLINICAL OUTCOMES

DONOR CHIMERISM EVALUATION OF MRD-SUSPECTED CELLS ISOLATED BY FLOW CELL SORTING IS AN ACCESSIBLE TOOL FOR MRD VERIFICATION IN PATIENTS AFTER ALLOGENEIC HSCT

ONE-STEP CHECK PURITY OF CD3+ SORTED CELLS ALONG MONITORING HEMATOPOIETIC CHIMAERISM AFTER HSCT
DONOR LYMPHOCYTE INFUSIONS AUGMENT GRAFT VERSUS MALIGNANCY EFFECT FOLLOWING ALEMTUZUMAB-BASED REDUCED INTENSITY ALLOGRAFTS: REFLECTIONS ON A SINGLE CENTRE STUDY

MYELOID-DERIVED SUPPRESSOR CELLS RECOVER QUICKLY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS

PERSISTENT MIXED CHIMERISM WITHOUT RELAPSE IN CHILDREN AFTER HSCT FOR HEMATOLOGIC MALIGNANCY

e-Posters
08:30 - 19:00
ePoster Area

Multiple myeloma

DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF HIGH-RISK PATIENTS IN CASSIOPEIA

EVALUATION OF PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (PET/CT) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PHASE 3 CASSIOPEIA STUDY PATIENTS: CASSIOPET STUDY RESULTS

CONCORDANCE OF POSTCONSOLIDATION MINIMAL RESIDENT DISEASE RATES BY MULTIPARAMETRIC FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING IN CASSIOPEIA

LONG-TERM FOLLOW-UP OF THE RANDOMIZED PHASE 3 PETHEMA/GEM 2005MENOS65 STUDY SUPPORTS THE USE OF VTD (BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE) AS PRETRANSPLANT INDUCTION REGIMEN FOR MULTIPLE MYELOMA (MM)

DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE

HOW TO ASSESS RISK OF PROGRESSION IN MULTIPLE MYELOMA PATIENTS ACHIEVING COMPLETE REMISSION AFTER AUTOLOGOUS TRANSPLANT: SUB ANALYSIS FROM THE GEM2012MENOS65 PHASE III CLINICAL TRIAL

OUTCOMES OF ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS

25 YEARS OF AUTOLOGOUS TRANSPLANTATION FOR MYELOMA IN EBMT CENTRES - CHANGING PRACTICE PATTERNS

PROGNOSIS IN DIFFERENT RISK-GROUPS OF MULTIPLE MYELOMA WITH MINIMAL RESIDUAL DISEASE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BORTEZOMIB-INTEGRATED CONDITIONING: A SINGLE-CENTER EXPERIENCE

UNINTERRUPTED MOBILIZATION AND TRANSPLANTATION PROCEDURE WITH NON-CRYOPRESERVED YIELD IS FEASIBLE WITHOUT INCREASEMENT OF COMPLICATION RISK IN MULTIPLE MYELOMA PATIENTS

CONDITIONING WITH BORTEZOMIB-MEL200 IN COMPARISON TO MEL200 IMPROVES SURVIVAL AMONG MYELOMA PATIENTS IN ≤PR PRIOR TO AUTO-HCT: A STUDY FROM THE CMWP OF THE EBMT

RESULTS OF DEFERRED AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED STAGES OF SYSTEMIC ALamyloidosis
IN VITRO STIMULATION WITH CD40L/IL-21 CAN RETRIEVE B-CELL DYSFUNCTION IN MULTIPLE MYELOMA PATIENTS SUFFERING FROM SECONDARY IMMUNODEFICIENCY

ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: EXCELLENT OUTCOMES FOR EARLY TRANSPLANTATION

SEQUENTIAL HEART TRANSPLANTATION FOLLOWED BY HIGH DOSE CHEMOTHERAPY PLUS AUTOLOGOUS STEM CELL REINFUSION IN CARDIAC ALAMYLOIDOSIS

AUTOGRAFT CELLULAR COMPOSITION AND OUTCOME IN MYELOMA PATIENTS: RESULTS OF THE PROSPECTIVE MULTICENTER GOA STUDY

RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE

PHASE 3, OPEN-LABEL, NONINFERIORITY STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R MMM): BODY WEIGHT SUBGROUP ANALYSIS OF COLUMBA

ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) IS A RELIABLE PREDICTOR FOR OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION

ABERRANT PHENOTYPE PLASMA CELL MULTIPARAMETRIC FLOW CYTOMETRY (MFC) DETECTION IN AUTOGRAFT PRODUCTS OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

RETROSPECTIVE MULTI-CENTER STUDY OF ADOLESCENT AND YOUNG ADULT (AYA) MULTIPLE MYELOMA IN KANSAI MYELOMA FORUM REGISTRY

MAINTENANCE THERAPY WITH ELOTUZUMAB AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

AUTOLOGOUS STEM CELL TRASPLANTATION CANDIDACY IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS

NOVEL PROTOCOL FOR AUTOLOGOUS HSCT IN MULTIPLE MYELOMA ACHIEVES ‘ZERO’ CENTRAL LINE ASSOCIATED BLOOD STREAM INFECTIONS (CLABSI)

OUTCOMES OF NON-CRYOPRESERVED VERSUS CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

DOWN REGULATION OF AUTOPHAGY ENHANCES BORTEZOMIB-INDUCED APOPTOSIS OF MYELOMA CELL BY UP REGULATION OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES

RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE

FAVORABLE LONG-TERM OUTCOMES WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HIGH RISK PATIENTS WITH MULTIPLE MYELOMA WHO ARE POSITIVE AT FDG-PET/CT

LONG TERM SURVIVAL OF MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELATION TO AVAILABILITY OF NOVEL DRUGS

MULTIPLE MYELOMA (MM) IN FIRST RELAPSE PATIENTS. ROLE OF THE SECOND AUTOLOGOUS STEM-CELL TRASPLANT (ASCT) IN REAL LIFE: EXPERIENCE OF TWO SPANISH CENTERS

ROLE OF ANALYSIS OF CHIMERISM IN MULTIPLE MYELOMA PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE
**Scientific Programme**

**USE OF NETUPITRANT/PALONOSETRON IN MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE**

**THE EFFECT OF UCP-2 AND NR3C1 GENES ON TREATMENT EFFICACY AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA**

**SAFETY AND EFFECTIVENESS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA IN FIRST LINE**

**PLASMAPHERESIS ASSISTED THE TREATMENT OF 1 CASE OF HYPERGLOBULINEMIA AFTER CART THERAPY**

**e-Posters**

**08:30 - 19:00**

**ePoster Area**

**Myelodysplastic syndromes**

**ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OF ADULT PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA: A NORDIC RETROSPECTIVE STUDY**

**DECITABINE MONOTHERAPY BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION RESULTED IN SUPERIOR SURVIVAL FOR MYELODYSPLASTIC SYNDROME PATIENTS WITH EXCESS BLASTS**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM: A STUDY FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT**

**IMPACT OF MUTATION PROFILE IN CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**NEW INSIGHTS OF MYELODYSPLASTIC SYNDROME (MDS) WITH ERYTHROID PREDOMINANCE BASED ON THE NEXT-GENERATION SEQUENCING AND SINGLE-CELL RNA SEQUENCING**

**IMPACT OF TREATMENT PRIOR TO ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: RESULTS OF THE LATIN AMERICAN BONE MARROW TRANSPLANT REGISTRY**

**RESULTS OF LATIN AMERICAN RECORD OF BONE MARROW TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME**

**OUTCOME AND MUTATIONAL PROFILE IN MDS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**New drug- and cell-based immune therapies**

**NIVOLUMAB INCREASES ANTIGEN SPECIFIC IMMUNE RESPONSES AGAINST LEUKEMIC PROGENITOR AND STEM CELLS (LSC/LPC)**

**PROPHYLACTIC OR PREEMPTIVE LOW-DOSE AZACITIDINE AND DONOR LYMPHOCYTE INFUSION TO PREVENT DISEASE RELAPSE FOLLOWING ALLOGENEIC TRANSPLANTATION IN 60 PATIENTS WITH HIGH RISK AML OR MDS**
Scientific Programme

ELTROMBOPAG FOR THE TREATMENT OF POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTS: A MULTICENTER SURVEY UPDATE

DONOR NK CELLS INFUSION AS A STRATEGY OF IMMUNOTHERAPY TO PREVENT HHV6 REACTIVATION IN PEDIATRIC PATIENTS AFTER CD45RA-DEPLETED TRANSPLANTATION

DEVELOPMENT OF CELL VACCINE BASED ON AUTOLOGOUS DENDRITIC CELLS LOADED WITH LIPID NANOPARTICLES CONTAINING CMV PP65 MESSENGER RNA

SMAC MIMETICS (SM) AND NATURAL KILLER (NK) CELLS - A PROMISING COMBINATION TO OVERCOME CELL DEATH RESISTANCE OF RHABDOMYOSARCOMA (RMS) CELLS

'KIT' - MEDIATED BLAST MODULATION TO LEUKEMIA-DERIVED DC SIGNIFICANTLY IMPROVES ANTILEUKEMIC ACTIVITIES IN WHOLE BLOOD INDEPENDENT OF AML-PATIENTS' SUBTYPES

ROLE OF EXOSOMES AS PROMOTORS OR BIOMARKERS TO STUDY ACTIVATION OF LEUKEMIA-DERIVED DENDRITIC CELLS (DCLEU)-MEDIATED ANTILEUKEMIC ACTIVATION OF ADAPTIVE AND INNATE IMMUNE-REACTIVE CELLS AGAINST AML-BLASTS

HIGHER INCIDENCE OF SEVERE AUTOIMMUNE HEMOLYTIC ANEMIA AFTER TCRαβ+/CD19+ CELL DEPLETED HAPLOIDENTICAL-HSCT AND POSTGRAFT CELLULAR IMMUNOTHERAPIES: CTLA4-IG VERY EFFECTIVE THERAPEUTIC OPTION FOR THIS LIFE-THREATENING DISEASE

BLINATUMOMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA: REPORT FROM A SINGLE CENTER

IMMUNOMODULATION OF BLASTS WITH CLINICALLY APPROVED RESPONSE MODIFIERS TO IMPROVE ANTILEUKEMIC T-CELL REACTIVITY IN AML: AN EX VIVO SIMULATION OF THE CLINICAL SITUATION

IFNY SECRETION OF ADAPTIVE AND INNATE IMMUNE CELLS AS A PARAMETER TO DISPLAY LEUKAEMIA DERIVED DENDRITIC CELL (DC<sub>LEU</sub>) MEDIATED IMMUNE RESPONSES IN AML

TREATMENT OF SEVERE HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA) WITH THE MASP-2 INHIBITOR NARSOPILMAB (OMS721)

e-Posters
08:30 - 19:00
ePoster Area

Non-haematopoietic stem cells

THE POTENTIAL ROLES OF MUCOSA-ASSOCIATED INVARIANT T CELLS IN THE PATHOGENESIS OF GUT GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

FACTORS INFLUENCING THE PRESENCE OF BONE MARROW MESENCHYMAL STEM CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

ANALYSIS OF THE GENETIC STABILITY OF DONORS' BONE MARROW STROMA MESENCHYMAL CELLS DURING CULTIVATION

EFFECT OF MATERNAL AND NEONATAL FACTORS ON THE YIELD OF WHARTON'S JELLY MESENCHYMAL STEM CELLS

THE POLISH EXPERIENCE OF WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF PAEDIATRIC PATIENTS
THE POLISH EXPERIENCE OF WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF ADULT PATIENTS

A RETROSPECTIVE ANALYSIS OF BONE MARROW EXAMINATION RESULTS FROM A SINGLE CENTER INSTITUTION: CAN WE REDUCE THE OCCURRENCE OF UNNECESSARY BONE MARROW EXAMINATIONS?

e-Posters
08:30 - 19:00
ePoster Area

Non-infectious early complications

IMPACT OF DONOR-DIRECTED HLA ALLO-ANTIBODIES ON PRIMARY GRAFT FAILURE AFTER UNRELATED DONOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION

ELTROMBOPAG TREATMENT AIDED IN PLATELET RECOVERY AND REDUCED PLATELET INFUSION FOR PATIENTS WITH POST-TRANSPLANTATION THROMBOCYTOPENIA

IMPACT OF FLUID OVERLOAD (FO) IN POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETICCELL TRANSPLANTATION FOR HEMATOLOGICAL DISEASES

INCIDENCE, RISK FACTORS, AND OUTCOMES OF PATIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER STEM CELL TRANSPLANT: A MULTI-INSTITUTIONAL ANALYSIS

USE OF ECULIZUMAB IN CHILDREN WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY - A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF IEWP AND PDWP EBMT

REDUCED POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSES IN T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES

ABO ISOAGGLUTININ LEVELS IN GUIDED MANAGEMENT OF ABO INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

METHYLPREDNISOLONE STRATIFIED INTERVENTION BASED ON RISK CLASSIFICATION IN THE TREATMENT OF PRE-ENGRAFTMENT SYNDROME AFTER UNRELATED CORD BLOOD TRANSPLANTATION: A PROSPECTIVE, NON-RANDOMIZED, AND OPEN-LABEL STUDY

PRETRANSPLANT NUTRITION MEASURES AND SYSTEMIC INFLAMMATORY RESPONSE PREDICT OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

A MULTI-CENTRE, MULTI-NATIONAL, PROSPECTIVE OBSERVATIONAL REGISTRY STUDY OF DEFIBROTIDE IN PATIENTS DIAGNOSED WITH SEVERE VENO-OCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)

DEFIBROTIDE TREATMENT FOR VENO-OCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES BY SEVERITY AND MULTI-ORGAN FAILURE STATUS IN AN OBSERVATIONAL REGISTRY STUDY

INTRODUCTION OF NEW PEDIATRIC EBMT CRITERIA FOR VOD <b>Diagnosis: </b> IS IT LIFE-SAVING OR MONEY-WASTING?

PROSPECTIVE PILOT STUDY ON FRAILTY AND FUNCTION ASSESSMENT DURING CLINICS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
HISTOLOGIC FEATURES OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY WITH AND WITHOUT CONCOMITANT ACUTE GRAFT-VERSUS-HOST DISEASE

HIGH SURVIVAL RATE OF PEDIATRIC PATIENTS WITH PRIMARY GRAFT FAILURE WHO UNDERGO A SECOND PROCEDURE. THE EXPERIENCE OF 3 SPANISH PEDIATRIC TRANSPLANT UNITS

CHEMOTHERAPY-INDUCED GUT MUCOSAL INJURY INITIATES MICROBIAL DISRUPTION IN STEM CELL TRANSPLANT RECIPIENTS

BACTERIAL AND METABOLIC PROFILING OF THE SALIVA IDENTIFIES UNIQUE PATTERNS OF MICROBIOTA INJURY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT WITH SEVERE ORAL MUCOSITIS

DIAGNOSIS AND MANAGEMENT OF SECONDARY HLH/MAS FOLLOWING HSCT AND CAR-T CELL THERAPY IN ADULTS: AN EBMT-WIDE SURVEY ON BEHALF OF THE ADWP AND TCWP

IMPACT OF ABO INCOMPATIBILITY ON COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION- RETROSPECTIVE, INTERNATIONAL, MULTICENTER ANALYSIS BY THE TRANSPLANT COMPLICATIONS WORKING PARTY EBMT

HYPOALBUMINEMIA PRIOR ALLOHCT IS A RELEVANT NEGATIVE PREDICTOR FOR SURVIVAL

INCIDENCE AND CLINICAL IMPACT OF ATRIAL FIBRILLATION DIAGNOSED DURING HOSPITAL STAY FOR ALLOGENEIC STEM CELL TRANSPLANTATION

TRANSPLANTATION-ASSOCIATED MICROANGIOPATHY (TAM) IN RECIPIENTS OF UNMANIPULATED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTS USING PTCY FOR GVHD PROPHYLAXIS: INCIDENCE AND OUTCOME

IGF-1 AND IGFBP-3 GENE POLYMORPHISMS PREDICT CIRCULATING IGF LEVELS AND SYSTEMIC INFLAMMATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

LOW RISK OF EARLY TOXICITY AND UNPLANNED 100-DAY READMISSIONS AFTER MATCHED AND MISMATCHED RELATED AND UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

KERATINOCYTE GROWTH FACTOR DECREASES HOSPITAL READMISSION AND REGIMEN-RELATED TOXICITIES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA

ELTROMBOPAG FOR TREATING THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE

SYSTEMIC CORTICOSTEROID THERAPY IS UNLIKELY TO BE THE PRIMARY CAUSE OF HYPERGLYCEMIA FOLLOWING TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE

COST-EFFECTIVENESS ANALYSIS OF DEFIBROTIDE FOR THE TREATMENT OF SEVERE VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME IN SPAIN

NEUROLOGIC COMPLICATIONS IN 169 CONSECUTIVE ALLOGENEIC STEM CELL TRANSPLANTS: ETIOLOGY, CLINICAL SYNDROMES AND OUTCOME

VENETOCLAX, HYPOMETHYLATING AGENTS AND DLI FOR SALVAGE TREATMENT OF MYELOID MALIGNANCIES RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EVALUATION OF TGF-BETA LEVEL AFTER SUPPLEMENTATION WITH WHEY PROTEIN CONCENTRATE FOR ORAL MUCOSITIS PROPHYLAXIS

TREOSULFAN-INDUCED MYALGIA IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
VALIDATION OF EARLY INCREASE OF SC5B-9 AS A PREDICTIVE MARKER FOR LATER TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY

DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF HEPATIC VENO-OCCCLUSIVE DISEASE AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

EARLY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION IMPROVES OUTCOME OF VERY SEVERE HEPATIC VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER UNMANIPULATED HAPLOIDENTICAL HSCT WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

DOES THE TYPE OF NUTRITIONAL SUPPORT AFFECT THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION? A PEDIATRIC CENTER EXPERIENCE

NEUROLOGICAL COMPLICATIONS IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY

ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS ADMITTED TO THE INTENSIVE CARE UNIT - REAPPRAISAL OF PROGNOSIS AND PROGNOSTIC FACTORS: A SINGLE CENTER STUDY

ENTERAL VERSUS PARENTERAL NUTRITION IN ADULT HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS SUFFERING FROM GASTROINTESTINAL MUCOSITIS

DELAYED ENGRAFTMENT AND PROLONGED HOSPITAL STAY FOLLOWING OMISSION OF FOLINIC ACID AFTER METHOTREXATE FOR GVHD PROPHYLAXIS IN ALLOGENEIC TRANSPLANT RECIPIENTS

THE USEFULNESS OF LIVER STIFFNESS MEASUREMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT SINUSOIDAL OBSTRUCTION SYNDROME

ENDOTHELIAL CELL COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION, A SINGLE CENTRE ANALYSIS ON 99 CONSECUTIVE PATIENTS UNDERGOING ALLO-SCT
Giorgia Mancini, Matteo Candelora, Giuseppina Urbano, Francesco Saraceni, Monica Poiani, Marianna Mariani, Irene Federici, Giuseppe Tarantino, Ilaria Scortechini, Attilio Olivieri (Italy)

INFLUENCE OF ABO-INCOMPATIBILITY ON THE OUTCOME OF STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY ON CHILDREN AND YOUNG ADULTS

EASIX IS USEFUL FOR PREDICTING THE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS

SECOND TRANSPLANTATION USING A NOVEL CONDITIONING REGIMEN WITH DIFFERENT DONOR FOR GRAFT FAILURE AFTER FIRST HAPLOIDENTICAL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

A SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME

VENO-OCCCLUSIVE DISEASE: ONLINE, INTERPROFESSIONAL, CASE-BASED EDUCATION SIGNIFICANTLY IMPROVES KNOWLEDGE AND SKILLS OF THE ENTIRE CARE TEAM

HYPERHEMOLYSIS SYNDROME IS A NOVEL CAUSE OF SEVERE HEMOLYTIC ANEMIA AFTER ALLOGENEIC TRANSPLANTATION WITH VERY POOR RESPONSE TO TREATMENT AND OUTCOME

EASIX AS A PREDICTIVE BIOMARKER OF COMPLICATIONS AND OUTCOME IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

SURVIVAL WITH NORMAL PULMONARY FUNCTION IS POSSIBLE DESPITE SIGNIFICANT AND PROLONGED RESPIRATORY SUPPORT, INCLUDING PROLONGED HIGH FREQUENCY OSCILLATORY VENTILATION (HFOV) IN CHILDREN
**USE OF INTRAVESICAL HYALURONIC ACID TO TREAT HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION**

**CURRENT PRACTICE IN NUTRITION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AUSTRIA, GERMANY AND SWITZERLAND**

**INCIDENCE AND SEVERITY OF CYTOKINE RELEASE SYNDROME FOLLOWING HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL INFUSION**

**ENGRAFTMENT SYNDROME FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY FROM A SINGLE CENTER**

**WERNICKE’S ENCEPHALOPATHY IN A CHILD WITH B LYMPHOBLASTIC LYMPHOMA AFTER HAPLO-HSCT**

**ECULIZUMAB FOR THE TREATMENT OF SEVERE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: MULTICENTER EXPERIENCE**

**IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) AS GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN TERMS OF SINUSOIDAL OBSTRUCTION SYNDROME (SOS)**

**ISCHEMIC STROKE IN CHILDREN AND YOUNG ADULTS WITH MALIGNANT HEMATOLOGICAL AND ONCOLOGICAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**MELPHALAN DOSE ADJUSTMENT AND CRYOTHERAPY REDUCE ORAL MUCOSITIS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CLINICAL FEATURES AND RISK FACTORS OF ENGRAFTMENT SYNDROME IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**REAL-LIFE EXPERIENCE OF TWO ITALIAN HEMATOLGY CENTRES ON EFFICACY AND SAFETY OF ORAL NEPA (NETUPITANT/PALONOSETRON) IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EARLY TREATMENT WITH DARATUMUMAB FOR REFRACTORY POST-ALLOGENEIC STEM CELL TRANSPLANT PURE RED CELL APLASIA**

**PROGNOSTIC FACTORS FOR EARLY MORTALITY OF HEMATOLOGICAL PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT: PRELIMINARY RESULTS OF A PROSPECTIVE MULTICENTER STUDY**

**ACUTE KIDNEY INJURY DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS: INCIDENCE AND RISK FACTORS**

**T-PA/UROKINASE IN COMBINATION WITH TPE AS A SUBSTITUTIONAL THERAPY FOR TREATMENT OF TA-TMA**

**HEMOGAMOCYTIC SYNDROME AFTER EX-VIVO LYMPHODEPLETED HEMATOPOIETIC TRANSPLANTATION**

**IMMUNOADSORPTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MAJOR ABO INCOMPATIBILITY**

**IMMUNE-MEDIATED FEVER AFTER T-CELL REPLETE HAPLOIDENTICAL HSCT USING PERIPHERAL BLOOD STEM CELL GRAFTS AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

---

**Non-infectious late effects, quality of life and fertility**
Scientific Programme

EASIX-1YEAR- THE FIRST BIOMARKER PREDICTING LATE MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

AN UPDATED REPORT ON SECONDARY SOLID CANCER FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THALASSEMA MAJOR

ALLOGENEIC STEM-CELL TRANSPLANTATION IN AML AND MDS USING CONDITIONING REGIMENS WITH DIFFERENT DOSE-INTENSITIES; 15 YEARS LATER

EMPLOYMENT STATUS AND RETURN TO WORK AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: RESULTS FROM A NATIONWIDE SURVEY

FUNCTIONAL OUTCOME MEASURES IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): FOCUS ON THE 2-MINUTE WALK TEST

FERTILITY IN ADULT FEMALE ALLOGENEIC STEM CELL RECIPIENTS

A RISK SCORE MODEL (HAD-TCG) TO EVALUATE THE RISK OF STROKE IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

BRONCHIOLITIS OBLITERANS SYNDROME IN THE CHANGING LANDSCAPE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

CURRENT STATUS AND NEEDS OF LONG-TERM FOLLOW-UP CLINICS FOR HEMATOPOIETIC CELL TRANSPLANT SURVIVORS: RESULTS OF A NATIONWIDE SURVEY IN JAPAN

SURVIVORSHIP CARE FOR ALLOGENEIC TRANSPLANT PATIENTS IN THE UK: CURRENT SERVICE PROVISION AND BARRIERS TO IMPLEMENTATION

CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN EPSTEIN-BARR VIRUS RELATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (EBV-PTLD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)

INCIDENCE, RISK FACTORS AND OUTCOMES OF DIFFUSE ALVEOLAR HEMORRHAGE AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION

WHOLE BODY VIBRATION TRAINING DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION - THE EFFECTS ON PATIENTS' PHYSICAL CAPACITY, FATIGUE, BODY COMPOSITION AND QUALITY OF LIFE

MULTI-MORBIDITY IN ADULT SURVIVORS OF STEM CELL TRANSPLANTATION (SCT)

GONADOTOXICITY AFTER TREOSULFAN-BASED MYELOABLATIVE CONDITIONING REGIMEN FOR ALLOGENEIC HSCT IN GIRLS WITH LEUKEMIA

REDUCED-INTENSITY TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH HIGH-RISK OR ADVANCED HEMATOLOGICAL MALIGNANCIES IN LAST 10 YEARS - SINGLE CENTRE EXPERIENCE

FATHERHOOD AFTER A MYELOABLATIVE TREOSULFAN BASED ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS ON 453 PATIENTS

COMPARISON OF CENTRAL NERVOUS SYSTEM RELAPSE OUTCOMES FOLLOWING HAPLOIDENTICAL VS IDENTICAL-SIBLING TRANSPLANT FOR ACUTE LYMPHOBLASTIC LEUKEMIA

OLDER AGE AND PERIPHERAL BLOOD AS A STEM CELL SOURCE ARE THE MAJOR NEGATIVE PREDICTORS OF SURVIVAL LONG TERM

PREVALENCE OF BRONCHIOLITIS OBLITERANS SYNDROME (BOS) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLOHSCT) IN THE US, EUROPE AND JAPAN
NETUPITANT-PALONOSETRON (NEPA) TO PREVENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MULTIPLE MIELOMA (MM) PATIENTS RECEIVING HIGH-DOSE (HD) MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)

MOST FREQUENT LATE EFFECTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA DOES NOT SEEM TO WORSEN PERFORMANCE STATUS

INVOLVING STEM CELL TRANSPLANT PATIENTS AND THEIR FAMILIES TO IMPROVE THE ANTHONY NOLAN MY TRANSPLANT TRACKER APP

EARLY MENOPAUSE AND RISK FACTORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PREMENOPAUSAL ADULT WOMEN

MUSCULOSKELETAL COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS

CLINICAL CHARACTERISTICS AND MANAGEMENT OF LATE RELAPSE OF ACUTE MYELOID LEUKAEMIA MORE THAN FIVE YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

FOLLOWING UP WITH ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING 5+ YEARS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

LOW BACK PAIN AND LASER ACUPUNCTURE IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELLS TRANSPLANTATION

EFFECTS OF CONTROLLED EXERCISE ON PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

LONG-TERM OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANT IN AN ASIAN POPULATION: A SINGLE-CENTER EXPERIENCE

DEVELOPMENT OF GUILLAIN-BARRE-LIKE SYNDROME IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELLS TRANSPLANTATION

PROSPECTIVE OPEN-LABEL PHASE II TRIAL OF INDIVIDUALIZED ANTI-THYMOCYTE GLOBULIN SHOWS IMPROVED EARLY CD4+ T-CELL RECONSTITUTION AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE PARACHUTE-TRIAL

EBMT LESSONS FROM 40 YEARS OF HIGH DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN NEUROBLASTOMA: A REPORT FROM THE PAEDIATRIC WORKING PARTY

INCIDENCE OF SECONDARY MALIGNANCIES AFTER TBI/VP16 CONDITIONING FOR CHILDHOOD ALL: RESULTS OF THE PROSPECTIVE ALL-SCT-BFM-2003 TRIAL

OUTCOME AND RISK FACTORS OF AUTOIMMUNE CYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY
EBMT SURVEY ON 40 YEARS OF HIGH-DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN EWING TUMOURS (ET). A REPORT FROM THE PAEDIATRIC WORKING PARTY
Ruth Ladenstein, Evgenia Glogova, Christelle Dufour, Edoardo Lanino, Jean Michon, Paul Veys, Roberto Luksch, Uta Dirkse, Krzysztof Kalwak, Stefan Burdach, Henk van den Berg, Boris Afanasyev, Franco Locatelli, Emmanuelle Nicolas-Virelizier, Shifra Ash, Nathalie Gaspar, Jeremy Whelan, Philippe Brault, Ulrike Poetschger, Selim Corbacioglu (Austria)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS IN CHILDREN - RETROSPECTIVE REPORT ON BEHALF OF I-BFM SCT COMMITTEE AND EBMT PEDIATRIC DISEASES WP

IS THE EBMT RISK SCORE PREDICTIVE OF OUTCOMES IN PAEDIATRIC ACUTE LEUKEMIA?

TCRαβ+/CD19+-DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION

THE GREAT ORMOND STREET (GOS) PAEDIATRIC CO-MORBIDITY SCORE FOR OUTCOME POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION

HIGH PREVALENCE OF CAROTID PLAQUES IN YOUNG ADULTS AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD

HAPLOIDENTICAL DONOR OR UNRELATED DONOR FOR INFANTS WITH SEVERE COMBINED IMMUNODEFICIENCY?

A ‘RISK-ADJUSTED’ CYTOREDUCTION WITHOUT RADIATION FOR PATIENTS WITH FANCONI ANEMIA UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION (HCT)

USE OF RUXOLITINIB IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD)

HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN REFRACTORY CYTOPENIA OF CHILDHOOD (RCC): IMPROVED ENGRAFTMENT FOLLOWING A TRESULFAN BASED CONDITIONING REGIMEN

PHARMACOKINETICS OF ACTIVE ATG IMPACTS T-CELL RECOVERY AFTER TCRαβ+/CD19-DEPLETED HSCT IN PAEDIATRIC PATIENTS

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A MULTICENTRE STUDY FROM INDIA

IMMUNE RECOVERY AND LONG-TERM SURVIVAL FOLLOWING HAPLOIDENTICAL T AND B CELL DEPLETED STEM CELL TRANSPLANTATION - INFLUENCE OF VARIOUS ATG DOSES

OUTCOMES OF HAPLOIDENTICAL VS MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC HIGH-RISK ALL AND AML IN 1ST AND 2ND CR

COMBINED TCR ALPHA BETA AND CD45RA DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BENIGN HAEMATOLOGICAL CONDITIONS, SINGLE CENTRE EXPERIENCE

GENETIC SUSCEPTIBILITY TO HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME IN PEDIATRIC PATIENTS UNDERGOING HSCT

HAPLO HSCT WITH IN VIVO T-CELL DEPLETION AFTER REDUCED INTENSITY CONDITIONING REGIMEN AND MYELOABLATIVE MUD AND MMUD DONOR HSCT IN PEDIATRIC PATIENTS AFFECTED BY MALIGNANCIES
THINKING BEYOND HLH: CLINICAL FEATURES OF PATIENTS WITH CONCURRENT PRESENTATION OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND THROMBOTIC MICROANGIOPATHY

LANDMARK ANALYSIS IN HIGH RISK CHILDHOOD ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE STUDY

DEFIBROTIDE IN HEMATOPOIETIC STEM CELL TRANSPLANT: AN STUDY OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYETICO (GETH) AND GRUPO ESPAÑOL DE TRASPLANTE DE MEDULA EN NIÑOS (GETMON)

NIVOLUMAB-BASED THERAPY PRIOR TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC HODGKIN’S LYMPHOMA

HUMAN LEUKOCYTE ANTIGEN DISPARITIES REDUCE RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH JUVENILE MYELOMONOCYTIC LEUKEMIA

SCHOOL DURING AND AFTER ALLOGENIC HSCT: A SURVEY OF PRACTICES IN THREE EUROPEAN COUNTRIES

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HURLER SYNDROME: SINGLE CENTER EXPERIENCE

IMPACT OF MEMORY T-CELL DOSES INFUSED WITH T-CELL DEPLETED HAPLOIDENTICAL STEM CELL GRAFTS ON TRANSPLANT OUTCOMES

THE ROLE OF DONOR KIR GENOTYPING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISORDERS

DETECTION OF RECIPIENT-SPECIFIC α/β-T-CELLS DURING THE PRE-ENgraftMENT PHASE DOES NOT PREDICT GRAFT REJECTION IN PATIENTS AFTER HAPLOSCT: PRELIMINARY RESULTS OF SINGLE CENTRE PROSPECTIVE TRIAL

IMPROVED SURVIVAL AFTER MIBG THERAPY IN COMBINATION WITH MEGACHEMOTHERAPY THAN AFTER STAND-ALONE THERAPY IN CHILDREN WITH NEUROBLASTOMA - POLISH NATION-WIDE RETROSPECTIVE STUDY

USE OF RIC REGIMENS COMBINED WITH TCRAB DEPLETION AND POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC MISMATCHED SCT

THE ROLE OF HLA-DP MATCHING IN DONOR SELECTION FOR MUD-HSCT IN CHILDREN WITH HEMATOLOGIC MALIGNANT DISEASES

CLINICAL IMPLICATION ON RECOVERY OF γδ T CELLS AFTER TCRαβ-DEPLETED HAPLOIDENTICAL HSCT IN PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE

EARLY INITIATION OF CYCLOSPORINE-MYCOPHENOLATE PLUS ANTITHYMOCYTE GLOBULIN IN HAPLO TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN: LOW INCIDENCE OF SEVERE ACUTE GVHD WITH ENCOURAGING SURVIVAL

FEASIBILITY AND SAFETY OF SURGICAL FERTILITY PRESERVATION TECHNIQUES PROXIMAL TO INITIATION OF CONDITIONING THERAPY IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT
VENO-OCCCLUSIVE DISEASE WITH EMPHASIS ON RENAL MANIFESTATIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS: A SINGLE CENTER EXPERIENCE

OUTCOME AFTER HSCT IN CHILDREN WITH JMML FROM A HISTORICAL POINT OF VIEW

THE IMPACT RECOVERY ABSOLUTE LYMPHOCYTE COUNT AT DAYS +21 ON OUTCOME ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC ALL

T-CELL-RICH HAPLOIDENTICAL STEM CELL TRANSPLANTATION IMPROVES SURVIVAL IN CHILDREN WITH ACUTE LEUKEMIA RELAPSED AFTER ALLOGENEIC TRANSPLANTATION

HIGH PREVALENCE OF VITAMIN C DEFICIENCY IN A LARGE PAEDIATRIC COHORT UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE FROM 2003-2019

EX VIVO T CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE

LONG-TERM ERYTHROPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: HOST DETERMINES RESULT

BOOST WITH CD34+ CELLS FOR POOR GRAFT FUNCTION TREATMENT AFTER HSCT IN PAEDIATRIC PATIENTS. A MULTICENTER STUDY

NO DIFFERENCE IN SURVIVAL AFTER HLA MISMATCHED VERSUS HLA MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION

ALLOGENIC STEM CELL TRANSPLANTATION FOR FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE

STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-ANAPLASTIC PERIPHERAL T-CELL LYMPHOMA ON BEHALF OF THE EBMT-PEDIATRIC DISEASES WORKING PARTY

FIRST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RASGRP1 DEFICIENCY

SUCCESSFUL HSCT IN IMMUNE DISREGULATORY DISEASES

LEVOFLOXACIN BASED PROPHYLAXIS IN CHILDREN RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT AFFECT THE INCIDENCE OF ACUTE GVHD AND BLOODSTREAM INFECTIONS

RITUXIMAB-INDUCED SECONDARY HYPOGAMMAGLOBULINEMIA: MEMORIAL SLOAN KETTERING’S 10-YEAR EXPERIENCE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS

‘INCURABLE’ PAEDIATRIC MYELOID LEUKAEMIA TREATED WITH NOVEL CELL-BASED THERAPEUTICS

EFFECT OF SERUM PANEL REACTIVE ANTIBODIES ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE

SINGLE CENTRE EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR INHERITED BONE MARROW FAILURE SYNDROMES

IS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION A GOOD INDICATION FOR PATIENTS WITH SIFD SYNDROME?

TIME COURSE AND IMPACT OF BODY WEIGHT CHANGE EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HIGH RISK EWING SARCOMA, A SINGLE CENTER EXPERIENCE
Scientific Programme

CONDITIONING FOR RETRANSPLANTATION FROM THE SAME DONOR AFTER PARTIAL AUTOLOGOUS RECONSTITUTION IN PATIENTS WITH PID: IMMUNOSUPPRESSION IS NOT REQUIRED

TOCILIZUMAB TREATMENT FOR CRS IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

IDIOPATHIC PNEUMONIA SYNDROME (IPS) AFTER PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FROM UNRELATED DONOR FOR HURLER SYNDROME (MUCOPOLYSACCHARIDOSIS TYPE 1) SUCCESSFULLY TREATED WITH ETANERCEPT AND STEROIDS

EFFECT OF DESENSITIZATION PROTOCOL ON TRANSPLANTATION SUCCESS IN CHILDREN WITH ANTI-HLA ANTIBODIES

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOHSCT) WITH DIFFERENT INTENSITY CONDITIONING REGIMENS IN INFANT AML

VENETOCLAX/DECITABINE FOR PEDIATRIC MDR-AML RELAPSED AFTER TWO ALLO HSCTS

HIGHER INCIDENCE OF CMV AND BKV REACTIVATION IN HAPLOIDENTICAL TRANSPLANTS COMPARATIVE TO MUD OR MSD TRANSPLANTS - SINGLE CENTRE RETROSPECTIVE ANALYSIS

USE OF POLYCLONAL IGM-ENRICHED IMMUNOGLOBULINS FOR THE TREATMENT OF SEPTIC EPISODES IN CHILDREN WITH ONCOHEMATOLOGICAL DISEASES

PAEDIATRIC BONE MARROW TRANSPLANT CARE ON BMT VERSUS NON-BMT PAEDIATRIC WARDS

CHRONIC HEALTH PROBLEMS IN CHILDREN AFTER ALLOGENEIC HSCT: THE TOP OF THE ICEBERG?

HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: SINGLE-CENTER SERIES OF 14 CASES

NON-WHITE HISPANIC ETHNICITY AS A RISK FACTOR FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC TRANSPLANT

THE CHALLENGES AND OUTCOMES SURROUNDING INTRAVESICAL CIDOFOVIR ADMINISTRATION: A PAEDIATRIC PHARMACY PERSPECTIVE

THE EXPERIENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RARE HEMATOLOGIC DISEASE

SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH DNA LIGASE IV DEFICIENCY WITH NONMYELOABLATIVE CONDITIONING REGIMEN

PNEUMATOSIS INTESTINALIS AS A RARE POST-TRANSPLANT COMPLICATION IN PEDIATRIC PATIENTS

HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT-HD-CYCLOPHOSPHAMIDE FOR RELAPSED B-LYMPHOBLASTIC LYMPHOMA (B-LBL) WITH MLL-REARRANGEMENT IN 1 Y.O. CHILD: A CLINICAL CASE

Pharmacology

ELTROMBOPAG THERAPY IN STEM CELL TRANSPLANT RECIPIENTS SHOWS EFFECTIVE IRON MOBILISATION
scientific programme

Clinical Impact of Model PK Guided-Cyclosporine Dose Individualization in Children Undergoing HSCT

Influence of CYP2D6 Metabolizer Status on the Control of Chemotherapy Induced Nausea and Vomiting by Ondansetron on Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Estimation of Glomerular Filtration Rate in Adults After Allogeneic Stem Cell Transplantation: Cystatin C Versus Creatinine

Use of Sublingual Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Recipients with History of Anaphylaxis to Intravenous Cyclosporine

Oral Clonazepam for Seizure Prophylaxis in Adult Patients Treated with High Dose Busulfan

Dissolution Time for Conventional and Lyophilized Cyclophosphamide: A Single Center Study

Outcomes of EBV Viremia and PTLD After Rituximab: A Pharmacoeconomic Analysis

Pharmacological Interactions in the Post-Transplant Phase of Hematopoietic Progenitors Transplantation

Evaluation of Side Effects and Efficacy of Lomustine (CCNU) and Bandamustine in Patients with Lymphoma

e-Posters
08:30 - 19:00
ePoster Area

Psychological issues

Investigating the Long-Term Outcomes of Adult Patients Who Underwent Hematopoietic Stem Cell Transplant for Primary Immunodeficiency During Childhood

The Impact of Medical and Social Rehabilitation on the Quality of Life in Children with Oncologic and Hematologic Diseases

The Impact of Pre-Transplant Depression and Anxiety on the Outcome of Allogeneic Stem Cell Transplantation, a Study of the TCWP of the EBMT

Associations Between Family Function Domains and Coping Strategies of Adolescents Undergoing HSCT

How Patients’ Views Are Helping Shape Plans for a New Transplant Psychology Service

Changes in Health-Related Quality of Life in Patients Following Hematopoietic Stem Cell Transplantation: Two Different Analytical Approaches

ARC Clinic: Applying Psychological Insights to Promote Early Rehabilitation in Myeloma Post-Transplant

From Hospitalization to Return Home: A Transitional Action Research in the Hematology Sector

1000 in 10 . 10 years of Clinical Psychology Practice with 1000 Patients in the Same BMT Unit in Marseille, France
Scientific Programme

IMPLEMENTATION OF PSYCHOLOGICAL SUPPORT AND DEVELOPMENT OF EDUCATIONAL PROGRAM FOR CHILDREN AND ADOLESCENTS UNDERGOING HSCT AND THEIR PARENTS IN RUSSIA

e-Poster Area
08:30 - 19:00

Quality Management

COMPARING COMPLIANCE FOR COLLECTION FACILITY JACIE STANDARDS 6.1 AND 7TH EDITIONS

INTEGRATION OF THEORY AND PRACTICE: SCENARIO-BASED SKILL TRAINING IN ADMINISTERING CAR-T CELLS

“TPFMEA”, AN INTERNATIONAL MODEL FOR ASSESSING RISKS IN A STEM CELL TRANSPLANT PROGRAM

DEFINING PATIENT-IMPORTANT OUTCOMES AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT

IMPLEMENTATION OF JACIE ACCREDITATION AT A NOVEL TRANSPLANT PROGRAM: THE IMPACT ON THE CLINICAL PRACTICE

HOW ONE PROCESSING CENTRE PREPARED FOR ITS FIRST JACIE INSPECTION?

TIPS FOR GENERATING SUCCESSFUL ‘TEAMWORKING’ IN OUR HEALTHCARE FACILITIES: THE EXPERIENCE OF A HOSPITAL UNIT IN A FRENCH CANCER CENTER

IMPLEMENTATION OF A QUALITY SYSTEM FOR RUNNING A CELL AND GENE THERAPY CLINICAL TRIAL WITHIN A JACIE-ACCREDITED TRANSPLANT PROGRAM

NEW ONLINE PLATFORMS IN QUALITY MANAGEMENT: COORDINATION AND MULTIDISCIPLINARY CARE

RISK MANAGEMENT ASSESSMENT IN IMPLEMENTING CAR-T CELL THERAPY IN A CLINICAL UNIT

FEBRILE REACTION AFTER HSC INFUSION IS MORE FREQUENT IF NO STEROID PREMEDICATION IS GIVEN WHICH RESULTS IN MORE FREQUENT USE OF ANTIBIOTICS EARLY POST-TRANSPLANT

SEARCHING FOR OTHER TOPICS OF QUALIFICATION PLANS IN THE TRANSPLANT PROGRAM CLINICAL PART - THE ONE CENTER EXPERIENCE

PRACTICE PATTERNS IN CHRONIC GVHD PATIENT MANAGEMENT AND PATIENT REPORTED OUTCOME MEASURES ACROSS THE EBMT ALLOGENEIC TRANSPLANTATION NETWORK

MAINTAINING DONOR SAFETY AND WELFARE THROUGHOUT CELLULAR THERAPY PRODUCT DONATION

DIGITAL JACIE AT THE CHRISTIE

INTEGRATION OF CELLULAR THERAPY IN THE JACIE (JOINT ACCREDITATION COMMITTEE ISCT-EBMT) QUALITY MANAGEMENT PLAN. SINGLE CENTER EXPERIENCE

AUDIT - A METHOD TO EVALUATE INTERVENTIONS - EXPERIENCES FROM AN ATTEMPT TO IMPROVE NUTRITIONAL STATUS IN PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
QUALITY OF LIFE ASSESSMENT AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

RETROSPECTIVE ANALYSIS OF TIME TO ALTERNATIVE DONOR IDENTIFICATION AND HEMATOPOIETIC STEM CELLS PROCUREMENT IN THE ABSENCE OF MATCHED-SIBLING DONORS IN A SINGLE CENTER IN SPAIN

GOVERNANCE, RISKS AND Regulatory aspects of UNLICENSED LENTIVIRAL VECTOR-MODIFIED AUTOLOGOUS STEM CELL TREATMENT

UNIQUE SUPPORTIVE CARE ALGORITHMS FOR CHILDREN UNDERGOING HAPLOIDENTICAL HSCT FOR BENIGN HAEMATOLOGICAL DISORDERS

QUALITY OF LIFE IN PARENTS OF TURKISH AND SYRIAN PEDIATRIC BONE MARROW TRANSPLANT AND ONCOLOGY PATIENTS

COLLECTION OF AUTOLOGOUS MONONUCLEAR CELLS IN NON-CYTOKINE STIMULATED DONORS: COMPARING TWO APHERESIS METHODS

EFFECTIVE CAR-T CELL DELIVERY: A MULTIDISCIPLINARY APPROACH AT MFT

HAEMATOPOIETIC PROGENITOR CELL PROFICIENCY TESTING

VALIDATION AND COMPARISON OF AEROBIC AND ANAEROBIC BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ALERT (R) 3D (TM) AND VIRTUO (TM) MICROBIAL BIOBURDEN SYSTEMS FOR HAEMATOPOIETIC PROGENITOR CELLS (HPC)

START-UP OF AN ADHERENCE RECEPTION FOR ALLOGENIC STEM CELL TRANSPLANTED PATIENTS AT THE HEMATOLOGICAL DEPARTMENT LINKÖPING, SWEDEN

ENUMERATION OF RESIDUAL RED BLOOD CELLS IN MIS-MATCHED ALLOGENEIC PBSC COLLECTIONS - TRADITIONAL HAEMATOLOGY ANALYSER VS FLOW CYTOMETRY

INVESTIGATION AND ANALYSIS OF FACTORS AFFECTING GASTROINTESTINAL NUTRITION RECOVERY AFTER MULTIPLE MYELOMA AUTOLOGOUS STEM CELL TRANSPLANTATION AND EFFECTS OF NUTRITIONAL INTERVENTION

CHARACTERISTICS OF IRON DEFICIENCY ANEMIA IN PRE-MENOPAUSAL WOMEN IN KOREA

LEUKEMIA AND ITS TYPES

Regenerative medicine

WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL THERAPY IMPROVES THE QUALITY OF LIFE AND SELF-SUFFICIENCY OF CHILDREN WITH AUTISM SPECTRUM DISORDER

MARROW DERIVED CELLS BRING A LONG LASTING RELIEF WHEN INJECTED INTRAARTICULARLY TO THE JOINTS WITH DEGENERATIVE ARTHRITIS

OSTEOGENIC DIFFERENTIATION CAPACITY OF ADIPOSE-DERIVED STEM CELLS AFFECTED WITH COLD STORAGE
e-Posters
08:30 - 19:00  
ePoster Area

**Solid tumours**

SUCCESSFUL KIR ALLOREACTIVE HSCT IN A CHILD WITH RESISTANT EWING SARCOMA

TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED OR REFRactory GERM CELL TUMORS

VOC PATTERN RECOGNITION OF LUNG CANCER: A COMPARATIVE EVALUATION OF DIFFERENT DOG- AND ENOSE-BASED STRATEGIES USING DIFFERENT SAMPLING MATERIALS

---

**Statistics**

USE OF VARIABLE SELECTION METHODS TO IDENTIFY CLINICAL AND IMMUNOLOGICAL FACTORS ASSOCIATED WITH THE CLINICAL OUTCOME OF PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

THE IMPACT OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION ON WORK AND PRODUCTIVITY LOSS IN PATIENTS WITH ACUTE LEUKAEMIA: RESULTS FROM A RAPID REVIEW

GEOGRAPHIC AND SOCIOECONOMIC IMPACTS ON SURVIVAL AMONG ALLOGENEIC TRANSPLANT RECIPIENTS

---

**Stem cell donor**

DONOR-RECIPIENT HLA MATCHING FOR UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION \(<b>Outcomes: \</b> A STUDY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY (CTIWP) OF THE EBMT

PRESENCE OF AGE-RELATED CLONAL HEMATOPOIESIS (ARCH) IN DONOR DOES NOT INCREASE THE RISK OF LATE SECONDARY MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Kyoung Ha Kim, Tae Hyung Kim, Jae-Sook Ahn, Ivan Pasic, Zeyad Al-Shaibani, Arjun Law, Wilson Lam, Fotios Michelis, Armin Gerbirtz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Zhaolei Zhang, Tamir Biezuner, Liran Shlush, Dennis Dong Hwan Kim (Canada)

SERIOUS EVENTS AND ADVERSE REACTIONS IN RELATION TO BLOOD STEM CELL DONATION REPORTED TO WMDA IN 2018

THE IMPROVEMENT IN OVERALL SURVIVAL FROM UNRELATED DONOR TRANSPLANT IN AUSTRALIA AND NEW ZEALAND IS DRIVEN BY A REDUCTION IN TRANSPLANT RELATED MORTALITY

POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING, UNRELATED AND HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA, A COMPARATIVE STUDY OF THE ALWP EBMT

ALLOREACTIVITY AGAINST HLA-DPB1 IN HOST-VERSUS-GRAFT DIRECTION IS ASSOCIATED WITH INCREASED RISK OF GRAFT FAILURE AFTER MATCHED UNRELATED DONOR TRANSPLANTATION FOR NONMALIGNANT DISEASES
Scientific Programme

IMPACT OF KIR ON PATIENTS WITH LYMPHOID DISEASES AFTER T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

INDICATIONS AND SAFETY OF MULTIPLE BONE MARROW HARVESTS IN PEDIATRIC DONORS FOR MATCHED SIBLING RECIPIENT TRANSPLANTATION

HEALTHY VOLUNTARY STEM CELL DONORS: FOLLOW UP AFTER HPC APHERESIS DONATION: THE EXPERIENCE OF ITALIAN BONE MARROW DONOR REGISTRY

ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH INHERITED DISORDERS

HAPLOIDENTICAL REDUCED-INTENSITY HEMATOPOIETIC CELL TRANSPLANTATION USING BUSULFAN, FLUDARABINE, AND ANTITHYMOCYTE GLOBULIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

THE RESULTS OF A TELECONFERENCE ABOUT THE EXPERIENCES AND EXPECTATIONS OF RELATED HEMATOPOIETIC STEM CELL DONORS AFTER DONATION

IMPACT OF THE ESTABLISHMENT OF THE TURKISH NATIONAL DONOR REGISTRY (TURKOK) ON A SINGLE CENTER'S TRANSPLANT OUTCOME: INTERNATIONAL STEM CELL DONORS VERSUS NATIONAL

YOUNG MALE DONORS MAY RESULT IN BETTER OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA WITH PT-CY

DONORS OF PERIPHERAL HEMATOPOIETIC STEM CELLS, OUR EXPERIENCE FOR LAST 10 YEARS

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS OVER 70 YEARS: A MONOCENTRIC EXPERIENCE OF 48 PATIENTS

COMPARISON OF TRANSPLANT OUTCOMES AND ECONOMIC COSTS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML AND MDS BETWEEN THE DIFFERENT TYPE OF DONORS

HIGH DISEASE-FREE SURVIVAL OF THE SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH DONOR CHANGE AND MAINLY REDUCED-INTENSITY CONDITIONING IN RELAPSED HEMATOLOGICAL MALIGNANCIES

EPIDEMIOLOGICAL STUDY OF RARE ANTIGENS OF THE MAIN HISTOCOMPATIBILITY COMPLEX AMONG HEMATOPOIETIC STEM CELL DONORS IN BELARUS

IMPACT OF DONOR-RECIPIENT SEX MISMATCH IN PATIENTS RECEIVING PARTIAL T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE MONOCENTRIC STUDY

HAPLOIDENTICAL DONOR SELECTION AND ITS IMPLICATIONS IN TRANSPLANTATION OUTCOME. OUR EXPERIENCE AT HUDGC DR. NEGRÍN

OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ACCORDING TO DONOR AVAILABILITY, DURATION FROM DIAGNOSIS TO TRANSPLANT AND DONOR-SPECIFIC PARAMETERS - A SINGLE CENTER ANALYSIS

THE BENEFITS OF HLA-MATCHED RELATED DONORS FOR PATIENTS LACKING HLA-IDENTICAL SIBLING IN THE ABSENCE OF POWERFUL LOCAL UNRELATED REGISTRY IN COUNTRIES WITH PREVALENT COUSIN MARRIAGES

DONOR AGE INFLUENCES THE GRAFT-VERSUS-HOST-DISEASE-FREE AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANT IN ELDERLY PATIENTS IN LATIN AMERICA

A STUDY OF THE UNCERTAINTY, UNCERTAINTY APPRAISAL AND GROWTH AND THE Affected FACTORS ON HEMATOPOIETIC STEM CELL DONORS
WITHDRAWL OF VOLUNTEER DONORS FROM THE INTERNATIONAL REGISTRIES: A SINGLE CENTRE EXPERIENCE

OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION FOR AML AND MYELODYSPLASTIC SYNDROME IN ELDERLY WITH REDUCED-INTENSITY CONDITIONING

HAPLOIDENTICAL VS UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS WITH HEMATOLOGIC MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS

HEPATITIS E VIRUS (HEV) CONTAMINATED HEMATOPOIETIC STEM CELL GRAFT IN A MATCHED UNRELATED DONOR TRANSPLANTATION

HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MATCH RELATED DONORS IN CHILDHOOD: SINGLE CENTER EXPERIENCE

FIRST EXPERIENCE WITH UNRELATED STEM CELL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN A TRANSPLANT CENTER FROM NORTH MACEDONIA

STEM CELL MOBILIZATION, COLLECTION AND ENGINEERING

TWO YEAR ANALYSIS OF A PROSPECTIVE PHASE I/II CLINICAL TRIAL IN ADULTS USING TCR ALPHA/BETA DEPLETED STEM CELL TRANSPLANTATION FROM MATCHED RELATED AND UNRELATED DONORS

A NEW BSA-BASED THRESHOLD PREDICTS OPTIMAL PBSC COLLECTION IN T-CELL DEPLETED HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION

PHASE 1 CLINICAL STUDY OF MGTA-145 IN COMBINATION WITH PLERIXAFOR SHOWS RAPID SINGLE-DAY MOBILIZATION AND COLLECTION OF CD34+ HSCS WITHOUT G-CSF

DEPLETION OF αβ T-CELLS AND B-CELLS BEFORE HLA-HAPLOIDENTICAL HSCT IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISORDERS: A REPORT OF 473 PROCEDURES

ACOUSTOPHORESIS ENABLES THE LABEL-FREE SEPARATION OF DISTINCT SUBSETS FROM CULTURED BONE MARROW STROMAL CELLS

FEASIBILITY OF MODIFIED CD45RA NEGATIVE DONOR LYMPHOCYTES INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

BEYOND STEM CELLS - DOES IT MATTER WHAT’S IN THE BAG IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA AND LYMPHOMA?

EXPRESSIONS OF CO-INHIBITORY MARKERS INCREASE EFFECTOR MEMORY T CELLS IN G-CSF MOBILIZED PERIPHERAL STEM CELLS

LIPEGFILGRASTIM COMBINED WITH CHEMOTHERAPY WAS MORE COST-EFFECTIVE THAN PEGFILGRASTIM IN THE MOBILIZATION OF CD34+ CELLS IN NHL PATIENTS

MOBILIZATION AND HARVEST OF PERIPHERAL BLOOD STEM CELLS (PBSC) FOR ALLOGENEIC STEM CELL TRANSPLANTATION FROM 335 PEDIATRIC SIBLING HEALTHY DONORS
Scientific Programme

A COMPARISON OF CHEM-FREE STRATEGY WITH G-CSF PLUS PLERIXAFOR ON DEMAND VERSUS ID-CYCLOPHOSPHAMIDE AND G-CSF AS PBSC MOBILIZATION IN MULTIPLE MYELOMA: AN EXPLORATIVE COST ANALYSIS

EVALUATION OF VIA FREEZETM QUAD FOR LIQUID NITROGEN-FREE CGMP-COMPATIBLE CONTROLLED-RATE FREEZING OF HEMATOPOIETIC PROGENITOR CELL GRAFTS

CD34 + CELL SUBSETS IN STEM CELL PRODUCTS AND THEIR RELATIONSHIP WITH ENGRAFTMENT KINETICS

PLERIXAFOR ON DEMAND IN COMBINATION WITH LOW-DOSE CYCLOPHOSPHAMIDE AND G-CSF FOR THE MOBILIZATION OF HSC IN MULTIPLE MYELOMA PATIENTS: HIGH EFFICACY AND LOW TOXICITY

PERFORMANCE QUALIFICATION OF LOVOTM MEDICAL DEVICE FOR WASHING AND CONCENTRATING 3 AND MORE HEMATOPOIETIC PROGENITOR CELL CRYOPRESERVED BAGS

FROM WORK-UP REQUEST TO DONATION IN THREE WEEKS: A DEDICATED REGISTRY INTEGRATED UNRELATED DONOR STEM CELL COLLECTION CENTER IS SAFE, EFFICIENT AND CONVENIENT FOR DONORS

LOW-DOSE CYCLOPHOSPHAMIDE + G-CSF IS NO MORE EFFECTIVE THAN G-CSF ALONE WHEN MOBILIZING AND COLLECTING STEM CELLS FOR AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA PATIENTS

FIRST INTERIM RESULTS OF NIS OPTIMOB - NATIONWIDE TRIAL OF MOBILIZATION AND COLLECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS

THE IMPACT OF PLERIXAFOR ‘ON DEMAND’ ON THE HEMATOPOIETIC STEM CELL (HSC) COLLECTION, PRODUCT’S QUALITY AND ENGRAFTMENT

ELEVATED SERUM LACTATE DEHYDROGENASE AFTER STEM CELL MOBILISATION PREDICTS SUCCESSFUL STEM CELL COLLECTION IN CHILDREN

INFLUENCE OF THE DMSO WASH STRATEGY ON ADVERSE REACTIONS DURING INFUSION OF HEMATOPOIETIC PROGENITORS

BONE MARROW DONOR CHARACTERISTICS: INFLUENCE ON HARVEST YIELD AND DONOR RECOVERY

PLERIXAFOR SALVAGES AUTOLOGOUS STEM CELL MOBILISATION PROCEDURES IN MYELOMA PATIENTS PREVIOUSLY TREATED WITH LENALIDOMIDE OR AUTOLOGOUS HSCT: COST-EFFECTIVENESS OF UPFRONT USE SHOULD BE EXPLORED

EFFECT OF SHIPPING TIME AND TRANSPORT CONDITIONS ON THE VIABILITY OF CORD BLOOD LEUKOCYTES

OPTIMIZATION OF A STEM CELL MOBILIZATION STRATEGY FOR PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA

AUTOLOGOUS LYMPHAPHERESIS FOR THE PRODUCTION OF CAR-T CELLS

RED BLOOD CELL DEPLETION AND/OR VOLUME REDUCTION IN BONE MARROW PROCESSING: A COMPARISON OF TWO METHODS

CORRELATION OF INTRA-OPERATIVE TOTAL NUCLEATED COUNT AND DONOR CHARACTERISTICS WITH FINAL ALLOGENEIC BONE MARROW GRAFT CHARACTERISTICS AND RECIPIENT CLINICAL OUTCOMES

MULTICENTRE EVALUATION OF THE HPC MODUS (XN-20) FOR TIMING THE HARVEST OF STEM CELLS FROM PERIPHERAL BLOOD
Scientific Programme

IMPACT OF CHANGE OF MOBILISATION METHOD ON ADEQUACY OF STEM CELL COLLECTION IN MULTIPLE MYELOMA PATIENTS: SINGLE CENTRE EXPERIENCE

TWO DIFFERENT PLERIXAFORE STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE

AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS (PBSCS) MOBILIZATION AND COLLECTION - PRINCESS NOORAH ONCOLOGY CENTER EXPERIENCE, KAMC - JEDDAH - SAUDI ARABIA

REVIEW OF PLERIXAFORE USE IN A TERTIARY PAEDIATRIC ONCOLOGY CENTRE

UNUSUAL HIGH COUNT OF CD34+ AFTER CHEMO MOBILIZATION WITH MATRIX IN PATIENT WITH PRIMARY CNS LYMPHOMA IS ASSOCIATED WITH PROMPT AND ROBUST ENGRAFTMENT

LEUKOCTYPHERESIS - ONE TECHNIQUE, DIVERSE OPPORTUNITIES IN THE THERAPY OF PATIENTS

COMPARISON OF CONTINUOUS MONONUCLEAR CELL COLLECTION (CMNC) AND MONONUCLEAR CELL CELL (MNC) METHODS FOR CELL PROLIFERATION (APHERESIS) IN PATIENTS WITH BONE MARROW TRANSPLANTATION

Stem cell source

OPTIMIZING OUTCOMES OF ACUTE LEUKEMIA AFTER TRANSPLANTS WITH SINGLE UNRELATED CORD BLOOD UNITS SELECTED ACCORDING TO CURRENT INTERNATIONAL RECOMMENDATIONS FOR CELL DOSE AND HLA MATCH

IMPACT OF HLA-MISMATCH ON OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE ANALYSIS BY THE JSHCT HLA WORKING GROUP

CLINICAL IMPACT OF DONOR EPITOPE-SPECIFIC HLA ANTIBODIES AND THIRD-PARTY HLA ANTIBODIES IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION

ADDITION OF TOCILIZUMAB TO CYCLOSPORINE-A AND MYCOPHENOLATE MOFETIL FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS SIGNIFICANTLY ABROGATES SEVERE ACUTE GVHD AFTER DOUBLE-UNIT CORD BLOOD TRANSPLANTATION IN ADULTS

THE USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) IN UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION

COMPARATIVE STUDY OF HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETION VS UNRELATED CORD BLOOD TRANSPLANT FOR ADULTS WITH HAEMATOLOGICAL MALIGNANCIES

USE OF G-CSF MOBILIZED BONE MARROW GRAFTS IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION (BMT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) DECREASES RISK OF SEVERE ACUTE GVHD

CMV-SPECIFIC FUNCTIONAL IMMUNE RECONSTITUTION IS SLOWER AFTER UMBILICAL CORD BLOOD COMPARED WITH MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION

REDUCED INTENSITY (RIC) VS MYELOABLATIVE CONDITIONING (MAC) IN CORD BLOOD TRANSPLANTATION FOR AML (40-60 YEARS) ACROSS MISMATCHED HLA BARRIERS - ANALYSIS BY CTIWP/EUROCORD OF EBMT
Scientific Programme

COST OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REAL WORLD: AN ANALYSIS USING THE JAPANESE NATIONAL DATABASE

ASSOCIATION BETWEEN THE DOSE OF CD3+ AND CD34+ CELLS IN THE GRAFT AND POST-TRANSPLANT OUTCOMES

HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A RELATED DONOR WITH HLA-1 ANTIGEN MISMATCH IN THE GRAFT-VERSUS-HOST DIRECTION USING LOW-DOSE ANTI-THYMOCYTE GLOBULIN: MULTICENTER PHASE II TRIAL

INTRA-BONE CORD-BLOOD TRANSPLANT OF UNWASHED UNITS WITH ATG-FREE AND SIROLIMUS-BASED GVHD PROPHYLAXIS: FAST IMMUNE-RECONSTITUTION AND LONG-TERM DISEASE CONTROL IN 22 PATIENTS WITH HIGH-RISK DISEASES

ANTI-HLA DONOR SPECIFIC ANTIBODIES (DSA) DOES NOT AFFECT GRAFT AND SURVIVAL IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) WITH ORIGINAL POST-TRANSPLANT CYCLOFOSFAMIDE (PT-CY) SCHEDULE

MESENCHYMAL STEM/STROMAL CELL PRODUCTION COMPLIANT WITH GOOD MANUFACTURING PRACTICE: COMPARISON BETWEEN BONE MARROW AND WHARTON’S JELLY

EFFICIENT DMSO REMOVAL AND HIGH CELL RECOVERY WITH LOVO CELL PROCESSING SYSTEM IN HPC-A CONCENTRATES: A SINGLE CENTRE EXPERIENCE

Nurses Posters - Adult

ROLE OF QUICKSOFA IN PREDICTING SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL PATIENTS

BOLUS: TARGETED SPECIALIST HAEMATOLOGY/BMT PODCASTS: AN EFFECTIVE METHOD OF EDUCATION

A PATHWAY FOR RECOVERY: D+100 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT) FOLLOW UP PILOT FOR LYMPHOMA

REDUCING ACCIDENTAL FALLS CAUSED BY ORTHOSTATIC HYPOTENSION IN BONE MARROW TRANSPLANT RECIPIENTS

THE EFFECT OF MOTIVATIONAL INTERVIEW PERFORMED AFTER STEM CELL TRANSPLANTATION ON SEXUAL EXPERIENCE, SEXUAL SELF-AWARENESS AND SEXUAL SELF-EFFICACY

STUDY ON COGNITIVE FUNCTION AND RELATED FACTORS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

THE EFFECT OF RELAXING BREATHING EXERCISES ON PAIN, FATIGUE AND LEUKOCYTE COUNT IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

UNDERSTANDING OF PROGNOSIS, QUALITY OF LIFE AND PSYCHIATRIC STATUS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY OF 348 PATIENTS

AN OUTPATIENT MODEL OF CARE TO SAFELY DELIVER AUTOLOGOUS STEM CELL TRANSPLANTATION

EFFECTS OF TREATMENTS FOR HAEMATOLOGICAL MALIGNANCIES ON SEXUALITY AND FERTILITY: WHEN DO PATIENTS NEED IT AND WHOM REALLY WANTS TO KNOW?
EFFICACY OF THERAPEUTIC EDUCATION TO REDUCE RISKS AND COMPLICATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OBSERVATIONAL PROSPECTIVE COHORT STUDY

SELF-EFFICACY AND SELF-CARE PRACTICES OF PATIENTS WHO HAVE BEEN TRANSPLANTED WITH ALLOGENEIC HEMATOPOIETIC STEM CELLS ACCORDING TO THE DEVELOPMENT OF AN INDIVIDUAL EDUCATION PROGRAM

DETERMINING THE SYMPTOMS AND COPING METHODS OF PATIENTS AT HOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

THE EFFECT OF ORAL CARE PROTOCOL ON ORAL MUCOSITIS IN PATIENTS HEMATOPOIETIC STEM CELL TRANSPLANTATION

PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) WITHIN AN AMBULATORY CARE SETTING; A PATIENTS’ PERSPECTIVE

REDUCING ANTITHYMOCYTE GLOBULIN (ATG) INFUSION RELATED REACTION BY INCREASING THE INFUSION DURATION IN ADULT SCT PATIENTS; A SINGLE INSTITUTION EXPERIENCE FROM SAUDI ARABIA

NURSE LED TELEPHONE FOLLOW UP FOR LATE EFFECTS SERVICE

NURSING CARE OF 15 PATIENTS WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CHIMERIC ANTIGEN RECEPTOR T CELLS

NURSING CARE OF A PATIENT WITH HEREDITARY DIFFUSE LEUKOENCEPHALOPATHY COMPLICATED WITH AXONAL DEGENERATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

EFFECT OF NURSES EDUCATION PROGRAM ON CATHETER RELATED BLOOD STREAM INFECTIONS

THE CURRENT SITUATION AND INFLUENCING FACTORS OF MANAGEMENT OF CENTER VENOUS ACCESS DEVICE-ASSOCIATED SKIN IMPAIRMENT DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION

EXERCISE SUPPORT FOR PEOPLE POST TREATMENT AS PART OF THEIR RETURN TO WORK JOURNEY: A CASE STUDY EXEMPLAR

ONCOSAFETY: A NEW TOOL FOR HEMATOLOGY NURSES TO AVOID CHEMOTHERAPY ERRORS

PATIENT INFORMATION SHEET FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION: THE IMPACT OF THE DISEASE AND TREATMENT ON SEXUAL FUNCTION AND SEXUALITY

CHANGING PRACTICE BY USING CYCLOPRIME 1.5G/M2 PRIMING REGIME UP FRONT FOR LYMPHOMA PATIENTS TO ENSURE GOOD MOBILISATION OF STEM CELLS

THE CHALLENGES OF LOOKING AFTER AN INCREASING NUMBER OF SURVIVORS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION

VENO-OCCCLUSIVE DISEASE (VOD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANT NURSING CONSIDERATIONS AND MANAGEMENT: A CASE STUDY

RECOGNIZING LOW HEALTH SKILLS AND LOW LITERACY DURING CONSULTATION

PRE-HABILITATION PRIOR TO STEM CELL TRANSPLANT - ONE CENTRES EXPERIENCE

THE IMPORTANCE OF NURSES TRAINING IN NEW THERAPY USING THE EXAMPLE OF CAR-T CELL THERAPY
Scientific Programme

PLASMAPHERESIS: TAKING THE EDGE OFF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTIBODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION

INCIDENCE & CHARACTERISTICS OF VARICELLA ZOSTER VIRUS INFECTION POST HEMATOPOEITIC STEM CELL TRANSPLANTATION; EXPERIENCE OF A SINGLE CENTER IN SAUDI ARABIA

SEMI-STRUCTURED INTERVIEW ASSESSMENT OF THE CLINICAL NURSE EDUCATOR ROLE IN SUPPORTING NEWLY QUALIFIED NURSES DURING TRANSITION TO POST-REGISTRATION PRACTICE INSIDE THE BONE MARROW TRANSPLANT SETTING

TRAINING NURSING PROGRAMME IN NEW THERAPIES: CAR T CELLS

NURSES’ ROLE IN IMPROVING PATIENTS’ FOOD INTAKE IN THE ACUTE HSCT PHASE

USE THE AVAILABLE KNOWLEDGE - ENSURE THAT THE PATIENT RECEIVES THE BEST CARE IN STEM CELL TRANSPLANTATION

THE PSYCHO EMOTIONAL DISAGUE IN ADULT PATIENTS SUBJECT TO MIDOLLO TRANSPLANT: INITIAL STUDY OF A SINGLE CENTER

NURSING CARE OF 15 PATIENTS WITH HEMATOLOGICAL MALIGNANT TUMOR COMPlicated WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CAR-T CELLS

RETROSPECTIVE OBSERVATIONAL STUDY ON THE TRANSMISSION OF HEALTHCARE ASSOCIATED INFECTIONS AMONG NEUTROPENIC PATIENTS WITHIN THE HEMATOLOGY UNIT OF PIACENZA HOSPITAL

GUIDE FOR PATIENTS AND DONORS BEFORE A PERIPHERAL BLOOD STEM CELL COLLECTION

Natalia Lorente del Río, Cristina Alberquilla Ramos, Salvadora Aleza Esteras, Isabel María Fernández Morales, Mª Del Carmen Freire Mourón, Ana García Carulla, Carmen Granado Rodilla, Mercedes Jiménez Meoro, Rosario López López, Marta Vela Garicano, Jesús Zalvide Torrente, Laura Bibiloni Martínez (Spain)

IMPACT OF AN IMPROVEMENT PLAN ON THE REDUCTION OF BACTERIEMIA BY CENTRAL CATHETER IN A PATIENT RECEIVER OF A CELLULAR THERAPY

ARE TYPHOMETER THERMOMETERS RELIABLE IN HEMATOPOIETIC STEM CELL RECIPIENTS?

RELATIONSHIPS BETWEEN THE HEALTHCARE NEEDS AND QUALITY OF LIFE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS

PAIN ASSESSMENT DURING BONE MARROW BIOPSY PROCEDURE AND BONE MARROW ASPIRATE PROCEDURE: A SPECIFIC NURSING ASSESSMENT

AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION IN SYSTEMIC SCLEROSIS: CASE STUDY

LEADERSHIP - LEADING THE TEAM

PAIN ASSESSMENT IN ONCO HEMATOLOGICAL PATIENT SUBJECTED TO CENTRAL VENOUS CATHETER POSITIONING (CVC) OR PERIPHERALLY INSERTED CENTRAL CATHETER POSITIONING (PICC)

TOCILIZUMAB MANAGEMENT IN THE CYTOKINE RELEASE SYNDROME

COMPLICATIONS ASSOCIATED WITH THE COLLECTION OF PERIPHERAL BLOOD PROGENITOR CELLS

IS IT WORTH FIGHTING TOGETHER FOR AN INDIVIDUAL ACCESS TO A MEDICINE WITH A NON REIMBURSEMENT DECISION? YES IT IS!

INCIDENCE OF ACUTE GUT GVHD IN PATIENTS WHO HAVE UNDERGONE ALLOGENIC STEM CELL TRANSPLANTATION: CASE STUDY

Page 145 / 353
**Scientific Programme**

**COMPLETION TIME TO HLA TYPING**

**GYNECOLOGICAL TREATMENT EXPERIENCE OF MENOPAUSAL SYNDROME AND SEXUAL DISORDERS IN FEMALE PATIENTS WHO UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION**

**e-Posters**

08:30 - 19:00  
ePoster Area

**Nurses Posters – Paediatric**

TRANSITION STRATEGY: FROM PEDIATRIC TO ADULT HEALTH CARE AND LONG TERM FOLLOW-UP

CAREGIVER EDUCATION AND TRAINING FOR SELF ADMINISTRATION OF ORAL DRUGS IN A PAEDIATRIC CENTER

EXERCISE THERAPY ON CANCER-RELATED FATIGUE AND QUALITY OF LIFE IN CHILDREN UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION

SEXUAL HEALTH FOR YOUNG PEOPLE UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION

EVALUATION OF A PREVENTIVE SKIN CARE PROTOCOL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS RECEIVING THIOTEPA

CAR-T: THE DUTCH PEDIATRIC NURSING EXPERIENCE

SUBSTITUTIVE THERAPY WITH S.C. IMMUNOGLOBULINS IN PEDIATRIC HSCT RECEPIENTS: A SINGLE CENTER EXPERIENCE

PEDIATRIC PHOTOAPHAERESIS: THE DILEMMA OF VASCULAR ACCESSES

TOTALLY IMPLANTABLE VASCULAR ACCESS DEVICES RUPTURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: PROPHYLAXIS AND TREATMENT

USE OF VOLUMETRIC PUMPS FOR THE INFUSION OF HEMATOPOIETIC STEM CELLS AS A STANDARD METHOD IN PEDIATRIC PATIENTS

PEDIATRIC PATIENT TRANSFER FROM A TPH WARD TO ICU: HOW CAN WE IMPROVE OUR COMMUNICATION?

CARING FOR MINOR SIBLING DONORS

EFFECTIVE MOBILISATION WITH PLERIXAFOR FOLLOWING CRANIA-SACRAL RADIOTHERAPY AND HIGH-DOSE CHEMOTHERAPY: A CASE REPORT OF AN ELEVEN-YEAR OLD BOY WITH GLIOBLASTOMA MULTIFORME

EARLY RECOGNITION OF PEDIATRIC GVHD: EDUCATION AND AWARENESS AMONGST NURSES

RISK ASSESSING PAEDIATRIC PATIENTS’ NUTRITIONAL NEEDS PRIOR TO BONE MARROW TRANSPLANT

**Nurses Posters – Research**

---

Page 146 / 353
FAMILY CAREGIVERS SUPPORT NEEDS DURING ALLO-HSCT - A LONGITUDINAL STUDY (PRELIMINARY RESULTS)

PAIN AND ANXIETY MANAGEMENT DURING BONE MARROW ASPIRATES IN ITALIAN TRANSPLANT PROGRAMS. A NATIONWIDE SURVEY ON BEHALF OF GITMO NG

PREVALENCE, PREDICTORS AND OUTCOMES OF CLABSI AMONG HSCT PATIENTS

CREATION OF THE LBMT NURSES GROUP

SYMPTOMS AND QUALITY OF LIFE OF CHILDREN AND ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY

SOCIAL SUPPORT MODERATES THE EFFECTS OF HEALTH STRESSORS ON HEALTH CARE ADHERENCE AND PSYCHOLOGICAL DISTRESS IN LONG-TERM HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS

SYMPTOM DISTRESS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A PROSPECTIVE STUDY

NURSE INVOLVEMENT AND IMPACT OF JACIE ACCREDITATION ON NURSE PRACTICE

CONSTRUCTION OF QUALITY INDICATORS SYSTEM OF NUTRITION CARE FOR ADULT PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION THROUGH AN EVIDENCE-BASED APPROACH

ARE CAREGIVERS RECEIVING ENOUGH INFORMATION TO CARE? A PILOT STUDY ON A HEMATOLOGICAL TRANSPLANT UNIT

MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A THREE YEARS FOLLOWING UP

VENOUS ACCESS IN AUTOLOGOUS VERSUS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT DONORS: A RETROSPECTIVE STUDY OF AN APHERESIS UNIT

A STUDY TO ASSESS THE LEVEL OF BURNOUT AMONG NURSES WORKING IN BONE MARROW TRANSPLANT (BMT) UNIT OF A TERTIARY CARE CANCER HOSPITAL

DO WE KNOW ENOUGH ABOUT THE BONE MARROW DONATION?

ASSOCIATION OF AIR BORN PARTICLE SIZE AND PARTICLE COUNT WITH INCIDENCE OF INFECTIONS IN HEPA FILTERED ROOMS-A SINGLE CENTRE EXPERIENCE

SYSTEMATIC REVIEW OF SIGNS AND SYMPTOMS OF THE HUMAN HERPES VIRUS 6 AND THEIR ASSESSMENT TOOLS

A STUDY TO ASSESS PERCEIVED STRESSORS AND COPING STRATEGIES ADOPTED BY PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL INFUSION IN SELECTED CANCER HOSPITAL, INDIA

ROLE OF THERAPEUTIC APHERESIS IN ALLOGENEIC TRANSPLANTATION: A CASE REPORT

SYMPTOMS OF ELDERLY PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER INDUCTION CHEMOTHERAPY
## Scientific Programme

### CME Symposium
08:45 - 10:00  
Auditorium 3

**IS3, GMMG CME Symposium: Stem cell transplantation in Multiple Myeloma**

**Chairs:**  
Hartmut Goldschmidt (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 - 08:59</td>
<td>Role of allo-TPX in Multiple Myeloma</td>
</tr>
<tr>
<td></td>
<td>Nicolaus Kröger (Germany)</td>
</tr>
<tr>
<td>08:59 - 09:13</td>
<td>Impact of age on the decision of auto-TPX in Multiple Myeloma</td>
</tr>
<tr>
<td></td>
<td>Hans Salwender (Germany)</td>
</tr>
<tr>
<td>09:13 - 09:27</td>
<td>Predictive factors in Multiple Myeloma</td>
</tr>
<tr>
<td></td>
<td>Hartmut Goldschmidt (Germany)</td>
</tr>
<tr>
<td>09:27 - 09:41</td>
<td>Treatment of high-risk Multiple Myeloma</td>
</tr>
<tr>
<td></td>
<td>Katja Weisel (Germany)</td>
</tr>
<tr>
<td>09:41 - 09:55</td>
<td>Cellular Therapy in Multiple Myeloma</td>
</tr>
<tr>
<td></td>
<td>Christoph Scheid (Germany)</td>
</tr>
<tr>
<td>09:55 - 10:00</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>

### Industry Symposium
10:30 - 12:00  
Auditorium 2

**IS4, Practical considerations for CAR-T Cell Therapy use in lymphomas - Novartis**

**Industry Symposium**

**Chairs:**  
Anna Sureda (Spain)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:35</td>
<td>Introduction and opening remarks</td>
</tr>
<tr>
<td></td>
<td>Anna Sureda (Spain)</td>
</tr>
<tr>
<td>10:35 - 10:55</td>
<td>CAR-T Cell Therapy in the DLBCL continuum of care: Efficacy and safety</td>
</tr>
<tr>
<td></td>
<td>in key clinical trials and the real world</td>
</tr>
<tr>
<td></td>
<td>Matthew Frigault (United States)</td>
</tr>
<tr>
<td>10:55 - 11:10</td>
<td>Patient selection for CAR-T Cell Therapy: What we know and what we</td>
</tr>
<tr>
<td></td>
<td>have yet to find out</td>
</tr>
<tr>
<td></td>
<td>Anna Sureda (Spain)</td>
</tr>
<tr>
<td>11:10 - 11:30</td>
<td>Treatment landscape in DLBCL: New developments, and when to take the</td>
</tr>
<tr>
<td></td>
<td>CAR instead?</td>
</tr>
<tr>
<td></td>
<td>Edmund K Waller (United States)</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>How to apply CAR-T Cell Therapy in DLBCL: Interactive case-based panel</td>
</tr>
<tr>
<td></td>
<td>Pere Barba (Spain)</td>
</tr>
<tr>
<td>11:45 - 11:55</td>
<td>Panel discussion</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>11:55 - 12:00</td>
<td>Closing remarks</td>
</tr>
<tr>
<td></td>
<td>Anna Sureda (Spain)</td>
</tr>
</tbody>
</table>
Industry Symposium
10:30 - 11:15

**IS5, Maintenance of complete remission in AML - Celgene | Bristol Myers Squibb Industry Symposium**

**Chairs:**
Martin Bornhäuser (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:30 - 10:35 | **Welcome and introduction**
Martin Bornhäuser (Germany)                                           |
| 10:35 - 10:50 | **Kinetics of clonal evolution and relapse in AML patients in complete response**
Maria Teresa Voso (Italy)                                           |
| 10:50 - 11:05 | **Current and upcoming pharmacological options to prolong complete response in AML**
Charles Craddock (United Kingdom)                                     |
| 11:05 - 11:15 | **Closing remarks**
Martin Bornhäuser (Germany)
Maria Teresa Voso (Italy)
Charles Craddock (United Kingdom)                                      |

Industry Symposium
10:30 - 12:00

**IS6, Case Studies on Innovative Treatment Approaches for CMV in HCT: A Clinical Forum - Industry Symposium supported by an educational grant from Takeda**

**Chairs:**
Jan Styczynski (Poland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:30 - 10:35 | **Welcome and Introductions**
Jan Styczynski (Poland)                                           |
| 10:35 - 11:05 | **HCT CASE 1 - Patient with Refractory or Resistant Disease and Panel Discussion**
Per Ljungman (Sweden)                                             |
| 11:05 - 11:10 | **Audience Q&A**
Johan Maertens (Belgium)                                           |
| 11:10 - 11:40 | **HCT CASE 2 - Patient with Late CMV Disease and Panel Discussion**
Johan Maertens (Belgium)                                           |
| 11:40 - 12:00 | **Audience Q&A, Closing Remarks**                                                            |
Industry Symposium
10:30 - 12:00

**IS7, Your decisions in action: The reality of severe hepatic VOD management - Jazz Pharmaceuticals Industry Symposium**

**Chairs:**
Mohamad Mohty (France)

- **Welcome and introduction**
  Mohamad Mohty (France) 10:30 - 10:35
- **The patient: your important initial choices in action**
  Rafael Duarte (Spain) 10:35 - 10:50
- **Assessment and monitoring, what now?**
  Rafael Duarte (Spain) 10:50 - 11:05
  Mohamad Mohty (France)
- **Outcome: the reality of severe hepatic VOD**
  Mohamad Mohty (France) 11:05 - 11:20
- **Informed decision-making for paediatric hepatic VOD**
  Selim Corbacioglu (Germany) 11:20 - 11:35
- **Live Q&A**
  Mohamad Mohty (France) 11:35 - 11:55
- **Summary and close**
  Mohamad Mohty (France) 11:55 - 12:00

Patient, Family Donor Day
10:30 - 12:40

**PFD1, Patient, Family and Donor Day**

**Chairs:**
Sarah Hutton (United Kingdom)
Guy Bouguet (France)

- **Welcome by moderators**
  Guy Bouguet (France) 10:30 - 10:35
  Sarah Hutton (United Kingdom)
- **Patient’s testimony on impact on life and self**
  Agnès Huet-Vicens (France) 10:35 - 10:45
- **Introduction to speaker**
  10:45 - 10:46
- **Overview HSCT and GVHD**
  Régis Peffault de Latour (France) 10:46 - 11:06
- **Q&A**
  11:06 - 11:21
- **Break**
  11:21 - 11:26
- **Introduction to speaker**
  11:26 - 11:27
Psychological well-being on transplant patients 11:27 - 11:47
Anna Barata (United States)

Q&A 11:47 - 12:02

Introduction to speaker 12:02 - 12:03

CAR-T Cell Therapy 12:03 - 12:23
Jürgen Kuball (Netherlands)

Q&A 12:23 - 12:38

Closing remarks 12:38 - 12:40

Industry Symposium
12:30 - 14:00
Auditorium 1

IS8, Improving outcomes: Transplant and beyond in patients with high-risk AML* - Jazz Pharmaceuticals Industry Symposium

*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

Chairs:
Charles Craddock (United Kingdom)

Welcome and introduction
Charles Craddock (United Kingdom)

Current considerations for patient selection for HSCT
Fabio Ciceri (Italy)

Strategies for optimising long-term outcomes from HSCT in patients with high-risk AML
Charles Craddock (United Kingdom)

Optimising outcomes with pre-transplant treatment selection in high-risk AML
Donal McLornan (United Kingdom)

Q&A

Summary and close
Charles Craddock (United Kingdom)

Industry Symposium
12:30 - 14:00
Auditorium 2

IS9, Steroid-refractory GvHD: Current challenges and future advances - Novartis Industry Symposium

Chairs:
Franco Locatelli (Italy)

Welcome and introduction 12:00 - 12:35
Franco Locatelli (Italy)
Scientific Programme

GvHD and steroid-refractory GvHD in 2020  12:35 - 12:55
Jeff Szer (Australia)

Today's challenges in managing acute and chronic steroid-refractory GvHD  12:55 - 13:00
Franco Locatelli (Italy)

Panel discussion  13:00 - 13:10

The future of steroid-refractory GvHD: Acute and chronic GvHD  13:10 - 13:40
Madan Jagasia (United States)
Robert Zeiser (Germany)

Panel discussion  13:40 - 13:55

Concluding remarks  13:55 - 14:00
Franco Locatelli (Italy)

Industry Symposium  
12:30 - 14:00  Auditorium 3

IS10, Current status and potential of CAR T cell therapies in B-cell malignancies - Celgene | Bristol Myers Squibb Industry Symposium

Chairs:
Catherine Thieblemont (France)

Welcome and introduction  12:30 - 12:35
Catherine Thieblemont (France)

CAR T in DLBCL: The latest data and future perspectives  12:35 - 12:55
Pere Barba (Spain)

Beyond DLBCL: CAR T in high-risk or relapsing B-cell malignancies  12:55 - 13:15
Tom van Meerten (Netherlands)

The impact of CAR T on patient care organization  13:15 - 13:35
Catherine Thieblemont (France)

Summary and Q&A  13:35 - 14:00
Catherine Thieblemont (France)

Industry Symposium  
12:30 - 14:00  Auditorium 4

IS11, Established and cutting-edge applications for cell therapies - Miltenyi Biotec Industry Symposium

Chairs:
Rafael Duarte (Spain)

Welcome and introduction  12:30 - 12:40
Rafael Duarte (Spain)
Scientific Programme

**Picking your favorite tapas: Which cell populations to include in the allograft**  
Miguel-Angel Perales (United States)  
12:40 - 12:55

**Discussion - Q/A**  
12:55 - 13:00

**TCRa/β CD19 depleted haploidentical HSCT in adult patients - Final results of the TCRalpha/beta-Haplo2010 study**  
Wolfgang Bethge (Germany)  
13:00 - 13:15

**Discussion - Q/A**  
13:15 - 13:20

**Improved survival rate in T cell-depleted haploidentical hematopoietic cell transplantation utilizing CD45RA-depleted grafts**  
Brandon Triplett (United States)  
13:20 - 13:35

**Discussion - Q/A**  
13:35 - 13:40

**Semi-automated CAR T cell manufacturing: focus on the UCL CAR T-cell programme**  
Claire Roddie (United Kingdom)  
13:40 - 13:55

**Discussion - Q/A**  
13:55 - 14:00

---

**Industry Symposium**  
12:30 - 14:00  
Auditorium 5

**IS12, GVHD: What's new in 2020? - Sanofi Genzyme Industry Symposium**

**Chairs:**  
Mohamad Mohty (France)

**Welcome and introduction**  
Mohamad Mohty (France)  
12:30 - 12:40

**The mycobiota: A new player in GVHD pathophysiology**  
Florent Malard (France)  
12:40 - 12:55

**ATG and/or post-Cy for GVHD prophylaxis**  
Mohamad Mohty (France)  
12:55 - 13:10

**Personalized ATG dosage: The PARACHUTE trial**  
Jaap Jan Boelens (United States)  
13:10 - 13:25

**Nutritional support for GVHD patients**  
Zinaida Peric (Croatia)  
13:25 - 13:40

**Round table discussion**  
13:40 - 14:00

---

**Social Events**  
12:50 - 13:23  
Auditorium 6

**Health with Every Bite - Nutrition and healing**
IS13, Curative intent in R/R DLBCL: A case-based discussion - Kite Industry Symposium

Chairs:
Frederick Locke (United States)

**Introduction**
Frederick Locke (United States)  
14:30 - 14:33

**Curative intent for DLBCL patients at 3rd-line: What are the current data?**
Frederick Locke (United States)  
14:33 - 14:53

**Patient case session**
Francis Ayuk (Germany)  
Ibrahim Yakoub-Agha (France)  
Nuria Martínez-Cibrian (Spain)  
Pierre Sesques (France)  
14:53 - 15:38

**Panel discussion and live Q&A: Review of the cases - what have we learnt?**
15:38 - 15:58

**Meeting close**
Frederick Locke (United States)  
15:58 - 16:00

IS14, From kilometer zero - Navigating the myeloma treatment journey - Amgen Industry Symposium

Chairs:
Mohamad Mohty (France)

**Introduction**
Mohamad Mohty (France)  
14:30 - 14:40

**Off to a good start - Optimal induction regimen for transplant eligible patients**
Francesca Gay (Italy)  
14:40 - 15:05

**The road beyond relapse - Therapeutic options for hard-to-treat patients**
Mohamad Mohty (France)  
15:05 - 15:30

**Panel discussion**
15:30 - 16:00
Industry Symposium  
14:30 - 16:00  
Auditorium 3

**IS15, Targeted therapy for adult ALL: New horizons in the setting of alloHSCT - Amgen Industry Symposium**

**Chairs:**  
Josep M. Ribera (Spain)

- **Welcome and introduction**  
  Josep M. Ribera (Spain)  
  14:30 - 14:35

- **Overview of conventional approaches**  
  Josep M. Ribera (Spain)  
  14:35 - 14:45

- **Antibody-drug conjugates**  
  Matthias Stelljes (Germany)  
  14:45 - 15:05

- **T-cell engaging immuno-oncology (BiTE® and CAR T)**  
  Nicola Gökbuget (Germany)  
  15:05 - 15:35

- **Live Q&A**  
  15:35 - 16:00

Industry Symposium  
14:30 - 16:00  
Auditorium 4

**IS16, Targeted interventions in the natural history of Hodgkin Lymphoma - Takeda Industry Symposium**

**Chairs:**  
Anton Hagenbeek (Netherlands)

- **Welcome and introduction**  
  Anton Hagenbeek (Netherlands)  
  14:30 - 14:40

- **Latest developments in first-line treatment of Hodgkin lymphoma**  
  Martin Hutchings (Denmark)  
  14:40 - 15:05

- **Prolongation of remission with post-ASCT strategies in Hodgkin lymphoma**  
  Anna Sureda (Spain)  
  15:05 - 15:30

- **Concluding remarks, panel discussion and audience Q&A**  
  Anton Hagenbeek (Netherlands)  
  Martin Hutchings (Denmark)  
  Anna Sureda (Spain)  
  15:30 - 16:00

Industry Symposium  
14:30 - 16:00  
Auditorium 5

**IS17, Nurse Symposium: Power of knowledge: Nurses at the forefront of patient survival of severe hepatic VOD - Jazz Pharmaceuticals Industry Symposium**

**Chairs:**  
Michelle Kenyon (United Kingdom)
Scientific Programme

Welcome and introduction  14:30 - 14:34
Michelle Kenyon (United Kingdom)

Joint discussion - Nurses at the forefront: Whose responsibility is it to identify patients with hepatic VOD?  14:34 - 14:59
Michelle Kenyon (United Kingdom)
Mairead Ni Chonghaile (Ireland)

Knowledge is power: paediatric hepatic VOD  14:59 - 15:14
Selim Corbacioglu (Germany)

Knowledge is power: paediatric hepatic VOD  15:14 - 15:24
Zofia Szmit (Poland)

The knowledge of the nurse: a case of severe hepatic VOD  15:24 - 15:39
Emmanouil Nikolousis (United Kingdom)

Live Q&A  15:39 - 15:59

Close  15:59 - 16:00
Michelle Kenyon (United Kingdom)

Industry Symposium 16:30 - 18:00  Auditorium 1

IS18, The role of ECP in the treatment of GVHD - Therakos Industry Symposium

Chairs:
Andrea Bacigalupo (Italy)

Introduction  16:30 - 16:35
Andrea Bacigalupo (Italy)

GVHD: Treatment goals and current definitions  16:35 - 17:00
Madan Jagasia (United States)

ECP role in GVHD treatment  17:00 - 17:25
Hildegard Greinix (Austria)

ECP in combination therapies  17:25 - 17:50
Robert Zeiser (Germany)

Q&A  17:50 - 18:00

Industry Symposium 16:30 - 18:00  Auditorium 2

IS19, Cellular immune therapies for multiple myeloma - Celgene | Bristol Myers Squibb Industry Symposium

Chairs:
María-Victoria Mateos (Spain)
### Scientific Programme

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and introduction</td>
<td>16:30 - 16:35</td>
</tr>
<tr>
<td>María-Victoria Mateos (Spain)</td>
<td></td>
</tr>
<tr>
<td>State-of-the-art therapy in multiple myeloma and unmet needs in 2020</td>
<td>16:35 - 16:55</td>
</tr>
<tr>
<td>María-Victoria Mateos (Spain)</td>
<td></td>
</tr>
<tr>
<td>Overview of CAR T cell treatment strategies in multiple myeloma</td>
<td>16:55 - 17:10</td>
</tr>
<tr>
<td>Xavier Leleu (France)</td>
<td></td>
</tr>
<tr>
<td>Management and optimization of CAR T cell therapy</td>
<td>17:10 - 17:25</td>
</tr>
<tr>
<td>Michel Delforge (Belgium)</td>
<td></td>
</tr>
<tr>
<td>Summary and Q&amp;A</td>
<td>17:25 - 18:00</td>
</tr>
</tbody>
</table>

### Industry Symposium

**IS20, CMV prophylaxis in transplantation – From implementation to follow up - MSD**

**Chairs:**
- Catherine Cordonnier (France)

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and introduction</td>
<td>16:30 - 16:35</td>
</tr>
<tr>
<td>Catherine Cordonnier (France)</td>
<td></td>
</tr>
<tr>
<td>CMV prophylaxis in allogeneic stem cell transplantation: How to optimize clinical care?</td>
<td>16:35 - 16:55</td>
</tr>
<tr>
<td>Rafael Duarte (Spain)</td>
<td></td>
</tr>
<tr>
<td>Real-life experience with CMV prophylaxis in allogeneic stem cell transplantation</td>
<td>16:55 - 17:15</td>
</tr>
<tr>
<td>Michael Schmitt (Germany)</td>
<td></td>
</tr>
<tr>
<td>Evolving strategies in CMV prevention</td>
<td>17:15 - 17:35</td>
</tr>
<tr>
<td>Miguel-Angel Perales (United States)</td>
<td></td>
</tr>
<tr>
<td>Panel discussion</td>
<td>17:35 - 17:45</td>
</tr>
<tr>
<td>Live Q&amp;A and closing remarks</td>
<td>17:45 - 18:00</td>
</tr>
</tbody>
</table>

### Industry Symposium

**IS21, Nurse Symposium: Optimising the patient’s CAR T-cell therapy journey - Kite**

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction: Meet our patient</td>
<td>16:30 - 16:35</td>
</tr>
<tr>
<td>Graham Collins (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Starting the journey: DLBCL diagnosis and first-line therapy</td>
<td>16:35 - 16:45</td>
</tr>
<tr>
<td>Graham Collins (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Stephen Scowcroft (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Órla Stewart (United Kingdom)</td>
<td></td>
</tr>
</tbody>
</table>
## Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45 - 17:00</td>
<td>Salvage chemotherapy and planning for transplant</td>
</tr>
<tr>
<td></td>
<td>Graham Collins (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Claire Roddie (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Órla Stewart (United Kingdom)</td>
</tr>
<tr>
<td>17:00 - 17:15</td>
<td>Choosing CAR T with curative intent</td>
</tr>
<tr>
<td></td>
<td>Graham Collins (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Claire Roddie (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Surabhi Chaturvedi (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Órla Stewart (United Kingdom)</td>
</tr>
<tr>
<td>17:15 - 17:30</td>
<td>Linking referral and delivery for optimal care</td>
</tr>
<tr>
<td></td>
<td>Graham Collins (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Claire Roddie (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Órla Stewart (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Surabhi Chaturvedi (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Jackie Chappell (United Kingdom)</td>
</tr>
<tr>
<td>17:30 - 17:45</td>
<td>Navigating the first 28 days post-infusion together</td>
</tr>
<tr>
<td></td>
<td>Claire Roddie (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Órla Stewart (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Surabhi Chaturvedi (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Jackie Chappell (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Antony Wilson (United Kingdom)</td>
</tr>
<tr>
<td>17:45 - 18:00</td>
<td>Life beyond CAR T: the road ahead</td>
</tr>
<tr>
<td></td>
<td>Graham Collins (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Claire Roddie (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Stephen Scowcroft (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Surabhi Chaturvedi (United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>Órla Stewart (United Kingdom)</td>
</tr>
</tbody>
</table>

Meet the Expert

18:00 - 19:00

**MTE8, Meet the Expert Session 8 - Room MTE1**

**HSCT in high-risk MDS**

David Valcárcel Ferreiras (Spain)

Meet the Expert

18:00 - 19:00

**MTE9, Meet the Expert Session 9 - Room MTE2**

**Prophylaxis of acute graft versus host disease: ATG or not ATG?**

Francesca Bonifazi (Italy)

Meet the Expert

18:00 - 19:00

**MTE10, Meet the Expert Session 10 - Room MTE3**

Meet the Expert

18:00 - 19:00
Scientific Programme

Clinical hurdles for academic development of clinical Advanced Therapies: The perspective from the GMP Lab
Fermín Sánchez-Guijo (Spain)

Meet the Expert
18:00 - 19:00
Meet the Expert Rooms

MTE11, Meet the Expert Session 11 - Room MTE4

The fast changing paradigm of myeloma treatment: What's best in 2020?
Sergio Giralt (United States)

Meet the Expert
18:00 - 19:00
Meet the Expert Rooms

MTE12, Meet the Expert Session 12 - Room MTE5

How I manage double hit lymphomas
Andrew Davies (United Kingdom)

Meet the Expert
18:00 - 19:00
Meet the Expert Rooms

MTE13, Meet the Expert Session 13 - Room MTE6

The role of HSCT in mantle cell lymphoma in 2020
Olivier Hermine (France)

Meet the Expert
18:00 - 19:00
Meet the Expert Rooms

MTE14, Meet the Expert Session 14 - Room MTE7

Maintenance strategies after allogeneic HSCT in patients with AML
Ali Bazarbachi (Lebanon)
Monday, 31 August 2020

**E5, Emerging and personalized approaches in MDS and MF**

**Chairs:**
Juan Carlos Hernández-Boluda (Spain)
Christoph Scheid (Germany)

- **Allogeneic transplantation in myelofibrosis**
  09:30 - 09:42
  Nicolaus Kröger (Germany)

- **Microtransplantation**
  09:42 - 09:54
  Micha Srour (France)

- **Emerging and personalized cellular therapy approaches for myeloid diseases**
  09:54 - 10:06
  Marco Davila (United States)

- **Risk assessment of patients with CMML**
  10:06 - 10:18
  Francesco Onida (Italy)

- **Q&A**
  10:18 - 10:30

**How do I ... ?**

- **After antibody and ImIDS based induction in MM patients**
  09:30 - 09:45
  Francesca Gay (Italy)

- **If tandem transplant is planned in myeloma**
  09:45 - 10:00
  Patrick Wuchter (Germany)

- **By optimizing apheresis centre time**
  10:00 - 10:15
  José Luis Bueno (Spain)

- **Q&A**
  10:15 - 10:30
Scientific Programme

Nurses Group
09:30 - 10:30 Auditorium 3

NG04, Nurses Programme Opening Session

Chairs:
John Murray (United Kingdom)
Julia Ruiz Pato (Spain)

Welcome and overview 09:30 - 09:40
John Murray (United Kingdom)

Presentation of the 12th Distinguished Merit Award 09:40 - 09:50
John Murray (United Kingdom)

Nursing and lockdown 09:50 - 10:20
Julia Ruiz Pato (Spain)
Isabel Salcedo (Spain)

Q&A 10:20 - 10:30

Cell therapy
09:30 - 10:30 Auditorium 4

CTD1, Cell Therapy Day: Biotechnological developments

Chairs:
Annalisa Ruggeri (France)

Evolving technologies for gene modification / gene editing of haematopoietic stem cells and immune effector cells 09:30 - 09:50
Chiara Bonini (Italy)

Where are we with mesenchymal stem cells in 2020? 09:50 - 10:16
Francesco Dazzi (United Kingdom)

Q&A 10:16 - 10:30

Transplant Coordinator Day
09:30 - 10:30 Auditorium 5

TCD1, EBMT-WMDA Transplant Coordinators Day: Lessons learnt from COVID-19 - Continuity of care: How to ensure provision of stem cells

Chairs:
Annette Rasche (Germany)

The European start of the pandemic - Italian experience 09:30 - 09:45
Nicoletta Sacchi (Italy)

Donor care - Medical aspects in COVID-19 pandemic 09:45 - 10:00
Rachel Pawson (United Kingdom)

Patient Care - Alternative grafts 10:00 - 10:15
Irina Evseeva (United Kingdom)
Scientific Programme

Text chat Q&A 10:15 - 10:30

Special Session 09:30 - 10:30 Auditorium 6

SS3, Multi-stakeholder Forum on Innovative Cellular Therapies

Chairs:
Christian Chabannon (France)
Harry Dolstra (Netherlands)

EMA's Regulatory Science to 2025 in the area HSCT and gene/cellular therapies
Jordi Llinares (Netherlands) 09:30 - 09:42

The regulatory framework for innovative cellular therapies
Sol Ruiz (Spain) 09:42 - 09:54

How are cellular therapies translated from academia to industrial partners. Pitfalls and opportunities
Jürgen Kuball (Netherlands) 09:54 - 10:06

Where's the access bottleneck for CART cells: centres, industry, authorities?
Joaquín Martínez-López (Spain) 10:06 - 10:18

Q&A 10:18 - 10:30

Industrial Theatre 09:30 - 19:00 Industry Theatre

IT1, TLS in the context of new treatments in hematology - Sanofi Genzyme Industry Theatre Session

Industrial Theatre 09:30 - 19:00 Industry Theatre

IT3, Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite Industry Theatre Session

Industrial Theatre 09:30 - 19:00 Industry Theatre

IT2, Clinical Data on Treosulfan-based Conditioning Treatment (Trecondi®) in Paediatric Patients - Medac Industry Theatre Session

Page 162 / 353
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),
29 August to 1 September 2020

Scientific Programme

Industrial Theatre
09:30 - 19:00

IT4, KYMRIAH in the Real World - Novartis Industry Theatre Session

Industrial Theatre
09:30 - 19:00

IT5, How I manage CMV in HSCT patients - MSD Industry Theatre Session

Industrial Theatre
09:30 - 19:00

IT6, Gene therapy: From clinical trials to clinical practice - Bluebirdbio Industry Theatre Session

Chairs:
Franco Locatelli (Italy)

Acute leukaemia

ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH HIV-INFECTION: AN UPDATED PAIR-MATCHED COHORT STUDY BY THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION

COMPARABLE OUTCOMES OF AML PATIENTS RECEIVING HAPLO-HCT WITH THIOTEPA/BUSULFAN/FLUDARABINE CONDITIONING AND POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS A MATCHED UNRELATED DONOR WITH FLUDARABINE/BUSULFAN CONDITIONING, REGARDLESS OF DISEASE STATUS

TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOEITIC CELL TRANSPLANT: IMPROVED SURVIVAL FOR YOUNG PATIENTS IN RECENT YEARS

ANTI-CD3/CD33 BISPECIFIC ANTIBODIES EFFICIENTLY REDIRECT DONOR T CELLS AGAINST HLA LOSS LEUKEMIA RELAPSES

POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) EMERGES AS A KEY DRIVER OF HLA CLASS II NEGATIVE POST-TRANSPLANTATION RELAPSE

ALLOGENEIC HCT FOR ADULTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA HARBORING <i>IKZF1</i> GENE MUTATIONS: A STUDY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT IN CHILDREN AND ADULTS WITH RELAPSED/REFRACTORY B-ALL: FOCUS ON ANTI-CD19, ANTI-CD22 MONOCLONAL ANTIBODIES

THE VALUE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH AND WITHOUT <i>ASXL</i>1-, <i>RUNX</i>1- AND <i>TP53</i>-53 MUTATIONS

Page 163 / 353
ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT

RIC COMBINED WITH ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE PROVIDES HIGHER GVHD-FREE/RELAPSE FREE SURVIVAL IN FIT YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA

LOW-DOSE MEMORY DONOR LYMPHOCYTE INFUSION AFTER αβ T CELL-DEPLETED HSCT AMONG CHILDREN WITH HIGH-RISK LEUKEMIA: RESULTS OF A PROSPECTIVE RANDOMIZED SINGLE-CENTER TRIAL

DEVELOPMENT OF A CORD BLOOD STEM CELL-DERIVED DENDRITIC CELL VACCINE TO PREVENT RELAPSE AFTER CORD BLOOD TRANSPLANTATION IN AML

THE BRAZILIAN EXPERIENCE WITH HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTS (HAPLO-HCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

BETTER LEUKEMIA-FREE SURVIVAL WITH ALLOGENEIC THAN WITH AUTOLOGOUS HCT IN AML PATIENTS WITH ISOLATED TRISOMY 8: A STUDY FROM THE ALWP OF THE EBMT

ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML PATIENTS WITH RUNX1 MUTATION IN FIRST COMPLETE REMISSION: A STUDY ON BEHALF OF THE ALWP OF THE EBMT

Johanna Waidhauser, Myriam Labopin, Jordi Esteve, Nicolaus Kröger, Jan Cornelissen, Tobias Gedde-Dahl, Gwendolyne Van Gorkom, Jürgen Finke, Montserrat Rovira, Nicolaas Schapa, Eefke Petersen, Dietrich Bieelen, Donald Bunjes, Christoph Schmid, Arnon Nagler, Mohamad Mohty (Germany)

GRAFT FAILURE AFTER UNMANIPULATED HAPLO-HSCT WITH PT-CY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION, ON BEHALF OF THE ALWP-EBMT

Annalisa Ruggeri, Myriam Labopin, Emanuele Angelucci, Didier Blaise, Fabio Ciceri, Yener Koc, Jose Luiz Diez-Martin, Luca Castagna, Benedetto Bruno, Zafer Gülbas, Andrea Bacigalupo, Arnon Nagler, Mohamad Mohty (Italy)

IMPLICATIONS OF NOVEL RISKS SCORES (AML-DRG AND AML-HCT-CR) IN ALLOGENEIC CD34+ SELECTED GRAFT TRANSPLANT OUTCOMES


DOWNREGULATION OF HLA-DR IN BLASTS OF PATIENTS WITH ACUTE LEUKAEMIA RELAPSING AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION

ESTABLISHMENT OF A NATIONAL STEM CELL TRANSPLANT CLINICAL TRIALS NETWORK: THE UK IMPACT PARTNERSHIP FOR ACCELERATED CELLULAR THERAPIES

David I Marks, Shamyla Siddique, Ronjon Chakraverty, Aimee Jackson, Victoria Potter, Ram Malladi, Andy Peniket, Paresh Vyas, Pamela Kearns, Charles Craddock (United Kingdom)

DIFFERENTIAL IMPACT OF NPM1 MUTATION ON THE POST-TRANSPLANT OUTCOME OF ADULT FLT3ITD MUTATED AML RECEIVING ALLOGENEIC TRANSPLANT IN CR1 AND AFTER CR1

Su-Peng Yeh, Ming Yao, Bor-Sheng Ko, Jyh-Pyng Gau, Tzeon-Jye Chiou, Tran-Der Tan, Po-Nan Wang, Yeu-Chin Chen, Chieh-Lin Teng, Ciyuan-Jheng Wang, Tsai-Yun Chen, Ta-Chih Liu, Ming-Sun Yu, Wei-Han Huang (Taiwan, Republic of China)
A REGION-WIDE RETROSPECTIVE ANALYSIS OF OUTCOME FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA
Shuichi Ota, Akio Shigematsu, Ryoji Kobayashi, Takeshi Kondo, Tomoyuki Endo, Yutaka Tsutsumi, Hajime Kobayashi, Yasutaka Kakinoki, Satoshi Yamamoto, Yuichi Konuma, Takuto Miyagishima, Tetsuya Igashira, Takanori Oda, Hajime Sakai, Toshimichi Ishihara, Masahiro Yoshida, Takahiro Nagashima, Kazuya Sato, Yuji Kanisawa, Yoshihito Haseyama, Yasuo Hirayama, Mitsutoshi Kurosawa (Japan)

PRE-HARVEST HIGHER DONOR FOXP3 MRNA AND LOWER CD4+ T CELL CONCENTRATION PREDICT INCREASED RISK OF ALL RELAPSE AFTER MYELOABLATIVE HCT WITH T-REPLETE BONE MARROW GRAFTS
Niels Jacobsen, Tina Frisch, Niels Keiding, Carsten Heilman, Henrik Sengeløv, Hans Madsen, Hanne Marquart, Mette Andersen, Claus Christiansen, Lars Ryder (Denmark)

EPIDEMIOLOGY, MANAGEMENT AND ECONOMIC IMPACT OF ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME IN SPAIN: A CLAIMS DATABASE ANALYSIS

PRE-TRANSPLANT BONE MARROW CELLULARITY AND BLOOD COUNT RECOVERY ARE NOT ASSOCIATED WITH RELAPSE OR SURVIVAL RISK FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT FOR AML IN CR1
Igor Novitzky Basso, Shiyi Chen, Jeffrey Lipton, Dennis Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun Law, Zeyad Al-Shaibani, Armin Gerbitz, Ivan Pasic, Jonas Mattsson, Fotios Michelis (Canada)

IMMUNOTHERAPY SALVAGE FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS BY THE ALWP OF THE EBMT

COMPARISON OF PRE-TRANSPLANT COMORBIDITY INDICES IN ACUTE LEUKAEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Zeynep Arzu Yeğin, Asena Dikyar, Lale Aydın Kaynar, Zübeysde Nur Özçkurt, Münci Yağcı (Turkey)

SALVAGE USE OF VENETOCLAX-BASED THERAPY FOR RELAPSED AML POST ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT

FACTORS PREDICTING THE OUTCOME OF ALLOGENIC STEM CELL TRANSPLANTATION IN PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Olga Pirogova, Ksenia Afanaseva, Elena Morozova, Sergey Bondarenko, Inna Markova, Ivan Moiseev, Boris Afanasev (Russian Federation)

ROLE OF CHIMERISM AND FLOW-CYTOMETRIC MONITORING OF MEASURABLE RESIDUAL DISEASE (MRD) AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN PREDICTING RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)
Guldane Cengiz Seval, Eliz Bahar Ulas, Selami Kocak Toprak, Sinem Civriz Bozdag, Meltem Kurt Yuksel, Pervin Topcuoglu, Kla Ra Da, Onder Arslan, Muhi Ozcan, Taner Demirel, Osman Ilhan, Hamdi Akan, Meral Beksaç, Gunhan Gurman (Turkey)

SORAFENIB PROLONGED MAINTENANCE IN FLT3-MUTATED AML POST TRANSPLANTATION
Carmine Liberatore, Matteo Giovannia Carrabba, Federica Ardizzoia, Andrea Assaneli, Carlo Messina, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Fabio Ciceri, Maria Teresa Lupo Stanghellini (Italy)

PULMONARY COMPLICATIONS (PC) AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN CHILDREN WITH HIGH-RISK ACUTE LEUKEMIA (AL)

MORE THAN TWO CYCLES OF CONSOLIDATION THERAPY PRE-TRANSPLANTATION BENEFITS AML PATIENTS IN CR1 WHO UNDERWENT HLA-MATCHED SIBLING ALLOGRAFTS: A MULTICENTER STUDY
WHAT CAN CNV ANALYSIS ADD TO THE ROUTINE GENETIC DESCRIPTION OF AML CASES?
Emilia Jaskula, Mariola Sedzimirksa, Monika Mordak-Domaqala, Janusz Lange, Krzysztof Suchnicki, Anna Sobczynska-Konefal, Marta Lemieszewska, Helena Pakos, Agnieszka Tarnowska, Andrzej Lange (Poland)

COMPARISON OF THE PROGNOSTIC ABILITY OF THE HCT-CI THE MODIFIED EBMT AND THE EBMT-ADT PRE-TRANSPLANT RISK SCORES FOR ACUTE LEUKEMIA
Eshrak Al-Shaibani, Sunu Cyriac, Shiyi Chen, Jeffrey H. Lipton, Dennis D. Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun Law, Zeyad Al-Shaibani, Armin Gerbitz, Ivan Pasic, Jonas Mattsson, Fotios V. Michelis (Canada)

GO-FLAG REGIMEN AS A BRIDGE THERAPY TO ALLOGENEIC STEM CELL TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS

THE IMPACT OF ALLOGENEIC TRANSPLANTATION IN AML AND MDS WITH CHROMOSOME 3 ABNORMALITIES
Maria Rhida Bautista, Shiyi Chen, Wilson Lam, Fotios Michelis, Dennis Kim, Jeffrey Lipton, Auro Viswabandya, Rajat Kumar, Ivan Pasic, Armin Gerbitz, Jonas Mattson, Zeyad Al-Shaibani, Arjun Law (Canada)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS CHEMOTHERAPY-ALONE IN THE TREATMENT OF PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS WITH MIXED LINEAGE LEUKEMIA (MLL) REARRANGEMENTS: SINGLE CENTER EXPERIENCE

POSTTRANSPLANTATION BENDAMUSTINE FOR GVHD PROPHYLAXIS IN REFRACTORY ACUTE LEUKEMIA PATIENTS
Ivan Moiseev, Sergey Bondarenko, Elena Darskaya, Alexandr Alyanskiy, Anastasiya Beynarovich, Evgeniya Borzenkova, Anna Dotcenko, Olga Kudyasheva, Varvara Ovechkina, Olga Pirogova, Valentina Porunova, Tatyana Rudakova, Olesya Smikova, Boris Afanasyev (Russian Federation)

IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE

FLAT REGIMEN AS MYELOABLATIVE CONDITIONING WITH LIMITED TOXICITIES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS IN 30 PATIENTS

TYROSINE KINASE INHIBITOR TREATMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBластIC LEUKEMIA
Yu-Hsiang Chang, Xiu-Wen Liao, Jia-Hau Liu, Ming Yao, Bor-Sheng Ko, Chi-Cheng Li, Cheng-Hong Tsai, Shang-Ju Wu, Hui-Hsuan Huang, Tai-Chung Huang, Hsia-An Hou, Wen-Chen Chou, Feng-Ming Tien, Yun-Chu Lin, Meng-Yao Lu, Kai-Hsin Lin, Jih-Luh Tang (Taiwan, Republic of China)

OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR CYTOGENETIC INTERMEDIATE-RISK AML ACCORDING TO THE MOLECULAR RISK BASED ON ELN 2017 RISK STRATIFICATION SYSTEM; SINGLE CENTER EXPERIENCE IN KOREA
Haerim Chung, Ji Eun Jang, SooJeong Kim, Jin Seok Kim, Yoo Hong Min, June-Won Cheong (Korea, Republic of)

THE PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY WT1 GENE EXPRESSION IN PERIPHERAL BLOOD BEFORE AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN AML PATIENTS
IMPACT OF POSTTRANSPLANT TYROSINE KINASE INHIBITORS ADMINISTRATION ON LONG TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
Ksenia Afanaseva, Elena Morozova, Olga Pirogova, Yulia Vlasova, Anna Smirnova, Sergey Bondarenko, Ivan Moiseev, Boris Afanasyev (Russian Federation)

THE INFLUENCE OF ANTI-THYMOCYTE GLOBULIN (ATG) ON THE OUTCOMES OF PATIENTS WITH AML W/WO MEASURABLE RESIDUAL DISEASE (MRD) AT THE TIME OF UNRELATED DONOR TRANSPLANTATION
Guldane Cengiz Seval, Ekin Kircali, Mehmet Akif Baltaci, Sinem Civriz Bozdag, Meltem Kurt Yuksel, Pervin Topcuoglu, Klara Dalva, Onder Arslan, Muhit Ozcan, Taner Demirer, Gunhan Gurman, Osman Ilhan, Hamdi Akan, Meral Beksac, Selami Kocak Toprak (Turkey)

MLL-AF6 FUSION GENE POSITIVE AML TREATED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION HAS EXCELLENT OVERALL SURVIVAL
Wei Ma, Xingyu Cao, Wei Zhang, Min Xiong, Jianping Zhang, Yue Lu, Ruijuan Sun, Zhijie Wei, Deyan Liu, Yanli Zhao, Jiarui Zhou (China)

BENEFICIAL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

INDUCTION OF SYNERGISTIC APOPTOSIS AND OVERCOMING OF DRUG RESISTANCE BY COTARGETING OF BCL-2 AND NA/H EXCHANGER 1 PATHWAY IN ACUTE MYELOID LEUKEMIA CELLS
Shin Young Hyun, Eun Jung Na, Ji Eun Jang, Haerim Chung, Soo Jeong Kim, Jin Seok Kim, Yoo Hong Min, June-Won Cheong (Korea, Republic of)

GEMTUZUMAB-OZOGAMICIN FOR BRIDGING TO TRANSPLANT IN REFRACTORY/RELAPSED CD33 POSITIVE ACUTE LEUKEMIA - IS IT WORTHWHILE?
Michael Stadler, Vanessa Oberstaedt, Elke Dammann, Lothar Hambach, Eva M. Weissinger, Catherina Lueck, Gernot Beutel, Matthias Eder, Arnold Ganser (Germany)

THE EFFECTS OF CYTOMEGALOVIRUS INFECTION ON TRANSPLANT OUTCOMES IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

AZACYTIDINE AND DONOR LYMPHOCYTES INFUSIONS IN RELAPSED AML AFTER ALLOGENEIC HSCT: RESULTS IN 40 PATIENTS
Carmine Liberatore, Francesca Lorentino, Matteo Giovanni Carrabba, Carlo Messina, Luca Vago, Sara Mastaglio, Raffaella Greco, Francesca Pavesi, Sarah Marktel, Francesca Farina, Raffaella Milani, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Maria Teresa Lupo Stanghellini, Fabio Ciceri (Italy)

THE RESULTS OF AML RELAPSE AFTER ALLOGENEIC TRANSPLANTATION TREATMENT, SINGLE CENTRE APPROACH EVALUATION

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A SINGLE CENTER ANALYSIS

THE OPTIMAL TIME FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
Sergey Bondarenko, Ivan Moiseev, Elena Morozova, Olga Pirogova, Elena Darskaya, Anna Smirnova, Nikolai Tsvetkov, Anastasiya Beynarovich, Irina Samorodova, Tatyana Gindina, Elena Babenko, Ildar Barkhatov, Alexander Alyanskij, Alexander Kulagin, Boris Afanasyev (Russian Federation)

IMPACT OF ABO MISMATCH ALLOGENEIC TRANSPLANT IN ACUTE MYELOID LEUKEMIA: A SINGLE CENTRE EXPERIENCE
Fahad Shaikh, Ganapathi Bhat, Suresh Advani, Samir Shah, Reetu Jain (India)
Scientific Programme

DONOR SOURCE IMPACTS ON LONG TERM SURVIVAL FOLLOWING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN AML PATIENTS AGED 60 AND ABOVE
William Hayhurst, Asterios Giotas, Chloe Anthias, Sandra Easdale, David Taussig, Mike Potter, Mark Ethell, Joy Brennan, Maria Mulligan, Kim Davis, Emma Thistlethwayte, Emma Nicholson (United Kingdom)

EXTRA-MEDULLARY RECURRENCE OF ACUTE MYELOID LEUKEMIA AS MYELOID SARCOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE SERIES
Zeynep Tugba Guven, Serhat Çelik, Leylagul Kaynar, Bulent Eser, Mustafa Cetin, Ali Unal (Turkey)

SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA: SINGLE CENTER EXPERIENCE
ALLOGENEIC STEM CELL TRANSPLANTS IN ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE EXPERIENCE
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA NOT RESPONDING TO FIRST INDUCTION THERAPY

Aplastic anaemia

LNP023 - A NEW ORAL COMPLEMENT FACTOR-B INHIBITOR NORMALIZES HEMOGLOBIN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH POOR RESPONSE TO ECULIZUMAB, BOTH AS ADD-ON AND MONOTHERAPY

EPIGENETIC AGING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH POOR SURVIVAL IN PATIENTS WITH SEVERE APLASTIC ANEMIA: RESULTS FROM DNA-METHYLATION GRIMAGE

GVHD AND RELAPSE FREE SURVIVAL (GRFS) AFTER ALLOGENEIC TRANSPLANTATION FOR IDIOPATHIC SEVERE APLASTIC ANEMIA: AN ANALYSIS FROM THE SAAWP DATA QUALITY INITIATIVE PROGRAM OF EBMT

OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANAEMIA: A STUDY ON BEHALF OF THE EBMT SAAWP AND PDWP

REDUCED INTENSITY CONDITIONING IS EFFECTIVE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND-BLACKFAN ANEMIA

PROSPECTIVE STUDY OF ECULIZUMAB BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMOLYTIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA / APLASTIC ANEMIA

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT FOR FANCONI ANEMIA IN INDIA

ALTERNATE DONOR HSCT FOR 109 CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA: A SINGLE CENTER RETROSPECTIVE ANALYSIS

SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS WITH REFRACTORY ACTIVE INFECTION: A PROSPECTIVE MULTICENTER CLINICAL STUDY IN CHINA

INCIDENCE AND MANAGEMENT OF APLASTIC ANEMIA IN SPAIN (IMAS). AN AMBISPECTIVE STUDY OF BIODONOSTIA / PETHEMA
Carlos Vallejo, Ana Rosell, Blanca Xicoy, Carmen García, Carmen Albo, Marta Polo, Isidro Jarque (Spain)
ALLOGENEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS FOR CHILDREN WITH APLASTIC ANEMIA


OUTCOME OF PEDIATRIC ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE

OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT FOR SEVERE APLASTIC ANEMIA IN PAKISTAN: DATA FROM A DEVELOPING COUNTRY

IMPACT OF CD34+-STEM CELL BOOST ON OUTCOME AND HEMATOLOGICAL RECONSTITUTION IN PATIENTS WITH SEVERE APLASTIC ANEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY

Rashit Bogdanov, Mareike Gocht, Amin Turki, Markus Ditschkowski, Dietrich W. Beelen (Germany)

HEMATOPOIETIC STEM CELL TRANSPLANT IN ADULTS WITH ACQUIRED SEVERE APLASTIC ANEMIA

Gilbert Wilfred, Sen Mui Tan, Tee-Chuan Ong, Sh. Shahnaz Syed Abd Kadir, Kim Wah Ho, Boon Liaw Kian, Jameela Sathar (Malaysia)

HEMATOPOIETIC STEM CELL TRANSPLANT IN FANCONI ANEMIA USING MATCHED RELATED AND HAPLOIDENTICAL DONORS- A SINGLE CENTRE EXPERIENCE

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC SEVERE APLASTIC ANEMIA: RESULTS OF A SINGLE CENTER

EFFECT OF SINGLE UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION ON APLASTIC ANEMIA IN CHILDREN

IMMUNOSUPPRESSIVE THERAPY IN PEDIATRIC APLASTIC ANEMIA, SINGLE CENTRE EXPERIENCE

CYCLOSPORINE, DANAZOL AND ROMIPLOSTIM IN SEVERE APLASTIC ANEMIA IN PRETRANSPLANT PERIOD: RETROSPECTIVE ANALYSIS OF FIVE CASES

Nilesh Wasekar, Girish Badarkhe, Sudarshan Pandit, Raj Nagarkar (India)

Autoimmune diseases

AUTOLOGOUS NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR STIFF PERSON SYNDROME

BEAM VS CYCLOPHOSPHAMIDE-BASED CONDITIONING REGIMEN IN AGGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE ANALYSIS OF EUROPEAN BLOOD AND MARROW TRANSPLANTATION SOCIETY

A NOVEL TARGETED APPROACH TO ACHIEVE IMMUNE SYSTEM RESET: CD45-TARGETED ANTIBODY DRUG CONJUGATES AMELIORATE DISEASE IN PRECLINICAL AUTOIMMUNE DISEASE MODELS AND ENABLE AUTOHSCT

LONG TERM FOLLOW UP OF SYSTEMIC SCLEROSIS FRENCH PATIENTS INCLUDED IN THE ASTIS TRIAL USING SCOT TRIAL GLOBAL RANK COMPOSITE SCORE (GRCS)
ADVENTES IN MULTIPLE SCLEROSIS (MS) TREATMENT: CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION

POST TRANSPLANTATION CYCLOPHOSPHAMIDE IMPROVES OUTCOME AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ANIMAL MODEL OF MULTIPLE SCLEROSIS

THE LONG-TERM SAFETY AND EFFICACY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS INDIRECTLY COMPARED TO ALEMTUZUMAB: A SYSTEMATIC REVIEW

Owain Greaves, Amit Patel (United Kingdom)

RECONSTITUTION OF NATURAL OR VACCINATION-DRIVEN IMMUNITY AFTER AHSCT IN MULTIPLE SCLEROSIS

HIGH-DOSE IMMUNODEPLETION WITH AUTOLOGOUS STEM CELL RESCUE FOR TREATMENT OF AGGRESSIVE MULTIPLE SCLEROSIS

HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT CHANGE THE EXPRESSION OF ENDOTHELIAL MARKERS IN SKIN BIOPSIES OF SYSTEMIC SCLEROSIS PATIENTS

Maynara Santana, Djulio Zanin, Deisy Silva, Marianna Vasconcelos, Daniela Moraes, Juliana Dias, Vanessa Leopoldo, Marilíia Oliveria, Álvaro Henrique-Neto, Kelen Farias, Leandra Ramalho, Maria Carolina Oliveira (Brazil)

AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NON HEMATOLOGICAL DISEASES. THE DUTCH EXPERIENCE OF MS PATIENTS GOING ABROAD

Ellen P.A. Kramer, Bram Platel, Frederike J.A.E Ambagtsheer, Gerald J.D. Hengstman, Otto Visser (Netherlands)

ANALYSIS OF COST AND CHARGES FOR NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES

Richard Burt, Kathleen Quigley, Indira Arnautovic, Xiaoqiang Han (United States)

AUTOLOGOUS STEM CELL TRANSPLANTATION IN BEHÇET’S DISEASE: A RETROSPECTIVE STUDY

Mathieu Puyade, Amit Patel, Yeong Ler Lim, Norbert Blank, Manuela Badoglio, Francesca Gualandi, David Ma, Natalia Maximova, Tobias Alexander, John Snowden (France)

SAFETY AND TOLERABILITY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE SCLEROSIS: A SINGLE CENTER EXPERIENCE

Pawan Kumar Singh, Isha Gambhir, Ragesh Radhakrishnan Nair, Rohan Halder, Zahier Ahmad Shekib, Manish Mahajan, Sumit Singh (India)

OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR REFRACTORY TAKAYASU ARTERITIS, A RETROSPECTIVE SURVEY FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EBMT

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS IN NORWAY

Maiken Schultz, Øyvind Midvedt, Øyvind Molberg, Tobias Gedde-Dahl, Ragnar Gunnarsson, Yngvar Fløisand (Norway)

THE USE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS AFTER ALEMTUZUMAB TREATMENT FAILURE: A CASE SERIES
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF SYSTEMIC SCLEROSIS, AN OPTION FOR REFRACTORY PATIENTS
Claudia Sossa, Javier Figueroa, Juan Manuel Herrera, Angela M Peña, Luis A Salazar, Manuel Rosales, Enrique Pedraza, Elena Mora, Xueyi Chen, Maria Luna-Gonzalez, Jose Patricio Lopez-Lopez (Colombia)

A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE
Richard Burt, Kathleen Quigley, Indira Arnautovic, Xiaoqiang Han (United States)

e-Posters
09:30 - 19:00
ePoster Area

CAR-based Cellular Therapy - clinical

KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): RESULTS FROM PHASE 2 OF ZUMA-2

SAFETY AND EFFICACY RESULTS FROM TRANSCEND NHL 001, A MULTICENTER PHASE 1 STUDY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

CD19/CD22 DUAL TARGETED (CHIMERIC ANTIGEN RECEPTOR) CAR-T THERAPY FOR RELAPSED OR REFRACORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)

AN UPDATE OF THE EBMT SURVEY ON CAR T-CELL ACTIVITY IN EUROPE. ON BEHALF OF THE CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY (CTIWP)

THIRD-GENERATION CAR T CELLS WITHIN THE HEIDELBERG CAR TRIAL 1 (HD-CAR-1) DISPLAY AN EXCELLENT SAFETY PROFILE AND MIGHT IMPROVE PERSISTENCE OF CAR T CELLS

OUTPATIENT TREATMENT WITH LISOCABTAGENE MARALEUCEL IN 3 CLINICAL STUDIES OF RELAPSED/REFRACTORY LARGE B-CELL NHL, INCLUDING SECOND-LINE TRANSPLANT NONELIGIBLE PATIENTS: TRANSCEND NHL 001, OUTREACH, AND PILOT

CORRELATIVE ANALYSES OF PATIENT AND CLINICAL CHARACTERISTICS ASSOCIATED WITH EFFICACY IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE JULIET TRIAL

CAR T CELLS (CART) OR ALLOGENEIC TRANSPLANTATION (ALLOHCT) FOR MULTIPLY RELAPSED DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)? A RETROSPECTIVE INTENT-TO-TREAT (ITT) COMPARISON

HIGH ACTIVATION OF BCMA CAR-T CELLS CONTRIBUTES TO INCREASED RESPONSE RATE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

A COMPARISON OF 2-YEAR OUTCOMES IN ZUMA-1 (AXICABTAGENE CILOLEUCEL; AXI-CEL) AND SCHOLAR-1 IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL)

CD19-TARGETED CAR-T CELL THERAPY FOR 32 B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS WHO RELAPSED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)

INTERNATIONAL PROGNOSTIC INDEX PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED AND REFRACORY LARGE DIFFUSE B CELL LYMPHOMA TREATED WITH COMMERCIAL CAR T CELLS

THE PHASE 1B PORTIA STUDY: SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
**REAL-WORLD EVIDENCE OF THE USE OF TISAGENLECLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY AGRESSIVE B-CELL LYMPHOMAS. THE SPANISH EXPERIENCE**

**NATIONAL IMPLEMENTATION OF THE USE OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN NATIONAL HEALTH SERVICE ENGLAND (NHSE)**

Caroline Louise Furness, Rachael Hough, Michelle Cummins, Gillian Murphy, Persis Amrolia, Claire Riddie, Maeve O'Reilly, Robert Wynn, Denise Bonney, David Marks, Sridhar Chaganti, Geoff Shenton, Anna Castleton, Eleni Tholouli, Deborah Yallop, Peter Clark, John Snowden (United Kingdom)

**REAL-WORLD CLINICAL FEATURES OF NEUROTOXICITY COMPLICATING CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR HIGH GRADE LYMPHOMA AND MANAGEMENT INCLUDING THE OFF-LABEL USE OF ANAKINRA**

Shafqat Inam, Sean Apap Mangion, Victoria Potter, Reuben Benjamin, Andrea Kuhnl, Robert Hadden, Robin Sanderson (United Kingdom)

**CORRELATIVE MARKERS OF TOXICITY IN PATIENTS WITH DLBCL TREATED WITH CD19 CAR T CELL THERAPY**

Rawan Faramand, Michael Jain, Verena Staedtke, Hiroshi Kotani, Renyuan Bai, Saebom Lee, Kayla Reid, Kristen Spitter, Julio Chavez, Farhad Khimani, Aleksandr Lazaryan, Bijal Shah, Christina Bachmeier, Marian Dam, Brigit Brandjes, Ricardo Gonzalez, John Mullinax, Xuefeng Wang, Mohammad Hussaini, Frederick Lock, Marco Davila (United States)

**EARLIER STEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)**

Francis Ayuk, Anita Badbaran, Carolina Berger, Tanja Sonntag, Kritoffer Riecken, Maria Geffken, Dominic Wichmann, Nicolaus Kröger, Boris Fehse (Germany)

**SIMPLIFIED-EASIX (SEASIX) IS AN EARLY PREDICTOR OF SEVERE CYTOKINE RELEASE SYNDROME AND IMMUNE-EFFECTOR-CELLS-ASSOCIATED NEUROTOXICITY SYNDROME IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T CELLS**

Martina Pennisi, Miriam Sanchez-Escamilla, Jessica Flynn, Roni Shouval, Yakup Batlevi, Mari Lynn Silverberg, Connie Batlevi, Renier Brentjens, Parastoo B Dahi, Sean M Devlin, Claudia Diamonte, Sergio Giralt, Elizabeth Halton, Tania Jain, Molly Maloy, Elena Mead, Maria Lia Palomba, Bianca D Santomasso, Craig Sauter, Micheal Scordo, Gunjan Shah, Jae H Park, Lucrecia Yanez San Segundo, Miguel Angel Perales (United States)

**NIVOLUMAB AS SALVAGE THERAPY IN PATIENTS WHO FAILED TO ACHIEVE COMPLETE REMISSION AFTER ANTI-CD19 CAR T-CELL THERAPY FOR DLBCL**

Houli Zhao, Yongxian Hu, Wei Ding, Arnon Nagler, He Huang (China)

**SURVEILLANCE OF MINIMAL RESIDUAL DISEASE (MRD) IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) BY CIRCULATING TUMOR DNA (CTDNA) PROFILING AFTER CHIMERIC ANTIGEN RECEPTOR T (CAR-T)**

Boris Fehse, Anita Badbaran, Carolina Berger, Tanja Sonntag, Kristoffer Riecken, Maria Geffken, Nicolaus Kröger, Francis A. Ayuk (Germany)

**FEASIBILITY OF MANUFACTURING TISAGENLECLEUCEL IN PATIENTS LESS THAN 3 YEARS OF AGE WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA**
AXICABTAGENE CILOLEXUCEL CD19 CAR T-CELLS FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: REAL-WORLD OUTCOMES, TOXICITY AND PREDICTORS OF RESPONSE FROM A PROSPECTIVE UK COHORT
Robin Sanderson, Reuben Benjamin, Piers Patten, Victoria Potter, Deborah Yallup, Kirsty Cuthill, Orla Stewart, Tony Pagliuca, Pramila Krishnamurphy, Shafqat Inam, Mili Shah, Shu Wong, Catherine Hockings, Victoria Metaxa, Andrea Kuhnl (United Kingdom)

MARKERS OF INITIAL AND LONG-TERM RESPONSES TO IDECABTAGENE VICILEXUCEL (IDE-CEL; BB2121) IN THE CRB-401 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
Valentín Ortiz-Maldonado, Anna Alonso-Saladrigues, Miguel Caballero-Baños, Maria Castella, Anna Boronat, Enric García-Rey, Tycho Baumann, Marina Díaz-Beyá, Montserrat Torrebadell, Anna Faura, Albert Català, Federico Ramos, Alicia Palomino, Marta Gómez-Hernando, Carlos Jiménez-Vicente, Joan Cid, Miquel Lozano, Cristina Llanos, Adrián Téllez, Sara Fernández, Pedro Castro, Iolanda Jordán, Jordi Esteve, Josep Maria Canals, Esteve Trias, Jordi Yagüe, Maria Suárez-Lledó, Montserrat Rovira, Alvaro Urbano-Izpizua, Manel Juan, Susana Rives, Jordi Delgado (Spain)

HUMORAL IMMUNE RESPONSE IN PATIENTS WITH CD19-POSITIVE RELAPSED/REFRACTORY B-CELL MALIGNANCIES RECRUITED INTO THE CART19-BE-01 CLINICAL TRIAL, AN ACADEMIC CAR19
Nela Klein-González, E. Azucena González-Navarro, Ariadna Bartoló-Ibars, Valentín Ortiz-Maldonado, Montserrat Torrebadell, Maria Castellà, Daniel Benítez, Miguel Caballero-Baños, Raquel Cabezón, Marta Español-Regó, Tycho Baumann, Eva Giné, Pedro Castro, Jordi Esteve, Jordi Yagüe, Susana Rives, Álvaro Urbano-Ispizua, Julio Delgado, Manel Juan (Spain)

REAL-WORLD DATA FROM KINGS COLLEGE HOSPITAL: INFECTION COMPLICATIONS POST CAR-T TREATMENT IN HIGH-GRADE B CELL NON-HODGKIN LYMPHOMA
Shu Min Wong, Mili Shah, Shafqat Inam, Andrea Kuhnl, Robin Sanderson (United Kingdom)

SENESCENT/EXHAUSTED PHENOTYPE OF CD19-TARGETED CAR-T CELLS AND IMMUNOREGULATORY ENVIRONMENT CORRELATE WITH REDUCED RESPONSE TO CAR-T CELL THERAPY IN RELAPSED/REFRACTORY B CELL MALIGNANCIES

CHARACTERISATION OF EARLY AND LATE CYTOPENIAS IN LYMPHOMA PATIENTS FOLLOWING TREATMENT WITH ANTI-CD19 CAR-T THERAPY
Catherine Hockings, Andrea Kuhnl, Shu Wong, Mili Shah, Shafqat Inam, Piers Patten, Kirsty Cuthill, Tony Pagliuca, Deborah Yallop, Reuben Benjamin, Victoria Potter, Robin Sanderson (United Kingdom)

CD4+ CAR-T CELLS MAINTAIN MEMORY PHENOTYPES AND MEDIATE LONGER-TERM ANTITUMOR ACTIVITY IN VIVO

IMPACT OF ETHNICITY IN R/R DLBCL AND B-CELL ALL PATIENTS TREATED WITH TISAGENLECLEUCEL

IMPACT OF DIFFERENT CHEMOTHERAPY REGIMENS AND DURATION OF DLBCL ON LYMPHOPHERESIS AND CAR-T T-CELL IMMUNOPHENOTYPING

CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY IMPROVE PROGRESSION FREE SURVIVAL IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
CHALLENGES IN PROVIDING GOOD LEUKAPHERESIS PRODUCTS FOR THE PRODUCTION OF CAR T CELLS FOR PATIENTS WITH RELAPSED/REFRACTORY NHL OR ALL
Felix Korell, Sascha Laier, Sandra Sauer, Sonia Jaramillo-Segura, Elisabeth Lasitschka, Kaya Veelken, Hannah Hennemann, Marie-Luisa Schubert, Tim Sauer, Petra Pavel, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt (Germany)

NKG2D CAR T CELLS ARE NOT AFFECTED BY SOLUBLE NKG2D LIGANDS
Adrián Fernández, Lucía Fernández, Isabel Mirones, Adela Escudero, Leila Cardoso, Gloria Esteso, Raquel De Paz, Joaquín Martínez-López, Mar Valés, Antonio Pérez-Martínez (Spain)

EMERGING CYTOKINE RELEASE SYNDROME IS ASSOCIATED WITH REDUCTION OF CD4+CD25HIGH127DIM T REGULATORY CELLS IN PATIENTS AFTER CAR T CELL THERAPY
Christian R Schultze-Florey, Victoria Panagiota, Ivan Odak, Sultan Bektas, Tabea C Froehlich, Aleksandra Gladysz, Zhixiong Li, Gernot Beutel, Matthias Eder, Immo Prinz, Reinhold Foerster, Arnold Ganser, Christian Koenecke (Germany)

EXCELLENT PROLIFERATION AND PERSISTENCE OF ALLOGENEIC CAR-T CELLS DESPITE IMMUNOSUPPRESSION WITH CYCLOSPORINE A
Francis Ayuk, Boris Fehse, Dietlinde Janson, Carolina Berger, Kristoffer Riecken, Nicolaus Kröger (Germany)

A FRENCH BIOBANKING NETWORK TO CREATE A UNIQUE COLLECTION OF SAMPLES OF PATIENTS TREATED WITH CAR-T CELLS

CAR T CELL THERAPY DIRECTED AGAINST CD19 IN PATIENTS WITH B-CELL LYMPHOMA AFTER AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IS FEASIBLE AND SAFE

LYMPHOCYTE COLLECTION FOR GENERATION OF CAR T-CELLS IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE
Giovanna Del Principe, Giovanna Leone, Annalisa Ruggeri, Simone Biagini, Stefania Lazzaro, Antonella Meschini, Francesca Del Bufalo, Manuel Broglia, David Malaspina, Katia Feri, Federica Galaverna, Pietro Merli, Valentina Bertaina, Mattia Algeri, Mauro Montanari, Andrea Onetti Muda, Giuseppina Li Pira, Franco Locatelli (Italy)

BASELINE HYPOALBUMINEMIA DOES NOT APPEAR TO BE AN ADVERSE PROGNOSTIC FACTOR IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMAS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)

FACTORS PREDICTING CD3+ COLLECTION FOR THE PRODUCTION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS

CYTOPENIAS AFTER TISAGENLECLEUCEL IN PAEDIATRIC/YOUNG ADULT PATIENTS WITH REFRACTORY/RELAPSE B-CELL ACUTE LYMPHOBlastic LEUKAEMIA (R/R B-ALL): A REAL-LIFE SINGLE-CENTRE EXPERIENCE
Ignacio Gómez-Centurión, Saskia Burridge, Juliana Silva, Arina Lazareva, María Gabelli, Oana Mirci-Danicar, Giovanna Lucchini, Robert Chiesa, Kanchan Rao, Sujith Samarasinghe, Paul Veys, Ajay Vora, Persis Amrolia, Sara Ghorashian (Spain)

THE RISK OF HEPATITIS B REACTIVATION IS CONTROLLABLE IN B-CELL MALIGNANCIES PATIENTS WITH CONCOMITANT HEPATITIS B VIRUS INFECTION AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
Fang Ni, Yongxian Hu, Alex Hong Chang, He Huang (China)
Scientific Programme

CUMULATIVE RITUXIMAB EXPOSURE PRIOR TO AXICABTAGENE CILOLEUCEL IS NOT ASSOCIATED WITH PERSISTENT LEUKOPENIA AND THROMBOCYTOPENIA AT DAY +90 POST INFUSION
Madiha Iqbal, Sangeetha Gandhi, Abdullah Alselah, Muhamad Alhaj Moustafa, Ernesto Ayala, Hemant Murthy, Allison Rosenthal, Jilan Kubusek, Justin Haynes, Tuan Troung, Patrick Johnston, Stephen Ansell, Nora Bennani, Jonas Paludo, Jose Villasboas Bisneto, Breana Estby, Eva Brandes, Gina Lange, Januario Castro, Yi Lin, Mohamed Kharfan-Dabaja (United States)

COMPREHENSIVE IMMUNE CELL MONITORING REVEALS AN ALTERED LYMPHOCYTE SUBSET PHENOTYPE IN PATIENTS NOT RESPONDING TO TISAGENLECLEUCEL ONE MONTH POST INFUSION
Christian R Schultze-Florey, Victoria Panagiota, Ivan Odak, Sultan Bektas, Tabea C Froehlich, Aleksandra Gladysz, Zhixiong Li, Gernot Beutel, Matthias Eder, Immo Prinz, Reinhold Foerster, Arnold Ganser, Christian Koenecce (Germany)

NEUROTOXICITY ASSOCIATED WITH CAR T CELL THERAPY: NEUROLOGICAL MANAGEMENT AND WORK-UP OF 11 ADULT PATIENTS

NUTRITIONAL ASSESSMENT OF PATIENTS UNDERGOING CD19-TARGETED CAR-T THERAPY FOR NON-HODGKIN’S LYMPHOMA AND THE SHORT TERM EFFECT OF TREATMENT ON NUTRITIONAL STATUS

EFFECTIVENESS OF AUTOLOGOUS LEUKAPHERESIS COLLECTIONS FOR CAR T-CELL MANUFACTURING IN PATIENTS WITH B-CELL MALIGNANCIES

DEFINITION AND IMPLEMENTATION OF CLINICAL AND QUALITY ENDPOINTS IN CENTERS ADMINISTERING A COMMERCIAL CAR-T PRODUCT

CAR-T IN BREAST AND OTHER EXTRA-MEDULLARY RELAPSED/REFRACTORY ALL
Francesco Paolo Tambaro, Sajad Khazal, Dristhi Ragoonanan, Priti Tewari, Demetrios Petropolous, Jeffrey A Miller, William G Wierda, Richard E Champlin, Kris M Mahadeo (Italy)

PREDICTING CAR T-CELL INFUSION AFTER SUCCESSFUL MANUFACTURING: REAL-WORLD DATA
Georg-Nikolaus Franke, Eberhard Schleyer, Konstantin Weibl, Hansjakob Fries, Sophia Michel, Rosmarie Pointner, Dominic Brauer, Sandra Otto, Uwe Platzbecker, Vladan Vucinic (Germany)

EVALUATION OF THE INTEREST OF A DRUG RECONCILIATION ACTIVITY IN PATIENTS TREATED WITH CAR T-CELLS: A DESCRIPTIVE STUDY

CAR-based Cellular Therapy - preclinical

MODULATION OF CYTOSOLIC CA\textsuperscript{2+} REGULATES CAR-T CELL DIFFERENTIATION AND THERAPEUTIC POTENCY

BREAKING PD-L1-MEDIATED RESISTANCE IN ANTI-CD19 AND ANTI-CD22 CAR T CELLS WITH PD-1/CD28 FUSION RECEPTORS

ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR-INVARIANT NATURAL KILLER T CELLS EXERT BOTH DIRECT AND INDIRECT ANTITUMOR EFFECTS THROUGH HOST CD8 T CELL CROSS-PRIMING
Federico Simonetta, Toshihito Hirai, Juliane K. Lohmeyer, Kristina Maas-Bauer, Maite Alvarez, Arielle S. Wenokur, Jeanette Baker, Amin Aalipour, Samuel Haile, Crystal L. Mackall, Robert S. Negrin (United States)
DUVELISIB GENERATES CAR T CELLS WITH ENHANCED MITOCHONDRIAL BIOGENESIS AND REDUCED EXPRESSION OF PD-1, TIM-3, AND LAG-3, ENABLING GREATER ANTI-LEUKEMIA CYTOTOXICITY AGAINST CLL

NK2D CHIMERIC ANTIGEN RECEPTOR-EXPRESSING LYMPHOCYTES TARGET ACUTE MYELOID LEUKEMIA CELLS

CLINICAL-GRADe MANUFACTURING OF ROR1 CAR T-CELLS USING A NOVEL VIRUS-FREE PROTOCOL
Katrin Mestermann, Marie Eichler, Markus Machwirth, Kati Kebbel, Ulrike Köhl, Hermann Einsele, Claudia Müller, Jörg Lehmann, Tamás Raskó, Felix Lundberg, Zsuzsanna Izsák, Gerno Schmiedeknecht, Michael Hudecek (Germany)

LENTIVIRALLY AND ALPHARETROVIRALLY ENGINEERED CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS ARE HIGHLY CYTOTOXIC AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA

NOVEL STRATEGIES TO ENHANCE THE SAFETY OF CAR T-CELL IMMUNOTHERAPY: THE IMSAVAR PROJECT
Miriam Alb, Jonathan Moggs, Lars Wallstabe, Benedikte Hatz, Hermann Einsele, Peter Loskill, Andries van der Meer, Scott Wagers, Ulrike Köhl, Michael Hudecek (Germany)

ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD NK CELLS ARE GOOD SOURCES FOR EFFECTIVE CAR THERAPY AGAINST CD19 POSITIVE LEUKEMIC CELLS
Lara Herrera, Silvia Santos, Miguel Angel Vesga, Juan Anguita, Itziar Martin-Ruiz, Tomás Carrasco, Manel Juan, Cristina Eguizabal (Spain)

ENHANCEMENT OF CYTOTOXICITY, EXPANSION AND PERSISTENCE OF CD19 CAR-T CELLS VIA PRE-SENSITIZATION OF B CELL MALIGNANCIES BY BCL-2 SELECTIVE INHIBITORS

TYROSINE KINASE INHIBITOR FOLLOWED BY CART THERAPY FOR THE TREATMENT OF RELAPSED PHILADELPHIA CHROMOSOME-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Cellular Therapies other than CARs

Cellular Therapies other than CARs

CTLA4Ig PRIMED SEQUENTIAL DLI IMPROVES GVHD AND RELAPSE-FREE SURVIVAL COMPARED TO UNPRIMED DLI IN PATIENTS UNDERGOING PTCY-BASED HAPLOIDENTICAL HCT FOR ADVANCED HEMATOLOGICAL MALIGNANCIES

HLA-MISMATCHED MOBILIZED CELLULAR THERAPY (MICROTTRANSPLANT, MST) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES

DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH PTCY: A STUDY ON BEHALF OF THE CTIWP OF THE EBMT

SAFETY, EFFECTIVENESS AND PERSISTENCE OF LOW-DOSE DONOR MEMORY T CELL INFUSIONS AFTER AB T CELL-DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION

PROPHYLACTIC DONOR LYMPHOCYTE INFUSION AFTER T-CELL-REPLETE ALLOGENEIC HSCT PREVENTS DISEASE RELAPSE AND PROLONGS SURVIVAL IN PATIENTS WITH HIGH-RISK ACUTE LEUKEMIA

BASELINE IMMUNE STATUS PREDICTS RESPONSE TO ADOPTIVE THERAPY WITH CMV CTLS FOR REFRACTORY CMV
EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY ON BEHALF OF GETH (GRUPO ESPAÑOL TRASPLANTE HEMATOPOYÉTICO)

PHASE I STUDY OF ADOPTIVE TRANSFER OF HAPLOIDENTICAL EXPANDED NK CELLS

OFF-TARGET HLA CROSS-REACTIVITY BY (THIRD PARTY) VIRUS-SPECIFIC T CELLS IS SURPRISINGLY AFFECTED BY HLA RESTRICTION AND HLA BACKGROUND BUT NOT BY VIRUS SPECIFICITY

ADOPTIVE IMMUNOTHERAPY OF REFRACTORY VIRAL INFECTIONS AFTER ALLOGENEIC HSCT: AN ACADEMIC NETWORK FRAME THE USE OF AN ATMP UNDER HOSPITAL EXEMPTION

HOW TO BENEFIT FROM EXHAUSTION: PATIENT-DERIVED INHIBITED T CELLS AS A NOVEL SOURCE OF TUMOR-REACTIVE T CELL CLONES
Francesco Manfredi, Lorena Stasi, Danilo Abbati, Sara Mastaglio, Fabio Ciceri, Eliana Ruggiero, Chiara Bonini (Italy)

EFFICIENT CRISPR/CAS9-MEDIATED INACTIVATION OF THE GLUCOCORTICOID RECEPTOR FOR ANTIGEN-SPECIFIC T-CELL IMMUNOTHERAPY

COMPARISON OF OUTCOME POST-SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION VERSUS DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS
Eshrak Al-Shaibani, Jeffrey H. Lipton, Dennis D. Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun Law, Zeyad Al-Shaibani, Armin Gerblitz, Ivan Pasic, Jonas Mattsson, , Fotios V. Michelis (Canada)

AUTOMATED APPLICATION FOR DEPLETION OF TCRαβ+, CD19+ AND CD45RA+ CELLS FROM APHERESIS PRODUCTS USING THE CLINIMACS PRODIGY (R)
Julia Dzionek, Carina Thießen, Felix Hebbeker, Stephanie Soltenborn, Joanna Justyna Stenzel, Burgund Kauling, René Meißner, Nikolas Kaltz, Kirsten Langeveld, Michaela Mauchow, Mario Assenmacher, Andreas Bosio, Eleni Papanikolaou (Germany)

THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES

GOOD RESPONSE RATES OF WJ-MSC, COMPAREABLE TO BM-MSC, IN THE TREATMENT OF REFRACTORY GVHD
Sílvia Torrents, Laura Alonso, Joaquim Vives, Luciano Rodríguez, Georgina Morón-Cazalilla, Izaskun Elorza, María Luz Uría, María Isabel Benítez, Rocío Parody, Guillermo Ortí, María Trabazo, Jesús Fernandez-Sojo, Margarita Codinach, Laura Medina, Isabel Badell, Cristina Díaz de Heredia, Sergi Querol (Spain)

AN 'ALL IN ONE' T-CELL PRODUCT FROM NON-TRANSPLANTABLE CORD BLOOD UNITS FOR VIRUS- AND LEUKEMIA-SPECIFIC T-CELL IMMUNOTHERAPY

CLINICAL SUCCESS OF GRANULOCYTE TRANSFUSIONS IN ADULT NEUTROPENIC PATIENTS AFTER CHEMOTHERAPY AND/OR ALLOGENIC TRANSPLANTATION - TIME MATTERS!
Kira Inkari Thies, Michael Kramer, Friedrich Stölzel, Martin Bornhäuser, Johannes Schetelig, Simone von Bonin, Ralph Schneider, Kristina Hölig (Germany)

IMPACT OF LONG-TERM CRYOPRESERVATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS PRODUCTS

OPTIMIZING LENTIVIRAL VECTOR TRANSDUCTION TO GENE MODIFY CORD BLOOD CD8+ T CELLS FOR OFF-THE-SHELF ADOPTIVE CELL THERAPY TO TREAT CANCER
Vania Lo Presti, Esther Dunnebach, Maud Plantinga, Annelisa Cornel, Jurgen Kulbah, Jaap Jan Boelens, Niek van Til *, Stefan Nierkens * (Netherlands)

DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTRE EXPERIENCE
CASE REPORT: CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION (CAEBV) CONTROLLED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) AND TRANSFUSION OF EBV-SPECIFIC T-CELLS

Elisabeth Meedt, Daniela Weber, Britta Eiz-Vesper, Britta Maecker-Kolhoff, Agnes Bonifacius, Klaus Schwarz, Myriam Lorenz, Susanne Delecluse, Henri-Jacques Delecluse, Ernst Holler, Wolfgang Herr, Matthias Edinger, Daniel Wolff (Germany)

e-Posters
09:30 - 19:00

ePoster Area

Chronic leukaemia and other myeloproliferative disorders

TIMING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A JOINT STUDY FROM THE INTERNATIONAL MDS/MPN WORKING GROUP AND EBMT

RELAPSE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IN THE PATHWAY INHIBITOR (PI) ERA: NO LONGER A DEAD-END STREET

THE 10-YEARS <u>E</u>BMT <u>L</u>ANDSCAPE OF <u>A</u>LLLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) FOR <u>C</u>HRONIC LYMPHOCYTIC LEUKEMIA

DETERMINANTS OF SURVIVAL IN MYELOFIBROSIS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY BY THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT

SPLENECTOMY DOESN'T PRECLUDE SUBSEQUENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MYELOFIBROSIS PATIENTS: A FRENCH NATIONWIDE STUDY USING A MULTISTATE MODEL

INCIDENCE OF LATE RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS

Isik Kaygusuz Atagunduz, Anita Badbaran, Gaby Zeck, Christine Wolschke, Francis Ayuk, Maximilian Christopeit, Nicolaus Kröger (Germany)

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: THE EXPERIENCE OF THREE UNIVERSITY TRANSPLANT CENTRES IN ROME

AUSTRALASIAN TRENDS IN ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS IN MOLECULAR ERA

Yadanar Lwin, Simon He, Andrew Spencer, Duncan Purtill, Ashley Mcewan, Peter Browett, Andrew Butler, John Carter, Peter Bardy, Glen Kennedy, Jeffrey Szer, David Ritchie, Matthew Greenwood, Stephen Larsen, Sam Milliken, Hock Lai, David Gottlieb, John Kwan, Donna Aarons, Steven Tran, Nada Hamad (Australia)

CML RELAPSE AFTER ALLOGENEIC HSCT: SURVIVAL, TREATMENT EFFICACY AND PROGNOSTIC FACTORS FOR OUTCOME

Dunja Kampelmann, Dietrich W. Beelen, Rashit Bogdanov, Vesna Klisanin, Michael Koldehoff, Lambros Kordelas, Rudolf Trensche, Markus Ditschkowski (Germany)

CHRONIC MYELOID LEUKEMIA: ALLOGENEIC HEMOPOIETIC STEM CELLS TRANSPLANTATION IN THE ERA OF TYROSINE KINASE INHIBITORS
REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT WITH CAMPATH T-CELL DEPLETION FOR MYELOFIBROSIS IN THE ERA OF JAK INHIBITORS- A SINGLE CENTRE EXPERIENCE
Claire Horgan, Shereef Elmoamly, Alex Kanellopoulos, Richard Lovell, Shankara Paneesha, Bhuvan Kishore, Mary Dillon, Katie O’Collins, Kathy Holder, Emmanouil Nikolousis (United Kingdom)

ALLOGENIC STEM CELL TRANSPLANTATION IN ADVANCED SYSTEMIC MASTOCYTOSIS AFTER CYTOREDUCTIVE TREATMENT WITH CLADRIBINE - A SINGLE CENTER EXPERIENCE ON TWO PATIENTS
Christoph Buhl, Emin Abdullayev, Johanna Kerschbaum, Herrad Baermann, Andreas Reiter, Bertram Glaß (Germany)

ALLOGENEIC STEM CELL TRANSPLANTATION FOR IDIOPATIC MYELOFIBROSIS: A SINGLE CENTRE EXPERIENCE

A CASE OF SUCCESSFUL SECOND HAPLOIDENTICAL BONE MARROW TRANSPLANTATION AFTER SECONDARY GRAFT FAILURE IN A PATIENT WITH REFRACTORY CHRONIC MYELOID LEUKEMIA
Nadezhda Shnalieva, Anna Melikhova, Iurii Osipov, Galina Salogub, Vladimir Ivanov, Elza Lomaia (Russian Federation)

**Scientific Programme**

**Reduced Intensity Allogeneic Stem Cell Transplant with Campath T-Cell Depletion for Myelofibrosis in the Era of Jak Inhibitors**
Claire Horgan, Shereef Elmoamly, Alex Kanellopoulos, Richard Lovell, Shankara Paneesha, Bhuvan Kishore, Mary Dillon, Katie O’Collins, Kathy Holder, Emmanouil Nikolousis (United Kingdom)

**Allogeneic Stem Cell Transplantation in Advanced Systemic Mastocytosis After Cytoreductive Treatment with Cladribine**
Christoph Buhl, Emin Abdullayev, Johanna Kerschbaum, Herrad Baermann, Andreas Reiter, Bertram Glaß (Germany)

**Allogeneic Stem Cell Transplantation for Idiopathic Myelofibrosis: A Single Centre Experience**

**A Case of Successful Second Haploidentical Bone Marrow Transplantation After Secondary Graft Failure in a Patient with Refractory Chronic Myeloid Leukemia**
Nadezhda Shnalieva, Anna Melikhova, Iurii Osipov, Galina Salogub, Vladimir Ivanov, Elza Lomaia (Russian Federation)

**Conditioning Regimens**

- The Impact of Conditioning in Children and Adolescents with ALL: A Prospective Randomized Multicenter-Study “Forum” on Behalf of AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG and EBMT-PD-WP
- Population Pharmacokinetic Estimation of ATG Exposure Predicts Immune Reconstitution and Survival in Adults Undergoing Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation
- Flamsa-Based Reduced Intensity Conditioning Versus Myeloablative Conditioning in Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Transplantation: An ALWP/EBMT Analysis
- Total Body Irradiation/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Adults with Acute Lymphoblastic Leukemia Treated with Haploidentical HCT. A Study by Acute Leukemia Working Party of the EBMT
- Busulfan-Cyclophosphamide Versus Cyclophosphamide-Busulfan as Conditioning Regimen Before Allogeneic Hematopoietic Cell Transplantation: A Prospective Randomized Trial
- Rabbit Anti-Thymocyte Globulin (ATG) Exposure After Ex Vivo T-Cell-Depleted Hematopoietic Cell Transplantation Is Variable and Impacts Immune Reconstitution and Survival in Children and Young Adults
- A Retrospective Comparative Study of BEAM vs FEAM vs TEAM Conditioning Regimens in Lymphoma Patients Undergoing Autologous Stem Cell Transplant
- Reduced Intensity Versus Myeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients < 60 with Acute Lymphoblastic Leukemia: A Multi-Center Canadian Experience
COMBINING CLOFARABINE AND FLUDARABINE WITH EXPOSURE TARGETED BUSULFAN FOR PEDIATRIC LEUKEMIA: AN EFFECTIVE, LOW TOXIC, TBI-FREE CONDITIONING REGIMEN
Anne Birgitta Versluys, Coco de Koning, Marc Bierings, Stefan Nierkens, Caroline Lindemans, Dorine Bresters, Wouter Kollen, Arjan Lankester, Jaap Jan Boelens (Netherlands)

BENDA-BEAM HIGH-DOSE THERAPY PRIOR TO AUTO-SCT IS EFFECTIVE IN RESISTANT/RELAPSED DLBCL: A PHASE II STUDY

REDUCED-TOXICITY CONDITIONING WITH FLUDARABINE, THIOTEPA AND MELPHALAN IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH IMPAIRED LUNG FUNCTION
Jesus Duque-Afonso, Gabriele Ihorst, Miguel Waterhouse, Robert Zeiser, Ralph Wäsch, Hartmut Bertz, Mehtap Yücel, Thomas Köhler, Joachim Müller-Quernheim, Reinhard Marks, Jürgen Finke (Germany)

ALLOGENEIC STEM CELL TRANSPLANT WITH MINIMAL-INTENSITY CONDITIONING IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA: A SINGLE CENTRE RETROSPECTIVE REVIEW
Marianne Gallanagh, Amy Brown, Angharad Pryce, Richard Szydlo, Stephen Morris, Renuka Paliancawandar, Edward Kanfer (United Kingdom)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT

A PROSPECTIVE COHORT STUDY COMPARING LONG-TERM OUTCOMES WITH AND WITHOUT PALIFERMIN IN PATIENTS RECEIVING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES
Wael Saber, Patricia Steinert, Mei-Jie Zhang, Min Chen, Andrea Pope, Armand Keating, John Wingard, Karen Balles, Patrick Stiff, Miguel-Angel Perales, Stephen Forman, Richard Champlin, Amelia Langston, Torbjorn Kullenberg, Mattias Rudebeck, Mary Horowitz (United States)

PHARMACOKINETICS OF MELPHALAN IN LYMPHOMA PATIENTS UNDERGOING BEAM AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT
Parastoo Dahi, Andrew Lin, Jessica Flynn, Christian Uruburo, Ian Mcgeary, Ryan Schofield, Valkal Bhatt, Lauren Desrespiris, Bradley Figgins, Meagan Griffin, Carmen Lau, Anthony Proli, Dean Carlow, Christina Cho, Oscar Lahoud, Miguel Perales, Craig Sauter, Michael Scordo, Gunjan Shah (United States)

MELPHALAN IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION: DOES ONE SIZE FIT ALL?
Roni Tamari, Andrew Lin, Valkal Bhatt, Boglarka Gyurkocza, Esperanza Papadopoulos, Ann Jakubowski, Christina Cho, Brian Shaffer, Doris Ponce, Sergio Giralt, Gunjan Shah (United States)

COMPARISON OF TOTAL BODY IRRADIATION- VS CHEMOTHERAPY-BASED CONDITIONINGS FOR EARLY COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ALL

DIFFERENTIAL ALEMTUZUMAB DOSAGES IN T-CELL DEPLETE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTS FOR MYELOID MALIGNANCIES
Varun Mehra, Daniele Avenoso, Ximena C Castellano, Adrian Choy, Stefani Widya, Mili Shah, Shafqat Inam, Shreyans Gandhi, Austin Kulasekararaj, Pramila Krishnamurthy, Francesco Dazzi, Hugues de Lavallade, Victoria Potter, Ghulam J Mufti, Tony Pagliuca (United Kingdom)

THE INFLUENCE OF TDM ON ACHIEVING BUSULFAN TARGET EXPOSURE AND RELATED DETERMINANTS, IN BOTH CHILDREN AND ADULTS WHO UNDERWENT AN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Jill Boss, Arief Lalmohamed, Paul van der Linden, Jaap Jan Boelens, Erik van Maarseveen (Netherlands)
NOVEL REDUCED INTENSITY CONDITIONING (RIC) APPROACH TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH BENIGN AND MALIGNANT DISORDERS OF T CELL PROLIFERATION OR DYSREGULATION
Dimana Dimitrova, Gulbu Uzel, Luigi D. Notarangelo, Amanda K. Ombrello, Deborah Stone, Mark Parta, Ellen Carroll, Jennifer Wilder, Stephanie N. Hicks, Jennifer L. Sadler, Daniel H. Fowler, Ronald E. Gress, Christopher G. Kanakry, Jennifer A. Kanakry (United States)

PROFOUND LYMPHOPENIA AT THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION IS NOT PREDICTIVE OF SURVIVALS AFTER ALLO-TRANSPLANTATION
LIPID CORE NANOPARTICLES AS VEHICLE FOR ETOPOSIDE IN THE CONDITIONING REGIMEN OF MARROW TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA NOT RESPONDING TO INDUCTION THERAPY: A PILOT STUDY
Raul Cavalcante Maranhao, Thauny Martins Tavoni, Aleksandra Tiemi Morikawa, Debora Fernandes Deus, Jose Salvador Rodrigues Oliveira (Brazil)

A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF SHORT-TERM EVEROLIMUS IN ADDITION TO POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-EVER)
Simona Piemontese, Lorenzo Lazzari, Magda Marcatti, Fabio Giglio, Raffaella Greco, Daniela Clerici, Maria Teresa Lupo Stanghellini, Andrea Assanelli, Francesca Farina, Francesca Lorentino, Sara Mastaglio, Sarah Marktel, Matteo Carrabba, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Fabio Ciceri (Italy)

BUTYRYLCHOLINESTERASE ACTIVITY AFTER CYCLOPHOSPHAMIDE CONDITIONING AS A PREDICTIVE MARKER OF LIVER TRANSPLANT-RELATED COMPLICATIONS AND ITS CORRELATION WITH TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS
Antonio Grasso, Giulia Caddeo, Davide Zanon, Alessandra Maestro, Roberto Simenone, Natalia Maximova (Italy)

TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE IMPROVES THE OUTCOME OF PATIENTS WITH POOR-RISK ACUTE LEUKEMIA
A CD45-TARGETED ANTIBODY DRUG CONJUGATE ENABLES ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS A SINGLE AGENT IN MICE
Sharon Hyzy, Rahul Palchaudhuri, Jennifer Proctor, Bradley Pearse, Ganapathy Sarma, Geoff Gillard, Asim Saha, Tahirih Lamotho, Melissa Brooks, Katelyn Hammond, Anjali Bhat, Charlotte McDonagh, Hans-Peter Kiem, John Wagner, Bruce Blazar, Anthony Boitano, Michael Cooke (United States)

INFLUENCE OF THE CELL SOURCE TYPE AND CONDITIONING TYPE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME
Fernando Barroso Duarte, Anna Thawanny Gadelha Moura, Vanuessa Araújo Moreira Funke, Virgílio Antônio Reni Colturato, Nelson Hamerschalk, Neysiméia Costa Vilela, Luiz Fernando Lopes, Maria Cristina Martins de Almeida Macedo, Afonso Celso Vigorito, Rodolfo Daniel de Almeida Soares, Alessandra Paz, Mariana Stevenazzi, Lilián Díaz, Abrahao Elias Hallack Neto, Gustavo Bettareli, Breno Moreno de Gusmão, Marco Aurélio Salvino, Rodolfo Froes Calixto, Maria Cláudia Rodrigues Moreira, Gustavo Machado Teixeira, Cinthya Corrêa da Silva, Anderson Simioni, Romélia Pinheiro Gonçalves Lemes (Brazil)

PRECONDITIONING INTENSITY IMPACTS ON IMMUNE RECONSTITUTION AND OUTCOMES FOLLOWING CORD BLOOD TRANSPLANTATION
Taiki Ando, Taisei Suzuki, Takayoshi Tachibana, Masatsugu Tanaka, Heiwa Kanamori, Hideaki Nakajima (Japan)

FINAL RESULTS OF A PROSPECTIVE, MULTICENTER, NON-INTERVENTIONAL STUDY ON THIOPETA-BASED AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (ASCT) FOR CNS OR NON-CNS LYMPHOMA
Herbert Gottfried Sayer, Mathias Witzens-Harig, Mohammad Wattad, Agnieszka Korfel, Inken Hilgendorf, Georg-Nikolaus Franke, Gerald Ilerhaus, Michael Heinsch, Bernd Metzner, Eva Bettina Zingrebe, Nadezda Basara, Mascha Binder, Mark Ringhoffer, Alexander Röth, Thomas Geer, Volker Schmidt, Peter Dreger (Germany)

POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY), CYCLOSPORIN (CSA) AND MYCOPHENOLATE (MMF) FOR PATIENTS GRAFTED FROM HLA IDENTICAL SIBLINGS OR MATCHED UNRELATED DONORS
COMPARISON OF FLUDARABINE + BUSULFAN AND FLUDARABINE+BUSUFAN+ LOW-DOSE ATG CONDITIONING REGIMENS IN PATIENTS WITH MYELOID MALIGNANCIES WHO HAD ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPADIME
Zafer Gulbas, Elif Birtas Atesoglu, Imran Dora, Cigdem Eren, Suat Celik, Gokhan Kusdemir, Kader Caliskan (Turkey)

CONDITIONING REGIMEN COMPARISON FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-HODGKIN LYMPHOMA
Kristen Peterson, Andrew Lin, Josel Ruiz, Junting Zheng, Sean Devlin, Guan Shah, Michael Scordo, Craig Sauter, Miguel Perales, Sergio Giralt, Larry Buie, Parastoo Dah (United States)

PK-GUIDED BUSULFAN CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) WITH PTCY AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNENCIES
A THIOTEPA BASED INTENSIFIED REDUCED INTENSITY CONDITIONING REGIME IN ADULT CORD BLOOD TRANSPLANT IS A PROMISING ALTERNATIVE IN PATIENTS UNABLE TO RECEIVE MYELOABLATIVE CONDITIONING
Ian Wu, Tangia Muquith, Yeh Ching Linn, Michelle Poon, Lip Kun Tan, Belinda Tan, Yelly Yelly, Teck Guan Soh, Davanaliz Gonzales Ramos, William Hwang, Liang-Piu Koh (Singapore)

HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE USING AS CONDITIONING FLUDARABINE MELPHALAN PLUS LOW DOSES OF TOTAL BODY IRRADIATION. LONG TERM FOLLOW-UP OF 60 PATIENTS
Amado Jose Karduss, Rosendo Perez, Giovani Ruiz, Angelica Cardona, Juan Alejo Jimenez, Luis Rodolfo Gomez, Pedro Reyes (Colombia)
TREOSULFAN-BASED CONDITIONING IN PAEDIATRIC T-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE
Frances Yeap, Chintan Tarunkumar Vyas, Cheryl Neoh, Mariflor S Villegas, Poh Lin Tan (Singapore)

COMPARISON OF BEAM AND TEAM AS CONDITIONING REGIMEN FOR LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

ASSESSMENT OF THE SAFETY AND EFFICACY OF THE CONDITIONING REGIMEN BEEAC BEFORE AUTO-HSCT FOR THE TREATMENT OF PRIMARY-REFRACTORY AND RELAPSED FORMS OF MALIGNANT LYMPHOMAS
Anastasiia Samoylova, Vladislav Sarzhevsky, Vladimir Melnichenko, Nikita Mochkin, Julia Dubinina, Elena Smirnova, Anna Bannikova, Vladimir Bogatyrev (Russian Federation)

ALLOGENEIC STEM CELL TRANSPLANTATION AFTER TOTAL-BODY IRRADIATION USING HELICAL TOMOTHERAPY: A SINGLE CENTER EXPERIENCE
Thomas Heinicke, Ana-Maria Waldleben, Denise Wolleschak, Thomas Brunner, Günther Gademann, Thomas Fischer, Hans-Joachim Ochel (Germany)

FEASIBILITY OF CLAMSA-RIC AS AN ALTERNATIVE CONDITIONING REGIMEN COMPARED TO FLAMSA-RIC IN HEAVILY PRETREATED REFRACTORY AML PATIENTS - A RETROSPECTIVE SINGLE CENTER ANALYSIS

THIOTEPA, BUSULPHAN AND FLUDARABINE CONDITIONING IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA

FLAMSA-BASED HIGH-DOSE SEQUENTIAL CONDITIONING REGIMEN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): IS IT EFFECTIVE IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED ACUTE LEUKEMIA?
Guldane Cengiz Seval, Ekin Kircali, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Onder Arslan, Muhit Ozcan, Taner Demirer, Gunhan Gurman, Osman Ilhan, Hamdi Akan, Meral Beksac, Pervin Topcuoglu (Turkey)

INCREASING IN SERUM TOTAL AMYLASE LEVELS AFTER TOTAL BODY IRRADIATION CONDITIONING REGIMEN AS A PREDICTIVE MARKER OF TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS
Antonio Grasso, Rossella Vidimari, Francesca Ciriello, Roberto Simenone, Fabrizio Cupardo, Natalia Maximova (Italy)

EVOLUTION OF DONOR CHIMERISM AFTER HAPLOIDENTICAL STEM CELL TRANSPLANT - CLINICAL CORRELATIONS
Carla Alves, Nuno Miranda, Pedro Sousa, Isabelina Ferreira, Gilda Teixeira, Ana Sofia Jorge, Maria Joao Gutierrez, Fernando Leal-da-Costa, Manuel Abecasis (Portugal)

THIOTEPA-BUSULFAN-FLUDARABINE AS CONDITIONING REGIMEN FOR PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

THE RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA-HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE REGIMEN IN CHILDREN

ANALYSIS OF DIFFERENCES IN PREVENTIVE MEASURES AFTER HIGH-DOSE CYCLOPHOSPHAMIDE AMONG BELGIAN STEM CELL TRANSPLANT CENTRES
Eva De Backer, Dries Deeren (Belgium)

IRRADIATION-FREE RE-CONDITIONING FOR T-CELL DEPLETED HAPLO-IDENTICAL STEM CELL TRANSPLANTATION
Susanne Aydin, Ingo Müller (Germany)
LOW GRAFT CD4 CELL DOSE PREDICTS RELAPSE IN THE ATG-BASED MYELOABLATIVE CONDITIONING REGIMEN
Nabil Yafour, Faiza Serradj, Soufi Osmani, Mohamed Brahimi, Sihem Bekadja, Amel Mihoubi, Rachid Bouhass, Abdessamad Arabi, Mohamed Amine Bekadja (Algeria)

CLINICAL EFFICACY OF HAPLOID TRANSPLANTATION WITH BU/CY/MEL PRETREATMENT SCHEME TO IMPROVE 68 CASES OF UNICENTRIC REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA

REDUCING INTENSITY CONDITIONING (RIC) PROTOCOL HARMONISATION IN THE UK
Nick Duncan, Amritpal Atwal, Sumantha Gabriel, Matthew Collin (United Kingdom)

HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN HIGH-RISK HEMATOLOGICAL MALIGNancies, Algerian experience

INTERRUPTION OF CONDITIONING FOR ALLO-HCT DOES NOT AFFECT CLINICAL OUTCOMES OTHER THAN CHRONIC GVHD
Satoru Matsushima, Ryoji Kobayashi, Daiki Hori, Masato Yanagi, Koya Kodama, Daisuke Suzuki, Atsushi Manabe, Kunihiko Kobayashi (Japan)

THERAPEUTIC DRUG MONITORING OF BUSULFAN IN PEDIATRIC POPULATION
Gulen Tuysuz Kintrup, Funda Tayfun Kupesiz, Hilal Akbas, Ayse Nur Akinel, Cigdem Sivrice, Elif Guler, Alphan Kupesiz (Turkey)

REDUCED INTENSITY CONDITIONING FOLLOWED BY HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION (RIC-HAPLOHCT) AND POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS, FOR HEMATOLOGICAL DISORDERS: SINGLE CENTRE EXPERIENCE
Vinod Patil, Reghu Sukumaran, Mita Roychowdhury, Sayak Chaudhuri, Jeevan Kumar, Saurabh Bhave, Rizwan Javed, Niharendu Ghara, Reena Nair, Vivek Radhakrishnan, Mammen Chandy (India)

HIGH DOSE TREATMENT WITH LEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION DURING THE SHORTAGE OF MOSTLY USED AGENTS IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA

REDUCED DOSE ALEMTUZUMAB IN REDUCED INTENSITY CONDITIONING VOLUNTEER DONOR UNRELATED TRANSPLANT FOR MYELOID MALIGNANCIES IS SAFE AND EFFICACIOUS. A SINGLE CENTRE EXPERIENCE

DESCRIBE AND EXPLORE A PATIENTS’ OUTLOOK ON DENTAL CARE IN THE CONTEXT OF THEIR MEDICAL DIAGNOSIS AND TREATMENT PRIOR TO AND FOLLOWING ALLOGENEIC HSCT
Charlotte Wilson-Dewhurst, Amit Patel, Shelagh Thompson (United Kingdom)

SAFETY AND EFFICACY OF LOW-DOSE BENDA-EAM AS COMPARED TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION OF REFRACTORY/RELAPSED LYMPHOMA PATIENTS

CONDITIONING REGIMEN WITH FLUDARABIN/TREOSULFAN COMPARED TO BUSULFAN/CYCLOPHOSPHAMID PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN YOUNGER PATIENTS WITH AML AND MDS: A SINGLE CENTER RETROSPECTIVE ANALYSIS
Alix Pianka, Peter Herhaus, Krischan Braitsch, Katrin Holzhauser, Katharina Götze, Florian Bassermann, Mareike Verbeek (Germany)

OUTCOMES OF UNRELATED DONOR STEM CELL TRASPLANTATION WITH OR WITHOUT ANTI-THYMOCYTE GLOBULIN USED AS GRAFT-VERSUS HOST DISEASE (GVHD) PROPHYLAXIS: A SINGLE CENTER EXPERIENCE
Georgina Gener Ricós, Montserrat Batlle Massana, Mireia Morgades de la Fe, María Josefa Jiménez Lorenzo, Christelle Ferrà Coll, Juan Manuel Sancho Cía, Mireia Franch Sarto, Mireia Santos Gómez, Susana Vives Polo, Miriam Moreno Velázquez, Anna Torrent Catarineu, Blanca Xicoi Cirici, Laura Abril Sabater, Gladys Ibarra Fernández, Alícia Senín Magán, Albert Oriol Rocafiguera, Josep Maria Ribera Santasusana (Spain)
BUSULFAN-FLUDARABINE CONDITIONING REGIMEN FOR CORD BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE TWO-CENTER STUDY

ATG IN CONDITIONING FOR SIBLING ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE
Lazar Chadievski, Aleksandra Pivkova Veljanovska, Irina Panovska Stavridis, Zlate Stojanoski, Lidija Cevreska, Nevenka Ridova, Marija Popova Labacevska, Zaklina Ancevska, Gabriela Trajkovska, Borce Georgievski (North Macedonia, the Republic of)

e-Posters
09:30 - 19:00 ePoster Area

Gene Therapy

CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT β-THALASSEmia

LENTIVIRAL HEMATOPOIETIC STEM AND PROGENITOR CELL GENE THERAPY (HSPC-GT) FOR METACHROMATIC LEUKODYSTROPHY (MLD): CLINICAL OUTCOMES FROM 33 PATIENTS

A SINGLE DOSE OF SHORT HALF-LIFE CD117 ANTIBODY DRUG CONJUGATE ENABLES HEMATOPOIETIC STEM CELL BASED GENE THERAPY IN NONHUMAN PRIMATES

LENTI-D HEMATOPOIETIC STEM CELL GENE THERAPY STABILIZES NEUROLOGIC FUNCTION IN BOYS WITH CEREBRAL ADRENOLEUKODYSTROPHY

SAFETY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH GENE ADDITION THERAPY FOR TRANSFUSION-DEPENDENT β-THALASSEmia, SICKLE CELL DISEASE, AND CEREBRAL ADRENOLEUKODYSTROPHY

EX-VIVO AUTOLOGOUS HAEMATOPOIETIC STEM CELL GENE THERAPY IN MUCOPOLYSACCHARIDOSIS TYPE IIIA
Jane Kinsella, Simon Jones, Heather Church, Ceri Jones, Stuart Ellison, Claire Booth, Karen Buckland, Diego Leon Rico, Brian Bigger, Adrian J Thrasher, Robert Wynn (United Kingdom)

Graft-versus-host disease - clinical

KD025 FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) - LONG-TERM FOLLOW-UP OF A PHASE 2A STUDY (KD025-208)

A PHASE 2 STUDY OF F-652, A NOVEL TISSUE-TARGETED RECOMBINANT HUMAN INTERLEUKIN-22 (IL-22) DIMER, FOR TREATMENT OF NEWLY DIAGNOSED ACUTE LOWER GI GVHD

THE MAGIC BIOMARKER ALGORITHM PREDICTS OUTCOMES FOR CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE

A NOVEL TREATMENT IN CHRONIC OCULAR GRAFT-VS-HOST DISEASE (OGVHD): A PHASE II CLINIC TRIAL WITH TRANSDERMAL PROGESTERONE

EARLY CD4+ T-CELL RECONSTITUTION IS AN EXCELLENT PREDICTOR OF OUTCOMES IN PEDIATRIC PATIENTS WHO DEVELOP MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST-DISEASE: A DUAL CENTER VALIDATION
**EFFECT OF SINGLE OR DOUBLE MISMATCHES AT EACH HLA LOCUS ON THE OUTCOMES AFTER SINGLE CORD BLOOD TRANSPLANTATION: THE JSHCT HLA WG STUDY**

**INTERIM ANALYSIS OF KD025-213: A PHASE 2, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KD025 IN SUBJECTS WITH CGVHD (THE ROCKSTAR STUDY)**

**ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) AND RITUXIMAB FOR IMMUNOMODULATION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT FAILURE IN PATIENTS WITH NON-MALIGNANT DISORDERS: RESULTS OF A MULTICENTRE, RANDOMIZED, OPEN-LABEL STUDY**

**EXPERIENCE USING DUAL T-CELL DEPLETION WITH ATG AND PTCY FOR GVHD PROPHYLAXIS IN RIC ALLOHCT USING IN 10/10 MATCHED RELATED AND UNRELATED DONORS**

**MACHINE LEARNING APPLIED TO THE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE IMPROVES SURVIVAL ESTIMATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**SINGLE-CELL MOLECULAR ANALYSIS DEFINES CHARACTERIZATION OF SPECIFIC T CELL SUBSETS CORRELATE WITH HUMAN CHRONIC GVHD AND BRONCHIOLITIS OBLITERANS**

**A PHASE II TRIAL EVALUATING THE USE OF THE HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PREVENTION**

**REDUCED CALCIUM SIGNALING IS ASSOCIATED WITH GVHD: RESULTS FROM PRECLINICAL ALLOSCT MODELS AND FROM A PROSPECTIVE MULTICENTER STUDY**

**IDENTIFICATION OF PREDICTIVE MODELS INCLUDING POLYMORPHISMS IN CYTOKINES GENES ASSOCIATED WITH ACUTE GRAFT VERSUS HOST DISEASE AND OVERALL SURVIVAL AFTER IDENTICAL HLA-ALLOGENEIC STEM-CELL TRANSPLANTATION**

**SEARCH FOR CIRCULATING ENDOTHELIAL CELLS OF DONOR ORIGIN AFTER ALLO-HSCT: POTENTIAL CLINICALLY RELEVANT IMPLICATIONS IN THE CONTEXT OF GRAFT-VERSUS-HOST DISEASE**

**DOUBLE LUNG TRANSPLANTATION IN ADULTS FOR CHRONIC PULMONARY GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Ram Vasudevan Nampoothiri, Peter Riddell, Susan Chernenko, Matthew Binnie, Lianne Singer, Stephen Juvet, Jeffrey Howard Lipton (Canada)

**REDUCED INFLAMMATORY TISSUE INFILTRATION DURING INTESTINAL STEROID-REFRACTORY GVHD**

Katarina Riesner, Steffen Cordes, Maria Bartosova, Martina Kalupa, Sarah Mertlitz, Lars Bullinger, Igor Wolfgang Blau, Claus Peter Schmitt, Gernot Beutel, Olaf Penack (Germany)

**IMPACT OF ANTI-THYMOCYTE GLOBULIN DOSE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN STEM CELL TANSPLANTATION FROM UNRELATED DONORS**

**DECREASED SOLUBLE HLA-E LEVELS IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ARE ASSOCIATED WITH SEVERE ACUTE AND EXTENDED CHRONIC GRAFT-VERSUS-HOST DISEASE AND INFERIOR OVERALL SURVIVAL**

**EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON PRODUCTION OF SERUM SOLUBLE CD163: RELATIONSHIP TO IMMUNOSUPPRESSION AND DISEASE ACTIVITY IN CHRONIC GRAFT VERSUS HOST DISEASE**

Nick C. Matthisews, Charlotte Burton, Arun Alfred (United Kingdom)

**POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE OVERCOMES THE DETRIMENTAL EFFECT OF A SINGLE-LOCUS HLA MISMATCHED IN UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**
ALLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS FROM HAPLOIDENTICAL AND MATCHED DONORS: ‘SIRPTCY’ RESULTS IN 249 PATIENTS
Raffaella Greco, Serena Albanese, Francesca Lorentino, Maria Teresa Lupo Stanghellini, Fabio Giglio, Simona Piemontese, Magda Marcatti, Daniela Clerici, Lorenzo Lazzari, Rosamaria Nitti, Carmine Liberatore, Sara Mastaglio, Andrea Assanelli, Luca Vago, Chiara Bonini, Consuelo Corti, Massimo Bernardi, Fabio Ciceri, Jacopo Peccatori (Italy)

A NEW HOPE IN THE TREATMENT OF STEROID-REFRACTORY GRAFT VERSUS HOST DISEASE (SR-GVHD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSC): RUXOLITINIB

AZACITIDINE IS SAFE AND ACTIVE IN THE TREATMENT OF STEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST-DISEASE - INTERIM RESULTS OF THE PHASE II AZTEC TRIAL

BASILIXIMAB AS TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

EFFICACY AND TOLERANCE OF NILOTINIB IN PATIENTS WITH REFRACTORY CHRONIC GVHD WHO ARE REFRACATORY/INTOLERANT TO IMATINIB: A PROSPECTIVE MULTICENTER PHASE II STUDY OF THE SFGM-TC

EVALUATION OF THE PROGNOSTIC VALUE OF HISTOLOGIC ASSESSMENT OF ACUTE GRAFT-VERSUS-HOST-DISEASE OF THE UPPER GASTROINTESTINAL TRACT ACCORDING TO LERNER EARLY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Abed Alahad Sarraf, Renate Schmelz, Henning Baldauf, Daniela Aust, Friedrich Stölzel, Jan Moritz Middeke, Katja Sockel, Raphael Teipel, Stefan Brückner, Marco Berning, Sebastian Zeissig, Jana Babatz, Christian Kirsch, Gustavo Barettón, Martin Bornhäuser, Jochen Hampe, Johannes Schetelig (Germany)

CYCLOSPORINE A ALONE VERSUS MYCOPHENOLATE MOFETIL PLUS CYCLOSPORINE A BASED GVHD PROPHYLAXIS FOR PATIENTS WITH AML UNDERGOING MUD TRANSPLANTATION. A STUDY FROM THE ALWP

TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS INDEPENDENTLY ASSOCIATED WITH RUXOLITINIB ADMINISTRATION IN PATIENTS WITH GRAFT-VERSUS-HOST-DISEASE
Eleni Gavrilaki, Ioanna Sakellari, Zoi Bousiou, Thomas Chatzikonstantinou, Despina Mallouri, Marianna Masmanidou, Anna Vardi, Eudoxia-Evangelia Koravou, Foteini Kika, Tasoula Touloumenidou, Apostolia Papalexandri, Evangelia Yannaki, Ioannis Batsis, Achilles Anagnostopoulos (Greece)

DIAGNOSTIC SIGNIFICANCE OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD)
Georg Evers, Wolfgang Roll, Joern Christian Albring, Christian Reicherts, Rebecca Strotmann, Georg Lenz, Michael Schaefers, Matthias Stelljes (Germany)

LONG TERM OUTCOMES OF RUXOLITINIB THERAPY IN STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN AND ADULTS
Tatiana Bykova, Ivan Moiseev, Elena Morozova, Elena Darskaya, Olesya Paina, Anna Smirnova, Anna Dotchenko, Evgenia Borzenkova, Alexander Galimov, Yana Gudognikova, Kirill Ekushev, Polina Kozhokar, Anna Osipova, Olga Pirogova, Tatiana Rudakova, Olesya Shakheeva, Nikolay Tcvetkov, Egor Kulagin, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)
INVESTIGATING ANTIBIOTIC EXPOSURE AND RISK OF SEVERE ACUTE GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Razan Mohty, Rémy Duléry, Giorgia Battipaglia, Eolia Brissot, Clémence Médiavilla, Simona Sestilli, Toune Ledraa, Beatrice Gaugler, Agnes Bonnin, Mohamad Mohty, Florent Malard (France)

Efficacy and Toxicity of Ruxolitinib in Patients with Steroid-Resistant Acute and Chronic Graft-Versus-Host Disease After Hematopoietic Cell Transplantation

PATIENT CHARACTERIZATION AND SURVIVAL OUTCOMES IN PAEDIATRIC CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS: A POPULATION-BASED STUDY IN SWEDEN
Frida Schain, Nurgul Batyrbekova, Annica Dominicus, Simona Baculea, Mats Remberger, Jonas Mattsson, Jacek Toporski (Sweden)

CYTOKINE LEVELS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION: A MATCH-PAIR ANALYSIS OF HOME CARE VERSUS HOSPITAL CARE
Olle Ringdén, Mats Remberger, Johan Torlen, Sigrun Finnbogadottir, Britt-Marie Svahn, Behnam Sadeghi (Sweden)

Fecal Microbiota Transplantation in Patients with Steroid-Resistant Graft versus Host Disease Colonized by Antibiotic-Resistant Bacteria - Single-Center Analysis of 15 Procedures
Jarosław Biliński, Karol Lis, Agnieszka Tomaszewska, Paweł Grzesiowski, Aleksandra Pechcinska, Tomasz Dzieciatkowski, Kazimierz Halaburda, Magdalena Tormanowska, Martyna Tyszka, Krzysztof Małdys, Ewa Karakuśka-Prystupiuk, Alicja Walesiak, Wiesław Wiktor Jedrzejczak, Grzegorz W. Basak (Poland)

INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE: RESULTS FROM A PROSPECTIVE MULTICENTRE ANALYSIS OF 2 COHORTS
Antonela Lelas, Ronja Langer, Michael Rittenschober, Lana Desnica, Hildegard Greinix, Anne Dickinson, Marit Inngjerdingen, Anita Lawitschka, Radovan Vrhovac, Drazen Pulanic, Stefan Klein, Jan Moritz Middeke, Matthias Edinger, Daniel Wolff (Croatia)

THE CXCL9 POLYMORPHISM RS884304 COUNTERACTS CALCINEURIN-INHIBITOR REPRESSION OF EARLY CXCL9 RECONSTITUTION AND ASSOCIATES WITH SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE
Hao Dai, Sivaramakrishna P. Rachakonda, Olaf Penack, Olga Blau, Aleksandar Radujkovic, Carsten Müller-Tidow, Peter Dreger, Rajiv Kumar, Thomas Luft (Germany)

EARLY INTRODUCTION OF RUXOLITINIB FOR CHILDREN WITH GRAFT VERSUS HOST DISEASE - A STITCH IN TIME SAVES NINE
Revathi Raj, Ramya Uppuluri, Venkateswaran Vellaichamy, Nikila Ravichandran, Kesavan Iyer (India)

POST-TRANSPLANT CYCLOPHOSPHAMIDE AS AN EFFECTIVE STRATEGY FOR GVHD PREVENTION IN BOTH HLA-MATCHED AND MISMATCHED ALLOGENEIC TRANSPLANTS
Irene García-Cadenas, Albert Esquirol, Rahinatu Awol, Silvana Saavedra, Silvana Novelli, Ana Garrido, Jordi López, Carol Moreno, Miquel Granell, Javier Briones, Salut Brunet, Jordi Sierra, Rodrigo Martino (Spain)

SERUM AUTOANTIBODIES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY
Ivan Pasic, Ashley Di Meo, Ioannis Prassas, Ihor Batruch, Leann Wilson, Eleftherios P. Diamandis, Fotios V. Michalis (Canada)

OPTIMIZED STARTING DOSE OF CYCLOSPORINE REDUCES RISK OF ACUTE GVHD AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Jérémie Hérétier, Michael Medinger, Dominik Heim, Helen Baldomero, Christian Arranto, Jörg Halter, Jakob R. Passweg, Martina Kleber (Switzerland)
SUCCESS OF IMMUNOSUPPRESSION IN PATIENTS WITH CHRONIC GVHD: ANALYSIS ON 108 ADULT LONG-TERM SURVIVORS AFTER MATCHED AND HAPLO HSCT
Maria Teresa Lupo-Stanghellini, Francesca Lorentino, Fabio Serpentino, Andrea Assanelli, Carlo Messina, Sara Mastaglio, Stefania Girlanda, Fabio Giglio, Raffaella Greco, Sarah Marktel, Francesca Lunghi, Elena Guggiari, Magda Marcatti, Matteo G. Carrabba, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Fabio Ciceri (Italy)

INCIDENCE AND OUTCOME OF LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE DURING TAPERING OR AFTER STOPPING CALCINEURIN INHIBITORS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING AND MATCHED UNRELATED COMPARED TO HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, A STUDY ON BEHALF OF GETH
Mi Kwon, Rebeca Bailén, Maria Jesus Pascual Cascon, Lucia Lopez Corral, Arancha Bermudez, Pilar Herrera, Antonia Sampol, Inmaculada Heras, Carmen Martin Calvo, Jaime Sanz, Isabel Sanchez Ortega, Melissa Torres, Jose Rifen Roca, Karem Humala, Cristina Muñoz, Ignacio Gomez Centurion, Gillen Oarbeacoa, Nieves Durado, Jose Luis Diez Martin (Spain)

MESENCHYMAL STROMAL CELLS (MSC) FOR STEROID-REFRACTORY ACUTE GVHD, A SINGLE CENTER PHASE I/II TRIAL

T-LYMPHOCYTE TRANSCRIPTIONAL SIGNATURE IN ECP-TREATED PAEDIATRIC PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE
Aisling M Flinn, Janet Chou, Anna Ehrlich, Xiao Nong Wang, Raif S Geha, Andrew R Gennery (United Kingdom)

EFFICACY OF LOW-DOSE RUXOLITINIB AS SAVAGE THERAPY IN HEAVILY PRETREATED PATIENTS WITH MODERATE/SEVERE STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
Yanmin Zhao, Jumin Shi, Yi Luo, Yamin Tan, Jian Yu, Huarui Fu, Xiaoyu Lai, He Huang (China)

RESTRICTIVE USE OF INTRAVENOUS ANTIBIOTICS IN ALLOGENEIC SCT PTS WITH FEVER DUE TO CYTOKINE RELEASE SYNDROME ALLOWS MICROBIOTA PROTECTION WITHOUT INCREASE OF INFECTIONS AND TRM
Ernst Holler, Daniela Weber, Joachim Hahn, Cornelia Mittermaier, Klaus-Georg Kreitmeier, Andreas Heregeist, Bernd Salzberger, Daniel Wolff, Andre Gessner, Wolfgang Herr, Matthias Edinger (Germany)

EXTRACORPOREAL PHOTOPHERESIS (ECP) AS FIRST-LINE TREATMENT FOR ACUTE GVHD (AGVHD) IN PEDIATRIC PATIENTS WHO UNDERWENT T-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION (APLO-HSCT)

EFFICACY OF METHOXSALEN STERILE SOLUTION IN CONJUNCTION WITH THE THERAKOS (R) CELLEX (R) PHOTOPHERESIS SYSTEM IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD: INTERIM ANALYSIS
Carrie Lynn Kitko, Stefania Gaspari (United States)

MICRO RNA PROFILING OF ACOUSTICALLY-ISOLATED EXTRACELLULAR VESICLES IDENTIFIES POTENTIAL BIOMARKERS FOR POST-ALLO-HSCT COMPLICATIONS
Hooi Ching Lim, Shamit Soneji, Robert Palmason, Stig Lenhoff, Thomas Laurell, Stefan Scheding (Sweden)

COLONIZATION PLAYS AN IMPORTANT ROLE IN THE OUTCOME OF ALLOGENEIC TRANSPLANTATION
ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) SCORE AT THE ONSET OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PREDICTING OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS

CARFILZOMIB IN ADDITION TO STANDARD CYCLOSPORINE/ METHOTREXATE COMBINATION EFFECTIVELY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS
Avichai Shimoni, Noga Shem-Tov, Ivetta Danylesko, Ronit Yerushalmi, Arnon Nagler (Israel)

COMPARISON OF EXCLUSIVE POSTTRANSPLANT CYCLOPHOSPHAMIDE VERSUS A CALCINEURIN INHIBITOR BASED REGIMEN AS GVHD PROPHYLAXIS IN ALLOGENEIC BONE MARROW TRANSPLANTATION FROM HLA IDENTICAL SIBLING

SIROLIMUS VERSUS CYCLOSPORINE WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND MYCOPHENOLATE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN HAPLOIDENTICAL TRANSPLANTS: A RETROSPECTIVE ANALYSIS OF ONE SINGLE INSTITUTION
Mario Andres Sanchez Salinas, Rafael Hernani Morales, Ana Benzaquen Vallejos, Juan Carlos Hernandez Boluda, Ariadna Perez Martinez, Paula Amat Martinez, Montserrat Gomez Calafat, Rosa Goterris Viciedo, Carlos Solano Vercet (Spain)

TARGETED SEQUENCE CAPTURE METAGENOMICS (VIROCAP) TO DETECT VIRUS IN STOOL SAMPLES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS
Suze A. Jansen, Wouter Nijhuis, Helen Leavis, Annelies Riezebos-Brilman, Caroline A. Lindemans, Rob Schuurman (Netherlands)

EXTRACORPOREAL PHOTOPHERESIS AND PRODUCTION OF SERUM IL-34 AND ELAFIN IN CHRONIC GRAFT VERSUS HOST DISEASE
Charlotte Burton, Nick C. Mattthews, Arun Alfred (United Kingdom)

IMPACT OF UPPER AND LOWER ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE ON GRADING AND OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS IN 122 CONSECUTIVE PATIENTS
Monica Poiani, Francesco Saraceni, Ilaria Scortechini, Giorgia Mancini, Marianna Mariani, Giorgia Micucci, Chiara Montagna, Giuseppina Urbano, Federica Monaco, Giuseppe Tarantino, Irene Federici, Attilio Olivieri (Italy)

PRELIMINARY EXPERIENCE WITH THE USE OF RUXOLITINIB, IBRUTINIB OR IMATINIB FOR THE TREATMENT OF ACUTE OR CHRONIC GVHD
Carolina Secreto, Martina Tonelli, Alessandro Busca, Matilde Scaldaferri, Chiara Della Casa, Luisa Giaccone, Lucia Brunello, Sara Butera, Giorgia Iovino, Francesco Cattel, Benedetto Bruno (Italy)

RUXOLITINIB WITH OR WITHOUT IBRUTINIB AS AN ALTERNATIVE FIRST LINE THERAPY FREE OF CORTICOSTEROIDS OR CALCINEURIN INHIBITORS IN TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE
Rong Xie, Qin Liu, Dan Han, Wenlan Chen, Han Yan, Fanjun Cheng, Yong You, Ping Zou, Zhaodong Zhong (China)

CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS
Chiara Montagna, Maria Teresa Lupo Stanghellini, Ilaria Scortechini, Magda Marcatti, Raffaella Greco, Fabio Giglio, Andrea Assanelli, Consuelo Corti, Monica Poiani, Federica Monaco, Giuseppina Urbano, Giorgia Mancini, Irene Federici, Jacopo Peccatori, Fabio Ciceri, Attilio Olivieri, Simona Piemontese (Italy)

IMPACT OF KIR/HLA INCOMPATIBILITIES AFTER POSTTRANSPLANT CYCLOPHOSPHAMIDE BASED T CELL-REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
Scientific Programme

ELEVATED PTH LEVELS AMONG CHRONIC GRAFT-VERSUS-HOST DISEASE PATIENTS AND OTHER LONG TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPANTATION
Antonela Lelas, Lana Desnica, Ivan Sabol, Zlatko Giljevic, Tina Dusek, Dina Ljubas Kelecic, Irena Karas, Nadira Durakovic, Zinaida Peric, Ranka Serventi Seiwerth, Radovan Vrhovac, Steven Z. Pavletic, Drazen Pulanic (Croatia)

CONCURRENCE OF GVHD AND NON-INFECTIOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION
Mohammad Sheikh, Shahrukh Hashmi (Pakistan)

ACUTE GVHD INCIDENCE IN MISMATCHED UNRELATED DONOR HSCT IN PAEDIATRIC ADULT PATIENTS: A STUDY FROM THE TURIN METROPOLITAN TRANSPLANT CENTER
Massimo Berger, Marta Barone, Francesco Saglio, Fabrizio Carnevale-Schianca, Marco De Gobbi, Luca Parnuzzo, Paolo Nicoli, Manuela Spadea, Daniela Caravelli, Elena Ernestina Vassallo, Massimo Aglietta, Franca Fagioli (Italy)

PRACTICAL IMPLEMENTATION OF THE NIH DIAGNOSTIC CRITERIA FOR ORAL CHRONIC GVHD IN A MULTIDISCIPLINARY TEAM IN THE LATE FOLLOW UP OF ALLOGENIC HSCT PATIENTS
The Impact of Antibiotic-Mediated Modification of the Intestinal Microbiome on Outcomes of Allogeneic Hematopoietic Cell Transplantation: Systematic Review and Meta-Analysis
Maria Gavriilaki, Ioanna Sakellari, Achilles Anagnostopoulos, Eleni Gavriilaki (Greece)

CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS FROM WHARTON’S JELLY IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE
Michał Piątek, Izabela Zdolińska-Malinowska, Maciej Rojek, Monika Mielcarek-Siedziuk, Krzysztof Kałwak, Katarzyna Drabko, Agnieszka Zaucha-Prażmo, Dominik Grabowski, Janina Marta Choma, Mirosław Markiewicz, Monika Dzierzak Mietla, Katarzyna Goździk, Robert Dębski, Anna Krenska, Jan Styczyński, Mariusz Wysocki, Dariusz Boruczkowski (Poland)

PREDICTIVE ROLE OF ENDOSCOPIC/HISTOLOGICAL EXAMINATIONS FOR GASTRO-INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENIC STEM CELLS TRANSPLANT: ‘A POSTERIORI’ ANALYSIS IN A SINGLE CENTER

THE INCIDENCE, RISK FACTORS, AND OUTCOMES OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC HAPLOIDENTICAL HSCT: PROGNOSTIC CT FINDINGS AROUND THE ONSET OF ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE
Shinpei Harada, Koichiro Minauchi, Hajime Senjo, Naoki Miyashita, Tomohiro Yamakawa, Junko Iwasaki, Shojiro Takahashi, Kohei Okada, Akio Shigematsu, Masahiro Imamura, Naoki Kobayashi, Shuichi Ota (Japan)

THYMOGLOBULIN AND GRAFALON EFFECT ON ALLOGENIC STEM CELL TRANSPLANT - POOLED DATA FROM WROCŁAW MEDICAL UNIVERSITY, POLAND AND UNIVERSITY MEDICAL CENTER LJUBLJANA, SLOVENIA

THE ROLE OF LOW-DOSE ANTI-THYMOCYTE GLOBULIN IN MATCHED SIBLING DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES
Daihong Liu, Lijing Dou, Lu Wang, Fei Li, Lijun Wang (China)

NEPHROTIC SYNDROME AFTER ALLOGENIC STEM CELL TRANSPLANTATION AS A FORM OF CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE
CORRELATION AMONG TOTAL NUCLEATED CELLS (TNC), CD34+, CD3+ CELL CONTENT IN G-CSF-PRIMED BONE MARROW COLLECTIONS AND THEIR RELATIVE INFLUENCE ON DEVELOPMENT OF ACUTE GVHD
Stalin Ramprakash, Rajat Kumar Agarwal, C P Raghuram, Pallavi Mehta, Paula Tacia, S Sandeep, Rakesh Dhanya, Lawrence Faulkner (India)

PREDICTION FOR LETHAL ACUTE GRAFT VERSUS HOST DISEASE AND NON-RELAPSE MORTALITY BY EARLY PLASMA BIOMARKERS: A SINGLE CENTER RETROSPECTIVE STUDY IN JAPAN
Hideaki Yoshimura, Atsushi Satake, Masaaki Hotta, Takahisa Nakanishi, Aya Nakaya, Shinya Fujita, Tomoki Ito, Kazuyoshi Ishii, Shosaku Nomura (Japan)

RUXOLITINIB IN THE TREATMENT OF CORTICOSTEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD): ONE SINGLE CENTER EXPERIENCE
Melissa Torres Ochando, Paula Fernández-Caldas González, Haridian de la Nuez Melián, Cynthia Acosta Fleitas, Santiago Jiménez Bravo de Laguna, María Perera Álvarez, Leslie González Pinedo, Luisa Guerra Domínguez, Alexia Suárez Cabrera, Luz María González del Castillo, Leonor Pérez Ortiz, Teresa Molero Labarta (Spain)

OUTCOME OF PATIENTS ALIVE AT 1-YEAR POST ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM A SINGLE INSTITUTION

RUXOLITINIB IN STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: EXPERIENCE IN OUR CENTRE

LOW-DOSE OF RUXOLITINIB: AN EFFECTIVE THERAPY FOR REFRACTORY BOS PATIENTS
Yangping Ji, Baolin Tang, Xiaoyu Zhu, Huilan Liu, Kaidi Song, Xiang Wan, Wen Yao, Guangyu Sun, Zimin Sun (China)

SIROLIMUS BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PAEDIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT FOR BENIGN DISEASE
Gaurav Kharya, Archana Rauthan, Manju Joseph, Himshikha Yadav, Bharti Sharma, Atish Bakane (India)

DETECTION OF BIOMARKERS PREDICTIVE OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY

OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) AFTER PD-1 BLOCKADE IN RELAPSED/REFRACTORY (R/R) LYMPHOMAS: A SINGLE CENTER EXPERIENCE
Xabier Gutiérrez López de Ocariz, Elena Vera-Guerrero, María Calbacho, Jose Maria Sánchez-Pina, Ana Jiménez-Ubieto, Antonia Rodríguez, Sara Redondo, Marta Hidalgo-Soto, Rodrigo De Nicolás, Nieves López-Muñoz, Buenaventura Buendía-Ureña, Joaquin Martinez-Lopez (Spain)

CD3+ DOSE IN PERIPHERAL BLOOD PROGENITOR CELLS PRODUCTS FOR ALLOTRANSPLANT FROM MATCHED UNRELATED DONORS FOR AML: IMPACT ON CHRONIC GRAFT VERSUS HOST DISEASE AND SURVIVAL

CYCLOPHOSPHAMIDE FOR SALVAGE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE ANALYSIS
Matthias Alexander Fante, Tobias Wertheimer, Anna-Sophia Kattner, Daniela Weber, Barbara Holler, Ernst Holler, Matthias Edinger, Wolfgang Herr, Daniel Wolff (Germany)

A ROLE OF METHOTREXATE IN THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE - A MULTICENTER OBSERVATIONAL STUDY ON BEHALF OF POLISH ADULT LEUKEMIA GROUP (PALG)

EVALUATION OF EXTRACORPOREAL PHOTOPHERESIS USED AS SECOND-LINE TREATMENT FOR GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HSCT IN A BRAZILIAN CENTER
THE OPTIMAL GVHD PROPHYLAXIS IN UNRELATED TRANSPLANTATIONS OF NON-MANIPULATED HEMATOPOIETIC STEM CELLS IN CHILDREN

ANALYSIS OF HISTOLOGY’S IMPACT IN PATIENTS WITH ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Elena María Gámez Jiménez, Pedro Antonio González Sierra, Elisa López Fernández, Lucía Moratalla López, Zoraida Mesa Morales, Antonio Romero Aguilar, Manuel Jurado Chacón (Spain)

RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE

IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT). UNICENTRIC EXPERIENCE

FECAI MICROBIOTA TRANSPLANTATION FOR TREATING STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE OF THE GUT: A PILOT STUDY
Won-Hyoung Seo, Ik-Chan Song, Myung-Won Lee, Sang-Hoon Yeon, Yoon-Seok Choi, Bu-Yeon Heo, Jaeyul Kwon, Deog-Yeon Jo (Korea, Republic of)

EARLY RECOVERY OF LYMPHOCYTES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS RISK FACTOR OF CGVHD
Masato Yanagi, Ryoji Kobayashi, Satoru Matsushima, Daiki Hori, Koya Kodama, Daisuke Suzuki, Kunihiro Kobayashi (Japan)

FAVORABLE OUTCOME USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN HAPLOIDENTICAL (HAPLO-SCT) AND MATCHED RELATED DONORS (MRD): SINGLE CENTER EXPERIENCE IN CHILE
Matias Sanchez, Marcela Vargas, Javiera Donoso, Natalia Aranguiz, Alejandro Berkowits, Sebastian Ewoldt, Veronica Bustamante, Laura Paredes, Teresa Dibarrart, Patricia Lobos, Leonardo Cabrera (Chile)

COMBINED THERAPY WITH MSC INFUSIONS TO OVERCOME STEROID-DEPENDENCY IN A CASE OF SEVERE PULMONARY CGVHD
Francesca Compagno, Antonia Avanzini, Elena Bergami, Stella Boghen, Tommaso Mina, Santina Recupero, Elisa Lenta, Stefania Croce, Laura Catenacci, Alessandra Tolva, Federico Bonetti, Giovanna Giorgiani, Patrizia Comoli, Marco Zecca (Italy)

MULTIPLE STRICTURES OF THE SMALL INTESTINE DEMANDING SURGICAL INTERVENTION AS A COMPLICATION OF GRAFT VERSUS HOST DISEASE: A CASE REPORT

A REMARKABLY LONG REMISSION ACHIEVED WITH IBRUTINIB MONOTHERAPY IN A PATIENT WHO WAS DIAGNOSED WITH STEROID REFRACTORY SCLEROISNG CHRONIC GVHD

INCREASED RISK OF ACUTE GVHD IN PATIENTS WITH MYELOFIBROSIS AFTER ALLO TRANSPLANT IN THE ABSENCE OF JAK-STAT INHIBITION
Sami Brake (United States)

AUTOIMMUNE MYOSTITIS AS PARANEOPLASTIC COMPLICATION OF A SQUAMOUS CELL CARCINOMA OF THE TONGUE AFTER SEVERE CHRONIC GRAFT VERSUS HOST DISEASE

UNUSUAL CAUSE OF DYSPNEA IN POST-TRANSPLANT PATIENT

Graft-versus-host disease - preclinical and animal models

DIETARY STEARIC ACID LEADS TO A SEVERE AGVHD BY MODULATING THE GUT MICROBIOTA AND GLUCOSE METABOLISM
GRANULOCYTE COLONY-STIMULATING FACTOR-PRIMED DONOR T CELLS ATTENUATE MURINE ACUTE GVHD THROUGH REGULATING T CELL DIFFERENTIATION IN TARGET ORGANS

MTOR REGULATE GENERATION AND FUNCTION OF PMN-MDSCS AND PLAY PROTECTION ROLE IN ACUTE GRAFT-VERSUS-HOST DISEASE

FULL REGULATORY T CELL RECONSTITUTION BEFORE T CELL TRANSFER PREVENTS GRAFT-VERSUS-HOST DISEASE BY SUPPRESSING COSTIMULATION AND T CELL ACTIVATION IN A HAPLOIDENTICAL MODEL

TARGETING OF CHEMOKINE RECEPTOR 7 PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE

ENHANCING REGULATORY T CELL FUNCTION AND HOMING TO THE GUT TO IMPROVE GRAFT-VERSUS-HOST DISEASE PREVENTION AFTER ADOPTIVE TRANSFER IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION

Antonella Mancusi, Samanta Bonato, Rachele Del Sordo, Sara Piccinelli, Eni Hoxha, Tiziana Zei, Roberta Iacucci Ostini, Franca Falzetti, Alessandra Carotti, Loredana Ruggeri, Michele Giansanti, Robert S. Negrin, Massimo F. Martelli, Andrea Velardi, Antonio Pierini (Italy)

LYG1-DEFICIENT DONOR SPLENOCYTES ATTENUATED THE SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE VIA SKEWING CD4+ T CELL POLARIZATION TOWARDS TREG CELLS

Huihui Liu, Zhengyu Yu, Bo Tang, Chengchao Miao, Chenchen Qin, Miao Yan, Zhengyang Song, Hanyun Ren, Yujun Dong (China)

ATTENUATION OF MURINE CHRONIC GRAFT VERSUS HOST DISEASE BY THE NRF2 ACTIVATOR MANGIFERIN

Kang Sun, Ping Chen, Mengran Lee, Jun Ruan, Yuxue Xia, Mei Hong, Jun Fang, Hao Tang (China)

CHEMOTHERAPY AND INFLAMMATION INDUCED DAMAGE OF INTESTINAL EPITHELIUM IS ASSOCIATED WITH INCREASED T CELL CHEMOTAXIS

Suze A. Jansen, Marliek van Hoesel, Michal Mokry, Leire Saiz Sierra, Shuichiro Takashima, Edward E.S. Nieuwenhuis, Alan M. Hanash, Caroline A. Lindemans (Netherlands)

INKT CELLS PROMOTE IMMUNE TOLERANCE BY SELECTIVE DENDRITIC CELL APOPTOSIS

Emmanuelle Moraes Ribeiro, Hannes Schmid, Ruoyun Dong, Kathy-Ann Secker, Hildegard Keppeler, Corina Schneidawind, Dominik Schneidawind (Germany)

ACTIVE PARTICIPATION OF CXCR4+ T LYMPHOCYTES IN ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC TRANSPLANTATION

A MURINE MODEL REVEALS A CRITICAL ROLE FOR REACTIVE OXYGEN SPECIES IN HYPERACUTE GRAFT-VERSUS-HOST DISEASE

MAPPING THE ROAD OF GVHD AND GVT. A LONGTUDINAL STUDY OF IMMUNE-TRANSCRIPTOME SIGNATURES AS NOVEL APPROACH TO SOLVE POST-ALLOGENEIC TRANSPLANTATION DILEMMAS

Merav Bar, Mohammed Toufiq, Darawan Rinchai, Mohammed Elanbari, Valentina Mattei, Rebecca Mathew, Irene Cavattoni, Sabine Forer, Clarisa Brown, Marco Zecca, Patrizia Comoli, Giovanni Grillo, Catherine Cole, Chiara Cugno, Sara Tomei, Damien Chaussabel, Sara Deola (Qatar)

CELL-FREE DNA LEVELS ARE INCREASED IN ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS AND MICE

Anna Kroeze, Anne Cornelissen, Fernanda Pascutti, Sjoerd Klarenbeek, Achia Ait Soussan, Tom van der Poll, Mette Hazenberg, Erfan Nur, Ellen van der Schoot, Carlijn Voermans, Sacha Zeerleder (Switzerland)

DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION

ENDOTHELIAL MICROPARTICLES DELIVERING lncRNA NEAT1 ARE INVOLVED IN THE PATHOPHYSIOLOGY OF AGVHD FOLLOWING ALLO-HSCT
Scientific Programme

B-T CELL INTERACTIONS IN GRAFT-VERSUS-HOST DISEASE
Dhanya Kizhakayil, Abhirami Sathappan, Zoltan Pos, Nikolett Lupsa, Christophe M Raynaud, Giusy Gentilcore, Mohammad A Al-Aghbar, Cristina Maccalli, Jean-Charles Grivel, Nicholas van Panhuys, Sara Deola (Qatar)

IDENTIFICATION OF POTENTIAL MICROBIOME MARKERS FOR AGVHD EARLY DIAGNOSIS
Dhinoth K Bangarusamy, Arun P Lakshmanan, Sara Deola, Dhany Kizhakayil, Zoltan Pos, Nikolett Lupsa, Annalisa Terranegra (Qatar)

e-Posters
09:30 - 19:00

Granulocyte and osteoclast disorders

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR OSTEOPETROSIS
Ehud Even-Or, Irina Zaidman, Polina Stepensky (Israel)

e-Posters
09:30 - 19:00

Haemoglobinopathy and inborn errors

SUCCESSFUL HLA-MISMATCHED HSCT IN PAEDIATRIC PATIENTS WITH HEMOGLOBINOPATHIES USING ATG SEROTHERAPY AND POSTTRANSPLANT CYCLOPHOSPHAMIDE

OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH CEREBRAL ADRENOLEUKODYSTROPHY VARY BY DONOR CELL SOURCE, CONDITIONING REGIMEN, AND STAGE OF CEREBRAL DISEASE STATUS

OUTCOME OF NON MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE SICKLE CELL DISEASE: A 100 PATIENT EXPERIENCE FROM SAUDI ARABIA

HIGH DOSE STEM CELL THERAPIES, LIKE MGTA-456, ENABLE COMPLETE NEURAL AND PERIPHERAL DISEASE CROSS-CORRECTION THROUGH RAPID AND ROBUST HEMATOPOIETIC ENGRAFTMENT

HLA SET-UP IS A MAJOR PREDICTOR OF ENGRAFTMENT IN HAPLO-IDENTICAL TRANSPLANT FOR SEVERE THALASSEMA (ST) USING POST-CYCLOPHOSPHAMIDE (PTCY)
Stalin Ramprakash, C P Raghuram, Pallavi Mehta, Paula Tacia, Priya Mawah, Rajpreet Soni, Deepa Trivedi, Vaibhav Shah, Rakesh Dhanya, Rajat Kumar Agarwal, Lawrence Faulkner (India)

CTLA4IG-BASED T CELL COSTIMULATION BLOCKADE IN PTCY BASED HAPLOIDENTICAL HCT FOR THALASSEMA MAJOR [TM] AND SICKLE CELL DISEASE [SCD] RESULTS IN IMPROVED DISEASE-FREE SURVIVAL WITHOUT GVHD
Sarita Rani laiswal, Prakash Bhakuni, Hema Malini Aiyer, Aditi Chakrabarti, Satish Bansil, Suparno Chakrabarti (India)

LENTIGLOBIN GENE THERAPY TREATMENT OF TWO PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMA
Mattia Alqeri, Richard A. Colvin, Weijian Liu, Ge Tao, Franco Locatelli (Italy)
BONE MARROW TRANSPLANT IN PATIENTS WITH SICKLE CELL ANAEMIA. EXPERIENCE IN ONE CENTRE
Marina García Morín, Laura Escobar Fernández, Eduardo Bardón Cancho, Cristina Beléndez Bieler, Jorge Huerta Aragonés, Carmen Garrido Colino, Cristina Mata Fernández, Elena Cela de Julián (Spain)

OUTCOMES IN CEREBRAL ADRENOLEUKODYSTROPHY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE
Maria Escolar, Nicholas Bascou, Bridget Kiely, Aleksandra Safonova, Maria Beltran, Michele Poe, Paul Szabolcs (United States)

HEMATOPOIETIC RECOVERY AND TRANSFUSION NEED AFTER HAPLOIDENTICAL TRANSPLANTATION IN BETA THALASSEMAIA PATIENTS
Pre- and post-transplant rituximab reduces the high incidence of primary graft failure and immune-mediated cytopenia following cord blood transplant for lysosomal storage disease in children
Hemalatha Doss, Denise Bonney, Helen Campbell, David Deambrosis, Simon James, Kay Poulton, Wendy Ogden, Wynn Robert F (United Kingdom)

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE: THE SPANISH EXPERIENCE

LONG-TERM QUALITY OF LIFE IN PATIENTS WITH THALASSEMAIA MAJOR FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD
Oruc Ali Quliyev, Gulcihan Ozek, Savas Kansoy, Serap Aksoylar (Turkey)

HIGH INCIDENCE OF AUTOIMMUNE CYTOPENIAS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH THALASSEMAIA AND SICKLE CELL DISEASE: THE IMPACT OF MATCHED UNRELATED DONOR
Christina Oikonomopoulou, Anna Paisiou, Eleni-Dikaia Ioannidou, Aikaterini Kaisari, Anna Komitopoulou, Maria Theodoraki, Eftichia Petrakou, Ioulia Peristeri, George Vessalas, Evgenios Goussetis, Vassiliki Kitra-Roussou (Greece)

ADDING AZATHIOPRINE/HYDROXYUREA PRECONDITIONING TO ALEMTUZUMAB/TBI MAY REDUCE RISK OF GRAFT FAILURE IN MATCHED SIBLING DONOR ALLOGENEIC HSCT IN ADULT SICKLE CELL PATIENTS
Erfan Nur, Sacha Sergio Zeerleder, Aafke Gaartman, Caroline Rutten, Liesbeth Suijk, Charlotte van Tuijn, Judith Wenthold, Mette Hazenberg, Bart Biemond (Netherlands)

A PHASE II STRATIFIED TRIAL TO ASSESS HAPLOIDENTICAL T-DEPLETED STEM CELL TRANSPLANTATION IN PATIENTS WITH SICKLE CELL DISEASE WITH NO AVAILABLE SIBLING DONOR
Jürgen Föll, Katharina Kleinschmidt, Anja Tröger, Petra Turowski, Rainer Spachholz, Norbert Ahrens, Andreas-Michael Brosig, Matthias Evert, René Schmidt, Daniel Wolff, Matthias Edinger, Matthias Eyrich, Rupert Handgretinger, Susanne Ellinger, Selim Corbacioglu (Germany)

COMBINED UMBILICAL CORD BLOOD AND BONE MARROW FROM HLA-IDENTICAL SIBLING DONORS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMAIA MAJOR

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF METABOLISM USING ALTERNATE DONORS: A PROSPECTIVE SINGLE STUDY
Xiaowen Zhai, Xiaowen Qian, Ping Wang, Hongsheng Wang, Wenjin Jiang (China)

UMBILICAL CORD BLOOD TRANSPLANTATION IN CHILDREN WITH LEUKODYSTROPHIES: SINGLE CENTER EXPERIENCE IN CHINA
PEARSON SYNDROME IN A PATIENT TRANSPLANTED FOR DIAMOND-BLACKFAN ANEMIA

CHALLENGES AND SUCCESSES WITH PRE-TRANSPLANT IMMUNE SUPPRESSION IN ALTERNATIVE DONOR TRANSPLANTS
Gaurav Kharya, Archana Rauthan, Manju Joseph, Himshikha Yadav, Bharti Sharma, Atish Bakane (India)

HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CLASS 3 THALASSEMIA MAJOR USING POST-TRANSPLANT CYCLOPHOSPHAMIDE
Eman Khattab, Rula Najjar, Abdelghani Tbakhi, Rawad Rihani, Mayada Abu Shanap, Hasan Hashem, Aram Ahmod, Nilly Hussein, Iyad Sultan (Jordan)

Multiple myeloma

DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF HIGH-RISK PATIENTS IN CASSIOPEIA

EVALUATION OF PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (PET/CT) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PHASE 3 CASSIOPEIA STUDY PATIENTS: CASSIOPET STUDY RESULTS

CONCORDANCE OF POSTCONSOLIDATION MINIMAL RESIDUAL DISEASE RATES BY MULTIPARAMETRIC FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING IN CASSIOPEIA

LONG-TERM FOLLOW-UP OF THE RANDOMIZED PHASE 3 PETHEMA/GEM 2005MENOS65 STUDY SUPPORTS THE USE OF VTD (BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE) AS PRETRANSPLANT INDUCTION REGIMEN FOR MULTIPLE MYELOMA (MM)

DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE

HOW TO ASSESS RISK OF PROGRESSION IN MULTIPLE MYELOMA PATIENTS ACHIEVING COMPLETE REMISSION AFTER AUTOLOGOUS TRANSPLANT: SUB ANALYSIS FROM THE GEM2012MENOS65 PHASE III CLINICAL TRIAL

OUTCOMES OF ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS

25 YEARS OF AUTOLOGOUS TRANSPLANTATION FOR MYELOMA IN EBMT CENTRES - CHANGING PRACTICE PATTERNS

PROGNOSIS IN DIFFERENT RISK-GROUPS OF MULTIPLE MYELOMA WITH MINIMAL RESIDUAL DISEASE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BORTEZOMIB-INTEGRATED CONDITIONING: A SINGLE-CENTER EXPERIENCE

UNINTERRUPTED MOBILIZATION AND TRANSPANTATION PROCEDURE WITH NON-CRYOPRESERVED YIELD IS FEASIBLE WITHOUT INCREASEMENT OF COMPLICATION RISK IN MULTIPLE MYELOMA PATIENTS
Zübeyde Nur Özkurt, Ayse Asena Dikyar, Zeynep Arzu Yeğin, Lale Aydin Kaynar, Özlem Karacaoglu, Emin Ateş (Turkey)
CONDITIONING WITH BORTEZOMIB-MEL200 IN COMPARISON TO MEL200 IMPROVES SURVIVAL AMONG MYELOMA PATIENTS IN≤PR PRIOR TO AUTO-HCT: A STUDY FROM THE CMWP OF THE EBMT

RESULTS OF DEFERRED AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED STAGES OF SYSTEMIC ALAMYLOIDOSIS

IN VITRO STIMULATION WITH CD40L/IL-21 CAN RETRIEVE B-CELL DYSFUNCTION IN MULTIPLE MYELOMA PATIENTS SUFFERING FROM SECONDARY IMMUNODEFIENCY
Clarissa Heck, Sophie Steiner, Marco Frentsch, Friedrich Wittenbecher, Carmen Scheibenbogen, Axel Nogai, Philipp le Coutre, Lars Bullinger, Igor Wolfgang Blau, Il-Kang Na (Germany)

ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA; EXCELLENT OUTCOMES FOR EARLY TRANSPLANTATION

SEQUENTIAL HEART TRANSPLANTATION FOLLOWED BY HIGH DOSE CHEMOTHERAPY PLUS AUTOLOGOUS STEM CELL REINFUSION IN CARDIAC ALAMYLOIDOSIS

AUTOGRAFT CELLULAR COMPOSITION AND OUTCOME IN MYELOMA PATIENTS: RESULTS OF THE PROSPECTIVE MULTICENTER GOA STUDY
Antti Turunen, Anu Partanen, Jaakko Valtola, Antti Ropponen, Timo Siitonen, Mervi Putkonen, Marja Sankelo, Eeva-Riitta Savolainen, Marja Pyörälä, Taru Kuittinen, Raija Silvennoinen, Karri Penttilä, Anu Sikiö, Lasse Agren, Pentti Mäntymaa, Jukka Pelkonen, Ville Varma, Essa Jantunen (Finland)

RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE

PHASE 3, OPEN-LABEL, NONINFERIORITY STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): BODY WEIGHT SUBGROUP ANALYSIS OF COLUMBA
Maria-Victoria Mateos, Saad Z. Usmani, Sebastian Grosicki, Vladimir Vorobyev, Ivan Spicka, Vania Hungria, Sibirina Korenkova, Nizar Bahlis, Max Flogegard, Joan Bladé, Philippe Moreau, Martin Kaiser, Shinsuke Ida, Jacob Laubach, Tara Masterson, Kristen Lantz, Lisa O'Rourke, Xiang Qin, Dolly A Parasramraja, Christoph Heuck, Ming Qi, Hareth Nahi (Spain)

ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) IS A RELIABLE PREDICTOR FOR OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION

ABERRANT PHENOTYPE PLASMA CELL MULTIPARAMETRIC FLOW CYTOMETRY (MFC) DETECTION IN AUTOGRAFT PRODUCTS OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

RETROSPECTIVE MULTI-CENTER STUDY OF ADOLESCENT AND YOUNG ADULT (AYA) MULTIPLE MYELOMA IN KANSAI MYELOMA FORUM REGISTRY
Aya Nakaya, Takae Kohara, Hirohiko Shibayama, Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Toru Kida, Satoru Kosugi, Jun Ishikawa, Ryosuke Yamamura, Yutaka Shimazu, Hirokazu Tanaka, Shin-Ichi Fuchida, Yuji Shimura, Miki Kiyota, Katsuya Wada, Tomoki Ito, Nobuhiko Uoshima, Hideo Yagi, Satoshi Yoshihara, Kensuke Ohta, Chihiro Shimazaki, Masayuki Hino, Akifumi Takaoka, Kiyohiko Uoshima, Yuzuru Nomura (Japan)

MAINTENANCE THERAPY WITH ELOTUZUMAB AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Nobuhiro Tsukada, Junichiro Nashimoto, Yui Uto, Kota Sato, Kanji Miyazaki, Mizuki Ogura, Yuiko Yoshiki, Yu Abe, Kiyoshi Okazuka, Tadao Ishida, Kensi Suzuki (Japan)
AUTOLOGOUS STEM CELL TRASPLANTATION CANDIDACY IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS

NOVEL PROTOCOL FOR AUTOLOGOUS HSCT IN MULTIPLE MYELOMA ACHIEVES ‘ZERO’ CENTRAL LINE ASSOCIATED BLOOD STREAM INFECTIONS (CLABSI)
Emilian Snarski, Agnieszka Tomaszewska, Martyna Maciejewska, Michał Górka, Anna Brodziak, Sara Zawadzka-Leska, Anna Waszczyk-Gajda, Jarosław Biliński, Marcin Jasiński, Karol Lis, Kamila Skwierawska, Hubert Heleniak, Mateusz Ziarkiewicz, Dorota Zduńczyk, Wojciech Sachs, Elżbieta Urbanowska, Magdalena Feliksbroń - Bratosiewicz, Małgorzata Król, Maria Król, Wiesław Wiktor-Jędrzejczak, Grzegorz Basak (Poland)

OUTCOMES OF NON-CRYOPRESERVED VERSUS CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
Pokpong Piriyakhuntorn, Adisak Tantiworawit, Thanawat Rattanathammethe, Sasinee Hantrakool, Chatree Cha-Adisaksopha, Ekarat Rattaritamrong, Lalita Norasetthada (Thailand)

DOWN REGULATION OF AUTOPHAGY ENHANCES BORTEZOMIB-INDUCED APOPTOSIS OF MYELOMA CELL BY UP REGULATION OF MITOCONDRIAL REACTIVE OXYGEN SPECIES
Yeung-Chul Mun, Jee-Young Ahn, Eun Sun Yoo, Kyoung Eun Lee, Eunmi Nam, Soon Nam Lee, Hyun Ae Woo, Sue Goo Rhee, Chu Myong Seong (Korea, Republic of)

RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE
Avse Tülin Tuglular, Tayfun Elibol, Arda Bayar, Belgin Aldag, Ozen Oruc, Tarik Erkan, Yildiz Ipek, Fatma Arikan, Asu Fergün Yilmaz, Işık Atagündüz, Tayfur Toptas (Turkey)

FAVORABLE LONG-TERM OUTCOMES WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HIGH RISK PATIENTS WITH MULTIPLE MYELOMA WHO ARE POSITIVE AT FDG-PET/CT
Hee Jeong Cho, Dong Won Baek, Ju Hyung Kim, Sung Hoon Jung, Sang Kyun Sohn, Joon Ho Moon (Korea, Republic of)

LONG TERM SURVIVAL OF MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELATION TO AVAILABILITY OF NOVEL DRUGS
Ozren Jaksic, Zeljko Prka, Mario Piracic, Zdravko Mitrovic, Ena Soric, David Cicic, Tamara Vasilj, Zeljko Jonjic, Marko Lucijanic, Ivana Maricic, Gorana Dzepina, Rajko Kusec, Vlatko Pejsa (Croatia)

MULTIPLE MYELOMA (MM) IN FIRST RELAPSE PATIENTS. ROLE OF THE SECOND AUTOLOGOUS STEM-CELL TRANSPLANT (ASCT) IN REAL LIFE: EXPERIENCE OF TWO SPANISH CENTERS
N Amer, MT Villalobos, R Del Campo, Jb Borràs, A Porcel, Jm Guerra, A Jaramillo, A Cladera, M Mascaró, J Perales-Amengual, M Canet, P Vélez, J Perales, A Muntañola, Ja Soler, M López, M Díaz, F Vall-Ilovea, Jm Martí, J Bargay (Spain)

ROLE OF ANALYSIS OF CHIMERISM IN MULTIPLE MYELOMA PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE

USE OF NETUPITRANT/PALONOSETRON IN MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE

THE EFFECT OF UCP-2 AND NR3C1 GENES ON TREATMENT EFFICACY AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA
Ilknur Demir, Sacide Pehlivan, Vahap Okan, Handan Sahin, Sertac Durusoys, Yasemin Oyaci, Mustafa Pehlivan (Turkey)

SAFETY AND EFFECTIVENESS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA IN FIRST LINE
Myelodysplastic syndromes

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OF ADULT PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA: A NORDIC RETROSPECTIVE STUDY

DECITABINE MONOTHERAPY BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION RESULTED IN SUPERIOR SURVIVAL FOR MYELODYSPLASTIC SYNDROME PATIENTS WITH EXCESS BLASTS

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM: A STUDY FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT

IMPACT OF MUTATION PROFILE IN CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

NEW INSIGHTS OF MYELODYSPLASTIC SYNDROME (MDS) WITH ERYTHROID PREDOMINANCE BASED ON THE NEXT-GENERATION SEQUENCING AND SINGLE-CELL RNA SEQUENCING

IMPACT OF TREATMENT PRIOR TO ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: RESULTS OF THE LATIN AMERICAN BONE MARROW TRANSPLANT REGISTRY

RESULTS OF LATIN AMERICAN RECORD OF BONE MARROW TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME
OUTCOME AND MUTATIONAL PROFILE IN MDS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Nikolai Tcvetkov, Elena Morozova, Ildar Barkhatov, Ivan Moiseev, Maria Barabanshikova, Artem Tishkov, Dmitrij Bug, Ekaterina Izmailova, Sergey Bondarenko, Boris Afanasyev (Russian Federation)

Non-infectious late effects, quality of life and fertility

EASIX-1YEAR- THE FIRST BIOMARKER PREDICTING LATE MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

AN UPDATED REPORT ON SECONDARY SOLID CANCER FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THALASSEMIA MAJOR

ALLOGENEIC STEM-CELL TRANSPLANTATION IN AML AND MDS USING CONDITIONING REGIMENS WITH DIFFERENT DOSE-INTENSITIES; 15 YEARS LATER

EMPLOYMENT STATUS AND RETURN TO WORK AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: RESULTS FROM A NATIONWIDE SURVEY

FUNCTIONAL OUTCOME MEASURES IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): FOCUS ON THE 2-MINUTE WALK TEST

FERTILITY IN ADULT FEMALE ALLOGENEIC STEM CELL RECIPIENTS

A RISK SCORE MODEL (HAD-TCG) TO EVALUATE THE RISK OF STROKE IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

BRONCHIOLITIS OBLITERANS SYNDROME IN THE CHANGING LANDSCAPE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Egor Kulagin, Alisa Volkova, Ilya Nikolaev, Julia Rabik, Victoria Timchick, Anna Smirnova, Tatiana Bykova, Tatiana Rudakova, Elena Daranskaya, Alexander Alyanskiy, Ivan Moiseev, Sergey Bondarenko, Vasily Trofimov, Boris Afanasyev (Russian Federation)

CURRENT STATUS AND NEEDS OF LONG-TERM FOLLOW-UP CLINICS FOR HEMATOPOIETIC CELL TRANSPLANT SURVIVORS: RESULTS OF A NATIONWIDE SURVEY IN JAPAN

Saiko Kurosawa, Ayako Mori, Mayumi Tsukagoshi, Yasushi Onishi, Chikako Ohwada, Takehiko Mori, Hideki Goto, Yuki Asano-Mori, Yuichiro Nawa, Masayuki Hino, Tomoko Fukuchi, Yasuo Mori, Reiko Yamahana, Yoshihiro Inamoto, Takahiro Fukuda (Japan)

SURVIVORSHIP CARE FOR ALLOGENEIC TRANSPLANT PATIENTS IN THE UK: CURRENT SERVICE PROVISION AND BARRIERS TO IMPLEMENTATION

Fiona Dignan, Angela Hamblin, Amelia Chong, Julia Perry, Michelle Kenyon, Paul Miller, Maria Gilleece, Hannah Hunter, John Snowden (United Kingdom)

CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN EPSTEIN-BARR VIRUS RELATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (EBV-PTLD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)

INCIDENCE, RISK FACTORS AND OUTCOMES OF DIFFUSE ALVEOLAR HEMORRHAGE AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION

WHOLE BODY VIBRATION TRAINING DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION - THE EFFECTS ON PATIENTS' PHYSICAL CAPACITY, FATIGUE, BODY COMPOSITION AND QUALITY OF LIFE

MULTI-MORBIDITY IN ADULT SURVIVORS OF STEM CELL TRANSPLANTATION (SCT)
GONADOTOXICITY AFTER TREOSULFAN-BASED MYELOABLATIVE CONDITIONING REGIMEN FOR ALLOGENEIC HSC IN GIRLS WITH LEUKEMIA
Irina Kostareva, Yulia Skvortsova, Elena Illina, Nataliya Radlevich, Lyudmila Papusha, Dmitriy Balashov, Anna Livshits, Andrey Abrosimov, Larisa Shelikhova, Darya Shasheleva, Kirill Voronin, Michael Maschan, Aleksey Maschan (Russian Federation)

REDUCED-INTENSITY TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH HIGH-RISK OR ADVANCED HEMATOLOGICAL MALIGNANCIES IN LAST 10 YEARS - SINGLE CENTRE EXPERIENCE
Michal Karas, Katerina Steinerova, Marcela Hrabetova, Daniel Lysak, Alexandra Jungova, Lekaa Mohammad, Jiri Sramek, Pavel Jindra (Czech Republic)

FATHERHOOD AFTER A MYELOABLATIVE TREOSULFAN BASED ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS ON 453 PATIENTS
Maria Teresa Lupo-Stanghellini, Andrea Assanelli, Fabio Giglio, Carlo Messina, Raffaella Greco, Daniela T. Clerici, Sara Mastaglio, Francesca Pavesi, Francesca Farina, Stefania Girlanda, Francesca Lorentino, Simona Plemontese, Sarah Marktel, Francesca Lunghi, Matteo G Carrabba, Magda Marcatti, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Fabio Ciceri (Italy)

COMPARISON OF CENTRAL NERVOUS SYSTEM RELAPSE OUTCOMES FOLLOWING HAPLOIDENTICAL VS IDENTICAL-SIBLING TRANSPLANT FOR ACUTE LYMPHOBLASTIC LEUKEMIA

OLDER AGE AND PERIPHERAL BLOOD AS A STEM CELL SOURCE ARE THE MAJOR NEGATIVE PREDICTORS OF SURVIVAL LONG TERM

PREVALENCE OF BRONCHIOLITIS OBLITERANS SYNDROME (BOS) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLOHSC) IN THE US, EUROPE AND JAPAN
Emilie Hofstetter, Dominik Kappeler, Noreen Roth Henig, Anne Bergeron (Germany)

NETUPITANT-PALONOSETRON (NEPA) TO PREVENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MULTIPLE MIELOMA (MM) PATIENTS RECEIVING HIGH-DOSE (HD) MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
Vincenzo Apolito, Simone Ferrero, Mattia D'Agostino, Giusy Cetani, Francesca Bonello, Federica Martella, Danilo Faraci, Sara Butera, Giuseppe Lanzarone, Alessandra Larocco, Stefania Oliva, Lucia Brunello, Luisa Giaccone, Mario Boccadore, Dario Ferrero, Benedetto Bruno, Marco Cerrano (Italy)

MOST FREQUENT LATE EFFECTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA DOES NOT SEEM TO WORSEN PERFORMANCE STATUS
Irati Ormazabal Velez, Marina Quesada Sánchez, Angela Figuera Álvarez (Spain)

INVOLVING STEM CELL TRANSPLANT PATIENTS AND THEIR FAMILIES TO IMPROVE THE ANTHONY NOLAN MY TRANSPLANT TRACKER APP

EARLY MENOPAUSE AND RISK FACTORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PREMENOPAUSAL ADULT WOMEN
Yoo Jin Lee, Jeong Sook Kim, Jae-Cheol Jo, Jaekyoung Cheon, SuJin Koh, Young Joo Min, Kukju Kweon, Sang-Hyuk Park, Jun-Woo Ahn, Yunsuk Choi (Korea, Republic of)

MUSCULOSKELETAL COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS

CLINICAL CHARACTERISTICS AND MANAGEMENT OF LATE RELAPSE OF ACUTE MYELOID LEUKAEMIA MORE THAN FIVE YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Shafqat Inam, Shu Wong, Michelle Kenyon, Victoria Potter, Austin Kulasekararaj (United Kingdom)
FOLLOWING UP WITH ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING 5+ YEARS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Yuta Katayama, Ryouta Imanaka, Koji Iwato, Tatsuya Terasaki, Takuya Nunomura, Fumiaki Jinnouchi, Takeshi Okatani, Kohei Kyo, Mitsuhiro Itagaki, Shinya Katsutani, Tsuyoshi Muta, Hideki Asaoku (Japan)

LOW BACK PAIN AND LASER ACUPUNCTURE IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELLS TRANSPLANTATION

EFFECTS OF CONTROLLED EXERCISE ON PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

LONG-TERM OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANT IN AN ASIAN POPULATION: A SINGLE-CENTER EXPERIENCE
Melinda Tan, Jeffrey Quek, Yeh Ching Linn, William Hwang, Yvonne Loh, Yeow Tee Goh, Jing Jing Lee, Aloysius Ho (Singapore)

DEVELOPMENT OF GUILLAIN-BARRE-LIKE SYNDROME IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELLS TRANSPLANTATION

Psychological issues

INVESTIGATING THE LONG-TERM OUTCOMES OF ADULT PATIENTS WHO UNDERWENT HAEMATOPOIETIC STEM CELL TRANSPLANT FOR PRIMARY IMMUNODEFICIENCY DURING CHILDHOOD

THE IMPACT OF MEDICAL AND SOCIAL REHABILITATION ON THE QUALITY OF LIFE IN CHILDREN WITH ONCOLOGIC AND HEMATOLOGIC DISEASES

THE IMPACT OF PRE-TRANSPLANT DEPRESSION AND ANXIETY ON THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION, A STUDY OF THE TCWP OF THE EBMT

ASSOCIATIONS BETWEEN FAMILY FUNCTION DOMAINS AND COPING STRATEGIES OF ADOLESCENTS UNDERGOING HSCT

HOW PATIENTS’ VIEWS ARE HELPING SHAPE PLANS FOR A NEW TRANSPLANT PSYCHOLOGY SERVICE

CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: TWO DIFFERENT ANALYTICAL APPROACHES

ARC CLINIC: APPLYING PSYCHOLOGICAL INSIGHTS TO PROMOTE EARLY REHABILITATION IN MYELOMA POST-TRANSPLANT
Alex King, Julian Jacob, Lizzie Jones, Anna Bootle, Vijai Glackin, Angela Daniel, Clair LeBoutillier (United Kingdom)

FROM HOSPITALIZATION TO RETURN HOME: A TRANSITIONAL ACTION RESEARCH IN THE HEMATOLOGY SECTOR
Sandrine Letrecher (France)

1000 IN 10 . 10 YEARS OF CLINICAL PSYCHOLOGY PRACTICE WITH 1000 PATIENTS IN THE SAME BMT UNIT IN MARSEILLE, FRANCE
Patrick Ben Soussan, Yolande Arnault, Laurence Caymaris, Didier Blaise (France)
Scientific Programme

IMPLEMENTATION OF PSYCHOLOGICAL SUPPORT AND DEVELOPMENT OF EDUCATIONAL PROGRAM FOR CHILDREN AND ADOLESCENTS UNDERGOING HSCT AND THEIR PARENTS IN RUSSIA
Natalia Klipinina, Natalia Nikolskaya, Larisa Shelikhova, Zhanna Shekhovtsova, Maria Ilushina, Rimma Khismatullina, Ekaterina Shutkova, Alina Khain (Russian Federation)

Nurses Posters - Adult

ROLE OF QUICKSOFA IN PREDICTING SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL PATIENTS

<i>BOLUS;</i> TARGETED SPECIALIST HEMATOLOGY/BMT PODCASTS: AN EFFECTIVE METHOD OF EDUCATION

A PATHWAY FOR RECOVERY: D+100 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT) FOLLOW UP PILOT FOR LYMPHOMA

REDUCING ACCIDENTAL FALLS CAUSED BY ORTHOSTATIC HYPOTENSION IN BONE MARROW TRANSPLANT RECIPIENTS

THE EFFECT OF MOTIVATIONAL INTERVIEW PERFORMED AFTER STEM CELL TRANSPLANTATION ON SEXUAL EXPERIENCE, SEXUAL SELF-AWARENESS AND SEXUAL SELF-EFFICACY

STUDY ON COGNITIVE FUNCTION AND RELATED FACTORS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

THE EFFECT OF RELAXING BREATHING EXERCISES ON PAIN, FATIGUE AND LEUKOCYTE COUNT IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

UNDERSTANDING OF PROGNOSIS, QUALITY OF LIFE AND PSYCHIATRIC STATUS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY OF 348 PATIENTS
Xia Yan, Ting Wang, Wei Hu, Xiaodong Xu, Shujia Liu (China)

AN OUTPATIENT MODEL OF CARE TO SAFELY DELIVER AUTOLOGOUS STEM CELL TRANSPLANTATION

EFFECTS OF TREATMENTS FOR HAEMATOLOGICAL MALIGNANCIES ON SEXUALITY AND FERTILITY: WHEN DO PATIENTS NEED IT AND WHOM REALLY WANTS TO KNOW?
C Eeltink, B Lissenberg, I Nauta, J Rood, L Incrocci, I Verdonck-de Leeuw, S Zweegman (Netherlands)

EFFICACY OF THERAPEUTIC EDUCATION TO REDUCE RISKS AND COMPLICATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OBSERVATIONAL PROSPECTIVE COHORT STUDY
Marco Ciocé, Laura Orlando, Stefano Botti, Gianpaolo Gargiulo (Switzerland)

SELF-EFFICACY AND SELF-CARE PRACTICES OF PATIENTS WHO HAVE BEEN TRANSPLANTED WITH ALLOGENEIC HEMATOPOIETIC STEM CELLS ACCORDING TO THE DEVELOPMENT OF AN INDIVIDUAL EDUCATION PROGRAM

DETERMINING THE SYMPTOMS AND COPING METHODS OF PATIENTS AT HOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kader Caliskan, Gulbeyaz Can (Turkey)
THE EFFECT OF ORAL CARE PROTOCOL ON ORAL MUCOSITIS IN PATIENTS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kwan Suk Jo, Seung Nam Zang, Ga Yeon Kim, Hye Yun Cho, Yang Sook You (Korea, Republic of)

PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) WITHIN AN AMBULATORY CARE SETTING; A PATIENTS' PERSPECTIVE
Noemi Gianni, Tania Arthurs, Yvonne Patefield-Smith, Kirsten Rendall, Jo Wyatt, Rachel Miller (United Kingdom)

REDUCING ANTITHYMOCYTE GLOBULIN (ATG) INFUSION RELATED REACTION BY INCREASING THE INFUSION DURATION IN ADULT SCT PATIENTS; A SINGLE INSTITUTION EXPERIENCE FROM SAUDI ARABIA
Suha Alkhraisat, Moussab Damlaj, Maybelle Balili, Samer Ghazi, Innaam Shehabeddine, Isam Mahasneh, Bader Ahmari, Heba Alshobaki, Mohsen Alzahrani (Saudi Arabia)

NURSE LED TELEPHONE FOLLOW UP FOR LATE EFFECTS SERVICE
NURSING CARE OF 15 PATIENTS WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CHIMERIC ANTI-GEN RECEPTOR T CELLS
NURSING CARE OF A PATIENT WITH HEREDITARY DIFFUSE LEUKOENCEPHALOPATHY COMPLICATED WITH AXONAL DEGENERATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
EFFECT OF NURSES EDUCATION PROGRAM ON CATHETER RELATED BLOOD STREAM INFECTIONS
Roberta Gironi, Marco Fabbrini, Daniela Clerici, Chiara Oltolini, Raffaella Greco, Consuelo Corti, Fabio Ciceri, Antonella Biella (Italy)

THE CURRENT SITUATION AND INFLUENCING FACTORS OF MANAGEMENT OF CENTER VENOUS ACCESS DEVICE-ASSOCIATED SKIN IMPAIRMENT DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Ting Wang, Xia Yan, Linnan Wang, Xinxin He, Boning Liu (China)

EXERCISE SUPPORT FOR PEOPLE POST TREATMENT AS PART OF THEIR RETURN TO WORK JOURNEY: A CASE STUDY EXEMPLAR
ONCOSAFETY: A NEW TOOL FOR HEMATOLOGY NURSES TO AVOID CHEMOTHERAPY ERRORS
Llara Roca Gimeno, Elisabeth Lazaro Lora, Marta Yusta Arnal, Iria Gonzalez Alvarez (Spain)

PATIENT INFORMATION SHEET FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION: THE IMPACT OF THE DISEASE AND TREATMENT ON SEXUAL FUNCTION AND SEXUALITY
C Eeltink, L Incrocci, I Verdonck-de Leeuw, S Zweegman (Netherlands)

CHANGING PRACTICE BY USING CYCLOPRIME 1.5G/M2 PRIMING REGIME UP FRONT FOR LYMPHOMA PATIENTS TO ENSURE GOOD MOBILISATION OF STEM CELLS
Jennefer Rose, Sophie Jones, Wendy Ingram (United Kingdom)

THE CHALLENGES OF LOOKING AFTER AN INCREASING NUMBER OF SURVIVORS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION
Lara Rowley, Amanda Ellis, Denise Wareham, Daja Barton, Emma Shaw, Olivia Hilsdon, Francesca Toselli, Shirley Hudson (United Kingdom)

VENO-OCCLUSIVE DISEASE (VOD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANT NURSING CONSIDERATIONS AND MANAGEMENT: A CASE STUDY
Marie Waller, Christopher Heron, Hayley Dyos, Eleni Tholouli (United Kingdom)

RECOGNIZING LOW HEALTH SKILLS AND LOW LITERACY DURING CONSULTATION
Lian Schoonhoven-Bos (Netherlands)
PRE- HABILITATION PRIOR TO STEM CELL TRANSPLANT - ONE CENTRES EXPERIENCE

THE IMPORTANCE OF NURSES TRAINING IN NEW THERAPY USING THE EXAMPLE OF CAR-T CELL THERAPY

PLASMAFHERESIS: TAKING THE EDGE OFF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTIBODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION

Sinju Thomas, Adrien Quintela, Arthi Anand, Karen Bradley (United Kingdom)

INCIDENCE & CHARACTERISTICS OF VARICELLA ZOSTER VIRUS INFECTION POST HEMATOPOIETIC STEM CELL TRANSPLANTATION; EXPERIENCE OF A SINGLE CENTER IN SAUDI ARABIA

SEMI-STRUCTURED INTERVIEW ASSESSMENT OF THE CLINICAL NURSE EDUCATOR ROLE IN SUPPORTING NEWLY QUALIFIED NURSES DURING TRANSITION TO POST-REGISTRATION PRACTICE INSIDE THE BONE MARROW TRANSPLANT SETTING

Luke White, Kathryn Vowden (United Kingdom)

TRAINING NURSING PROGRAMME IN NEW THERAPIES: CAR T CELLS

NURSES' ROLE IN IMPROVING PATIENTS' FOOD INTAKE IN THE ACUTE HSCT PHASE

USE THE AVAILABLE KNOWLEDGE - ENSURE THAT THE PATIENT RECEIVES THE BEST CARE IN STEM CELL TRANSPLANTATION

Anncarin Svanberg (Sweden)

THE PSYCHO EMOTIONAL DISAGUE IN ADULT PATIENTS SUBJECT TO MIDOLLO TRANSPLANT: INITIAL STUDY OF A SINGLE CENTER

NURSING CARE OF 15 PATIENTS WITH HEMATOLOGICAL MALIGNANT TUMOR COMPPLICATED WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CAR-T CELLS

Lorella Cappucciati, Chiara Buraschi, Cinzia Merlini, Sabrina Sbizzirro, Silvia Fava, Stefano Gandolfi, Donatella Petrucci, Luca Pasquali, Mirella Gubbelini, Andrea Contini (Italy)

GUIDE FOR PATIENTS AND DONORS BEFORE A PERIPHERAL BLOOD STEM CELL COLLECTION

ARE TYMPANIC THERMOMETERS RELIABLE IN HEMATOPOIETIC STEM CELL RECIPIENTS?

RELATIONSHIPS BETWEEN THE HEALTHCARE NEEDS AND QUALITY OF LIFE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS

PAIN ASSESSMENT DURING BONE MARROW BIOPSY PROCEDURE AND BONE MARROW ASPIRATE PROCEDURE: A SPECIFIC NURSING ASSESSMENT

AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION IN SYSTEMIC SCLEROSIS: CASE STUDY

Page 206 / 353
Scientific Programme

LEADERSHIP - LEADING THE TEAM
Kiara Kabatova Maxova (Czech Republic)

PAIN ASSESSMENT IN ONCO_HEMATOLOGICAL PATIENT SUBJECTED TO CENTRAL VENOUS CATHETER POSITIONING (CVC) OR PERIPHERALLY INSERTED CENTRAL CATHETER POSITIONING (PICC)
Lorella Cappucciati, Giovanna Buonanno, Corrado Gozzo, Francesco Oleari, Raffaella Maestri, Noemi Paladini, Patrizio Imbriani, Lucrezia Maria Zagononi, Sara Posla, Mirella Gubbelini, Andrea Contini (Italy)

TOCILIZUMAB MANAGEMENT IN THE CYTOKINE RELEASE SYNDROME
Lucília Carreiro, Carla Gonçalves, Fátima Pereira, Rosa Romão, Cândida Damião (Portugal)

IS IT WORTH FIGHTING TOGETHER FOR AN INDIVIDUAL ACCESS TO A MEDICINE WITH A NON REIMBURSEMENT DECISION? YES IT IS!
Isabel Salcedo, Esther Ortiz, Juana María Acebes, Mari Luz Pascual, Beatriz Sanchez Sevillano, Almudena Laiglesia, Ana Alarcón, Rafael F Duarte (Spain)

INCIDENCE OF ACUTE GUT GVHD IN PATIENTS WHO HAVE UNDERGONE ALLOGENIC STEM CELL TRANSPLANT: CASE STUDY
Poonam Thorat, Meera Sharad Achrekar, Deepti Ghonge (India)

COMPLETION TIME TO HLA TYPING

GYNECOLOGICAL TREATMENT EXPERIENCE OF MENOPAUSAL SYNDROME AND SEXUAL DISORDERS IN FEMALE PATIENTS WHO UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION

Nurses Posters - Paediatric

TRANSITION STRATEGY: FROM PEDIATRIC TO ADULT HEALTH CARE AND LONG TERM FOLLOW-UP

CAREGIVER EDUCATION AND TRAINING FOR SELF ADMINISTRATION OF ORAL DRUGS IN A PAEDIATRIC CENTER

EXERCISE THERAPY ON CANCER-RELATED FATIGUE AND QUALITY OF LIFE IN CHILDREN UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION

SEXUAL HEALTH FOR YOUNG PEOPLE UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION

EVALUATION OF A PREVENTIVE SKIN CARE PROTOCOL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS RECEIVING THIOTEPA
Kim van der Niet, Lisa Rozendaal, Dagmar Berghuis, Eileen van der Stoep-Yap, Erik von Asmuth, Maria de Taeye-Veldhuizen, Arjan Lankester, Hilda Mekelenkamp (Netherlands)

CAR-T: THE DUTCH PEDIATRIC NURSING EXPERIENCE
Ida Bremer Ophorst, Tineke Terlouw (Netherlands)

SUBSTITUTIVE THERAPY WITH S.C. IMMUNOGLOBULINS IN PEDIATRIC HSCT RECEPIENTS: A SINGLE CENTER EXPERIENCE
Rosanna Ceresoli, Stefano Benvenuti, Patrizia Bevilacqua, Mirella Savoldi, Fulvio Porta (Italy)
Scientific Programme

PEDIATRIC PHOTOPHOREAHERESIS: THE DILEMMA OF VASCULAR ACCESSES
Rosanna Ceresoli, Stefano Benvenuti, Emilio Ferrari, Fulvio Porta (Italy)

TOTALLY IMPLANTABLE VASCULAR ACCESS DEVICES RUPTURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: PROPHYLAXIS AND TREATMENT

USE OF VOLUMETRIC PUMPS FOR THE INFUSION OF HEMATOPOIETIC STEM CELLS AS A STANDARD METHOD IN PEDIATRIC PATIENTS
Nuria Caballero, Marian Cerezuela, Isabel Badell Serra (Spain)

PEDIATRIC PATIENT TRANSFER FROM A TPH WARD TO ICU: HOW CAN WE IMPROVE OUR COMMUNICATION?
Almudena Pérez, Alba Martínez, Anna Negre, Laura Lahuerta (Spain)

CARING FOR MINOR SIBLING DONORS
Eugenia Trigoso Arjona, Estrella Larios Reyes, Maria Sol Abert Velert (Spain)

EFFECTIVE MOBILISATION WITH PLERIXAFOR FOLLOWING CRANIA-SACRAL RADIOTHERAPY AND HIGH-DOSE CHEMOTHERAPY: A CASE REPORT OF AN ELEVEN-YEAR OLD BOY WITH GLIOBLASTOMA MULTIFORME
Anna Tailby, Julia Nixon, Alison Bridgman, Angela Burns, Abigail Cotton, Hannah Ezard, Josephine Nicholls, Melanie Rooney, Elisabeth Thomas, Ilian Uri, Marita Macken, Sarah Lawson, Martin English (United Kingdom)

EARLY RECOGNITION OF PEDIATRIC GVHD: EDUCATION AND AWARENESS AMONGST NURSES
Bart Maertzdorf, Anouk Jongekrijg (Netherlands)

RISK ASSESSING PAEDIATRIC PATIENTS' NUTRITIONAL NEEDS PRIOR TO BONE MARROW TRANSPLANT

Nurses Posters - Research

FAMILY CAREGIVERS SUPPORT NEEDS DURING ALLO-HSCT - A LONGITUDINAL STUDY (PRELIMINARY RESULTS)

PAIN AND ANXIETY MANAGEMENT DURING BONE MARROW ASPIRATES IN ITALIAN TRANSPLANT PROGRAMS. A NATIONWIDE SURVEY ON BEHALF OF GITMO NG

PREVALENCE, PREDICTORS AND OUTCOMES OF CLABSI AMONG HSCT PATIENTS

CREATION OF THE LABMT NURSES GROUP

SYMPTOMS AND QUALITY OF LIFE OF CHILDREN AND ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY

SOCIAL SUPPORT MODERATES THE EFFECTS OF HEALTH STRESSORS ON HEALTH CARE ADHERENCE AND PSYCHOLOGICAL DISTRESS IN LONG-TERM HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS

SYMPTOM DISTRESS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A PROSPECTIVE STUDY
Scientific Programme

NURSE INVOLVEMENT AND IMPACT OF JACIE ACCREDITATION ON NURSE PRACTICE
Carmen Conde, Ariadna Domenech, Iria González, Verónica Linde Blazquez, Eugenia Trigoso Arjona, Julia Ruiz Pato (Spain)

CONSTRUCTION OF QUALITY INDICATORS SYSTEM OF NUTRITION CARE FOR ADULT PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION THROUGH AN EVIDENCE-BASED APPROACH
Yun Fang, Minjie Liu, Chen Xie (China)

ARE CAREGIVERS RECEIVING ENOUGH INFORMATION TO CARE? A PILOT STUDY ON A HAEMATOLOGICAL TRANSPLANT UNIT

MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A THREE YEARS FOLLOWING UP
Yaya Song, Xiating Zhu, Yin Lu, Yongqin Ge, Qin Li, Fang Tang, Ying Chen, Yaohong Li (China)

VENOUS ACCESS IN AUTOLOGOUS VERSUS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT DONORS: A RETROSPECTIVE STUDY OF AN APHERESIS UNIT
Isabel Salcedo, Angela Salas, Laura Vicente, Lucia Paola Cuéllar, Virginia Infante, Carmen de la Puente, Jose Luis Bueno (Spain)

A STUDY TO ASSESS THE LEVEL OF BURNOUT AMONG NURSES WORKING IN BONE MARROW TRANSPLANT (BMT) UNIT OF A TERTIARY CARE CANCER HOSPITAL
Shreya Ludbe, Meera Sharad Achrekar, Rynel Quadras (India)

DO WE KNOW ENOUGH ABOUT THE BONE MARROW DONATION?

ASSOCIATION OF AIR BORN PARTICLE SIZE AND PARTICLE COUNT WITH INCIDENCE OF INFECTIONS IN HEPA FILTERED ROOMS-A SINGLE CENTRE EXPERIENCE

SYSTEMATIC REVIEW OF SIGNS AND SYMPTOMS OF THE HUMAN HERPES VIRUS 6 AND THEIR ASSESSMENT TOOLS
Rodrigo Serrano Villegas, Beatriz del Amo Mateos, Claudia Pina Pino, María Teresa Abellán Garrido, Gema Hernández Sanchez, MarÌa Cabezas López de Sosoaga, Montserrat Pilar Barrilero Lopez (Spain)

A STUDY TO ASSESS PERCEIVED STRESSORS AND COPING STRATEGIES ADOPTED BY PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL INFUSION IN SELECTED CANCER HOSPITAL, INDIA
Bhushan Shelar (India)

ROLE OF THERAPEUTIC APERATURESIS IN ALLOGENEIC TRANSPLANTATION: A CASE REPORT
Cristina Alberquilla Ramos, Salvador Aleza Estera, Josefa Navarrete Ruiz, Beatriz Alonso Gonzalez, Rocío Rico Muñoz, Ana Isabel Torre Polo, Pilar Herreros López, Julia Ruiz Pato (Spain)

SYMPTOMS OF ELDERLY PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER INDUCTION CHEMOTHERAPY
Yaohong Li, Xiating Zhu, Yi Lu, Fang Tang, Yongqin Ge, Qin Li, Ying Chen, Yaya Song (China)

Solid tumours

SUCCESSFUL KIR ALLOREACTIVE HSCT IN A CHILD WITH RESISTANT EWING SARCOMA
Scientific Programme

TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS
Sara Redondo Velas, María Calbacho Robles, Doris Elizabeth Cueva Arica, Maria Liz Paciello Coronel, Buenaventura Buendia Ureña, Ana Jimenez, José María Sanchez Pina, Daniel Castellano, Guillermo De Velasco, Rosa Ayala Díaz, Joaquín Martínez López (Spain)

VOC PATTERN RECOGNITION OF LUNG CANCER: A COMPARATIVE EVALUATION OF DIFFERENT DOG- AND ENOSE-BASED STRATEGIES USING DIFFERENT SAMPLING MATERIALS
Wiebke Biehl, Akira Hattesohl, Rudolf Jörres, Thomas Duell, Ulrike Althöhn, Rembert Koczulla, Helga Schmetzer (Germany)

e-Posters
09:30 - 19:00  ePoster Area

Stem cell donor

DONOR-RECIPIENT HLA MATCHING FOR UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION <b>Outcomes: </b>A STUDY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY (CTIWP) OF THE EBMT
Kyoung Ha Kim, Tae Hyung Kim, Jae-Sook Ahn, Ivan Pasic, Zeyad Al-Shaibani, Arjun Law, Wilson Lam, Fotios Michalis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Zhaolei Zhang, Tamir Biezuner, Liran Shlush, Dennis Dong Hwan Kim (Canada)

PRESENCE OF AGE-RELATED CLONAL HEMATOPOIESIS (ARCH) IN DONOR DOES NOT INCREASE THE RISK OF LATE SECONDARY MALIGNANCIES AFTER ALOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

THE IMPROVEMENT IN OVERALL SURVIVAL FROM UNRELATED DONOR TRANSPLANT IN AUSTRALIA AND NEW ZEALAND IS DRIVEN BY A REDUCTION IN TRANSPLANT RELATED MORTALITY

SERIOUS EVENTS AND ADVERSE REACTIONS IN RELATION TO BLOOD STEM CELL DONATION REPORTED TO WMDA IN 2018

THE IMPROVEMENT IN OVERALL SURVIVAL FROM UNRELATED DONOR TRANSPLANT IN AUSTRALIA AND NEW ZEALAND IS DRIVEN BY A REDUCTION IN TRANSPLANT RELATED MORTALITY

POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING, UNRELATED AND HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA, A COMPARATIVE STUDY OF THE ALWP EBMT

ALLOREACTIVITY AGAINST HLA-DPB1 IN HOST-VERSUS-GRRAFT DIRECTION IS ASSOCIATED WITH INCREASED RISK OF GRAFT FAILURE AFTER MATCHED UNRELATED DONOR TRANSPLANTATION FOR NONMALIGNANT DISEASES

IMPACT OF KIR ON PATIENTS WITH LYMPHOID DISEASES AFTER T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
Yanmin Zhao, Fei Gao, Yibo Wu, Jimin Shi, Yi Luo, Yamin Tan, Jian Yu, Xiaoyu Lai, He Huang (China)

SERIOUS EVENTS AND ADVERSE REACTIONS IN RELATION TO BLOOD STEM CELL DONATION REPORTED TO WMDA IN 2018

INDICATIONS AND SAFETY OF MULTIPLE BONE MARROW HARVESTS IN PEDIATRIC DONORS FOR MATCHED SIBLING RECIPIENT TRANSPLANTATION

HEALTHY VOLUNTARY STEM CELL DONORS: FOLLOW UP AFTER HPC APHERESIS DONATION: THE EXPERIENCE OF ITALIAN BONE MARROW DONOR REGISTRY
Aurora Vassanelli, Denise Pavone, Simona Pollichieni, Nicoletta Sacchi (Italy)

ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH INHERITED DISORDERS
Tatiana Bykova, Anna Osipova, Varvara Ovetchkina, Anna Dotcenko, Alexander Galimov, Alexander Alyanskiy, Ivan Moisseev, Alexander Kulagin, Elena Semenova, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)
HAPLOIDENTICAL REDUCED-INTENSITY HEMATOPOIETIC CELL TRANSPLANTATION USING BUSULFAN, FLUDARABINE, AND ANTITHYMOCYTE GLOBULIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Min Kyoung Kim, Sung Hwa Bae, Je-Hwan Lee, Ho Sup Lee, Sung-Nam Lim, Won Sik Lee, Jung-Hee Lee, Eun-Ji Choi, Han-Seung Park, Sun-Hye Ko, Kyoo-Hyung Lee (Korea, Republic of)

THE RESULTS OF A TELECONFERENCE ABOUT THE EXPERIENCES AND EXPECTATIONS OF RELATED HEMATOPOIETIC STEM CELL DONORS AFTER DONATION

IMPACT OF THE ESTABLISHMENT OF THE TURKISH NATIONAL DONOR REGISTRY (TURKOK) ON A SINGLE CENTER’S TRANSPLANT OUTCOME: INTERNATIONAL STEM CELL DONORS VERSUS NATIONAL

Mutlu Arat, Nurcan Ozcelik, Deniz Goren Sahin, Tulay Ozcelik (Turkey)

YOUNG MALE DONORS MAY RESULT IN BETTER OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA WITH PT-CY

DONORS OF PERIPHERAL HEMATOPOIETIC STEM CELLS, OUR EXPERIENCE FOR LAST 10 YEARS

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS OVER 70 YEARS :A MONOCENTRIC EXPERIENCE OF 48 PATIENTS

Samia Harbi, Raynier Devillier, Sabine Furst, Angela Granata, Thomas Pagliardini, Luca Castagna, Faezeh Legrand, Christian Chabannon, Claude Lemarie, Boris Calmels, Maud Cecile, Cecile Braticic, Pierre Jean Weiller, Didier Blaise (France)

COMPARISON OF TRANSPLANT OUTCOMES AND ECONOMIC COSTS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML AND MDS BETWEEN THE DIFFERENT TYPE OF DONORS

Yolanda Gonzalez Romero, Joan Manuel Mora, Sara Fernandez-Luis, David Gomez-Lamas, Jose Calvo-Sanchez, Sergio Fernandez-Garcia, Jose Luis Arroyo, Aranzazu Bermudez, Enrique Ocio, Lucrecia Yañez (Spain)

HIGH DISEASE-FREE SURVIVAL OF THE SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH DONOR CHANGE AND MAINLY REDUCED-INTENSITY CONDITIONING IN RELAPSED HEMATOLOGICAL MALIGNANCIES

Yongqiang Zhao, Yanzhi Song, Fan Yang, Zhihui Li, Min Jiang, Tong Wu (China)

EPIDEMIOLOGICAL STUDY OF RARE ANTIGENS OF THE MAIN HISTOCOMPATIBILITY COMPLEX AMONG HEMATOPOIETIC STEM CELL DONORS IN BELARUS

Alena Hlaz, Ihar Iskrou, Olga Krasko, Anatoly Uss (Belarus)

IMPACT OF DONOR-RECIPIENT SEX MISMATCH IN PATIENTS RECEIVING PARTIAL T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE MONOCENTRIC STUDY

HAPLOIDENTICAL DONOR SELECTION AND ITS IMPLICATIONS IN TRANSPLANTATION OUTCOME. OUR EXPERIENCE AT HUDGC DR. NEGRÍN

OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ACCORDING TO DONOR AVAILABILITY, DURATION FROM DIAGNOSIS TO TRANSPLANT AND DONOR-SPECIFIC PARAMETERS - A SINGLE CENTER ANALYSIS

Jennifer Kaivers, Isabela Niculae, Elke Porbadnik, Christina Rautenberg, Esther Schuler, Jürgen Enczmann, Rüdiger Sorg, Johannes Fischer, Mustafa Kondakci, Rainer Haas, Ulrich Germing, Thomas Schroeder, Guido Kobbe (Germany)
THE BENEFITS OF HLA-MATCHED RELATED DONORS FOR PATIENTS LACKING HLA-IDENTICAL SIBLING IN THE ABSENCE OF POWERFUL LOCAL UNRELATED REGISTRY IN COUNTRIES WITH PREVALENT COUSIN MARRIAGES
Amir Ali Hamidieh, Alieh Safari-Sharari, Rashin Mohseni, Mahnaz Jamee, Zeynab Nikfetrat, Leila Hejazipour, Hamideh Keykani, Fahimeh Jafari, Pouria Salajegheh, Maryam Behfar (Iran, Islamic Republic of)

DONOR AGE INFLUENCES THE GRAFT-VERSUS-HOST-DISEASE-FREE AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANT IN ELDERLY PATIENTS IN LATIN AMERICA

A STUDY OF THE UNCERTAINTY, UNCERTAINTY APPRAISAL AND GROWTH AND THE AFFECTED FACTORS ON HEMATOPOIETIC STEM CELL DONORS
Eun Jung Joo, Jongheon Jung (Korea, Republic of)

WITHDRAWL OF VOLUNTEER DONORS FROM THE INTERNATIONAL REGISTRIES: A SINGLE CENTRE EXPERIENCE

OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION FOR AML AND MYELODYSPLASTIC SYNDROME IN ELDERLY WITH REDUCED-INTENSITY CONDITIONING
Seug Yun Yoon, Seong Kyu Park, Se Hyung Kim, Sung Hee Lim, Jong Ho Won, Dae Sik Hong (Korea, Republic of)

HAPLOIDENTICAL VS UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS WITH HEMATOLOGIC MALIGANACIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Seung Yun Yoon, Min-Young Lee, Namsu Lee, Sung Kyu Park, Jong-Ho Won (Korea, Republic of)

HEPATITIS E VIRUS (HEV) CONTAMINATED HEMATOPOIETIC STEM CELL GRAFT IN A MATCHED UNRELATED DONOR TRANSPLANTATION
Ksenia Boriskina, Per Ljungman, Lyda Osorio Fernandez, Stephan Mielke (Sweden)

HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MATCH RELATED DONORS IN CHILDHOOD: SINGLE CENTER EXPERIENCE

FIRST EXPERIENCE WITH UNRELATED STEM CELL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN A TRANSPLANT CENTER FROM NORTH MACEDONIA

OPTIMIZING OUTCOMES OF ACUTE LEUKEMIA AFTER TRANSPLANTS WITH SINGLE UNRELATED CORD BLOOD UNITS SELECTED ACCORDING TO CURRENT INTERNATIONAL RECOMMENDATIONS FOR CELL DOSE AND HLA MATCH

IMPACT OF HLA-MISMATCH ON OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE ANALYSIS BY THE JSHCT HLA WORKING GROUP
Itaru Kato, Hirotsushi Sakaguchi, Shunichi Kato, Mako Sato, Maiko Noguchi, Nao Yoshida, Masami Inoue, Yoshiko Hashii, Ken Tabuchi, Yoshiko Atsuta, Satoko Morishima, Junya Kanda (Japan)
Scientific Programme

CLINICAL IMPACT OF DONOR EPITOPE-SPECIFIC HLA ANTIBODIES AND THIRD-PARTY HLA ANTIBODIES IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION
Michiko Taniguchi, Dongyun Yang, Salman Otoukesh, Haris Ali, Shukaib Arslan, Chatchada Karanes, David Snyder, Guido Marcucci, Stephen J. Forman, Ryotaro Nakamura, Auayporn Nademanee, Ketevan Gandzekhadze, Monzr M. Al Malki (United States)

ADDITION OF TOCILIZUMAB TO CYCLOSPORINE-A AND MYCOPHENOLATE MOFETIL FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS SIGNIFICANTLY ABROGATES SEVERE ACUTE GVHD AFTER DOUBLE-UNIT CORD BLOOD TRANSPLANTATION IN ADULTS

THE USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) IN UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION

COMPARATIVE STUDY OF HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETION VS UNRELATED CORD BLOOD TRANSPLANT FOR ADULTS WITH HAEMATOLOGICAL MALIGNANCIES
Yin Jie Koh, Ian Wu, Yeh Ching Linn, Lip Kun Tan, Michelle Poon, Liang Piu Koh (Singapore)

USE OF G-CSF MOBILIZED BONE MARROW GRAFTS IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION (BMT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) DECREASES RISK OF SEVERE ACUTE GVHD

CMV-SPECIFIC FUNCTIONAL IMMUNE RECONSTITUTION IS SLOWER AFTER UMBILICAL CORD BLOOD COMPARED WITH MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION
Nelli Bejanyan, Irina St Louis, Hesham Mohei, Qing Cao, Najla El Jurdi, Claudio Brunstein (United States)

REDUCED INTENSITY (RIC) VS MYELOABLATIVE CONDITIONING (MAC) IN CORD BLOOD TRANSPLANTATION FOR AML (40-60 YEARS) ACROSS MISMATCHED HLA BARRIERS - ANALYSIS BY CTIWP/EUROCORD OF EBMT
Vipul Sheth, Fernanda Volt, Jaime Sanz, Laurence Clement, Jan Cornelissen, Didier Blaise, Jorge Sierra, Mauricette Michallet, Riccardo Saccardi, Eliane Gluckman, Christian Chabannon, Annalisa Ruggeri (United States)

COST OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REAL WORLD: AN ANALYSIS USING THE JAPANESE NATIONAL DATABASE
Mizuki Watanabe, Shosuke Ohtera, Junya Kanda, Shusuke Hiragi, Tomohide Iwao, Tomohiro Kuroda, Akifumi Takaori-Kondo, Genta Kato (Japan)

ASSOCIATION BETWEEN THE DOSE OF CD3+ AND CD34+ CELLS IN THE GRAFT AND POST-TRANSPLANT OUTCOMES
Tomoe Ichiki, Tatsunori Goto, Yosuke Domon, Kohei Ishigiwa, Kenichiro Takeda, Motohito Okabe, Yuka Kawaguchi, Rena Matsumoto, Marie Ohbiki, Masahide Osaki, Takanobu Morishita, Yukiyasu Ozawa, Koichi Miyamura (Japan)

HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A RELATED DONOR WITH HLA-1 ANTIGEN MISMATCH IN THE GRAFT-VERSUS-HOST DIRECTION USING LOW-DOSE ANTI-THYMCYTO GLOBULIN: MULTICENTER PHASE II TRIAL
Junya Kanda, Toshihiko Ando, Shun-Ichi Kimura, Shin-Ichi Fujiwara, Kazunori Imada, Shin Fujisawa, Takayoshi Tachibana, Yoshiko Atsuta, Yoshinobu Kanda (Japan)

INTRA-BONE CORD-BLOOD TRANSPLANT OF UNWASHED UNITS WITH ATG-FREE AND SIROLIMUS-BASED GVHD PROPHYLAXIS: FAST IMMUNE-RECONSTITUTION AND LONG-TERM DISEASE CONTROL IN 22 PATIENTS WITH HIGH-RISK DISEASES

ANTI-HLA DONOR SPECIFIC ANTIBODIES (DSA) DOES NOT AFFECT GRAFT AND SURVIVAL IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) WITH ORIGINAL POST-TRANSPLANT CYCLOFOSMAMIDE (PT-CY) SCHEDULE

MESENCHYMAL STEM/STROMAL CELL PRODUCTION COMPLIANT WITH GOOD MANUFACTURING PRACTICE: COMPARISON BETWEEN BONE MARROW AND WHARTON’S JELLY
**EFFICIENT DMSO REMOVAL AND HIGH CELL RECOVERY WITH LOVO CELL PROCESSING SYSTEM IN HPC-A CONCENTRATES: A SINGLE CENTRE EXPERIENCE**

Maria Bianchi, Nicoletta Orlando, Caterina Giovanna Valentini, Fernando Scavone, Silvano Rovardi, Fabio Del Mondo, Sabrina Sparnacci, Luciana Teofili (Italy)

**Pharmacology**

**ELTROMBOPAG THERAPY IN STEM CELL TRANSPLANT RECIPIENTS SHOWS EFFECTIVE IRON MOBILISATION**

**CLINICAL IMPACT OF MODEL PK GUIDED-CYCLOSPORINE DOSE INDIVIDUALIZATION IN CHILDREN UNDERGOING HSCT**

**INFLUENCE OF CYP2D6 METABOLIZER STATUS ON THE CONTROL OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING BY ONDANSETRON ON PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Andrea Edwards, Ashley Teusink-Cross, Lisa Martin, Parinda A. Mehta, Cynthia Prows, Laura Ramsey (United States)

**ESTIMATION OF GLOMERULAR FILTRATION RATE IN ADULTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: CYSTATIN C VERSUS CREATININE**

Claudia Langebrake, Daria Jilani, Christine Wolschke, Maximilian Christopeit, Francis Ayuk, Nicolaus M. Kröger (Germany)

**USE OF SUBLINGUAL TACROLIMUS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH HISTORY OF ANAPHYLAXIS TO INTRAVENOUS CYCLOSPORINE**

Rajesh Patil, H.N. Ramya, Pranoti Kini, Ratna Sharma, Santosh Khude, Amit Jain, Liza Bulsara, Mamta Manglani (India)

**ORAL CLONAZEPAM FOR SEIZURE PROPHYLAXIS IN ADULT PATIENTS TREATED WITH HIGH DOSE BUSULFAN**

**DISSOLUTION TIME FOR CONVENTIONAL AND LYOPHILIZED CYCLOPHOSPHAMIDE: A SINGLE CENTER STUDY**

**OUTCOMES OF EBV VIREMIA AND PTLD AFTER RITUXIMAB: A PHARMACOCOST ANALYSIS**

**PHARMACOLOGICAL INTERACTIONS IN THE POST-TRANSPLANT PHASE OF HEMATOPOIETIC PROGENITORS TRANSPLANTATION**

Maria Saez-Garrido, Alberto Espuny-Miro, Agustina Ruiz-Gomez, Miguel Almanche-Rivadeneyra, Andres Sanchez-Salinas, Maria Sacramento Diaz-Carrasco (Spain)

**EVALUATION OF SIDE EFFECTS AND EFFICACY OF LOMUSTINE (CCNU) AND BANDAMUSTINE IN PATIENTS WITH LYMPHOMA**

Mehrdad Payandeh, Sakineh Ghorbani, Azam Elahi, Nastaran Ahmadi Rad, Roya Chageh Lorestani (Iran, Islamic Republic of)
**Scientific Programme**

**COMPARING COMPLIANCE FOR COLLECTION FACILITY JACIE STANDARDS 6.1 AND 7TH EDITIONS**

**INTEGRATION OF THEORY AND PRACTICE: SCENARIO-BASED SKILL TRAINING IN ADMINISTERING CAR-T CELLS**

**“TPFMEA”, AN INTERNATIONAL MODEL FOR ASSESSING RISKS IN A STEM CELL TRANSPLANT PROGRAM**

**DEFINING PATIENT-IMPORTANT OUTCOMES AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT**

**IMPLEMENTATION OF JACIE ACCREDITATION AT A NOVEL TRANSPLANT PROGRAM: THE IMPACT ON THE CLINICAL PRACTICE**

**HOW ONE PROCESSING CENTRE PREPARED FOR ITS FIRST JACIE INSPECTION?**
Tina Cirman, Vesna Galvani, Primož Poženel, Marko Cukjati (Slovenia)

**TIPS FOR GENERATING SUCCESSFUL ‘TEAMWORKING’ IN OUR HEALTHCARE FACILITIES: THE EXPERIENCE OF A HOSPITAL UNIT IN A FRENCH CANCER CENTER**

**IMPLEMENTATION OF A QUALITY SYSTEM FOR RUNNING A CELL AND GENE THERAPY CLINICAL TRIAL WITHIN A JACIE-ACCREDITED TRANSPLANT PROGRAM**
Simone Biagini, Mario D'Angelo, Giuseppina Li Pira, Elia Girolami, Valentina Cirillo, Maria Giuseppina Cefalo, Gianpiero Conflitti, Pietro Merli, Mattia Algeri, Federica Galaverna, Annalisa Ruggeri, Vincenzo Iaconianni, Franco Locatelli (Italy)

**NEW ONLINE PLATFORMS IN QUALITY MANAGEMENT: COORDINATION AND MULTIDISCIPLINARY CARE**

**RISK MANAGEMENT ASSESSMENT IN IMPLEMENTING CAR-T CELL THERAPY IN A CLINICAL UNIT**
Ann-Mari Berthelsen, Jeanette Holder, Camilla Borch Jacobsen, Søren Lykke Petersen, Anne Fischer-Nielsen (Denmark)

**FEBRILE REACTION AFTER HSC INFUSION IS MORE FREQUENT IF NO STEROID PREMEDICATION IS GIVEN WHICH RESULTS IN MORE FREQUENT USE OF ANTIBIOTICS EARLY POST-TRANSPLANT**
Ann-Mari Berthelsen, Jeanette Holder, Camilla Borch Jacobsen, Søren Lykke Petersen, Anne Fischer-Nielsen (Denmark)

**SEARCHING FOR OTHER TOPICS OF QUALIFICATION PLANS IN THE TRANSPLANT PROGRAM CLINICAL PART - THE ONE CENTER EXPERIENCE**
Marie Dobrovolna, Jan Vydra (Czech Republic)

**PRACTICE PATTERNS IN CHRONIC GVHD PATIENT MANAGEMENT AND PATIENT REPORTED OUTCOME MEASURES ACROSS THE EBMT ALLOGENEIC TRANSPLANTATION NETWORK**

**MAINTAINING DONOR SAFETY AND WELFARE THROUGHOUT CELLULAR THERAPY PRODUCT DONATION**

**DIGITAL JACIE AT THE CHRISTIE**

**INTEGRATION OF CELLULAR THERAPY IN THE JACIE (JOINT ACCREDITATION COMMITTEE ISCT-EBMT) QUALITY MANAGEMENT PLAN. SINGLE CENTER EXPERIENCE**
Scientific Programme

AUDIT - A METHOD TO EVALUATE INTERVENTIONS - EXPERIENCES FROM AN ATTEMPT TO IMPROVE NUTRITIONAL STATUS IN PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Lea Brandt Kristensen, Stine Skriver Bregenov (Denmark)

QUALITY OF LIFE ASSESSMENT AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

RETROSPECTIVE ANALYSIS OF TIME TO ALTERNATIVE DONOR IDENTIFICATION AND HEMATOPOIETIC STEM CELLS PROCUREMENT IN THE ABSENCE OF MATCHED-SIBLING DONORS IN A SINGLE CENTER IN SPAIN
Gracia Bravo, María Jesús Lorenzo, Emilio Ojeda, María Esther Martínez-Muñoz, Guiomar Bautista, Carlos de Miguel, Carlos Vilches, Rafael Cabrera, Rafael Duarte (Spain)

GOVERNANCE, RISKS AND REGULATORY ASPECTS OF UNLICENSED LENTIVIRAL VECTOR-MODIFIED AUTOLOGOUS STEM CELL TREATMENT
Beatriz Duran Jimenez, Jane Kinsella, Wendy Ogden, Simon Jones, Brian Bigger, Robert Wynn (United Kingdom)

UNIQUE SUPPORTIVE CARE ALGORITHMS FOR CHILDREN UNDERGOING HAPLOIDENTICAL HSCT FOR BENIGN HAEMATOLOGICAL DISORDERS

QUALITY OF LIFE IN PARENTS OF TURKISH AND SYRIAN PEDIATRIC BONE MARROW TRANSPLANT AND ONCOLOGY PATIENTS
Gülay Sezgin, Asiye Yaylaci, Ilker Ünal, Ibrahim Bayram (Turkey)

COLLECTION OF AUTOLOGOUS MONONUCLEAR CELLS IN NON-CYTOKINE STIMULATED APHERESIS METHODS

EFFECTIVE CAR-T CELL DELIVERY: A MULTIDISCIPLINARY APPROACH AT MFT
Wendy Ogden, Beatrix Duran (United Kingdom)

HAEMOPOIETIC PROGENITOR CELL PROFICIENCY TESTING
Karieshma Kabani, Kon Zarkos, Craig Wright, Stephen Larsen (Australia)

VALIDATION AND COMPARISON OF AEROBIC AND ANAEROBIC BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ALERT (R) 3D (TM) AND VIRTUO (TM) MICROBIAL BIOBURDEN SYSTEMS FOR HAEMATOPOIETIC PROGENITOR CELLS (HPC)
Craig Wright, Julie Allerton, Karieshma Kabani, Kon Zarkos (Australia)

START-UP OF AN ADHERENCE RECEPTION FOR ALLOGENIC STEM CELL TRANSPLANTED PATIENTS AT THE HEMATOLOGICAL DEPARTMENT LINKÖPING, SWEDEN
Malene Bokinge (Sweden)

ENUMERATION OF RESIDUAL RED BLOOD CELLS IN MIS-MATCHED ALLOGENIC PBSC COLLECTIONS - TRADITIONAL HAEMATOLOGY ANALYSER VS FLOW CYTOMETRY
James Pittson (United Kingdom)

INVESTIGATION AND ANALYSIS OF FACTORS AFFECTING GASTROINTESTINAL NUTRITION RECOVERY AFTER MULTIPLE MYELOMA AUTOLOGOUS STEM CELL TRANSPLANTATION AND EFFECTS OF NUTRITIONAL INTERVENTION

CHARACTERISTICS OF IRON DEFICIENCY ANEMIA IN PRE-MENOPAUSAL WOMEN IN KOREA
Hyun Jung Lee, Myung Hee Chang, Hae Yong Pak (Korea, Republic of)

LEUKEMIA AND ITS TYPES
Scientific Programme

Data Management

SUPPORTING TOOLS FOR ACCURATE DATA COLLECTION - DO WE GET THE BENEFIT?

ARE TRANSPLANTS TRULY AVAILABLE TO ALL, REGARDLESS OF GEOGRAPHY, SOCIOECONOMIC STATUS AND ETHNIC GROUP? A BSBMTCT REPORT

MISMATCHED DONOR AND GRADE 2 TO 4 ACUTE GVHD AS TWO-RISK MODEL FOR CYTOMEGALOVIRUS VIREMIA AND DISEASE AFTER ALLOGENEIC TRANSPLANTATION - SINGLE INSTITUTE ANALYSIS OF 1180 PATIENTS

Experimental stem cell transplantation

LOW-DOSE DECITABINE IMPROVES REFRACTORY PROLONGED ISOLATED THROMBOCYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A RANDOMIZED MULTICENTER CLINICAL TRIAL

AUTOPHAGY IN ENDOTHELIAL CELLS REGULATES THEIR HAEMATOPOIESIS-SUPPORTING ABILITY

2ND ALLO-HSCT FOR PATIENTS WHO DIAGNOSED RECURRENCE ALL AFTER THE 1ST ALLO-HSCT

ESTABLISHING A TRANSPLANT SHARING PROGRAM

Experimental transplantation

SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOThERAPEUTICS

IMPACT OF GUT FUNgal COMPOSITION ON OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

MONITORING HEMATOPOIETIC CELL MICROPARTICLES IN ALLOGRAFTS AND TRANSPLANT RECIPIENTS

EARLY HEPATIC COMPLICATIONS DURING THE FIRST YEAR AFTER BONE MARROW TRANSPLANTATION IN PATIENTS WITH LEUKEMIA

PERFORMANCE OF BONE MARROW TRANSPLANTATION CENTER IN IMAM REZA HOSPITAL, KERMANSHAH, IRAN

Haematopoietic stem cells
HAPLOIDENTICAL DONOR BEATS MATCHED SIBLING DONOR FOR PRE-TRANSPLANTATION MRD POSITIVE ALL: A PHASE 3 BIOLOGICALLY RANDOMIZED STUDY

RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED RELATED DONOR WITH TCRαβ+/CD19+-DEPLETION AND A FIXED DOSE MEMORY T CELL (CD45RA-DEPLETED) ADD-BACK

CLONAL DYNAMICS AND GENOMIC INTEGRITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN HUMAN ALLOGENEIC TRANSPLANTATION RECIPIENTS

ALLOGENEIC TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELL GRAFTS RESULTS IN A MASSIVE DECREASE OF PRIMITIVE HEMATOPOIETIC PROGENITOR FREQUENCIES IN RECONSTITUTED BONE MARROWS

TREATMENT OF PURE RED CELL APLASIA AFTER MAJOR ABO INCOMPATIBLE ALLOGENIC STEM CELL TRANSPLANTATION: A FRENCH RETROSPECTIVE STUDY

FEASIBILITY AND OUTCOMES OF A THIRD ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM THE ALWP OF EBMT

CHANGES IN VIABILITY MARKERS OF HAEMATOPOIETIC STEM CELLS FOLLOWING LONG-TERM CRYOPRESERVATION

HIGH PRE-TRANSPLANT INTERLEUKIN-18 IS ASSOCIATED WITH POOR HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND PREDICTS INCREASED NON-RELAPSE MORTALITY

MICROBIAL DIVERSITY, SURVIVAL, AND ACUTE GVHD IN ADULT RECIPIENTS OF ALLO-HSCT AFTER MYELOABLATIVE CONDITIONING: RESULTS OF A NUTRITIONAL INTERVENTION TRIAL

UK EXPERIENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACTIVATING PI3K MUTATIONS

RECONSTRUCTION OF THE DONOR-RECIPIENT HAEMATOPOIETIC CELL PHYLOGENY USING SOMATIC MUTATIONS TO ESTABLISH NUMBERS OF ENGRAFTING LONG-TERM HSCS IN REAL-WORLD TRANSPLANTATION

SUCCESSFUL CLEARANCE OF DONOR SPECIFIC ANTI-HLA ANTIBODIES AFTER DESENSITIZATION WITH RITUXIMAB, VELCADE AND PLASMA-EXCHANGE FOLLOWED BY A HAPLOIDENTICAL STEM CELL TRANSPLANTION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

IMPACT OF PRE-TRANSPLANTATION MINIMAL RESIDUAL DISEASE DETERMINED BY FLOW CYTOMETRY ON OUTCOME OF ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

ECONOMIC BURDEN OF CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SPANISH MULTICENTER, RETROSPECTIVE STUDY

INCIDENCE AND OUTCOME OF CLONAL AND MALIGNANT TRANSFORMATION (CMT) AMONG PEDIATRIC PATIENTS WITH INHERITED BONE MARROW FAILURE SYNDROMES (IBMFSS)

IMPACT OF POST-TRANSPLANT IMMUNOSUPPRESSION WEAN VS. BOOST IN EARLY MIXED CHIMERISM FOLLOWING G-CSF-PRIMED MARROW TRANSPLANT IN THALASSEMIC PATIENTS

COMPARISON OF THE CONDITIONING REGIMENS WITH TMI, NON-RADIATION AND TBI FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

VALIDATION OF DISEASE RISK COMORBIDITY INDEX (DRCI) FOR OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) WITH PARTIALLY T-CELL DEPLETED GRAFT
ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS PRETREATED WITH JAK1/JAK2 INHIBITORS

THE DETERMINATIVE ROLE OF PATIENT-CONTROLLED-ANALGESIA (PCA) IN THE EARLY COURSE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

HIGH SURVIVAL RATE AND LOW INCIDENCE OF AGVHD AFTER CD34+ STEM CELLS SELECTION AND CD3+ T CELLS ADDBACK IN PEDIATRIC MUD HSCT

IMPACT OF ABO INCOMPATIBILITY ON OUTCOMES AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA

COMPARISON OF OUTCOMES AFTER HAPLOIDENTICAL VERSUS UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER REVIEW

EFFECT OF DIFFERENT TIMINGS OF UMBILICAL CORD CLAMPING ON THE LEVEL OF CD34+ CELLS IN FULL-TERM NEONATES

SEQUENTIAL CONDITIONING REGIMEN (FLAMSA-BU-MEL) IN HLA-MATCHED OR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN REFRACTORY MYELOID DISEASE

SEQUENCE CYTOTOXIC CHEMOTHERAPY FOLLOWED BY MA CONDITIONING REGIMEN HSCT WITH INTERMEDIATE - OR ADVERSE RISK AML IN CR: A SINGLE CENTER STUDY

INVESTIGATION OF VIROLOGICAL FEATURES AND CLINICAL OUTCOMES ASSOCIATED WITH PRE-ENGRAFTMENT CYTOMEGALOVIRUS DNAEMIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS

CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE AS A PREDICTOR OF ENGRAFTMENT AND SURVIVAL IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

USE OF PLERIXAFOR IN POOR MOBILIZER PATIENTS WITH MYELOMA AND LYMPHOMA: CLONOGENIC CAPACITY AND ENGRAFTMENT DATA

OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRICS: A SINGLE CENTER EXPERIENCE FROM INDIA

RELAPSE/REFRACTORY FOLLICULAR LYMPHOMA: LONG TERM OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA

PRE-EMPTIVE USE OF SORAFENIB COMBINED WITH DLI POST HSCT IN AML FLT3+: A SINGLE CENTER EXPERIENCE

USE OF ELTROMBOPAG FOR THE MANAGEMENT OF POOR GRAFT FUNCTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN

TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH ELTROMBOPAG

EFFICACY OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED TO CHEMOTHERAPY AS POST-REMISSION TREATMENT FOR CHILDREN WITH INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION

THE TREATMENT OF BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA IRREVERSIBLY DEPLETES NAÏVE T LYMPHOCYTES
DESENSITIZATION PROTOCOL IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH ANTI-HLA DONOR-SPECIFIC ANTIBODIES (DSA): A SINGLE-CENTER EXPERIENCE

ASSOCIATION BETWEEN METABOLIC ALTERATION WITH TYPE AND INDICATION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION

RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES FOR PATIENTS RECEIVING UMBILICAL CORD BLOOD TRANSPLANTS AT THE ROYAL MARSDEN HOSPITAL BETWEEN 2007 AND 2017

HIGHER COST AND NO SURVIVAL BENEFIT WITH ADDITION OF RITUXIMAB TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL

ASSOCIATION BETWEEN METABOLIC ALTERATIONS WITH AGE AND GENDER OF PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION

HAPLOIDENTICAL HSCT IN CHILDREN WITH VERY HIGH-RISK HAEMATOLOGIC MALIGNANCIES: A SINGLE-CENTRE EXPERIENCE

COMPARATIVE STUDY OF THE HEMATOPOIETIC RECONSTITUTION

INFUSED TOTAL NUCLATED CELL DOSE IS NOT ASSOCIATED WITH ENGRAFTMENT IN AUTOLOGOUS STEM CELL TRANSPLANTATION

A COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND BFM 95 CHEMOTHERAPY PROTOCOL IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

THE IMPACT OF CD34+ CELL AND IMMUNEFFECTOR CELL DOSE ON TRANSPLANT OUTCOMES

TREOSULFAN COMBINED WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANTATION OF MYELOID DISEASES, ALLOWS HIGH OVERALL SURVIVAL WITH LOW RELATED TOXICITY

OUTCOME OF RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

MOTIVATION FOR ANTIFUNGAL USE IN PEDIATRIC HSCT PATIENTS IN AN INSTITUTION IN SOUTHERN BRAZIL

IMPACT OF THE USE OF GRANULOCYTIC COLONY-STIMULATING FACTOR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN RARE FORMS OF PRIMARY IMMUNODEFICIENCIES (PIDS) IN ARGENTINA

PHASE II STUDY OF PLERIXAFLOR AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL,PET POSITIVE AFTER TWO R-DHAP

THE EFFECT OF CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE ON THE HEMATOPOIETIC RECOVERY AND SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION

THE EVENTUAL ROLE OF DONOR AND RECIPIENT VITAMIN D LEVELS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT SETTING

AVERAGE LENGTH OF HOSPITAL STAY FOR PEDIATRIC BLOOD AND MARROW TRANSPLANTS IN THE BACKDROP OF CELL SOURCE, TRANSPLANT TYPE AND OUTCOME

ONE CENTER EXPERIENCE IN OFFLINE TECHNIQUE VALIDATION WITH BIOLOGICAL QUALITY TESTS
A MONOCENTRIC CLINICAL OBSERVATION OF ALLOGENEIC TRANSPLANTATION IN 22 PATIENTS WITH ACUTE MEGAKARYOCYTIC LEUKEMIA

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN IN SCIENTIFIC CENTRE OF PEDIATRICS AND CHILD SURGERY

THE OUTCOME OF ALLOTRANSPLANT USING TBF CONDITIONING FROM MATCHED SIBLING RELATED DONORS IN HIGH RISK MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE SINGLE CENTER EXPERIENCE

EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA: RETROSPECTIVE ANALYSIS IN OUR CENTER

CARDIOVASCULAR RISK IN PATIENTS BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

INFECTIONS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PEDIATRIC RECIPIENTS IN PERU: EXPERIENCE OF A REFERRAL CENTER

HAEMATOPOIETIC STEM CELL PRODUCT VIABILITY: A COMPARATIVE STUDY BETWEEN BAGS AND VIALS

TRANSFUSION SUPPORT IN THE FIRST 30 AND 100 DAYS AFTER HAPLOIDENTICAL VERSUS HLA-MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MACS IN A PERUVIAN HEALTH CHILDRENS INSTITUTE: THREE-YEAR EXPERIENCE

COLLECTION, CRYOPRESERVATION AND AUTOLOGOUS TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELLS IN KAUNAS, LITHUANIA 2015-2019

EVALUATION OF OVERALL SURVIVAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT): UNICENTRIC EXPERIENCE

MONITORING OF THE EXPRESSION OF THE VEGF-A GENE (VASCULAR ENDOTHELIAL GROWTH FACTOR) DURING THE EVOLUTION OF PEDIATRIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION. A PILOT STUDY

REFRACTORY T-CELL CUTANEOUS LYMPHOMA TREATED WITH ALLOGENEIC HAPLOIDENTIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT

VITAMIN D DEFICIENCY AND OUTCOMES IN ADULT ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE OVER LAST YEARS

CAUSES OF COMPLICATIONS IN ADULTS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Immunodeficiency diseases and macrophages
IMPACT OF DIFFERENT <i>EX VIVO</i> T-CELL DEPLETION STRATEGIES ON OUTCOMES FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY

OUTCOMES AND IMMUNE RECONSTITUTION AFTER T-CELL REPLETE HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FOR PEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCIES

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY IN JAPAN: OVERVIEW OF A NATIONWIDE RETROSPECTIVE ANALYSIS

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY IN JAPAN: A NATIONWIDE RETROSPECTIVE ANALYSIS

UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY: SINGLE-INSTITUTION EXPERIENCE IN CHINA

IMMUNODEFICIENCY - CENTROMERIC INSTABILITY - FACIAL DYSMORPHISM (ICF) SYNDROME: EVALUATION OF CHARACTERISTICS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

THIOTEPA VERSUS MELPHALAN CONTAINING CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATIONS WITH TCRαβ/CD19 GRAFT DEPLETION FOR PRIMARY IMMUNODEFICIENCIES

IMPROVED TRANSPLANT SURVIVAL AND LONG-TERM DISEASE OUTCOME FOR CHILDREN WITH CD40 LIGAND DEFICIENCY

HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES INCLUDING IMMUNE RECONSTITUTION IN PRIMARY IMMUNODEFICIENCIES: 5 YEARS OF SINGLE CENTRE EXPERIENCE

OUTCOMES OF STEM CELL TRANSPLANT FOR RIPK1 DEFICIENCY: A SINGLE CENTRE EXPERIENCE

IMPROVING THE RESULT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY WITH SERIOUS INFECTION IN DEVELOPING COUNTRIES USING RIC REGIMENT

SINGLE-CENTER EXPERIENCE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCR αβ DEPLETION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCY SYNDROMES

HAPLO-IDENTICAL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY - A TERTIARY CARE CENTRE EXPERIENCE FROM SOUTH INDIA

NECROTIZING ENTEROCOLITIS IN A TWO-MONTH-OLD SCID PATIENT AFTER BONE MARROW TRANSFUSION - SURGICAL INTERVENTION AT DAY +1: YES OR NO?

UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH TWO DIFFERENT CONDITIONING REGIMENS FOR CHRONIC GRANULOMATOUS DISEASE: SINGLE-INSTITUTION EXPERIENCE IN CHINA

THE OUTCOMES OF UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE IN CHILDREN WITH RAG GENE MUTATION

LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) IN ADA-SCID PATIENTS: THE SHADOW OF MALIGNANCIES

HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR X-LINKED AGAMMAGLOBULINAEMIA COMPLICATED BY CHRONIC NOROVIRUS ENTEROPATHY
HEMATOPOETIC STEM CELL TRANSPLANTATION IN CD40 LIGAND DEFICIENCY

DIAGNOSTIC MARKERS FOR AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR CHRONIC GRANULOMATOUS DISEASE (CGD) IN CHILDHOOD

Infectious complications

PNEUMOCYSTIS PNEUMONIA AFTER ALLOGENEIC HCT: A CASE-CONTROL STUDY ON RISK FACTORS, TIMING, AND PCR USE, FROM THE IDWP OF EBMT

UPPER AND/OR LOWER RESPIRATORY TRACT INFECTION CAUSED BY HUMAN CORONAVIRUS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

SUCCESSFUL TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WITH JCV-TARGETED T-CELL THERAPY

EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY

TUBERCULOSIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT

FAECAL MICROBIOTA TRANSPLANT (FMT) CAN REDUCE THE HIGH NRM ASSOCIATED WITH MULTI-DRUG RESISTANT ORGANISM (MDRO) COLONISATION PRIOR TO ALLOGENEIC HCT

EPIDEMIOLOGY, RISK FACTORS AND OUTCOMES OF CMV INFECTION IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT): A SINGLE INSTITUTIONAL COHORT STUDY

USE OF LETERMOVIR IN OFF-LABEL INDICATIONS: INFECTIOUS DISEASES WORKING PARTY EBMT RETROSPECTIVE STUDY

RISK OF INFECTIOUS COMPLICATIONS IN ADULT PATIENTS AFTER ALLOGENEIC HSCT DEPENDING ON THE SITE OF CENTRAL VENOUS CATHETER INSERTION - MULTICENTRE PROSPECTIVE STUDY

INFECTION PREVENTION PRACTICES AMONG EBMT HEMATOPOIETIC CELL TRANSPLANT CENTERS: A SURVEY OF THE INFECTIOUS DISEASES WORKING PARTY OF THE EBMT

PRIMARY LETERMOVIR PROPHYLAXIS IN CMV SEROPosITIVE PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL LIFE EXPERIENCE

HEV INFECTION IN HCT RECIPIENTS - RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY (IDWP) OF EBMT

THE ROLE OF COMBINATION PROPHYLAXIS IN PREVENTING CYTOMEGALOVIRUS (CMV) INFECTION AFTER EX VIVO AB T-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANT (HHCT) IN CHILDREN

IMPACT OF CMV SEROSTATUS AND CMV REACTIVATION AFTER HAPLOIDENTICAL-SCT WITH PT-CY
COMPARISON OF IMMUNE CELL RESPONSE TO CYTOMEGALOVIRUS PROTEINS VERSUS PEPTIDES USING AN IFN-γ ELISPOT ASSAY TO MONITOR CYTOMEGALOVIRUS-SPECIFIC IMMUNITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

HUMAN HERPESVIRUS TYPE 6 REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION: RISK FACTORS AND CLINICAL IMPACT

INCREMENTAL INPATIENT HEALTHCARE RESOURCE USE AND COSTS AMONG CMV SEROPositIVE ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS MANAGED THROUGH PREEMPTIVE APPROACH

POOR RECOVERY AND IMPAIRED FUNCTION OF V61+ T CELLS IN REFRACTORY/RECURRENT CMV REACTIVATION AFTER HEMATOPOIETIC TRANSPLANTATION

SAFETY AND EFFICACY OF BRINCIDOFOVIR FOR REFRACTORY ADENOVIRUS INFECTION IN CHILDREN RECEIVING ALLOGENEIC SCT: A RETROSPECTIVE ANALYSES FROM THE ITALIAN PEDIATRIC HEMATOLOGY ONCOLOGY ASSOCIATION (AIEOP)

ALLOPLUS: RESULTS OF THE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIV PATIENTS, A RETROSPECTIVE STUDY OF THE SFGM-TC

SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN PATIENTS WHO UNDERWENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A PROSPECTIVE STUDY TO MEASURE FEASIBILITY, SAFETY AND HEALTH CARE RESOURCE USE

FREQUENCY, RISK FACTORS AND OUTCOME OF ACTIVE TUBERCULOSIS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

INFECTIOUS COMPLICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY Hodgkin’S LYMPHOMA AFTER NEW AGENTS’ THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION

SURVEILLANCE FOR REACTIVATION OF TOXOPLASMA GONDII USING POLYMERASE CHAIN REACTION ASSAY AND PRE-EMPTIVE THERAPY AVOIDS UNIVERSAL PROPHYLAXIS AND PREVENTS SYMPTOMATIC INFECTION

CYTOMEGALOVIRUS (CMV) IMPACT ON CLINICAL OUTCOMES AND RESOURCE USE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE INFLUENCE OF RECURRENT EPISODES OF CMV INFECTION

FECAL MICROBIOTA TRANSPLANTATION IN CHILDREN TO TREAT ACUTE GVHD OR MULTI-DRUG RESISTANT BACTERIA COLONIZATION

VACCINATION AGAINST TICK-BORNE ENCEPHALITIS (TBE) AFTER AUTOLOGOUS AND ALLOGENEIC BONE MARROW TRANSPLANTATION

RIFAXIMIN USE FAVOURED MICAFUNGIN RESISTANT CANDIDA SPP INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

BASELINE CHARACTERISTICS AND EARLY POLY-FUNCTIONAL ASSESSMENT OF T CELLS TO IDENTIFY PATIENTS AT HIGHER RISK TO DEVELOP SEVERE HCMV REACTIVATION AFTER ALLOGENEIC HSCT

IMPACT OF HHV-6 REACTIVATION AFTER T-REG/T-CON IMMUNOTHERAPY IN ALLOGENEIC TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE STUDY

ADENOVIRUS INFECTIONS AFTER HCT: INFECTIOUS DISEASES WORKING PARTY RETROSPECTIVE EBMT REGISTRY STUDY

CLINICAL IMPACT OF COLONIZATION BY MULTIDRUG-RESISTANT ENTEROBACTERIACEAE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
POST-ALLOGENEIC TRANSPLANTATION PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, CLINICAL AND BIOLOGICAL FEATURES, TREATMENT AND OUTCOMES: A RETROSPECTIVE STUDY FROM THE SFGM-TC

RESPIRATORY VIRAL INFECTIONS IN ADULT PATIENTS UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION FROM UNRELATED DONORS AFTER MYELOABLATIVE CONDITIONING REGIMEN

EFFICACY OF LETERMOVIR FOR PROPHYLAXIS OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTI CENTER RETROSPECTIVE ANALYSIS AMONG JAPANESE PATIENTS

RISK FACTORS AND CLINICAL OUTCOMES OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL AND MATCHED-SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

STANDARDIZED MONITORING OF CYTOMEGALOVIRUS-SPECIFIC CELLULAR IMMUNITY CAN IMPROVE RISK STRATIFICATION OF RECURRENT CYTOMEGALOVIRUS REACTIVATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

IMPACT OF LEVOFLOXACIN FOR PROPHYLAXIS OF PRE-ENgraftMENT BLOODSTREAM INFECTIONS AFTER ALLOGENEIC HSCT: A SINGLE-CENTER MATCHED ANALYSIS IN AN ENDEMIC COUNTRY FOR CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) AFTER HCT - A RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT

ORAL RIBAVIRIN IS A HIGHLY EFFICACIOUS TREATMENT FOR LOWER RESPIRATORY TRACT INFECTION DUE TO RESPIRATORY SYNCYTIAL OR PARAINFLUENZA VIRUS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS

TIMING OF INDUCTION TREATMENT FOR REACTIVATION OF CYTOMEGALOVIRUS IMPACTS OVERALL SURVIVAL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

PREDICTION OF BLOODSTREAM INFECTION RISK USING CITRULLINE AS BIOMARKER OF INTESTINAL MUCOSITIS IN HEMATO-ONCOLOGY PATIENTS

PREDICTION OF CMV REACTIVATION BY THE RECIPIENT IGG TITER BEFORE ALLO-HCT

COMPARISON OF INFECTIOUS COMPLICATIONS AMONG PATIENTS RECEIVING UNMANIPULATED HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETED HAPLOIDENTICAL TRANSPLANT

THE CUMULATIVE INCIDENCE OF MULTIPLE DNA VIRUS REACTIVATION IS NOT DIFFERENT IN NON-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION AND UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION

NEUTROPHILS RESPONSE TO HUMAN CMV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

CLINICAL EFFICACY OF LETERMOVIR PROPHYLAXIS FOR CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

AT-HOME FOSCARNET ADMINISTRATION IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION PATIENTS WITH CYTOMEGALOVIRUS INFECTION: A SAFETY FEASIBLE MODEL

EFFECTS OF THE ANTIBIOTICS CHANGE OR THE ADDITION OF ANTI-MRSA DRUGS FOR PERSISTENT FEBRILE NEUTROPHILIA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION

THERAPEUTIC DRUG MONITORING OF POSACONAZOLE AND SUBSEQUENT DOSING IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
IS PREEMPTIVE STRATEGY ENOUGH? RELATIONSHIP BETWEEN CMV REACTIVATION AND STEROID THERAPY FOR GHVD IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: 97 PATIENTS FROM TURKEY

PROPHYLAXIS WITH AZITHROMYCIN IN ALLOGENEIC CORD BLOOD TRANSPLANT AND ASSOCIATION WITH RELAPSE RATE AND TRANSPLANT OUTCOMES

REACTIVATED VARICELLA ZOSTER (VZV) INFECTION (SHINGLES), AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HCT) FOR HAEMATOLOGICAL DISEASE IN CHILDREN: A SIGNIFICANT PROBLEM AND PROPOSAL FOR FUTURE MANAGEMENT

LETTERMOVIR PROPHYLAXIS REDUCES INPATIENT RESOURCE CONSUMPTION BY BEING EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REAL-WORLD EXPERIENCE

ANALYSIS OF CMV REACTIVATION RISK AFTER T CELL REPLETE HAPLOIDENTICAL AND MATCHED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

INCIDENCE AND IMPACT OF EPSTEIN-BARR VIRUS EVENTS IN THE EARLY PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

ASPERGILLUS NON-FUMIGATUS INVASIVE ASPERGILLOSIS IN CHILDREN AND ADULTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) & CHEMOTHERAPY

INTRAVENOUS PENTAMIDINE FOR PNEUMOCYSTIS JIROVECII PROPHYLAXIS IN HEMATOLOGICAL PATIENTS TREATED WITH CHEMOTHERAPY, HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) AND CAR-T CELL THERAPY

INTENSIFICATION OF CMV PROPHYLAXIS WITH THE USE OF GANCICLOVIR DURING THE CONDITIONING IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. COMPARISON WITH A STANDARD STRATEGY. 113 PATIENTS

LOW RELAPSE RISK FOR REDUCED INTENSITY CONDITIONED ALEMTUZUMAB-BASED ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMAS IS OFFSET BY CYTOMEGALOVIRUS RISK: DATA FROM SINGLE CENTRE STUDY

PROPHYLACTIC DOSE TRIMETHOPRIM/SULFAMETHOXAZOLE DOES NOT LEAD TO DELAYED NEUTROPHIL AND PLATELET ENGRAFTMENT IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

HIGH DOSE VALACICLOVIR AS CMV PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION

EPIDEMIOLOGICAL SCREENING FOR BACTERIAL RESISTANCE BY DIFFERENT TECHNIQUES IN ALLO-HSCT PATIENTS

INVASIVE MOLD DISEASE IN A REAL-WORLD HEMATO-ONCOLOGY SETTING: VALUE OF A DIAGNOSTIC-DRIVEN CARE PATHWAY

SINGLE CENTER ANALYSIS ON THE MANAGEMENT OF ACYCVLOR RESISTANT HERPES SIMPLEX VIRUS STOMATITIS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

EARLY BACTEREMIA FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION WITHOUT THE USE OF PROPHYLACTIC ANTIBIOTIC: CHANGING EPIDEMIOLOGY AND ANTIMICROBIAL RESISTANCE (2016-2018)

DIAGNOSTIC YIELD OF BRONCHOALVEOLAR LAVAGE (BAL) IN HAEMATOLOGICAL PATIENTS AFTER ALLOGENEIC/ AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) - COMPARISON WITH BAL PERFORMANCE IN NON-TRANSPLANTED PATIENTS

A NOVEL EFFICIENCY STRATEGY TO PREVENT HBV-RELATED HEPATITIS AFTER ALLOGENEIC HSCT FROM HBSAG- POSITIVE DONORS TO RECIPIENTS
BK VIRUS EFFECT ON DEVELOPING LATE HEMORRHAGIC CYSTITIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS: SINGLE CENTER EXPERIENCE

VERSATILE EFFECTS OF LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-INSTITUTION ANALYSIS

IMPACT OF A CHANGE IN ANTIBACTERIAL PROPHYLAXIS IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION IN ONE SINGLE CENTER

INTRAVESICAL INSTILLATION OF CIDOFOFIR IS EFFICIENT FOR THE TREATMENT OF BK VIRUS HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC TRANSPLANTATION

MANAGEMENT OF BK POLYOMA VIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE

RISK FACTORS AND OUTCOME OF EARLY CLOSTRIDIUM DIFFICILE INFECTION IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

RISK FACTORS FOR CYTOMEGALOVIRUS INFECTION IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

IMPACT OF HYPOGAMMAGLOBULINEMIA ON OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

THE USE OF RIFAXIMINE IN ANTI-BACTERIAL PROPHYLAXIS IN PATIENT UNDERGOING HSCT

BKV VIRUS - HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: INCIDENCE, SEVERITY AND RISK FACTORS

RUXOLITINIB FOR STEROID-REFRACTORY GVHD ABOLISHES ANTIVIRAL IMMUNE RESPONSE FOLLOWING T-CELL TRANSFER FOR REFRACTORY ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION

RISK FACTORS FOR CMV REACTIVATION AND DISEASE AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - DEFINING THE TARGET POPULATION FOR LETERMOVIR PROPHYLAXIS

ISAVUCONAZOLE (ISA) USE IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) RECIPIENTS: A SINGLE-CENTER EXPERIENCE

TIME- AND THERAPY-DEPENDENT BACTERIURIA IN CHILDREN AND YOUNG ADULTS FOLLOWING ALLOGENEIC HSCT

PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF MARIBAVIR COMPARED WITH VALGANCICLOVIR FOR TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) RECIPIENTS (STUDY DESIGN)

INCIDENCE AND RISK FACTORS OF VIRAL COMPLICATIONS IN ADULT PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM HUNGARY

CONTRIBUTING FACTORS TO PRE ENGRAFTMENT BACTEREMIA AND PNEUMONIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A LEBAANESE SINGLE CENTER EXPERIENCE

UNICENTRIC STUDY: PROPHYLAXIS STRATEGY AGAINST GVHD WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (CPYT) AND ITS RELATIONSHIP WITH CYTOMEGALOVIRUS

EPIDEMIOLOGY AND CLINICAL FEATURES OF FEBRILE NEUTROPENIC EPISODES: THREE YEARS EXPERIENCE AT HEMATOLOGY WARDS
Scientific Programme

USE OF CMV-HYPERIMMUNE GLOBULINS (CMV-HYG) AS PRE-EMPTIVE THERAPY OR TREATMENT OF CMV INFECTION IN HSCT RECIPIENTS

TOXOPLASMOSIS DISEASE AFTER ALLO-HSCT. WHAT HAVE WE LEARNT?

TUBERCULOSIS IN PATIENTS WHO RECEIVE AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT. TWO CASE REPORT

POLYOMAVIRUS BK INFECTION IN BONE MARROW TRANSPLANTATION RECIPIENTS. A COMPARATIVE ANALYSIS ON CHILDREN AND ADULTS

LEFLUNOMIDE, SUCCESSFUL PRE-EMPTIVE THERAPY IN RESISTANT CYTOMEGALOVIRUS REACTIVATION IN A HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT

LETÉRMOMIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

INFECTIONOUS COMPLICATIONS IN HEMATOLOGIC PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION

EARLY MORTALITY IN PATIENTS WITH MULTIPLE MYELOMA - A SINGLE CENTER EXPERIENCE

CMV RETINITIS IN A STEM CELL TRANSPLANT RECIPIENT TREATED WITH FOSCARNET INTRAVITREAL INJECTION AND CMV SPECIFIC IMMUNOGLOBULIN

Lymphoma

LONG TERM SURVIVAL AFTER 2 YEARS EVENT FREE SURVIVAL IN RELAPSED DLBCL AFTER AUTOLOGOUS TRANSPLANTATION IN THE TWO RANDOMIZED TRIALS LY.12 AND CORAL

EXPLORATORY ANALYSIS OF BRENTUXIMAB VEDOTIN PLUS CHP (A+CHP) AS FRONTLINE TREATMENT FOR PATIENTS WITH CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMAS (ECHERON-2): IMPACT OF CONSOLIDATIVE STEM CELL TRANSPLANT

BRENTUXIMAB VEDOTIN FOR RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN LYMPHOMA: A STUDY OF THE LWP-EBMT

ALLOGENEIC STEM CELL TRANSPLANTATION AS A CURATIVE OPTION IN RELAPSE/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GETH/GETLAMO STUDY

ADAM17 INHIBITOR INCB7839 WITH RITUXIMAB AS CONSOLIDATION AFTER AUTOLOGOUS HCT FOR DIFFUSE LARGE B CELL LYMPHOMA: A NOVEL RELAPSE PREVENTION STRATEGY

COMPARISON OF REDUCED-INTENSITY CONDITIONING (RIC) REGIMENS FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT) FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A CIBMTR ANALYSIS

HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH NON-HODGKIN LYMPHOMA: THE SPANISH EXPERIENCE

EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSIONS FOR PATIENTS AFFECTED BY ADVANCED LYMPHOID MALIGNANCIES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY
BRENTUXIMAB-VEDOTIN IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY PRIOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HODGKIN LYMPHOMA: REAL-WORLD DATA FROM A TWO CENTERS STUDY

NON-MYELOABLATIVE CONDITIONING REGIMEN BEFORE T-CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ADVANCED LYMPHOMA

IMPACT OF KIR LIGAND MISMATCH AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY IN 383 PATIENTS FROM THE SFGM-TC

THE IMPACT AND CHALLENGES OF PERFORMING BEAM CONDITIONED AUTOLOGOUS TRANSPLANTS IN ‘OLDER’ PATIENTS WITH LYMPHOMA

ACCESSIBILITY AND IMPACT ON LONG-TERM OVERALL SURVIVAL OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS: A SINGLE INSTITUTION INTENTION-TO-TREAT ANALYSIS

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TRANSFORMED FOLLICULAR LYMPHOMA (FL): RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY FROM GELTH/GELTAMO GROUP

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANTATION

SIGNIFICANT ROLE OF UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA

HIGH DOSE CHEMOTHERAPY TEAM FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN LYMPHOMA: RESULTS OF A PROSPECTIVE STUDY

AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIV+ AND HIV- LYMPHOMA PATIENTS: A PROPENSITY SCORE MATCHED ANALYSIS

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DOUBLE HIT LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

ALLOGENEIC STEM CELL TRANSPLANTATION CAN BE SUCCESSFULLY DELIVERED FOLLOWING BTKI THERAPY FAILURE FOLLOWING R-BAC RE-INDUCTION CHEMOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA

CLINICAL OUTCOMES OF EBV+ PTLD PATIENTS FOLLOWING HCT WHO FAIL RITUXIMAB: A RETROSPECTIVE CHART REVIEW STUDY FROM FRANCE

THE IMPACT OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) ON THE OUTCOME OF POOR-RISK NON-HODGKIN LYMPHOMA (NHL): UPDATE OF A RETROSPECTIVE INTENT-TO-TRANSPLANT (ITT) ANALYSIS

REDUCING THE COST OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMAS AT LIMITED-RESOURCE CENTERS IN DEVELOPING COUNTRIES

COMPARISON OF MITOXANTRONE - MELPHALAN AND BEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS

NIVOLUMAB RE-CHALLENGE IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: WHERE IS THE PLACE FOR ALLOHSCT?

OUTCOME OF TRANSPLANT ELIGIBLE MANTLE CELL LYMPHOMA PATIENTS WITH FIRST-LINE REGIMENS IN A REAL-WORLD SETTING: A PORTUGUESE MULTICENTER RETROSPECTIVE ANALYSIS
EVALUATION OF FRACTIONATED ICE AS AN ALTERNATIVE OUTPATIENT OPTION FOR RELAPSED/REFRACTORY LYMPHOMAS

EFFICACY OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

RISK FACTORS FOR INTENSIVE CARE UNIT ADMISSION IN PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B-CELL LYMPHOMA

DIFFERENT OUTCOMES WITH DIFFERENT DONORS IN ALLOGENEIC STEM CELL TRANSPLANTATIONS IN MALIGNANT LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE

THE IRISH EXPERIENCE OF THIOTEPA, CARMUSTINE AND ETOPOSIDE CONDITIONING PRIOR TO ASCT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS

TARGETED AND IMMUNOCHEMOTHERAPY IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AS TREATMENT OPTION FOR RARE TRANSDIFFERENTIATION OF LYMPHOID NEOPLASMS INTO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS TO ACHIEVE LONG-TERM SURVIVAL

OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH PERIPHERAL T CELL LYMPHOMAS: A RETROSPECTIVE ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG)

TREATMENT OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA AFTER HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. A STUDY OF THE POLISH LYMPHOMA RESEARCH GROUP

PLACE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH T-CELL LYMPHOMAS: PAVLOV UNIVERSITY EXPERIENCE

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA: TOXICITY AND SURVIVAL STUDY

AUTOIMMUNE COMPLICATIONS IN CHILDREN WITH HODGKIN DISEASE (HD) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT)

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIV-RELATED LYMPHOMA

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS OF 23 PATIENTS

NIVOLUMAB BASED RESPONSE ADAPTED TREATMENT IN PRIMARY REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS

AUTOLOGOUS STEM CELL TRANSPLANT IN A SEROPOSITIVE A PATIENT WITH PLASMABLASTIC LYMPHOMA (PBL)

COMPAIRING THE EFFICACY AND TOXICITY BETWEEN TWO CONDITIONING REGIMEN IN LYMPHOMA PATIENTS IN WEST OF IRAN (BENDAMUSTIN) OR (CCNU) WITH (ETOPOSIDE, CITARABINE, MELPHALANE)
Minimal residual disease, tolerance, chimerism and immune reconstitution

**T CELL CHIMERISM AFTER HCT DOES NOT PREDICT FOR GRAFT LOSS IN NON-MALIGNANT DISEASES, AND IS A FAILURE OF MYELOSUPPRESSION RATHER GRAFT REJECTION**

**FASTER ENGRAFTMENT AND RECONSTITUTION OF INNATE-IMMUNITY AFTER ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) THAN POST-TRANSPLANT-CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS AFTER MYELOABLATIVE CONDITIONING (MAC) PERIPHERAL-BLOOD-STEM-CELL (PBSC) ALLOGENEIC-TRANSPLANTATION (ALLO-SCT)**

**CMV SEROPOSITIVITY DRIVES T CELL RECONSTITUTION AFTER CD34-SELECTED ALLOGENEIC HCT DESPITE REDUCTION OF VIREMIA WITH LETERMOVIR**

**COMPARING OUTCOMES OF PATIENTS HAVING MIXED T CHIMERISM AND UNRELATED DONOR ALLOGRAFTS FOR ACUTE LEUKAEMIA/MDS TO PATIENTS WITH COMPLETE CHIMERISM - SINGLE CENTRE RETROSPECTIVE STUDY**

**CMV INFECTION IS ASSOCIATED WITH REDUCED THYMIC FUNCTION AND LESS REGULATORY T CELLS AFTER PEDIATRIC ALLOGENEIC HSCT**

**IMPACT OF PRE-TRANSPLANT MRD BURDEN MEASURED BY MULTICOLOR FLOW CYTOMETRY ON RELAPSE AND SURVIVAL IN AML PATIENTS UNDERGOING ALLO-SCT IN CR**

**FLOW-BASED PRE-TRANSPLANT MRD DETECTION STRONGLY IMPACTS ON THE OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION WITH AB T CELL DEPLETION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA**

**CMV-SPECIFIC T CELL COUNTS EARLY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION STRATIFY THE RISK OF SUBSEQUENT CMV REACTIVATIONS: RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY**

**IMPROVED RELAPSE-FREE-SURVIVAL IN PATIENTS WITH HIGH NATURAL KILLER CELL DOSES IN GRAFTS AND DURING EARLY IMMUNE RECONSTITUTION AFTER ALLOGENEIC TRANSPLANTATION WITH PERIPHERAL BLOOD STEM CELLS**

**POTENTIAL INFLUENCE OF IMMUNODEFICIENCY-RELATED HEREDITARY PREDISPOSITION GENE VARIANTS ON RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**COMPARABLE RESULTS OF PREEMPTIVE RECOMBINANT IL-2 AND DONOR LYMPHOCYTE INFUSION IN HEMATOLOGICAL MALIGNANCY PATIENTS WITH LATE-ONSET MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**SURVIVAL ANALYSIS ACCORDING TO MINIMAL RESIDUAL DISEASE BY FLOW CYTOMETRY BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA**

**IMPACT OF RESIDUAL CIRCULATING TUMOR DNA STATUS POST ALLOGENEIC SCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: INTERIM RESULTS OF A PROSPECTIVE STUDY**

**EARLY CD4+ T CELL RECONSTRUCTION AS PREDICTOR FOR OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULT PATIENTS: A VALIDATION COHORT ANALYSIS**

**PATTERN OF RECONSTITUTION OF RECENT THYMIC EMIGRANTS AFTER REDUCED INTENSITY CONDITIONING BASED ON TARGETED BUSULFAN IN PAEDIATRIC RECIPIENTS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION**
A RISK SCORE SYSTEM BASED ON POST-TRANSPLANTATION MINIMAL RESIDUAL DISEASE FOR STRATIFICATION OF RELAPSE IN B-ALL PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION

OUTCOME OF CHILDREN WITH HEMATOLOGICAL MALIGNANCIES WHO DEVELOP MIXED DONOR CHIMERSIM AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

PROPHYLACTIC HIGH-DOSE DONOR CD45RO+ MEMORY T-CELLS INFUSION AFTER ALLOGENEIC TRANSPLANTATION: SAFETY AND OUTCOME

MULTICOLOR FLOW CYTOMETRY PANEL WITH CCD79A GATING TO DETECT MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA POST ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT

NON-INVASIVE MONITORING OF MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE BY CIRCULATING CELL-FREE NUCLEIC ACIDS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

TORQUE TENO VIRUS AS BIOMARKER TO PREDICT COMPLICATIONS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

PREEMPTIVE INTERFERON-α TREATMENT COULD PROTECT AGAINST RELAPSE AND IMPROVE SURVIVAL OF ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

THE ADDITION OF BUSULFAN REDUCES THE INCIDENCE OF MIXED CHIMERISM FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA

A NEW MULTIVARIATE MODEL TO DESCRIBE IMPACT OF IMMUNE RECONSTITUTION ON THE DEVELOPMENT OF RELAPSE IN CHILDREN UNDERGOING ALLO-HSCT FOR HEMATOLOGIC MALIGNANCIES AT DAY +100

ACQUISITION OF COMPLETE CHIMERISM IN BONE MARROW, PERIPHERAL BLOOD AND LEUKOCYTE SUBSETS DEPENDS ON THE TRANSPLANT SETTING AND CORRELATES WITH THE CLINICAL OUTCOME

EARLY LYMPHOID SUBSETS RECONSTITUTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AS PREDICTOR OF RELAPSE AND SURVIVAL IN ACUTE LEUKEMIAS

COMPARISON OF IMMUNE RECONSTITUTION BETWEEN 30MG/KG AND 60MG/KG ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC MYELOABLATIVE PERIPHERAL BLOOD STEM CELL TRANSPLANTATION

FUNCTIONAL IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COMPARISON OF PRE- AND POST-TRANSPLANTATION CYTOKINE RESPONSES IN STIMULATED WHOLE-BLOOD

MEASURABLE RESIDUAL DISEASE (MRD) TESTING FOR ACUTE LEUKEMIA IN EBMT TRANSPLANT CENTERS: A SURVEY ON BEHALF OF THE ALWP OF THE EBMT

TBF REGIMEN INDUCES FULL DONOR CHIMERSIM AFTER ALLOGRAFTS IN MYELOFIBROSIS

REAL WORLD UTILITY OF TREATING MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA

COMPARISON OF IMMUNE RECOVERY IN CORD BLOOD AND T AND B DEPLETED HAPLOIDENTICAL GRAFTS RECIPIENTS

THE BCR-ABL P210 CHIMERIC TRANSCRIPT IN VITRO TRANSFER INTO BONE MARROW MESENCHYMAL STROMAL CELLS VIA EXOSOMES
PROGNOSTIC SIGNIFICANCE OF DONOR-SPECIFIC ISOAGGLUTININ RE-APPEARANCE IN ABO-MISMATCHED STEM CELL TRANSPLANT RECIPIENTS
Maryam Pourabdollah, Christine Cserti, Dennis Dong Hwan Kim, Eshetu Atenafu, Ivan Pasic, Zeyad Al-Shaibani, Aijun Law, Wilson Lam, Armin Gerbitz, Jeffery Lipton, Auro Viswabandya, Rajat Kumar, Jonas Mattson, Fotios Michelis, Nayana Sondi, Jacob Pendergrast (Canada)

IMMUNE-RECONSTITUTION OF LYMPHOCYTE SUBPOPULATIONS WITH RESPECT TO MSC-TREATMENT FOR STEROID REFRACTORY GVHD FOLLOWING HSCT

DAY+100 FULL DONOR CHIMERISM IN THE BONE MARROW CONFERS BETTER OVERALL SURVIVAL IN REDUCED INTENSITY CONDITIONED WITH ALEMTUZUMAB ALLOGENEIC STEM CELL TRANSPLANTATION FOR LYMPHOMAS

DONOR FACTORS INFLUENCE OUTCOMES OF PATIENTS RECEIVING DONOR LYMPHOCYTE INFUSION FOR MIXED CHIMERISM AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION

DETERMINE PATIENTS AT RISK OF RELAPSE AND DEATH IN ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME USING CHIMERISM ON BONE MARROW SAMPLES AT DAY 28 AFTER HSCT

CONCURRENT- SYNERGISTIC ASSESSMENT OF TWO TECHNIQUES IN MONITORING MINIMAL RESIDUAL DISEASE FOR PH(-) ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANTATION LEADS TO FAVORABLE CLINICAL OUTCOMES

DONOR CHIMERISM EVALUATION OF MRD-SUSPECTED CELLS ISOLATED BY FLOW CELL SORTING IS AN ACCESSIBLE TOOL FOR MRD VERIFICATION IN PATIENTS AFTER ALLOGENEIC HSCT

ONE-STEP CHECK PURITY OF CD3+ SORTED CELLS ALONG MONITORING HEMATOPOIETIC CHIMAERISM AFTER HSCT

DONOR LYMPHOCYTE INFUSIONS AUGMENT GRAFT VERSUS MALIGNANCY EFFECT FOLLOWING ALEMTUZUMAB-BASED REDUCED INTENSITY ALLOGRAFTS: REFLECTIONS ON A SINGLE CENTRE STUDY

MYELOID- DERIVED SUPPRESSOR CELLS RECOVER QUICKLY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS

PERSISTENT MIXED CHIMERISM WITHOUT RELAPSE IN CHILDREN AFTER HSCT FOR HEMATOLOGIC MALIGNANCY

New drug- and cell-based immune therapies

NIVOLUMAB INCREASES ANTIGEN SPECIFIC IMMUNE RESPONSES AGAINST LEUKEMIC PROGENITOR AND STEM CELLS (LSC/LPC)

PROPHYLACTIC OR PREEMPTIVE LOW-DOSE AZACITIDINE AND DONOR LYMPHOCYTE INFUSION TO PREVENT DISEASE RELAPSE FOLLOWING ALLOGENEIC TRANSPLANTATION IN 60 PATIENTS WITH HIGH RISK AML OR MDS

ELTROMBOPAG FOR THE TREATMENT OF POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTS: A MULTICENTER SURVEY UPDATE

DONOR NK CELLS INFUSION AS A STRATEGY OF IMMUNOTHERAPY TO PREVENT HHV6 REACTIVATION IN PEDIATRIC PATIENTS AFTER CD45RA-DEPLETED TRANSPLANTATION
Scientific Programme

DEVELOPMENT OF CELL VACCINE BASED ON AUTOLOGOUS DENDRITIC CELLS LOADED WITH LIPID NANOPARTICLES CONTAINING CMV PP65 MESSENGER RNA

SMAC MIMETICS (SM) AND NATURAL KILLER (NK) CELLS - A PROMISING COMBINATION TO OVERCOME CELL DEATH RESISTANCE OF RHABDOMYSARCOMA (RMS) CELLS

‘KIT’-MEDIATED BLASTMODULATION TO LEUKEMIA-DERIVED DC SIGNIFICANTLY IMPROVES ANTI-LEUKEMIC ACTIVITIES IN WHOLE BLOOD INDEPENDENT OF AML-PATIENTS’ SUBTYPES

ROLE OF EXOSOMES AS PROMOTORS OR BIOMARKERS TO STUDY ACTIVATION OF LEUKEMIA-DERIVED DENDRITIC CELLS (DCLEU)-MEDIATED ANTI-LEUKEMIC ACTIVATION OF ADAPTIVE AND INNATE IMMUNE-REACTIVE CELLS AGAINST AML-BLASTS

HIGHER INCIDENCE OF SEVERE AUTOIMMUNE HEMOLYTIC ANEMIA AFTER TCRαβ+/CD19+ CELL DEPLETED HAPLOIDENTICAL-HSCT AND POSTGRAFT CELLULAR IMMUNOTHERAPIES: CTLA4-IG VERY EFFECTIVE THERAPEUTIC OPTION FOR THIS LIFE-THREATENING DISEASE

BLINATUMOMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA: REPORT FROM A SINGLE CENTER

IMMUNOMODULATION OF BLASTS WITH CLINICALLY APPROVED RESPONSE MODIFIERS TO IMPROVE ANTI-LEUKEMIC T-CELL REACTIVITY IN AML: AN EX VIVO SIMULATION OF THE CLINICAL SITUATION

IFNY SECRETION OF ADAPTIVE AND INNATE IMMUNE CELLS AS A PARAMETER TO DISPLAY LEUKAEMIA DERIVED DENDRITIC CELL (DC<sub>LEU</sub>) MEDIATED IMMUNE RESPONSES IN AML

TREATMENT OF SEVERE HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA) WITH THE MASP-2 INHIBITOR NARSOPLIMAB (OMS721)

e-Posters
09:30 - 19:00 ePoster Area

Non-haematopoietic stem cells

THE POTENTIAL ROLES OF MUCOSA-ASSOCIATED INvariant T CELLS IN THE PATHOGENESIS OF GUT GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

FACTORS INFLUENCING THE PRESENCE OF BONE MARROW MESENCHYMAL STEM CELLS AFTER ALLOGENIC STEM CELL TRANSPLANTATION

ANALYSIS OF THE GENETIC STABILITY OF DONORS’ BONE MARROW STROMA MESENCHYMAL CELLS DURING CULTIVATION

EFFECT OF MATERNAL AND NEONATAL FACTORS ON THE YIELD OF WHARTON’S JELLY MESENCHYMAL STEM CELLS

THE POLISH EXPERIENCE OF WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF PAEDIATRIC PATIENTS

THE POLISH EXPERIENCE OF WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF ADULT PATIENTS

A RETROSPECTIVE ANALYSIS OF BONE MARROW EXAMINATION RESULTS FROM A SINGLE CENTER INSTITUTION: CAN WE REDUCE THE OCCURRENCE OF UNNECESSARY BONE MARROW EXAMINATIONS?
Non-infectious early complications

**IMPACT OF DONOR-DIRECTED HLA ALLO-ANTIBODIES ON PRIMARY GRAFT FAILURE AFTER UNRELATED DONOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION**

**ELTROMBOPAG TREATMENT AIDED IN PLATELET RECOVERY AND REDUCED PLATELET INFUSION FOR PATIENTS WITH POST-TRANSPLANTATION THROMBOCYTOPENIA**

**IMPACT OF FLUID OVERLOAD (FO) IN POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL DISEASES**

**INCIDENCE, RISK FACTORS, AND OUTCOMES OF PATIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER STEM CELL TRANSPLANT: A MULTI-INSTITUTIONAL ANALYSIS**

**USE OF ECULIZUMAB IN CHILDREN WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY - A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF IEWP AND PDWP EBMT**

**REDUCED POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSES IN T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

**ABO ISOAGGLUTININ LEVELS IN GUIDED MANAGEMENT OF ABO INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**METHYLprednisolone STRATIFIED INTERVENTION BASED ON RISK CLASSIFICATION IN THE TREATMENT OF PRE-ENGRaFTMENT SYNDROME AFTER UNRELATED CORD BLOOD TRANSPLANTATION: A PROSPECTIVE, NON-RANDOMIZED, AND OPEN-LABEL STUDY**

**PRETRANSPLANT NUTRITION MEASURES AND SYSTEMIC INFLAMMATORY RESPONSE PREDICT OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**A MULTI-CENTRE, MULTI-NATIONAL, PROSPECTIVE OBSERVATIONAL REGISTRY STUDY OF DEFIBROtIDE IN PATIENTS DIAGNOSED WITH SEVERE VENO-OCClUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)**

**DEFIBROtIDE TREATMENT FOR VENO-OCClUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES BY SEVERITY AND MULTI-ORGAN FAILURE STATUS IN AN OBSERVATIONAL REGISTRY STUDY**

**INTRODUCTION OF NEW PEDIATRIC EBMT CRITERIA FOR VOD <b>Diagnosis: </b> IS IT LIFE-SAVING OR MONEY-WASTING?**

**PROSPECTIVE PILOT STUDY ON FRAILTY AND FUNCTION ASSESSMENT DURING CLINICS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**HISTOLOGIC FEATURES OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY WITH AND WITHOUT CONCOMITANT ACUTE GRAFT-VERSUS-HOST DISEASE**

**HIGH SURVIVAL RATE OF PEDIATRIC PATIENTS WITH PRIMARY GRAFT FAILURE WHO UNDERGO A SECOND PROCEDURE. THE EXPERIENCE OF 3 SPANISH PEDIATRIC TRANSPLANT UNITS**

**CHEMOTHERAPY-INDUCED GUT MUCOSAL INJURY INITIATES MICROBIAL DISRUPTION IN STEM CELL TRANSPLANT RECIPIENTS**
BACTERIAL AND METABOLIC PROFILING OF THE SALIVA IDENTIFIES UNIQUE PATTERNS OF MICROBIOTA INJURY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT WITH SEVERE ORAL MUCOSITIS

DIAGNOSIS AND MANAGEMENT OF SECONDARY HLH/MAS FOLLOWING HSCT AND CAR-T CELL THERAPY IN ADULTS: AN EBMT-WIDE SURVEY ON BEHALF OF THE ADWP AND TCWP

IMPACT OF ABO INCOMPATIBILITY ON COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION- RETROSPECTIVE, INTERNATIONAL, MULTICENTER ANALYSIS BY THE TRANSPLANT COMPLICATIONS WORKING PARTY EBMT

HYPOALBUMINEMIA PRIOR ALLOHCT IS A RELEVANT NEGATIVE PREDICTOR FOR SURVIVAL

INCIDENCE AND CLINICAL IMPACT OF ATRIAL FIBRILLATION DIAGNOSED DURING HOSPITAL STAY FOR ALLOGENEIC STEM CELL TRANSPLANTATION

TRANSPLANTATION-ASSOCIATED MICROANGIOPATHY (TAM) IN RECIPIENTS OF UNMANIPULATED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTS USING PTCY FOR GVHD PROPHYLAXIS: INCIDENCE AND OUTCOME

IGF-1 AND IGFBP-3 GENE POLYMORPHISMS PREDICT CIRCULATING IGF LEVELS AND SYSTEMIC INFLAMMATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

LOW RISK OF EARLY TOXICITY AND UNPLANNED 100-DAY readmissions AFTER MATCHED AND MISMATCHED RELATED AND UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

KERATINOCYTE GROWTH FACTOR DECREASES HOSPITAL READMISSION AND REGIMEN-RELATED TOXICITIES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA

ELTROMBOPAG FOR TREATING THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE

SYSTEMIC CORTICOSTEROID THERAPY IS UNLIKELY TO BE THE PRIMARY CAUSE OF HYPERGLYCEMIA FOLLOWING TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE

COST-EFFECTIVENESS ANALYSIS OF DEFIBROTIDE FOR THE TREATMENT OF SEVERE VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME IN SPAIN

NEUROLOGIC COMPLICATIONS IN 169 CONSECUTIVE ALLOGENEIC STEM CELL TRANSPLANTS: ETIOLOGY, CLINICAL SYNDROMES AND OUTCOME

VENETOCLAX, HYPMETHYLATING AGENTS AND DLI FOR SALVAGE TREATMENT OF MYELOID MALIGNANCIES RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EVALUATION OF TGF-BETA LEVEL AFTER SUPPLEMENTATION WITH WHEY PROTEIN CONCENTRATE FOR ORAL MUCOSITIS PROPHYLAXIS

TREOSULFAN-INDUCED MYALGIA IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

VALIDATION OF EARLY INCREASE OF SC5B-9 AS A PREDICTIVE MARKER FOR LATER TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY

DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF HEPATIC VENO-OCCCLUSIVE DISEASE AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

EARLY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION IMPROVES OUTCOME OF VERY SEVERE HEPATIC VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER UNMANIPULATED HAPLOIDENTICAL HSCT WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE
DOES THE TYPE OF NUTRITIONAL SUPPORT AFFECT THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION? A PEDIATRIC CENTER EXPERIENCE

NEUROLOGICAL COMPLICATIONS IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY

ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS ADMITTED TO THE INTENSIVE CARE UNIT - REAPPRAISAL OF PROGNOSIS AND PROGNOSTIC FACTORS: A SINGLE CENTER STUDY

ENTERAL VERSUS PARENTERAL NUTRITION IN ADULT HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS SUFFERING FROM GASTROINTESTINAL MUCOSIS

DELAYED ENGRAFTMENT AND PROLONGED HOSPITAL STAY FOLLOWING OMISSION OF FOLINIC ACID AFTER METHOTREXATE FOR GVHD PROPHYLAXIS IN ALLOGENEIC TRANSPLANT RECIPIENTS

THE USEFULNESS OF LIVER STIFFNESS MEASUREMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT SINUSOIDAL OBSTRUCTION SYNDROME

ENDOTHELIAL CELL COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION, A SINGLE CENTRE ANALYSIS ON 99 CONSECUTIVE PATIENTS UNDERGOING ALLO-SCT

GIORGIA MANCINI, Matteo Candelora, Giuseppina Urbano, Francesco Saraceni, Monica Poiani, Marianna Mariani, Irene Federici, Giuseppe Tarantino, Ilaria Scortechini, Attilio Olivieri (Italy)

INFLUENCE OF ABO-INCOMPATIBILITY ON THE OUTCOME OF STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY ON CHILDREN AND YOUNG ADULTS

EASIX IS USEFUL FOR PREDICTING THE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS

SECOND TRANSPLANTATION USING A NOVEL CONDITIONING REGIMEN WITH DIFFERENT DONOR FOR GRAFT FAILURE AFTER FIRST HAPLOIDENTICAL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

A SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME

VENO-OCCCLUSIVE DISEASE: ONLINE, INTERPROFESSIONAL, CASE-BASED EDUCATION SIGNIFICANTLY IMPROVES KNOWLEDGE AND SKILLS OF THE ENTIRE CARE TEAM

HYPERHEMOLYSIS SYNDROME IS A NOVEL CAUSE OF SEVERE HEMOLYTIC ANEMIA AFTER ALLOGENEIC TRANSPLANTATION WITH VERY POOR RESPONSE TO TREATMENT AND OUTCOME

EASIX AS A PREDICTIVE BIOMARKER OF COMPLICATIONS AND OUTCOME IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

SURVIVAL WITH NORMAL PULMONARY FUNCTION IS POSSIBLE DESPITE SIGNIFICANT AND PROLONGED RESPIRATORY SUPPORT, INCLUDING PROLONGED HIGH FREQUENCY OSCILLATORY VENTILATION (HFOV) IN CHILDREN

USE OF INTRAVESICAL HYALURONIC ACID TO TREAT HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION

CURRENT PRACTICE IN NUTRITION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AUSTRIA, GERMANY AND SWITZERLAND

INCIDENCE AND SEVERITY OF CYTOKINE RELEASE SYNDROME FOLLOWING HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL INFUSION

ENGRAFTMENT SYNDROME FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY FROM A SINGLE CENTER
Scientific Programme

- WERNICKE’S ENCEPHALOPATHY IN A CHILD WITH B LYMPHOBLASTIC LYMPHOMA AFTER HAPLO-HSCT
- ECUILIZUMAB FOR THE TREATMENT OF SEVERE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: MULTICENTER EXPERIENCE
- IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) AS GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN TERMS OF SINUSOIDAL OBSTRUCTION SYNDROME (SOS)
- ISCHEMIC STROKE IN CHILDREN AND YOUNG ADULTS WITH MALIGNANT HEMATOLOGICAL AND ONCOLOGICAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
- MELPHALAN DOSE ADJUSTMENT AND CRYOTHERAPY REDUCE ORAL MUCOSITIS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
- CLINICAL FEATURES AND RISK FACTORS OF ENGRAFTMENT SYNDROME IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
- REAL-LIFE EXPERIENCE OF TWO ITALIAN HEMATOLOGY CENTRES ON EFFICACY AND SAFETY OF ORAL NEPA (NETUPITANT/PALONOSETRON) IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
- EARLY TREATMENT WITH DARATUMUMAB FOR REFRACTORY POST-ALLOGENEIC STEM CELL TRANSPLANT PURE RED CELL APLASIA
- PROGNOSTIC FACTORS FOR EARLY MORTALITY OF HEMATOLOGICAL PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT: PRELIMINARY RESULTS OF A PROSPECTIVE MULTICENTER STUDY
- ACUTE KIDNEY INJURY DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS: INCIDENCE AND RISK FACTORS
- T-PA/UKRINASE IN COMBINATION WITH TPE AS A SUBSTITUTIONAL THERAPY FOR TREATMENT OF TA-TMA
- HEMOPHAGOCYTIC SYNDROME AFTER EX-VIVO LYMPHODEPLETED HEMATOPOIETIC TRANSPLANTATION
- IMMUNOADSORPTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MAJOR ABO INCOMPATIBILITY
- IMMUNE-MEDIATED FEVER AFTER T-CELL REPLETE HAPLOIDENTICAL HSCT USING PERIPHERAL BLOOD STEM CELL GRAFTS AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

Paediatric issues

- PROSPECTIVE OPEN-LABEL PHASE II TRIAL OF INDIVIDUALIZED ANTI-THYMOCYTE GLOBULIN SHOWS IMPROVED EARLY CD4+ T-CELL RECONSTITUTION AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE PARACHUTE-TRIAL
- EBMT LESSONS FROM 40 YEARS OF HIGH DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN NEUROBLASTOMA: A REPORT FROM THE PAEDIATRIC WORKING PARTY
  - Ruth Ladenstein, Ulrike Poetschger, Penelope Brock, Roberto Luksch, Victoria Castel, Shifra Ash, Vassilios Papadakis, Geneviève Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz de Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Evgenia Glogova, Dominique Valteau-Couanet, Selim Corbacioglu (Austria)
Scientific Programme

INCIDENCE OF SECONDARY MALIGNANCIES AFTER TBI/VP16 CONDITIONING FOR CHILDHOOD ALL: RESULTS OF THE PROSPECTIVE ALL-SCT-BFM-2003 TRIAL

OUTCOME AND RISK FACTORS OF AUTOIMMUNE CYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY

EBMT SURVEY ON 40 YEARS OF HIGH-DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN EWING TUMOURS (ET). A REPORT FROM THE PAEDIATRIC WORKING PARTY

Ruth Ladenstein, Evgenia Glogova, Christelle Dufour, Edoardo Lanino, Jean Michon, Paul Veys, Roberto Luksch, Uta Dirksen, Krzysztof Kalwak, Stefan Burdach, Henk van den Berg, Boris Afanasyev, Franco Locatelli, Emmanuelle Nicolas-Virelizier, Shifra Ash, Nathalie Gaspar, Jeremy Whelan, Philippe Brault, Ulrike Poetschger, Selim Corbacioglu (Austria)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS IN CHILDREN - RETROSPECTIVE REPORT ON BEHALF OF I-BFM SCT COMMITTEE AND EBMT PEDIATRIC DISEASES WP

IS THE EBMT RISK SCORE PREDICTIVE OF OUTCOMES IN PAEDIATRIC ACUTE LEUKEMIA?

TCRαβ+/CD19+-DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION

THE GREAT ORMOND STREET (GOS) PAEDIATRIC CO-MORBIDITY SCORE FOR OUTCOME POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION

HIGH PREVALENCE OF CAROTID PLAQUES IN YOUNG ADULTS AFTER MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD

HAPLOIDENTICAL DONOR OR UNRELATED DONOR FOR INFANTS WITH SEVERE COMBINED IMMUNODEFICIENCY?

A ‘RISK-ADJUSTED’ CYTOREDUCTION WITHOUT RADIATION FOR PATIENTS WITH FANCONI ANEMIA UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION (HCT)

USE OF RUXOLITINIB IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD)

HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN REFRACTORY CYTOPENIA OF CHILDHOOD (RCC): IMPROVED ENGRAFTMENT FOLLOWING A TREOSULFAN BASED CONDITIONING REGIMEN

PHARMACOKINETICS OF ACTIVE ATG IMPACTS T-CELL RECOVERY AFTER TCRαβ/CD19-DEPLETED HSCT IN PAEDIATRIC PATIENTS

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A MULTICENTRE STUDY FROM INDIA

IMMUNE RECOVERY AND LONG-TERM SURVIVAL FOLLOWING HAPLOIDENTICAL T AND B CELL DEPLETED STEM CELL TRANSPLANTATION - INFLUENCE OF VARIOUS ATG DOSES

OUTCOMES OF HAPLOIDENTICAL VS MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOSPHOSPHAMIDE (PTCY) IN PEDIATRIC HIGH-RISK ALL AND AML IN 1ST AND 2ND CR

COMBINED TCR ALPHA BETA AND CD45RA DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BENIGN HAEMATOLOGICAL CONDITIONS, SINGLE CENTRE EXPERIENCE

GENETIC SUSCEPTIBILITY TO HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME IN PEDIATRIC PATIENTS UNDERGOING HSCT
**Scientific Programme**

HAPLO HSCT WITH IN VIVO T-CELL DEPLETION AFTER REDUCED INTENSITY CONDITIONING REGIMEN AND MYELOABLATIVE MUD AND MMUD DONOR HSCT IN PEDIATRIC PATIENTS AFFECTED BY MALIGNANCIES

THINKING BEYOND HLH: CLINICAL FEATURES OF PATIENTS WITH CONCURRENT PRESENTATION OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND THROMBOTIC MICROANGIOPATHY

LANDMARK ANALYSIS IN HIGH RISK CHILDHOOD ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE STUDY

DEFIBROTIDE IN HEMATOPOIETIC STEM CELL TRANSPLANT: AN STUDY OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYETICO (GETH) AND GRUPO ESPAÑOL DE TRASPLANTE DE MEDULA EN NINOS (GETMON)

NIVOLUMAB-BASED THERAPY PRIOR TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC HODGKIN'S LYMPHOMA

HUMAN LEUKOCYTE ANTIGEN DISPARITIES REDUCE RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH JUVENILE MYELOMONOCYTIC LEUKEMIA

SCHOOL DURING AND AFTER ALLOGENEIC HSCT: A SURVEY OF PRACTICES IN THREE EUROPEAN COUNTRIES

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HURLER SYNDROME: SINGLE CENTER EXPERIENCE

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH FANCONI ANAEMIA: EXPERIENCE OF THE SPANISH WORKING GROUP FOR BONE MARROW TRANSPLANTATION IN CHILDREN (GETMON)

IMPACT OF MEMORY T-CELL DOSES INFUSED WITH T-CELL DEPLETED HAPLOIDENTICAL STEM CELL GRAFTS ON TRANSPLANT OUTCOMES

THE ROLE OF DONOR KIR GENOTYPING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISORDERS

SINGLE-CENTER EXPERIENCE OF TCRαβ/CD19 DEPLETED STEM CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANEMIA

DETECTION OF RECIPIENT-SPECIFIC α/β-T-CELLS DURING THE PRE-ENGRAFTMENT PHASE DOES NOT PREDICT GRAFT REJECTION IN PATIENTS AFTER HAPLOSC: PRELIMINARY RESULTS OF SINGLE CENTRE PROSPECTIVE TRIAL

IMPROVED SURVIVAL AFTER MIBG THERAPY IN COMBINATION WITH MEGACHEMOTHERAPY THAN AFTER STAND-ALONE THERAPY IN CHILDREN WITH NEUROBLASTOMA - POLISH NATION-WIDE RETROSPECTIVE STUDY

THE IMPACT OF HOUSEHOLD INCOME ON ACUTE HOSPITALIZATION DAYS IN PEDIATRIC ALLOGENEIC TRANSPLANT RECIPIENTS

USE OF RIC REGIMENS COMBINED WITH TCRAB DEPLETION AND POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC MISMATCHED SCT

THE ROLE OF HLA-DP MATCHING IN DONOR SELECTION FOR MUD-HSCT IN CHILDREN WITH HEMATOLOGIC MALIGNANT DISEASES

CLINICAL IMPLICATION ON RECOVERY OF γδ T CELLS AFTER TCRαβ-DEPLETED HAPLOIDENTICAL HSCT IN PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE

EARLY INITIATION OF CYCLOSPORINE-MYCOPHENOLATE PLUS ANTITHYMOCYTE GLOBULIN IN HAPLO TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN: LOW INCIDENCE OF SEVERE ACUTE GVHD WITH ENCOURAGING SURVIVAL
FEASIBILITY AND SAFETY OF SURGICAL FERTILITY PRESERVATION TECHNIQUES PROXIMAL TO INITIATION OF CONDITIONING THERAPY IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT

VENO-OCCCLUSIVE DISEASE WITH EMPHASIS ON RENAL MANIFESTATIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS: A SINGLE CENTER EXPERIENCE

OUTCOME AFTER HSCT IN CHILDREN WITH JMML FROM A HISTORICAL POINT OF VIEW

THE IMPACT RECOVERY ABSOLUTE LYMPHOCYTE COUNT AT DAYS +21 ON OUTCOME ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC ALL

T-CELL-RICH HAPLOIDENTICAL STEM CELL TRANSPLANTATION IMPROVES SURVIVAL IN CHILDREN WITH ACUTE LEUKEMIA RELAPSED AFTER ALLOGENEIC TRANSPLANTATION

HIGH PREVALENCE OF VITAMIN C DEFICIENCY IN A LARGE PAEDIATRIC COHORT UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE FROM 2003-2019

EX VIVO T CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE

LONG-TERM ERYTHROPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: HOST DETERMINES RESULT

BOOST WITH CD34+ CELLS FOR POOR GRAFT FUNCTION TREATMENT AFTER HSCT IN PAEDIATRIC PATIENTS. A MULTICENTER STUDY

NO DIFFERENCE IN SURVIVAL AFTER HLA MISMATCHED VERSUS HLA MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION

ALLOGENIC STEM CELL TRANSPLANTATION FOR FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE

STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-ANAPLASTIC PERIPHERAL T-CELL LYMPHOMA ON BEHALF OF THE EBMT-PEDIATRIC DISEASES WORKING PARTY

FIRST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RASGRP1 DEFICIENCY

SUCCESSFUL HSCT IN IMMUNE DISREGULATORY DISEASES

LEVOFLOXACIN BASED PROPHYLAXIS IN CHILDREN RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT AFFECT THE INCIDENCE OF ACUTE GVHD AND BLOODSTREAM INFECTIONS

RITUXIMAB-INDUCED SECONDARY HYPOGAMMAGLOBULINEMIA: MEMORIAL SLOAN KETTERING'S 10-YEAR EXPERIENCE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS

‘INCURABLE’ PAEDIATRIC MYELOID LEUKAEMIA TREATED WITH NOVEL CELL-BASED THERAPEUTICS

EFFECT OF SERUM PANEL REACTIVE ANTIBODIES ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE

SINGLE CENTRE EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR INHERITED BONE MARROW FAILURE SYNDROMES

IS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION A GOOD INDICATION FOR PATIENTS WITH SIFD SYNDROME?
TIME COURSE AND IMPACT OF BODY WEIGHT CHANGE EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HIGH RISK EWING SARCOMA, A SINGLE CENTER EXPERIENCE

CONDITIONING FOR RETRANSPANTATION FROM THE SAME DONOR AFTER PARTIAL AUTOLOGOUS RECONSTITUTION IN PATIENTS WITH PID: IMMUNOSUPPRESSION IS NOT REQUIRED

TOCILIZUMAB TREATMENT FOR CRS IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

IDIOPATHIC PNEUMONIA SYNDROME (IPS) AFTER PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FROM UNRELATED DONOR FOR HURLER SYNDROME (MUCOPOLYSACCHARIDOSIS TYPE 1) SUCCESSFULLY TREATED WITH ETANERCEPT AND STEROIDS

EFFECT OF DESENSITIZATION PROTOCOL ON TRANSPLANTATION SUCCESS IN CHILDREN WITH ANTI-HLA ANTIBODIES

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOHSCT) WITH DIFFERENT INTENSITY CONDITIONING REGIMENS IN INFANT AML

VENETOCLAX/DECITABINE FOR PEDIATRIC MDR-AML RELAPSED AFTER TWO ALLO HSCTS

HIGHER INCIDENCE OF CMV AND BKV REACTIVATION IN HAPLOIDENTICAL TRANSPLANTS COMPARATIVE TO MUD OR MSD TRANSPLANTS - SINGLE CENTRE RETROSPECTIVE ANALYSIS

USE OF POLYCLONAL IGM-ENRICHED IMMUNOGLOBULINS FOR THE TREATMENT OF SEPTIC EPISODES IN CHILDREN WITH ONCOHEMATOLOGICAL DISEASES

PAEDIATRIC BONE MARROW TRANSPLANT CARE ON BMT VERSUS NON-BMT PAEDIATRIC WARDS

CHRONIC HEALTH PROBLEMS IN CHILDREN AFTER ALLOGENEIC HSCT: THE TOP OF THE ICEBERG?

HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: SINGLE-CENTER SERIES OF 14 CASES

NON-WHITE HISPANIC ETHNICITY AS A RISK FACTOR FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC TRANSPLANT

THE CHALLENGES AND OUTCOMES SURROUNDING INTRAVESICULAR CIDOFOVIR ADMINISTRATION: A PAEDIATRIC PHARMACY PERSPECTIVE

THE EXPERIENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RARE HEMATOLOGIC DISEASE

SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH DNA LIGASE IV DEFICIENCY WITH NONMYELOABLATIVE CONDITIONING REGIMEN

PNEUMATOSIS INTESTINALIS AS A RARE POST-TRANSPLANT COMPLICATION IN PEDIATRIC PATIENTS

HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT-HD-CYCLOPHOSPHAMIDE FOR RELAPSED B-LYMPHOBLASTIC LYMPHOMA (B-LBL) WITH MLL-REARRANGEMENT IN 1 Y.O. CHILD: A CLINICAL CASE
Regenerative medicine

WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL THERAPY IMPROVES THE QUALITY OF LIFE AND SELF-SUFFICIENCY OF CHILDREN WITH AUTISM SPECTRUM DISORDER

MARROW DERIVED CELLS BRING A LONG LASTING RELIEF WHEN INJECTED INTRAARTICULARLY TO THE JOINTS WITH DEGENERATIVE ARTHRITIS

OSTEOGENIC DIFFERENTIATION CAPACITY OF ADIPOSE-DERIVED STEM CELLS AFFECTED WITH COLD STORAGE

Statistics

USE OF VARIABLE SELECTION METHODS TO IDENTIFY CLINICAL AND IMMUNOLOGICAL FACTORS ASSOCIATED WITH THE CLINICAL OUTCOME OF PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

THE IMPACT OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION ON WORK AND PRODUCTIVITY LOSS IN PATIENTS WITH ACUTE LEUKAEMIA: RESULTS FROM A RAPID REVIEW

GEOGRAPHIC AND SOCIOECONOMIC IMPACTS ON SURVIVAL AMONG ALLOGENEIC TRANSPLANT RECIPIENTS

Stem cell mobilization, collection and engineering

TWO YEAR ANALYSIS OF A PROSPECTIVE PHASE I/II CLINICAL TRIAL IN ADULTS USING TCR ALPHA/BETA DEPLETED STEM CELL TRANSPLANTATION FROM MATCHED RELATED AND UNRELATED DONORS

A NEW BSA-BASED THRESHOLD PREDICTS OPTIMAL PBSC COLLECTION IN T-CELL DEPLETED HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION

PHASE 1 CLINICAL STUDY OF MGTA-145 IN COMBINATION WITH PLERIXAFOR SHOWS RAPID SINGLE-DAY MOBILIZATION AND COLLECTION OF CD34+ HSCS WITHOUT G-CSF

DEPLETION OF αβ T-CELLS AND B-CELLS BEFORE HLA-HAPLOIDENTICAL HSCT IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISORDERS: A REPORT OF 473 PROCEDURES

ACOUSTOPHORESIS ENABLES THE LABEL-FREE SEPARATION OF DISTINCT SUBSETS FROM CULTURED BONE MARROW STROMAL CELLS

FEASIBILITY OF MODIFIED CD45RA NEGATIVE DONOR LYMPHOCYTES INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

BEYOND STEM CELLS - DOES IT MATTER WHAT'S IN THE BAG IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA AND LYMPHOMA?
EXPRESSIONS OF CO-INHIBITORY MARKERS INCREASE EFFECTOR MEMORY T CELLS IN G-CSF MOBILIZED PERIPHERAL STEM CELLS

LIPEGFILGRASTIM COMBINED WITH CHEMOTHERAPY WAS MORE COST-EFFECTIVE THAN PEGFILGRASTIM IN THE MOBILIZATION OF CD34+ CELLS IN NHL PATIENTS

MOBILIZATION AND HARVEST OF PERIPHERAL BLOOD STEM CELLS (PBSC) FOR ALLOGENEIC STEM CELL TRANSPANTATION FROM 335 PEDIATRIC SIBLING HEALTHY DONORS

A COMPARISON OF CHEMO-FREE STRATEGY WITH G-CSF PLUS PLERIXAFOR ON DEMAND VERSUS ID-CYCLOPHOSPHAMIDE AND G-CSF AS PBSC MOBILIZATION IN MULTIPLE MYELOMA: AN EXPLORATIVE COST ANALYSIS

EVALUATION OF VIA FREEZETM QUAD FOR LIQUID NITROGEN-FREE CGMP-COMPATIBLE CONTROLLED-RATE FREEZING OF HEMATOPOIETIC PROGENITOR CELL GRAFTS

CD34+ CELL SUBSETS IN STEM CELL PRODUCTS AND THEIR RELATIONSHIP WITH ENGRAFTMENT KINETICS

PLERIXAFOR ON DEMAND IN COMBINATION WITH LOW-DOSE CYCLOPHOSPHAMIDE AND G-CSF FOR THE MOBILIZATION OF HSC IN MULTIPLE MYELOMA PATIENTS: HIGH EFFICACY AND LOW TOXICITY

PERFORMANCE QUALIFICATION OF LOVOTM MEDICAL DEVICE FOR WASHING AND CONCENTRATING 3 AND MORE HEMATOPOIETIC PROGENITOR CELL CRYOPRESERVED BAGS

FROM WORK-UP REQUEST TO DONATION IN THREE WEEKS: A DEDICATED REGISTRY INTEGRATED UNRELATED DONOR STEM CELL COLLECTION CENTER IS SAFE, EFFICIENT AND CONVENIENT FOR DONORS

LOW-DOSE CYCLOPHOSPHAMIDE + G-CSF IS NO MORE EFFECTIVE THAN G-CSF ALONE WHEN MOBILIZING AND COLLECTING STEM CELLS FOR AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA PATIENTS

FIRST INTERIM RESULTS OF NIS OPTIMOB - NATIONWIDE TRIAL OF MOBILIZATION AND COLLECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS

THE IMPACT OF PLERIXAFOR ‘ON DEMAND’ ON THE HEMATOPOIETIC STEM CELL (HSC) COLLECTION, PRODUCT’S QUALITY AND ENGRAFTMENT

ELEVATED SERUM LACTATE DEHYDROGENASE AFTER STEM CELL MOBILISATION PREDICTS SUCCESSFUL STEM CELL COLLECTION IN CHILDREN

INFLUENCE OF THE DMSO WASH STRATEGY ON ADVERSE REACTIONS DURING INFUSION OF HEMATOPOIETIC PROGENITORS

BONE MARROW DONOR CHARACTERISTICS: INFLUENCE ON HARVEST YIELD AND DONOR RECOVERY

PLERIXAFOR SALVAGES AUTOLOGOUS STEM CELL MOBILISATION PROCEDURES IN MYELOMA PATIENTS PREVIOUSLY TREATED WITH LENALIDOMIDE OR AUTOLOGOUS HSCT: COST-EFFECTIVENESS OF UPFRONT USE SHOULD BE EXPLORED

EFFECT OF SHIPPING TIME AND TRANSPORT CONDITIONS ON THE VIABILITY OF CORD BLOOD LEUKOCYTES

OPTIMIZATION OF A STEM CELL MOBILIZATION STRATEGY FOR PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA

AUTOLOGOUS LYMPHAPHERESIS FOR THE PRODUCTION OF CAR-T CELLS
Scientific Programme

RED BLOOD CELL DEPLETION AND/OR VOLUME REDUCTION IN BONE MARROW PROCESSING: A COMPARISON OF TWO METHODS

CORRELATION OF INTRA-OPERATIVE TOTAL NUCLATED COUNT AND DONOR CHARACTERISTICS WITH FINAL ALLOGENEIC BONE MARROW GRAFT CHARACTERISTICS AND RECIPIENT CLINICAL OUTCOMES

MULTICENTRE EVALUATION OF THE HPC MODUS (XN-20) FOR TIMING THE HARVEST OF STEM CELLS FROM PERIPHERAL BLOOD

IMPACT OF CHANGE OF MOBILISATION METHOD ON ADEQUACY OF STEM CELL COLLECTION IN MULTIPLE MYELOMA PATIENTS: SINGLE CENTRE EXPERIENCE

TWO DIFFERENT PLERIXAFOR STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE

AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS (PBSCS) MOBILIZATION AND COLLECTION: PRINCESS NOORAH ONCOLOGY CENTER EXPERIENCE, KAMC - JEDDAH - SAUDI ARABIA

REVIEW OF PLERIXAFOR USE IN A TERTIARY PAEDIATRIC ONCOLOGY CENTRE

UNUSUAL HIGH COUNT OF CD34+ AFTER CHEMO MOBILIZATION WITH MATRIX IN PATIENT WITH PRIMARY CNS LYMPHOMA IS ASSOCIATED WITH PROMPT AND ROBUST ENGRAFTMENT

LEUKOCYTAPHERESIS - ONE TECHNIQUE, DIVERSE OPPORTUNITIES IN THE THERAPY OF PATIENTS

COMPARISON OF CONTINUOUS MONONUCLEAR CELL COLLECTION (CMNC) AND MONONUCLEAR CELL CELL (MNC) METHODS FOR CELL PROLIFERATION (APHERESIS) IN PATIENTS WITH BONE MARROW TRANSPLANTATION

Educational
11:00 - 12:00
Auditorium 1

E6, Allogeneic transplantation from family donors

Chairs:
Marie Robin (France)
Antònia Sampol (Spain)

Chinese experience on matched siblings vs. haploidentical
Xiaojun Huang (China)  
11:00 - 11:15

Matched siblings vs. haploidentical in AML
Arnon Nagler (Israel)  
11:15 - 11:30

Matched siblings vs. haploidentical in lymphoma
Didier Blaise (France)  
11:30 - 11:45

Q&A  
11:45 - 12:00

Page 245 / 353
**Scientific Programme**

How do I … ?
11:00 - 12:00  
**Auditorium 2**

**HDI2, How Do I... manufacture T-cells for cellular therapies - Supported through an unrestricted educational grant by Miltenyi Biotec**

**Chairs:**
João Lacerda (Portugal)

- **Home-brew CAR T-Cells**
  Michael Schmitt (Germany)  
  11:00 - 11:15

- **Generating antiviral T-cells for clinical application**
  Britta Eiz-Vesper (Germany)  
  11:15 - 11:30

- **Generation of T regulatory cells**
  Mauro Di Ianni (Italy)  
  11:30 - 11:45

- **Q&A**  
  11:45 - 12:00

**Nurses Group**
11:00 - 12:00  
**Auditorium 3**

**NG05, Care of the caregivers**

**Chairs:**
Janet Baker (United Kingdom)

- **Empowering the caregivers: Social worker**
  Rebecca Parker (United Kingdom)  
  11:00 - 11:25

- **Implementation of a tool to support parents of your patients**
  Marijke Quaghebeur (Belgium)  
  11:25 - 11:50

- **Q&A**  
  11:50 - 12:00

**Cell therapy**
11:00 - 12:00  
**Auditorium 4**

**CTD2, Cell Therapy Day: Conditions for implementation of innovative haematopoietic cellular therapies**

**Chairs:**
Jürgen Kuball (Netherlands)  
Éliane Gluckman (France)

- **Law and ethics beyond gene editing**
  Aurélie Mahalatchimy (France)  
  11:00 - 11:20

- **Integration of care and research leading to individualized treatment**
  Cornelis Punt (Netherlands)  
  11:20 - 11:40

- **Q&A**  
  11:40 - 12:00
Scientific Programme

Transplant Coordinator Day
11:00 - 12:00  
Auditorium 5

TCD2, EBMT-WMDA Transplant Coordinators Day: Lessons learnt from COVID-19 - Transport: Crossing borders in Corona pandemic

Chairs:
Irina Evseeva (United Kingdom)

Ensuring continuity of care - Transport of stem cells between EU Member States
Fabian Bosbach (Germany)  
11:00 - 11:15

Ensuring continuity of care - Transport of stem cells between continents
Ray Hornung (United States)  
11:15 - 11:30

What has changed at the transplant centre side? 
Effie Petersdorf (United States) 
11:30 - 11:45

Text chat Q&A 
11:45 - 12:00

How do I ...?
11:00 - 12:15  
Auditorium 6

HD13, How Do I... reduce therapeutic toxicity in GVHD therapy - Supported through an unrestricted educational grant by Mallinckrodt

Chairs:
Daniel Wolff (Germany)

Strategies to avoid CNI as GVHD prophylaxis 
Olaf Penack (Germany)  
11:00 - 11:25

Cell based option to treat GVHD 
Hildegard Greinix (Austria)  
11:25 - 12:05

Q&A 
12:05 - 12:15

Social Events
12:15 - 12:48  
Auditorium 1

Health with Every Bite - Nutrition and healing

CME Symposium
13:00 - 14:00  
Auditorium 2

IS22, Gene Therapy for β-Thalassemia: The future is now - CME Symposium

Chairs:
Evangelia Yannaki (Greece)

Test your knowledge 
Evangelia Yannaki (Greece)  
13:00 - 13:10
**Scientific Programme**

**Gene Therapy strategies: Past, present, future**
Christof von Kalle (Germany)  
13:10 - 13:20

**Gene Therapy in β-Thalassemia: The clinical data**
Franco Locatelli (Italy)  
13:20 - 13:35

**The nuts and bolts of implementing Gene Therapy: Patient-case studies**
Evangelia Yannaki (Greece)  
Franco Locatelli (Italy)  
13:35 - 13:50

**Audience Q&A**  
13:50 - 14:00

**Industry Symposium**  
13:00 - 14:00  
Auditorium 3

**IS23, Nurse Symposium: Therakos ECP Immunomodulation - How and why - Therakos Industry Symposium**

**Chairs:**
John Murray (United Kingdom)

**Welcome and introduction**
John Murray (United Kingdom)  
13:00 - 13:05

**The role of nurses in delivering ECP - Special patient conditions**
Britt Storm Tråsdahl (Denmark)  
13:05 - 13:20

**ECP: evaluation of cell collection efficiency**
Nina Worel (Austria)  
13:20 - 13:40

**My GVHD and ECP journey - A patient story**
Wilfred Emmanuel-Jones (United Kingdom)  
13:40 - 13:55

**Q&A**  
13:55 - 14:00

**Statistics**  
13:00 - 14:00  
Auditorium 5

**Stat1, Statistics symposium**

**Chairs:**
Hein Putter (Netherlands)

**Methods for missing data in competing risks**
É. F. Bonneville, M Resche-Rigon, L. C. de Wreede, H. Putter (Netherlands)  
13:00 - 13:20

**Bayesian methods for early detection of treatment effects in phase 3 trials with survival endpoints**
Lucie Biard (France)  
13:20 - 13:40

**Text chat Q&A**  
13:40 - 14:00
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),
29 August to 1 September 2020

Scientific Programme

Industry Symposium
13:00 - 14:00
Meet the Expert Rooms

**IS24, Celgene Industry Meet the Expert Lunch - Room MTE1**

Pre-registration required via the general registration form (free of charge). If you have already registered, you can modify your bookings on the official registration form: https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration

**Management of cellular therapies in RRMM**
Paula Rodríguez Otero (Spain)

Industry Symposium
13:00 - 14:00
Meet the Expert Rooms

**IS25, Takeda Industry Meet the Expert Lunch - Room MTE2**

Pre-registration required via the general registration form (free of charge).

**Treatment paradigm in higher-risk MDS**
Guillermo Sanz Santillana (Spain)

Industry Symposium
13:00 - 14:00
Meet the Expert Rooms

**IS26, MSD Industry Meet the Expert Lunch 1 - Room MTE3**

Pre-registration required via the general registration form (free of charge).

**Roundtable Discussion: CMV Management**
Roy Chemaly (United States)

General
14:30 - 16:00
Auditorium 1

**GS2, Presidential Symposium**

**Van Bekkum Award - Introduction**
Nicolaus Kröger (Germany)
RESULTS OF THE EBMT SAAWP PHASE III PROSPECTIVE RANDOMIZED MULTICENTER RACE STUDY OF HORSE ATG AND CICLOSPORIN WITH OR WITHOUT ELTROMBOPAG IN NAÏVE SAA PATIENTS

Basic Science Award - Introduction
Rafael Duarte (Spain)

JUN ACTIVATION IN DERMAL FIBROBLASTS PROMOTES FIBROSIS AND INFLAMMATION IN SCLERODERMATOUS GRAFT-VS-HOST DISEASE IN MICE AND HUMANS
Antonia Müller, Lu Cui, Tristan Lerbs, Megan King, Claire Muscat, Tyler Shibata, Jessica Chen Lee, Ryanne Brown, Sebastian Fernandez-Pol, Sally Arai, Judith Shizuru, Gerlinde Wernig (Switzerland)

SUPERIOR EVENT-FREE SURVIVAL WITH BLINATUMOMAB VERSUS CHEMOTHERAPY IN CHILDREN WITH HIGH-RISK FIRST RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A RANDOMIZED, CONTROLLED PHASE 3 TRIAL
Franco Locatelli, Gerhard Zugmaier, Carmelo Rizzari, Joan Morris, Bernd Gruhn, Thomas Klaus, Rosanna Parasole, Christin Lindemamp, Christian Flotho, Arnaud Petit, Concetta Micalizzi, Noemi Mengen, Abeera Mohammad, Cornelia Eckert, Anja Möricke, Mary Sartor, Ondrej Hrusak, Christina Peters, Vaskar Saha, Arnd von Stackelberg (Italy)

RESULTS OF BMT CTN PROTOCOL 1101 A MULTICENTER PHASE III RANDOMIZED TRIAL OF TRANSPLANTATION OF DOUBLE UMBILICAL CORD BLOOD VS. HLA-HAPLOIDENTICAL-RELATED BONE MARROW

TREOSULFAN EXPOSURE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH EARLY TOXICITY BUT NOT WITH EVENT-FREE SURVIVAL
Eileen van der Stoep, Alice Bertaina, Dirk Jan Moes, Mattia Algeri, Robbert Bredius, Frans Smiers, Henk-Jan Guchelaar, Franco Locatelli, Juliette Zwaveling, Arjan Lankester (Netherlands)

RANDOMIZED PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF RUXOLITINIB VS BEST AVAILABLE THERAPY IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT VS HOST DISEASE (AGVHD)
Robert Zeiser, Nikolas von Bubnow, Jason Butler, Mohamad Mohty, Dietger Niederwieser, Reuven Or, Jeff Szer, Eva Maria Wagner, Tsila Zuckerman, Bruyère Mahuzier, Judith Xu, Kunal K. Gandhi, Gérard Socie (Germany)
Scientific Programme

HOST T CELLS IN SKIN AND GUT SURVIVE STEM CELL TRANSPLANTATION AND CONTRIBUTE TO ACUTE GVHD  

15:44 - 15:54

Nurses Group
14:30 - 16:00  
Auditorium 3

NG06, Back to basics: How can I improve my skills?

Chairs:  
Sandra Schoenfeld (Switzerland)

Oral care during inpatient haematopoietic cell transplantation  
Barry Quinn (United Kingdom)  
14:30 - 14:50

Recognising sepsis  
Jan Styczynski (Poland)  
14:50 - 15:10

CVC management  
Emilian Snarski (Poland)  
15:10 - 15:30

Tumor lysis  
Janet Baker (United Kingdom)  
15:30 - 15:50

Q&A  
15:50 - 16:00

Cell therapy
14:30 - 15:50  
Auditorium 4

CTD3, Cell Therapy Day: Large-scale access to marketed CAR T-Cells

Chairs:  
Olaf Penack (Germany)  
Manel Juan (Spain)

Collecting autologous MNC for industry manufactured CAR T-cells: When and how  
Elad Jacoby (Israel)  
14:30 - 14:50

Addressing bottlenecks in CAR T-cell manufacturing  
Ulrike Köhl (Germany)  
14:50 - 15:10

Management of OOS CAR T-cell products  
Alexey Bersenev (United States)  
15:10 - 15:30

Q&A  
15:30 - 15:50
Transplant Coordinator Day
14:30 - 16:00
Auditorium 5

**TCD3, EBMT-WMDA Transplant Coordinators Day: Lessons learnt from COVID-19 - Cryopreservation: Reality for the next 18 months?**

**Chairs:**
Bronwen Shaw (United States)
Suzanna M. van Walraven (Netherlands)

- **Cryopreservation - View from the donor centre**
  Thilo Mengling (Germany)
  14:30 - 14:55
- **Cryopreservation - View from an Australian transplant centre**
  Jeff Szer (Australia)
  14:55 - 15:20
- **Cryopreservation - View from a European transplant centre**
  Jesús Fernández Sojo (Spain)
  15:20 - 15:45
- **Panel discussion and Q&A**
  15:45 - 16:00

**Educational**
16:30 - 18:00
Auditorium 1

**E7, Gene Therapy for Inherited Disorders in 2020**

**Chairs:**
Cristina Díaz de Heredia (Spain)
Arjan Lankester (Netherlands)

- **Gene therapy in Fanconi Anaemia**
  Juan Bueren (Spain)
  16:30 - 16:50
- **Gene therapy in leucodystrophies and other metabolic disorders**
  M. Ester Bernardo (Italy)
  16:50 - 17:10
- **Haemoglobinopathies**
  Selim Corbacioglu (Germany)
  17:10 - 17:30
- **The future of gene therapy for primary immunodeficiencies**
  Claire Booth (United Kingdom)
  17:30 - 17:50
- **Q&A**
  17:50 - 18:00

**CME Symposium**
16:30 - 18:00
Auditorium 2

**IS27, Antibody Therapy in Acute Leukemia: Understanding Clinical Considerations for Use in Conjunction with HSCT - CME Symposium, supported by an educational grant from Pfizer, ECMEC® Symposium**

**Chairs:**
David I. Marks (United Kingdom)
**Scientific Programme**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 16:35</td>
<td>Welcome and introduction</td>
<td>David I. Marks (United Kingdom)</td>
</tr>
<tr>
<td>16:35 - 17:00</td>
<td>MasterClass 1: Understanding the transplant context in AML and considerations with antibody therapy</td>
<td>Farhad Ravandi (United States)</td>
</tr>
<tr>
<td>17:00 - 17:25</td>
<td>MasterClass 2: Insights on the integration of novel antibodies as options for transplant-eligible patients with ALL</td>
<td>David I. Marks (United Kingdom)</td>
</tr>
</tbody>
</table>
| 17:25 - 17:50 | Practicum: A case-based exploration of antibody therapy in AML/ALL transplant recipients | David I. Marks (United Kingdom)
|           |                                            | Farhad Ravandi (United States)         |
|           |                                            | Matthias Stelljes (Germany)             |
| 17:50 - 18:00 | Summary and reflection                   | David I. Marks (United Kingdom)         |

**Industry Symposium**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 18:00</td>
<td>IS28, HSCT-TMA - Omeros Industry Symposium</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>IS28, HSCT-TMA - Omeros Industry Symposium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Rafael Duarte (Spain)</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:35</td>
<td>Welcome and introduction</td>
<td>Rafael Duarte (Spain)</td>
</tr>
<tr>
<td>16:35 - 17:00</td>
<td>Complement activation in Endothelial Injury Syndromes</td>
<td>Eleni Gavrilaki (Greece)</td>
</tr>
<tr>
<td>17:00 - 17:20</td>
<td>Diagnostic challenges in HSCT-TMA</td>
<td>Sonata Jodele (United States)</td>
</tr>
<tr>
<td>17:20 - 17:50</td>
<td>MASP-2 inhibition with the investigational agent narsoplimab for the treatment of HSCT-TMA: Overview of data and case discussion</td>
<td>Rafael Duarte (Spain)</td>
</tr>
<tr>
<td>17:50 - 18:00</td>
<td>Question-and-Answer session</td>
<td></td>
</tr>
</tbody>
</table>

**Cell therapy**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 17:50</td>
<td>CTD4, Cell Therapy Day: Modern developments in immunogenetics and immunology in the context of HSCT</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>CTD4, Cell Therapy Day: Modern developments in immunogenetics and immunology in the context of HSCT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Katharina Fleischhauer (Germany)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Luca Vago (Italy)</td>
</tr>
</tbody>
</table>
Scientific Programme

**Immunogenetics in the era of NGS and haplo-mismatched transplantations**
Valérie Dubois (France)
16:30 - 16:50

**Immunogenetics of haematopoietic stem cell transplantation**
Effie Petersdorf (United States)
16:50 - 17:10

**Immune monitoring of patients treated with immune effector cells**
Raffaella Greco (Italy)
17:10 - 17:30

**Q&A**
17:30 - 17:50

**Joint Session**
16:30 - 17:50

**JS2, Joint session WBMT: International access to HCT drugs: Impact on transplant practice and patients**

**Chairs:**
Daniel Weisdorf (United States)
Carlos Solano (Spain)

**Causes of drug shortages**
Daniel Weisdorf (United States)
16:30 - 16:45

**How can pharmacists help the HCT team in drug shortages and cost of medications**
Gunar Stemer (Austria)
16:45 - 17:10

**Successful models of cooperation to offer essential drugs in the care of HCT patients: Role of WBMT**
Hildegard Greinix (Austria)
17:10 - 17:35

**Q&A**
17:35 - 17:50

**Industry Symposium**
16:30 - 18:00

**HDI4, How Do I... Expect, predict and improve survival of severe hepatic VOD? - Supported by Jazz Pharmaceuticals**

**Chairs:**
Nicolaus Kröger (Germany)

**Welcome and introduction**
Nicolaus Kröger (Germany)
16:30 - 16:34

**Expect severe hepatic VOD**
Antonio Colecchia (Italy)
16:34 - 16:49

**Ultrasound and Doppler in action**
Nathalie Lassau (France)
16:49 - 17:14
Scientific Programme

Predict severe hepatic VOD - EASIX biomarker panel
Thomas Luft (Germany)
17:14 - 17:29

Predict severe hepatic VOD - EBMT severity grading
Emmanouil Nikolousis (United Kingdom)
17:29 - 17:44

Improve survival of severe hepatic VOD
Emmanouil Nikolousis (United Kingdom)
17:44 - 17:59

Close
Nicolaus Kröger (Germany)
17:59 - 18:00

Meet the Expert
18:00 - 19:00

MTE16, Meet the Expert session 16 - Room MTE2
HSCT and gene therapy in inherited metabolic diseases
Robert Wynn (United Kingdom)
18:00 - 19:00

MTE17, Meet the Expert session 17 - Room MTE3
Current challenges facing emerging donor registries in 2020
Mahmoud Aljurf (Saudi Arabia)
18:00 - 19:00

MTE18, Meet the Expert session 18 - Room MTE4
HSCT indications in paediatric MDS
Charlotte Niemeyer (Germany)
18:00 - 19:00

MTE19, Meet the Expert session 19 - Room MTE5
Ex vivo cellular manipulation and therapy as the platform of choice for allogeneic HSCT in 2020
Stephan Mielke (Sweden)
18:00 - 19:00
Meet the Expert Rooms

MTE20, Meet the Expert session 20 - Room MTE6

**Current role of mesenchymal stromal cells in HSCT**
Peter Bader (Germany)

18:00 - 19:00

MTE21, Meet the Expert session 21 - Room MTE7

**HSCT in MS and immune-mediated neurological diseases: Patient selection and follow-up**
Basil Sharrack (United Kingdom)

18:00 - 19:00

MTE15, Meet the Expert Session 15 - Room MTE1

**Fungal infections in HSCT recipients - The challenges in 2020**
Livio Pagano (Italy)

18:00 - 19:00

Abstract Awards

18:05 - 18:35

AA1, Abstracts Awards Ceremony

**Jian-Jian Luan Award - Introduction**
Bertram Glass (Germany)

18:05 - 18:08

**OFATUMUMAB AS PART OF REDUCED INTENSITY CONDITIONING IN HIGH RISK B-CELL LYMPHOMA PATIENTS: RESULTS FROM A PROSPECTIVE MULTICENTER PHASE-II TRIAL**
Monica Cabrero, Estefania Perez-Lopez, Isidro Jarque, Fatima de la Cruz-Vicente, Ana Africa Martin-Lopez, David Valcarcel, Jaime Sanz, Alejandro Martin, Ildefonso Espigado, Guillermo Orti, Carmen Martín-Calvo, Carlos Grande, Lucia Lopez-Corral, Dolores Caballero (Spain)

18:08 - 18:18

**Jon J. van Rood Award - Introduction**
Christian Chabannon (France)

18:18 - 18:21

**Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation**
Cristina Toffalori (Italy)

18:21 - 18:31

**Best Young Abstracts**
Harry Dolstra (Netherlands)

18:31 - 18:35
**Scientific Programme**

**Tuesday, 01 September 2020**

**Educational**
09:30 - 10:30  
**Auditorium 1**

**E8, Bone marrow failure: From diagnosis to treatment in 2020**

**Chairs:**
Carlos Vallejo (Spain)
Andrea Bacigalupo (Italy)

1. **Constitutional BMF diagnosis work-up in the era of NGS and gene panels**  
   Carlo Dufour (Italy)  
   09:30 - 09:45

2. **Guidelines for the use of eltrombopag in aplastic anaemia in Europe**  
   Régis Peffault de Latour (France)  
   09:45 - 10:00

3. **New complement inhibitors: Time for the show**  
   Antonio Risitano (Italy)  
   10:00 - 10:15

4. **Q&A**  
   10:15 - 10:30

**Educational**
09:30 - 10:30  
**Auditorium 2**

**E9, Novel immunotherapies in Multiple Myeloma**

**Chairs:**
Ibrahim Yakoub-Agha (France)

1. **CD38-targeting monoclonal antibodies**  
   Niels van de Donk (Netherlands)  
   09:30 - 09:46

2. **Bispecific antibodies and BiTEs**  
   Mohamad Mohty (France)  
   09:46 - 09:58

3. **CAR T-cells**  
   Noopur Raje (United States)  
   09:58 - 10:10

4. **How should we position immunotherapies in the changing paradigm of myeloma treatment?**  
   Meral Beksac (Turkey)  
   10:10 - 10:22

5. **Q&A**  
   10:22 - 10:30

**Nurses Group**
09:30 - 10:30  
**Auditorium 3**

**NG07, Nurse Care**

**Chairs:**
Michelle Kenyon (United Kingdom)
Scientific Programme

Mindfulness and tips and trick for self-care 09:30 - 09:45
Troy Chase (United Kingdom)

Leadership 09:45 - 10:00
Klara Kabatova Maxova (Czech Republic)

Q&A 10:00 - 10:30

Paediatric Day 09:30 - 10:30 Auditorium 4

Paediatrics1, Paediatric Diseases Working Party Session

Chairs:
Selim Corbacioglu (Germany)
Christina Peters (Austria)

PDWP update on prospective activities 09:30 - 09:37
Selim Corbacioglu (Germany)

Cell based therapies in children

Overview of novel developments in CAR T 09:37 - 09:44
Patrick Schlegel (Germany)

CD5- and CD7-directed CAR T Cells for T-cell malignancies 09:44 - 09:51
Maksim Mamonkin (United States)

Adoptive transfer of multivirus-specific T-cells 09:51 - 09:58
Tobias Feuchtinger (Germany)

Real world Data: Relapse after CAR T 09:58 - 10:05
Susana Rives (Spain)

"Real World Data" on CAR T: HSCT vs. CAR T in leukaemia 10:05 - 10:12
Peter Bader (Germany)

Q&A 10:12 - 10:27

Educational 09:30 - 10:30 Auditorium 5

E10, Waldenström Macroglobulinaemia

Chairs:
Anna Sureda (Spain)

How biology in Waldenström Macroglobulinaemia may affect treatment strategy? 09:30 - 09:45
Véronique Leblond (France)

Conventional and new drugs 09:45 - 10:00
Ramón García-Sanz (Spain)
### Scientific Programme

**Haematopoietic stem cell transplantation in Waldenström Macroglobulinaemia**
Charalampia Kyriakou (United Kingdom)

10:00 - 10:18

**Q&A**
10:18 - 10:30

---

**Joint Session**
09:30 - 10:30
Auditorium 6

**JS3, Joint session EHA: Moving CAR T-Cell Therapy in Europe**

**Chairs:**
John Gribben (United Kingdom)
Nicolaus Kröger (Germany)

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academic CAR T-cell development in Europe</td>
<td>09:30 - 09:45</td>
</tr>
<tr>
<td>Álvaro Urbano-Ispizua (Spain)</td>
<td></td>
</tr>
<tr>
<td>The CART cell process in Europe: Guidance for centers</td>
<td>09:45 - 10:00</td>
</tr>
<tr>
<td>Jorge Sierra (Spain)</td>
<td></td>
</tr>
<tr>
<td>Sharing CAR T-cell data: Governance structure of EBMT Cellular Therapy registry</td>
<td>10:00 - 10:15</td>
</tr>
<tr>
<td>Jürgen Kuball (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Q&amp;A</td>
<td>10:15 - 10:30</td>
</tr>
</tbody>
</table>

---

**Industrial Theatre**
09:30 - 18:00

**IT1, TLS in the context of new treatments in hematology - Sanofi Genzyme Industry Theatre Session**

**IT2, Clinical Data on Treosulfan-based Conditioning Treatment (Trecondi®) in Paediatric Patients - Medac Industry Theatre Session**

**IT3, Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite Industry Theatre Session**
Industrial Theatre
09:30 - 18:00
**IT4, KYMRIAH in the Real World - Novartis Industry Theatre Session**

Industrial Theatre
09:30 - 18:00
**IT5, How I manage CMV in HSCT patients - MSD Industry Theatre Session**

Industrial Theatre
09:30 - 18:00
**IT6, Gene therapy: From clinical trials to clinical practice - Bluebirdbio Industry Theatre Session**

**Chairs:**
Franco Locatelli (Italy)

**e-Posters**
09:30 - 18:00
ePoster Area

**New drug- and cell-based immune therapies**

**NIVOLUMAB INCREASES ANTIGEN SPECIFIC IMMUNE RESPONSES AGAINST LEUKEMIC PROGENITOR AND STEM CELLS (LSC/LPC)**

**PROPHYLACTIC OR PREEMPTIVE LOW-DOSE AZACITIDINE AND DONOR LYMPHOCYTE INFUSION TO PREVENT DISEASE RELAPSE FOLLOWING ALLOGENEIC TRANSPLANTATION IN 60 PATIENTS WITH HIGH RISK AML OR MDS**

**ELTROMBOPAG FOR THE TREATMENT OF POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTS: A MULTICENTER SURVEY UPDATE**

**DONOR NK CELLS INFUSION AS A STRATEGY OF IMMUNOTHERAPY TO PREVENT HHV6 REACTIVATION IN PEDIATRIC PATIENTS AFTER CD45RA-DEPLETED TRANSPLANTATION**

Mercedes Gasior Kabat, Luisa Sisinni, Raquel De Paz, David Bueno, Yasmina Mozo, Antonio Marcos, Ana Belen Romero, Aida Constanzo, Victor Jimenez Yuste, Antonio Pérez-Martínez (Spain)

**DEVELOPMENT OF CELL VACCINE BASED ON AUTOLOGOUS DENDRITIC CELLS LOADED WITH LIPID NANOPARTICLES CONTAINING CMV PP65 MESSENGER RNA**

Ruslan Nikolaev, Yana Bayzyanova, Natalya Khripkova, Mariya Efimenko, Timofei Zatsepin, Elena Osipova, Michael Maschan (Russian Federation)

**SMAC MIMETICS (SM) AND NATURAL KILLER (NK) CELLS - A PROMISING COMBINATION TO OVERCOME CELL DEATH RESISTANCE OF Rhabdomyosarcoma (RMS) CELLS**

Vinzenz Särchen, Lisa Marie Reindl, Jonas Heck, Meike Vogler, Thomas Bukur, Valesca Bukur, Thomas Klingebiel, Simone Fulda, Evelyn Ullrich (Germany)
‘KIT’-MEDIATED BLAST MODULATION TO LEUKEMIA-DERIVED DC SIGNIFICANTLY IMPROVES ANTILEUKEMIC ACTIVITIES IN WHOLE BLOOD INDEPENDENT OF AML-PATIENTS’ SUBTYPES
Selda Ugur, Lara Kristina Klauer, Christian Blasi, Fatemah Doraneh-Gard, Caroline Plett, Carina Gunsilius, Daniel Amberger, Melanie Weinnmann, Olga Schutti, Zuzanna Stankova, Erdem Özkaya, Michael Atzler, Elena Pepeldjyska, Antje Völker, Jörg Schmohl, Christoph Schmid, Doris Kraemer, Helga Maria Schmetzer (Germany)

ROLE OF EXOSOMES AS PROMOTORS OR BIOMARKERS TO STUDY ACTIVATION OF LEUKEMIA-DERIVED DENDRITIC CELLS (DCLEU)-MEDIATED ANTILEUKEMIC ACTIVATION OF ADAPTIVE AND INNATE IMMUNE-REACTIVE CELLS AGAINST AML-BLASTS

HIGHER INCIDENCE OF SEVERE AUTOIMMUNE HEMOLYTIC ANEMIA AFTER TCRαβ+/CD19+ CELL DEPLETED HAPLOIDENTICAL-HSCT AND POSTGRAFT CELLULAR IMMUNOTHERAPIES: CTLA4-IG VERY EFFECTIVE THERAPEUTIC OPTION FOR THIS LIFE-THREATENING DISEASE
Laszlo Gopcsa, Aniko Barta, Zoltan Csukly, Zita Farkas, Aniko Fodor, Apor Hardi, Lilla Lengyel, Melinda Paksi, Marienn Reti, Eszter Sari, Janos Sinko, Eva Torbagyi, Illdiko Zsigmond-Soos, Istvan Valyi-Nagy, Tamas Masszi, Peter Remenyi (Hungary)

BLINATUMOMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY B-ACUTE LYMPHOBlastic LEUKEMIA: REPORT FROM A SINGLE CENTER

IMMUNOMODULATION OF BLASTS WITH CLINICALLY APPROVED RESPONSE MODIFIERS TO IMPROVE ANTILEUKEMIC T-CELL REACTIVITY IN AML: AN EX VIVO SIMULATION OF THE CLINICAL SITUATION
Christoph Kugler, Helga Schmetzer (Germany)

IFNY SECRETION OF ADAPTIVE AND INNATE IMMUNE CELLS AS A PARAMETER TO DISPLAY LEUKAEMIA DERIVED DENDRITIC CELL (DC<SUB>LEU</SUB>) MEDIATED IMMUNE RESPONSES IN AML

TREATMENT OF SEVERE HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA) WITH THE MASP-2 INHIBITOR NARSOPLIMAB (OMS721)

Non-infectious early complications

IMPACT OF DONOR-DIRECTED HLA ALLO-ANTIBODIES ON PRIMARY GRAFT FAILURE AFTER UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

ELTROMBOPAG TREATMENT AIDED IN PLATELET RECOVERY AND REDUCED PLATELET INFUSION FOR PATIENTS WITH POST-TRANSPLANTATION THROMBOCYTOPENIA

IMPACT OF FLUID OVERLOAD (FO) IN POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL DISEASES

INCIDENCE, RISK FACTORS, AND OUTCOMES OF PATIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER STEM CELL TRANSPLANT: A MULTI-INSTITUTIONAL ANALYSIS

USE OF ECULIZUMAB IN CHILDREN WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY - A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF IEWP AND PDWP EBMT
REDUCED POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSES IN T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES

ABO ISOAGGLUTININ LEVELS IN GUIDED MANAGEMENT OF ABO INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

METHYLPREDNISOLONE STRATIFIED INTERVENTION BASED ON RISK CLASSIFICATION IN THE TREATMENT OF PRE-ENGRAFTMENT SYNDROME AFTER UNRELATED CORD BLOOD TRANSPLANTATION: A PROSPECTIVE, NON-RANDOMIZED, AND OPEN-LABEL STUDY

PRETRANSPLANT NUTRITION MEASURES AND SYSTEMIC INFLAMMATORY RESPONSE PREDICT OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

A MULTI-CENTRE, MULTI-NATIONAL, PROSPECTIVE OBSERVATIONAL REGISTRY STUDY OF DEFIBROTIDE IN PATIENTS DIAGNOSED WITH SEVERE VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)

DEFIBROTIDE TREATMENT FOR VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES BY SEVERITY AND MULTI-ORGAN FAILURE STATUS IN AN OBSERVATIONAL REGISTRY STUDY

INTRODUCTION OF NEW PEDIATRIC EBMT CRITERIA FOR VOD: IS IT LIFE-SAVING OR MONEY-WASTING?

PROSPECTIVE PILOT STUDY ON FRAILTY AND FUNCTION ASSESSMENT DURING CLINICS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

HISTOLOGIC FEATURES OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY WITH AND WITHOUT CONCOMITANT ACUTE GRAFT-VERSUS-HOST DISEASE

HIGH SURVIVAL RATE OF PEDIATRIC PATIENTS WITH PRIMARY GRAFT FAILURE WHO UNDERGO A SECOND PROCEDURE. THE EXPERIENCE OF 3 SPANISH PEDIATRIC TRANSPLANT UNITS

CHEMOTHERAPY-INDUCED GUT MUCOSAL INJURY INITIATES MICROBIAL DISRUPTION IN STEM CELL TRANSPLANT RECIPIENTS

BACTERIAL AND METABOLIC PROFILING OF THE SALIVA IDENTIFIES UNIQUE PATTERNS OF MICROBIOTA INJURY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT WITH SEVERE ORAL MUCOSIS

Roni Shouval, Adi Eshel, Amir Kuperman, Ivetta Danylesko, Bar Dubovski, Joshua A Fein, Shalev Fried, Mika Geva, Elizaveta Kouniavsky, Efrat Muller, Elhanan Borenstein, Yoram Louzoun, Omry Koren, Arnon Nagler (Israel)

DIAGNOSIS AND MANAGEMENT OF SECONDARY HLH/MAS FOLLOWING HSCT AND CAR-T CELL THERAPY IN ADULTS: AN EBMT-WIDE SURVEY ON BEHALF OF THE ADWP AND TCWP

IMPACT OF ABO INCOMPATIBILITY ON COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION- RETROSPECTIVE, INTERNATIONAL, MULTICENTER ANALYSIS BY THE TRANSPLANT COMPLICATIONS WORKING PARTY EBMT

Michal Gorka, Christophe Peczynski, Emmanuelle Polge, Karol Lis, Riitta Niittyvuopio, Hélène Labussière Wallet, Zinaida Peric, Helene Schoemans, Olaf Penack, Nina Worel, Christian Koeenecke, Grzegorz Wladyslaw Basak (Poland)

HYPOALBUMINEMIA PRIOR ALLOHCT IS A RELEVANT NEGATIVE PREDICTOR FOR SURVIVAL
INCIDENCE AND CLINICAL IMPACT OF ATRIAL FIBRILLATION DIAGNOSED DURING HOSPITAL STAY FOR ALLOGENEIC STEM CELL TRANSPLANTATION
Catherina Lueck, Gernot Beutel, Victoria Panagiota, Elke Dammann, Dominik Markel, Maleen Beck, Souheila Tayeb, Adrian Schwarzer, Daniel Kharazipour, Michael Stadler, Arnold Ganser, Matthias Eder (Germany)

TRANSPLANTATION-ASSOCIATED MICROANGIOPATHY (TAM) IN RECIPIENTS OF UNMANIPULATED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTS USING PTCY FOR GVHD PROPHYLAXIS: INCIDENCE AND OUTCOME
IGF-1 AND IGFBP-3 GENE POLYMORPHISMS PREDICT CIRCULATING IGF LEVELS AND SYSTEMIC INFLAMMATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
IGF-1 AND IGFBP-3 GENE POLYMORPHISMS PREDICT CIRCULATING IGF LEVELS AND SYSTEMIC INFLAMMATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Maria Schou Ebbesen, Christian Enevold, Anders Juul, Carsten Heilmann, Henrik Sengelev, Klaus Müller (Denmark)

LOW RISK OF EARLY TOXICITY AND UNPLANNED 100-DAY READMISSIONS AFTER MATCHED AND MISMATCHED RELATED AND UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE
Irene García-Cadenas, Albert Esquirol, Rahinatu Awol, Silvana Saavedra, Silvana Novelli, Ana Garrido, Jordi López, Carol Moreno, Miquel Granell, Javier Briones, Salut Brunet, Jordi Sierra, Rodrigo Martino (Spain)

KERATINOUCYTE GROWTH FACTOR DECREASES HOSPITAL READMISSION AND REGIMEN-RELATED TOXICITIES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA
Naila El Jurdi, Christiana Fair, John Rogosheske, Ryan Shanley, Daniel Weisdorf, Shernan Holtan, Mukta Arora, Veronika Bachanova, Claudia Brunstein (United States)

ELTROMBOPAG FOR TREATING THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE
Zeynep Tugba Guven, Serhat Celik, Leylaş Tül Kaynar, Bulent Eser, Mustafa Cetin, Ali Ünal (Turkey)

SYSTEMIC CORTICOSTEROID THERAPY IS UNLIKELY TO BE THE PRIMARY CAUSE OF HYPERGLYCEMIA FOLLOWING TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE
Anna Guo, LaQuisa Hill, Gabriela Rondon, Richard E. Champlin, Amin M. Alousi, Rima M. Saliba (United States)

COST-EFFECTIVENESS ANALYSIS OF DEFIBROTIDE FOR THE TREATMENT OF SEVERE VENO-OCCULSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME IN SPAIN
David Carcedo Rodriguez, Teresa Arto Artola Urrain, Anabel Chinea Rodriguez, Estefanía García Torres, Marta González Vicent, Gonzalo Gutiérrez-García, Alexandra Regueiro García, Marcos Calvo Hidalgo, Alba Villacampa (Spain)

NEUROLOGIC COMPLICATIONS IN 169 CONSECUTIVE ALLOGENEIC STEM CELL TRANSPLANTS: ETIOLOGY, CLINICAL SYNDROMES AND OUTCOME
VENETOCLAX, HYPOMETHYLATING AGENTS AND DLI FOR SALVAGE TREATMENT OF MYELOID MALIGNANCIES RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Esther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, Gesine Bug, Martina Crysandt, Sabine Dressler, Andreas Haßmann, Daniela Heidenreich, Klaus Hirschbühl, Matthias Hoepfing, Edgar Jost, Jennifer Kaivers, Stefan Klein, Lambros Kordelas, Oliver Kriege, Lutz Müller, Christina Rautenberg, Judith Schaffrath, Christoph Schmid, Daniel Wolff, Rainer Haas, Martin Bornhäuser, Thomas Schroeder, Guido Kobbe (Germany)

EVALUATION OF TGF-BETA LEVEL AFTER SUPPLEMENTATION WITH WHEY PROTEIN CONCENTRATE FOR ORAL MUCOSITIS PROPHYLAXIS
Ana Carolina Amaral de Sao Jose Perrone, Clarissa Ferreira Cunha, Ana Paula da Silva Pinheiro, Italo Tuler Perrone, Leonardo Barbosa de Almeida, Kelli Borges dos Santos, Rodrigo Stephani, Henrique Couto Teixeira, Paula Alexandra da Graça Morais, Antonio Fernandes de Carvalho, Abrahao Elias Hallack Neto (Brazil)
TREOSULFAN-INDUCED MYALGIA IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Eileen van der Stoep, Dagmar Berghuis, Robbert Bredius, Emmeline Buddingh, Henk-Jan Guchelaar, Alex Mohseny, Irene Claassen, Frans Smiers, Arjan Lankester, Juliette Zwaveling (Netherlands)

VALIDATION OF EARLY INCREASE OF SC5B-9 AS A PREDICTIVE MARKER FOR LATER TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY

DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF HEPATIC VENO-OCCULSIVE DISEASE AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

EARLY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION IMPROVES OUTCOME OF VERY SEVERE HEPATIC VENO-OCCULSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER UNMANIPULATED HAPLOIDENTICAL HSCT WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE
Ignacio Gómez-Centurión, Cristina Muñoz, Arturo Alvárez Luque, Miguel Echenagusia Boyra, Diego Rincón, Nieves Dorado, Rebeca Bailén, Gillen Oarbeascoa, Javier Anguita, José Luis Díez-Martín, Mi Kwon (Spain)

DOES THE TYPE OF NUTRITIONAL SUPPORT AFFECT THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION? A PEDIATRIC CENTER EXPERIENCE

NEUROLOGICAL COMPLICATIONS IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY

ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS ADMITTED TO THE INTENSIVE CARE UNIT - REAPPRAISAL OF PROGNOSIS AND PROGNOSTIC FACTORS: A SINGLE CENTER STUDY

ENTERAL VERSUS PARENTERAL NUTRITION IN ADULT HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS SUFFERING FROM GASTROINTESTINAL MUCOSITIS
Lenneke van Groningen, Doris Kalter, Wim Tissing, Walter van der Velden, Nicole Blijlevens (Netherlands)

DELAYED ENGRAFTMENT AND PROLONGED HOSPITAL STAY FOLLOWING OMISSION OF FOLINIC ACID AFTER METHOTREXATE FOR GVHD PROPHYLAXIS IN ALLOGENEIC TRANSPLANT RECIPIENTS
Duncan Purtill, Ghassan Zammar, Hutchison Andrew, Julian Cooney, Paul Cannell, Matthew Wright (Australia)

THE USEFULNESS OF LIVER STIFFNESS MEASUREMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT SINUSOIDAL OBSTRUCTION SYNDROME
Vera Radici, Chiara Rosignoli, Rossella Stella, Maria Vittoria Dubbini, Alessandra Sperotto, Michela Cerno, Antonella Geromin, Marta Lisa Battista, Giorgio Soardo, Laura Scatà, Renato Fanin, Francesca Patriarca (Italy)

ENDOTHELIAL CELL COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION, A SINGLE CENTRE ANALYSIS ON 99 CONSECUTIVE PATIENTS UNDERGOING ALLO-SCT
Giorgia Mancini, Matteo Candelora, Giuseppina Urbano, Francesco Saraceni, Monica Poiani, Marianna Mariani, Irene Federici, Giuseppe Tarantino, Ilaria Scortechini, Attilio Olivieri (Italy)

INFLUENCE OF ABO-INCOMPATIBILITY ON THE OUTCOME OF STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY ON CHILDREN AND YOUNG ADULTS
Volker Witt, Herbert Pichler (Austria)

EASIX IS USEFUL FOR PREDICTING THE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS
Michiko Ebihara, Akihito Shinohara, Satoko Otsanai, Michiko Ryuzaki, Yuki Izuka, Aya Watanabe, Norina Tanaka, Midori Ishiyama, Hiroshi Kazama, Shotaro Hagiwara, Kentaro Yoshinaga, Masayuki Shiseki, Junji Tanaka (Japan)
SECOND TRANSPLANTATION USING A NOVEL CONDITIONING REGIMEN WITH DIFFERENT DONOR FOR GRAFT FAILURE AFTER FIRST HAPLOIDENTICAL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

A SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME
Selim Corbacioglu, Saurabh Aggarwal, Ozlem Topaloglu, William Tappe (Germany)

VENO-OCCCLUSIVE DISEASE: ONLINE, INTERPROFESSIONAL, CASE-BASED EDUCATION SIGNIFICANTLY IMPROVES KNOWLEDGE AND SKILLS OF THE ENTIRE CARE TEAM
Lauren Willis, Mindy Tanzola, Tristin Abair, Pan Chen, Cathryn Jennissen, Alison Bemis, Angela R. Smith (United States)

HYPERHEMOLYSIS SYNDROME IS A NOVEL CAUSE OF SEVERE HEMOLYTIC ANEMIA AFTER ALLOGENEIC TRANSPLANTATION WITH VERY POOR RESPONSE TO TREATMENT AND OUTCOME
José Luis Bueno, Azucena Losa, Clara González Santillana, Begoña Perez de Camino, Guiomar Bautista, Irene Romera, Ana Alarcón, Daniel Naya, Cristina Teresa Fernández-Maqueda, Carlos de Miguel, María Esther Martínez-Muñoz, Almudena De Laiglesia, Laura Vicente, José Antonio García-Marco, Rafael Forés, José Rafael Cabrera, Rafael F Duarte (Spain)

EASIX AS A PREDICTIVE BIOMARKER OF COMPLICATIONS AND OUTCOME IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

SURVIVAL WITH NORMAL PULMONARY FUNCTION IS POSSIBLE DESPITE SIGNIFICANT AND PROLONGED RESPIRATORY SUPPORT, INCLUDING PROLONGED HIGH FREQUENCY OSCILLATORY VENTILATION (HFOV) IN CHILDREN
Ramya Nataraj, Praveen Kurup, Alok Ekka, Gayathri Subramanian, Omendra Narayan, Denise Bonney, Helen Campbell, Hemalatha Doss, Robert Wynn (United Kingdom)

USE OF INTRAVESICAL HYALURONIC ACID TO TREAT HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION

CURRENT PRACTICE IN NUTRITION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AUSTRIA, GERMANY AND SWITZERLAND
Rosa Toenges, Matthias Edinger, Gesine Bug, Anita Lawitschka, Hildegard Greinix, Jörg Halter, Jann Arends, Francis Ayuk, Stefan Klein, Jan-Moritz Middeke, Eva Wagner-Drouet, Inken Hilgendorf, Annic Baumgartner, Daniel Wolff (Germany)

INCIDENCE AND SEVERITY OF CYTOKINE RELEASE SYNDROME FOLLOWING HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL INFUSION
Frank Cirrone, Jamie Pavlennis, Kelli Cole, Maher Abdul-Hay, Doyun Park, A Samer Al-Homsi (United States)

ENCEPHALOPATHY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY FROM A SINGLE CENTER
Dorra Belloumi, Rimel Kanoun, Rim Cherni, Rym El Fatmi, Lamia Torjemane, Nour Abdeljelili, Amel Lakhal, Saloua Ladeb, Tarek Ben Othman (Tunisia)

WERNICKE'S ENCEPHALOPATHY IN A CHILD WITH B LYMPHOBLASTIC LYMPHOMA AFTER HAPLO-HSCT
Natalya Natrusova, Evgeny Burtsev, Bulat Kurmanov, Inna Schederkina, Gleb Bronin (Russian Federation)

ECULIZUMAB FOR THE TREATMENT OF SEVERE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: MULTICENTER EXPERIENCE

IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) AS GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN TERMS OF SINUSOIDAL OBSTRUCTION SYNDROME (SOS)
Scientific Programme

ISCHEMIC STROKE IN CHILDREN AND YOUNG ADULTS WITH MALIGNANT HEMATOLOGICAL AND ONCOLOGICAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Alexey Polushin, Oleg Goloshchapov, Tatiana Khutornaya, Olesya Paina, Tatiana Bykova, Asmik Gevorgian, Zhamal Rahmanova, Anastasia Frolova, Maria Vladovskaya, Ivan Moiseev, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

MELPHALAN DOSE ADJUSTMENT AND CRYOTHERAPY REDUCE ORAL MUCOSITIS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Marcin Jasiński, Martyna Maciejewska, Michał Górka, Anna Brodziak, Kamila Skwierawska, Wiesław Wiktor-Jędrzejczak, Agnieszka Tomaszewska, Grzegorz Basak, Emilian Snarski (Poland)

CLINICAL FEATURES AND RISK FACTORS OF ENGRAFTMENT SYNDROME IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Berta Michael Fernández, Valentín García Gutiérrez, Irene García García, Fernando Martín Moro, Adolfo Sáez Marín, Alejandro Luna de Abia, Claudia Núñez-Torrón Stock, Pilar Herrera Puente, Anabelle Chinea Rodríguez, Gemma Moreno Jiménez, Javier López Jiménez (Spain)

REAL-LIFE EXPERIENCE OF TWO ITALIAN HEMATOLOGY CENTRES ON EFFICACY AND SAFETY OF ORAL NEPA (NETUPITANT/PALONOSETRON) IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

EARLY TREATMENT WITH DARATUMUMAB FOR REFRACTORY POST-ALLOGENEIC STEM CELL TRANSPLANT PURE RED CELL APLASIA
Rahinatu Awol, Irene García-Cadenas, Albert Esquivrol Santfeliu, Silvana Saavedra Gerosa, Jordi Sierra Gil, Rodrigo Martino Bufarull (Spain)

PROGNOSTIC FACTORS FOR EARLY MORTALITY OF HEMATOLOGICAL PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT: PRELIMINARY RESULTS OF A PROSPECTIVE MULTICENTER STUDY

ACUTE KIDNEY INJURY DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS: INCIDENCE AND RISK FACTORS

T-PA/UKRINASE IN COMBINATION WITH TPE AS A SUBSTITUTIONAL THERAPY FOR TREATMENT OF TA-TMA
Fei Zhou, Xuefeng He (China)

HEMOPHAGOCYTIC SYNDROME AFTER EX-VIVO LYMPHODEPLETED HEMATOPOIETIC TRANSPLANTATION
Luisa Sisinni, Yasmina Mozo, David Bueno, Raquel De Paz, Eduardo Lopez-Granados, Antonio Perez-Martinez (Spain)

IMMUNOADSORPTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MAJOR ABO INCOMPATIBILITY
Martina Crysandt, Eva Jennes, Klaus Strathmann, Uta Kunter, Stefan Wilop, Gerda Silling, Tim H Brümmendorf, Fabian Beier, Edgar Jost (Germany)

IMMUNE-MEDIATED FEVER AFTER T-CELL REPLETE HAPLOIDENTICAL HSC UT USING PERIPHERAL BLOOD STEM CELL GRAFTS AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE
Prashant Melhta, Rahul Arora, Vikash Kumar, Siddharth Sood, Swati Pabbi, Jagsahib Kaur (India)
LOW-DOSE DECITABINE IMPROVES REFRACTORY PROLONGED ISOLATED THROMBOCYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A RANDOMIZED MULTICENTER CLINICAL TRIAL

AUTOPHAGY IN ENDOTHELIAL CELLS REGULATES THEIR HAEMATOPOIESIS-SUPPORTING ABILITY

2ND ALLO-HSCT FOR PATIENTS WHO DIAGNOSED RECURRENCE ALL AFTER THE 1ST ALLO-HSCT

ESTABLISHING A TRANSPLANT SHARING PROGRAM

e-Posters
09:30 - 18:00 ePoster Area

Experimental transplantation

SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOETHERAPEUTICS

IMPACT OF GUT FUNGAL COMPOSITION ON OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Florent Malard, Aonghus Lavelle, Giorgia Battipaglia, Béatrice Gaugler, Rémy Dulery, Eolia Brissot, Tounes Ledraa, Razan Mohty, Harry Sokol, Mohamad Mohty (France)

MONITORING HEMATOPOIETIC CELL MICROPARTICLES IN ALLOGRAFTS AND TRANSPLANT RECIPIENTS

EARLY HEPATIC COMPLICATIONS DURING THE FIRST YEAR AFTER BONE MARROW TRANSPLANTATION IN PATIENTS WITH LEUKEMIA
Mehrdad Payandeh, Sakineh Ghorbani, Azam Elahi, Roya Chagneh Lorestani (Iran, Islamic Republic of)

PERFORMANCE OF BONE MARROW TRANSPLANTATION CENTER IN IMAM REZA HOSPITAL, KERMANSHAH, IRAN
Mehrdad Payandeh, Sakineh Ghorbani, Farzaneh Chahardoli, Fouzieh Rahimzadeh (Iran, Islamic Republic of)

e-Posters
09:30 - 18:00 ePoster Area

Haematopoietic stem cells

HAPLOIDENTICAL DONOR BEATS MATCHED SIBLING DONOR FOR PRE-TRANSPLANTATION MRD POSITIVE ALL: A PHASE 3 BIOLOGICALLY RANDOMIZED STUDY

RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED RELATED DONOR WITH TCRd8+/CD19+-DEPLETION AND A FIXED DOSE MEMORY T CELL (CD45RA-DEPLETED) ADD-BACK

CLONAL DYNAMICS AND GENOMIC INTEGRITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN HUMAN ALLOGENEIC TRANSPLANTATION RECIPIENTS
Flavia Peci, Markus J. van Roosmalen, Rurika Oka, Marc Bierings, Ruben Boxtel, Mirjam Belderbos (Netherlands)
ALLOGENIC TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELL GRAFTS RESULTS IN A MASSIVE DECREASE OF PRIMITIVE HEMATOPOIETIC PROGENITOR FREQUENCIES IN RECONSTITUTED BONE MARROWS

TREATMENT OF PURE RED CELL APLASIA AFTER MAJOR ABO INCOMPATIBLE ALLOGENIC STEM CELL TRANSPLANTATION: A FRENCH RETROSPECTIVE STUDY

FEASIBILITY AND OUTCOMES OF A THIRD ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM THE ALWP OF EBMT

CHANGES IN VIABILITY MARKERS OF HEMATOPOIETIC STEM CELLS FOLLOWING LONG-TERM CRYOPRESERVATION
Lisa O'Connor, Nicola Gardiner, Ashique Khan, Valerie Broderick, Paul Browne, Patrick J. Hayden (Ireland)

HIGH PRE-TRANSPLANT INTERLEUKIN-18 IS ASSOCIATED WITH POOR HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND PREDICTS INCREASED NON-RELAPSE MORTALITY

MICROBIAL DIVERSITY, SURVIVAL, AND ACUTE GVHD IN ADULT RECIPIENTS OF ALLO-HSCT AFTER MYELOABLATIVE CONDITIONING: RESULTS OF A NUTRITIONAL INTERVENTION TRIAL
Kristin Skaarud, Johannes R. Hov, Simen H. Hansen, Martin Kummer, Tobias Gedde-Dahl, Asta Bye, Vemund Paulsen, Knut E. A. Lundin, Marius Trørøseid, Geir E. Tjønnfjord, Per O. Iversen (Norway)

UK EXPERIENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACTIVATING PI3K MUTATIONS
Zohreh Nademi, Kanchan Rao, Su Han Lum, Stephen Jolles, Colin Steward, Stephen Hughes, Robert Wynn, Winnie Ip, Austen Worth, Paul Veys, Arjan Lankester, Maria Elena Maccari, Terry Flood, Sophie Hambleton, Andrew Gennery, Mary Slatter (United Kingdom)

RECONSTRUCTION OF THE DONOR-RECIPIENT HEMATOPOIETIC CELL PHYLOGENY USING SOMATIC MUTATIONS TO ESTABLISH NUMBERS OF ENGRAFTING LONG-TERM HSCS IN REAL-WORLD TRANSPLANTATION
Michael Spencer Chapman, C. Matthias Wilk, Steffen Boettcher, Markus G. Manz, Peter Campbell (United Kingdom)

SUCCESSFUL CLEARANCE OF DONOR SPECIFIC ANTI-HLA ANTIBODIES AFTER DESENSITIZATION WITH RITUXIMAB, VELCADE AND PLASMA-EXCHANGE FOLLOWED BY A HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

IMPACT OF PRE-TRANSPLANTATION MINIMAL RESIDUAL DISEASE DETERMINED BY FLOW CYTOMETRY ON OUTCOME OF ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Tangia Muquith, Michele Lm Poon, Tan Lip Kun, Koh Liang piu (Singapore)

ECONOMIC BURDEN OF CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SPANISH MULTICENTER, RETROSPECTIVE STUDY

INCIDENCE AND OUTCOME OF CLONAL AND MALIGNANT TRANSFORMATION (CMT) AMONG PEDIATRIC PATIENTS WITH INHERITED BONE MARROW FAILURE SYNDROMES (IBMFS)

IMPACT OF POST-TRANSPLANT IMMUNOSUPPRESSION WEAN VS. BOOST IN EARLY MIXED CHIMERISM FOLLOWING G-CSF-PRIMED MARROW TRANSPLANT IN THALASSEMIC PATIENTS
Paula Arruda Tacla, Rajat Kumar Agarwal, Rakesh Dhanya, C P Raghuram, Pallavi Mehta, Deepa Deepa Trivedi, Vaibhav Shah, Priya Marwah, Rajpreet Soni, Sadaf Khalid, S Sandeep, Sarah Sarah Khan Gilani, Aliya Batool, Lallindra Gooneratne, Ruwangi Dissanayake, Fatima Itra, Tatheer Zahra, Lawrence Faulkner, Stalin Ramprakash (Brazil)
COMPARISON OF THE CONDITIONING REGIMENS WITH TMLI, NON-RADIATION AND TBI FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

VALIDATION OF DISEASE RISK COMORBIDITY INDEX (DRCI) FOR OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) WITH PARTIALLY T-CELL DEPLETED GRAFT

ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS PRETREATED WITH JAK1/JAK2 INHIBITORS
Maria Barabanshikova, Elena Morozova, Ivan Moiseev, Julia Vlasova, Vadim Baykov, Inna Ushal, Gennadij Rodionov, Sergey Moiseev, Ildar Barkhatov, Ksenija Afanasyeva, Sergey Bondarenko, Boris Afanasyev (Russian Federation)

THE DETERMINATIVE ROLE OF PATIENT-CONTROLLED-ANALGESIA (PCA) IN THE EARLY COURSE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kübra Haşimoglu, Ferda Can, Oktay Tertemiz, Asena Dikyar, Didem Akçalı, Züleyde Nur Özkurt, Zeynep Arzu Yeğin (Turkey)

HIGH SURVIVAL RATE AND LOW INCIDENCE OF AGVHD AFTER CD34+ STEM CELLS SELECTION AND CD3+ T CELLS ADDBACK IN PEDIATRIC MUD HSCT

IMPACT OF ABO INCOMPATIBILITY ON OUTCOMES AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA

COMPARISON OF OUTCOMES AFTER HAPLOIDENTICAL VERSUS UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER REVIEW
Seyed Asadollah Mousavi, Maryam Barkhordar, Tanaz Bahri, Sahar Tavakoli, Leila Mirzakhani, Leyla Sharifi Aliabadi (Iran, Islamic Republic of)

EFFECT OF DIFFERENT TIMINGS OF UMBILICAL CORD CLAMPING ON THE LEVEL OF CD34+ CELLS IN FULL-TERM NEONATES

SEQUENTIAL CONDITIONING REGIMEN (FLAMSA-BU-MEL) IN HLA-MATCHED OR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN REFRACTORY MYELOID DISEASE
Ludovic Jondreville, Laetitia Souchet, Françoise Norol, Madalina Uzunov, Stéphanie Nguyen (France)

SEQUENCE CYTOREDUCTIVE CHEMOTHERAPY FOLLOWED BY MA CONDITIONING REGIMEN HSCT WITH INTERMEDIATE - OR ADVERSE RISK AML IN CR: A SINGLE CENTER STUDY

INVESTIGATION OF VIROLOGICAL FEATURES AND CLINICAL OUTCOMES ASSOCIATED WITH PRE-ENGRAFTMENT CYTOMEGALOVIRUS DNAEMIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
Carlos Solano, Lourdes Vázquez, Estela Giménez, Eliseo Albert, Montserrat Rovira, Ildelfonso Espigado, Carmen Martín, Anabelle Chinea, Albert Esquirol, Ariadna Pérez, Aranzazu Bermúdez, Rafael De la Cámara, Raquel Saldaña, Inmaculada Heras, Ana Julia González-Huerta, Tamara Torrado, Monserrat Batlle, Santiago Jiménez, Carlos Vallejo, Pere Barba, Maria Ángeles Cuesta, José Luis Piñana, David Navarro (Spain)

CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE AS A PREDICTOR OF ENGRAFTMENT AND SURVIVAL IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
Elifcan Aladag, Haluk Demiroglu, Yahya Buyukasik, Hakan Goker (Turkey)

USE OF PLERIXAFOR IN POOR MOBILIZER PATIENTS WITH MYELOMA AND LYMPHOMA: CLONOGENIC CAPACITY AND ENGRAFTMENT DATA
Laura M. Pezzetti, Giambattista Bertani, Liliana Intrpido, Tiziana Lamacchia, Francesca Bosè, Elisa Zucchetti, Giovanni Grillo, Mauro Turrini, Michela Anghilieri, Roberto Cairoli (Italy)
OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRICS: A SINGLE CENTER EXPERIENCE FROM INDIA

RELAPSE/REFRACTORY FOLLICULAR LYMPHOMA: LONG TERM OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA

PRE-EMPTIVE USE OF SORAFENIB COMBINED WITH DLI POST HSCT IN AML FLT3+: A SINGLE CENTER EXPERIENCE

USE OF ELTROMBOPAG FOR THE MANAGEMENT OF POOR GRAFT FUNCTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN

TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH ELTROMBOPAG

Ekin Kircali, Guldane Cengiz Seval, Derya Koyun, Cemaleddin Ozturk, Atilla Uslu, Sinem Civriz Bozdag, Selami Kocak Toprak, Pervin Topcuoglu, Onder Arslan, Muhit Ozcan, Taner Demirer, Hamdi Akan, Osman Ilhan, Gunhan Gurman, Meral Kurt Yuksel (Turkey)

EFFICACY OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED TO CHEMOTHERAPY AS POST-REMISSION TREATMENT FOR CHILDREN WITH INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION

THE TREATMENT OF BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE

Barbaros Sahin Karagun, Bulent Antmen, Ilgen Sasmaz (Turkey)

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA IRREVERSIBLY DEPLETES NAÏVE T LYMPHOCYTES

Mª Del Pilar Sanz Martin, Yaiza Pérez García, Paula Díaz Fernandez, Víctor López Huete, Lorena Vega Piris, Ana Arteche López, Adrián Alegre Amor, Cecilia Muñoz Calleja (Spain)

DESENSITIZATION PROTOCOL IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH ANTI-HLA DONOR-SPECIFIC ANTIBODIES (DSA): A SINGLE-CENTER EXPERIENCE

ASSOCIATION BETWEEN METABOLIC ALTERATION WITH TYPE AND INDICATION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION

Claudia Sossa, Ardila-Baez Manuel, Wandurraga Edwin, Sergio Serrano, Maria Luna-Gonzalez, Luis A Salazar, Jimenez Sara I, Manuel Rosales, Angela M Peña, Xuhey Chen, Juan J Rey, Maria A Chacon (Colombia)

RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES FOR PATIENTS RECEIVING UMBILICAL CORD BLOOD TRANSPLANTS AT THE ROYAL MARSDEN HOSPITAL BETWEEN 2007 AND 2017

Sandra Easdale, Chloe Anthias Anthias, Emma Nicholson, Joy Brennan, Maria Mulligan, Mike Potter, Mark Ethell (United Kingdom)

HIGHER COST AND NO SURVIVAL BENEFIT WITH ADDITION OF RITUXIMAB TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL


ASSOCIATION BETWEEN METABOLIC ALTERATIONS WITH AGE AND GENDER OF PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION

Claudia Sossa, Manuel Ardila-Baez, Edwin Wandurraga, Sergio Serrano, Maria Luna-Gonzalez, Luis A Salazar, Sara I Jimenez, Manuel Rosales, Angela M Peña, Xuhey Chen, Juan J Rey, Maria A Chacon (Colombia)
HAPLOIDENTICAL HSCT IN CHILDREN WITH VERY HIGH-RISK HAEMATOLOGIC MALIGNANCIES: A SINGLE-CENTRE EXPERIENCE
Sie Chong Doris Lau, Seong Lin Khaw, Chia Huan Ng, David Hughes, Jacqueline Fleming, Diane Hanna, Rachel Conyers, Francoise Mechinaud (Australia)

COMPARATIVE STUDY OF THE HEMATOPOIETIC RECONSTITUTION
Miguel Angel Martínez Hernández, Dennis Lumpuy Obregón, Agnerys López Sacerio, Bárbaro Andrés Medina Rodriguez, Carlos Rodriguez Fadragaz, Jorge Félix Guerra Rodriguez (Cuba)

INFUSED TOTAL NUCLATED CELL DOSE IS NOT ASSOCIATED WITH ENGRAFTMENT IN AUTOLOGOUS STEM CELL TRANSPLANTATION
A COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND BFM 95 CHEMOTHERAPY PROTOCOL IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
Haluk Demiroğlu, Elifcan Aladag, Yahya Buyukasik, Salih Aksu, Hakan Goker (Turkey)

THE IMPACT OF CD34+ CELL AND IMMUNEFECTOR CELL DOSE ON TRANSPLANT OUTCOMES
TREOSULFAN COMBINED WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANTATION OF MYELOID DISEASES, ALLOWS HIGH OVERALL SURVIVAL WITH LOW RELATED TOXICITY
Yolanda Gonzalez Romero, Lucrecia Yañez, Miguel Angel Cortes, Andres Insunza, Joan Manuel Mora, Miriam Sanchez-Escamilla, Sara Fernandez-Luis, David Gomez-Lamas, Jose Calvo-Sanchez, Sergio Fernandez-Garcia, Guillermo Martin-Sanchez, Mercedes Colorado, Enrique Ocío, Aranzazu Bermúdez (Spain)

OUTCOME OF RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Zofia Szmit, Anna Król, Krzysztof Kalwak, Marek Ussowicz, Małgorzata Salamonowicz-Bodziach, Jowita Frączkiewicz, Monika Mielcarek-Siedziuk, Justyna Miśkiewicz-Bujna, Izabella Miśkiewicz-Migoń, Ewa Gorczyńska (Poland)

MOTIVATION FOR ANTIFUNGAL USE IN PEDIATRIC HSCT PATIENTS IN AN INSTITUTION IN SOUTHERN BRAZIL

IMPACT OF THE USE OF GRANULOCYTIC COLONY-STIMULATING FACTOR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN RARE FORMS OF PRIMARY IMMUNODEFICIENCIES (PIDS) IN ARGENTINA
Silvia Pizzì, Mariana Roizen, Danila Labonia, Analía Julia, Carlos Figueroa Turienzo, Agustín Gonzalez Correas, Valeria Santidrián, German Carli, Ana Laura Naso, Raquel Staciuk (Argentina)

PHASE II STUDY OF PLERIXAFLOR AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL, PET POSITIVE AFTER TWO R-DHAP

THE EFFECT OF CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE ON THE HEMATOPOIETIC RECOVERY AND SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION
Elifcan Aladag, Haluk Demiroğlu, Yahya Buyukasik, Salih Aksu, Hakan Goker (Turkey)

THE EVENTUAL ROLE OF DONOR AND RECIPIENT VITAMIN D LEVELS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT SETTING
Asena Dikyar, Erhan Hocaoglu, Lale Aydin Kaynar, Zübeyde Nur Öz Kurt, Zeynep Arzu Yeğin (Turkey)

AVERAGE LENGTH OF HOSPITAL STAY FOR PEDIATRIC BLOOD AND MARROW TRANSPLANTS IN THE BACKDROP OF CELL SOURCE, TRANSPLANT TYPE AND OUTCOME
ONE CENTER EXPERIENCE IN OFFLINE TECHNIQUE VALIDATION WITH BIOLOGICAL QUALITY TESTS
María Liz Paciello Coronel, Alejandra Leivas Aldea, Sara Redondo Velao, Encarnación Güemes Arce, Yolanda Paredes, Patricia Pérez Tomás, Mercedes Hernández, Borja Andrades Velazquez, Desire Sánchez Lozano, María Nieves Elvira Cortaberría, Consuelo Carralero, Joaquín Martínez López (Spain)

A MONOCENTRIC CLINICAL OBSERVATION OF ALLOGENEIC TRANSPLANTATION IN 22 PATIENTS WITH ACUTE MEGAKARYOCYTIC LEUKEMIA
Zhijie Wei, Fei Pan, Rong Yang, Guanlan Yue, Kang Gao, Hui Li, Shuquan Ji, Peihua Lu (China)

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN IN SCIENTIFIC CENTRE OF PEDIATRICS AND CHILD SURGERY
Aigul Tulebayeva, Ergaly Sarsekbaev, Riza Boranbayeva, Kulan Omarova (Kazakhstan)

THE OUTCOME OF ALLOTRANSPLANT USING TBF CONDITIONING FROM MATCHED SIBLING RELATED DONORS IN HIGH RISK MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE SINGLE CENTER EXPERIENCE
Khalid Halahleh, Waleed Da’an, Husam Abu-ja’zar, Mohamad Ma’koseh, Salwa Saadah, Rozan Al Far, Abdelghani Tbaki (Jordan)

EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA: RETROSPECTIVE ANALYSIS IN OUR CENTER
Yolanda Gonzalez Romero, Joan Manuel Mora, Miguel Angel Cortes, Sara Fernandez-Luis, David Gomez-Lamas, Aranzazu Bermudez, Andres Insunza, Lucrecia Yañez, Cristina Amunarriz, Mercedes Colorado, Enrique Ocio, Guillermo Martin-Sanchez (Spain)

CARDIOVASCULAR RISK IN PATIENTS BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Claudia Sossa, Manuel Ardila-Baez, Edwin Wandurraga, Sergio Serrano, Maria Luna-Gonzalez, Luis A Salazar, Sara I Jiménez, Manuel Rosales, Angela M Peña, Xueyi Chen, Juan J Rey, Maria A Chacon (Colombia)

INFECTIONS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Essy Maradiegue, Sharon Chávez (Peru)

HAEMATOPOIETIC STEM CELL PRODUCT VIABILITY: A COMPARATIVE STUDY BETWEEN BAGS AND VIALS
Nadia Tanya Glatt, Colwyn Poole, Bibi Rhode, Matlholi Moalosi, Khensani Mathye (South Africa)

TRANSFUSION SUPPORT IN THE FIRST 30 AND 100 DAYS AFTER HAPLOIDENTICAL VERSUS HLA-MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
Mireia Santos Gómez, Agueda Ancochea Serra, Eva Alonso Nogué, Joan Ramon Grifols Ronda, Mireia Morgades de la Fe, Mireia Franch Sarto, Georgina Gener Ricós, Christelle Ferrà Coll, Susana Vives Polo, Anna Torrent Catarineu, Miriam Moreno Velázquez, Montserrat Batlle Massana, Blanca Xicoy Cirici, Laura Abril Sabater, Gladys Ibarra Fernández, Alicia Senín Magán, Albert Oriol Rocaguiruera, Josep Maria Ribera Santasusana, Juan Manuel Sancho Cia (Spain)

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MACS IN A PERUVIAN HEALTH CHILDRENS INSTITUTE: THREE-YEAR EXPERIENCE
Sergio Murillo-Vizcarra, Karina Rojas-Fernandez, Carolina Benavides-Vallve, Karina Pinto-Gossin, Carlos Vidurriaga-De Amezaga (Peru)
COLLECTION, CRYOPRESERVATION AND AUTOLOGOUS TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELLS IN KAUNAS, LITHUANIA 2015-2019
Ieva Golubickaite, Birute Sabaniene, Inga Valanciute, Elona Juozaityte, Rolandas Gerbutavicius, Domas Vaitiekus, Aurija Kalasauskiene, Diana Remeikiene, Jonas Surkus, Ruta Leksiene, Milda Rudzianskiene, Martyna Beinieriene, Vilma Svetickiene, Ruta Dambrauskiene, Vaida Didziariekiene, Daiva Urbioniene, Dietger Niederwieser (Lithuania)

EVALUATION OF OVERALL SURVIVAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT): UNICENTRIC EXPERIENCE

REFRACTORY T-CELL CUTANEOUS LYMPHOMA TREATED WITH ALLOGENEIC HAPLOIDENTIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT
Marcia Silva, Natalia Laso, Maria Claudia Moreira, Simone Lermontov, Rita De cassia Barbosa, Simone Maradei, Marta Colares, Yung Gonzaga, Leonardo Arcuri, Renato Araujo, Decio Lerner (Brazil)

VITAMIN D DEFICIENCY AND OUTCOMES IN ADULT ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE OVER LAST YEARS

CAUSES OF COMPLICATIONS IN ADULTS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Bosco Martin McNally Guillen, Brenda Lizeth Acosta Maldonado, Liliana Mey Rivera Fong, José Manuel Téllez Araujo, Oyuky Gissell Aguirre Reyes, José Luis Estrada Rico, Alejandra Mendoza Torres, Luis Manuel Valero Saldaña (Mexico)

Impact of different <i>ex vivo</i> T-cell depletion strategies on outcomes following hematopoietic cell transplantation for children with primary immunodeficiency

Outcomes and immune reconstitution after T-cell replete haploidentical stem cell transplantation with post-transplantation cyclophosphamide (PTCY) for pediatric patients with primary immunodeficiencies

Hematopoietic stem cell transplantation for inborn errors of immunity in Japan: overview of a nationwide retrospective analysis

Hematopoietic stem cell transplantation for severe combined immunodeficiency in Japan: a nationwide retrospective analysis
Satoshi Miyamoto, Masakatsu Yanagimachi, Katsutsgu Umeda, Akihiro Iguchi, Yoji Sasahara, Hidetoshi Takada, Yoshiyuki Takahashi, Michiko Kajiwara, Masami Inoue, Koji Kato, Yoshiko Hashii, Yoshiko Atsuta, Hiromasa Yabe, Kohsuke Imai, Tomohiro Morio (Japan)

UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY: SINGLE-INSTITUTION EXPERIENCE IN CHINA
Xiaowen Zhai, Xiaowen Qian, Hongsheng Wang, Wenjin Jiang, Ping Wang (China)
IMMUNODEFICIENCY - CENTROMERIC INSTABILITY - FACIAL DYSMORPHISM (ICF) SYNDROME: EVALUATION OF CHARACTERISTICS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Dagmar Berghuis, Lisanne van Leeuwen, Jorinde Hoogenboom, Corry Weemaes, Mary Slatter, Reem Elfeky, Michael Albert, Roland Meisel, Alexandra Laberko, Akif Yesilipek, Lubna Mehyar, Andrew Gennery, Arjan Lankester (Netherlands)

THIOTECTA VERSUS MELPHALAN CONTAINING CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATIONS WITH TCRαβ/CD19 GRAFT DEPLETION FOR PRIMARY IMMUNODEFICIENCIES
Alexandra Laberko, Elvira Sultanova, Yulia Skvortsova, Irina Shipitsina, Svetlana Kozlovskaya, Svetlana Radygina, Anna Livshits, Aishat Kantulaeva, Elena Kurnikova, Anna Shcherbina, Alexei Maschan, Michael Maschan, Dmitry Balashov (Russian Federation)

IMPROVED TRANSPLANT SURVIVAL AND LONG-TERM DISEASE OUTCOME FOR CHILDREN WITH CD40 LIGAND DEFICIENCY
Su Han Lum, Sahar Habibollah, Peter McNaughton, Zohreh Nademi, Terry Flood, Andrew Cant, Mario Abinun, Sophie Hambleton, Mary Slatter, Andrew Gennery (United Kingdom)

HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES INCLUDING IMMUNE RECONSTITUTION IN PRIMARY IMMUNODEFICIENCIES: 5 YEARS OF SINGLE CENTRE EXPERIENCE
OUTCOMES OF STEM CELL TRANSPLANT FOR RIPK1 DEFICIENCY: A SINGLE CENTRE EXPERIENCE
Peter McNaughton, Su Han Lum, Zohreh Nademi, Terry Flood, Eleri Williams, Andrew Cant, Mario Abinun, Andrew R Gennery, Sophie Hambleton, Mary Slatter, Stephen Owens (United Kingdom)

IMPROVING THE RESULT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY WITH SERIOUS INFECTION IN DEVELOPING COUNTRIES USING RIC REGIMENT
SINGLE-CENTER EXPERIENCE OF HAPLOIDENTIC ALLOGENEIC STEM CELL TRANSPLANTATION WITH TCRαβ DEPLETION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCY SYNDROMES
haplo-identical transplant using post-transplant cyclophosphamide (ptcy) in children with severe combined immunodeficiency - a tertiary care centre experience from south India
Stalin Ramprakash, C P Raghuram, Chetan Ginigeri, Fulvio Porta, Sagar Bhattad (India)

NECROTIZING ENTEROCOLITIS IN A TWO-MONTH-OLD SCID PATIENT AFTER BONE MARROW TRANSFUSION - SURGICAL INTERVENTION AT DAY +1: YES OR NO?
UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH TWO DIFFERENT CONDITIONING REGIMEN FOR CHRONIC GRANULOMATOUS DISEASE: SINGLE-INSTITUTION EXPERIENCE IN CHINA
Xiaowen Qian, Xiaowen Zhai, Hongsheng Wang, Wenjin Jiang, Ping Wang (China)

THE OUTCOMES OF UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE IN CHILDREN WITH RAG GENE MUTATION
Xiaowen Qian, Xiaowen Zhai, Chaofan Liu, Hongsheng Wang, Ping Wang, Wenjin Jiang (China)

LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) IN ADA-SCID PATIENTS: THE SHADOW OF MALIGNANCIES
HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR X-LINKED AGAMMAGLOBULINAEMIA COMPLICATED BY CHRONIC NOROVIRUS ENTEROPATHY
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CD40 LIGAND DEFICIENCY
**Scientific Programme**

**DIAGNOSTIC MARKERS FOR AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME**  
Emese Molnar, Nesrine Radwan, Gabor Kovacs, Siobhan Burns, Hajnalka Andrikovics, Matthew Buckland, Kimberly Gilmour (United Kingdom)

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR CHRONIC GRANULOMATOUS DISEASE (CGD) IN CHILDHOOD**

---

**Infectious complications**

**PNEUMOCYSTIS PNEUMONIA AFTER ALLOGENEIC HCT: A CASE-CONTROL STUDY ON RISK FACTORS, TIMING, AND PCR USE, FROM THE IDWP OF EBMT**

**UPPER AND/OR LOWER RESPIRATORY TRACT INFECTION CAUSED BY HUMAN CORONAVIRUS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**SUCCESSFUL TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WITH JCV-TARGETED T-CELL THERAPY**

**EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY**

**TUBERCULOSIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT**

**FAECAL MICROBIOTA TRANSPLANT (FMT) CAN REDUCE THE HIGH NRM ASSOCIATED WITH MULTI-DRUG RESISTANT ORGANISM (MDRO) COLONISATION PRIOR TO ALLOGENEIC HCT**

**EPIDEMIOLOGY, RISK FACTORS AND OUTCOMES OF CMV INFECTION IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT): A SINGLE INSTITUTIONAL COHORT STUDY**

**USE OF LETERMOVIR IN OFF-LABEL INDICATIONS: INFECTIOUS DISEASES WORKING PARTY EBMT RETROSPECTIVE STUDY**

**RISK OF INFECTIOUS COMPLICATIONS IN ADULT PATIENTS AFTER ALLOGENEIC HSCT DEPENDING ON THE SITE OF CENTRAL VENOUS CATHETER INSERTION - MULTICENTRE PROSPECTIVE STUDY**  
Emilian Sniarski, Jacqui Stringer, Małgorzata Mikulska, Lidia Gil, Gloria Tidello, Paul Bosman, Jennifer Hoek, Michal Karas, Samo Zver, Catherina Lueck, Nicole Blijlevens, Iria González, Małgorzata Ociepa-Wasilkowska, Michał Górka, Isabel Sánchez-Ortega, Inger Andersson, Lucrecia Yáñez, Mohamed Amine Bekadja, Jan Styczynski (Poland)

**INFECTION PREVENTION PRACTICES AMONG EBMT HEMATOPOIETIC CELL TRANSPLANT CENTERS: A SURVEY OF THE INFECTIOUS DISEASES WORKING PARTY OF THE EBMT**  
Moshe Yeshurun, Uri Rozovski, Liat Shargian, Oren Pasvolsky, Diana Averbuch, Steffie van der Werf, Nina Knelange, Małgorzata Mikulska, Jan Styczynski (Poland)

**PRIMARY LETERMOVIR PROPHYLAXIS IN CMV SEROPosITIVE PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL LIFE EXPERIENCE**

**HEV INFECTION IN HCT RECIPIENTS - RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY (IDWP) OF EBMT**  
Małgorzata Mikulska, Olaf Penack, Lotus Wendel, Nina Knelange, J.J. Cornelissen, Nicole Blijlevens, Jakob Passweg, Nicolaus Kroger, Anke Bruns, Arnold Ganser, Marc Bierings, Helen Labussière-Wallet, Gilles Salles, Jan Styczynski (Italy)
THE ROLE OF COMBINATION PROPHYLAXIS IN PREVENTING CYTOMEGALOVIRUS (CMV) INFECTION AFTER EX VIVO AB T-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANT (HHCT) IN CHILDREN
Sung Han Kang, Jae Won Yoo, Jin Kyung Seo, Hyery Kim, Kyung-Nam Ko, Eun Seok Choi, Seongsoo Jang, Chan-Jeoung Park, Jong Jin Seo, Ho Joon Im (Korea, Republic of)

IMPACT OF CMV SEROSTATUS AND CMV REACTIVATION AFTER HAPLOIDENTICAL-SCT WITH PT-CY
COMPARISON OF IMMUNE CELL RESPONSE TO CYTOMEGALOVIRUS PROTEINS VERSUS PEPTIDES USING AN IFN-γ ELISPOT ASSAY TO MONITOR CYTOMEGALOVIRUS-SPECIFIC IMMUNITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Eva Wagner, Daniel Teschner, Christine Wolschke, Dietlinde Janson, Kerstin Schäfer-Eckart, Johannes Gärtnér, Stephan Mielke, Martin Schreder, Guido Kobbe, Mustafa Kondakci, Inken Hilgendorf, Marie von Lilienfeld-Toal, Stefan Klein, Daniela Heidenreich, Sebastian Kreil, Mareike Verbeek, Sandra Grass, Markus Ditschkowski, Tanja Gromke, Martina Koch, Monika Lindemann, Thomas Hünig, Traudel Schmidt, Anne Rasche, Harald Guldan, Sascha Barabas, Ludwig Deml, Ralf Wagner, Daniel Wolff (Germany)

HUMAN HERPESVIRUS TYPE 6 REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION: RISK FACTORS AND CLINICAL IMPACT
INCREMENTAL INPATIENT HEALTHCARE RESOURCE USE AND COSTS AMONG CMV SEROPositive ALLOGENIC STEM CELL TRANSPLANT RECIPIENTS MANAGED THROUGH PREEMPTIVE APPROACH
Jiaqi Fang, Phaedon D. Zavras, Yiqi Su, Amit Raval, Yuexin Tang, Anat Stern, Miguel-Angel Perales, Sergio Giralt, Genovefa A. Papanicolaou (United States)

POOR RECOVERY AND IMPAIRED FUNCTION OF V61+ T CELLS IN REFRACTORY/RECURRENT CMV REACTIVATION AFTER HEMATOPOIETIC TRANSPLANTATION
SAFETY AND Efficacy OF BRINCIDOFOVIR FOR REFRACTORY ADENOVIRUS INFECTION IN CHILDREN RECEIVING ALLOGENIC SCT: A RETROSPECTIVE ANALYSES FROM THE ITALIAN PEDIATRIC HEMATOLOGY ONCOLOGY ASSOCIATION (AIEOP)
ALLOPLUS: RESULTS OF THE ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS -POSITIVE PATIENTS, A RETROSPECTIVE STUDY OF THE SFGM-TC
Ana Berceanu, Kevin Bouiller, Etienne Daguindau, Anne Thiebaut-Bertrand, Regis Peffault de Latour, Felipe Suarez, Bruno Lioure, Helene Labussière-Wallet, Marion Simonet, Sylvain Chantepie, Florence Beckerich, Marie-Therese Rubio, Stephanie Nguyen-Quoc (France)

SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN PATIENTS WHO UNDERWENT ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A PROSPECTIVE STUDY TO MEASURE FEASIBILITY, SAFETY AND HEALTH CARE RESOURCE USE
Ivan Pasic, Wael Alanazi, George Dranitsaris, Lani Lieberman, Auro Viswabandya, Dennis D. Kim, Jeffrey H. Lipton, Fotios V. Michelas (Canada)

FREQUENCY, RISK FACTORS AND OUTCOME OF ACTIVE TUBERCULOSIS FOLLOWING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
INFECTIONComplications IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN’S LYMPHOMA AFTER NEW AGENTS’ THERAPY AND ALLOGENIC STEM CELL TRANSPLANTATION
Yuliya Rogacheva, Marina Popova, Kirill Lepik, Yuriy Zalylov, Lilia Stelmakh, Alisa Volkova, Iliya Nikolaev, Anastasia Beinarovich, Olga Pirogova, Evgeniya Borzenkova, Oleg Goloshchapov, Sergey Bondarenko, Ivan Moiseev, Vadim Baykov, Nataliya Mikhailova, Nikolay Klimko, Boris Afnasyev (Russian Federation)

SURVEILLANCE FOR REACTIVATION OF TOXOPLASMA GONDII USING POLYMERASE CHAIN REACTION ASSAY AND PRE-EMPTIVE THERAPY AVOIDS UNIVERSAL PROPHYLAXIS AND PREVENTS SYMPTOMATIC INFECTION
CYTOMEGALOVIRUS (CMV) IMPACT ON CLINICAL OUTCOMES AND RESOURCE USE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE INFLUENCE OF RECURRENT EPISODES OF CMV INFECTION

FECAL MICROBIOTA TRANSPLANTATION IN CHILDREN TO TREAT ACUTE GVHD OR MULTI-DRUG RESISTANT BACTERIA COLONIZATION

VACCINATION AGAINST TICK-BORNE ENCEPHALITIS (TBE) AFTER AUTOLOGOUS AND ALLOGENEIC BONE MARROW TRANSPLANTATION
Sigrun Einarsdottir, Malin Nicklasson, Malin Veje, Tomas Bergström, Per Jungman, Berit Johansson, Mikael Olsson, Björn Andreasson, Marie Studahl, Benedicte Piauger, Anette Roth, Mats Brune (Sweden)

RIFAXIMIN USE FAVOURED MICAFUNGIN RESISTANT CANDIDA SPP INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

BASELINE CHARACTERISTICS AND EARLY POLY-FUNCTIONAL ASSESSMENT OF T CELLS TO IDENTIFY PATIENTS AT HIGHER RISK TO DEVELOP SEVERE HCMV REACTIVATION AFTER ALLOGENEIC HSCT
Elisa Gabanti, Oscar Borsani, Daniela Caldera, Anna Amelia Colombo, Virginia Ferretti, Emilio Paolo Alessandrino, Paolo Bernasconi, Daniele Lilleri (Italy)

IMPACT OF HHV-6 REACTIVATION AFTER T-REG/T-CON IMMUNOTHERAPY IN ALLOGENEIC TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE STUDY
Chiara Camerini, Alessandra Carotti, Loredana Ruggeri, Adelmo Terenzi, Franca Falzetti, Silvia Bozza, Roberto Castronari, Samanta Bonato, Genni Casarola, Rita Felicini, Mario Griselli, Francesca Marzutti, Matteo Paradiso, Sara Tricarico, Antonella Mencacci, Andrea Velardi, Antonio Pierini (Italy)

ADENOVIRUS INFECTIONS AFTER HCT: INFECTIOUS DISEASES WORKING PARTY RETROSPECTIVE EBMT REGISTRY STUDY
Jan Styczynski, Gloria Tridello, Nina Knelange, Joan Hendrik Veelken, Gerard Socie, Stephan Mielke, Beneditc Neven, John A. Snowden, Jean-Hugues Dalle, Marie-Thérèse Rubio, Charles Crawley, Johan Maertens, Jurgen Kuball, Patrice Chevallier, Gérard Michel, Peter J. Shaw, Ram Malladi, Robert F. Wynn, Yves Bertrand, Nicole Blijlevens, Charlotte Jubert, Tobias Gedde-Dahl, Ibrahim Yakoub-Agha, Maia Itàlia-Remes, Lidia Gil, Simone Cesaro, Malgorzata Mikulska (Poland)

CLINICAL IMPACT OF COLONIZATION BY MULTIDRUG-RESISTANT ENTEROBACTERIACEAE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

POST-ALLOGENEIC TRANSPLANTATION PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, CLINICAL AND BIOLOGICAL FEATURES, TREATMENT AND OUTCOMES: A RETROSPECTIVE STUDY FROM THE SFGM-TC
Alexis Genthon, Sylvain Chantepie, Amandine Le Bourgeois, Jacques Olivier Bay, Marie-Thérèse Rubio, Ali Bazarbachi, Stephanie Nguyen, Yves Beguin, Xavier Poiré, Amandine Charbonnier, Nathalie Fegueux, Michaël Loschi, Micha Srour, Folie Brissot (France)

RESPIRATORY VIRAL INFECTIONS IN ADULT PATIENTS UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION FROM UNRELATED DONORS AFTER MYELOABLATIVE CONDITIONING REGIMEN

EFFICACY OF LETERMOVIR FOR PROPHYLAXIS OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTI CENTER RETROSPECTIVE ANALYSIS AMONG JAPANESE PATIENTS
Yasuo Moro, Goichi Yoshimoto, Tetsuya Eto, Koji Nagafuji, Hiromi Iwasaki, Yoshikiyo Ito, Yuju Ohno, Tomohiko Kamimura, Ryosuke Ogawa, Akihiko Numata, Koji Kato, Katsuto Takenaka, Toshihiro Miyamoto, Koichi Akashi (Japan)

RISK FACTORS AND CLINICAL OUTCOMES OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL AND MATCHED-SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
STANDARDIZED MONITORING OF CYTOMEGALOVIRUS-SPECIFIC CELLULAR IMMUNITY CAN IMPROVE RISK STRATIFICATION OF RECURRENT CYTOMEGALOVIRUS REACTIVATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

Eva Wagner, Daniel Teschner, Christine Wolschke, Dietlinde Janson, Kerstin Schäfer-Eckart, Johannes Gärtnner, Stephan Mielke, Martin Schreder, Guido Kobbe, Mustafa Kondakci, Inken Hilgendorf, Marie von Lilienfeld-Toal, Stefan Klein, Daniela Heidenreich, Sebastian Kreil, Mareike Verbeek, Sandra Grass, Markus Ditschkowski, Tanja Gromke, Martina Koch, Monika Lindemann, Thomas Hünig, Traudel Schmidt, Anne Rasche, Harald Guidan, Sascha Barabas, Ludwig Demi, Ralf Wagner, Daniel Wolff (Germany)

IMPACT OF LEVOFLOXACIN FOR PROPHYLAXIS OF PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS AFTER ALLOGENEIC HSCT: A SINGLE-CENTER MATCHED ANALYSIS IN AN ENDEMIC COUNTRY FOR CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) AFTER HCT - A RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT

ORAL RIBAVIRIN IS A HIGHLY EFFICACIOUS TREATMENT FOR LOWER RESPIRATORY TRACT INFECTION DUE TO RESPIRATORY SYNCYTIAL OR PARAINFLUENZA VIRUS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS

Ioannis Tsonis, Ioannis Baltadakis, Maria Stamouli, Konstantinos Gkirkas, Christina Economidou, Dimitra Gardeli, Thomas Thomopoulos, Anna Paisiou, Dimitra Oikonomopoulou, Tiatina Tzenou, Nikolaos Siafakas, Spyridon Pournaras, Anastasia Antoniadou, Aggeliki Karagiannidi, Eirini Grispou, Joseph Meletiadis, Dimitra Kavatha, Stavros Gigantes, Evgenios Goussetis, Dimitrios Karakasis, Panagiotis Tsirigotis (Greece)

TIMING OF INDUCTION TREATMENT FOR REACTIVATION OF CYTOMEGALOVIRUS IMPACTS OVERALL SURVIVAL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT

Christine Camacho-Bydume, Irene Rodriguez-Sanchez, Audrey Mauguen, Genovefa Papanicolaou, Susan Prockop, Elizabeth Klein, Nancy Kernan, Jaap-Jan Boelen, Maria Cancio (United States)

PREDICTION OF BLOODSTREAM INFECTION RISK USING CITRULLINE AS BIOMARKER OF INTESTINAL MUCOSIS IN HEMATO-ONCOLOGY PATIENTS

Charlotte de Mooij, Walter van der Velden, Antoninus de Haan, Lenneke van Groningen, Nicole Blijlevens (Netherlands)

PREDICTION OF CMV REACTIVATION BY THE RECIPIENT IGG TITER BEFORE ALLO-HCT


COMPARISON OF INFECTIOUS COMPLICATIONS AMONG PATIENTS RECEIVING UNMANIPULATED HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETED HAPLOIDENTICAL TRANSPLANT

Louis-Pierre Girard, Yin Jie Koh, Xin Liu, Davanaliz Gonzales Ramos, Teck Guan Soh, Lip Kun Tan, Michelle LM Poon, Lionel Lum, Liang Piu Koh (United Kingdom)

THE CUMULATIVE INCIDENCE OF MULTIPLE DNA VIRUS REACTIVATION IS NOT DIFFERENT IN NON-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION AND UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION

NEUTROPHILS RESPONSE TO HUMAN CMV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

Atsushi Satake, Jun Ichikawa, Ryo Saito, Akiko Konishi, Masaaki Hotta, Takahisa Nakanishi, Aya Nakaya, Shinya Fujita, Tomoki Ito, Kazuyoshi Ishii, Shosaku Nomura (Japan)
Scientific Programme

AT-HOME FOSCARNET ADMINISTRATION IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION PATIENTS WITH CYTOMEGALOVIRUS INFECTION: A SAFETY FEASIBLE MODEL

EFFECTS OF THE ANTIBIOTICS CHANGE OR THE ADDITION OF ANTI-MRSA DRUGS FOR PERSISTENT FEBRILE NEUTROPENIA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION


THERAPEUTIC DRUG MONITORING OF POSACONAZOLE AND SUBSEQUENT DOSING IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS

IS PREEMPTIVE STRATEGY ENOUGH? RELATIONSHIP BETWEEN CMV REACTIVATION AND STEROID THERAPY FOR GHVD IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: 97 PATIENTS FROM TURKEY

Muhammet Erdem, Vildan Ozkocaman, Ismail Anaç, Fahir Özkalemeş (Turkey)

PROPHYLAXIS WITH AZITHROMYCIN IN ALLOGENEIC CORD BLOOD TRANSPLANT AND ASSOCIATION WITH RELAPSE RATE AND TRANSPLANT OUTCOMES

José Miguel Mateos Pérez, José Ramon Alamo Moreno, Carlos De Miguel Jiménez, Clara González Santillana, Alonso Trillo Rosalia, Sara Garrido Paniagua, Ángela Benéitez Fernández, Lucía Núñez Martín-Buitrago, Ana Bocanegra Pérez-Vizcaíno, Marta Liébana Villela, Ana Alarcón Tomás, María Esther Martínez, Ana Fernandez-Cruiz, Guiliom Bautista Carrascosa, José Rafael Cabrera Marín, Antonio Ramos Marín, Rafael F. Duarte (Spain)

REACTIVATED VARICELLA ZOSTER (VZV) INFECTION (SHINGLES), AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HCT) FOR HAEMATOLOGICAL DISEASE IN CHILDREN: A SIGNIFICANT PROBLEM AND PROPOSAL FOR FUTURE MANAGEMENT

Dafydd Stonehewer, Joanne Ellis, Tasneem Khalid, Stephen Hughes, Robert Wynn (United Kingdom)

LETTERMOVIR PROPHYLAXIS REDUCES INPATIENT RESOURCE CONSUMPTION BY BEING EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REAL-WORLD EXPERIENCE

Patrick Derigs, Maria-Luisa Schubert, Paul Schnitzler, Tilman Schöning, Carsten Müller-Tidow, Thomas Luft, Peter Dreger, Michael Schmitt (Germany)

ANALYSIS OF CMV REACTIVATION RISK AFTER T CELL REPLETE HAPLOIDENTICAL AND MATCHED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

INCIDENCE AND IMPACT OF EPSTEIN-BARR VIRUS EVENTS IN THE EARLY PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

ASPERGILLUS NON-FUMIGATUS INVASIVE ASPERGILLOSIS IN CHILDREN AND ADULTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) & CHEMOTHERAPY

INTRAVENOUS PENTAMIDINE FOR PNEUMOCYSTIS JIROVECCI PROPHYLAXIS IN HEMATOLOGICAL PATIENTS TREATED WITH CHEMOTHERAPY, HEMATOPOIETIC STEM-CELL TRANSPLANT (HCT) AND CAR-T CELL THERAPY

INTENSIFICATION OF CMV PROPHYLAXIS WITH THE USE OF GANCICLOVIR DURING THE CONDITIONING IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. COMPARISON WITH A STANDARD STRATEGY. 113 PATIENTS

Amado Karduss, Angela Trujillo, Angelica Cardona, Rosendo Perez, Giovanni Ruiz, Gloria Suarez (Colombia)

LOW RELAPSE RISK FOR REDUCED INTENSITY CONDITIONED ALEMTUZUMAB-BASED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMAS IS OFFSET BY CYTOMEGALOVIRUS RISK: DATA FROM SINGLE CENTRE STUDY
PROPHYLACTIC DOSE TRIMETHOPRIM/SULFAMETHOXAZOLE DOES NOT LEAD TO DELAYED NEUTROPHIL AND PLATELET ENGRAFTMENT IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
Rachael Biggart, Sarah Bird, Chloe Anthias, Sandra Easdale, Michael Potter, Joy Brennan, Maria Mulligan, Emma Thistlethwaite, Kim Davis, Mark Ethell, Unell Riley, Emma Nicholson (United Kingdom)

HIGH DOSE VALACICLOVIR AS CMV PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
Genevieve Douglas, Michelle Yong, Shioyen Tio, Maggie Chau, Joe Sasadeusz, Monica Slavin, David Ritchie, Lynette Chee (Australia)

EPIDEMIOLOGICAL SCREENING FOR BACTERIAL RESISTANCE BY DIFFERENT TECHNIQUES IN ALLO-HSCT PATIENTS
Elizabeth de Kort, Walter van der Velden, Paul Verweij, Nicole Blijlevens (Netherlands)

SINGLE CENTER ANALYSIS ON THE MANAGEMENT OF ACYCLOVIR RESISTANT HERPES SIMPLEX VIRUS STOMATITIS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Daniela Heidenreich, Sebastian Kreil, Nadine Mueller, Mohamad Jawhar, Florian Nolte, Wolf-Karsten Hofmann, Stefan A. Klein (Germany)

EARLY BACTEREMIA FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION WITHOUT THE USE OF PROPHYLACTIC ANTIBIOTIC: CHANGING EPIDEMIOLOGY AND ANTIMICROBIAL RESISTANCE (2016-2018)
Nour Ben Abdeljelil, Rihab Ouerghi, Dorra Belloumi, Amel Lakhal, Lamia Torjemane, Rym El Fatmi, Wafa Achour, Saloua Ladeb, Tarek Ben Othman (Tunisia)

DIAGnostic YIELD OF BRONCHOALVEOLAR LAVAGE (BAL) IN HAEMATOLOGICAL PATIENTS AFTER ALLOGENEIC/ AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) - COMPARISON WITH BAL PERFORMANCE IN NON-TRANSPLANTED PATIENTS
A NOVEL EFFICIENCY STRATEGY TO PREVENT HBV-RELATED HEPATITIS AFTER ALLOGENEIC HSCT FROM HBsAG-POSITIVE DONORS TO RECIPIENTS

BK VIRUS EFFECT ON DEVELOPING LATE HEMORRHAGIC CYSTITIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS: SINGLE CENTER EXPERIENCE
Ismail Anac, Vildan Ozkocaman, Muhammet Erdem, Fahir Ozkalemkas (Turkey)

VERSATILE EFFECTS OF LETERMOMIR PROPHYLAXIS FOR CYTOMEGALOVIRUS ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-INSTITUTION ANALYSIS
Fumiaki Innouchi, Yuta Katayama, Ryota Imanaka, Tatsuya Terasaki, Takuya Nunomura, Takeshi Okatani, Kohei Kyo, Mitsuhiro Itagaki, Shinya Katsutani, Tsuyoshi Muta, Hideki Asaoku, Koji Iwato (Japan)

IMPACT OF A CHANGE IN ANTIBACTERIAL PROPHYLAXIS IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION IN ONE SINGLE CENTER
INTRAVESICAL INSTILLATION OF CIDOVIR/FIR IS EFFICIENT FOR THE TREATMENT OF BK VIRUS HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC TRANSPLANTATION
MANAGEMENT OF BK POLYOMA VIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE
RISK FACTORS AND OUTCOME OF EARLY CLOSTRIDIUM DIFFICILE INFECTION IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Chiara Rosignoli, Vera Radici, Rossella Stella, Alessandra Sperotto, Antonella Geromin, Marta Lisa Battista, Michela Cerno, Renato Fanin (Italy)

RISK FACTORS FOR CYTOMEGALOVIRUS INFECTION IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Bernd Gruhn, Pania Mokthari (Germany)

IMPACT OF HYPOGAMMAGLOBULINEMIA ON OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

THE USE OF RIFAXIMINE IN ANTI-BACTERIAL PROPHYLAXIS IN PATIENT UNDERGOING HSCT
Magdalena Dutka, Agata Szymańska, Patryk Sobieralski, Maria Bieniaszewska (Poland)

BKV VIRUS - HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: INCIDENCE, SEVERITY AND RISK FACTORS
Rebecca E. Schultze-Florey, Sabine Tischer-Zimmermann, Hans-Gert Heuft, Christoph Priesner, Britta Lamottke, Albert Heim, Martin Sauer, Karl-Walter Sykora, Rainer Blasczyk, Britta Eiz-Vesper, Britta Maecker-Kolhoff (Germany)

RISK FACTORS FOR CMV REACTIVATION AND DISEASE AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - DEFINING THE TARGET POPULATION FOR LETERMOVIR PROPHYLAXIS

ISAVUCONAZOLE (ISA) USE IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) RECIPIENTS: A SINGLE-CENTER EXPERIENCE

TIME- AND THERAPY-DEPENDENT BACTERIURIA IN CHILDREN AND YOUNG ADULTS FOLLOWING ALLOGENEIC HSCT

PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF MARIBAVIR COMPARED WITH VALGANCICLOVIR FOR TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) RECIPIENTS (STUDY DESIGN)

INCIDENCE AND RISK FACTORS OF VIRAL COMPLICATIONS IN ADULT PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM HUNGARY

CONTRIBUTING FACTORS TO PRE ENGRAFTMENT BACTEREMIA AND PNEUMONIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A LEBANESE SINGLE CENTER EXPERIENCE

UNICENTRIC STUDY: PROPHYLAXIS STRATEGY AGAINST GVHD WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (CPYT) AND ITS RELATIONSHIP WITH CYTOMEGALOVIRUS
Ana Lerma Verdejo, Clara Cuéllar Pérez-Ávila, Begoña Pérez de Camino Gaisse, Javier Cornago Navascués (Spain)

EPIDEMIOLOGY AND CLINICAL FEATURES OF FEBRILE NEUTROPENIC EPISODES: THREE YEARS EXPERIENCE AT HEMATOLOGY WARDS

USE OF CMV-HYPERIMMUNE GLOBULINS (CMV-HYG) AS PRE-EMPTIVE THERAPY OR TREATMENT OF CMV INFECTION IN HSCT RECIPIENTS

TOXOPLASMOSIS DISEASE AFTER ALLO-HSCT. WHAT HAVE WE LEARNT?
Laura Escobar Fernandez, Marina García Morín, Eduardo Bardón Cancho, Jorge Huerta Aragonés, Cristina Beléndez Bieler, Elena Rincón López, María Slocker Barrio, Elena Cela de Julián (Spain)
Scientific Programme

**TUBERCULOSIS IN PATIENTS WHO RECEIVE AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT. TWO CASE REPORT**
Haridian de la Nuez Melián, Melissa Torres Ochando, Leslie González Pinedo, Santiago Jiménez Bravo de Laguna, María Del Mar Perera Álvarez, Paula Fernández-Caldas González, Leonor Pérez Ortiz, Joan González Fernández, Asunción Borrero Borrego, Juan Francisco López Rodríguez, Luisa Guerra Domínguez, Teresa Molero Labarta (Spain)

**POLYOMAVIRUS BK INFECTION IN BONE MARROW TRANSPLANTATION RECIPIENTS. A COMPARATIVE ANALYSIS ON CHILDREN AND ADULTS**
Gloria Elena Mora, María Jose Lopez Mora, Enrique Pedraza, Herman Esguerra, Javier Figueroa, Oscar Peña, Sergio Ardila, Angie Guarín, Diego Orlando Díaz, Licet Villamizar, César Lamadrí, Gustavo Adolfo López (Colombia)

**LEFLUNOMIDE, SUCCESSFUL PRE-EMPTIVE THERAPY IN RESISTANT CYTOMEGALOVIRUS REACTIVATION IN A HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT**
Gloria Elena Mora, María Jose Lopez Mora, Enrique Pedraza, Herman Esguerra, Javier Figueroa, Oscar Peña, Sergio Ardila, Angie Guarín, Diego Orlando Díaz, Licet Villamizar, César Lamadrí, Gustavo Adolfo López (Colombia)

**LETTERMOVIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**INFECTIOUS COMPLICATIONS IN HEMATOLOGIC PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION**
Vitalii Chebotkevich, Alena Kuleshova, Anastasia Zhernyakova, Catherine Kiseleva, Sergey Gritsaev, Stanislav Bessmeltsev (Russian Federation)

**EARLY MORTALITY IN PATIENTS WITH MULTIPLE MYELOMA - A SINGLE CENTER EXPERIANCE**
Zlate Stojanoski, Aleksandra Pivkova Veljanovska, Lazar Cadievski, Sonja Genadieva-Stavrid, Aleksandar Stojanovik, Oliver Karianfiski, Martin Ivanovski, Irina Panovska-Stavridis, Lidija Cevreska, Borce Georgievski (North Macedonia, the Republic of)

**CMV RETINITIS IN A STEM CELL TRANSPLANT RECIPIENT TREATED WITH FOSCARNET INTRAVITREAL INJECTION AND CMV SPECIFIC IMMUNOGLOBULIN**
Francesco Vassallo, Alessandro Busca, Chiara Della Casa, Lucia Brunello, Luisa Giaccone, Sara Butera, Giorgia Iovino, Francesco Giuseppe De Rosa, Raffaele Nuzzi, Ilaria Cattani, Benedetto Bruno (Italy)

**Lymphoma**

**LONG TERM SURVIVAL AFTER 2 YEARS EVENT FREE SURVIVAL IN RELAPSED DLBCL AFTER AUTOLOGOUS TRANSPLANTATION IN THE TWO RANDOMIZED TRIALS LY.12 AND CORAL**

**EXPLORATORY ANALYSIS OF BRENTUXIMAB VEDOTIN PLUS CHP (A+CHP) AS FRONTLINE TREATMENT FOR PATIENTS WITH CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMAS (ECHELON-2): IMPACT OF CONSOLIDATIVE STEM CELL TRANSPLANT**

**BRENTUXIMAB VEDOTIN FOR RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN LYMPHOMA: A STUDY OF THE LWP-EBMT**

**ALLOGENEIC STEM CELL TRANSPLANTATION AS A CURATIVE OPTION IN RELAPSE/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GETH/GELTAMO STUDY**

**ADAM17 INHIBITOR INCB7839 WITH RITUXIMAB AS CONSOLIDATION AFTER AUTOLOGOUS HCT FOR DIFFUSE LARGE B CELL LYMPHOMA: A NOVEL RELAPSE PREVENTION STRATEGY**
COMPARISON OF REDUCED-INTENSITY CONDITIONING (RIC) REGIMENS FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT) FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A CIBMTR ANALYSIS

HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH NON-HODGKIN LYMPHOMA: THE SPANISH EXPERIENCE

EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSIONS FOR PATIENTS AFFECTED BY ADVANCED LYMPHOID MALIGNANCIES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY

Elisa Diral, Raynier Devillier, Sabine Furst, Angela Granata, Stefania Bramanti, Samia Harbi, Jacopo Mariotti, Chiara De Philippis, Barbara Sarina, Thomas Pagliardini, Valerio Maisano, Rocco Piazza, Reda Bouabdallah, Carmelo Carlo-Stella, Armando Santoro, Didier Blaise, Luca Castagna (France)

BRENTUXIMAB-VEDOTIN IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY PRIOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HODGKIN LYMPHOMA: REAL-WORLD DATA FROM A TWO CENTERS STUDY

NON-MYELOABLATIVE CONDITIONING REGIMEN BEFORE T-CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ADVANCED LYMPHOMA

IMPACT OF KIR LIGAND MISMATCH AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY IN 383 PATIENTS FROM THE SFGM-TC

Jean-Edouard Martin, Stéphane Morisset, Regis Peffault De La Tour, Nathalie Fegueux, Edouard Forcade, Sylvie François, Jean-Baptiste Mear, Patrice Chevallier, Eric Deconinck, Hélène Labussière-Wallet, Claude-Eric Bulabois, Jacques-Olivier Bay, Mohamad Mohty, Marie-Thérèse Rubio, Didier Blaise, Stéphanie Nguyen (France)

THE IMPACT AND CHALLENGES OF PERFORMING BEAM CONDITIONED AUTOLOGOUS TRANSPLANTS IN ‘OLDER’ PATIENTS WITH LYMPHOMA

David Davies, Keith Wilson, Sarah Doherty, Emma Kempshall, Hamdi Sati, Wendy Ingram (United Kingdom)

ACCESSIBILITY AND IMPACT ON LONG-TERM OVERALL SURVIVAL OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS: A SINGLE INSTITUTION INTENTION-TO-TREAT ANALYSIS

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TRANSFORMED FOLLICULAR LYMPHOMA (FL): RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY FROM GELTH/GELTAMO GROUP

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANTATION

Masatoshi Sakurai, Takehiko Mori, Souichi Shiratori, Toshio Wakayama, Naoyuki Uchida, Hikaru Kobayashi, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Eisei Kondo (Japan)

SIGNIFICANT ROLE OF UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA

Dae Sik Kim, Sung-Hoon Jung, Deok-Hwan Yang, Youngil Koh, Junshik Hong, Ho-Young Yhim, Won Sik Lee, Yoo Jin Lee, Jeong-Ok Lee, Hye Jin Kang, Sung Yong Oh, Yun-Suk Choi, Ho Sup Lee, Jung-Hee Lee, Yong Park, Byung Bae Park, Young Rok Do, Ho-Jin Shin (Korea, Republic of)

HIGH DOSE CHEMOTHERAPY TEAM FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN LYMPHOMA: RESULTS OF A PROSPECTIVE STUDY

AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIV+ AND HIV- LYMPHOMA PATIENTS: A PROPENSITY SCORE MATCHED ANALYSIS
AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR DOUBLE HIT LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

ALLOGENEIC STEM CELL TRANSPLANTATION CAN BE SUCCESSFULLY DELIVERED FOLLOWING BTKI THERAPY FAILURE FOLLOWING R-BAC RE-INDUCTION CHEMOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA

CLINICAL OUTCOMES OF EBV+ PTLD PATIENTS FOLLOWING HCT WHO FAIL RITUXIMAB: A RETROSPECTIVE CHART REVIEW STUDY FROM FRANCE
Gérard Socié, Arnaud Pigneux, Charles Herbaux, Paul Chauvet, Hairong Xu, Dhanalakshmi Thirumalai, Norma Guzman-Becerra, Arie Barlev, John Reitan, Mohamad Mohty (France)

THE IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) ON THE OUTCOME OF POOR-RISK NON-HODGKIN LYMPHOMA (NHL): UPDATE OF A RETROSPECTIVE INTENT-TO-TRANSPLANT (ITT) ANALYSIS
Lorenz Selberg, Peter Stadttherr, Sascha Dietrich, Thomas Luft, Ute Hegnerbart, Andrea Bondong, Julia Meissner, Nora Liebers, Michael Schmitt, Carsten Müller-Tidow, Peter Dregé (Germany)

REDUCING THE COST OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMAS AT LIMITED-RESOURCE CENTERS IN DEVELOPING COUNTRIES
Eucario Leon Rodriguez, Monica Magdalena Rivera Franco (Mexico)

COMPARISON OF MITOXANTRONE - MELPHALAN AND BEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS
Ahmet Kursad Gunes, Ilknur Demir, Serpil Sarifakioglu, Salih Sertac Durusoy, Dervis Murat Akkurt, Idris Ince, Gulkan Ozkan, Mustafa Pehlivan (Turkey)

NIVOLUMAB RE-CHALLENGE IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: WHERE IS THE PLACE FOR ALLOHSCT?
Liudmila Fedorova, Kirill Lepik, Natalia Mikhailova, Elena Kondakova, Yuri Zalyalov, Vadim Baykov, Elena Babenko, Evgeniya Borzenkova, Lilia Stelmakh, Boris Afanasyev (Russian Federation)

OUTCOME OF TRANSPLANT ELIGIBLE MANTLE CELL LYMPHOMA PATIENTS WITH FIRST-LINE REGIMENS IN A REAL-WORLD SETTING: A PORTUGUESE MULTICENTER RETROSPECTIVE ANALYSIS
Pedro Chorão, Teresa Ribeiro, Maria Gomes Silva, Raquel Guilherme, Filipa Saraiva, Joana Vieira, Inês Carvalhais, Sérgio Chacim, José Mário Mariz, Daniela Alves, Fernando Príncipe (Portugal)

EVALUATION OF FRACTIONATED ICE AS AN ALTERNATIVE OUTPATIENT OPTION FOR RELAPSED/REFRACTORY LYMPHOMAS
Reyad Dada, Ehab Abdelghany, Tarek Boubakr, Emily Lenore Goldman-Heaphy, Azhar Nawaz (Saudi Arabia)

EFFICACY OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Anastasiya Beynarovich, Kirill Lepik, Natalia Mikhailova, Elena Kondakova, Yuri Zalyalov, Eugenia Borzenkova, Elena Babenko, Lena Darskaya, Alexander Aliynski, Ivan Moiseev, Boris Afanasyev (Russian Federation)

RISK FACTORS FOR INTENSIVE CARE UNIT ADMISSION IN PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B-CELL LYMPHOMA

DIFFERENT OUTCOMES WITH DIFFERENT DONORS IN ALLOGENEIC STEM CELL TRANSPLANTATIONS IN MALIGNANT LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE
THE IRISH EXPERIENCE OF THIOTEPA, CARMUSTINE AND ETOPOSIDE CONDITIONING PRIOR TO ASCT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS

TARGETED AND IMMUNOCHEMOTHERAPY IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AS TREATMENT OPTION FOR RARE TRANSDIFFERENTIATION OF LYMPHOID NEOPLASMS INTO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS TO ACHIEVE LONG-TERM SURVIVAL

Andriyana Bankova, Urs Schanz, Eugenia Haralambieva, Ewerton Maggio, Corinne Widmer (United States)

OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH PERIPHERAL T CELL LYMPHOMAS: A RETROSPECTIVE ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG)

TREATMENT OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA AFTER HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. A STUDY OF THE POLISH LYMPHOMA RESEARCH GROUP

Joanna Romejko-Jarosinska, Ewa Paszkiewicz-Kozik, Małgorzata Krawczyk-Kulis, Patrycja Mensah-Glanowska, Łukasz Targonski, Agnieszka Giza, Tomasz Czerw, Katarzyna Domanska-Czyz, Kseniya Kviatkouskaya, Paulina Małgorzata, Włodzimierz Mentrek, Beata Ostrowska, Maria Sadus-Wojciechowska, Sebastian Giebel, Jan Walewski (Poland)

PLACE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH T-CELL LYMPHOMAS: PAVLOV UNIVERSITY EXPERIENCE

Elena Lepik, Andrey Kozlov, Evgenia Borzenkova, Yuri Zalyalov, Kirill Lepik, Elena Kondakov, Vadim Baykov, Aleksander Alyanskiy, Ivan Moiseev, Tatiana Schneider, Natalia Mikhaylova, Boris Afanasyev (Russian Federation)

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA: TOXICITY AND SURVIVAL STUDY

Khouloud Touihri, Rym El Fatmi, Lamia Torjemane, Dorra Belloumi, Nour Ben Abdeljelil, Amel Lakhal, Saloua Ladeb, Tarek Ben Othman (Tunisia)

AUTOIMMUNE COMPLICATIONS IN CHILDREN WITH HODGKIN DISEASE (HD) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT)

Natalia Kavardakova, Oleg Ryzhak, Julia Basaluk, Sofia Matsiboh, Olena Kreminska, Tatiana Ponomarenko, Tatiana Smolenska, Alexandra Sharamok, Olena Zinchuk, Olga Kohut, Svitlana Donska (Ukraine)

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIV-RELATED LYMPHOMA

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS OF 23 PATIENTS

Dariusz Kata, Agata Wieczorkiewicz-Kabut, Grzegorz Helbig, Małgorzata Koperka, Aleksandra Zimnoch, Kamil Witosz (Poland)

NIVOLUMAB BASED RESPONSE ADAPTED TREATMENT IN PRIMARY REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS

AUTOLOGOUS STEM CELL TRANSPLANT IN A SEROPOSITIVE A PATIENT WITH PLASMABLASTIC LYMPHOMA (PBL)

Fahad Shaikh, Reetu Jain, Samir Shah, Ganapathi Bhat (India)
POSSIBLE INFLUENCE OF IMMUNODEFICIENCY-RELATED HEREDITARY PREDISPOSITION GENE VARIANTS ON RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
Zhihui Li, Tong Wu, Qinglong Zheng, Caiyan Zhang, Yongqiang Zhao, Yanzhi Song (China)
COMPARABLE RESULTS OF PREEMPTIVE RECOMBINANT IL-2 AND DONOR LYMPHOCYTE INFUSION IN HEMATOLOGICAL MALIGNANCY PATIENTS WITH LATE-ONSET MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

SURVIVAL ANALYSIS ACCORDING TO MINIMAL RESIDUAL DISEASE BY FLOW CYTOMETRY BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA

IMPACT OF RESIDUAL CIRCULATING TUMOR DNA STATUS POST ALLOGENEIC SCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: INTERIM RESULTS OF A PROSPECTIVE STUDY


EARLY CD4+ T CELL RECONSTRUCTION AS PREDICTOR FOR OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULT PATIENTS: A VALIDATION COHORT ANALYSIS

Susan Prockop, Ichelle van Roessel, Elizabeth Klein, Farid Boulad, Andromachi Scaradavou, Barbara Spitzer, Andrew Kung, Kevin Curran, Maria Cancio, Richard O'Reilly, Nancy Kernan, Jaap Jan Boelens (United States)

PATTERN OF RECONSTITUTION OF RECENT THYMIC EMIGRANTS AFTER REDUCED INTENSITY CONDITIONING BASED ON TARGETED BUSULFAN IN PAEDIATRIC RECIPIENTS OF ALLOGENIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION

Daniel Drozdov, Katrin Petermann, Leonhard Held, Tayfun Güngör, Mathias Hauri-Hohl (Switzerland)

A RISK SCORE SYSTEM BASED ON POST-TRANSPLANTATION MINIMAL RESIDUAL DISEASE FOR STRATIFICATION OF RELAPSE IN B-ALL PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION

Yang Zhou, Le-Qing Cao, Yan-Rong Liu, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Kai-Yan Liu, Qiao-Zhen Fan, Ying-Jun Chang, Xiao-Jun Huang (China)

OUTCOME OF CHILDREN WITH HEMATOLOGICAL MALIGNANCIES WHO DEVELOP MIXED DONOR CHIMERSIM AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION


PROPHYLACTIC HIGH-DOSE DONOR CD45RO+ MEMORY T-CELLS INFUSION AFTER ALLOGENEIC TRANSPLANTATION: SAFETY AND OUTCOME

Mercedes Gasior Kabat, Luisa Sisinni, Raquel De Paz, David Bueno, Yasmina Mozó, Beatriz De La Cruz, Antonio Marcos, Ana Belen Romero, Víctor Jiménez Yuste, Antonio Pérez-Martínez (Spain)

MULTICOLOR FLOW CYTOMETRY PANEL WITH CCD79A GATING TO DETECT MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-LYMPHOMBLASTIC LEUKEMIA/LYMPHOMA POST ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT

NON-INVASIVE MONITORING OF MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE BY CIRCULATING CELL-FREE NUCLEIC ACIDS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Miquel Waterhouse, Sandra Patricia Pennisi, Dietmar Pfeifer, Justus Duyster, Hartmut Bertz, Jürgen Finke, Jesus Duque-Afonso (Germany)
TORQUE TENO VIRUS AS BIOMARKER TO PREDICT COMPLICATIONS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Amandine Pradier, Stavroula Masouridi-Levrat, Carole Bossard, Carole Dantin, Diem-Lan Vu, Marie-Céline Zanella, Elsa Boely, Caroline Tapparel, Laurent Kaiser, Yves Chalandon, Federico Simonetta, Eddy Roosnek (Switzerland)

PREEMPTIVE INTERFERON-α TREATMENT COULD PROTECT AGAINST RELAPSE AND IMPROVE SURVIVAL OF ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Si-Ning Liu, Xue-Yi Luo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Hua-Ning Yan, Huan Chen, Yu-Hong Chen, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Dong Mo (China)

THE ADDITION OF BUSULFAN REDUCES THE INCIDENCE OF MIXED CHIMERISM FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA
A NEW MULTIVARIATE MODEL TO DESCRIBE IMPACT OF IMMUNE RECONSTITUTION ON THE DEVELOPMENT OF RELAPSE IN CHILDREN UNDERGOING ALLO-HSCT FOR HEMATOLOGIC MALIGNANCIES AT DAY +100
Manuela Spadea, Francesco Saglio, Massimo Berger, Francesca Carraro, Rosanna Pessolano, Emanuela Ricotti, Elena Ernestina Vassallo, Franca Fagioli (Italy)

ACQUISITION OF COMPLETE CHIMERISM IN BONE MARROW, PERIPHERAL BLOOD AND LEUKOCYTE SUBSETS DEPENDS ON THE TRANSPLANT SETTING AND CORRELATES WITH THE CLINICAL OUTCOME
Almudena Navarro-Bailon, Diego Carbonell, Julia Suárez-González, María Chicano, Mi Kwon, Rebeca Bailén, Nieves Dorado, José Luis Díez-Martín, Carolina Martínez-Laperche, Ismael Buño (Spain)

EARLY LYMPHOID SUBSETS RECONSTITUTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AS PREDICTOR OF RELAPSE AND SURVIVAL IN ACUTE LEUKEMIAS
COMPARISON OF IMMUNE RECONSTITUTION BETWEEN 30MG/KG AND 60MG/KG ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC MYELOABLATIVE PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
FUNCTIONAL IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COMPARISON OF PRE- AND POST-TRANSPLANTATION CYTOKINE RESPONSES IN STIMULATED WHOLE-BLOOD
Lars Klingen Gjærde, Sisse Rye Ostrowski, Niels Smedegaard Andersen, Lone Smidstrup Friis, Brian Thomas Kornblit, Søren Lykke Petersen, Ida Schjædt, Henrik Sengeløv (Denmark)

MEASURABLE RESIDUAL DISEASE (MRD) TESTING FOR ACUTE LEUKEMIA IN EBMT TRANSPLANT CENTERS: A SURVEY ON BEHALF OF THE ALWP OF THE EBMT
Arnon Nagler, Myriam Labopin, Emmanuelle Polge, Jordi Esteve, Ali Bazarbachi, Eolia Brissot, Gesine Bug, Fabio Ciceri, Sebastian Giebel, Maria Gilleece, Norbert-Claude Gorin, Francesco Lanza, Zina Peric, Annalisa Ruggeri, Jaime Sanz, Bipin Savani, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, Frederic Baron, Mohamad Mohty (Israel)

TBF REGIMEN INDUCES FULL DONOR CHIMERISM AFTER ALLOGRAFTS IN MYELOFIBROSIS
REAL WORLD UTILITY OF TREATING MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA
COMPARISON OF IMMUNE RECOVERY IN CORD BLOOD AND T AND B DEPLETED HAPLOIDENTICAL GRAFTS RECIPIENTS
Chiara Mainardi, Giulia Reggiani, Manuela Tumino, Antonio Marzollo, Elisabetta Calore, Marta Pillon, Maria Vittoria Gazzola, Roberta Destro, Daniela Bovo, Piero Marson, Tiziana Tison, Anna Colpo, Alessandra Biffi (Italy)

THE BCR-ABL P210 CHIMERIC TRANSCRIPT IN VITRO TRANSFER INTO BONE MARROW MESENCHYMAL STROMAL CELLS VIA EXOSOMES
PROGNOSTIC SIGNIFICANCE OF DONOR-SPECIFIC ISOAGGLUTININ RE-APPEARANCE IN ABO-MISMATCHED STEM CELL TRANSPLANT RECIPIENTS
Maryam Pourabdollah, Christine Cserti, Dennis Dong Hwan Kim, Eshetu Atenafu, Ivan Pasic, Zeyad Al-Shaibani, Aijun Law, Wilson Lam, Armin Gerbitz, Jeffery Lipton, Auro Viswabandya, Rajat Kumar, Jonas Mattson, Fotios Michalis, Nayana Sondi, Jacob Pendergrast (Canada)

IMMUNE-RECONSTITUTION OF LYMPHOCYTE SUBPOPULATIONS WITH RESPECT TO MSC-TREATMENT FOR STEROID REFRACTORY GVHD FOLLOWING HSCT

DAY+100 FULL DONOR CHIMERISM IN THE BONE MARROW CONFERS BETTER OVERALL SURVIVAL IN REDUCED INTENSITY CONDITIONED WITH ALEMTUZUMAB ALLOGENEIC STEM CELL TRANSPLANTATION FOR LYMPHOMAS

DONOR FACTORS INFLUENCE OUTCOMES OF PATIENTS RECEIVING DONOR LYMPHOCYTE INFUSION FOR MIXED CHIMERISM AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION
Jose Ros Soto, John A Snowden, Richard Szydlo, Emma Nicholson, Alejandro Madrigal, Sandra Easdale, Mark Ethell, Mike Potter, Chloe Anthias (United Kingdom)

DETERMINE PATIENTS AT RISK OF RELAPSE AND DEATH IN ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME USING CHIMERISM ON BONE MARROW SAMPLES AT DAY 28 AFTER HSCT

CONCURRENT- SYNERGISTIC ASSESSMENT OF TWO TECHNIQUES IN MONITORING MINIMAL RESIDUAL DISEASE FOR PH(-) ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANTATION LEADS TO FAVORABLE CLINICAL OUTCOMES

DONOR CHIMERISM EVALUATION OF MRD-SUSPECTED CELLS ISOLATED BY FLOW CELL SORTING IS AN ACCESSIBLE TOOL FOR MRD VERIFICATION IN PATIENTS AFTER ALLOGENEIC HSCT
Alexandra Semchenkova, Vladimir Zhogov, Varvara Brilliantova, Olga Illarionova, Larisa Shelikhova, Michael Maschan, Alexander Popov (Russian Federation)

ONE-STEP CHECK PURITY OF CD3+ SORTED CELLS ALONG MONITORING HEMATOPOIETIC CHIMAERISM AFTER HSCT

DONOR LYMPHOCYTE INFUSIONS AUGMENT GRAFT VERSUS MALIGNANCY EFFECT FOLLOWING ALEMTUZUMAB-BASED REDUCED INTENSITY ALLOGRAFTS: REFLECTIONS ON A SINGLE CENTRE STUDY
Rebecca Lloyd, Graham McIlroy, Nervana Abou-Zeid, Claire Horgan, Richard Lovell, Bhuvan Kishore, Julie Suhr, Charmaine Campbell, Kathleen Holder, Beena Salhan, Shankara Paneesha, Emmanouil Nikolousis, Alexandros Kanellopoulos (United Kingdom)

MYELOID-DERIVED SUPPRESSOR CELLS RECOVER QUICKLY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS

PERSISTENT MIXED CHIMERISM WITHOUT RELAPSE IN CHILDREN AFTER HSCT FOR HEMATOLOGIC MALIGNANCY
Etai Adam, Elad Jacoby, Bella Bielorai, Natalia Ilin, Daphna Hutt, Amos Toren (Israel)

e-Posters
09:30 - 18:00
ePoster Area

Non-haematopoietic stem cells

THE POTENTIAL ROLES OF MUCOSA-ASSOCIATED INvariant T CELLS IN THE PATHOGENESIS OF GUT GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Scientific Programme

FACTORS INFLUENCING THE PRESENCE OF BONE MARROW MESENCHYMAL STEM CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Judith Schaffrath, Ole Vollstädt, Jana Lützkendorf, Christiane Katzerke, Josephine Schneider, Lisa Maria Siol, Mascha Binder, Lutz P. Müller (Germany)

ANALYSIS OF THE GENETIC STABILITY OF DONORS’ BONE MARROW STROMA MESENCHYMAL CELLS DURING CULTIVATION

EFFECT OF MATERNAL AND NEONATAL FACTORS ON THE YIELD OF WHARTON’S JELLY MESENCHYMAL STEM CELLS

THE POLISH EXPERIENCE OF WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF PAEDIATRIC PATIENTS
Maciej Rojek, Michał Piątek, Izabela Zdolińska-Malinowska, Dariusz Boruczkowski (Poland)

THE POLISH EXPERIENCE OF WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF ADULT PATIENTS

A RETROSPECTIVE ANALYSIS OF BONE MARROW EXAMINATION RESULTS FROM A SINGLE CENTER INSTITUTION: CAN WE REDUCE THE OCCURRENCE OF UNNECESSARY BONE MARROW EXAMINATIONS?
Seug Yun Yoon, Sung Kyu Park, Jong-Ho Won (Korea, Republic of)

e-Posters
09:30 - 18:00
ePoster Area

Paediatric issues

PROSPECTIVE OPEN-LABEL PHASE II TRIAL OF INDIVIDUALIZED ANTI-THYMOCYTE GLOBULIN SHOWS IMPROVED EARLY CD4+ T-CELL RECONSTITUTION AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE PARACHUTE-TRIAL

EBMT LESSONS FROM 40 YEARS OF HIGH DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN NEUROBLASTOMA: A REPORT FROM THE PAEDIATRIC WORKING PARTY
Ruth Ladenstein, Ulrike Poetschger, Penelope Brock, Roberto Luksch, Victoria Castel, Shifra Ash, Vassilios Papadakis, Geneviève Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz de Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Evgenia Glogova, Dominique Valteau-Couanet, Selim Corbacioglu (Austria)

INCIDENCE OF SECONDARY MALIGNANCIES AFTER TBI/VP16 CONDITIONING FOR CHILDHOOD ALL: RESULTS OF THE PROSPECTIVE ALL-SCT-BFM-2003 TRIAL

OUTCOME AND RISK FACTORS OF AUTOIMMUNE CYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY

EBMT SURVEY ON 40 YEARS OF HIGH-DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN EWING TUMOURS (ET). A REPORT FROM THE PAEDIATRIC WORKING PARTY
Ruth Ladenstein, Evgenia Glogova, Christelle Dufour, Edoardo Lanino, Jean Michon, Paul Veys, Roberto Luksch, Uta Dirksen, Krzysztof Kaliwak, Stefan Burdach, Henk van den Berg, Boris Afanasyev, Franco Locatelli, Emmanuelle Nicolas-Vrelizier, Shifra Ash, Nathalie Gaspar, Jeremy Whelan, Philippe Brault, Ulrike Poetschger, Selim Corbacioglu (Austria)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS IN CHILDREN - RETROSPECTIVE REPORT ON BEHALF OF I-BFM SCT COMMITTEE AND EBMT PEDIATRIC DISEASES WP
IS THE EBMT RISK SCORE PREDICTIVE OF OUTCOMES IN PAEDIATRIC ACUTE LEUKEMIA?

TCRαβ+/CD19+-DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION

THE GREAT ORMOND STREET (GOS) PAEDIATRIC CO-MORBIDITY SCORE FOR OUTCOME POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION

HIGH PREVALENCE OF CAROTID PLAQUES IN YOUNG ADULTS AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD

HAPLOIDENTICAL DONOR OR UNRELATED DONOR FOR INFANTS WITH SEVERE COMBINED IMMUNODEFICIENCY?
Su Han Lum, Zohreh Nademi, Terry Flood, Andrew Cant, Sophie Hambleton, Andrew Gennery, Mary Slatter (United Kingdom)

A ‘RISK-ADJUSTED’ CYTOREDUCTION WITHOUT RADIATION FOR PATIENTS WITH FANCONI ANEMIA UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION (HCT)

USE OF RUXOLITINIB IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD)

HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN REFRACTORY CYTOPENIA OF CHILDHOOD (RCC): IMPROVED ENGRAFTMENT FOLLOWING A TRESOSULFAN BASED CONDITIONING REGIMEN
Brigitte Strahm, Ayami Yoshimi, Miriam Erlacher, Michael Albert, Jochen Buechner, Birgit Burkhardt, Barbara De Moerloose, Kristian Kallay, Peter Lang, Ricardo Masetti, Roland Meisel, Herbert Pichler, Ansgar Schulz, Karl-Walter Sykora, Dominik Turkiewitz, Franco Locatelli, Charlotte Niemeyer (Germany)

PHARMACOKINETICS OF ACTIVE ATG IMPACTS T-CELL RECOVERY AFTER TCRαβ/CD19-DEPLETED HSCT IN PAEDIATRIC PATIENTS
Lisa V.E. Oostenbrink, Alexandra Laberko, Elvira Sultanova, Els C.M. Jol-van der Zijde, Anja M. Jansen-Hoogendijk, Carly Vervat, Dmitry Bredius, Maarten J.D. van Tol, Michael Maschan, Marco W. Schilham, Dmitri Balashov, Arjan C. Lankester (Netherlands)

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A MULTICENTRE STUDY FROM INDIA
Sunil Bhat, Revathi Raj, Arun Danewa, Gaurav Kharya, Biju George, Mehdi Intezar, Neha Rastogi, Vikram Mathews, Badiger Shobha, Atish Bakane, Ramya Uppuluri, Satya Prakash Yadav (India)

IMMUNE RECOVERY AND LONG-TERM SURVIVAL FOLLOWING HAPLOIDENTICAL T AND B CELL DEPLETED STEM CELL TRANSPLANTATION - INFLUENCE OF VARIOUS ATG DOSES
Claus-Philipp Maier, Friedhelm Schuster, Bernd Gruhn, Roland Meisel, Patrick Schlegel, Anne-Marie Lang, Wolfgang Schwinger, Tobias F. Feuchtlinger, Holger Martinius, Rupert Handgretinger, Peter Lang (Germany)

OUTCOMES OF HAPLOIDENTICAL VS MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC HIGH-RISK ALL AND AML IN 1ST AND 2ND CR
Olesia Paina, Zhemal Rakhmanov, Polina Kozhokar, Anastasia Frolova, Lubov Tsvetkova, Kirill Ekushov, Inna Markova, Sergey Bondarenko, Elena Babenko, Aleksandr Alyanskiy, Ildar Barkhatov, Elena Semeneva, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

COMBINED TCR ALPHA BETA AND CD45RA DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BENIGN HAEMATOLOGICAL CONDITIONS, SINGLE CENTRE EXPERIENCE
Rajat Bhattacharyya, Ah Moy Tan, Michaela Su Fern Seng, Mya Nwe Soe, Prasad Iyer, Anh Thi Ngoc, Vijayakumari K, Wing Leung (Singapore)
GENETIC SUSCEPTIBILITY TO HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME IN PEDIATRIC PATIENTS UNDERGOING HSCT
Marc Ansari, Kateryna Petrykey, Mohamad Aziz Rezgui, Veronica Del Vecchio, Jacques Cortyl, Reginald-Olivier Ralph, Tiago Nava, Patrick Beaulieu, Pascal St-Onge, Simona Jurkovic Mikar, Patricia Huzzo-Diaz Curtis, Chakradhara Rao S. Uppugunduri, Laurence Lesne, Yves Theoret, Yves Chalandon, Imke H. Bartelink, Jaap-Jan Boelens, Robbert G. M. Bredium, Jean-Hughes Dalle, Victor Lewis, Bill S. Kangarlo, Christina Peters, Daniel Sinnet, Henrique Bittencourt, Maja Krajnovic (Switzerland)

HAPLO HSCT WITH IN VIVO T-CELL DEPLETION AFTER REDUCED INTENSITY CONDITIONING REGIMEN AND MYELOABLATIVE MUD AND MMUD DONOR HSCT IN PEDIATRIC PATIENTS AFFECTED BY MALIGNANCIES
Francesco Saglio, Massimo Berger, Manuela Spadea, Francesca Carraro, Rosanna Pessolano, Paola Quarello, Elena Vassallo, Franca Fagioli (Italy)

THINKING BEYOND HLH: CLINICAL FEATURES OF PATIENTS WITH CONCURRENT PRESENTATION OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND THROMBOTIC MICROANGIOPATHY
Nicholas Gloude, Christopher Dandoy, Stella Davies, Kasiani Myers, Michael Jordan, Rebecca Marsh, Ashish Kumar, Jack Bleesing, Ashley Teusink-Cross, Sonata Jodele (United States)

LANDMARK ANALYSIS IN HIGH RISK CHILDHOOD ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE STUDY
Blanca Molina Angulo, Marta Gonzalez Vicent, Ivan Lopez Torija, Ana Castillo, Manuel Ramirez, Miguel Angel Diaz Perez (Spain)

DEFIBROTIDE IN HEMATOPOIETIC STEM CELL TRANSPLANT: AN STUDY OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYETICO (GETH) AND GRUPO ESPAÑOL DE TRASPLANTE DE MEDULA EN NIÑOS (GETMON)
Marta Gonzalez Vicent, Cristina Diaz de Heredia, Jesus Gonzalez de Pablo, Blanca Molina, Alexandra Regueiro, Antonio Perez, Pilar Palomo, Laura Prieto, Estefania Garcia, Jose Maria Fernandez, Ariadna Perez, Maria Jose Jimenez, Manuel Regueiro, Carlos Vallejo, Ana Isabel Gallardo, Oriana Lopez, Ana Benito, Julia Marsal, Monica Lopez, Leyre Bento, Isabel Badell, Alexandra Pedraza, Ana Jimenez, Pedro Gonzalez, Mi Kwon, Lissette Costilla, Cristina Belendez, Albert Esquiro, Ildefonso Espigado, Esperanza Lavilla, Miguel Angel Diaz (Spain)

NIVOLUMAB-BASED THERAPY PRIOR TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC Hodgkin's Lymphoma

HUMAN LEUKOCYTE ANTIGEN DISPARITIES REDUCE RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH JUVENILE MYELOMONOCYTIC LEUKEMIA

SCHOOL DURING AND AFTER ALLOGENEIC HSCT: A SURVEY OF PRACTICES IN THREE EUROPEAN COUNTRIES
Fanette Bernard, Caroline de Pesters, Claire Galambur, Mary Slatter, Charlotte Jubert, Nicolas Von der Weid, Eva De Berranger, Cecile Renard, Ben Carpenter, Benedicte Neven, Fanny Rialland, Jean-Hugues Dalle, Persis Amrolia, Mark Ansari, Catherine Paillard (Switzerland)

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HURLER SYNDROME: SINGLE CENTER EXPERIENCE

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH FAUNCONI ANAEMIA: EXPERIENCE OF THE SPANISH WORKING GROUP FOR BONE MARROW TRANSPLANTATION IN CHILDREN (GETMON)

IMPACT OF MEMORY T-CELL DOSES INFUSED WITH T-CELL DEPLETED HAPLOIDENTICAL STEM CELL GRAFTS ON TRANSPLANT OUTCOMES
Poh Lin Tan, Chintan Vyas, Marifulor Villegas, Frances Yeap, Teck Guan Soh (Singapore)

THE ROLE OF DONOR KIR GENOTYPING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISORDERS
SINGLE-CENTER EXPERIENCE OF TCRαβ/CD19 DEPLETED STEM CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANEMIA
Svetlana Radygina, Larisa Shelikhova, Irina Shipitsina, Yulia Skvortsova, Anna Vasilieva, Svetlana Kozlovskaya, Rimma Khismatullina, Anna Livshits, Alexei Maschan, Michael Maschan, Dmitry Balashov (Russian Federation)

DETECTION OF RECIPIENT-SPECIFIC α/β-T-CELLS DURING THE PRE-ENGRAFTMENT PHASE DOES NOT PREDICT GRAFT REJECTION IN PATIENTS AFTER HAPLOSCT: PRELIMINARY RESULTS OF SINGLE CENTRE PROSPECTIVE TRIAL
Ladislav Król, Dominik Turkiewicz, Stig Lenhoff, Annika Hult, Annika Kisch, Mari-Louise Römerbo, Lisette Hollender, Ingrid Øra, Josefine Dykes (Sweden)

IMPROVED SURVIVAL AFTER MIBG THERAPY IN COMBINATION WITH MEGACHEMOTHERAPY THAN AFTER STAND-ALONE THERAPY IN CHILDREN WITH NEUROBLASTOMA - POLISH NATION-WIDE RETROSPECTIVE STUDY
Marek Ussowicz, Aleksandra Wieczorek, Agnieszka Dlużniewska, Anna Pieczonka, Katarzyna Drabko, Robert Dębski, Jolanta Goździk, Jacek Wachowiak, Walentyna Balwierz, Daria Handkiewicz-Junak (Poland)

THE IMPACT OF HOUSEHOLD INCOME ON ACUTE HOSPITALIZATION DAYS IN PEDIATRIC ALLOGENEIC TRANSPLANT RECIPIENTS
USE OF RIC REGIMENS COMBINED WITH TCRAB DEPLETION AND POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC MISMATCHED SCT
Peter Lang, Michaela Doering, Anne-Marie Lang, Patrick Schlegel, Christian Seitz, Robin Fischer, Marina Schmidt, Martin Ebinger, Ursula Holzer, Ines Brecht, Rupert Handgretinger (Germany)

THE ROLE OF HLA-DP MATCHING IN DONOR SELECTION FOR MUD-HSCT IN CHILDREN WITH HEMATOLOGIC MALIGNANT DISEASES
Manuela Tumino, Giulia Reggiani, Chiara Mainardi, Elisabetta Calore, Antonio Marzollo, Elisa Carraro, Maria Vittoria Gazzola, Roberta Destro, Matteo Barioni, Aurora Strano, Marta Pillon, Alessandra Biffi (Italy)

CLINICAL IMPLICATION ON RECOVERY OF γδ T CELLS AFTER TCRαβ-DEPLETED HAPLOIDENTICAL HSCT IN PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE
Eun Seok Choi, Sung Han Kang, Jin Kyung Suh, Hyeri Kim, Kyung Nam Koh, Ho Joon Im (Korea, Republic of)

EARLY INITIATION OF CYCLOSPORINE-MYCOPHENOLATE PLUS ANTITHYMOCYTE GLOBULIN IN HAPLO TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN: LOW INCIDENCE OF SEVERE ACUTE GVHD WITH ENCOURAGING SURVIVAL
Angela María Trujillo Gaviria, Amado Jose Karduss U, Gloria Suarez, Angelica Cardona, Monica Ramirez, Jose Betancurt (Colombia)

FEASIBILITY AND SAFETY OF SURGICAL FERTILITY PRESERVATION TECHNIQUES PROXIMAL TO INITIATION OF CONDITIONING THERAPY IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT
Katelynn Brodigan, Lindsay Frazier, Christine Duncan, Richard Yu, Marc Lauder, Brent Weil, Elizabeth Ginsburg, Serene Srouji, Leslie Lehmann (United States)

VENO-OCLUSION DISEASE WITH EMPHASIS ON RENAL MANIFESTATIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS: A SINGLE CENTER EXPERIENCE
Aharon Gefen, Shirley Pollack, Irina Zeidman, Neta Nevo, Israel Eisenstein, Daniella Magen, Myriam Weyl-Ben Arush (Israel)

OUTCOME AFTER HSCT IN CHILDREN WITH JMML FROM A HISTORICAL POINT OF VIEW
THE IMPACT RECOVERY ABSOLUTE LYMPHOCYTE COUNT AT DAYS +21 ON OUTCOME ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC ALL
Lubov Tsvetkova, Olesia Paina, Zhemal Rakhmanova, Polina Kozhokar, Anastasia Frolova, Kirill Ekushov, Inna Markova, Sergey Bondarenko, Elena Babenko, Aleksandr Alyanskiy, Ildar Barkhatov, Elena Semenova, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

T-CELL-RICH HAPLOIDENTICAL STEM CELL TRANSPLANTATION IMPROVES SURVIVAL IN CHILDREN WITH ACUTE LEUKEMIA RELAPSED AFTER ALLOGENEIC TRANSPLANTATION
Nobuhisa Takahashi, Shogo Kobayashi, Hideki Sano, Kazuhiro Mochizuki, Yoshihiro Ohara, Hitoshi Ohto, Kazuhiro Ikeda, Atsushi Kikuta (Japan)

HIGH PREVALENCE OF VITAMIN C DEFICIENCY IN A LARGE PAEDIATRIC COHORT UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE FROM 2003-2019
Rebecca Fisher, Jun Cai, Peter Shaw, Melissa Gabriel (Australia)

EX VIVO T CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE
Ho Joon Im, Eun Seok Choi, Sung Han Kang, Jin Kyung Suh, Hyery Kim, Kyung-Nam Koh (Korea, Republic of)

LONG-TERM ERYTHROPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: HOST DETERMINES RESULT
Erik von Asmuth, Marco Schilham, Hein Putter, Alexander Mohseny, Arjan Lankester (Netherlands)

BOOST WITH CD34+ CELLS FOR POOR GRAFT FUNCTION TREATMENT AFTER HSCT IN PAEDIATRIC PATIENTS. A MULTICENTER STUDY
Massimo Berger, Francesco Saglio, Maura Faraci, Aracangelo Prete, Franca Fagioli (Italy)

NO DIFFERENCE IN SURVIVAL AFTER HLA MISMATCHED VERSUS HLA MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION
Uwe Thiel, Sebastian Schober, Andreas Ranft, Susanne Jabar, Hendrik Gaßmann, Peter Bader, Ewa Koscielniak, Bernd Gruhn, Uta Dirksen, Jürgens Heribert, Stefan Burdach, Peter Lang (Germany)

ALLOGENIC STEM CELL TRANSPLANTATION FOR FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE
Eman Khattab, Abdelghani Tbaksi, Rula Najjar, Mayada Abu Shanap, Rawad Rihani, Hasan Hashem, Wafa Hdeib, Rawan Abed Alrahman, Du’A Darabseh, Nilly Hussien, Iyad Sultan (Jordan)

STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-ANAPLASTIC PERIPHERAL T-CELL LYMPHOMA ON BEHALF OF THE EBMT-PEDIATRIC DISEASES WORKING PARTY
Olga Moser, Arnaud Dalissier, Wilhelm Woessmann, Birgit Burkhardt, Karin Mellgren, Andre Manfred Willasch, Udo Kontny (Germany)

FIRST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RASGRP1 DEFICIENCY

SUCCESSFUL HSCT IN IMMUNE DISREGULATORY DISEASES

LEVOFLOXACIN BASED PROPHYLAXIS IN CHILDREN RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT AFFECT THE INCIDENCE OF ACUTE GVHD AND BLOODSTREAM INFECTIONS
Davide Leardini, Daniele Zama, Edoardo Muratore, Andrea Tozzi, Teresa Papaleo, Francesco Bacelli, Tamara Belotti, Elena Legnani, Arcangelo Prete, Andrea Pession, Riccardo Masetti (Italy)
RITUXIMAB-INDUCED SECONDARY HYPOGAMMAGLOBULINEMIA: MEMORIAL SLOAN KETTERING’S 10-YEAR EXPERIENCE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
Zahra Hudda, Montserrat Cols Vidal, Susan Prockop, Richard O’Reilly, Nancy Kernan, Jayanta Chaudhuri (United States)

‘INCURABLE’ PAEDIATRIC MYELOID LEUKAEMIA TREATED WITH NOVEL CELL-BASED THERAPEUTICS
Mariflor Villegas, Yeap Frances, Doris Tan, Poh Lin Tan (Singapore)

EFFECT OF SERUM PANEL REACTIVE ANTIBODIES ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE
Cristina Jercan, Ana Maria Bica, Letitia-Elena Radu, Alexandra Ionete, Ileana Constantinescu, Carmen Calugaroiu, Aurora Dragomiristeanteanu, Anca Colita (Romania)

IS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION A GOOD INDICATION FOR PATIENTS WITH SIFD SYNDROME?
Victoria Bordon, Patrick Verloo, Catharina Dhooge (Belgium)

TIME COURSE AND IMPACT OF BODY WEIGHT CHANGE EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS
Kenji Kishimoto, Daichihiro Hasegawa, Sayaka Nakamura, Akihiro Tamura, Aiko Kozaki, Asturo Saito, Toshiaki Mori, Takeshi Aoki, Yoshiyuki Kosaka (Japan)

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HIGH RISK EWING SARCOMA, A SINGLE CENTER EXPERIENCE
Hila Rosenfeld Keidar, Amit Dotan, Sabina Edelman, Ronit Elhasid (Israel)

CONDITIONING FOR RETRANSPANTATION FROM THE SAME DONOR AFTER PARTIAL AUTOLOGOUS RECONSTITUTION IN PATIENTS WITH PID: IMMUNOSUPPRESSION IS NOT REQUIRED
Sarah Maria Bauer, Mehtap Sirin, Kerstin Felgentreff, Eva-Maria Jacobsen, Klaus-Michael Debatin, Ansgar Schulz, Manfred Hoening (Germany)

TOCILIZUMAB TREATMENT FOR CRS IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Kinan Kafa, Claudia Bettoni da Cunha-Riehm, Tayfun Küngör, Jan-Henning Klusmann (Germany)

EFFECT OF DESENSITIZATION PROTOCOL ON TRANSPLANTATION SUCCESS IN CHILDREN WITH ANTI-HLA ANTIBODIES
Zhendal Rakhmanova, Olesya Paina, Polina Kozhokar, Anastasia Frolova, Lubov Tsvetkova, Kirill Ekushov, Elena Babenko, Tatyana Gindina, Aleksandr Alyanskiy, Il'dar Barkhatov, Elena Semenova, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

VENETOCLAX/DECITABINE FOR PEDIATRIC MDR-AML RELAPSED AFTER TWO ALLO HSCTS
Johannes Raedler, Sita Heyde, Marie Kolokythas, Anna Eichinger, Vera Binder, Tobias Feuchtiger, Michael Albert (Germany)
HIGHER INCIDENCE OF CMV AND BKV REACTIVATION IN HAPLOIDENTICAL TRANSPLANTS COMPARATIVE TO MUD OR MSD TRANSPLANTS - SINGLE CENTRE RETROSPECTIVE ANALYSIS
Nicoletta Abram, Valentina Baretta, Federico Mercolini, Gloria Tridello, Margherita Mauro, Simone Cesaro (Italy)

PAEDIATRIC BONE MARROW TRANSPLANT CARE ON BMT VERSUS NON-BMT PAEDIATRIC WARDS
CHRONIC HEALTH PROBLEMS IN CHILDREN AFTER ALLOGENEIC HSCT: THE TOP OF THE ICEBERG?
Victoria Bordon, Kathleen De Waele, Sophie Van Lancker, Catharina Dhooge (Belgium)

HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: SINGLE-CENTER SERIES OF 14 CASES
Iván López Torija, Marta Gómez Vicent, Blanca Molina Angulo, Jesús González de Pablos, Miguel Ángel Díaz Pérez (Spain)

PNEUMATOSIS INTESTINALIS AS A RARE POST-TRANSPLANT COMPLICATION IN PEDIATRIC PATIENTS
Johanna Schepp, Mehtap Sirin, Kerstin Felgentreff, Carolin Grimm, Klaus-Michael Debatin, Ansgar Schulz, Manfred Hoenig (Germany)

THE EXPERIENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RARE HEMATOLOGIC DISEASE
SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH DNA LIGASE IV DEFICIENCY WITH NONMYELOABLATIVE CONDITIONING REGIMEN

WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELL THERAPY IMPROVES THE QUALITY OF LIFE AND SELF-SUFFICIENCY OF CHILDREN WITH AUTISM SPECTRUM DISORDER
Izabela Zdolińska-Malinowska, Magdalena Chrościnska-Krawczyk, Michał Piątek, Maciej Rojek, Dariusz Boruczkowski (Poland)

MARROW DERIVED CELLS BRING A LONG LASTING RELIEF WHEN INJECTED INTRAARTICULARLY TO THE JOINTS WITH DEGENERATIVE ARTHRITIS
Agata Borowik, Arkadiusz Janusz, Janusz Lange, Danuta Sosnowska, Emilja Jaskula, Andrzej Lange (Poland)
OSTEOGENIC DIFFERENTIATION CAPACITY OF ADIPOSE-DERIVED STEM CELLS AFFECTED WITH COLD STORAGE
Hee-Hoon Yoon, In Keun Jang, O Kyu Noh, Jang Hoon Lee, Kwang Chul Lee, Jun Eun Park (Korea, Republic of)

e-Posters
09:30 - 18:00

Stem cell mobilization, collection and engineering
TWO YEAR ANALYSIS OF A PROSPECTIVE PHASE I/II CLINICAL TRIAL IN ADULTS USING TCR ALPHA/BETA DEPLETED STEM CELL TRANSPLANTATION FROM MATCHED RELATED AND UNRELATED DONORS

A NEW BSA-BASED THRESHOLD PREDICTS OPTIMAL PBSC COLLECTION IN T-CELL DEPLETED HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION

PHASE 1 CLINICAL STUDY OF MGTA-145 IN COMBINATION WITH PLERIXAFOR SHOWS RAPID SINGLE-DAY MOBILIZATION AND COLLECTION OF CD34+ HSCS WITHOUT G-CSF

DEPLETION OF αβ T-CELLS AND B-CELLS BEFORE HLA-HAPLOIDENTICAL HSCT IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISORDERS: A REPORT OF 473 PROCEDURES

ACOUSTOPHORESIS ENABLES THE LABEL-FREE SEPARATION OF DISTINCT SUBSETS FROM CULTURED BONE MARROW STROMAL CELLS
Franziska Olm, Hooi Ching Lim, Katharina Schallmoser, Dirk Strunk, Thomas Laurell, Stefan Scheding (Sweden)

FEASIBILITY OF MODIFIED CD45RA NEGATIVE DONOR LYMPHOCYTES INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

BEYOND STEM CELLS - DOES IT MATTER WHAT'S IN THE BAG IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA AND LYMPHOMA?
Holly Emms, Dara Qadir, Rowayda Peters, Claire Wiggins, Oliver Gittner, Andy Drake, Matthias Klammer (United Kingdom)

EXPRESSIONS OF CO-INHIBITORY MARKERS INCREASE EFFECTOR MEMORY T CELLS IN G-CSF MOBILIZED PERIPHERAL STEM CELLS
Jeong-A Kim, Misuk Yang, Youngrok Park, Young Hoon Park, Jae-Yong Kwak (Korea, Republic of)

LIPEGFILGRASTIM COMBINED WITH CHEMOTHERAPY WAS MORE COST-EFFECTIVE THAN PEGFILGRASTIM IN THE MOBILIZATION OF CD34+ CELLS IN NHL PATIENTS
Anu Partanen, Antti Turunen, Jaakko Valtola, Kaisa Vasala, Lasse Ägren, Karri Penttilä, Marja Pyörälä, Taru Kuitinen, Pentti Mäntymaa, Jukka Peltonen, Esa Jantunen, Ville Varmavuo (Finland)

MOBILIZATION AND HARVEST OF PERIPHERAL BLOOD STEM CELLS (PBSC) FOR ALLOGENEIC STEM CELL TRANSPLANTATION FROM 335 PEDIATRIC SIBLING HEALTHY DONORS
A COMPARISON OF CHEMO-FREE STRATEGY WITH G-CSF PLUS PLERIXAFOR ON DEMAND VERSUS 1D-CYCLOPHOSPHAMIDE AND G-CSF AS PBSC MOBILIZATION IN MULTIPLE MYELOMA: AN EXPLORATIVE COST ANALYSIS
EVALUATION OF VIA FREEZETM QUAD FOR LIQUID NITROGEN-FREE CGMP-COMPATIBLE CONTROLLED-RATE FREEZING OF HEMATOPOIETIC PROGENITOR CELL GRAFTS
Bechara Mfarrej, Olivier Vicari, Sophie Thevenet, Kerjean Elodie, Claude Lemarie, Christian Chabannon, Boris Calmels (France)

CD34+ CELL SUBSETS IN STEM CELL PRODUCTS AND THEIR RELATIONSHIP WITH ENGRAFTMENT KINETICS

PLERIXAFOR ON DEMAND IN COMBINATION WITH LOW-DOSE CYCLOPHOSPHAMIDE AND G-CSF FOR THE MOBILIZATION OF HSC IN MULTIPLE MYELOMA PATIENTS: HIGH EFFICACY AND LOW TOXICITY

PERFORMANCE QUALIFICATION OF LOVOTM MEDICAL DEVICE FOR WASHING AND CONCENTRATING 3 AND MORE HEMATOPOIETIC PROGENITOR CELL CRYOPRESERVED BAGS
Bechara Mfarrej, Guillaume Bouchet, Jerome Couquiaud, Lionel Regimbaud, Sophie Thevenet, Elodie Kerjean, Claude Lemarie, Christian Chabannon, Boris Calmels (France)

FROM WORK-UP REQUEST TO DONATION IN THREE WEEKS: A DEDICATED REGISTRY INTEGRATED UNRELATED DONOR STEM CELL COLLECTION CENTER IS SAFE, EFFICIENT AND CONVENIENT FOR DONORS
Isaac Yaniv, Tsippi Kestenbom, Sigal Manor, Bracha Zisser (Israel)

LOW-DOSE CYCLOPHOSPHAMIDE + G-CSF IS NO MORE EFFECTIVE THAN G-CSF ALONE WHEN MOBILIZING AND COLLECTING STEM CELLS FOR AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA PATIENTS
Antonio José Palma Vallellano, Rocío Zapata Bautista, Carmen Beltrán, Margarita Bendala, Ana R. Carranco, Miguel A. Castilla, Blanca Díaz, Juan Francisco Domínguez, Francisco Fernández, Encarnación Gil, Karol Gómez, Susana Ramírez, Juan Nicolás Rodríguez, María Solé, Pilar Velarde (Spain)

FIRST INTERIM RESULTS OF NIS OPTIMOB - NATIONWIDE TRIAL OF MOBILIZATION AND COLLECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS

THE IMPACT OF PLERIXAFOR ‘ON DEMAND’ ON THE HEMATOPOIETIC STEM CELL (HSC) COLLECTION, PRODUCT’S QUALITY AND ENGRAFTMENT

ELEVATED SERUM LACTATE DEHYDROGENASE AFTER STEM CELL MOBILISATION PREDICTS SUCCESSFUL STEM CELL COLLECTION IN CHILDREN

INFLUENCE OF THE DMSO WASH STRATEGY ON ADVERSE REACTIONS DURING INFUSION OF HEMATOPOIETIC PROGENITORS

BONE MARROW DONOR CHARACTERISTICS: INFLUENCE ON HARVEST YIELD AND DONOR RECOVERY

PLERIXAFOR SALVAGES AUTOLOGOUS STEM CELL MOBILISATION PROCEDURES IN MYELOMA PATIENTS PREVIOUSLY TREATED WITH LENALIDOMIDE OR AUTOLOGOUS HSCT: COST-EFFECTIVENESS OF UPFRONT USE SHOULD BE EXPLORED
Paul Miller, Janet Baker, Crischi Magsipoc, Joy Brennan, María Mulligan, Janet Wells, Helen McDonald, Kevin Boyd, Martin Kaiser, Mark Ethell, Mike Potter, Sandra Easdale, Chloe Anthias, Emma Nicholson (United Kingdom)

EFFECT OF SHIPPING TIME AND TRANSPORT CONDITIONS ON THE VIABILITY OF CORD BLOOD LEUKOCYTES
Izabela Zdolińska-Malinowska, Maciej Rojek, Michał Piątek, Dariusz Boruczkowski (Poland)

OPTIMIZATION OF A STEM CELL MOBILIZATION STRATEGY FOR PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA

AUTOLOGOUS LYMPHAPHERESIS FOR THE PRODUCTION OF CAR-T CELLS
RED BLOOD CELL DEPLETION AND/OR VOLUME REDUCTION IN BONE MARROW PROCESSING: A COMPARISON OF TWO METHODS
Limor Horev Azaria, Yakov Sverdlov, Michal Pearl-Yafe, Orad Shemesh, Alon Kalo, Dana Greenfeld, Jerry Stein (Israel)

CORRELATION OF INTRA-OPERATIVE TOTAL NUCLEATED COUNT AND DONOR CHARACTERISTICS WITH FINAL ALLOGENEIC BONE MARROW GRAFT CHARACTERISTICS AND RECIPIENT CLINICAL OUTCOMES
Jacob Kalin, Anh Thy Nguyen, Benjamin Oshrine (United States)

MULTICENTRE EVALUATION OF THE HPC MODUS (XN-20) FOR TIMING THE HARVEST OF STEM CELLS FROM PERIPHERAL BLOOD
Kathleen Deiteren, Jean-Philippe Defour, Kornelia Hummel, Holger Boysen, Hans Salwender, Jan-Dirk Studt, Antoine Mairesse, Katrien Vermeulen, Dominik Heim, Dimitrios A. Tsakiris (Switzerland)

IMPACT OF CHANGE OF MOBILISATION METHOD ON ADEQUACY OF STEM CELL COLLECTION IN MULTIPLE MYELOMA PATIENTS: SINGLE CENTRE EXPERIENCE
Valarmathi Anandhan, Emma Searle, Jaya Sudhir, Alberto Rocci (United Kingdom)

TWO DIFFERENT PLERIXAFOR STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE
Carmen Albo López, Concepción Andon, Dolores Vilarino, Esperanza Lavilla, Julio Del Río, Cristina Fonte, Angeles Cobas (Spain)

AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS (PBSCS) MOBILIZATION AND COLLECTION-PRINCESS NOORAH ONCOLOGY CENTER EXPERIENCE, KAMC - JEDDAH - SAUDI ARABIA
Mona Najib, Ahmed Alsaeed, Ihab Hemaidi, Sameer Al Amoudi, Mohammed Mohammad (Saudi Arabia)

REVIEW OF PLERIXAFOR USE IN A TERTIARY PAEDIATRIC ONCOLOGY CENTRE
Eileen Butler, Noeleen Comey, Cormac Owens (Ireland)

UNUSUAL HIGH COUNT OF CD34+ AFTER CHEMO MOBILIZATION WITH MATRIX IN PATIENT WITH PRIMARY CNS LYMPHOMA IS ASSOCIATED WITH PROMPT AND ROBUST ENGRAFTMENT

LEUKOCYTAPHERESIS - ONE TECHNIQUE, DIVERSE OPPORTUNITIES IN THE THERAPY OF PATIENTS
Zdenka Gasova, Zdenka Bhuiyan-Ludvikova, Martina Bohmova, Marketa Sloukova, Pavla Pecherkova, Jan Vydra (Czech Republic)

COMPARISON OF CONTINUOUS MONONUCLEAR CELL COLLECTION (CMNC) AND MONONUCLEAR CELL CELL (MNC) METHODS FOR CELL PROLIFERATION (APHERESIS) IN PATIENTS WITH BONE MARROW TRANSPLANTATION
Mehrdad Payandeh, Sakineh Ghorbani, Azam Eiahi, Roya Chagneh Lorestani (Iran, Islamic Republic of)
ARE TRANSPLANTS TRULY AVAILABLE TO ALL, REGARDLESS OF GEOGRAPHY, SOCIOECONOMIC STATUS AND ETHNIC GROUP? A BSBMTCT REPORT
Rachel Pearce, Julia Lee, Ruth Paul, Marie Wilson, Clementina Abamba, Kim Orchard (United Kingdom)

MISMATCHED DONOR AND GRADE 2 TO 4 ACUTE GVHD AS TWO-RISK MODEL FOR CYTOMEGALOVIRUS VIREMIA AND DISEASE AFTER ALLOGENEIC TRANSPLANTATION - SINGLE INSTITUTE ANALYSIS OF 1180 PATIENTS
Xiu-Wen Liao, Jia-Hau Liu, Ming Yao, Bor-Sheng Ko, Cheng-Hong Tsai, Shang-Ju Wu, Shang-Yi Huang, Sheng-Chieh Chou, Hui-Hsuan Huang, Tai-Chung Huang, Hsin-An Ho, Wen-Chien Chou, Feng-Ming Tien, Jih-Luh Tang (Taiwan, Republic of China)

e-Posters
09:30 - 18:00
ePoster Area

Statistics

USE OF VARIABLE SELECTION METHODS TO IDENTIFY CLINICAL AND IMMUNOLOGICAL FACTORS ASSOCIATED WITH THE CLINICAL OUTCOME OF PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Chloé Pasin, Ran Reshef, Andrew J Yates (United States)

THE IMPACT OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION ON WORK AND PRODUCTIVITY LOSS IN PATIENTS WITH ACUTE LEUKAEMIA: RESULTS FROM A RAPID REVIEW GEOGRAPHIC AND SOCIOECONOMIC IMPACTS ON SURVIVAL AMONG ALLOGENEIC TRANSPLANT RECIPIENTS

e-Posters
09:30 - 18:00
ePoster Area

Nurses Posters - Adult

ROLE OF QUICKSOFA IN PREDICTING SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL PATIENTS

<i>BOLUS:</i> TARGETED SPECIALIST HAEMATOLOGY/BMT PODCASTS: AN EFFECTIVE METHOD OF EDUCATION

A PATHWAY FOR RECOVERY: D+100 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT) FOLLOW UP PILOT FOR LYMPHOMA

REDUCING ACCIDENTAL FALLS CAUSED BY ORTHOSTATIC HYPOTENSION IN BONE MARROW TRANSPLANT RECIPIENTS

THE EFFECT OF MOTIVATIONAL INTERVIEW PERFORMED AFTER STEM CELL TRANSPLANTATION ON SEXUAL EXPERIENCE, SEXUAL SELF-AWARENESS AND SEXUAL SELF-EFFICACY

STUDY ON COGNITIVE FUNCTION AND RELATED FACTORS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

THE EFFECT OF RELAXING BREATHING EXERCISES ON PAIN, FATIGUE AND LEUKOCYTE COUNT IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
UNDERSTANDING OF PROGNOSIS, QUALITY OF LIFE AND PSYCHIATRIC STATUS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY OF 348 PATIENTS
Xia Yan, Ting Wang, Wei Hu, Xiaodong Xu, Shujia Liu (China)

AN OUTPATIENT MODEL OF CARE TO SAFELY DELIVER AUTOLOGOUS STEM CELL TRANSPLANTATION

EFFECTS OF TREATMENTS FOR HAEMATOLOGICAL MALIGNANCIES ON SEXUALITY AND FERTILITY: WHEN DO PATIENTS NEED IT AND WHOM REALLY WANTS TO KNOW?
C Eeltink, B Lissenberg, I Nauta, J Rood, L Incrocci, I Verdonck- de Leeuw, S Zweegman (Netherlands)

EFFICACY OF THERAPEUTIC EDUCATION TO REDUCE RISKS AND COMPLICATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OBSERVATIONAL PROSPECTIVE COHORT STUDY
Marco Cioce, Laura Orlando, Stefano Botti, Gianpaolo Gargiulo (Switzerland)

SELF-EFFICACY AND SELF-CARE PRACTICES OF PATIENTS WHO HAVE BEEN TRANSPLANTED WITH ALLOGENEIC HEMATOPOIETIC STEM CELLS ACCORDING TO THE DEVELOPMENT OF AN INDIVIDUAL EDUCATION PROGRAM

DETERMINING THE SYMPTOMS AND COPING METHODS OF PATIENTS AT HOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kader Caliskan, Gulbeyaz Can (Turkey)

THE EFFECT OF ORAL CARE PROTOCOL ON ORAL MUCOSITIS IN PATIENTS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kwan Suk Jo, Seung Nam Zang, Ga Yeon Kim, Hye Yun Cho, Yang Sook You (Korea, Republic of)

PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) WITHIN AN AMBULATORY CARE SETTING; A PATIENTS’ PERSPECTIVE
Noemi Gianni, Tania Arthurs, Yvonne Patefield-Smith, Kirsten Rendall, Jo Wyatt, Rachel Miller (United Kingdom)

REDUCING ANTITHYMOCYTE GLOBULIN (ATG) INFUSION RELATED REACTION BY INCREASING THE INFUSION DURATION IN ADULT SCT PATIENTS; A SINGLE INSTITUTION EXPERIENCE FROM SAUDI ARABIA
Suha Alkhraisat, Moussab Damajl, Maybelle Balili, Samer Ghazi, Innaam Shehab eddine, Isam Mahasneh, Bader Ahmari, Heba Alshobaki, Mohsen Alzahrani (Saudi Arabia)

NURSE LED TELEPHONE FOLLOW UP FOR LATE EFFECTS SERVICE

NURSING CARE OF 15 PATIENTS WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CHIMERIC ANTIGEN RECEPTOR T CELLS

NURSING CARE OF A PATIENT WITH HEREDITARY DIFFUSE LEUKOENCEPHALOPATHY COMPLICATED WITH AXONAL DEGENERATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

EFFECT OF NURSES EDUCATION PROGRAM ON CATHETER RELATED BLOOD STREAM INFECTIONS
Roberta Gironi, Marco Fabbrini, Daniela Clerici, Chiara Oltolini, Raffaella Greco, Consuelo Corti, Fabio Ciceri, Antonella Biella (Italy)

THE CURRENT SITUATION AND INFLUENCING FACTORS OF MANAGEMENT OF CENTER VENOUS ACCESS DEVICE-ASSOCIATED SKIN IMPAIRMENT DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Ting Wang, Xia Yan, Linnan Wang, Xinxin He, Boning Liu (China)

EXERCISE SUPPORT FOR PEOPLE POST TREATMENT AS PART OF THEIR RETURN TO WORK JOURNEY: A CASE STUDY EXEMPLAR
ONCOSAFETY: A NEW TOOL FOR HEMATOLOGY NURSES TO AVOID CHEMOTHERAPY ERRORS
Llara Roca Gimeno, Elisabeth Lazaro Lora, Marta Yusta Arnal, Iria Gonzalez Alvarez (Spain)

PATIENT INFORMATION SHEET FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION: THE IMPACT OF THE DISEASE AND TREATMENT ON SEXUAL FUNCTION AND SEXUALITY
C Eeltink, L Incrocci, I Verdonck-de Leeuw, S Zweegman (Netherlands)

CHANGING PRACTICE BY USING CYCLOPRIME 1.5G/M2 PRIMING REGIME UP FRONT FOR LYMPHOMA PATIENTS TO ENSURE GOOD MOBILISATION OF STEM CELLS
Jennefer Rose, Sophie Jones, Wendy Ingram (United Kingdom)

THE CHALLENGES OF LOOKING AFTER AN INCREASING NUMBER OF SURVIVORS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION
Lara Rowley, Amanda Ellis, Denise Wareham, Daja Barton, Emma Shaw, Olivia Hilsdon, Francesca Toselli, Shirley Hudson (United Kingdom)

VENO-OCCCLUSIVE DISEASE (VOD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANT NURSING CONSIDERATIONS AND MANAGEMENT: A CASE STUDY
Marie Waller, Christopher Heron, Hayley Dyos, Eleni Tholouli (United Kingdom)

RECOGNIZING LOW HEALTH SKILLS AND LOW LITERACY DURING CONSULTATION
Lian Schoonhoven-Bos (Netherlands)

PRE-HABILITATION PRIOR TO STEM CELL TRANSPLANT - ONE CENTRES EXPERIENCE

THE IMPORTANCE OF NURSES TRAINING IN NEW THERAPY USING THE EXAMPLE OF CAR-T CELL THERAPY

PLASMAPHERESIS: TAKING THE EDGE OFF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTI-BODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Sinju Thomas, Adrien Quintela, Arthi Anand, Karen Bradley (United Kingdom)

INCIDENCE & CHARACTERISTICS OF VARICELLA ZOSTER VIRUS INFECTION POST HEMATOPOIETIC STEM CELL TRANSPLANTATION; EXPERIENCE OF A SINGLE CENTER IN SAUDI ARABIA

SEMI-STRUCTURED INTERVIEW ASSESSMENT OF THE CLINICAL NURSE EDUCATOR ROLE IN SUPPORTING NEWLY QUALIFIED NURSES DURING TRANSITION TO POST-REGISTRATION PRACTICE INSIDE THE BONE MARROW TRANSPLANT SETTING
Luke White, Kathryn Vowden (United Kingdom)

TRAINING NURSING PROGRAMME IN NEW THERAPIES: CAR T CELLS

NURSES' ROLE IN IMPROVING PATIENTS' FOOD INTAKE IN THE ACUTE HSCT PHASE

USE THE AVAILABLE KNOWLEDGE - ENSURE THAT THE PATIENT RECEIVES THE BEST CARE IN STEM CELL TRANSPLANTATION
Anncarin Svanberg (Sweden)

THE PSYCHO EMOTIONAL DISAGUE IN ADULT PATIENTS SUBJECT TO MIDOLLO TRANSPLANT: INITIAL STUDY OF A SINGLE CENTER

NURSING CARE OF 15 PATIENTS WITH HEMATOLOGICAL MALIGNANT TUMOR COMPLICATED WITH SEVERE CYTOKINIE RELEASE SYNDROME TREATED BY CAR-T CELLS
RETROSPECTIVE OBSERVATIONAL STUDY ON THE TRANSMISSION OF HEALTHCARE ASSOCIATED INFECTIONS AMONG NEUTROPENIC PATIENTS WITHIN THE HEMATOLOGY UNIT OF PIACENZA HOSPITAL
Lorella Cappucciati, Chiara Buraschi, Cinzia Merlini, Sabrina Sbizzirro, Silvia Fava, Stefano Gandolfi, Donatella Petrucci, Luca Pasquali, Mirella Gubbelini, Andrea Contini (Italy)

GUIDE FOR PATIENTS AND DONORS BEFORE A PERIPHERAL BLOOD STEM CELL COLLECTION
Natalia Lorente del Río, Cristina Alberquilla Ramos, Salvador Aleza Esteras, Isabel María Fernández Morales, Mª Del Carmen Freire Mourón, Ana García Carulla, Carmen Granado Rodilla, Mercedes Jiménez Meoro, Rosario López López, Marta Vela Garicano, Jesús Zalvide Torrente, Laura Bibiloni Martínez (Spain)

IMPACT OF AN IMPROVEMENT PLAN ON THE REDUCTION OF BACTERIEMIA BY CENTRAL CATHETER IN A PATIENT RECEIVER OF A CELLULAR THERAPY
Marina Sedlar, Marijana Maric, Lana Desnica, Radovan Vrhovac, Ivan Sabol, Nurka Rustan (Croatia)

ARE TYPANIC THERMOMETERS RELIABLE IN HEMATOPOIETIC STEM CELL RECIPIENTS?
Marina Sedlar, Marijana Maric, Lana Desnica, Radovan Vrhovac, Ivan Sabol, Nurka Rustan (Croatia)

ARE TYPANIC THERMOMETERS RELIABLE IN HEMATOPOIETIC STEM CELL RECIPIENTS?
Marina Sedlar, Marijana Maric, Lana Desnica, Radovan Vrhovac, Ivan Sabol, Nurka Rustan (Croatia)

RELATIONSHIPS BETWEEN THE HEALTHCARE NEEDS AND QUALITY OF LIFE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS
PAIN ASSESSMENT DURING BONE MARROW BIOPSY PROCEDURE AND BONE MARROW ASPIRATE PROCEDURE: A SPECIFIC NURSING ASSESSMENT
Lorella Cappucciati, Fabio Pollini, Vincenzo Matteo Quitadamo, Ramona Patras, Angelica Cravedi, Maria Teresa Borsotti, Ilaria Filati, Rosaria Scopelliti, Cinzia Merlini, Andrea Contini, Mirella Gubbellini (Italy)

AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION IN SYSTEMIC SCLEROSIS: CASE STUDY
Lucília Carreiro, Rosa Romão, Candida Damião (Portugal)

LEADERSHIP - LEADING THE TEAM
Klara Kabatova Maxova (Czech Republic)

PAIN ASSESSMENT IN ONCO_HEMATOLOGICAL PATIENT SUBJECTED TO CENTRAL VENOUS CATHETER POSITIONING (CVC) OR PERIPHERALLY INSERTED CENTRAL CATHETER POSITIONING (PICC)
Lorella Cappucciati, Giovanna Buonanno, Corrado Gozzo, Francesco Oleari, Raffaele Maestri, Noemi Paladini, Patrizio Imbriani, Lucrezia Maria Zagnoni, Sara Posla, Mirella Gubbelini, Andrea Contini (Italy)

TOCILIZUMAB MANAGEMENT IN THE CYTOKINE RELEASE SYNDROME
Complilations associated with the collection of peripheral blood progenitor cells
Lucília Carreiro, Carla Gonçalves, Fátima Pereira, Rosa Romão, Cândida Damião (Portugal)

IS IT WORTH FIGHTING TOGETHER FOR AN INDIVIDUAL ACCESS TO A MEDICINE WITH A NON REIMBURSEMENT DECISION? YES IT IS!
Isabel Salcedo, Esther Ortiz, Juana María Acebes, Mari Luz Pascual, Beatriz Sanchez Sevilla, Almudena Laiglesia, Ana Alarcón, Rafael F Duarte (Spain)

INCIDENCE OF ACUTE GUT GVHD IN PATIENTS WHO HAVE UNDERGONE ALLOGENIC STEM CELL TRANSPLANT: CASE STUDY
Poonam Thorat, Meera Sharad Achrekar, Deepti Ghonge (India)

COMPLETION TIME TO HLA TYPING
Gynecological treatment experience of menopausal syndrome and sexual disorders in female patients who undergoing allogeneic stem cell transplantation
Nurses Posters - Paediatric

TRANSITION STRATEGY: FROM PEDIATRIC TO ADULT HEALTH CARE AND LONG TERM FOLLOW-UP

CAREGIVER EDUCATION AND TRAINING FOR SELF ADMINISTRATION OF ORAL DRUGS IN A PAEDIATRIC CENTER

EXERCISE THERAPY ON CANCER-RELATED FATIGUE AND QUALITY OF LIFE IN CHILDREN UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION

SEXUAL HEALTH FOR YOUNG PEOPLE UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION

EVALUATION OF A PREVENTIVE SKIN CARE PROTOCOL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS RECEIVING THIOTEPA

Kim van der Niet, Lisa Rozendaal, Dagmar Berghuis, Eileen van der Stoep-Yap, Erik von Asmuth, Maria de Taeye-Veldhuizen, Arjan Lankester, Hilda Mekelenkamp (Netherlands)

CAR-T: THE DUTCH PEDIATRIC NURSING EXPERIENCE

Ida Bremer Ophorst, Tineke Terlouw (Netherlands)

SUBSTITUTIVE THERAPY WITH S.C. IMMUNOGLOBULINS IN PEDIATRIC HSCT RECEPIENTS: A SINGLE CENTER EXPERIENCE

Rosanna Ceresoli, Stefano Benvenuti, Patrizia Bevilacqua, Mirella Savoldi, Fulvio Porta (Italy)

PEDIATRIC PHOTOAPHAERESIS: THE DILEMMA OF VASCULAR ACCESSES

Rosanna Ceresoli, Stefano Benvenuti, Emilio Ferrari, Fulvio Porta (Italy)

TOTALLY IMPLANTABLE VASCULAR ACCESS DEVICES RUPTURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: PROPHYLAXIS AND TREATMENT

USE OF VOLUMETRIC PUMPS FOR THE INFUSION OF HEMATOPOIETIC STEM CELLS AS A STANDARD METHOD IN PEDIATRIC PATIENTS

Nuria Caballero, Marian Cerezuela, Isabel Badell Serra (Spain)

PEDIATRIC PATIENT TRANSFER FROM A TPH WARD TO ICU: HOW CAN WE IMPROVE OUR COMMUNICATION?

Almudena Pérez, Alba Martínez, Anna Negre, Laura Lahuerta (Spain)

CARING FOR MINOR SIBLING DONORS

Eugenia Trigoso Arjona, Estrella Larios Reyes, Maria Sol Abert Velert (Spain)

EFFECTIVE MOBILISATION WITH PLERIXAFOR FOLLOWING CRANIA-SACRAL RADIOTHERAPY AND HIGH-DOSE CHEMOTHERAPY: A CASE REPORT OF AN ELEVEN-YEAR OLD BOY WITH GLIOBLASTOMA MULTIFORME

Anna Tailby, Julia Nixon, Alison Bridgman, Angela Burns, Abigail Cotton, Hannah Ezard, Josephine Nicholls, Melanie Rooney, Elisabeth Thomas, Ilian Uri, Marita Macken, Sarah Lawson, Martin English (United Kingdom)

EARLY RECOGNITION OF PEDIATRIC GVHD: EDUCATION AND AWARENESS AMONGST NURSES

Bart Maertzdorf, Anouk Jongekrijg (Netherlands)

RISK ASSESSING PAEDIATRIC PATIENTS’ NUTRITIONAL NEEDS PRIOR TO BONE MARROW TRANSPLANT
Nurses Posters - Research

FAMILY CAREGIVERS SUPPORT NEEDS DURING ALLO-HSCT - A LONGITUDINAL STUDY (PRELIMINARY RESULTS)

PAIN AND ANXIETY MANAGEMENT DURING BONE MARROW ASPIRATES IN ITALIAN TRANSPLANT PROGRAMS. A NATIONWIDE SURVEY ON BEHALF OF GITMO NG

PREVALENCE, PREDICTORS AND OUTCOMES OF CLABSI AMONG HSCT PATIENTS

CREATION OF THE LABMT NURSES GROUP

SYMPTOMS AND QUALITY OF LIFE OF CHILDREN AND ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY

SOCIAL SUPPORT MODERATES THE EFFECTS OF HEALTH STRESSORS ON HEALTH CARE ADHERENCE AND PSYCHOLOGICAL DISTRESS IN LONG-TERM HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS

SYMPTOM DISTRESS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A PROSPECTIVE STUDY

NURSE INVOLVEMENT AND IMPACT OF JACIE ACCREDITATION ON NURSE PRACTICE
Carmen Conde, Ariadna Domenech, Iria González, Verónica Linde Blazquez, Eugenia Trigoso Arjona, Julia Ruiz Pato (Spain)

CONSTRUCTION OF QUALITY INDICATORS SYSTEM OF NUTRITION CARE FOR ADULT PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION THROUGH AN EVIDENCE-BASED APPROACH
Yun Fang, Minjie Liu, Chen Xie (China)

ARE CAREGIVERS RECEIVING ENOUGH INFORMATION TO CARE? A PILOT STUDY ON A HAEMATOLOGICAL TRANSPLANT UNIT

MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A THREE YEARS FOLLOWING UP
Yaya Song, Xiaoming Zhu, Yin Lu, Yongqin Ge, Qin Li, Fang Tang, Ying Chen, Yaohong Li (China)

VENOUS ACCESS IN AUTOLOGOUS VERSUS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT DONORS: A RETROSPECTIVE STUDY OF AN APHERESIS UNIT
Isabel Salcedo, Angela Salas, Laura Vicente, Lucia Paola Cuéllar, Virginia Infante, Carmen de la Puente, Jose Luis Bueno (Spain)

A STUDY TO ASSESS THE LEVEL OF BURNOUT AMONG NURSES WORKING IN BONE MARROW TRANSPLANT (BMT) UNIT OF A TERTIARY CARE CANCER HOSPITAL
Shreya Ludbe, Meera Sharad Achrekar, Rynel Quadras (India)

DO WE KNOW ENOUGH ABOUT THE BONE MARROW DONATION?

ASSOCIATION OF AIR BORN PARTICLE SIZE AND PARTICLE COUNT WITH INCIDENCE OF INFECTIONS IN HEPA FILTERED ROOMS-A SINGLE CENTRE EXPERIENCE

SYSTEMATIC REVIEW OF SIGNS AND SYMPTOMS OF THE HUMAN HERPES VIRUS 6 AND THEIR ASSESSMENT TOOLS
Rodrigo Serrano Villegas, Beatriz del Amo Mateos, Claudia Pina Pino, María Teresa Abellán Garrido, Gema Hernández Sanchez, María Cabezas López de Sosoaga,Montserrat Pilar Barrilero Lopez (Spain)
Scientific Programme

A STUDY TO ASSESS PERCEIVED STRESSORS AND COPING STRATEGIES ADOPTED BY PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL INFUSION IN SELECTED CANCER HOSPITAL, INDIA
Bhushan Shelar (India)

ROLE OF THERAPEUTIC APHERESIS IN ALLOGENEIC TRANSPLANTATION: A CASE REPORT
Cristina Alberquilla Ramos, Salvadora Aleza Estera, Josefa Navarrete Ruiz, Beatriz Alonso González, Rocío Rico Muñoz, Ana Isabel Torre Polo, Pilar Herreros López, Julia Ruiz Pato (Spain)

SYMPTOMS OF ELDERLY PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER INDUCTION CHEMOTHERAPY
Yaohong Li, Xiaming Zhu, Yin Lu, Fang Tang, Yongqin Ge, Qin Li, Ying Chen, Yaya Song (China)

Acute leukaemia

ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH HIV-INFECTION: AN UPDATED PAIR-MATCHED COHORT STUDY BY THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION

COMPARABLE OUTCOMES OF AML PATIENTS RECEIVING HAPLO-HCT WITH THIOTEPA/BU HSVLAN/FLUDARABINE CONDITIONING AND POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS A MATCHED UNRELATED DONOR WITH FLUDARABINE/ BUSULFAN CONDITIONING, REGARDLESS OF DISEASE STATUS

TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOEITIC CELL TRANSPLANT: IMPROVED SURVIVAL FOR YOUNG PATIENTS IN RECENT YEARS

ANTI-CD3/CD33 BISPECIFIC ANTIBODIES EFFICIENTLY REDIRECT DONOR T CELLS AGAINST HLA LOSS LEUKEMIA RELAPSES

POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) EMERGES AS A KEY DRIVER OF HLA CLASS II NEGATIVE POST-TRANSPLANTATION RELAPSE

ALLOGENEIC HCT FOR ADULTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA HARBORING <i>IKZF1</i> GENE MUTATIONS: A STUDY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT IN CHILDREN AND ADULTS WITH RELAPSED/REFRACTORY B-ALL: FOCUS ON ANTI-CD19, ANTI-CD22 MONOClonAL ANTIBODIES

THE VALUE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH AND WITHOUT <i>ASXL</i>1-, <i>RUNX</i>1- AND <i>TP</i>-53 MUTATIONS

ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT

RIC COMBINED WITH ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE PROVIDES HIGHER GVHD-FREE/RELAPSE FREE SURVIVAL IN FIT YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA
LOW-DOSE MEMORY DONOR LYMPHOCYTE INFUSION AFTER αβ T CELL-DEPLETED HSCT AMONG CHILDREN WITH HIGH-RISK LEUKEMIA: RESULTS OF A PROSPECTIVE RANDOMIZED SINGLE-CENTER TRIAL

DEVELOPMENT OF A CORD BLOOD STEM CELL-DERIVED DENDRITIC CELL VACCINE TO PREVENT RELAPSE AFTER CORD BLOOD TRANSPLANTATION IN AML

THE BRAZILIAN EXPERIENCE WITH HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTS (HAPLO-HCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

BETTER LEUKEMIA-FREE SURVIVAL WITH ALLOGENEIC THAN WITH AUTOLOGOUS HCT IN AML PATIENTS WITH ISOLATED TRISOMY 8: A STUDY FROM THE ALWP OF THE EBMT

ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML PATIENTS WITH RUNX1 MUTATION IN FIRST COMPLETE REMISSION: A STUDY ON BEHALF OF THE ALWP OF THE EBMT

GRAFT FAILURE AFTER UNMANIPULATED HAPLO-HSCT WITH PT-CY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION, ON BEHALF OF THE ALWP-EBMT

IMPLICATIONS OF NOVEL RISKS SCORES (AML-DRG AND AML-HCT-CR) IN ALLOGENEIC CD34+ SELECTED GRAFT TRANSPLANT OUTCOMES

DOWNREGULATION OF HLA-DR IN BLASTS OF PATIENTS WITH ACUTE LEUKAEMIA RELAPSING AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION

ESTABLISHMENT OF A NATIONAL STEM CELL TRANSPLANT CLINICAL TRIALS NETWORK: THE UK IMPACT PARTNERSHIP FOR ACCELERATED CELLULAR THERAPIES

DIFFERENTIAL IMPACT OF NPM1 MUTATION ON THE POST-TRANSPLANT OUTCOME OF ADULT FLT3ITD MUTATED AML RECEIVING ALLOGENEIC TRANSPLANT IN CR1 AND AFTER CR1

A REGION-WIDE RETROSPECTIVE ANALYSIS OF OUTCOME FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA

PRE-HARVEST HIGHER DONOR FOXP3 MRNA AND LOWER CD4+ T CELL CONCENTRATION PREDICT INCREASED RISK OF ALL RELAPSE AFTER MYELOABLATIVE HCT WITH T-REPLETE BONE MARROW GRAFTS

EPIDEMIOLOGY, MANAGEMENT AND ECONOMIC IMPACT OF ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME IN SPAIN: A CLAIMS DATABASE ANALYSIS

PRE-TRANSPLANT BONE MARROW CELLULARITY AND BLOOD COUNT RECOVERY ARE NOT ASSOCIATED WITH RELAPSE OR SURVIVAL RISK FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT FOR AML IN CR1

IMMUNOTHERAPY SALVAGE FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS BY THE ALWP OF THE EBMT

COMPARISON OF PRE-TRANSPLANT COMORBIDITY INDICES IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

SALVAGE USE OF VENETOCLAX-BASED THERAPY FOR RELAPSED AML POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
FACTORS PREDICTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA

ROLE OF CHIMERISM AND FLOW-CYTOMETRIC MONITORING OF MEASURABLE RESIDUAL DISEASE (MRD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN PREDICTING RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)

SORAFENIB PROLONGED MAINTENANCE IN FLT3-MUTATED AML POST TRANSPLANTATION

PULMONARY COMPLICATIONS (PC) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN CHILDREN WITH HIGH-RISK ACUTE LEUKEMIA (AL)

MORE THAN TWO CYCLES OF CONSOLIDATION THERAPY PRE-TRANSPLANTATION BENEFITS AML PATIENTS IN CR1 WHO UNDERWENT HLA-MATCHED SIBLING ALLOGRAFTS: A MULTICENTER STUDY

WHAT CAN CNV ANALYSIS ADD TO THE ROUTINE GENETIC DESCRIPTION OF AML CASES?

COMPARISON OF THE PROGNOSTIC ABILITY OF THE HCT-CI THE MODIFIED EBMT AND THE EBMT-ADT PRE-TRANSPLANT RISK SCORES FOR ACUTE LEUKEMIA

GO-FLAG REGIMEN AS A BRIDGE THERAPY TO ALLOGENEIC STEM CELL TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS

THE IMPACT OF ALLOGENEIC TRANSPLANTATION IN AML AND MDS WITH CHROMOSOME 3 ABNORMALITIES

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS CHEMOTHERAPY-ALONE IN THE TREATMENT OF PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS WITH MIXED LINEAGE LEUKEMIA (MLL) REARRANGEMENTS: SINGLE CENTER EXPERIENCE

POSTTRANSPLANTATION BENDAMUSTINE FOR GVHD PROPHYLAXIS IN REFRACTORY ACUTE LEUKEMIA PATIENTS

IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE

FLAT REGIMEN AS MYELOABLATIVE CONDITIONING WITH LIMITED TOXICITIES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS IN 30 PATIENTS

TYROSINE KINASE INHIBITOR TREATMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR CYTOGENETIC INTERMEDIATE-RISK AML ACCORDING TO THE MOLECULAR RISK BASED ON ELN 2017 RISK STRATIFICATION SYSTEM; SINGLE CENTER EXPERIENCE IN KOREA

THE PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY WT1 GENE EXPRESSION IN PERIPHERAL BLOOD BEFORE AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN AML PATIENTS

IMPACT OF POSTTRANSPLANT TYROSINE KINASE INHIBITORS ADMINISTRATION ON LONG TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

THE INFLUENCE OF ANTI-THYMOCYTE GLOBULIN (ATG) ON THE OUTCOMES OF PATIENTS WITH AML W/WO MEASURABLE RESIDUAL DISEASE (MRD) AT THE TIME OF UNRELATED DONOR TRANSPLANTATION

MLL-AF6 FUSION GENE POSITIVE AML TREATED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION HAS EXCELLENT OVERALL SURVIVAL
Scientific Programme

BENEFICIAL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

INDUCTION OF SYNERGISTIC APOPTOSIS AND OVERCOMING OF DRUG RESISTANCE BY COTARGETING OF BCL-2 AND NA/H EXCHANGER 1 PATHWAY IN ACUTE MYELOID LEUKEMIA CELLS

GEMTUZUMAB-OZOGAMICIN FOR BRIDGING TO TRANSPLANT IN REFRACTORY/RELAPSED CD33 POSITIVE ACUTE LEUKEMIA - IS IT WORTHWHILE?

THE EFFECTS OF CYTOMEGALOVIRUS INFECTION ON TRANSPLANT OUTCOMES IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

AZACYTIDINE AND DONOR LYMPHOCYTES INFUSIONS IN RELAPSED AML AFTER ALLOGENEIC HSCT: RESULTS IN 40 PATIENTS

THE RESULTS OF AML RELAPSE AFTER ALLOGENEIC TRANSPLANTATION TREATMENT, SINGLE CENTRE APPROACH EVALUATION

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A SINGLE CENTER ANALYSIS

THE OPTIMAL TIME FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

IMPACT OF ABO MISMATCH ALLOGENEIC TRANSPLANT IN ACUTE MYELOID LEUKEMIA: A SINGLE CENTRE EXPERIENCE

DONOR SOURCE IMPACTS ON LONG TERM SURVIVAL FOLLOWING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN AML PATIENTS AGED 60 AND ABOVE

EXTRA-MEDULLARY RECURRENCE OF ACUTE MYELOID LEUKEMIA AS MYELOID SARCOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE SERIES

SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA: SINGLE CENTER EXPERIENCE

ALLOGENEIC STEM CELL TRANSPLANTS IN ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE EXPERIENCE

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA NOT RESPONDING TO FIRST INDUCTION THERAPY

Aplastic anaemia

LNP023 - A NEW ORAL COMPLEMENT FACTOR-B INHIBITOR NORMALIZES HEMOGLOBIN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH POOR RESPONSE TO ECULIZUMAB, BOTH AS ADD-ON AND MONOTHERAPY

EPIGENETIC AGING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH POOR SURVIVAL IN PATIENTS WITH SEVERE APLASTIC ANEMIA: RESULTS FROM DNA-METHYLATION GRIMAGE

GVHD AND RELAPSE FREE SURVIVAL (GRFS) AFTER ALLOGENEIC TRANSPLANTATION FOR IDIOPATHIC SEVERE APLASTIC ANEMIA: AN ANALYSIS FROM THE SAAWP DATA QUALITY INITIATIVE PROGRAM OF EBMT
OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANAEMIA: A STUDY ON BEHALF OF THE EBMT SAAWP AND PDWP

REDUCED INTENSITY CONDITIONING IS EFFECTIVE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND-BLACKFAN ANEMIA

PROSPECTIVE STUDY OF ECUILIZUMAB BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMOLYTIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA / APLASTIC ANEMIA

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT FOR FANCONI ANEMIA IN INDIA

ALTERNATE DONOR HSCT FOR 109 CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA: A SINGLE CENTER RETROSPECTIVE ANALYSIS

SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS WITH REFRACTORY ACTIVE INFECTION: A PROSPECTIVE MULTICENTER CLINICAL STUDY IN CHINA

INCIDENCE AND MANAGEMENT OF APLASTIC ANEMIA IN SPAIN (IMAS). AN AMBISPECTIVE STUDY OF BIODONOSTIA / PETHEMA

ALLOGENEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS FOR CHILDREN WITH APLASTIC ANEMIA

OUTCOME OF PEDIATRIC ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE

OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT FOR SEVERE APLASTIC ANEMIA IN PAKISTAN: DATA FROM A DEVELOPING COUNTRY

IMPACT OF CD34+-STEM CELL BOOST ON OUTCOME AND HEMATOLOGICAL RECONSTITUTION IN PATIENTS WITH SEVERE APLASTIC ANEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY

HEMATOPOIETIC STEM CELL TRANSPLANT IN ADULTS WITH ACQUIRED SEVERE APLASTIC ANEMIA

HEMATOPOIETIC STEM CELL TRANSPLANT IN FANCONI ANEMIA USING MATCHED RELATED AND HAPLOIDENTICAL DONORS- A SINGLE CENTRE EXPERIENCE

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC SEVERE APLASTIC ANEMIA: RESULTS OF A SINGLE CENTER

EFFECT OF SINGLE UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION ON APLASTIC ANEMIA IN CHILDREN

IMMUNOSUPPRESSIVE THERAPY IN PEDIATRIC APLASTIC ANEMIA, SINGLE CENTRE EXPERIENCE

CYCLOSPORINE, DANAZOL AND ROMIPLOSTIM IN SEVERE APLASTIC ANEMIA IN PRETRANSPLANT PERIOD: RETROSPECTIVE ANALYSIS OF FIVE CASES

Autoimmune diseases

AUTOLOGOUS NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR STIFF PERSON SYNDROME
BEAM VS CYCLOPHOSPHAMIDE-BASED CONDITIONING REGIMEN IN AGGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE ANALYSIS OF EUROPEAN BLOOD AND MARROW TRANSPLANTATION SOCIETY

A NOVEL TARGETED APPROACH TO ACHIEVE IMMUNE SYSTEM RESET: CD45-TARGETED ANTIBODY DRUG CONJUGATES AMELIORATE DISEASE IN PRECLINICAL AUTOIMMUNE DISEASE MODELS AND ENABLE AUTOHSCT

LONG TERM FOLLOW UP OF SYSTEMIC SCLEROSIS FRENCH PATIENTS INCLUDED IN THE ASTIS TRIAL USING SCOT TRIAL GLOBAL RANK COMPOSITE SCORE (GRCS)

ADVANCES IN MULTIPLE SCLEROSIS (MS) TREATMENT: CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION

POST TRANSPLANTATION CYCLOPHOSPHAMIDE IMPROVES OUTCOME AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ANIMAL MODEL OF MULTIPLE SCLEROSIS

THE LONG-TERM SAFETY AND EFFICACY OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS INDIRECTLY COMPARED TO ALEMUTUZUMAB: A SYSTEMATIC REVIEW

RECONSTITUTION OF NATURAL OR VACCINATION-DRIVEN IMMUNITY AFTER AHSCT IN MULTIPLE SCLEROSIS

HIGH-DOSE IMMUNODEPLETION WITH AUTOLOGOUS STEM CELL RESCUE FOR TREATMENT OF AGGRESSIVE MULTIPLE SCLEROSIS

HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT CHANGE THE EXPRESSION OF ENDOTHELIAL MARKERS IN SKIN BIOPSIES OF SYSTEMIC SCLEROSIS PATIENTS

AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NON HEMATOLOGICAL DISEASES. THE DUTCH EXPERIENCE OF MS PATIENTS GOING ABROAD

ANALYSIS OF COST AND CHARGES FOR NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES

AUTOLOGOUS STEM CELL TRANSPLANTATION IN BEHÇET’S DISEASE: A RETROSPECTIVE STUDY

SAFETY AND TOLERABILITY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE SCLEROSIS: A SINGLE CENTER EXPERIENCE

OUTCOME OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY TAKAYASU ARTERITIS, A RETROSPECTIVE SURVEY FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EBMT

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS IN NORWAY

THE USE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AH SCT) IN MULTIPLE SCLEROSIS AFTER ALEMUTUZUMAB TREATMENT FAILURE: A CASE SERIES

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF SYSTEMIC SCLEROSIS, AN OPTION FOR REFRACTORY PATIENTS

A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE
CAR-based Cellular Therapy - clinical

KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): RESULTS FROM PHASE 2 OF ZUMA-2

SAFETY AND EFFICACY RESULTS FROM TRANSCEND NHL 001, A MULTICENTER PHASE 1 STUDY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

CD19/CD22 DUAL TARGETED (CHIMERIC ANTIGEN RECEPTOR) CAR-T THERAPY FOR RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)

AN UPDATE OF THE EBMT SURVEY ON CAR T-CELL ACTIVITY IN EUROPE. ON BEHALF OF THE CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY (CTIWP)

THIRD-GENERATION CAR T CELLS WITHIN THE HEIDELBERG CAR TRIAL 1 (HD-CAR-1) DISPLAY AN EXCELLENT SAFETY PROFILE AND MIGHT IMPROVE PERSISTENCE OF CAR T CELLS

OUTPATIENT TREATMENT WITH LISOCABTAGENE MARALEUCEL IN 3 CLINICAL STUDIES OF RELAPSED/REFRACTORY LARGE B-CELL NHL, INCLUDING SECOND-LINE TRANSPLANT NONELIGIBLE PATIENTS: TRANSCEND NHL 001, OUTREACH, AND PILOT

CORRELATIVE ANALYSES OF PATIENT AND CLINICAL CHARACTERISTICS ASSOCIATED WITH EFFICACY IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE JULIET TRIAL

CAR T CELLS (CART) OR ALLOGENEIC TRANSPLANTATION (ALLOHCT) FOR MULTIPLY RELAPSED DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)? A RETROSPECTIVE INTENT-TO-TREAT (ITT) COMPARISON

HIGH ACTIVATION OF BCMA CAR-T CELLS CONTRIBUTES TO INCREASED RESPONSE RATE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

A COMPARISON OF 2-YEAR OUTCOMES IN ZUMA-1 (AXICABTAGENE CILOLEUCEL; AXI-CEL) AND SCHOLAR-1 IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL)

CD19-TARGETED CAR-T CELL THERAPY FOR 32 B-CELL ACUTE LYMPHOBlastic LEUKEMIA (B-ALL) PATIENTS WHO RELAPSED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)

INTERNATIONAL PROGNOSTIC INDEX PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED AND REFRACTORY LARGE DIFFUSE B CELL LYMPHOMA TREATED WITH COMMERCIAL CAR T CELLS

THE PHASE 1B PORTIA STUDY: SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

REAL-WORLD EVIDENCE OF THE USE OF TISAGENLECLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS. THE SPANISH EXPERIENCE

NATIONAL IMPLEMENTATION OF THE USE OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBlastic LEUKAEMIA (ALL) IN NATIONAL HEALTH SERVICE ENGLAND (NHSE)

REAL-WORLD CLINICAL FEATURES OF NEUROTOXICITY COMPLICATING CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR HIGH GRADE LYMPHOMA AND MANAGEMENT INCLUDING THE OFF-LABEL USE OF ANAKINRA
**Scientific Programme**

- **CORRELATIVE MARKERS OF TOXICITY IN PATIENTS WITH DLBCL TREATED WITH CD19 CAR T CELL THERAPY**

- **EARLIER STEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)**

- **ASSOCIATION OF AXI-CEL CAR-T CELL CONCENTRATION WITH TREATMENT RESPONSE AND SIDE EFFECTS AND IMPACT OF DEXAMETHASONE TREATMENT ON KINETICS**

- **SIMPLIFIED-EASIX (SEASIX) IS AN EARLY PREDICTOR OF SEVERE CYTOKINE RELEASE SYNDROME AND IMMUNE-EFFECTOR-CELLS-ASSOCIATED NEUROTOXICITY SYNDROME IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T CELLS**

- **NIVOLUMAB AS SALVAGE THERAPY IN PATIENTS WHO FAILED TO ACHIEVE COMPLETE REMISSION AFTER ANTI-CD19 CAR T-CELL THERAPY FOR DLBCL**

- **SURVEILLANCE OF MINIMAL RESIDUAL DISEASE (MRD) IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) BY CIRCULATING TUMOR DNA (CTDNA) PROFILING AFTER CHIMERIC ANTIGEN RECEPTOR T (CAR-T)**

- **A DIGITAL-PCR ASSAY FOR PRECISE IN-VIVO QUANTIFICATION OF ADOPTIVELY TRANSFERRED CD19-CAR T CELLS AFTER TREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)**

- **FEASIBILITY OF MANUFACTURING TISAGENLECLEUCEL IN PATIENTS LESS THAN 3 YEARS OF AGE WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA**

- **AXICABTAGENE CILOLEUCEL CD19 CAR T-CELLS FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: REAL-WORLD OUTCOMES, TOXICITY AND PREDICTORS OF RESPONSE FROM A PROSPECTIVE UK COHORT**

- **MARKERS OF INITIAL AND LONG-TERM RESPONSES TO IDEcabtagene Vicleucel (IDE-CEL; BB2121) IN THE CRB-401 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA**

- **SINUSOIDAL OBSTRUCTION SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) TREATED WITH ARI-0001 CELLS**

- **HUMORAL IMMUNE RESPONSE IN PATIENTS WITH CD19-POSITIVE RELAPSED/REFRACTORY B-CELL MALIGNANCIES RECRUITED INTO THE CART19-BE-01 CLINICAL TRIAL, AN ACADEMIC CAR19 REAL-WORLD DATA FROM KINGS COLLEGE HOSPITAL: INFECTION COMPLICATIONS POST CAR-T TREATMENT IN HIGH-GRADE B CELL NON-HODGKIN LYMPHOMA**

- **SENEGMENTED/EXHAUSTED PHENOTYPE OF CD19-TARGETED CAR-T CELLS AND IMMUNOREGULATORY ENVIRONMENT CORRELATE WITH REDUCED RESPONSE TO CAR-T CELL THERAPY IN RELAPSED/REFRACTORY B CELL MALIGNANCIES**

- **CHARACTERISATION OF EARLY AND LATE CYTOPENIAS IN LYMPHOMA PATIENTS FOLLOWING TREATMENT WITH ANTI-CD19 CAR-T THERAPY**

- **CD4+ CAR-T CELLS MAINTAIN MEMORY PHENOTYPES AND MEDIATE LONGER-TERM ANTITUMOR ACTIVITY IN VIVO**

- **IMPACT OF ETHNICITY IN R/R DLBCL AND B-CELL ALL PATIENTS TREATED WITH TISAGENLECLEUCEL**

- **IMPACT OF DIFFERENT CHEMOTHERAPY REGIMENS AND DURATION OF DLBCL ON LYMPHOPHERESIS AND CAR-T T-CELL IMMUNOPHENOTYPING**

- **CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY IMPROVE PROGRESSION FREE SURVIVAL IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA**
CHALLENGES IN PROVIDING GOOD LEUKAPHERESIS PRODUCTS FOR THE PRODUCTION OF CAR T CELLS FOR PATIENTS WITH RELAPSED/REFRACTORY NHL OR ALL

NKG2D CAR T CELLS ARE NOT AFFECTED BY SOLUBLE NKG2D LIGANDS

EMERGING CYTOKINE RELEASE SYNDROME IS ASSOCIATED WITH REDUCTION OF CD4+CD25HIGH127DIM T REGULATORY CELLS IN PATIENTS AFTER CAR T CELL THERAPY

EXCELLENT PROLIFERATION AND PERSISTENCE OF ALLOGENEIC CAR-T CELLS DESPITE IMMUNOSUPPRESSION WITH CYCLOSPORINE A

A FRENCH BIOBANKING NETWORK TO CREATE A UNIQUE COLLECTION OF SAMPLES OF PATIENTS TREATED WITH CAR-T CELLS

CAR T CELL THERAPY DIRECTED AGAINST CD19 IN PATIENTS WITH B-CELL LYMPHOMA AFTER AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IS FEASIBLE AND SAFE

LYMPHOCYTE COLLECTION FOR GENERATION OF CAR T-CELLS IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE

BASELINE HYPOALBUMINEMIA DOES NOT APPEAR TO BE AN ADVERSE PROGNOSTIC FACTOR IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMAS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)

FACTORS PREDICTING CD3+ COLLECTION FOR THE PRODUCTION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS

CYTOPENIAS AFTER TISAGENLECLEUCEL IN PAEDIATRIC/YOUNG ADULT PATIENTS WITH REFRACTORY/RELAPSE B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL): A REAL-LIFE SINGLE-CENTRE EXPERIENCE

THE RISK OF HEPATITIS B REACTIVATION IS CONTROLLABLE IN B-CELL MALIGNANCIES PATIENTS WITH CONCOMITANT HEPATITIS B VIRUS INFECTION AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY

CUMULATIVE RITUXIMAB EXPOSURE PRIOR TO AXICABTAGENE CILOLEUCEL IS NOT ASSOCIATED WITH PERSISTENT LEUKOPENIA AND THROMBOCYTOPENIA AT DAY +90 POST INFUSION

COMPREHENSIVE IMMUNE CELL MONITORING REVEALS AN ALTERED LYMPHOCYTE SUBSET PHENOTYPE IN PATIENTS NOT RESPONDING TO TISAGENLECLEUCEL ONE MONTH POST INFUSION

NEUROTOXICITY ASSOCIATED WITH CAR T CELL THERAPY: NEUROLOGICAL MANAGEMENT AND WORK-UP OF 11 ADULT PATIENTS

NUTRITIONAL ASSESSMENT OF PATIENTS UNDERGOING CD19-TARGETED CAR-T THERAPY FOR NON-HODGKIN’S LYMPHOMA AND THE SHORT TERM EFFECT OF TREATMENT ON NUTRITIONAL STATUS

EFFECTIVENESS OF AUTOLOGOUS LEUKAPHERESIS COLLECTIONS FOR CAR T-CELL MANUFACTURING IN PATIENTS WITH B-CELL MALIGNANCIES

DEFINITION AND IMPLEMENTATION OF CLINICAL AND QUALITY ENDPOINTS IN CENTERS ADMINISTERING A COMMERCIAL CAR-T PRODUCT

CAR-T IN BREAST AND OTHER EXTRA-MEDULLARY RELAPSED/REFRACTORY ALL

PREDICTING CAR T-CELL INFUSION AFTER SUCCESSFUL MANUFACTURING: REAL-WORLD DATA
EVALUATION OF THE INTEREST OF A DRUG RECONCILIATION ACTIVITY IN PATIENTS TREATED WITH CAR T-CELLS: A DESCRIPTIVE STUDY

**e-Posters**
09:30 - 18:00  ePoster Area

**CAR-based Cellular Therapy - preclinical**

MODULATION OF CYTOSOLIC CA\(^{2+}\) REGULATES CAR-T CELL DIFFERENTIATION AND THERAPEUTIC POTENCY

BREAKING PD-L1-MEDIATED RESISTANCE IN ANTI-CD19 AND ANTI-CD22 CAR T CELLS WITH PD-1/CD28 FUSION RECEPTORS

ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR-INVARIANT NATURAL KILLER T CELLS EXERT BOTH DIRECT AND INDIRECT ANTITUMOR EFFECTS THROUGH HOST CD8 T CELL CROSS-PRIMING

DUVELISIB GENERATES CAR T CELLS WITH ENHANCED MITOCHONDRIAL BIOGENESIS AND REDUCED EXPRESSION OF PD-1, TIM-3, AND LAG-3, ENABLING GREATER ANTI-LEUKEMIA CYTOTOXICITY AGAINST CLL

NK2G2D CHIMERIC ANTIGEN RECEPTOR-EXPRESSING LYMPHOCYTES TARGET ACUTE MYELOID LEUKEMIA CELLS

CLINICAL-GRADE MANUFACTURING OF ROR1 CAR T-CELLS USING A NOVEL VIRUS-FREE PROTOCOL

LENTIVIRALLY AND ALPHARETROVIRALLY ENGINEERED CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS ARE HIGHLY CYTOTOXIC AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA

NOVEL STRATEGIES TO ENHANCE THE SAFETY OF CAR T-CELL IMMUNOTHERAPY: THE IMSAVAR PROJECT

ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD NK CELLS ARE GOOD SOURCES FOR EFFECTIVE CAR THERAPY AGAINST CD19 POSITIVE LEUKEMIC CELLS

ENHANCEMENT OF CYTOTOXICITY, EXPANSION AND PERSISTENCE OF CD19 CAR-T CELLS VIA PRE-SENSITIZATION OF B CELL MALIGNANCIES BY BCL-2 SELECTIVE INHIBITORS

TYROSINE KINASE INHIBITOR FOLLOWED BY CART THERAPY FOR THE TREATMENT OF RELAPSED PHILADELPHIA CHROMOSOME-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

**Cellular Therapies other than CARs**

CTLA4IG PRIMED SEQUENTIAL DLI IMPROVES GVHD AND RELAPSE-FREE SURVIVAL COMPARED TO UNPRIMED DLI IN PATIENTS UNDERGOING PTCY-BASED HAPLOIDENTICAL HCT FOR ADVANCED HEMATOLOGICAL MALIGNANCIES

HLA-MISMATCHED MOBILIZED CELLULAR THERAPY (MICROTTRANSPLANT, MST) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH PTCY: A STUDY ON BEHALF OF THE CTIWP OF THE EBMT

SAFETY, EFFECTIVENESS AND PERSISTENCE OF LOW-DOSE DONOR MEMORY T CELL INFUSIONS AFTER AB T CELL-DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION

PROPHYLACTIC DONOR LYMPHOCYTE INFUSION AFTER T-CELL-REPLETE ALLOGENEIC HSCT PREVENTS DISEASE RELAPSE AND PROLONGS SURVIVAL IN PATIENTS WITH HIGH-RISK ACUTE LEUKEMIA

BASELINE IMMUNE STATUS PREDICTS RESPONSE TO ADOPTIVE THERAPY WITH CMV CTLS FOR REFRACTORY CMV

EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY ON BEHALF OF GETH (GRUPO ESPANOL TRASPLANTE HEMATOPOYETICO)

PHASE I STUDY OF ADOPTIVE TRANSFER OF HAPLOIDENTICAL EXPANDED NK CELLS

OFF-TARGET HLA CROSS-REACTIVITY BY (THIRD PARTY) VIRUS-SPECIFIC T CELLS IS SURPRISINGLY AFFECTED BY HLA RESTRICTION AND HLA BACKGROUND BUT NOT BY VIRUS SPECIFICITY

ADOPTIVE IMMUNOTHERAPY OF REFRACOTORY VIRAL INFECTIONS AFTER ALLOGENEIC HSCT: AN ACADEMIC NETWORK FRAMING THE USE OF AN ATMP UNDER HOSPITAL EXEMPTION

HOW TO BENEFIT FROM EXHAUSTION: PATIENT-DERIVED INHIBITED T CELLS AS A NOVEL SOURCE OF TUMOR-REACTIVE T CELL CLONES

EFFICIENT CRISPR/CAS9-MEDIATED INACTIVATION OF THE GLUCOCORTICOID RECEPTOR FOR ANTIGEN-SPECIFIC T-CELL IMMUNOTHERAPY

COMPARISON OF OUTCOME POST-SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION VERSUS DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS

AUTOMATED APPLICATION FOR DEPLETION OF TCRαβ+, CD19+ AND CD45RA+ CELLS FROM APHERESIS PRODUCTS USING THE CLINIMACS PRODIGY (R)

THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES

GOOD RESPONSE RATES OF WJ-MSC, COMPARABLE TO BM-MSC, IN THE TREATMENT OF REFRACTORY GVHD

AN ‘ALL IN ONE’ T-CELL PRODUCT FROM NON-TRANSPLANTABLE CORD BLOOD UNITS FOR VIRUS- AND LEUKEMIA-SPECIFIC T-CELL IMMUNOTHERAPY

CLINICAL SUCCESS OF GRANULOCYTE TRANSFUSIONS IN ADULT NEUTROPENIC PATIENTS AFTER CHEMOTHERAPY AND/OR ALLOGENEIC TRANSPLANTATION - TIME MATTERS!

IMPACT OF LONG-TERM CRYOPRESERVATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS PRODUCTS

OPTIMIZING LENTIVIRAL VECTOR TRANSDUCTION TO GENE MODIFY CORD BLOOD CD8+ T CELLS FOR OFF-THE-SHELF ADOPTIVE THERAPY TO TREAT CANCER

DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTRE EXPERIENCE

CASE REPORT: CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION (CAEBV) CONTROLLED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) AND TRANSFUSION OF EBV-SPECIFIC T-CELLS
e-Posters
09:30 - 18:00
ePoster Area

**Chronic leukaemia and other myeloproliferative disorders**

- **TIMING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A JOINT STUDY FROM THE INTERNATIONAL MDS/MPN WORKING GROUP AND EBMT**

- **RELAPSE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IN THE PATHWAY INHIBITOR (PI) ERA: NO LONGER A DEAD-END STREET**

- **THE 10-YEARS <u>E</u>BMT <u>L</u>ANDSCAPE OF <u>A</u>LLLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) FOR <u>C</u>HRONIC LYMPHOCYTIC LEUKEMIA**

- **DETERMINANTS OF SURVIVAL IN MYELOFIBROSIS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY BY THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT**

- **SPLENECTOMY DOESN'T PRECLUDE SUBSEQUENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MYELOFIBROSIS PATIENTS: A FRENCH NATIONWIDE STUDY USING A MULTISTATE MODEL**

- **INCIDENCE OF LATE RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS**

- **HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: THE EXPERIENCE OF THREE UNIVERSITY TRANSPLANT CENTRES IN ROME**

- **AUSTRALASIAN TRENDS IN ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS IN MOLECULAR ERA**

- **CML RELAPSE AFTER ALLOGENEIC HSCT: SURVIVAL, TREATMENT EFFICACY AND PROGNOSTIC FACTORS FOR OUTCOME**

- **CHRONIC MYELOID LEUKEMIA: ALLOGENEIC HEMOPOIETIC STEM CELLS TRANSPLANTATION IN THE ERA OF TYROSYNE KINASE INHIBITORS**

- **REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT WITH CAMPATH T-CELL DEPLETION FOR MYELOFIBROSIS IN THE ERA OF JAK INHIBITORS- A SINGLE CENTRE EXPERIENCE**

- **ALLOGENIC STEM CELL TRANSPLANTATION IN ADVANCED SYSTEMIC MASTOCYTOSIS AFTER CYTOREDUCTIVE TREATMENT WITH CLADRIBINE - A SINGLE CENTER EXPERIENCE ON TWO PATIENTS**

- **ALLOGENEIC STEM CELL TRANSPLANTATION FOR IDIOPATIC MYELOFIBROSIS: A SINGLE CENTRE EXPERIENCE**

- **A CASE OF SUCCESSFUL SECOND HAPLOIDENTICAL BONE MARROW TRANSPLANTATION AFTER SECONDARY GRAFT FAILURE IN A PATIENT WITH REFRACTORY CHRONIC MYELOID LEUKEMIA**

---

**Conditioning regimens**

---

Page 317 / 353

POPULATION PHARMACOKINETIC ESTIMATION OF ATG EXPOSURE PREDICTS IMMUNE RECONSTITUTION AND SURVIVAL IN ADULTS UNDERGOING EX VIVO CD34-SELECTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

FLAMSA-BASED REDUCED INTENSITY CONDITIONING VERSUS MYELOABLATIVE CONDITIONING IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH ACTIVE DISEASE AT THE TIME OF TRANSPLANTATION: AN ALWP/EBMT ANALYSIS

TOTAL BODY IRRADIATION/FLUDARABINE VERSUS THIOTEPA/BUSULFAN/FLUDARABINE FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH HAPLOIDENTICAL HCT. A STUDY BY ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

BUSULFAN-CYCLOPHOSPHAMIDE VERSUS CYCLOPHOSPHAMIDE-BUSULFAN AS CONDITIONING REGIMEN BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A PROSPECTIVE RANDOMIZED TRIAL

RABBIT ANTI-THYMOCYTE GLOBULIN (ATG) EXPOSURE AFTER EX VIVO T-CELL-DEPLETED HEMATOPOIETIC CELL TRANSPLANTATION IS VARIABLE AND IMPACTS IMMUNE RECONSTITUTION AND SURVIVAL IN CHILDREN AND YOUNG ADULTS

A RETROSPECTIVE COMPARATIVE STUDY OF BEAM VS FEAM VS TEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT

REDUCED INTENSITY VERSUS MYELOABLATIVE CONDITIONING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS < 60 WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTI-CENTER CANADIAN EXPERIENCE

COMBINING CLOfarABINE AND FLUDARABINE WITH EXPOSURE TARGETED BUSULFAN FOR PEDIATRIC LEUKEMIA: AN EFFECTIVE, LOW TOXIC, TBI-FREE CONDITIONING REGIMEN

BENDA-BEAM HIGH-DOSE THERAPY PRIOR TO AUTO-SCT IS EFFECTIVE IN RESISTANT/RELAPSED DLBCL: A PHASE II STUDY

REDUCED-TOXICITY CONDITIONING WITH FLUDARABINE, THIOTEPA AND MELPHALAN IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH IMPAIRED LUNG FUNCTION

ALLOGENEIC STEM CELL TRANSPLANT WITH MINIMAL-INTENSITY CONDITIONING IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA: A SINGLE CENTRE RETROSPECTIVE REVIEW

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT

A PROSPECTIVE COHORT STUDY COMPARING LONG-TERM OUTCOMES WITH AND WITHOUT PALIFERMIN IN PATIENTS RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES

PHARMACOKINETICS OF MELPHALAN IN LYMPHOMA PATIENTS UNDERGOING BEAM AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT

MELPHALAN IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION: DOES ONE SIZE FIT ALL?

COMPARISON OF TOTAL BODY IRRADIATION- VS CHEMOTHERAPY-BASED CONDITIONINGS FOR EARLY COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ALL
DIFFERENTIAL ALEMTUZUMAB DOSAGES IN T-CELL DEPLETE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTS FOR MYELOID MALIGNANCIES

THE INFLUENCE OF TDM ON ACHIEVING BUSULFAN TARGET EXPOSURE AND RELATED DETERMINANTS, IN BOTH CHILDREN AND ADULTS WHO UNDERWENT AN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

NOVEL REDUCED INTENSITY CONDITIONING (RIC) APPROACH TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH BENIGN AND MALIGNANT DISORDERS OF T CELL PROLIFERATION OR DYSREGULATION

PROFOUND LYMPHOPENIA AT THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION IS NOT PREDICTIVE OF SURVIVALS AFTER ALLO-TRANSPLANTATION

LIPID CORE NANOPARTICLES AS VEHICLE FOR ETOPOSIDE IN THE CONDITIONING REGIMEN OF MARROW TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA NOT RESPONDING TO INDUCTION THERAPY: A PILOT STUDY

A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF SHORT-TERM EVEROLIMUS IN ADDITION TO POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-EVER)

ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS ≥ 65 YEARS WITH HEMATOLOGICAL MALIGNANCIES AFTER MYELOABLATIVE TREOSULFAN-BASED CONDITIONING: RESULTS IN 118 PATIENTS

BUTYRYLCHOLINESTERASE ACTIVITY AFTER CYCLOPHOSPHAMIDE CONDITIONING AS A PREDICTIVE MARKER OF LIVER TRANSPLANT-RELATED COMPLICATIONS AND ITS CORRELATION WITH TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS

FLUDARABINE-MELPHALAN CONDITIONING RESULTS IN FAVORABLE LEUKEMIA-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH ACTIVE OR MEASURABLE RESIDUAL AML

SEQUENTIAL CONDITIONING: FLAMSA-TBI VERSUS FLAMSA-TREO IN HIGH RISK ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS)

INCREASED NON-RELAPSE MORTALITY AND POOR OVERALL SURVIVAL IN ELDERLY PATIENTS TREATED WITH FLUDARABINE AND MYELOABLATIVE DOSE OF BUSULFAN: TRANSPLANT COMPLICATIONS WORKING GROUP OF THE JSHCT

TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE IMPROVES THE OUTCOME OF PATIENTS WITH POOR-RISK ACUTE LEUKEMIA

A CD45-TARGETED ANTIBODY DRUG CONJUGATE ENABLES ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS A SINGLE AGENT IN MICE

INFLUENCE OF THE CELL SOURCE TYPE AND CONDITIONING TYPE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME

PRECONDITIONING INTENSITY IMPACTS ON IMMUNE RECONSTITUTION AND OUTCOMES FOLLOWING CORD BLOOD TRANSPLANTATION

FINAL RESULTS OF A PROSPECTIVE, MULTICENTER, NON-INTERVENTIONAL STUDY ON THIOTEPA-BASED AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (ASCT) FOR CNS OR NON-CNS LYMPHOMA

POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY), CYCLOSPORIN (CSA) AND MYCOPHENOLATE (MMF) FOR PATIENTS GRAFTED FROM HLA IDENTICAL SIBLINGS OR MATCHED UNRELATED DONORS
COMPARISON OF FLUDARABINE + BUSULFAN AND FLUDARABINE+BUSUFAN+ LOW-DOSE ATG CONDITIONING REGIMENS IN PATIENTS WITH MYELOID MALIGNANCIES WHO HAD ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE

CONDITIONING REGIMEN COMPARISON FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-HODGKIN LYMPHOMA

PK-GUIDED BUSULFAN CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) WITH PTCY AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES

A THIOTEPA BASED INTENSIFIED REDUCED INTENSITY CONDITIONING REGIME IN ADULT CORD BLOOD TRANSPLANT IS A PROMISING ALTERNATIVE IN PATIENTS UNABLE TO RECEIVE MYELOABLATIVE CONDITIONING

HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE USING AS CONDITIONING FLUDARABINE MELPHALAN PLUS LOW DOSES OF TOTAL BODY IRRADIATION. LONG TERM FOLLOW-UP OF 60 PATIENTS

TRESULFAN-BASED CONDITIONING IN PAEDIATRIC T-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE

COMPARISON OF BEAM AND TEAM AS CONDITIONING REGIMEN FOR LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

ASSESSMENT OF THE SAFETY AND EFFICACY OF THE CONDITIONING REGIMEN BEEAC BEFORE AUTO-HSCT FOR THE TREATMENT OF PRIMARY-REFRACTORY AND RELAPSED FORMS OF MALIGNANT LYMPHOMAS

ALLOGENEIC STEM CELL TRANSPLANTATION AFTER TOTAL-BODY IRRADIATION USING HELICAL TOMOTHERAPY: A SINGLE CENTER EXPERIENCE

FEASIBILITY OF CLAMSA-RIC AS AN ALTERNATIVE CONDITIONING REGIMEN COMPARED TO FLAMSA-RIC IN HEAVILY PRETREATED REFRACTORY AML PATIENTS - A RETROSPECTIVE SINGLE CENTER ANALYSIS

THIOTEPA, BUSULPHAN AND FLUDARABINE CONDITIONING IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA

FLAMSA-BASED HIGH-DOSE SEQUENTIAL CONDITIONING REGIMEN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): IS IT EFFECTIVE IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED ACUTE LEUKEMIA?

INCREASING IN SERUM TOTAL AMYLASE LEVELS AFTER TOTAL BODY IRRADIATION CONDITIONING REGIMEN AS A PREDICTIVE MARKER OF TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS

EVOlUTION OF DONOR CHIMERISM AFTER HAPLOIDENTICAL STEM CELL TRANSPLANT - CLINICAL CORRELATIONS

THIOTEPA-BUSULFAN-FLUDARBINE AS CONDITIONING REGIMEN FOR PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

THE RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA-HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE REGIMEN IN CHILDREN

ANALYSIS OF DIFFERENCES IN PREVENTIVE MEASURES AFTER HIGH-DOSE CYCLOPHOSPHAMIDE AMONG BELGIAN STEM CELL TRANSPLANT CENTRES
IRRADIATION-FREE RE-CONDITIONING FOR T-CELL DEPLETED HAPLO-IDENTICAL STEM CELL TRANSPLANTATION

LOW GRAFT CD4 CELL DOSE PREDICTS RELAPSE IN THE ATG-BASED MYELOABLATIVE CONDITIONING REGIMEN

CLINICAL EFFICACY OF HAPLOID TRANSPLANTATION WITH BU/CY/MEL PRETREATMENT SCHEME TO IMPROVE 68 CASES OF UNICENTRIC REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA

REDUCING INTENSITY CONDITIONING (RIC) PROTOCOL HARMONISATION IN THE UK

HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN HIGH-RISK HEMATOLOGICAL MALIGNANCIES, ALGERIAN EXPERIENCE

INTERRUPTION OF CONDITIONING FOR ALLO-HCT DOES NOT AFFECT CLINICAL OUTCOMES OTHER THAN CHRONIC GVHD

THERAPEUTIC DRUG MONITORING OF BUSULFAN IN PEDIATRIC POPULATION

REDUCED INTENSITY CONDITIONING FOLLOWED BY HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION (RIC-HAPLOHCT) AND POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS, FOR HEMATOLOGICAL DISORDERS: SINGLE CENTRE EXPERIENCE

HIGH DOSE TREATMENT WITH LEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION DURING THE SHORTAGE OF MOSTLY USED AGENTS IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA

REDUCED DOSE ALEMTUZUMAB IN REDUCED INTENSITY CONDITIONING VOLUNTEER DONOR UNRELATED TRANSPLANT FOR MYELOID MALIGNANCIES IS SAFE AND EFFICACIOUS. A SINGLE CENTRE EXPERIENCE

DESCRIBE AND EXPLORE A PATIENTS’ OUTLOOK ON DENTAL CARE IN THE CONTEXT OF THEIR MEDICAL DIAGNOSIS AND TREATMENT PRIOR TO AND FOLLOWING ALLOGENEIC HSCT

SAFETY AND EFFICACY OF LOW-DOSE BENDA-EAM AS COMPARED TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION OF REFRACTORY/RELAPSED LYMPHOMA PATIENTS

CONDITIONING REGIMEN WITH FLUDARABIN/TREOSULFAN COMPARED TO BUSULFAN/CYCLOPHOSPHAMID PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN YOUNGER PATIENTS WITH AML AND MDS: A SINGLE CENTER RETROSPECTIVE ANALYSIS

OUTCOMES OF UNRELATED DONOR STEM CELL TRASPLANTATION WITH OR WITHOUT ANTI-THYMOCYTE GLOBULIN USED AS GRAFT-VERSUS HOST DISEASE (GVHD) PROPHYLAXIS: A SINGLE CENTER EXPERIENCE

BUSULFAN-FLUDARABINE CONDITIONING REGIMEN FOR CORD BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE TWO-CENTER STUDY

ATG IN CONDITIONING FOR SIBLING ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE
Scientific Programme

CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT β-THALASSEMIA

LENTIVIRAL HEMATOPOIETIC STEM AND PROGENITOR CELL GENE THERAPY (HSPC-GT) FOR METACHROMATIC LEUKODYSTROPHY (MLD): CLINICAL OUTCOMES FROM 33 PATIENTS

A SINGLE DOSE OF SHORT HALF-LIFE CD117 ANTIBODY DRUG CONJUGATE ENABLES HEMATOPOIETIC STEM CELL BASED GENE THERAPY IN NONHUMAN PRIMATES

LENTI-D HEMATOPOIETIC STEM CELL GENE THERAPY STABILIZES NEUROLOGIC FUNCTION IN BOYS WITH CEREBRAL ADRENOLEUKODYSTROPHY

SAFETY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH GENE ADDITION THERAPY FOR TRANSFUSION-DEPENDENT β-THALASSEMIA, SICKLE CELL DISEASE, AND CEREBRAL ADRENOLEUKODYSTROPHY

EX-VIVO AUTOLOGOUS HAEMATOPOIETIC STEM CELL GENE THERAPY IN MUCOPOLYSACCHARIDOSIS TYPE IIIA

e-Posters
09:30 - 18:00
ePoster Area

Graft-versus-host disease - clinical

KD025 FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) - LONG-TERM FOLLOW-UP OF A PHASE 2A STUDY (KD025-208)

A PHASE 2 STUDY OF F-652, A NOVEL TISSUE-TARGETED RECOMBINANT HUMAN INTERLEUKIN-22 (IL-22) DIMER, FOR TREATMENT OF NEWLY DIAGNOSED ACUTE LOWER GI GVHD

THE MAGIC BIOMARKER ALGORITHM PREDICTS OUTCOMES FOR CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE

A NOVEL TREATMENT IN CHRONIC OCULAR GRAFT-VS-HOST DISEASE (OGVHD): A PHASE II CLINIC TRIAL WITH TRANSDERMAL PROGESTERONE

EARLY CD4+ T-CELL RECONSTITUTION IS AN EXCELLENT PREDICTOR OF OUTCOMES IN PEDIATRIC PATIENTS WHO DEVELOP MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST-DISEASE: A DUAL CENTER VALIDATION

EFFECT OF SINGLE OR DOUBLE MISMATCHES AT EACH HLA LOCUS ON THE OUTCOMES AFTER SINGLE CORD BLOOD TRANSPLANTATION: THE JSHCT HLA WG STUDY

INTERIM ANALYSIS OF KD025-213: A PHASE 2, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KD025 IN SUBJECTS WITH CGVHD (THE ROCKSTAR STUDY)

ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) AND RITUXIMAB FOR IMMUNOMODULATION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT FAILURE IN PATIENTS WITH NON-MALIGNANT DISORDERS: RESULTS OF A MULTICENTRE, RANDOMIZED, OPEN-LABEL STUDY

EXPERIENCE USING DUAL T-CELL DEPLETION WITH ATG AND PTCY FOR GVHD PROPHYLAXIS IN RIC ALLOHCT USING IN 10/10 MATCHED RELATED AND UNRELATED DONORS

MACHINE LEARNING APPLIED TO THE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE IMPROVES SURVIVAL ESTIMATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
SINGLE-CELL MOLECULAR ANALYSIS DEFINES CHARACTERIZATION OF SPECIFIC T CELL SUBSETS CORRELATE WITH HUMAN CHRONIC GVHD AND BRONCHIOLITIS OBLITERANS

A PHASE II TRIAL EVALUATING THE USE OF THE HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PREVENTION

REDUCED CALCIUM SIGNALING IS ASSOCIATED WITH GVHD: RESULTS FROM PRECLINICAL ALLOSCT MODELS AND FROM A PROSPECTIVE MULTICENTER STUDY

IDENTIFICATION OF PREDICTIVE MODELS INCLUDING POLYMORPHISMS IN CYTOKINES GENES ASSOCIATED WITH ACUTE GRAFT VERSUS HOST DISEASE AND OVERALL SURVIVAL AFTER IDENTICAL HLA-ALLOGENEIC STEM-CELL TRANSPLANTATION

SEARCH FOR CIRCULATING ENDOThelial CELLS OF DONOR ORIGIN AFTER ALLO-HSCT: POTENTIAL CLINICALLY RELEVANT IMPLICATIONS IN THE CONTEXT OF GRAFT-VERSUS-HOST DISEASE

DOUBLE LUNG TRANSPLANTATION IN ADULTS FOR CHRONIC PULMONARY GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

REDUCED INFLAMMATORY TISSUE INFILTRATION DURING INTESTINAL STEROID-REFRACTORY GVHD

IMPACT OF ANTITHYMOCYTE GLOBULIN DOSE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN STEM CELL TANSPPLANTATION FROM UNRELATED DONORS

DECREASED SOLUBLE HLA-E LEVELS IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ARE ASSOCIATED WITH SEVERE ACUTE AND EXTENDED CHRONIC GRAFT-VERSUS-HOST DISEASE AND INFERIOR OVERALL SURVIVAL

EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON PRODUCTION OF SERUM SOLUBLE CD163: RELATIONSHIP TO IMMUNOSUPPRESSION AND DISEASE ACTIVITY IN CHRONIC GRAFT VERSUS HOST DISEASE

POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE OVERCOMES THE DETRIMENTAL EFFECT OF A SINGLE-LOCUS HLA MISMATCHED IN UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

ALLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS FROM HAPLOIDENTICAL AND MATCHED DONORS: ‘SIR-PTC’ RESULTS IN 249 PATIENTS

A NEW HOPE IN THE TREATMENT OF STEROID-REFRACTORY GRAFT VERSUS HOST DISEASE (SR-GVHD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSC): RUXOLITINIB

AZACITIDINE IS SAFE AND ACTIVE IN THE TREATMENT OF STEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST-DISEASE - INTERIM RESULTS OF THE PHASE II AZTEC TRIAL

BASILIXIMAB AS TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

EFFICACY AND TOLERANCE OF NILOTINIB IN PATIENTS WITH REFRACTORY CHRONIC GVHD WHO ARE REFRACTORY/INTOLERANT TO IMATINIB: A PROSPECTIVE MULTICENTER PHASE II STUDY OF THE SFGM-TC

EVALUATION OF THE PROGNOSTIC VALUE OF HISTOLOGIC ASSESSMENT OF ACUTE GRAFT-VERSUS-HOST-DISEASE OF THE UPPER GASTROINTESTINAL TRACT ACCORDING TO LERNER EARLY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
CYCLOSPORINE A ALONE VERSUS MYCOPHENOLATE MOFETIL PLUS CYCLOSPORINE A BASED GVHD PROPHYLAXIS FOR PATIENTS WITH AML UNDERGOING MUD TRANSPLANTATION. A STUDY FROM THE ALWP

TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS INDEPENDENTLY ASSOCIATED WITH RUXOLITINIB ADMINISTRATION IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE

DIAGNOSTIC SIGNIFICANCE OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD)

LONG TERM OUTCOMES OF RUXOLITINIB THERAPY IN STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN AND ADULTS

INVESTIGATING ANTIBIOTIC EXPOSURE AND RISK OF SEVERE ACUTE GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EFFICACY AND TOXICITY OF RUXOLITINIB IN PATIENTS WITH STEROID-RESISTANT ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION

PATIENT CHARACTERIZATION AND SURVIVAL OUTCOMES IN PAEDIATRIC CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS: A POPULATION-BASED STUDY IN SWEDEN

CYTOKINE LEVELS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION: A MATCH-PAIR ANALYSIS OF HOME CARE VERSUS HOSPITAL CARE

FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH STEROID-RESISTANT GRAFT VERSUS HOST DISEASE COLONIZED BY ANTIBIOTIC-RESISTANT BACTERIA - SINGLE-CENTER ANALYSIS OF 15 PROCEDURES

INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE: RESULTS FROM A PROSPECTIVE MULTICENTRE ANALYSIS OF 2 COHORTS

THE CXCL9 POLYMORPHISM RS884304 COUNTERACTS CALCINEURIN-INHIBITOR REPRESSION OF EARLY CXCL9 RECONSTITUTION AND ASSOCIATES WITH SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE

EARLY INTRODUCTION OF RUXOLINITIB FOR CHILDREN WITH GRAFT VERSUS HOST DISEASE - A STITCH IN TIME SAVES NINE

POST-TRANSPLANT CYCLOPHOSPHAMIDE AS AN EFFECTIVE STRATEGY FOR GVHD PREVENTION IN BOTH HLA-MATCHED AND MISMATCHED ALLOGENEIC TRANSPLANTS

SERUM AUTOANTIBODIES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY

OPTIMIZED STARTING DOSE OF CYCLOSPORINE REDUCES RISK OF ACUTE GVHD AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

SUCCESS OF IMMUNOSUPPRESSION IN PATIENTS WITH CHRONIC GVHD: ANALYSIS ON 108 ADULT LONG-TERM SURVIVORS AFTER MATCHED AND HAPLO HSCT

INCIDENCE AND OUTCOME OF LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE DURING TAPERING OR AFTER STOPPING CALCINEURIN INHIBITORS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING AND MATCHED UNRELATED COMPARED TO HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, A STUDY ON BEHALF OF GETH
Scientific Programme

MESENCHYMAL STROMAL CELLS (MSC) FOR STEROID-REFRACTORY ACUTE GVHD, A SINGLE CENTER PHASE I/II TRIAL

T-LYMPHOCYTE TRANSCRIPTIONAL SIGNATURE IN ECP-TREATED PAEDIATRIC PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE

EFFICACY OF LOW-DOSE RUXOLITINIB AS SAVAGE THERAPY IN HEAVILY PRETREATED PATIENTS WITH MODERATE/SEVERE STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE

RESTRICTIVE USE OF INTRAVENOUS ANTIBIOTICS IN ALLOGENEIC SCT PTS WITH FEVER DUE TO CYTOKINE RELEASE SYNDROME ALLOWS MICROBIOTA PROTECTION WITHOUT INCREASE OF INFECTIONS AND TRM

EXTRACORPOREAL PHOTOPHERESIS (ECP) AS FIRST-LINE TREATMENT FOR ACUTE GVHD (AGVHD) IN PEDIATRIC PATIENTS WHO UNDERWENT T-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION (APLO-HSCT)

EFFICACY OF METHOXSALEN STERILE SOLUTION IN CONJUNCTION WITH THE THERAKOS (R) CELLEX (R) PHOTOPHERESIS SYSTEM IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD: INTERIM ANALYSIS

MICRO RNA PROFILING OF ACOUSTICALLY-ISOLATED EXTRACELLULAR VESICLES IDENTIFIES POTENTIAL BIOMARKERS FOR POST-ALLO-HSCT COMPLICATIONS

COLONIZATION PLAYS AN IMPORTANT ROLE IN THE OUTCOME OF ALLOGENEIC TRANSPLANTATION

ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) SCORE AT THE ONSET OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PREDICTING OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS

CARFILZOMIB IN ADDITION TO STANDARD CYCLOSPORINE/ METHOTREXATE COMBINATION EFFECTIVELY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS

COMPARISON OF EXCLUSIVE POSTTRANSPLANT CYCLOPHOSPHAMIDE VERSUS A CALCINEURIN INHIBITOR BASED REGIMEN AS GVHD PROPHYLAXIS IN ALLOGENEIC BONE MARROW TRANSPLANTATION FROM HLA IDENTICAL SIBLING

SIROLIMUS VERSUS CYCLOSPORINE WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND MYCOPHENOLATE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN HAPLOIDENTICAL TRANSPLANTS: A RETROSPECTIVE ANALYSIS OF ONE SINGLE INSTITUTION

TARGETED SEQUENCE CAPTURE METAGENOMICS (VIROCAP) TO DETECT VIRUS IN STOOL SAMPLES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS

EXTRACORPOREAL PHOTOPHERESIS AND PRODUCTION OF SERUM IL-34 AND ELAFIN IN CHRONIC GRAFT VERSUS HOST DISEASE

IMPACT OF UPPER AND LOWER ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE ON GRADING AND OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS IN 122 CONSECUTIVE PATIENTS

PRELIMINARY EXPERIENCE WITH THE USE OF RUXOLITINIB, IBRUTINIB OR IMATINIB FOR THE TREATMENT OF ACUTE OR CHRONIC GVHD
RUXOLITINIB WITH OR WITHOUT IBRUTINIB AS AN ALTERNATIVE FIRST LINE THERAPY FREE OF CORTICOSTEROIDS OR CALCINEURIN INHIBITORS IN TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE

CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS

IMPACT OF KIR/HLA INCOMPATIBILITIES AFTER POSTTRANSPLANT CYCLOPHOSPHAMIDE BASED T CELL-REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

ELEVATED PTH LEVELS AMONG CHRONIC GRAFT-VERSUS-HOST DISEASE PATIENTS AND OTHER LONG TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

CONCURRENCE OF GVHD AND NON-INFECTIONOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION

ACUTE GVHD INCIDENCE IN MISMATCHED UNRELATED DONOR HSCT IN PAEDIATRIC ADULT PATIENTS: A STUDY FROM THE TURIN METROPOLITAN TRANSPLANT CENTER

PRACTICAL IMPLEMENTATION OF THE NIH DIAGNOSTIC CRITERIA FOR ORAL CHRONIC GVHD IN A MULTIDISCIPLINARY TEAM IN THE LATE FOLLOW UP OF ALLOGENIC HSCT PATIENTS

THE IMPACT OF ANTIBIOTIC-MEDIATED MODIFICATION OF THE INTESTINAL MICROBIOME ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: SYSTEMATIC REVIEW AND META-ANALYSIS

CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS FROM WHARTON’S JELLY IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE

PREDICTIVE ROLE OF ENDOSCOPIC/HISTOLOGICAL EXAMINATIONS FOR GASTRO-INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM CELLS TRANSPLANT: 'A POSTERIORI' ANALYSIS IN A SINGLE CENTER

THE INCIDENCE, RISK FACTORS, AND OUTCOMES OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

PROGNOSTIC CT FINDINGS AROUND THE ONSET OF ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE

THYMOGLOBULIN AND GRAFALON EFFECT ON ALLOGENEIC STEM CELL TRANSPLANT - POOLED DATA FROM WROCLAW MEDICAL UNIVERSITY, POLAND AND UNIVERSITY MEDICAL CENTER LJUBLJANA, SLOVENIA

THE ROLE OF LOW-DOSE ANTI THYMOCYTE GLOBULIN IN MATCHED SIBLING DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES

NEPHROTIC SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AS A FORM OF CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE

CORRELATION AMONG TOTAL NUCLEATED CELLS (TNC), CD34+, CD3+ CELL CONTENT IN G-CSF-PRIMED BONE MARROW COLLECTIONS AND THEIR RELATIVE INFLUENCE ON DEVELOPMENT OF ACUTE GVHD

PREDICTION FOR LETHAL ACUTE GRAFT VERSUS HOST DISEASE AND NON-RELAPSE MORTALITY BY EARLY PLASMA BIOMARKERS: A SINGLE CENTER RETROSPECTIVE STUDY IN JAPAN

RUXOLITINIB IN THE TREATMENT OF CORTICOSTEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD): ONE SINGLE CENTER EXPERIENCE

OUTCOME OF PATIENTS ALIVE AT 1-YEAR POST ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM A SINGLE INSTITUTION
Scientific Programme

RUXOLITINIB IN STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: EXPERIENCE IN OUR CENTRE

LOW-DOSE OF RUXOLITINIB: AN EFFECTIVE THERAPY FOR REFRACTORY BOS PATIENTS

SIROLIMUS BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PAEDIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT FOR BENIGN DISEASE

DETECTION OF BIOMARKERS PREDICTIVE OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY

OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) AFTER PD-1 BLOCKADE IN RELAPSED/REFRACTORY (R/R) LYMPHOMAS: A SINGLE CENTER EXPERIENCE

CD3+ DOSE IN PERIPHERAL BLOOD PROGENITOR CELLS PRODUCTS FOR ALLOTRANSPLANT FROM MATCHED UNRELATED DONORS FOR AML: IMPACT ON CHRONIC GRAFT VERSUS HOST DISEASE AND SURVIVAL

CYCLOPHOSPHAMIDE FOR SALVAGE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE ANALYSIS

A ROLE OF METHOTREXATE IN THE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE - A MULTICENTER OBSERVATIONAL STUDY ON BEHALF OF POLISH ADULT LEUKEMIA GROUP (PALG)

EVALUATION OF EXTRACORPOREAL PHOTOPHERESIS USED AS SECOND-LINE TREATMENT FOR GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HSCT IN A BRAZILIAN CENTER

THE OPTIMAL GVHD PROPHYLAXIS IN UNRELATED TRANSPLANTATIONS OF NON-MANIPULATED HEMATOPOIETIC STEM CELLS IN CHILDREN

ANALYSIS OF HISTOLOGY’S IMPACT IN PATIENTS WITH ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE

IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT). UNICENTRIC EXPERIENCE

FECAL MICROBIOTA TRANSPLANTATION FOR TREATING STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE OF THE GUT: A PILOT STUDY

EARLY RECOVERY OF LYMPHOCYTES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS RISK FACTOR OF CGVHD

FAVORABLE OUTCOME USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN HAPLOIDENTICAL (HAPLO-SCT) AND MATCHED RELATED DONORS (MRD): SINGLE CENTER EXPERIENCE IN CHILE

COMBINED THERAPY WITH MSC INFUSIONS TO OVERCOME STEROID-DEPENDENCY IN A CASE OF SEVERE PULMONARY CGVHD

MULTIPLE STRICTURES OF THE SMALL INTESTINE DEMANDING SURGICAL INTERVENTION AS A COMPLICATION OF GRAFT VERSUS HOST DISEASE: A CASE REPORT

A REMARKABLY LONG REMISSION ACHIEVED WITH IBRUTINIB MONOTHERAPY IN A PATIENT WHO WAS DIAGNOSED WITH STEROID REFRACTORY SCLerosING CHRONIC GVHD

INCREASED RISK OF ACUTE GVHD IN PATIENTS WITH MYELOFIBROSIS AFTER ALLO TRANSPLANT IN THE ABSENCE OF JAK-STAT INHIBITION
AUTOIMMUNE MYOSITIS AS PARANEOPLASTIC COMPLICATION OF A SQUAMOUS CELL CARCINOMA OF THE TONGUE AFTER SEVERE CHRONIC GRAFT VERSUS HOST DISEASE

UNUSUAL CAUSE OF DYSPNEA IN POST-TRANSPLANT PATIENT

e-Posters
09:30 - 18:00
ePoster Area

Graft-versus-host disease - preclinical and animal models

DIETARY STEARIC ACID LEADS TO A SEVERE AGVHD BY MODULATING THE GUT MICROBIOTA AND GLUCOSE METABOLISM

GRANULOCYTE COLONY-STIMULATING FACTOR-PRIMED DONOR T CELLS ATTENUATE MURINE ACUTE GVHD THROUGH REGULATING T CELL DIFFERENTIATION IN TARGET ORGANS

MTOR REGULATE GENERATION AND FUNCTION OF PMN-MDSCS AND PLAY PROTECTION ROLE IN ACUTE GRAFT-VERSUS-HOST DISEASE

FULL REGULATORY T CELL RECONSTITUTION BEFORE T CELL TRANSFER PREVENTS GRAFT-VERSUS-HOST DISEASE BY SUPPRESSING COSTIMULATION AND T CELL ACTIVATION IN A HAPLOIDENTICAL MODEL

TARGETING OF CHEMOKINE RECEPTOR 7 PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE

ENHANCING REGULATORY T CELL FUNCTION AND HOMING TO THE GUT TO IMPROVE GRAFT-VERSUS-HOST DISEASE PREVENTION AFTER ADOPTIVE TRANSFER IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION

LYG1-DEFICIENT DONOR SPLENOCYTES ATTENUATED THE SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE VIA SKEWING CD4+ T CELL POLARIZATION TOWARDS TREG CELLS

ATTENUATION OF MURINE CHRONIC GRAFT VERSUS HOST DISEASE BY THE NRF2 ACTIVATOR MANGIFERIN

CHEMOTHERAPY AND INFLAMMATION INDUCED DAMAGE OF INTESTINAL EPITHELIUM IS ASSOCIATED WITH INCREASED T CELL CHEMOTAXIS

INKT CELLS PROMOTE IMMUNE TOLERANCE BY SELECTIVE DENDRITIC CELL APOPTOSIS

ACTIVE PARTICIPATION OF CXCR4+ T LYMPHOCYTES IN ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC TRANSPLANTATION

A MURINE MODEL REVEALS A CRITICAL ROLE FOR REACTIVE OXYGEN SPECIES IN HYPERACUTE GRAFT-VERSUS-HOST DISEASE

MAPPING THE ROAD OF GVHD AND GVT. A LONGITUDINAL STUDY OF IMMUNE-TRANSCRIPTOME SIGNATURES AS NOVEL APPROACH TO SOLVE POST-ALLOGENEIC TRANSPLANTATION DILEMMAS

CELL-FREE DNA LEVELS ARE INCREASED IN ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS AND MICE

DS-2741A, ANTI-ORA11 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION

ENDOTHELIAL MICROPARTICLES DELIVERING LINCRNA NEAT1 ARE INVOLVED IN THE PATHOPHYSIOLOGY OF AGVHD FOLLOWING ALLO-HSCT

B-T CELL INTERACTIONS IN GRAFT-VERSUS-HOST DISEASE
IDENTIFICATION OF POTENTIAL MICROBIOME MARKERS FOR AGVHD EARLY DIAGNOSIS

e-Posters
09:30 - 18:00
ePoster Area

Granulocyte and osteoclast disorders

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR OSTEOPEKTOSIS

Haemoglobinopathy and inborn errors

SUCCESSFUL HLA-MISMATCHED HSCT IN PAEDIATRIC PATIENTS WITH HEMOGLOBINOPATHIES USING ATG SEROTHERAPY AND POSTTRANSPLANT CYCLOPHOSPHAMIDE

OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH CEREBRAL ADRENOLEUKODYSTROPHY VARY BY DONOR CELL SOURCE, CONDITIONING REGIMEN, AND STAGE OF CEREBRAL DISEASE STATUS

OUTCOME OF NON MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE SICKLE CELL DISEASE: A 100 PATIENT EXPERIENCE FROM SAUDI ARABIA

HIGH DOSE STEM CELL THERAPIES, LIKE MGTA-456, ENABLE COMPLETE NEURAL AND PERIPHERAL DISEASE CROSS-CORRECTION THROUGH RAPID AND ROBUST HEMATOPOIETIC ENGRAFTMENT

HLA SET-UP IS A MAJOR PREDICTOR OF ENGRAFTMENT IN HAPLO-IDENTICAL TRANSPLANT FOR SEVERE THALASSEMIA (ST) USING POST-CYCLOPHOSPHAMIDE (PTCY)

CTLA4IG-BASED T CELL COSTIMULATION BLOCKADE IN PTCY BASED HAPLOIDENTICAL HCT FOR THALASSEMIA MAJOR [TM] AND SICKLE CELL DISEASE [SCD] RESULTS IN IMPROVED DISEASE-FREE SURVIVAL WITHOUT GVHD

LENTIGLOBIN GENE THERAPY TREATMENT OF TWO PATIENTS WITH TRANSFUSION-DEPENDENT ß-THALASSEMIA

BONE MARROW TRANSPLANT IN PATIENTS WITH SICKLE CELL ANAEMIA. EXPERIENCE IN ONE CENTRE

Outcomes in cerebral adrenoleukodystrophy after hematopoietic stem cell transplantation: single center experience

Neurodevelopmental outcomes of hematopoietic stem cell transplantation for mucopolysaccharidosis type II: a prospective, longitudinal study

Hematopoietic recovery and transfusion need after haploidentical transplantation in beta thalassemia patients

Pre- and post-transplant rituximab reduces the high incidence of primary graft failure and immune-mediated cytopenia following cord blood transplant for lysosomal storage disease in children
Scientific Programme

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE: THE SPANISH EXPERIENCE

LONG-TERM QUALITY OF LIFE IN PATIENTS WITH THALASSEMA MAJOR FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD

HIGH INCIDENCE OF AUTOIMMUNE CYTOPENIAS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH THALASSEMA AND SICKLE CELL DISEASE: THE IMPACT OF MATCHED UNRELATED DONOR

ADDING AZATHIOPRINE/HYDROXYUREA PRECONDITIONING TO ALEMTUZUMAB/TBI MAY REDUCE RISK OF GRAFT FAILURE IN MATCHED SIBLING DONOR ALLOGENEIC HSCT IN ADULT SICKLE CELL PATIENTS

A PHASE II STRATIFIED TRIAL TO ASSESS HAPLOIDENTICAL T-DEPLETED STEM CELL TRANSPLANTATION IN PATIENTS WITH SICKLE CELL DISEASE WITH NO AVAILABLE SIBLING DONOR

COMBINED UMBILICAL CORD BLOOD AND BONE MARROW FROM HLA-IDENTICAL SIBLING DONORS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMA MAJOR

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF METABOLISM USING ALTERNATE DONORS: A PROSPECTIVE SINGLE STUDY

UMBILICAL CORD BLOOD TRANSPLANTATION IN CHILDREN WITH LEUKODYSTROPHIES: SINGLE CENTER EXPERIENCE IN CHINA

PEARSON SYNDROME IN A PATIENT TRANSPLANTED FOR DIAMOND-BLACKFAN ANEMIA

CHALLENGES AND SUCCESSES WITH PRE-TRANSPLANT IMMUNE SUPPRESSION IN ALTERNATIVE DONOR TRANSPLANTS

HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CLASS 3 THALASSEMA MAJOR USING POST-TRANSPLANT CYCLOPHOSPHAMIDE

Multiple myeloma

DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF HIGH-RISK PATIENTS IN CASSIOPEIA

EVALUATION OF PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (PET/CT) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PHASE 3 CASSIOPEIA STUDY PATIENTS: CASSIOPET STUDY RESULTS

CONCORDANCE OF POSTCONSOLIDATION MINIMAL RESIDUAL DISEASE RATES BY MULTIPARAMETRIC FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING IN CASSIOPEIA

LONG-TERM FOLLOW-UP OF THE RANDOMIZED PHASE 3 PETHEMA/GEM 2005MENO565 STUDY SUPPORTS THE USE OF VTD (BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE) AS PRETRANSPLANT INDUCTION REGIMEN FOR MULTIPLE MYELOMA (MM)

DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE
Scientific Programme

HOW TO ASSESS RISK OF PROGRESSION IN MULTIPLE MYELOMA PATIENTS ACHIEVING COMPLETE REMISSION AFTER AUTOLOGOUS TRANSPLANT: SUB ANALYSIS FROM THE GEM2012MENOS65 PHASE III CLINICAL TRIAL

OUTCOMES OF ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS

25 YEARS OF AUTOLOGOUS TRANSPLANTATION FOR MYELOMA IN EBMT CENTRES - CHANGING PRACTICE PATTERNS

PROGNOSIS IN DIFFERENT RISK-GROUPS OF MULTIPLE MYELOMA WITH MINIMAL RESIDUAL DISEASE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BORTEZOMIB-INTEGRATED CONDITIONING: A SINGLE-CENTER EXPERIENCE

UNINTERRUPTED MOBILIZATION AND TRANSPLANTATION PROCEDURE WITH NON-CRYOPRESERVED YIELD IS FEASIBLE WITHOUT INCREASEMENT OF COMPLICATION RISK IN MULTIPLE MYELOMA PATIENTS

CONDITIONING WITH BORTEZOMIB-MEL200 IN COMPARISON TO MEL200 IMPROVES SURVIVAL AMONG MYELOMA PATIENTS IN≤PR PRIOR TO AUTO-HCT: A STUDY FROM THE CMWP OF THE EBMT

RESULTS OF DEFERRED AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED STAGES OF SYSTEMIC AL AMYLOIDOSIS

IN VITRO STIMULATION WITH CD40L/IL-21 CAN RETRIEVE B-CELL DYSFUNCTION IN MULTIPLE MYELOMA PATIENTS SUFFERING FROM SECONDARY IMMUNODEFICIENCY

ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA; EXCELLENT OUTCOMES FOR EARLY TRANSPLANTATION

SEQUENTIAL HEART TRANSPLANTATION FOLLOWED BY HIGH DOSE CHEMOTHERAPY PLUS AUTOLOGOUS STEM CELL REINFUSION IN CARDIAC AL AMYLOIDOSIS

AUTOGRRAFT CELLULAR COMPOSITION AND OUTCOME IN MYELOMA PATIENTS: RESULTS OF THE PROSPECTIVE MULTICENTER GOA STUDY

RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE

PHASE 3, OPEN-LABEL, NONINFERIORITY STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): BODY WEIGHT SUBGROUP ANALYSIS OF COLUMBA

ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) IS A RELIABLE PREDICTOR FOR OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION

ABERRANT PHENOTYPE PLASMA CELL MULTIPARAMETRIC FLOW CYTOMETRY (MFC) DETECTION IN AUTOGRRAFT PRODUCTS OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

RETROSPECTIVE MULTI-CENTER STUDY OF ADOLESCENT AND YOUNG ADULT (AYA) MULTIPLE MYELOMA IN KANSAI MYELOMA FORUM REGISTRY

MAINTENANCE THERAPY WITH ELOTUZUMAB AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

AUTOLOGOUS STEM CELL TRASPLANTATION CANDIDACY IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS

NOVEL PROTOCOL FOR AUTOLOGOUS HSCT IN MULTIPLE MYELOMA ACHIEVES ‘ZERO’ CENTRAL LINE ASSOCIATED BLOOD STREAM INFECTIONS (CLABSI)
Scientific Programme

OUTCOMES OF NON-CRYOPRESERVED VERSUS CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

DOWN REGULATION OF AUTOPHAGY ENHANCES BORTEZOMIB-INDUCED APOPTOSIS OF MYELOMA CELL BY UP REGULATION OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES

RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE

FAVORABLE LONG-TERM OUTCOMES WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HIGH RISK PATIENTS WITH MULTIPLE MYELOMA WHO ARE POSITIVE AT FDG-PET/CT

LONG TERM SURVIVAL OF MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELATION TO AVAILABILITY OF NOVEL DRUGS

MULTIPLE MYELOMA (MM) IN FIRST RELAPSE PATIENTS. ROLE OF THE SECOND AUTOLOGOUS STEM-CELL TRANSPLANT (ASCT) IN REAL LIFE: EXPERIENCE OF TWO SPANISH CENTERS

ROLE OF ANALYSIS OF CHIMERISM IN MULTIPLE MYELOMA PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE

USE OF NETUPITRANT/PALONOSETRON IN MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE

THE EFFECT OF UCP-2 AND NR3C1 GENES ON TREATMENT EFFICACY AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA

SAFETY AND EFFECTIVENESS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA IN FIRST LINE

PLASMAPHERESIS ASSISTED THE TREATMENT OF 1 CASE OF HYPERGLOBULINEMIA AFTER CART THERAPY

e-Posters
09:30 - 18:00

Myelodysplastic syndromes

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OF ADULT PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA: A NORDIC RETROSPECTIVE STUDY

DECITABINE MONOTHERAPY BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION RESULTED IN SUPERIOR SURVIVAL FOR MYELODYSPLASTIC SYNDROME PATIENTS WITH EXCESS BLASTS

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM: A STUDY FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT

IMPACT OF MUTATION PROFILE IN CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

NEW INSIGHTS OF MYELODYSPLASTIC SYNDROME (MDS) WITH ERYTHROID PREDOMINANCE BASED ON THE NEXT-GENERATION SEQUENCING AND SINGLE-CELL RNA SEQUENCING
IMPACT OF TREATMENT PRIOR TO ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: RESULTS OF THE LATIN AMERICAN BONE MARROW TRANSPLANT REGISTRY

RESULTS OF LATIN AMERICAN RECORD OF BONE MARROW TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME

OUTCOME AND MUTATIONAL PROFILE IN MDS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Non-infectious late effects, quality of life and fertility

EASIX-1YEAR- THE FIRST BIOMARKER PREDICTING LATE MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

AN UPDATED REPORT ON SECONDARY SOLID CANCER FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THALASSEMIA MAJOR

ALLOGENEIC STEM-CELL TRANSPLANTATION IN AML AND MDS USING CONDITIONING REGIMENS WITH DIFFERENT DOSE-INTENSITIES; 15 YEARS LATER

EMPLOYMENT STATUS AND RETURN TO WORK AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: RESULTS FROM A NATIONWIDE SURVEY

FUNCTIONAL OUTCOME MEASURES IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): FOCUS ON THE 2-MINUTE WALK TEST

FERTILITY IN ADULT FEMALE ALLOGENEIC STEM CELL RECIPIENTS

A RISK SCORE MODEL (HAD-TCG) TO EVALUATE THE RISK OF STROKE IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

BRONCHIOLITIS OBLITERANS SYNDROME IN THE CHANGING LANDSCAPE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

CURRENT STATUS AND NEEDS OF LONG-TERM FOLLOW-UP CLINICS FOR HEMATOPOIETIC CELL TRANSPLANT SURVIVORS: RESULTS OF A NATIONWIDE SURVEY IN JAPAN

SURVIVORSHIP CARE FOR ALLOGENEIC TRANSPLANT PATIENTS IN THE UK: CURRENT SERVICE PROVISION AND BARRIERS TO IMPLEMENTATION

CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN EPSTEIN-BARR VIRUS RELATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (EBV-PTLD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)

INCIDENCE, RISK FACTORS AND OUTCOMES OF DIFFUSE ALVEOLAR HEMORRHAGE AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION

WHOLE BODY VIBRATION TRAINING DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION - THE EFFECTS ON PATIENTS' PHYSICAL CAPACITY, FATIGUE, BODY COMPOSITION AND QUALITY OF LIFE

MULTI-MORBIDITY IN ADULT SURVIVORS OF STEM CELL TRANSPLANTATION (SCT)

GONADOTOXICITY AFTER TRESULFAN-BASED MYELOABLATIVE CONDITIONING REGIMEN FOR ALLOGENEIC HSCT IN GIRLS WITH LEUKEMIA
REDUCED-INTENSITY TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH HIGH-RISK OR ADVANCED HEMATOLOGICAL MALIGNANCIES IN LAST 10 YEARS - SINGLE CENTRE EXPERIENCE

FATHERHOOD AFTER A MYELOABLATIVE TEO SULFAN BASED ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS ON 453 PATIENTS

COMPARISON OF CENTRAL NERVOUS SYSTEM RELAPSE OUTCOMES FOLLOWING HAPLOIDENTICAL VS IDENTICAL-SIBLING TRANSPLANT FOR ACUTE LYMPHOBLASTIC LEUKEMIA

OLDER AGE AND PERIPHERAL BLOOD AS A STEM CELL SOURCE ARE THE MAJOR NEGATIVE PREDICTORS OF SURVIVAL LONG TERM

PREVALENCE OF BRONCHIOLITIS OBLITERANS SYNDROME (BOS) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT (ALLOHSCT) IN THE US, EUROPE AND JAPAN

NETUPITANT-PALONOSETRON (NEPA) TO PREVENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MULTIPLE MIELOMA (MM) PATIENTS RECEIVING HIGH-DOSE (HD) MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)

MOST FREQUENT LATE EFFECTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA DOES NOT SEEM TO WORSEN PERFORMANCE STATUS

INVOLVING STEM CELL TRANSPLANT PATIENTS AND THEIR FAMILIES TO IMPROVE THE ANTHONY NOLAN MY TRANSPLANT TRACKER APP

EARLY MENOPAUSE AND RISK FACTORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PREMENOPAUSAL ADULT WOMEN

MUSCULOSKELETAL COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS

CLINICAL CHARACTERISTICS AND MANAGEMENT OF LATE RELAPSE OF ACUTE MYELOID LEUKAEMIA MORE THAN FIVE YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

FOLLOWING UP WITH ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING 5+ YEARS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE

LOW BACK PAIN AND LASER ACUPUNCTURE IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELLS TRANSPLANTATION

EFFECTS OF CONTROLLED EXERCISE ON PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

LONG-TERM OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANT IN AN ASIAN POPULATION: A SINGLE-CENTER EXPERIENCE

DEVELOPMENT OF GUILLAIN-BARRE-LIKE SYNDROME IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELLS TRANSPLANTATION
ELTROMBOPAG THERAPY IN STEM CELL TRANSPLANT RECIPIENTS SHOWS EFFECTIVE IRON MOBILISATION

CLINICAL IMPACT OF MODEL PK GUIDED-CYCLOSPORINE DOSE INDIVIDUALIZATION IN CHILDREN UNDERGOING HSCT

INFLUENCE OF CYP2D6 METABOLIZER STATUS ON THE CONTROL OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING BY ONDANSETRON ON PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION

ESTIMATION OF GLOMERULAR FILTRATION RATE IN ADULTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: CYSTATIN C VERSUS CREATININE

USE OF SUBLINGUAL TACROLIMUS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH HISTORY OF ANAPHYLAXIS TO INTRAVENOUS CYCLOSPORINE

ORAL CLONAZEPAM FOR SEIZURE PROPHYLAXIS IN ADULT PATIENTS TREATED WITH HIGH DOSE BUSULFAN

DISSOLUTION TIME FOR CONVENTIONAL AND LYOPHILIZED CYCLOPHOSPHAMIDE: A SINGLE CENTER STUDY

OUTCOMES OF EBV VIREMIA AND PTLD AFTER RITUXIMAB: A PHARMACO-COST ANALYSIS

PHARMACOLOGICAL INTERACTIONS IN THE POST-TRANSPLANT PHASE OF HEMATOPOYETIC PROGENITORS TRANSPLANTATION

EVALUATION OF SIDE EFFECTS AND EFFICACY OF LOMUSTINE (CCNU) AND BANDAMUSTINE IN PATIENTS WITH LYMPHOMA

Psychological issues

INVESTIGATING THE LONG-TERM OUTCOMES OF ADULT PATIENTS WHO UNDERWENT HEMATOPOIETIC STEM CELL TRANSPLANT FOR PRIMARY IMMUNODEFICIENCY DURING CHILDHOOD

THE IMPACT OF MEDICAL AND SOCIAL REHABILITATION ON THE QUALITY OF LIFE IN CHILDREN WITH ONCOLOGIC AND HEMATOLOGIC DISEASES

THE IMPACT OF PRE-TRANSPLANT DEPRESSION AND ANXIETY ON THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION, A STUDY OF THE TCWP OF THE EBMT

ASSOCIATIONS BETWEEN FAMILY FUNCTION DOMAINS AND COPING STRATEGIES OF ADOLESCENTS UNDERGOING HSCT

HOW PATIENTS’ VIEWS ARE HELPING SHAPE PLANS FOR A NEW TRANSPLANT PSYCHOLOGY SERVICE

CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: TWO DIFFERENT ANALYTICAL APPROACHES

ARC CLINIC: APPLYING PSYCHOLOGICAL INSIGHTS TO PROMOTE EARLY REHABILITATION IN MYELOMA POST-TRANSPLANT

FROM HOSPITALIZATION TO RETURN HOME: A TRANITIONAL ACTION RESEARCH IN THE HEMATOLOGY SECTOR
1000 IN 10. 10 YEARS OF CLINICAL PSYCHOLOGY PRACTICE WITH 1000 PATIENTS IN THE SAME BMT UNIT IN MARSEILLE, FRANCE

IMPLEMENTATION OF PSYCHOLOGICAL SUPPORT AND DEVELOPMENT OF EDUCATIONAL PROGRAM FOR CHILDREN AND ADOLESCENTS UNDERGOING HSCT AND THEIR PARENTS IN RUSSIA

Quality Management

COMPARING COMPLIANCE FOR COLLECTION FACILITY JACIE STANDARDS 6.1 AND 7TH EDITIONS

INTEGRATION OF THEORY AND PRACTICE: SCENARIO-BASED SKILL TRAINING IN ADMINISTERING CAR-T CELLS

“TPFMEA”, AN INTERNATIONAL MODEL FOR ASSESSING RISKS IN A STEM CELL TRANSPLANT PROGRAM

DEFINING PATIENT-IMPORTANCE OUTCOMES AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT

IMPLEMENTATION OF JACIE ACCREDITATION AT A NOVEL TRANSPLANT PROGRAM: THE IMPACT ON THE CLINICAL PRACTICE

HOW ONE PROCESSING CENTRE PREPARED FOR ITS FIRST JACIE INSPECTION?

TIPS FOR GENERATING SUCCESSFUL ‘TEAMWORKING’ IN OUR HEALTHCARE FACILITIES: THE EXPERIENCE OF A HOSPITAL UNIT IN A FRENCH CANCER CENTER

IMPLEMENTATION OF A QUALITY SYSTEM FOR RUNNING A CELL AND GENE THERAPY CLINICAL TRIAL WITHIN A JACIE-ACCREDITED TRANSPLANT PROGRAM

NEW ONLINE PLATFORMS IN QUALITY MANAGEMENT: COORDINATION AND MULTIDISCIPLINARY CARE

RISK MANAGEMENT ASSESSMENT IN IMPLEMENTING CAR-T CELL THERAPY IN A CLINICAL UNIT

FEBRILE REACTION AFTER HSC INFUSION IS MORE FREQUENT IF NO STEROID PREMEDICATION IS GIVEN WHICH RESULTS IN MORE FREQUENT USE OF ANTIBIOTICS EARLY POST-TRANSPLANT

SEARCHING FOR OTHER TOPICS OF QUALIFICATION PLANS IN THE TRANSPLANT PROGRAM CLINICAL PART - THE ONE CENTER EXPERIENCE

PRACTICE PATTERNS IN CHRONIC GVHD PATIENT MANAGEMENT AND PATIENT REPORTED OUTCOME MEASURES ACROSS THE EBMT ALLOGENEIC TRANSPLANTATION NETWORK

MAINTAINING DONOR SAFETY AND WELFARE THROUGHOUT CELLULAR THERAPY PRODUCT DONATION

DIGITAL JACIE AT THE CHRISTIE

INTEGRATION OF CELLULAR THERAPY IN THE JACIE (JOINT ACCREDITATION COMMITTEE ISCT-EBMT) QUALITY MANAGEMENT PLAN. SINGLE CENTER EXPERIENCE
Scientific Programme

AUDIT - A METHOD TO EVALUATE INTERVENTIONS - EXPERIENCES FROM AN ATTEMPT TO IMPROVE NUTRITIONAL STATUS IN PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

QUALITY OF LIFE ASSESSMENT AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

RETROSPECTIVE ANALYSIS OF TIME TO ALTERNATIVE DONOR IDENTIFICATION AND HEMATOPOIETIC STEM CELLS PROCUREMENT IN THE ABSENCE OF MATCHED-SIBLING DONORS IN A SINGLE CENTER IN SPAIN

GOVERNANCE, RISKS AND REGULATORY ASPECTS OF UNLICENSED LENTIVIRAL VECTOR-MODIFIED AUTOLOGOUS STEM CELL TREATMENT

UNIQUE SUPPORTIVE CARE ALGORITHMS FOR CHILDREN UNDERGOING HAPLOIDENTICAL HSCT FOR BENIGN HAEMATOLOGICAL DISORDERS

QUALITY OF LIFE IN PARENTS OF TURKISH AND SYRIAN PEDIATRIC BONE MARROW TRANSPLANT AND ONCOLOGY PATIENTS

COLLECTION OF AUTOLOGOUS MONONUCLEAR CELLS IN NON-CYTOKINE STIMULATED DONORS: COMPARING TWO APHERESIS METHODS

EFFECTIVE CAR-T CELL DELIVERY: A MULTIDISCIPLINARY APPROACH AT MFT

HAEMOPOIETIC PROGENITOR CELL PROFICIENCY TESTING

VALIDATION AND COMPARISON OF AEROBIC AND anaerobic BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ALERT (R) 3D (TM) AND VIRTUO (TM) MICROBIAL BIOBURDEN SYSTEMS FOR HAEMATOPOIETIC PROGENITOR CELLS (HPC)

START-UP OF AN ADHERENCE RECEPTION FOR ALLOGENIC STEM CELL TRANSPLANTED PATIENTS AT THE HAEMATOLOGICAL DEPARTMENT LINKÖPING, SWEDEN

ENUMERATION OF RESIDUAL RED BLOOD CELLS IN MIS-MATCHED ALLOGENEIC PBSC COLLECTIONS - TRADITIONAL HAEMATOLOGY ANALYSER VS FLOW CYTOMETRY

INVESTIGATION AND ANALYSIS OF FACTORS AFFECTING GASTROINTESTINAL NUTRITION RECOVERY AFTER MULTIPLE MYELOMA AUTOLOGOUS STEM CELL TRANSPLANTATION AND EFFECTS OF NUTRITIONAL INTERVENTION

CHARACTERISTICS OF IRON DEFICIENCY ANEMIA IN PRE-MENOPAUSAL WOMEN IN KOREA

LEUKEMIA AND ITS TYPES

Solid tumours

SUCCESSFUL KIR ALLOREACTIVE HSCT IN A CHILD WITH RESISTANT EWING SARCOMA

TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS

VOC PATTERN RECOGNITION OF LUNG CANCER: A COMPARATIVE EVALUATION OF DIFFERENT DOG- AND ENOSE-BASED STRATEGIES USING DIFFERENT SAMPLING MATERIALS
Stem cell donor

DONOR-RECIPIENT HLA MATCHING FOR UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION: Outcomes: A STUDY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY (CTIWP) OF THE EBMT

PRESENCE OF AGE-RELATED CLONAL HEMATOPOIESIS (ARCH) IN DONOR DOES NOT INCREASE THE RISK OF LATE SECONDARY MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Kyoung Ha Kim, Tae Hyung Kim, Jae-Sook Ahn, Ivan Pasic, Zeyad Al-Shaibani, Arjun Law, Wilson Lam, Fotios Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Zhaolei Zhang, Tamir Biezuner, Liran Shlush, Dennis Dong Hwan Kim (Canada)

SERIOUS EVENTS AND ADVERSE REACTIONS IN RELATION TO BLOOD STEM CELL DONATION REPORTED TO WMDA IN 2018

THE IMPROVEMENT IN OVERALL SURVIVAL FROM UNRELATED DONOR TRANSPLANT IN AUSTRALIA AND NEW ZEALAND IS DRIVEN BY A REDUCTION IN TRANSPLANT RELATED MORTALITY

POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING, UNRELATED AND HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA, A COMPARATIVE STUDY OF THE ALWP EBMT

ALLOREACTIVITY AGAINST HLA-DPB1 IN HOST-VERSUS-GRAFT DIRECTION IS ASSOCIATED WITH INCREASED RISK OF GRAFT FAILURE AFTER MATCHED UNRELATED DONOR TRANSPLANTATION FOR NONMALIGNANT DISEASES

IMPACT OF KIR ON PATIENTS WITH LYMPHOID DISEASES AFTER T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

INDICATIONS AND SAFETY OF MULTIPLE BONE MARROW HARVESTS IN PEDIATRIC DONORS FOR MATCHED SIBLING RECIPIENT TRANSPLANTATION

HEALTHY VOLUNTEER STEM CELL DONORS: FOLLOW UP AFTER HPC APHERESIS DONATION: THE EXPERIENCE OF ITALIAN BONE MARROW DONOR REGISTRY

ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH INHERITED DISORDERS

HAPLOIDENTICAL REDUCED-INTENSITY HEMATOPOIETIC CELL TRANSPLANTATION USING BUSULFAN, FLUDARABINE, AND ANTITHYMOCYTE GLOBULIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

THE RESULTS OF A TELECONFERENCE ABOUT THE EXPERIENCES AND EXPECTATIONS OF RELATED HEMATOPOIETIC STEM CELL DONORS AFTER DONATION

IMPACT OF THE ESTABLISHMENT OF THE TURKISH NATIONAL DONOR REGISTRY (TURKOK) ON A SINGLE CENTER’S TRANSPLANT OUTCOME: INTERNATIONAL STEM CELL DONORS VERSUS NATIONAL

YOUNG MALE DONORS MAY RESULT IN BETTER OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA WITH PT-CY

DONORS OF PERIPHERAL HEMATOPOIETIC STEM CELLS, OUR EXPERIENCE FOR LAST 10 YEARS

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS OVER 70 YEARS: A MONOCENTRIC EXPERIENCE OF 48 PATIENTS
COMPARISON OF TRANSPLANT OUTCOMES AND ECONOMIC COSTS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML AND MDS BETWEEN THE DIFFERENT TYPE OF DONORS

HIGH DISEASE-FREE SURVIVAL OF THE SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH DONOR CHANGE AND MAINLY REDUCED-INTENSITY CONDITIONING IN RELAPSED HEMATOLOGICAL MALIGNANCIES

EPIDEMIOLOGICAL STUDY OF RARE ANTIGENS OF THE MAIN HISTOCOMPATIBILITY COMPLEX AMONG HEMATOPOIETIC STEM CELL DONORS IN BELARUS

IMPACT OF DONOR-RECIPIENT SEX MISMATCH IN PATIENTS RECEIVING PARTIAL T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE MONOCENTRIC STUDY

HAPLOIDENTICAL DONOR SELECTION AND ITS IMPLICATIONS IN TRANSPLANTATION OUTCOME. OUR EXPERIENCE AT HUDGC DR. NEGRÍN

OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ACCORDING TO DONOR AVAILABILITY, DURATION FROM DIAGNOSIS TO TRANSPLANT AND DONOR-SPECIFIC PARAMETERS - A SINGLE CENTER ANALYSIS

THE BENEFITS OF HLA-MATCHED RELATED DONORS FOR PATIENTS LACKING HLA-IDENTICAL SIBLING IN THE ABSENCE OF POWERFUL LOCAL UNRELATED REGISTRY IN COUNTRIES WITH PREVALENT COUSIN MARRIAGES

DONOR AGE INFLUENCES THE GRAFT-VERSUS-HOST-DISEASE-FREE AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANT IN ELDERLY PATIENTS IN LATIN AMERICA

A STUDY OF THE UNCERTAINTY, UNCERTAINTY APPRAISAL AND GROWTH AND THE AFFECTED FACTORS ON HEMATOPOIETIC STEM CELL DONORS

WITHDRAWL OF VOLUNTEER DONORS FROM THE INTERNATIONAL REGISTRIES: A SINGLE CENTRE EXPERIENCE

OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION FOR AML AND MYELODYSPLASTIC SYNDROME IN ELDERLY WITH REDUCED-INTENSITY CONDITIONING

HAPLOIDENTICAL VS UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS WITH HEMATOLOGIC MALIGNACIES: A SYSTEMATIC REVIEW AND META-ANALYSIS

HEPATITIS E VIRUS (HEV) CONTAMINATED HEMATOPOIETIC STEM CELL GRAFT IN A MATCHED UNRELATED DONOR TRANSPLANTATION

HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MATCH RELATED DONORS IN CHILDHOOD: SINGLE CENTER EXPERIENCE

FIRST EXPERIENCE WITH UNRELATED STEM CELL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN A TRANSPLANT CENTER FROM NORTH MACEDONIA

e-Posters
09:30 - 18:00
ePoster Area

Stem cell source

OPTIMIZING OUTCOMES OF ACUTE LEUKEMIA AFTER TRANSPLANTS WITH SINGLE UNRELATED CORD BLOOD UNITS SELECTED ACCORDING TO CURRENT INTERNATIONAL RECOMMENDATIONS FOR CELL DOSE AND HLA MATCH
Scientific Programme

IMPACT OF HLA-MISMATCH ON OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE ANALYSIS BY THE JSHCT HLA WORKING GROUP

CLINICAL IMPACT OF DONOR EPITOPE-SPECIFIC HLA ANTIBODIES AND THIRD-PARTY HLA ANTIBODIES IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION

ADDITION OF TOCILIZUMAB TO CYCLOSPORINE-A AND MYCOPHENOLATE MOFETIL FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS SIGNIFICANTLY ABROGATES SEVERE ACUTE GVHD AFTER DOUBLE-UNIT CORD BLOOD TRANSPLANTATION IN ADULTS

THE USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) IN UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION

COMPARATIVE STUDY OF HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETION VS UNRELATED CORD BLOOD TRANSPLANT FOR ADULTS WITH HAEMATOLOGICAL MALIGNANCIES

USE OF G-CSF MOBILIZED BONE MARROW GRAFTS IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION (BMT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) DECREASES RISK OF SEVERE ACUTE GVHD

CMV-SPECIFIC FUNCTIONAL IMMUNE RECONSTITUTION IS SLOWER AFTER UMBILICAL CORD BLOOD COMPARED WITH MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION

REDUCED INTENSITY (RIC) VS MYELOABLATIVE CONDITIONING (MAC) IN CORD BLOOD TRANSPLANTATION FOR AML (40-60 YEARS) ACROSS MISMATCHED HLA BARRIERS - ANALYSIS BY CTIWP/EUROCORD OF EBMT

COST OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REAL WORLD: AN ANALYSIS USING THE JAPANESE NATIONAL DATABASE

ASSOCIATION BETWEEN THE DOSE OF CD3+ AND CD34+ CELLS IN THE GRAFT AND POST-TRANSPLANT OUTCOMES

HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A RELATED DONOR WITH HLA-1 ANTIGEN MISMATCH IN THE GRAFT-VERSUS-HOST DIRECTION USING LOW-DOSE ANTI-THYMOCYTE GLOBULIN: MULTICENTER PHASE II TRIAL

INTRA-BONE CORD-BLOOD TRANSPLANT OF UNWASHED UNITS WITH ATG-FREE AND SIROLIMUS-BASED GVHD PROPHYLAXIS: FAST IMMUNE-RECONSTITUTION AND LONG-TERM DISEASE CONTROL IN 22 PATIENTS WITH HIGH-RISK DISEASES

ANTI-HLA DONOR SPECIFIC ANTIBODIES (DSA) DOES NOT AFFECT GRAFT AND SURVIVAL IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) WITH ORIGINAL POST-TRANSPLANT CYCLOFOSFAMIDE (PT-CY) SCHEDULE

MESENCHYMAL STEM/STROMAL CELL PRODUCTION COMPLIANT WITH GOOD MANUFACTURING PRACTICE: COMPARISON BETWEEN BONE MARROW AND WHARTON’S JELLY

EFFICIENT DMSO REMOVAL AND HIGH CELL RECOVERY WITH LOVO CELL PROCESSING SYSTEM IN HPC-A CONCENTRATES: A SINGLE CENTRE EXPERIENCE

Social Events
10:35 - 11:57 Auditorium 1

Meditation session
Educational  
11:00 - 12:00  
Auditorium 1

**E11, Immune therapy beyond CAR T-cells**

**Chairs:**  
Antonio Pérez-Martínez (Spain)

- **Gamma-Delta T-cell Therapy**  
  Jürgen Kuball (Netherlands)  
  11:00 - 11:12

- **Stem cell derived NK cell Therapy**  
  Harry Dolstra (Netherlands)  
  11:12 - 11:24

- **MSC and extracellular vesicles in stem cell transplantation**  
  Fermín Sánchez-Guijo (Spain)  
  11:24 - 11:36

- **HLA-mismatched microtransplantation**  
  Huisheng Ai (China)  
  11:36 - 11:48

Q&A  
11:48 - 12:00

**Joint Session**  
11:00 - 12:00  
Auditorium 2

**JS4, Joint session KSBMT: Status of Next Generation Sequencing for indication and monitoring in stem cell transplantation 2020**

**Chairs:**  
Nicolaus Kröger (Germany)  
Hoon Kook (Korea, Republic of)

- **NGS for indication in myeloid malignancies**  
  Jae-Sook Ahn (Korea, Republic of)  
  11:00 - 11:25

- **Disease monitoring post transplant with NGS**  
  Maximilian Christopeit (Germany)  
  11:25 - 11:38

Discussion  
11:38 - 12:00

**How do I ... ?**  
11:00 - 12:00  
Auditorium 3

**HDI5, How Do I... consider patients' needs in induction and front line therapy for transplant (eligible patients with Multiple Myeloma) - Nurses' Session - Supported through an unrestricted educational grant by Janssen**

**Chairs:**  
Isabel Salcedo (Spain)

- **Treatment approaches for transplant eligible patients in front line Multiple Myeloma**  
  Laure Vincent (France)  
  11:00 - 11:15
Scientific Programme

11:15 - 11:30
How do new therapy combinations offer newly diagnosed Multiple Myeloma patients' benefits, case studies
Sarah Henshaw (United Kingdom)

11:30 - 11:45
How do I.....consider patients' needs from a psycho-social perspective?
Surabhi Chaturvedi (United Kingdom)

Q&A

Paediatric Day
11:00 - 12:00
Auditorium 4

Paediatrics2, Inborn Errors Working Party Session

Chairs:
Arjan Lankester (Netherlands)
Michael Albert (Germany)

11:00 - 11:12
Landscape of GT and allogeneic therapy in IEM: The next years
Robert Wynn (United Kingdom)

11:12 - 11:24
Therapeutic standards for patients with SCID - Still a matter of discussion
Manfred Hoenig (Germany)

11:24 - 11:36
Induction therapy in Inborn Errors of Immunity before HSCT
Victoria Tesch (Austria)

11:36 - 11:48
Inflammation and autoimmunity in PID: Does it matter for HSCT?
Bénédicte Neven (France)

Q&A

11:00 - 12:00
Auditorium 5

Data Management

DM1, Education session 1

Chairs:
Helen Baldomero (Switzerland)

11:00 - 11:20
Reporting on CAR-T Cell outcomes and LTFU: Role of the EBMT registry
Christian Chabannon (France)

11:20 - 11:35
Registry upgrade and other data collection news in the EBMT
Per Ljungman (Sweden)

Text chat Q&A

Page 342 / 353
Quality Management
11:00 - 12:00
Auditorium 6

QM1, Highlights of the Draft 8th Edition of the STD

Chairs:
Eugenia Trigoso Arjona (Spain)

- Clinical standards 11:00 - 11:10
  Kim Orchard (United Kingdom)
- Collections standards 11:10 - 11:20
  Nina Worel (Austria)
- Processing standards 11:20 - 11:30
  Ivan van Riet (Belgium)
- Quality Management standards 11:30 - 11:40
  Simon Hack (United Kingdom)
- Immune effector cells standards 11:40 - 11:50
  Riccardo Saccardi (Italy)

Text chat Q&A 11:50 - 12:00

Industry Symposium
13:00 - 14:15
Auditorium 1

IS29, An update on induction and front-line therapy for transplantation-eligible patients with MM - Janssen Industry Symposium

Chairs:
María-Victoria Mateos (Spain)
Mohamad Mohty (France)

- Introduction 13:00 - 13:05
  María-Victoria Mateos (Spain)
- Latest data on treatment approaches for transplant eligible patients in frontline MM 13:05 - 13:30
  Mohamad Mohty (France)
- How will recent data change your clinical practice? - A case study discussion 13:30 - 14:00
  María-Victoria Mateos (Spain)
  Niels van de Donk (Netherlands)

Panel discussion 14:00 - 14:15
  María-Victoria Mateos (Spain)
  Mohamad Mohty (France)
  Niels van de Donk (Netherlands)


**Scientific Programme**

**Industry Symposium**  
13:00 - 14:15  
Auditorium 2

**IS30, Antineoplastic treatments and Invasive Mould Disease - Should we be worried and what can we do? - Pfizer Industry Symposium**

**Chairs:**  
Samir Agrawal (United Kingdom)

- **Introduction**  
Samir Agrawal (United Kingdom)  
13:00 - 13:05

- **An introduction to IMD in the haematology unit and epidemiology**  
Rafael de la Cámara (Spain)  
13:05 - 13:20

- **Novel therapies in haematology-oncology and the changing face of fungal disease**  
Samir Agrawal (United Kingdom)  
13:20 - 13:35

- **PK/PD principles for choosing an invasive mould disease treatment in a complex environment**  
Federico Pea (Italy)  
13:35 - 13:50

- **Real-life decision-making pathways when treating invasive mould disease in the haematology unit: case study**  
Amit Patel (United Kingdom)  
13:50 - 14:05

- **Discussion and close**  
14:05 - 14:15

**Special Session**  
13:00 - 14:00  
Auditorium 3

**SS4, Gender Equality forum**

**Chairs:**  
Anna Sureda (Spain)  
John Murray (United Kingdom)

- **Physician’s (female) perspective**  
Silvia Montoto (United Kingdom)  
13:00 - 13:12

- **Physician’s (male) perspective**  
John Snowden (United Kingdom)  
13:12 - 13:24

- **Nurse’s perspective**  
John Murray (United Kingdom)  
13:24 - 13:36

- **The role of gender in doctor-patient interaction and outcomes**  
Natacha Bolanos (Spain)  
13:36 - 13:48

- **Q&A**  
13:48 - 14:00
Data Management
13:00 - 14:00
Auditorium 5

**DM2, Education session 2**

**Chairs:**
Jorinde Hoogenboom (Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:45</td>
<td>CAR T-cells - Moving into the mainstream</td>
<td>Reuben Benjamin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(United Kingdom)</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>Text chat Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

Quality Management
13:00 - 14:00
Auditorium 6

**QM2, Role of Quality Management Professionals in Stem Cell Transplant Programs**

**Chairs:**
Julia Ruiz Pato (Spain)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:20</td>
<td>Results of the survey QM role</td>
<td>Renza Monteleone</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Italy)</td>
</tr>
<tr>
<td>13:20 - 13:30</td>
<td>COVID-19 &amp; QM experience in Italy</td>
<td>Mara Magri</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Italy)</td>
</tr>
<tr>
<td>13:30 - 13:40</td>
<td>COVID-19 &amp; QM experience in UK</td>
<td>Sarah Holtby</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(United Kingdom)</td>
</tr>
<tr>
<td>13:40 - 13:50</td>
<td>COVID-19 &amp; QM experience in Spain</td>
<td>Christelle Ferrà</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Spain)</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td>Text chat Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

Industry Symposium
13:00 - 14:00
Meet the Expert Rooms

**IS31, Therakos Industry Meet the Expert Lunch - Room MTE1**

Pre-registration required via the general registration form (free of charge). [https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration][1]

If you have already registered, you can modify your bookings on the official registration form: [https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration][2]

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 14:00</td>
<td>Calibrating the intensity of GVHD therapy to allow clinical tolerance - A role for ECP?</td>
<td>Daniel Wolff</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Germany)</td>
</tr>
</tbody>
</table>
Industry Symposium
13:00 - 14:00
Meet the Expert Rooms

**IS32, Medac Industry Meet the Expert Lunch - Room MTE2**

Pre-registration required via the general registration form (free of charge). If you have already registered, you can modify your bookings on the official registration form: https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration

**Extending transplant indication for elderly patients by novel conditioning approaches**
Matthias Stelljes (Germany)

Industry Symposium
13:00 - 14:00
Meet the Expert Rooms

**IS33, MSD Industry Meet the Expert Lunch 2 - Room MTE3**

Pre-registration required via the general registration form (free of charge). If you have already registered, you can modify your bookings on the official registration form: https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration

**Roundtable Discussion: CMV Management**
Miguel-Angel Perales (United States)

Educational
14:30 - 15:30
Auditorium 1

**E12, New developments in the field of CAR T-cell therapy**

**Chairs:**
Christian Chabannon (France)
Álvaro Urbano-Ispizua (Spain)

**An independent evaluation of the economic value of the two approved CAR T-cells**
John K. Lin (United States)

**Safe and potent anti-CD19 CAR T-cell therapy - An experience from China**
Zhitao Ying (China)

**CAR T-cell technology and strategy for solid tumors**
Hinrich Abken (Germany)

**Future of CAR T-cell therapies**
Stéphane Depil (France)

**Q&A**
**Scientific Programme**

**Educational**
14:30 - 15:30  
Auditorium 2

**E13, Unusual GVHD manifestations**

**Chairs:**  
Zinaida Peric (Croatia)  
Olaf Penack (Germany)

- **Neurologic aspects of cGVHD**  
  Ervina Bilic (Croatia)  
  14:30 - 14:45

- **The kidney and GVHD - Is the kidney a target organ?**  
  Sangeeta Hingorani (United States)  
  14:45 - 15:00

- **Late acute GVHD and steroid refractory GVHD**  
  Robert Zeiser (Germany)  
  15:00 - 15:15

- **Q&A**  
  15:15 - 15:30

**Nurses Group**
14:30 - 15:30  
Auditorium 3

**NG08, How do I become an expert?**

**Chairs:**  
Marijke Quaghebeur (Belgium)

- **Sexual function assessment in care**  
  Corien Eeltink (Netherlands)  
  14:30 - 14:45

- **Late effects: Implementation of guidelines**  
  Michelle Kenyon (United Kingdom)  
  14:45 - 15:00

- **How I teach people to become an expert in CAR-T**  
  Ruth Clout (United Kingdom)  
  15:00 - 15:15

- **Q&A**  
  15:15 - 15:30

**Paediatric Day**
14:30 - 15:30  
Auditorium 4

**Paediatrics3, Paediatrics Diseases Oral Session**

**TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: ASSESSING, CONTAINING, AND EXTINGUISHING THE FIRESTORM**
Sonata Jodele, Christopher E Dandoy, Adam Lane, Ashley Teusink-Cross, Kasiani C Myers, Gregory Wallace, Adam Nelson, Nicholas J Gloude, Stella M Davies (United States)  
14:30 - 14:37

**ELEVATED MACROPHAGE ACTIVATION MARKERS SCD163 AND MANNOSE RECEPTOR ARE ASSOCIATED WITH OCCURRENCE OF AGVHD AND SOS AFTER PEDIATRIC ALLOGENEIC HSCT**
Laura Louise Fosgrau Hergel, Katrine Kielsen, Sarah Wegener Weischendorff, Marianne Segelcke Rosenkrantz Ilversen, Claus Nielsen, Henning Grønbæk, Klaus Gottlob Müller (Denmark)  
14:37 - 14:44
SURVEY OF TRANSPLANT ASSOCIATED MACROPHAGE ACTIVATION SYNDROME (TAMAS) FOLLOWING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND YOUNG ADULTS
Petr Sedlacek, Cristina Diaz de Heredia, Akit Yesilipek, Pietro Merli, Priya Marwah, Stalin Ramprakash, Giorgio Ottaviano, Selim Corbacioglu (Czech Republic)

THE EFFICACY AND TOXICITY OF UNMANIPULATED DLI AFTER HAPLOIDENTICAL EX-VIVO T-CELL DEPLETED STEM CELL TRANSPLANTATION IN CHILDREN - A RETROSPECTIVE COHORT STUDY
Sundén Gustav, Jacek Toporski, Ladišlav Krol, Josefinna Dykes, Albert N Békássy, Cornelis Jan Pronk, Dominik Turkiewicz (Sweden)

IMPACT OF AB0 INCOMPATIBILITY, AGE AND STEM CELL SOURCE ON OUTCOME PARAMETERS IN MSD HSCT FOR HEMOGLOBINOPATHIES: A RETROSPECTIVE STUDY ON BEHALF OF THE PDWP
Katharina Kleinschmidt, Josu de la Fuente, Jacques-Emmanuel Galimard, Arnaud Dalissier, Jean-Hugues Dalle, Abdelghani Tbaahi, Yves Bertrand, Xavier Poïré, Gulsun Karasu, Gérard Michel, Despina Moshous, Hakan Ozdogu, Emel Ünal, Catherine Paillard, Akit Yesilipek, Selim Corbacioglu (Germany)

THE ROLE OF HLA MATCHING IN UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE IN EUROPE

HAPLOIDENTICAL T-CELL DEPLETED HSCT REPRESENTS A SAFE THERAPEUTIC ALTERNATIVE TO MSD TRANSPLANTATION IN PATIENTS WITH TRANSFUSION-DEPENDENT ß-THALASSEMIA MAJOR
Katharina Kleinschmidt, Juergen Foell, Beatrix Pfirnster, Anja Troeger, Agnes Mayr, Pauline Dibbern, Andreas Brosig, Norbert Ahrens, Selim Corbacioglu (Germany)

ALPHABETA T AND B-CELL DEPLETED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (TBDEPL-HAPLOHSCT) IN CHILDREN WITH NON-MALIGNANT DISORDERS
Pietro Merli, Federica Galaverna, Mattia Algeri, Daria Pagliara, Stefania Gaspari, Roberto Carta, Marco Becilli, Michele Massa, Emilia Boccieri, Rita Maria Pinto, Giulia Bozza, Luciana Vinti, Luisa Strocchio, Giovanna Leone, Giovanna Del Principe, Giuseppina Li Pira, Annalisa Ruggeri, Franco Locatelli (Italy)
Quality Management  
14:30 - 15:30  
Auditorium 6

**QM3, QM and future development in HSCT**  
Chairs:  
Almudena de Laiglesia (Spain)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:45</td>
<td>TRANSPOSE EU Project - WP6</td>
</tr>
<tr>
<td></td>
<td>Suzanna M. van Walraven (Netherlands)</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>EuroGTPII: An interactive assessment tool for risk assessment of new processes</td>
</tr>
<tr>
<td></td>
<td>Aurora Vassanelli (Italy)</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>CAR T accreditation: What can you expect?</td>
</tr>
<tr>
<td></td>
<td>Mara Magri (Italy)</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>Text chat Q&amp;A</td>
</tr>
</tbody>
</table>

**Special Session**  
16:00 - 17:00  
Auditorium 1

**SS5, Hematological therapies at the crossroad of the COVID-19 pandemic**  
Chairs:  
Rafael de la Cámara (Spain)  
Mohamad Mohty (France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:12</td>
<td>Endothelial dysfunction in COVID-19 and its management</td>
</tr>
<tr>
<td></td>
<td>José María Moraleda (Spain)</td>
</tr>
<tr>
<td>16:12 - 16:24</td>
<td>Mesenchymal stromal cells</td>
</tr>
<tr>
<td></td>
<td>Felipe Prósper (Spain)</td>
</tr>
<tr>
<td>16:24 - 16:36</td>
<td>Convalescent donor plasma</td>
</tr>
<tr>
<td></td>
<td>Rafael Duarte (Spain)</td>
</tr>
<tr>
<td>16:36 - 16:52</td>
<td>Monoclonal antibodies and other forms of immunotherapy</td>
</tr>
<tr>
<td></td>
<td>Christian Chabannon (France)</td>
</tr>
<tr>
<td>16:52 - 17:00</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>

**Joint Session**  
16:00 - 17:00  
Auditorium 2

**JS5, Joint session ASTCT/CIBMTR: Bridging the gap in BMT and cellular therapy between North America and Europe**  
Chairs:  
Navneet Majhail (United States)  
Robert Soiffer (United States)  
Nicolaus Kröger (Germany)
Scientific Programme

A tale of two continents: Differences and similarities in BMT practices in North America and Europe 16:00 - 16:15
Robert Soiffer (United States)

Landscape of CAR T-cell therapy in North America and Europe: Lessons learned and future directions 16:15 - 16:30
Miguel-Angel Perales (United States)

Looking back and moving forward: Blueprint for collaborative international studies in BMT and Cellular therapy 16:30 - 16:45
Anna Sureda (Spain)

Q&A 16:45 - 17:00

Nurses Group
16:00 - 17:00
Auditorium 3

NG09, Paediatric Session

Chairs:
Teija Schröder (Finland)
Hilda Mekelenkamp (Netherlands)

Impact of a health information technology tool addressing information needs of caregivers of adult and paediatric haematopoietic stem cell transplantation patients 16:00 - 16:25
Sung Won Choi (United States)

Music therapy supported quality of life and coping strategies for children during and after haematopoietic stem cell transplant 16:25 - 16:50
Lena Uggla (Sweden)

Q&A 16:50 - 17:00

Paediatric Day
16:00 - 17:00
Auditorium 4

Paediatrics4, Inborn Errors Oral Session

HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCRαβ/CD19 GRAFT DEPLETION AMONG CHILDREN WITH PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: HIGH SURVIVAL WITH LOW RATE OF GVHD 16:00 - 16:07
Aishat Kantulaeva, Elena Gutovskaya, Alexandra Laberko, Yulia Skvortsova, Larisa Shelikhova, Julia Starichkova, Dmitry Pershin, Elena Kurnikova, Yakov Muzalevskii, Aleksy Kazachenok, Galina Novichkova, Aleksey Maschan, Dmitry Balashov, Michael Maschan (Russian Federation)

NATIONAL HEALTH SERVICE ENGLAND (NHSE) PROGRAM FOR SELECTION OF ADULT PRIMARY IMMUNODEFICIENCY PATIENTS FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION 16:07 - 16:14
Emma Morris, Venetia Bigley, Siobhan O Burns, Smita Patel, David Lowe, Arian Laurence, Suzanne Elcombe, Helen Baxendale, Benjamin Uttenthal, Aarnoud Huissoon, Ravishankar Sargur, Patrick Yong, Sarah Grace, Mari Campbell, Benjamin Carpenter, Rachael Hough, John Snowden, Matthew Collin, Ronjon Chakraverty (United Kingdom)
OUTCOME AFTER HAEMATOPOIETIC CELL TRANSPLANTATION IN ADOLESCENTS AND YOUNG ADULTS WITH PRIMARY IMMUNODEFICIENCY
Su Han Lum, Venetia Bigley, Daniel Drozdov, Zohreh Nademi, Terry Flood, Mario Abinun, Andrew Cant, Sophie Hambleton, Mary Slatter, Andrew Gennery (United Kingdom)

DONOR CHARACTERISTICS PREDICT THE SUCCESS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSAEMIA MAJOR: A SINGLE CENTRE ANALYSIS OF 250 PATIENTS
Revathi Raj, Ramya Uppuluri, Venkateswaran Vellaichamy, Nikila Ravichandran, Kesavan Iyer, David Dennison, Abdulhakim Alrawas (India)

LONG-TERM NEURODEVELOPMENTAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR LATE-INFANTILE KRABBE DISEASE
Maria Escolar, Isabel Yoon, Nicholas Bascou, Michele Poe (United States)

LENTIGLOBIN FOR SICKLE CELL DISEASE (SCD) GENE THERAPY (GT): UPDATED RESULTS IN GROUP C PATIENTS FROM THE PHASE 1/2 HGB-206 STUDY
Markus Y. Mapara, John F. Tisdale, Julie Kanter, Janet L. Kwiatkowski, Lakshmanan Krishnamurti, Manfred Schmidt, Alexandra L. Miller, Francis J. Pierciey Jr., Melissa Bonner, Wenmei Huang, Jean-Antoine Ribeil, Alexis A. Thompson, Mark C Walters (United States)

VERY LONG-TERM FOLLOW UP OF 83 ADULTS WHO UNDERWENT ALLOGENEIC HSCT IN CHILDHOOD FOR PRIMARY IMMUNODEFICIENCY (PID): A SINGLE CENTRE EXPERIENCE
James Day, Rupert Goodman, Bethany Nicholson, Austen Worth, Paul Veys, Ronjon Chakraverty, Benjamin Carpenter, Rachael Hough, Mari Campbell, Penny Titman, Deborah Ridout, Kit Sandford, Siobhan O Burns, Emma Morris (United Kingdom)

LENTIVIRAL HAEMATOPOIETIC STEM CELL THERAPY IN PATIENTS WITH WISKOTT ALDRICH SYNDROME (WAS): LONDON EXPERIENCE
Reem Elfeky, Christine Rivat, Katie Snell, Jinhua Xu-Bayford, Kimberly Gilmour, Stuart Adams, Emma Morris, Geralidine Honnet, Anne Galy, Claire Booth, Adrian J Thrasher (United Kingdom)

Data Management
16:00 - 17:00
Auditorium 5

DM4, Education session 4

Chairs:
Emmanuelle Polge (France)

Treatment of relapse after transplant (DLI, CAR T, second allograft) 16:00 - 16:45
Christoph Schmid (Germany)

Text chat Q&A 16:45 - 17:00
Scientific Programme

Quality Management
16:00 - 17:00
Auditorium 6

QM4, Auditing more than JACIE

Chairs:
Sarah Holtby (United Kingdom)

Introduction
Olga López Villar (Spain)
16:00 - 16:05

Spain / UK
Olga López Villar (Spain)
Anne Emmett (United Kingdom)
16:05 - 16:20

The Netherlands / Turkey
Nick van Sinderen (Netherlands)
Ilknur Kozanoglu (Turkey)
16:20 - 16:35

Italy / Belgium
Renza Monteleone (Italy)
Phuong Huynh (Belgium)
16:35 - 16:50

Text chat Q&A
16:50 - 17:00

General
17:00 - 17:35
Auditorium 1

GS3, General Assembly

Chairs:
Nicolaus Kröger (Germany)

President's Report
Nicolaus Kröger (Germany)
17:00 - 17:16

Treasurer's Financial Report
Harry Dolstra (Netherlands)
17:16 - 17:23

Secretary's Report
John Snowden (United Kingdom)
17:23 - 17:28

EBMT Brand: Mission and vision project
John Snowden (United Kingdom)
17:28 - 17:30

Text chat Q&A
17:30 - 17:35

Nurses Group
17:00 - 17:30
Auditorium 3

NG10, Nurses Group Closing Session

Chairs:
John Murray (United Kingdom)
Scientific Programme

**Highlights from physicians' sessions**
Izaskun Zeberio (Spain)

**Best of the Best: Presentation of NG Abstract prizes**
John Murray (United Kingdom)

**Presentation of Madrid 2021**
Julia Ruiz Pato (Spain)
Isabel Salcedo (Spain)

General
17:40 - 18:10
Auditorium 1

**GS4, Closing Ceremony**

**Chairs:**
Nicolaus Kröger (Germany)

**Presentation of the Springer Nature Poster Awards**
Nicolaus Kröger (Germany)

**Presentation of the results of the EBMT Fellowship grant 2019: Cord versus marrow: Are young stem cells superior for transplantation?**
Flavia Peci (Netherlands)

**Local President for EBMT 2021 Madrid: Welcome**
Rafael Duarte (Spain)

**EBMT President closing remarks**
Nicolaus Kröger (Germany)